Tape stripping methods for analysis of skin disease and pathological skin state

ABSTRACT

The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a microarray.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 11/710,661 filed Feb. 23, 2007, now issued as U.S. Pat. No. 7,989,165; which is a continuation application of U.S. application Ser. No. 10/816,457 filed Mar. 31, 2004, now issued as U.S. Pat. No. 7,183,057. The disclosure of each of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates generally to non-invasive diagnostics methods and more specifically to methods for isolating and analyzing nucleic acids from skin samples.

2. Background Information

Skin diseases represent major health care challenges today. For example, over five million Americans and over one hundred million people worldwide suffer from psoriasis. Detection, diagnosis, and staging of a skin disease is an important aspect of its management. Current diagnostic methods rely mainly on visible observation and biopsies. However, detection methods for skin diseases that rely on visible observation are not effective for diagnosing many skin diseases, and do not detect diseases until after clinical manifestation. Invasive methods such as biopsies, not only are traumatic for a subject being tested, they also increase the risk of infection. Furthermore, invasive methods do not provide an enriched sample of cells on the surface of skin, which are the cells involved in a surface reaction.

Detection and diagnosis of skin disease are important not only for patient management, but also to assess the safety and efficacy of new skin disease therapeutic agents and new skin care products. New therapeutic agents are required for many skin diseases where present therapeutic agents are not fully effective. Furthermore, diagnostic methods provide important information regarding the specific genetic changes underlying a subject's skin disease. Identifying these genetic changes identifies potential drug targets and may be critical in determining whether a person will respond to a particular therapeutic agent.

In addition to assessing new therapeutic agents, detection and diagnosis methods are also important to assess the safety of new skin care products. Skin care products, including cosmetics, are an important part of most people's daily grooming habits. The average adult uses at least seven different skin care products each day. Currently, all commercial skin care products are required to undergo safety testing. These tests take the form of Clinical Acute Primary Irritation and 14-day Cumulative Irritation Protocols followed by Human Repeat Insult Patch Testing (HRIPT) to detect sensitization (contact allergy). Visual analysis is used to determine the test results as described in Richard Berger and James Bowman, A reappraisal of the 21-day cumulative irritancy test in man, J. Toxicol-Cut and Ocular Toxicol 1(2), 101-107 (1982). Therefore, allergic reactions are not detected until they have manifested themselves in a visible reaction.

In addition to issues related to relatively late stages of detection, visible analysis cannot distinguish subtle skin reactions that are difficult to classify as irritant or allergic reactions. This classification distinction is very important because it can be used as the basis for deciding whether to continue to develop a new skin care product. Issues of irritation can be dealt with by reformulation, whereas issues of sensitization (i.e., an allergic reaction) can require more drastic product altering actions due to safety and liability concerns. Therefore, misdiagnosis of irritant dermatitis as allergic dermatitis can block a safe and efficacious skin care product from being available to people who could benefit from it.

SUMMARY OF THE INVENTION

The present invention is based on a non-invasive approach for recovering nucleic acids such as DNA or messenger RNA from the surface of skin via a simple tape stripping procedure that permits a direct quantitative and qualitative assessment of biomarkers. The method provides valuable genetic information, not obtainable using a visible detection method. Furthermore, although tape-harvested RNA is shown to be comparable in quality and utility to RNA recovered by biopsy, the method provides information regarding cells of the outermost layers of the skin that is not obtained using biopsy samples. Finally, the method is far less traumatic than a biopsy.

The method was applied to the analysis of gene expression during irritant contact dermatitis. Using SLS irritation as a model system, the utility of assaying changes in IL-1θ and IL-8 mRNA was tested as an indication of irritant skin reactions. It is show that both sampling methods allow the recovery of RNA, the analysis of which reveals cutaneous irritation. Data is presented that biopsy and tape-harvested RNA are likely derived from different cell populations and that tape harvesting is an efficient method for sampling the epidermis and identifying select differentially regulated epidermal biomarkers. Furthermore, the Examples provided herein illustrate the successful amplification of tape-harvested RNA for hybridization to DNA microarrays. These experiments show no significant gene expression level differences between replicate sites on a subject and minimal differences between a male and female subject. The array generated RNA profiles between normal and 24-hour 1% SLS-occluded skin were compared, and it was observed that SLS treatment resulted in statistically significant changes in the expression levels of more than 1,700 genes. These data illustrate that tape harvesting as a non-invasive method for capturing RNA from human skin for microarray analysis.

Accordingly, provided herein is a method for characterizing skin of a subject, including applying an adhesive tape to a target area of skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules. At least one nucleic acid molecule whose expression is informative of a skin disease or pathological skin state is detected in the epidermal sample The method of characterizing skin using tape stripping has a number of applications, such as the following: (i) disease classification/subclassification; (ii) monitoring disease severity and progression; (iii) monitoring treatment efficacy; and (iv) prediction of the most beneficial treatment regimen. All of these applications, which themselves represent embodiments disclosed herein, rely on the concept of noninvasive sampling to recover information that is otherwise difficult or impractical to recover (i.e., through the use of biopsies). This information is contained in the RNA of skin cells close to the surface of the skin. In one example, expression of one or more of the genes listed in Table VII, or a combination thereof, is detected in the epidermal sample to characterize the skin. This exemplary method is particularly useful for obtaining information related to an irritated state of the skin.

Certain embodiments of the invention are based in part on the discovery that in subjects afflicted with psoriasis, nucleic acid samples, for example RNA samples, readily obtained from the epidermis of skin areas that contain psoriatic lesions provide information regarding the disease. Accordingly, the present invention provides a non-invasive method for isolating or detecting a nucleic acid molecule from an epidermal sample of a psoriatic lesion of a human subject. The method includes applying an adhesive tape to the psoriatic lesion of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape. The epidermal sample includes a nucleic acid molecule that is then isolated and/or detected directly. The method of tape stripping psoriatic lesions can be used, for example, to monitor the responsiveness of a psoriasis patient to treatment. Furthermore, the method can be used to identify genes that are predictive of response to therapy.

Other embodiments are based in part on the discovery that for tape stripping of the skin, non-polar, pliable, adhesive tapes, especially pliable tapes with rubber adhesive, are more effective than other types of adhesive tapes. Using pliable tapes with rubber adhesives, as few as 10 or less tape strippings and in certain examples as few as 4 or even 1 tape stripping can be used to isolate and/or detect nucleic acid molecules from the epidermal layer of the skin.

Accordingly, provided herein is a method for isolating and/or detecting a nucleic acid molecule from an epidermal sample from skin, including applying an adhesive tape to a target area of the skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample comprises nucleic acid molecules, and wherein the tape includes a rubber-based adhesive and is pliable.

In another embodiment, the present invention provides a method for quantitatively assessing gene expression of an amplified nucleic acid in a skin sample that overcomes prior difficulties in such a method. Accordingly, provided herein is a method for detecting a change in gene expression, including applying an adhesive tape to a target area of skin and to an unaffected area of the skin, in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal samples comprise nucleic acid molecules; and for each of the target area sample and the normal area sample, amplifying a target nucleic acid molecule and a control nucleic acid molecule in the same experiment using similar sample volumes and similar probes, wherein a change in the relative amplified levels of the target nucleic acid molecule to the control nucleic acid molecule at the target area versus the normal area is indicative of a change in gene expression of the target nucleic acid molecule at the target area.

In addition, provided herein is a method for detecting a response of a subject to treatment for psoriasis, including applying an adhesive tape to the skin of the subject being treated for psoriasis, in a manner sufficient to isolate an epidermal sample, wherein the epidermal sample includes nucleic acid molecules; and detecting a target nucleic acid molecule in the sample comprising nucleic acid molecules. Expression of the target nucleic acid molecule is informative regarding psoriasis.

In another embodiment the invention provides a kit for isolation and detection of a nucleic acid from an epidermal sample, such as an epidermal sample from a psoriatic lesion or a target area of skin suspected of being inflamed. The kit includes an adhesive tape for performing methods provided herein. Accordingly, in one embodiment, provided herein is a kit that contains a pliable adhesive tape made up at least in part, of a non-polar polymer. In certain aspects, the tape is a rubber-based tape.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 diagrammatically illustrates the experimental design of the SLS irritation protocol disclosed in further detail in Example 2.

FIGS. 2A to 2C provide p-value distributions for gene expression changes upon induction of irritation by SLS exposure. The p-values, based on a regularized t-test distribution of all genes expressed at value above background in all replicate experiments grouped into 100 bins and plotted against the number of genes in each bin. Panel A, the 21,031 p-values of genes compared between untreated versus SLS occluded samples. Panel B, the 21,307 p-values of genes compared between SLS treated versus water occluded samples. Panel C, 21,164 p-values of genes compared between untreated versus water occluded samples. The dashed lines in Panels A and B indicate the uniform distribution of p-values under conditions of no differential expression.

DETAILED DESCRIPTION OF THE INVENTION

The specification hereby incorporates by reference in their entirety, the files contained on the compact disks filed herewith. Two copies of the compact disk are filed herewith. Each compact disk includes a file called “DERM1120.2 Tables.txt” created Jul. 27, 2011, which is 1,540 kilobytes in size. Columns 1 and 2 of that spreadsheet file are identical to the Table included in the Appendix.

The present invention is based on a non-invasive approach for recovering or analyzing nucleic acids such as DNA or RNA, from the surface of skin via a simple tape stripping procedure that permits a direct quantitative and qualitative assessment of pathologic and physiologic biomarkers. Tape-harvested RNA is shown to be comparable in quality and utility to RNA recovered by biopsy. The present method causes little or no discomfort to the patient. Therefore, it can be performed routinely in a physician's office, for example, for point of care testing. Accordingly, provided herein are methods and markers for non-invasive isolation and/or detection of nucleic acids from epidermal samples using tape stripping.

The methods are effective for analysis of skin that is diseased or in a pathological state, such as psoriatic skin or irritated skin. It is shown herein, that the methods can be used to characterize molecular differences in affected skin that visibly appears similar. Furthermore, it is shown herein that the method can be used to monitor response of skin to treatment.

The methods can utilize a −C_(t) value, which provides useful information regarding gene expression, especially in situations where it is difficult to obtain a “normal” nucleic acid sample, such as in tape stripping methods. Before the present disclosure it was taught that the −C_(t) value was not being appropriate for gene expression analysis.

Methods of the present invention include a rapid, non-invasive skin-sampling method for obtaining polynucleotides, including DNA and RNA. For example, mRNA is typically isolated in methods wherein gene expression is analyzed. It is illustrated herein that improved isolation of nucleic acid molecules is obtained using pliable tape with a rubber adhesive.

Accordingly, in methods provided herein, an epidermal sample is obtained by tape stripping the skin, which involves applying an adhesive tape to the skin in a manner sufficient to isolate an epidermal sample adhering to the tape that includes nucleic acid molecules. Tape stripping methods provided herein, for example a single application of 4 individual tapes, do not result in glistening of uninvolved skin, and thus do not bare the viable epidermis. In contrast, a shave biopsy is expected to include not only cells of the epidermis (primarily keratinocytes and melanocytes and immune cells) but fibroblasts from the upper dermis as well.

A “biomolecule” is a specific binding pair member found in nature, or derived from a molecule found in nature. As used herein, the term “specific binding pair member” refers to a molecule that specifically binds or selectively hybridizes to, or interacts with, another member of a specific binding pair. Specific binding pair members include, for example, analytes and biomolecules.

“Nucleic acid” means DNA, RNA, single-stranded, double-stranded or triple stranded and any chemical modifications thereof. Virtually any modification of the nucleic acid is contemplated. A “nucleic acid” can be of almost any length, from 10, 20, 30, 40, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, 10,000, 15,000, 20,000, 30,000, 40,000, 50,000, 75,000, 100, 000, 150, 000, 200, 000, 500,000, 1,000,000, 1,500,000, 2,000,000, 5,000,000 or even more bases in length, up to a full-length chromosomal DNA molecule. For methods that analyze expression of a gene, the nucleic acid isolated from a sample is typically RNA.

The term “polypeptide” is used broadly herein to mean two or more amino acids linked by a peptide bond. The term “fragment” or “proteolytic fragment” also is used herein to refer to a product that can be produced by a proteolytic reaction on a polypeptide, i.e., a peptide produced upon cleavage of a peptide bond in the polypeptide. A polypeptide of the invention contains at least about six amino acids, usually contains about ten amino acids, and can contain fifteen or more amino acids, particularly twenty or more amino acids. It should be recognized that the term “polypeptide” is not used herein to suggest a particular size or number of amino acids comprising the molecule, and that a peptide of the invention can contain up to several amino acid residues or more. A protein is a polypeptide that includes other chemical moieties other than amino acids, such as phosphate groups or carbohydrate moiety.

A “skin lesion” is a wound on the skin or injury to the skin. A ‘plaque” is a flattish, raised patch on the skin. “Scales” are thin flakes on the skin surface.

Throughout this application, the term “proliferative skin disorder” refers to a disease/disorder of the skin marked by unwanted or aberrant proliferation of cutaneous tissue. These conditions are typically characterized by epidermal cell proliferation or incomplete cell differentiation, and include, for example, X-linked ichthyosis, psoriasis, atopic dermatitis, allergic contact dermatitis, epidermolytic hyperkeratosis, and seborrheic dermatitis. For example, epidermodysplasia is a form of faulty development of the epidermis. Another example is “epidermolysis”, which refers to a loosened state of the epidermis with formation of blebs and bullae either spontaneously or at the site of trauma.

As used herein, the term “psoriasis” refers to a hyperproliferative skin disorder which alters the skin's regulatory mechanisms. In particular, lesions are formed which involve primary and secondary alterations in epidermal proliferation, inflammatory responses of the skin, and an expression of regulatory molecules such as lymphokines and inflammatory factors. Psoriatic skin is morphologically characterized by an increased turnover of epidermal cells, thickened epidermis, abnormal keratinization, inflammatory cell infiltrates into the dermis layer and polymorphonuclear leukocyte infiltration into the epidermis layer resulting in an increase in the basal cell cycle. Additionally, hyperkeratotic and parakeratotic cells are present.

The term “sample” refers to any preparation derived from skin of a subject. For example, a sample of cells obtained using the non-invasive method described above can be used to isolate polynucleotides, polypeptides, or lipids, preferably polynucleotides and polypeptides, most preferably nucleic acid molecules, such as polynucleotides, for the methods of the present invention. Samples for the present invention, typically are taken from a skin lesion, that is suspected of being the result of a disease or a pathological state, such as psoriasis or dermatitis. The samples are taken of the skin surface of the suspicious lesion using non-invasive skin sampling methods discussed herein.

The term “skin” refers to the outer protective covering of the body, consisting of the corium and the epidermis, and is understood to include sweat and sebaceous glands, as well as hair follicle structures. Throughout the present application, the adjective “cutaneous” can be used, and should be understood to refer generally to attributes of the skin, as appropriate to the context in which they are used. In a preferred embodiment, the skin is mammalian skin. In an illustrative embodiment the skin is human skin.

The tape stripping methods provided herein typically involve applying an adhesive tape to the skin of a subject and removing the adhesive tape from the skin of the subject one or more times. In certain examples, the adhesive tape is applied to the skin and removed from the skin about one to ten times. Alternatively, about ten adhesive tapes can be applied to the skin and removed from the skin. These adhesive tapes are then combined for further analysis. Accordingly, an adhesive tape can be applied to and removed from a target site 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 time, and/or 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 adhesive tape can be applied to and removed from the target site. In one illustrative example, the adhesive tape is applied to the skin between about one and eight times, in another example, between one and five times, and in another illustrative example the tape is applied and removed from the skin four times.

For the tape strippings, the same strip of tape can be repeatedly applied to, and removed from, a target site, such as a psoriatic lesion. However, in illustrative embodiments a fresh piece of adhesive tape is sequentially applied to a target site of the skin. The individual tape strips used to sample a site can then be combined into one extraction vessel for further processing such as nucleic acid extraction. In one illustrative example, the adhesive tape is applied to the skin between about one and eight times, in another example, between one and five times, and in another illustrative example the tape is applied and removed from the skin four times.

Factors such as the flexibility, softness, and composition of the adhesive tape used, the time the tape is allowed to adhere to the skin before it is removed, the force applied to the tape as it is applied to the skin, the prevalence of a gene product being analyzed, the disease status of the skin, and patient/patient variability are typically taken into account in deciding on a protocol useful for a particular tape stripping method in order to assure that sufficient nucleic acids are present in the epidermal sample. A tape stripped sample includes, but may not be limited to, tissues that are restricted to the surface of skin and preferentially recovers vellus hair follicles and cells lining sebaceous, eccrine, and sweat ducts (i.e., the adnexal structures associated with the stratum corneum and epidermis), as well as corneocytes. Tape stripping is stopped before viable epidermis is exposed by ceasing tape stripping before the tissue glistens. Therefore, the tape stripping method is considered a “noninvasive” method. Tape stripping sufficient to isolate an epidermal sample is tape stripping that is performed on the skin sufficient times to obtain an RNA sample, wherein the tape stripping is stopped before the tissue glistens (i.e., becomes shiny, appears “moistened” or reflective).

Certain aspects of the invention, which themselves are embodiments of the invention, are based in part on the discovery that non-polar, pliable adhesive tapes, especially plastic-based adhesive tapes, are more effective for obtaining nucleic acid samples from the skin than other types of adhesive tapes. Using non-polar, pliable adhesive tapes as few as 10 or less tape strippings and in certain examples as few as 4 or even 1 tape stripping can be used to obtain a nucleic acids that can be analyzed. The method can be used as part of various embodiments provided herein, to isolate an RNA sample from the epidermis of skin, for gene expression analysis.

Accordingly, provided herein is a method of detecting expression of genes in the skin, including applying an adhesive tape to a target area of the skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample comprises nucleic acid molecules, wherein the tape comprises a rubber adhesive, and wherein the tape is pliable. The nucleic acid molecules in the epidermal sample are then detected. The nucleic acid molecules, in certain examples, are applied to a microarray to detect the nucleic acid molecules.

In another embodiment, provided herein is a method for isolating a nucleic acid molecule from an epidermal sample from skin, including applying an adhesive tape to a target area of the skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules, wherein the tape includes a non-polar polymer adhesive, and wherein the tape is pliable. A nucleic acid molecule is then isolated from the epidermal sample. In illustrative examples, the non-polar polymer adhesive is a rubber-based adhesive.

The rubber based adhesive can be, for example, a synthetic rubber-based adhesive. The rubber based adhesive in illustrative examples, has high peel, high shear, and high tack. For example, the rubber based adhesive can have a peak force tack that is at least 25%, 50%, or 100% greater than the peak force tack of an acrylic-based tape such as D-squame™. D-squame™ has been found to have a peak force of 2 Newtons, wherein peak force of the rubber based adhesive used for methods provided herein, can be 4 Newtons or greater. Furthermore, the rubber based adhesive can have adhesion that is greater than 2 times, 5 times, or 10 times that of acrylic based tape. For example, D-squame™ has been found to have adhesion of 0.0006 Newton meters, whereas the rubber based tape provided herein can have an adhesion of about 0.01 Newton meters using a texture analyzer. Furthermore, in certain illustrative examples, the adhesive used in the methods provided herein has higher peel, shear and tack than other rubber adhesives, especially those used for medical application and Duct tape.

In addition to having higher peel, shear, and tack, the rubber-based adhesive is more hydrophobic than acrylic adhesives. Furthermore, the rubber based adhesive in illustrative examples is inert to biomolecules and to chemicals used to isolate biomolecules, especially nucleic acids such as DNA and RNA. Finally, the adhesive can be relatively soft compared to other tapes such as D-squame™.

The rubber-based adhesive is on a support, typically a film, that makes the tape pliable and flexible. In certain aspects, the tape can be soft and pliable. “Pliable” tape is tape that is easily bent or shaped. “Soft and pliable” tape is tape that is easily bent or shaped and yields readily to pressure or weight. The film can be made of any of many possible polymers, provided that the tape is pliable and can be used with a rubber adhesive. The thickness can be varied provided that the tape remains pliable. For example, the tape can be 0.5 mil to 10 mil in thickness, 1.0 to 5.0 mil in thickness. In one example, the tape contains a rubber adhesive on a 3.0 mil polyurethane film. For example the film can be a polyurethane film such as skin harvesting tape (Product No. 90068) available from Adhesives Research, Inc (Glen Rock, Pa.).

The Examples illustrate tape stripping methods provided herein. Generally, before contacting a skin site with adhesive tape, a skin site to be stripped is cleaned, for example using an antiseptic cleanser such as alcohol. Next, tape is applied to a skin site with pressure. Pressure can be applied for a fraction of a second, but can be applied for between 1 second and 5 minutes, typically between 10 seconds and 45 seconds. In certain illustrative examples, tape is applied for 30 seconds for each tape stripping. It will be understood that the amount of pressure applied to a skin site and the length of time for stripping can be varied to identify ideal pressures and times for a particular application. Generally, pressure is applied by manually pressing down the adhesive tape on the skin, however, objects, such as blunt, flat objects can be used to assist in applying the tape to the skin, especially for areas of the skin from which it is more difficult to obtain nucleic acid samples from skin, such as uninvolved skin of a subject afflicted with psoriasis.

Virtually any size and/or shape of adhesive tape and target skin site size and shape can be used and analyzed, respectively, by the methods of the present invention. For example, adhesive tape can be fabricated into circular discs of diameter between 10 millimeters and 100 millimeters, for example between 15 and 25 millimeters in diameter. The adhesive tape can have a surface area of between about 50 mm² and 1000 mm², between about 100 mm² to 500 mm² or about 250 mm².

As illustrated in the Examples provided herein, biopsy and tape stripping may not be equivalent sampling methods and therefore should not be expected to yield identical results. Not intended to be limited by theory, tape stripping, also referred to as “tape harvesting,” is restricted to the skin surface and therefore may preferentially recover vellus hair follicles and cells lining sebaceous, eccrine and sweat ducts as well as corneocytes (not predicted to contain RNA). Tape stripping methods provided herein, which typically utilize 10 or less tape strippings, for example a single application of 4 individual tapes, do not result in glistening of uninvolved skin and thus do not bare the viable epidermis. Thus, tape stripping methods provided herein, provide an epidermal sample. In contrast, a shave biopsy, in which a scalpel blade is use to slice a thin piece of skin from the surface (and which typically results in bleeding but does not require suturing), is expected to include not only cells of the epidermis (primarily keratinocytes and melanocytes and immune cells) but fibroblasts from the upper dermis. The potential enrichment of surface epidermis conveyed by tape stripping compared to a shave biopsy can be appreciated by considering that the surface area of a tape is 284 mm², while the surface area of a 2×2 mm shave biopsy is 4 mm². Thus, tape-harvested cells represent an enrichment of a sub-population of cells found in a shave biopsy. The data presented in Tables I and IV support the hypothesis that tape and biopsy-harvested RNA are derived from different cell populations.

The epidermis of the human skin comprises several distinct layers of skin tissue. The deepest layer is the stratum basalis layer, which consists of columnar cells. The overlying layer is the stratum spinosum, which is composed of polyhedral cells. Cells pushed up from the stratum spinosum are flattened and synthesize keratohyalin granules to form the stratum granulosum layer. As these cells move outward, they lose their nuclei, and the keratohyalin granules fuse and mingle with tonofibrils. This forms a clear layer called the stratum lucidum. The cells of the stratum lucidum are closely packed. As the cells move up from the stratum lucidum, they become compressed into many layers of opaque squamae. These cells are all flattened remnants of cells that have become completely filled with keratin and have lost all other internal structure, including nuclei. These squamae constitute the outer layer of the epidermis, the stratum corneum. At the bottom of the stratum corneum, the cells are closely compacted and adhere to each other strongly, but higher in the stratum they become loosely packed, and eventually flake away at the surface.

The skin sample obtained using the tape stripping method includes, epidermal cells including cells comprising adnexal structures. In certain illustrative examples, the sample includes predominantly epidermal cells, or even exclusively epidermal cells. The epidermis consists predominantly of keratinocytes (>90%), which differentiate from the basal layer, moving outward through various layers having decreasing levels of cellular organization, to become the cornified cells of the stratum corneum layer. Renewal of the epidermis occurs every 20-30 days in uninvolved skin. Other cell types present in the epidermis include melanocytes, Langerhans cells, and Merkel cells. As illustrated in the Examples herein, the tape stripping method of the present invention, is particularly effective at isolating epidermal samples.

Nucleic acids can be isolated from the lysed cells and cellular material by any number of means well known to those skilled in the art. For example, a number of commercial products available for isolating polynucleotides, including but not limited to, RNeasy™ (Qiagen, Valencia, Calif.) and TriReagent™ (Molecular Research Center, Inc, Cincinnati, Ohio) can be used. The isolated polynucleotides can then be tested or assayed for particular nucleic acid sequences, including a polynucleotide encoding a cytokine. Methods of detecting a target nucleic acid within a nucleic acid sample are well known in the art, and can include microarray analysis, as discussed in more detail herein.

In another embodiment, provided herein is a non-invasive method for identifying a predictive skin marker for response to treatment for a disease or pathological state, including: applying an adhesive tape to the skin of a subject afflicted with the disease or pathological state at a first time point, in a manner sufficient to isolate an epidermal sample including nucleic acid molecules and treating the subject for the disease or pathological state. It is then determined whether the disease or pathological state has responded to the treatment, and if so, whether expression of a nucleic acid molecule in the epidermal sample is predictive of response to treatment.

Expression of a nucleic acid molecule in the epidermal sample is predictive of response to treatment if expression of the nucleic acid molecule at the first time point is different in subjects that respond to treatment compared to subjects that do not respond to treatment. It will be understood that a variety of statistical analysis can be performed to identify a statistically significant association between expression of the nucleic acid molecule and response of the subject to the treatment. For example, expression of the nucleic acid in certain examples is elevated, in subjects that will not respond to treatment. Furthermore, expression of the nucleic acid can predict a level of response to treatment, for example partial or temporary response to treatment versus a full response.

In another embodiment, provided herein is a non-invasive method for predicting response to treatment for a disease or pathological state, including applying an adhesive tape to the skin of a subject afflicted with the disease or pathological state in a manner sufficient to isolate an epidermal sample that includes nucleic acid molecules. A target nucleic acid molecule is detected in the epidermal sample, whose expression is indicative of a response to treatment, thereby predicting response to treatment for the disease or pathological state.

The disease for embodiments directed at identifying a predictive skin marker, or predicting response to treatment by detecting a predictive skin marker, also referred to in these embodiments as a target nucleic acid molecule, can be virtually any skin disease. For example, the skin disease can be psoriasis or dermatitis, such as irritant contact dermatitis or allergic contact dermatitis. In aspects where the disease is psoriasis, the treatment can be, for example, a topical treatment, phototherapy, a systemic medication, or a biologic. Specific treatments are provided in Table VIII.

Samples from a tissue can be isolated by any number of means well known in the art. Invasive methods for isolating a sample include the use of needles, for example during blood sampling, as well as biopsies of various tissues. Due to the invasive nature of these techniques there is an increased risk of mortality and morbidity. The methods and kits of the present invention use a non-invasive sampling method to obtain a skin sample. In certain examples, these methods are used along with conventional methods, such as a skin biopsy, to provide additional information.

As mentioned above, tape-harvested cells appear to represent an enrichment of a sub-population of cells found in a shave biopsy. Accordingly, in certain aspects, in addition to a tape stripping method provided herein, a biopsy can be taken at the site of tape stripping, such as a psoriatic lesion site, or at another skin site. Nucleic acid molecules from the biopsy can be isolated and analyzed. Analysis of the biopsy data can be combined with analysis of data from a tape stripping method to provide additional information regarding the psoriatic lesion.

In certain aspects a nucleic acid molecule from uninvolved epidermal tissue is obtained by applying an adhesive tape to skin of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules and wherein the skin is unaffected by a disease to be tested. Then a nucleic acid molecule is isolated and detected from the epidermal sample of the unaffected skin.

In certain aspects, the uninvolved skin can be from the upper arm or the upper back. These sites appear to provide relatively plentiful quantities of nucleic acid molecules using tape strippings. For example, tape stripping can be performed on uninvolved skin over the deltoid or upper back over the scapular spine and the periauricular region. Tape stripping generally involves the skin surface and therefore may preferentially recover vellus hair follicles and cells lining sebaceous, eccrine and sweat ducts (i.e., adnexal structures) as well as corneocytes (not predicted to contain RNA).

Certain embodiments provided herein, are based in part on the discovery that the expression of certain genes can be used to monitor response to therapy. Accordingly, in another embodiment, provided herein is a method for monitoring a response of a human subject to treatment for a disease or pathological state, including applying an adhesive tape to the skin of the subject being treated for the disease or pathological state at a first-time point and at least a second time point, in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape at the first time point and at the second time point. The epidermal sample includes a nucleic acid molecule, wherein a change in expression of the nucleic acid molecule between the first time point and the second time point is indicative of a change in the disease or pathological state.

In a related embodiment, provided herein is a method for detecting a response of a subject to treatment for a disease or pathological state, comprising: treating the subject for a skin disease or pathological skin state; applying an adhesive tape to the skin of the subject in a manner sufficient to isolate an epidermal sample, wherein the epidermal sample includes nucleic acid molecules; and detecting a target nucleic acid molecule in the sample comprising nucleic acid molecules. Expression of the target nucleic acid molecule is informative regarding the disease or pathological state. Therefore, the method identifies a response of the subject to treatment for the disease or pathological state.

The detection can be a qualitative detection of whether the target gene is expressed, but is typically a quantitative expression level determination. The method can be performed both prior to treatment and after treatment. In one aspect, the method is performed after treatment, but before a change in disease or pathological state is observed visually.

Time points for the monitoring and response-to-treatment methods provided herein, can include any interval of time, but are typically at least 2 weeks, and more typically at least 1 month apart. For certain embodiments, time points are 2 months, 3 months, 6 months, 1 year, or 2 years apart. Samples can be taken at any number of time points, including 2, 3, 4, 5, etc. time points. Comparison of expression analysis data from different time points can be performed using any of the known statistical methods for comparing data points to assess differences in the data, including time-based statistical methods such as control charting. The disease or pathological state can be identified in the time series, for example, by comparing expression levels to a cut-off value, or by comparing changes in expression levels to determine whether they exceed a cut-off change value, such as a percent change cut-off value. In certain aspects, the first time point is prior to treatment, for example, prior to administration of a therapeutic agent, and the second time point is after treatment.

The disease or pathological state can be virtually any skin disorder. For example, the skin disorder can be psoriasis, dermatitis, or a skin infection, an allergic reaction, hives, seborrhea, irritant contact dermatitis, allergic contact dermatitis, hidradenitis suppurative, allergic purpura. Pityriasis rosea, Dermatitis herpetiformis, erythema nodosum, erythema multiforme, lupus erythematosus, a bruise, actinic keratoses, keloid, lipoma, a sebaceous cyst, a skin tag, xanthelasma, basal cell carcinoma, squamous cell carcinoma, or Kaposi's sarcoma. In certain aspects, the disease or pathological state is other than melanoma.

The change in expression levels of at least one nucleic acid molecule can be an increase or decrease in expression. Furthermore, depending on the particular nucleic acid and the particular disease or pathological state, an increase or decrease can indicate a response to treatment, or a lack of response. For example, the nucleic acid can encode a protein such as CD2, TNFI, or IFNγ, and a decrease in expression at the second time point as compared to the first time point is indicative of positive response to treatment for psoriasis. As another example, the method can detect a decrease in expression of TNFI, IFNγ, IL-12B, NPF, or IL-23B, wherein a decrease in expression is indicative of response to treatment for psoriasis. As another example, the method detects expression of a keratin 10, keratin 16, or keratin 17 gene product, wherein an increase in expression is indicative of response to treatment for dermatitis, such as irritant dermatitis.

In other aspects of this method, a population of genes are detected. For these aspects, the method can be performed using a microarray.

In another embodiment, provided herein is a method for characterizing skin of an animal subject, including applying an adhesive tape to a target area of skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules. A nucleic acid molecule whose expression is informative of a skin disease or pathological skin state is then detected in the epidermal sample. For example, expression of a gene listed in Table VII on the compact disks filed herewith can be detected in the epidermal sample to characterize the skin for an irritated state. The Appendix included herewith, includes the list of genes found on Table VII.

The method of characterizing skin has a number of applications, such as the following: (i) disease classification/subclassification; (ii) monitoring of disease severity and progression; (iii) monitoring of treatment efficacy; and (iv) prediction of most beneficial treatment regime. All of these applications, which themselves represent embodiments disclosed herein, rely on the concept of noninvasive sampling to recover information that is otherwise difficult or impractical to recover (i.e., through the use of biopsies). This information is contained in the RNA of skin cells close to the surface of the skin.

In one aspect of the method for characterizing skin, a test agent is applied to the target area before the adhesive tape is applied. Accordingly, in one embodiment, provided herein is a method for determining the effect of an agent, such as a test agent, on skin, including: contacting a target area of the skin with the agent and applying an adhesive tape to the target area of the skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules. Nucleic acid molecules are optionally isolated from the epidermal sample to determine an expression profile for the target site of the skin. The expression profile is indicative of a state of the skin, thereby providing a determination of the effect of the agent on the skin. The expression profile can be obtained using a microarray, as discussed in more detail herein.

A number of embodiments and aspects provided herein are directed at testing the effects of an agent, such as a test agent, on the skin. In these embodiments and aspects the agent can be applied until or before any visual symptoms become evident. For example, the agent can be applied for between 1 second to 12 hours to a skin site, more specifically the test agent can be applied between about 0.5 and 2 hours before it is removed and tape stripping is performed on the skin site contacted with the agent.

In certain aspects, after exposure to a test agent, a test site is interrogated by tape stripping and a molecular profile generated to classify an agent. For example, the agent can be classified as highly irritating or corrosive without damage to the skin. Furthermore, the agent can be classified as a specific type of irritant, for example a detergent or a dye.

The tape stripping according to these aspects of the invention is performed to obtain an epidermal as disclosed in more detail herein. For example, to obtain the epidermal sample, an adhesive tape can be applied and removed from the skin about one to ten times, as discussed in more detail herein.

Methods performed herein for determining the effects of a test agent on skin can be performed as part of a process testing the safety and/or efficacy of the test agent. For example, the testing can be part of testing performed as part of the approval process for marketing the test agent. As part of methods that analyze the effects of an agent, the agent is typically applied on the skin (i.e., topically). The agent can be formulated as a paste, an ointment, a lotion, or a shake lotion, for example. In certain aspects, the agent is a placebo.

In another aspect the invention provides a method of screening for agents or identifying agents that may cause skin disease or a pathological skin state, or which may be used to treat skin disease or a pathological skin state. In this aspect, for example, cells of the skin, such as epidermal cells, including keratinocytes and melanocytes, or dermal cells, such as fibroblasts, are contacted with a test agent. The expression of markers of the skin disease or pathological skin state is then detected.

The conditions under which contact is made are variable and will depend upon the type of agent, the type and amount of cells in the skin to be tested, the concentration of the agent in the sample to be tested, as well as the time of exposure to the agent. It will be understood that routine experimentation can be used to optimize conditions for contacting skin with the agent.

An “agent” as used herein is used broadly herein to mean any molecule to which skin is exposed. The term “test agent” or “test molecule” is used broadly herein to mean any agent that is being examined for an effect on skin in a method of the invention. For example, the agent can be a biomolecule or a small organic molecule. In illustrative examples, the agent is a peptide, polypeptide, or protein, a peptidomimetic, an oligosaccharide, a lipoprotein, a glycoprotein or glycolipid, a chemical, including, for example, a small organic molecule, which can be formulated as a drug or other pharmaceutical agent, or a nucleic acid, such as a polynucleotide.

In certain aspects, the agent is a skin care product. Skin care products are products designed to maintain healthy skin. They include astringents, moisturizers, and sunscreens. Skin care products as used herein, include personal care products, which are products that help keep skin and hair clean and fresh smelling include skin cleansers, shampoos, conditioners, and deodorants/antiperspirants. Furthermore, skin care products include cosmetics, which are skin care products designed to color and adorn a surface of the body, such as the skin. Therefore, skin care products, as used herein, includes, for example, fragrances, astringents, moisturizers, sunscreens, skin cleansers, hair care items, deodorants/antiperspirants, colored cosmetics, hair cosmetics, and nail cosmetics. Cosmeceuticals are skin care products designed to go beyond strictly coloring and adorning the skin. These products actually improve the functioning of the skin and may be helpful in preventing premature aging. Examples of these substances are alpha hydroxy acids, such as glycolic acid, beta hydroxy acid, and salicylic acid. These hydroxy acids increase skin exfoliation making aging skin appear smoother and feel softer. Some vitamins, such as vitamin A (retinal), improve the appearance of aging skin by making the skin function better.

Skin care products can cause dermatitis in some individuals. It is important to distinguish dermatitis that is the result of irritated skin from dermatitis that is caused by an allergy, because allergic contact dermatitis is a more severe condition. Presently, methods are not available for distinguishing allergic contact dermatitis from irritant contact dermatitis.

The Examples provided herein demonstrate using SLS irritation as a model system, the utility of assaying changes in IL-1+ and IL-8 mRNA has been tested as an indication of irritant skin reactions. The array generated RNA profiles between normal and 24-hour 1% SLS-occluded skin were compared, and it was observed that SLS treatment resulted in statistically significant changes in the expression levels of more than 1,700 genes. These data not only identify markers of irritated skin, but also illustrate that tape harvesting as a non-invasive method for capturing RNA from human skin for microarray analysis.

Accordingly, provided herein is a method for characterizing skin of an animal subject, including: applying an adhesive tape to a target area of skin suspected of including irritated skin in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules. A nucleic acid molecule expressed from a gene listed in Table VII, which are identical to the genes listed in the second column of the Table of the Appendix, or a combination thereof, is then detected in the epidermal sample, wherein expression of the nucleic acid molecule is altered in irritated skin, thereby characterizing skin of the subject.

In another embodiment, provided herein is a method for diagnosing a skin rash as an infection by tape stripping the rash using methods disclosed herein. Nucleic acids isolated from the site of the rash can be analyzed for the presence of nucleic acids of a microbe, wherein the presence of nucleic acids of the microbe is indicative of an infection by the microbe. The microbe can be, for example, a fungus, staphylococcus, or streptococcus.

In another embodiment, provided herein is a method for distinguishing an irritant contact dermatitis (ICD) from an allergic contact dermatitis (ACD) in a subject, including: applying an adhesive tape to an area of skin afflicted with dermatitis in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample comprises nucleic acid molecules. Then, determining expression levels of a gene associated with ICD or ACD, thereby distinguishing ICD with ACD. Before expression levels are determined ribonucleic acid RNA molecules can be optionally isolated from the epidermal sample.

In certain aspects, expression of more than one nucleic acid molecule can be detected to characterize the skin, for example to distinguish ICD from ACD. As illustrated in the examples, expression of about 1700 genes is altered in irritated versus uninvolved skin. Therefore, changes of skin state from normal to an irritated state, are accompanied by changes in at least 1700 genes. Therefore, in certain examples, methods provided herein characterize skin by analyzing expression of 2 or more, 5 or more, 10 or more, 25 or more, 50 or more, 100 or more, 500 or more, 1000 or more, 1500 or more, or all of the genes listed in Tables VII (provided on each of the compact disks in a file called “DERM1120.2 Tables.txt”) or the Table provided in the Appendix, which includes an identical list of genes as Table VII. In certain examples, expression is detected for a gene listed in Table VI, which lists 100 genes identified in the studies disclosed herein, with the most dramatic expression changes in irritated skin. For example, a detected nucleic acid can be an expression product of the IL-8 gene. In another example, the nucleic acid detected is the keratin 10, 16 and/or 17 gene, in illustrative examples the keratin 16 and/or 17 gene, wherein a down-regulation of the nucleic acid in a tape stripped skin is indicative of irritated skin.

The Examples provided herein illustrate the successful amplification of tape-harvested nucleic acids for hybridization to nucleic acid microarrays. These experiments show no significant gene expression level differences between replicate sites on a subject and minimal differences between a male and female subject.

Accordingly, in another embodiment, the present invention provides a method for identifying an expression profile indicative of a disease or pathological state of a human subject, including applying an adhesive tape to an area of skin afflicted with the disease or pathological state in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes nucleic acid molecules, and applying the nucleic acid molecules to a microarray. Nucleic acid molecules can optionally be isolated from the epidermal sample before being applied to the microarray. Expression levels of at least 10 genes is then determined using the microarray; wherein an altered expression level for at least 2, 3, 4, 5, 6, 7, 8, 9, or each of the at least 10 genes as compared with expression in an epidermal sample from a normal sample identifies skin afflicted with the disease or pathological state, thereby identifying the expression profile indicative of the disease or pathological state.

In another embodiment, provided herein is a method for identifying an expression profile indicative of a disease or pathological state of a human subject. The method includes applying an adhesive tape to an area of skin afflicted with the disease or pathological state in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape; and applying RNA molecules from the sample to a microarray to determine an expression pattern for the disease or pathological skin state sample and the unaffected sample. A difference in the expression profile is indicative of an expression profile of a disease or pathological state skin. The RNA molecules can optionally be isolated from the epidermal sample before being applied to the microarray.

In certain aspects, the disease or pathological state is dermatitis. In other aspects, the disease or pathological state is psoriasis.

In embodiments where expression of more than 1 gene is analyzed, the detection can be performed using a microarray. For example, the microarray can include an array of probes, for example, directed to 2 or more, 10 or more, 25 or more, 50 or more, 100 or more, 500 or more, 1000 or more, 1500 or more, 1700 or more, or all of the genes listed in Table VII, or the subset of genes listed in Table VI. The microarrays form another embodiment of the invention. Accordingly, in another embodiment, provided herein is a microarray that includes an array of probes, for example, directed to 2 or more, 10 or more, 25 or more, 50 or more, 100 or more, 500 or more, 1000 or more, 1500 or more, 1700 or more, or all of the genes listed in Table VII, or the subset of genes listed in Table VI.

For microarray expression analysis, approximately 0.1 to 1 milligram, typically 1 to 10 nanograms of RNA are isolated from an epidermal sample, for example obtained using a tape stripping method disclosed herein. Isolated RNA is then amplified and used for hybridization to probes on a biochip. Amplification typically results in a total of at least 1 microgram, and more typically at least 20 micrograms of amplified nucleic acid. For example, amplification can be performed using a MessageAmp™ aRNA kit (Ambion Inc.). Isolated RNA can be biotin labeled before contacting the biochip such that binding to the target array can be detected using streptavidin. The probes bind specifically to one or more of the genes listed in Tables VII and VIII, or a complement thereof.

Hybridization of amplified nucleic acids to probes on a microarray is typically performed under stringent hybridization conditions. Conditions for hybridization reactions are well known in the art and are available from microarray suppliers. For example, hybridization of a nucleic acid molecule with probes found on a microarray can be performed under moderately stringent or highly stringent physiological conditions, as are known in the art. For example, as illustrated in the Example section herein, hybridizations on a microarray can be carried out according to manufacturer's (Affymetrix) instructions. For example, hybridization can be carried out for 16 hours at 45° C. in a hybridization buffer composed of 100 mM MES, 1 M [Na+], 20 mM EDTA, 0.01% Tween 20. Washes can be carried out, for example, in a low stringency buffer ((6×SSPE, 0.01% Tween 20) at 25° C. followed by a high stringency buffer (100 mM MES, 0.1M [Na+], 0.01% Tween 20) at 50° C. Another example of progressively higher stringency conditions that can be used in the methods disclosed herein are as follows: 2×SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2×SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2×SSC/0.1% SDS at about 42° C. (moderate stringency conditions); and 0.1×SSC at about 68° C. (high stringency conditions). Washing can be carried out using only one of these conditions, for example, high stringency conditions, or each of the conditions can be used, for example, for 10 to 15 minutes each, in the order listed above, repeating any or all of the steps listed.

As illustrated in the Examples provided herein, the manufacture and use of biochips such as those involving microarrays, also known as bioarrays, are known in the art. (For reviews of Biochips and microarrays see, e.g., Kallioniemi O. P., “Biochip technologies in cancer research,” Ann Med, March; 33(2):142-7 (2001); and Rudert F., “Genomics and proteomics tools for the clinic,” Curr Opin. Mol. Ther., December; 2(6):633-42 (2000)) Furthermore, a number of biochips for expression analysis are commercially available (See e.g., microarrays available from Sigma-Genosys (The Woodlands, Tex.); Affymetrix (Santa Clara, Calif.), and Full Moon Biosystems (Sunnyvale, Calif.)).

Such microarrays can be analyzed using blotting techniques similar to those discussed below for conventional techniques of detecting polynucleotides and polypeptides, as illustrated in the Examples provided herein. Detailed protocols for hybridization conditions are available through manufacturers of microarrays. Other microfluidic devices and methods for analyzing gene expression, especially those in which more than one gene can be analyzed simultaneously and those involving high-throughput technologies, can be used for the methods of the present invention. A microarray can provide for the detection and analysis of at least 10, 20, 25, 50, 100, 200, 250, 500, 750, 1000, 2500, 5000, 7500, 10,000, 12,500, 25,000, 50,0000, or 100,000 genes.

Quantitative measurement of expression levels using bioarrays is also known in the art, and typically involve a modified version of a traditional method for measuring expression as described herein. For example, such quantitation can be performed by measuring a phosphor image of a radioactive-labeled probe binding to a spot of a microarray, using a phosphohor imager and imaging software.

Currently, primary irritation protocols are designed to detect highly irritating and corrosive materials through limited patch testing. However, some of clinical sequelae associated with these protocols can take days or weeks to manifest themselves. A testing protocol would be far superior if a substance could be applied for a shorter period of time, for example 0.5-2 hours, and removed before any visual symptoms become evident. If a test site could be interrogated by tape stripping and a molecular profile generated that could classify an agent as highly irritating or corrosive without damage to the skin, this would be an extremely useful and valuable test. Accordingly, presented herein is a method for predicting subclinical irritant skin reactions, and the rapid prediction of irritant skin reactions before the manifestation of clinical symptoms. These methods are useful to test the effects of an agent, such as a test agent on the skin.

Methods provided herein can be used to characterize the outer surface of virtually any animal. In certain aspects, the methods are used to characterize and/or otherwise analyze the outer surface of a body of a mammalian subject. For example, the methods can be used to tape strip rodents, such as mice, as well as, rabbits, or pigs. In illustrative examples, the methods are used to analyze human skin.

Certain embodiments of the invention relate specifically to psoriasis and are based in part on the discovery that nucleic acid samples, for example RNA samples, from the epidermis of the skin can be obtained from psoriatic lesions using tape stripping in psoriasis patients. Psoriasis is a chronic, genetic, noncontagious skin disorder that appears in many different forms and can affect any part of the body, including the nails and scalp. Psoriasis is categorized as mild, moderate, or severe, depending on the percentage of body surface involved and the impact on the patient's quality of life (QoL). Psoriasis may be one of several types: plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, guttate psoriasis or inverse psoriasis. As indicated herein, methods for staging provided herein, assist in determining the severity and type of psoriasis.

Although psoriasis may affect any area of the body, it is most commonly found on the scalp, elbows, knees, hands, feet, and genitals. Plaque psoriasis, the most common type of the disease, is characterized by raised, thickened patches of red skin covered with silvery-white scales. Other types of psoriasis are characterized by different signs and symptoms. For example, pustular psoriasis is characterized by pus-like blisters, erythrodermic psoriasis is characterized by intense redness and swelling of a large part of the skin surface, guttate psoriasis is characterized by small, drop-like lesions, and inverse psoriasis is characterized by smooth red lesions in the folds of the skin. Method provided herein help to distinguish between the various types of psoriasis.

Although psoriasis may be almost unnoticeable in its early stages, subjects often report an itching and/or burning sensation as the disease progresses. In particular, plaque psoriasis usually begins with small red bumps on the skin that progress to bigger, scaly patches that may become itchy and uncomfortable. As the scales accumulate, pink to deep red plaques with a white crust of silvery scales appear on the skin surface.

The lesion suspected of being a psoriatic lesion can be the result of Koebner's phenomenon. In this phenomenon psoriatic lesions appear at the site of injury, infection or other skin problem. The lesion may mark the initial onset of psoriasis, or may be a new lesion in an existing case of psoriasis. In certain examples, the site of tape stripping can be on the fingernails or toenails, which are known sites of psoriasis that can be involved in psoriatic arthritis.

A “psoriasis skin marker” is a gene whose expression level is different between skin samples at the site of a psoriatic lesion and skin samples of uninvolved skin. Therefore, expression of a psoriasis skin marker is related to, or indicative of, psoriasis. As discussed herein, all of the psoriasis skin markers illustrated herein exhibit increased expression in psoriatic lesion versus non-psoriatic skin cell. Methods provided herein, for examples methods using microarrays to perform gene expression analysis using samples obtained from tape stripped skin, can be used to identify additional psoriasis markers. The expression of these psoriasis makers can increase or decrease in psoriatic lesions.

Many statistical techniques are known in the art, which can be used to determine whether a statistically significant difference in expression is observed at a 90% or preferably a 95% confidence level. In certain examples, a greater than 4 fold increase or decrease can be used as a cut-off value for identifying a psoriasis skin marker. The Examples provided herein illustrate the identification of psoriasis skin markers. In certain examples, there is at least a four-fold difference in levels between a skin sample from a psoriatic lesion and non-lesional skin. Psoriasis skin markers identified herein include CD2, interferon K (IFNK), and tumor necrosis factor I (TNFI).

Accordingly, the present invention provides a non-invasive method for isolating or detecting a nucleic acid molecule from an epidermal sample of a psoriatic lesion of a human subject, including applying an adhesive tape to the psoriatic lesion of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape. The epidermal sample includes a nucleic acid molecule that is then isolated and/or detected.

The nucleic acid for example can encode a protein such as CD2, TNFI. or IFNγ. Expression of these genes can be analyzed in psoriatic lesions. These embodiments, are useful for monitoring response to treatment for psoriasis; for determining a treatment that is likely most effective, for genetically characterizing psoriasis; for diagnosing psoriasis; and for identifying and analyzing nucleic acids that are predictive for response to a treatment for psoriasis. Changes in expression of these genes is shown in the Examples provided herein to be associated with psoriasis. For example, expression of TNFI and CD2 are elevated in most patients with psoriasis. Furthermore, in certain patients TNFI, CD2, and IFNγ are elevated. Accordingly, in certain aspects, expression of TNFI and CD2 is analyzed. In other aspects, expression of TNFI, CD2, and IFNγ are analyzed.

Methods of the present invention which isolate and detect a nucleic acid sample from an epidermal sample of a psoriatic lesion have utility not only in detecting and staging a psoriatic lesion, but also in diagnosing, and prognosing psoriasis as well as monitoring response of a psoriatic lesion to treatment. These methods can also be used to identify a predictive skin marker to identify a lesion and/or a patient, that will respond to treatment for psoriasis.

A biologic is a molecule derived from a living organism. Biologics used to treat psoriasis typically target precise immune responses involved with psoriasis. Published data from studies suggests that pinpointing specific immune responses produces less-toxic side effects because the entire immune system is not affected and neither are organs, such as the liver and kidneys. Some biologics work by either interfering with the abnormal T cells or blocking TNF-α. Typically, biologics must be injected or infused to work.

The biologic can be, for example, alefacept or efalizumab, typically used for the treatment of adults who have moderate to severe chronic plaque psoriasis. Alefacept, which is typically given by intramuscular injection once a week for 12 weeks, targets and kills a select group of T cells that drive psoriasis.

Efalizumab, like alefacept, prevents T cells from becoming activated; and inhibits T cell trafficking. This prevents the T cells from entering the skin and causing inflammation. Efalizumab, which typically involves weekly shots, unlike other systemic medications used to treat psoriasis, provides continuous therapy and is meant for long-term use.

Etanercept™, Infliximab™ and Adalimumab™ are biologic agents that block TNF-α. In psoriasis, TNF-α is a chemical believed to be used by the immune system that signals the skin to reproduce and mature too quickly (Gribetz, C. et al. “Clearing Psoriasis: A New Era of Optimism.” Contemporary Dermatology 2003: Vol. 1, No. 1:1-8.). In certain illustrative examples, expression of a target gene believed to be involved in psoriasis is detected in a psoriatic lesion using a tape stripping method provided herein. If expression or elevated expression is detected, a treatment can be administered to the subject that blocks a function of the target gene. For example, expression of TNFI can be detected using the methods provided herein, and used to predict response to biologics which target TNFI, such as Etanercept™, Infliximab™ and Adalimumab™. For example, elevated levels of TNFI in an epidermal sample in skin can predict that a biologic that targets TNFI will be at least temporarily effective at treating psoriasis of the subject.

As illustrated herein, at least some psoriatic lesions express increased levels of TNFα. Therefore, methods herein to characterize a psoriatic lesion can be used to confirm that psoriatic lesions are expression TNFα before a subject is treated with a biologic such as Etanercept™, Infliximab™ and Adalimumab that block TNFα. Furthermore, as illustrated herein, IFNK is not overexpressed in the psoriatic lesions of some patients. Accordingly, in certain methods provided herein are used to characterize a psoriatic lesion for expression of IFNK in order to determine whether the subject is likely to respond to treatment with a biologic that targets abnormal T-cells. It is known that IFNK is expressed in T-cells.

TABLE VIII AAD Consensus Statement on Psoriasis Therapy (Callen, JP et. al. AAD Consensus statement on psoriasis therapies. J Amer Acad Dermatol 2003: 49: 897-899). Topicals Phototherapy Systemic Plaque Psoriasis Corticosteroids UVB (with or w/o Methotrexate (many topicals and with or Cyclosporin types/strengths) w/o oral retinoids) Retinoids Tazarotene Photochemotherapy (acitretin, Calcipotriene (with or w/o oral tazarotene*) Anthralin retinoids) Etanercept* Tar preparations Alefacept Keratolytic agents Efalizumab (salicylic acid, Infliximab* lactic acid, urea) (Therapies may be combined Lubrication or used products with topicals.) (Therapies may be combined or used in sequence shown.) Pustular Phototherapy Retinoids: (acitretin, isotretinoin*) Methotrexate Cyclosporine Immunobio-logics (sometimes called “biologics”) (Therapies may be combined.) Guttae Topical therapies Phototherapy (with or Systemic w/o tar) therapies Photochemotherapy as needed Erythrodermic Cyclosporine Methotrexate Retinoids (with or w/o phototherapy or photochemotherapy (Therapies may be combined.) *Not yet approved by the U.S. Food and Drug Administration (FDA) for psoriasis.

Certain embodiments of the present invention are based in part on the discovery that tape stripping psoriatic lesions can be used to monitor response of a subject to treatment for a skin disorder. For example, tape stripping can be used to monitor the response of one or more psoriatic lesions, to treatment. The tape stripping methods can be used to obtain a skin sample at a time point that is before a clinical change in a psoriatic lesion is observed or before a change in the severity of psoriasis is observable. Therefore, the tape stripping methods can be used to obtain information regarding whether a psoriasis patient is responding to treatment before current methods can detect a response to treatment, or lack thereof.

The type and severity of psoriasis are usually measured visually. For example the severity of psoriasis can be measured using the National Psoriasis Grading Score (NPGS), which uses a variety of observable factors, including redness, type of lesions, and amount of skin are affected by redness. Methods provided herein provide an indication of severity and the type of psoriasis based on expression levels of genes associated with psoriasis. These methods can be used to detect a change in psoriasis severity before these changes are observed visually, such as using the NPGS. In certain aspects, the methods of the present invention are used in combination with a visual method, to determine response to treatment.

In another embodiment, provided herein is a method for characterizing psoriasis in a subject including: analyzing expression of one or more nucleic acid molecules from an epidermal sample of a psoriatic lesion of a subject. For this embodiment, typically the subject is a human subject In certain aspects, at least one of the nucleic acid molecules analyzed is a nucleic acid whose level of expression can effect choice of treatment, such as TNFI, CD2 and/or IFNK. Furthermore, it is illustrated herein that the tape stripping method can be successfully employed in expression analysis using microarrays. Accordingly, microarray analysis can be used to identify additional genes whose expression level is different in psoriatic lesions of different patients, and whose expression level provides useful information regarding the type of psoriatic lesion, treatment choices, disease progression before clinical signs of change in disease, or the likelihood to respond to a therapy.

In another embodiment, the present invention provides a method for diagnosing psoriasis in a human subject, including: applying an adhesive tape to a lesion suspected of being a psoriatic lesion on the skin of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample includes a target nucleic acid molecule. The target nucleic acid molecule is the detected, wherein an altered expression of the target nucleic acid molecule as compared with expression in an epidermal sample from a sample not having psoriasis is indicative of psoriasis. In certain aspects, two or more target nucleic acid molecules are detected.

In certain aspects, two or more target nucleic acid molecules that encode two or more proteins selected from CD2, TNFI, IFNγ; GAPDH, θ-actin, IL-12B, IL-23A, Krt-16, Krt-17 are detected. In certain aspects, GAPDH and θ-actin are used as controls, for example in −C_(t) calculations. In certain aspects a biopsy is taken at the site of the skin, and a nucleic acid sample is obtained from the biopsy. For example, in the biopsied sample expression of a target nucleic acid molecule encoding a protein selected from TNFI, CD2, IFNγ, IL-12B, IL-23A, Krt-16, or Krt-17, is detected. Expression of all of these genes is known to be elevated in biopsied samples.

In the methods provided herein, tape stripping can be performed in a clinical setting by a first party that can send the tape strips to a second party for nucleic acid detection. Nucleic acid isolation can be performed by either the first party or the second party. For example, tape stripping can be performed in a physicians office by a nurse who sends the tape strips to a second party, such as an outside company who performs nucleic acid isolation and detection. Alternatively, nucleic acid isolation can be performed in the physicians office, who can send the isolated nucleic acid sample to a second party, such as an outside service provided, to perform nucleic acid detection and expression analysis.

Where two parties are involved in performing methods discussed herein, or where the methods disclosed herein are performed within the same entity, revenue could be generated for performing the methods disclosed herein. For example, revenue can be generated for a service that performs a portion of the methods by accepting revenue in exchange for nucleic acid detection and expression analysis from tape strips. Furthermore, the service could generate an RNA profile and/or a classification of the sample as ACD versus ICD or potentially corrosive. A corrosive substance can cause severe damage to the skin (e.g., sodium hydroxide, 10% acetic acid). Therefore, provided herein is a method of generating revenue by obtaining revenue for isolating and detecting a nucleic acid in an epidermal sample obtained using tape stripping. Furthermore, revenue can be generated by selling kits, disclosed herein, that include adhesive tape for tape stripping skin, such as rubber-based, pliable adhesive tape. The kits could include RNA isolation reagents and optionally primers and probes for genes whose expression is correlated with a skin disease or pathological skin state. Furthermore the kit could include primers and probes for control genes, such as housekeeping genes. The primers and probes for control genes can be used, for example, in −C_(t) calculations. The kits could also include instructions for performing tape strippings as well as for analyzing gene expression using −C_(t) calculations.

In another embodiment, provided herein is a method wherein tape stripping is used to tape harvest skin sites in need of classification. Samples could be mailed to a laboratory of a service provider for development of an RNA profile which would indicate a classification (i.e., ACD versus ICD or corrosive potential) with greater than 95% confidence. The RNA profile could be available over an intranet or internet for viewing by a customer of the service provider. In certain embodiments, a database is provided, of RNA profiles generated from epidermal samples.

Skin samples obtained on adhesive films can be frozen before being analyzed using the methods of the present invention. Typically, this is performed by snap-freezing a sample, as illustrated in the Examples herein, using liquid nitrogen or dry ice.

One or more of the nucleic acid molecules in a sample provided herein, such as a as an epidermal sample, can be amplified before or after they are isolated and/or detected. The term “amplified” refers to the process of making multiple copies of the nucleic acid from a single nucleic acid molecule. The amplification of nucleic acid molecules can be carried out in vitro by biochemical processes known to those of skill in the art. The amplification agent can be any compound or system that will function to accomplish the synthesis of primer extension products, including enzymes. It will be recognized that various amplification methodologies can be utilized to increase the copy number of a target nucleic acid in the nucleic acid samples obtained using the methods provided herein, before and after detection. Suitable enzymes for this purpose include, for example, E. coli DNA polymerase I, Taq polymerase, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, other available DNA polymerases, T4 or T7 RNA polymerase, polymerase muteins, reverse transcriptase, ligase, and other enzymes, including heat-stable enzymes (i.e., those enzymes that perform primer extension after being subjected to temperatures sufficiently elevated to cause denaturation or those using an RNA polymerase promoter to make aRNA from a DNA template, i.e., linearly amplified aRNA).

Suitable enzymes will facilitate incorporation of nucleotides in the proper manner to form the primer extension products that are complementary to each nucleotide strand. Generally, the synthesis will be initiated at the 3′-end of each primer and proceed in the 5′-direction along the template strand, until synthesis terminates, producing molecules of different lengths. There can be amplification agents, however, that initiate synthesis at the 5′-end and proceed in the other direction, using the same process as described above. In any event, the method of the invention is not to be limited to the amplification methods described herein since it will be understood that virtually any amplification method can be used.

One method of in vitro amplification, which can be used according to this invention, is the polymerase chain reaction (PCR) described in U.S. Pat. Nos. 4,683,202 and 4,683,195. It will be understood that optimal conditions for a PCR reaction can be identified using known techniques. In one illustrative example, RNA is amplified using the MessageAmp™ aRNA kit (as disclosed in the Examples herein).

The primers for use in amplifying the polynucleotides of the invention can be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof so long as the primers are capable of hybridizing to the polynucleotides of interest. One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition. The primer must prime the synthesis of extension products in the presence of the inducing agent for amplification.

Primers used according to the method of the invention are complementary to each strand of nucleotide sequence to be amplified. The term “complementary” means that the primers must hybridize with their respective strands under conditions, which allow the agent for polymerization to function. In other words, the primers that are complementary to the flanking sequences hybridize with the flanking sequences and permit amplification of the nucleotide sequence. The 3′ terminus of the primer that is extended can have perfect base paired complementarity with the complementary flanking strand, or can hybridize to the flanking sequences under high stringency conditions.

Upon isolation and optional amplification, expression of one or more genes is analyzed. Analyzing expression includes any qualitative or quantitative method for detecting expression of a gene, many of which are known in the art. Non-limiting methods for analyzing polynucleotides and polypeptides are discussed below. The methods of analyzing expression of the present invention can utilize a biochip, or other miniature high-throughput technology, for detecting expression of two or more genes.

The method of the present invention typically involve isolation of RNA, including messenger RNA (mRNA), from a skin sample. The RNA may be single stranded or double stranded. Enzymes and conditions optimal for reverse transcribing the template to DNA well known in the art can be used. Alternatively, the RNA can be amplified to form amplified RNA. The RNA can be subjected to RNAse protection assays. A DNA-RNA hybrid that contains one strand of each can also be used. A mixture of polynucleotides can also be employed, or the polynucleotides produced in a previous amplification reaction, using the same or different primers can be so used. In certain examples, a nucleic acid to be analyzed is amplified after it is isolated. It is not necessary that the sequence to be amplified be present initially in a pure form; it may be a minor fraction of a complex mixture.

In addition, RNAse protection assays can be used if RNA is the polynucleotide to be detected in the method. In this procedure, a labeled antisense RNA probe is hybridized to the complementary polynucleotide in the sample. The remaining unhybridized single-stranded probe is degraded by ribonuclease treatment. The hybridized, double stranded probe is protected from RNAse digestion. After an appropriate time, the products of the digestion reaction are collected and analyzed on a gel (see for example Ausubel et al., Current Protocols in Molecular Biology, section 4.7.1 (1987)). As used herein, “RNA probe” refers to a ribonucleotide capable of hybridizing to RNA in a sample of interest. Those skilled in the art will be able to identify and modify the RNAse protection assay specific to the polynucleotide to be measured, for example, probe specificity can be altered, hybridization temperatures, quantity of nucleic acid, etc. Additionally, a number of commercial kits are available, for example, RiboQuant™ Multi-Probe RNAse Protection Assay System (Pharmingen, Inc., San Diego, Calif.).

In another embodiment, a nucleic acid in the sample may be analyzed by a blotting procedure, typically a Northern blot procedure. For blotting procedures polynucleotides are separated on a gel and then probed with a complementary polynucleotide to the sequence of interest. For example, RNA is separated on a gel transferred to nitrocellulose and probed with complementary DNA to one of the genes disclosed herein. The complementary probe may be labeled radioactively, chemically etc.

Detection of a nucleic acid can include size fractionating the nucleic acid. Methods of size fractionating nucleic acids are well known to those of skill in the art, such as by gel electrophoresis, including polyacrylamide gel electrophoresis (PAGE). For example, the gel may be a denaturing 7 M or 8 M urea-polyacrylamide-formamide gel. Size fractionating the nucleic acid may also be accomplished by chromatographic methods known to those of skill in the art.

The detection of nucleic acids can optionally be performed by using radioactively labeled probes. Any radioactive label can be employed which provides an adequate signal. Other labels include ligands, colored dyes, and fluorescent molecules, which can serve as a specific binding pair member for a labeled ligand, and the like. The labeled preparations are used to probe for a nucleic acid by the Southern or Northern hybridization techniques, for example. Nucleotides obtained from samples are transferred to filters that bind polynucleotides. After exposure to the labeled polynucleotide probe, which will hybridize to nucleotide fragments containing target nucleic acid sequences, the binding of the radioactive probe to target nucleic acid fragments is identified by autoradiography (see Genetic Engineering, 1 ed. Robert Williamson, Academic Press (1981), pp. 72-81). The particular hybridization technique is not essential to the invention. Hybridization techniques are well known or easily ascertained by one of ordinary skill in the art. As improvements are made in hybridization techniques, they can readily be applied in the method of the invention.

Probes according to the present invention and used in a method of the present invention selectively hybridize to a target gene. In preferred embodiments, the probes are spotted on a bioarray using methods known in the art. As used herein, the term “selective hybridization” or “selectively hybridize,” refers to hybridization under moderately stringent or highly stringent conditions such that a nucleotide sequence preferentially associates with a selected nucleotide sequence over unrelated nucleotide sequences to a large enough extent to be useful in detecting expression of a skin marker. It will be recognized that some amount of non-specific hybridization is unavoidable, but is acceptable provide that hybridization to a target nucleotide sequence is sufficiently selective such that it can be distinguished over the non-specific cross-hybridization, for example, at least about 2-fold more selective, generally at least about 3-fold more selective, usually at least about 5-fold more selective, and particularly at least about 10-fold more selective, as determined, for example, by an amount of labeled oligonucleotide that binds to target nucleic acid molecule as compared to a nucleic acid molecule other than the target molecule, particularly a substantially similar (i.e., homologous) nucleic acid molecule other than the target nucleic acid molecule.

Conditions that allow for selective hybridization can be determined empirically, or can be estimated based, for example, on the relative GC:AT content of the hybridizing oligonucleotide and the sequence to which it is to hybridize, the length of the hybridizing oligonucleotide, and the number, if any, of mismatches between the oligonucleotide and sequence to which it is to hybridize (see, for example, Sambrook et al., “Molecular Cloning: A laboratory manual (Cold Spring Harbor Laboratory Press 1989)). An example of progressively higher stringency conditions is as follows: 2×SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2×SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2×SSC/0.1% SDS at about 42EC (moderate stringency conditions); and 0.1×SSC at about 68EC (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

A method for detecting one or more genes can alternatively employ the detection of a polypeptide product of one of these genes. For example, polypeptide products of one of the genes disclosed herein as associated with psoriasis or irritated skin, can be analyzed. The levels of such gene products are indicative of psoriasis or a skin irritation when compared to a normal or standard polypeptide profiles in a similar tissue. Thus, the expression pattern of a gene disclosed herein as associated with psoriasis or irritant dermatitis, will vary depending upon the presence and stage of psoriasis or irritant dermatitis respectively.

In this regard, the sample, as described herein, can be used as a source to isolate polypeptides. For example, following skin stripping, using the methods described above, cells isolated from the stratum corneum can be lysed by any number of means, and polypeptides obtained from the cells. These polypeptides can then be quantified using methods known to those of skill in the art, for example by protein microarrays, or ELISA analysis.

In another embodiment, the present invention provides a method for obtaining gene expression data from amplified nucleic acids that compensates for variability in amplification reactions. In this method, relative expression of a target nucleic acid molecule and a control nucleic acid molecule is compared to obtain relevant expression data. Accordingly, in certain embodiments provided herein, a −C_(t) value is determined in order to identify gene expression changes. This value and method, although illustrated herein with respect to tape stripped skin samples, can be used to identify differential gene expression in any tissue. It is especially useful, where it is relatively difficult to obtain sufficient RNA from a control sample.

The C_(t) values is the experimentally determined number of amplification (e.g., PCR) cycles required to achieve a threshold signal level (statistically significant increase in signal level (e.g., fluorescence) over background) for mRNA_(x) and a control mRNA (Gibson, Heid et al. 1996; Heid, Stevens et al. 1996). The Ct values are typically determined using a target nucleic acid (e.g., mRNAx) primer and probe set, and a control mRNA primer and probe set. A −C_(t) value is calculated by calculating a difference in the number of amplification cycles required to reach a threshold signal level between the target nucleic acid molecule and the control nucleic acid molecule. A difference in the −C_(t) value at a target area versus another area of a subject's skin, such as a normal area, or an unaffected area, is indicative of a change in gene expression of the target nucleic acid molecule at the target area.

Using this value, altered expression is detected by comparing expression of the target nucleic acid molecule with expression of a control nucleic acid molecule. The Examples provided herein, illustrate that the ΔC_(t) value, which is normally used to calculate a ΔΔC_(t) value (and thus a calibrated fold-change), is itself useful for characterizing the physiologic state of the epidermis without reference to a calibration site. Example 2 provides the formula and related disclosure for calculating a ΔC_(t) value. It is illustrated herein, that although the art teaches using a ΔΔC_(t) value and not a ΔC_(t) value for analyzing expression data, a ΔC_(t) value is useful for this purpose, and provides the advantage that it is not necessary to obtain a nucleic acid sample from a control site, where it may be difficult to obtain sufficient nucleic acid molecules.

The potential utility of ΔC_(t) values is illustrated in Example 2, by the ΔC_(t, IL-)8 for subject 4's SLS-treated skin (tape-harvested sample; Table IV). The ΔC_(t) is −1.28, however it cannot be used to calculate a ΔΔC_(t) value (and therefore a fold-change) because insufficient RNA was recovered from the unaffected and water-occluded control sites. However, comparison of this ΔC_(t) value to the remaining subjects' average SLS ΔC_(t, IL-8) value of −0.89 and average values from tape-harvested water-occluded and uninvolved skin sites (>2.49 for normal or 1.54 for tape) is highly suggestive that the ΔC_(t) value of −1.28 is in fact indicative of irritated skin. For example, the value of −1.28 implies that, compared to the average value for the 10 subjects, subject 4's SLS-site IL-8/β-actin mRNA ratio is at least 2^(−(−1.28−2.49)) or 13.6-fold higher than the average value for uninvolved skin. A similar calculation using the average ΔC_(t, IL-8) for water-occluded samples as the calibrator suggests that the IL-8/actin mRNA ratio is 2^(−(−1.28−1.54)) or 7.1-fold elevated. These data lead to the hypothesis that establishment of a database of ΔC_(t) values for different mRNA biomarkers might be useful to identify a physiologic skin state without reference to an intrasubject control site. This utility of ΔC_(t) values is predicated upon the consistency of the PCR reaction conditions and the use of identical probes between samples. Given these prerequisites, data in the Examples herein, support the potential for ΔC_(t) values being diagnostic indicators.

Accordingly, provided herein is a method for detecting a change in gene expression, including: applying a first adhesive tape to a target area of skin and a second adhesive tape to an unaffected area of the skin, in a manner sufficient to isolate an epidermal sample adhering to the first adhesive tape and the second adhesive tape, wherein the epidermal samples comprise nucleic acid molecules; and for each of the target area sample and the normal area sample, amplifying a target nucleic acid molecule and a control nucleic acid molecule. For each of the target area sample and the normal area sample, a target nucleic acid molecule and a control nucleic acid molecule are amplified and identifying, and a −C_(t) value by calculated by calculating a difference in the number of amplification cycles required to reach a threshold signal level between the target nucleic acid molecule and a control nucleic acid molecule, wherein a difference in the −C_(t) value at the target area versus the normal area is indicative of a change in gene expression of the target nucleic acid molecule at the target area. The Ct values are typically determined in the same amplification experiment (e.g., using separate reaction wells on the same multi-well reaction plate) using similar reaction conditions to other reactions.

The method for detecting a change in gene expression can be used along with the other embodiments provided herein to identify changes in gene expression. For example, the method can be used to diagnose a skin disease or pathological skin state. In certain aspects, the method can be used to detect a change in expression for any of the genes listed in Table VII, to assist in a characterization of a skin area as involving irritant contact dermatitis.

Accordingly to the tape stripping method provided herein, a first population of adhesive tapes can be applied to the target region, and a second population of adhesive tapes can be applied to a normal area of skin or an unaffected area of skin. For example, four separate tape strips can be applied to the target area of the skin and nucleic acids on the tape strips can be amplified together in a first reaction vessel. A different four separate tape strips can be applied to a normal area of the skin and nucleic acids on these tape strips can be amplified together in a second reaction vessel. In the first vessel and the second vessel, both the control nucleic acid and the target nucleic acid are can be amplified.

The target area for this embodiment, is typically an area of skin suspected containing diseased skin or skin in a pathological state. For example, the target area can include a psoriatic lesion or a region of skin with the characteristics of dermatitis.

In certain examples, the control nucleic acid molecule is expressed from a housekeeping gene. For example, the control nucleic aid molecule can encode β-actin, GAPDH, 18S rRNA, 28S rRNA, or tubulin. The adhesive tape is typically applied one to ten times, or between one and ten identical adhesive tapes are applied, as discussed herein related to the tape stripping method provided herein. Furthermore, a method according to this embodiment can utilize a microarray to detect a population of target nucleic acid molecules.

In another embodiment, the present invention provides a method for sampling an epidermal layer other than skin, using the tape stripping method provided herein. For example, the tape stripping method can be used to obtain a nucleic acid sample from an epidermal layer of the mouth, throat, or nose, or of an organ such as the liver, pancreas, kidney, intestines, stomach, bladder, brain, heart, or lungs, etc. by introducing a tape strip into a subject and applying it to a surface of the organ. The organ can be sampled within a body of the subject or after the organ is removed from the subject. Furthermore, the tape stripping method can be used to sample cells grown in vitro or organs reconstructed in vitro, for example for organ transplantation.

In another embodiment the invention provides a kit for isolation and detection of a nucleic acid from an epidermal sample, such as an epidermal sample from a psoriatic lesion or a target area of skin suspected of being inflamed. The kit can include an adhesive tape for performing methods provided herein. Accordingly, in one embodiment, provided herein is a kit, including a pliable adhesive tape made up at least in part, of a non-polar polymer. In certain aspects, the tape includes a rubber adhesive. In an illustrative example, the tape can be skin harvesting tape available (Product No 90068) from Adhesives Research, Inc (Glen Rock, Pa.).

In addition to adhesive tape, the kit typically includes one or more detection reagents, for example probes and/or primers for amplification of, or hybridization to, a target nucleic acid sequence whose expression is related to a skin disease or pathological state. The probes or primers can be labeled with an enzymatic, florescent, or radionuclide label. For example, the probe can bind to a target nucleic acid molecule encoding a protein selected from CD2, TNFI. IFNγ; GAPDH, or Krt-16. Alternatively, the probe can be, for example, an antibody that binds the encoded protein. The probes can be spotted on a microarray which is provided in the kit.

The term “detectably labeled deoxyribonucleotide” refers to a deoxyribonucleotide that is associated with a detectable label for detecting the deoxyribonucleotide. For example, the detectable label may be a radiolabeled nucleotide or a small molecule covalently bound to the nucleotide where the small molecule is recognized by a well-characterized large molecule. Examples of these small molecules are biotin, which is bound by avidin, and thyroxin, which is bound by anti-thyroxin antibody. Other labels are known to those of ordinary skill in the art, including enzymatic, fluorescent compounds, chemiluminescent compounds, phosphorescent compounds, and bioluminescent compounds.

The kit can include one or more primer pairs, including a forward primer that selectively binds upstream of a gene whose expression is associated with psoriasis or irritant dermatitis, for example, on one strand, and a reverse primer, that selectively binds upstream of a gene involved in psoriasis or irritant dermatitis on a complementary strand. Primer pairs according to this aspect of the invention are typically useful for amplifying a polynucleotide that corresponds to a skin marker gene associated with psoriasis or contact dermatitis using amplification methods described herein.

A kit provided herein can also include a carrier means being compartmentalized to receive in close confinement one or more containers such as vials, tubes, and the like, each of the containers comprising one of the separate elements to be used in a method provided herein. If present, a second container may include, for example, a lysis buffer. The kit can alternatively include a computer-type chip on which the lysis of the cell will be achieved by means of an electric current.

Accordingly, kits provided herein can include an adhesive tape for tape stripping skin, such as rubber-based, pliable adhesive tape. The kits could include RNA isolation reagents and optionally primers and probes for genes whose expression is correlated with a skin disease or pathological skin state. Furthermore the kit could include primers and probes for control genes, such as housekeeping genes. The primers and probes for control genes can be used, for example, in −C_(t) calculations. The kits could also include instructions for performing tape strippings as well as for analyzing gene expression using −C_(t) calculations.

The present invention is not to be limited in scope by the specific examples provided for below, which are intended as single illustrations of individual aspects of the invention and functionally equivalent methods and components are within the scope of the invention.

Example 1 Identification of Superior Tape Characteristics for Isolating Nucleic Acid Acids from Skin Samples

The objective of this experiment was to compare adhesive films of differing rigidity for the ability to remove epidermis and associated total RNA from of surface of the skin.

The experimental protocol described here is designed to test the hypothesis that rigid tapes will remove more epidermis (and hence recover more RNA) than an equivalent adhesive on a less rigid support.

TABLE 5 Product codes for adhesive tape test samples. Product Property Code Description Measured 413-201-1 3.0 mil clear PET (polyester film)/413- Stiff backing 166-A (approx. 2.9 mil/2.0 mil ARMS) Adhesive identical to sample 413-92-1 413-92-1 3.0 mil PU (polyurethane film)/413-92-A Flexible backing (approx. 2.9 mil/2.0 mil ARMS release liner)

Procedure:

Two main sites on the upper back with minimal hair were chosen for the tape stripping. Each site was about 40 mm×40 mm in size so as to allow three non-overlapping areas or “sub-sites” within the main site to be tape stripped. The main sites were in a similar anatomical location for all subjects. The main sites were cleansed with an alcohol pad and allowed to air dry 5 minutes. A test tape (obtained from Adhesive Research, Glen Rock, Pa.) was applied with pressure to one sub-site and removed. This procedure was repeated 3 additional times (4 total tape strips), each time with a fresh tape, to the same sub-site. A total of three sub-sites were tape-stripped. On each subject, one main site was tape stripped at the 3 sub-sites with tape 413-201-1; the other main site was tape stripped at the 3 sub-sites with tape 413-92-1. RNA was extracted from the tapes as described in Example 2 using a Qiagen RNeasy™ kit and quantified by quantitative RT-PCR using the standard curve method with total human spleen RNA as the standard.

Results and Discussion:

Table 6 shows the average mass of RNA recovered per site for each subject. The data in Table 6 clearly shows that the adhesive with the flexible (i.e., pliable) backing (92-1) is superior in the average amount of RNA recovered per site. Tape 92-1 collected on the average 6.1-fold more RNA than did tape 201-1.

TABLE 6 The average mass of total RNA recovered per site per subject using one adhesive formulation on two different backings Average mass recovered per site¹ Mass ratio Subject Tape 201-1 Tape 92-1 92-1/201-1 1 0.86 6.09 7.09 2 1.23 4.48 3.64 3 0.37 2.95 7.97 4 0.50 4.64 9.31 5 2.02 48.30 23.85 6 8.52 16.00 1.88 Average per site 2.25 13.74 6.11 across subjects (±1.27) (±7.17) (±SEM) ¹The average mass of total RNA in nanograms recovered per sub-site for each tape, in 6 subjects. RNA was quantitated using quantitative RT-PCR by the standard curve method.

From the data in Table 6 it is concluded that the synthetic rubber adhesive on a pliable polyurethane film is superior for the purposes of RNA recovery than the same adhesive on a stiff polyethylene film backing.

Next, a synthetic rubber adhesive formulation was compared to an acrylic adhesive formulation for the ability to retrieve RNA from epidermal cells recovered from the surface of uninvolved skin and water-occluded skin by tape stripping.

TABLE 7 Descriptions of adhesive tape films used in this protocol. Adhesive ID Description 413-92-1 3.0 mil polyurethane film; 413-92-A (approx. 2.9 mil/2.0 mil ARMS release liner); rubber-based adhesive (Product 90068) 413-92-3 3.0 mil polyurethane film; 413-92-C (approx. 2.8 mil/2.0 mil ARMS release liner); acrylic-based adhesive

Site Selection and Harvesting Procedure:

The back was chosen as the site for this protocol. Sites were cleansed with alcohol and allowed to air dry before applying the water soaked patch. The water patches contained 0.25 ml of distilled, sterile water. Patches remained attached for 24-hours.

Subjects returned to the clinic 24-hours later for patch removal. Once the patches were removed, the patched sites were not cleansed, but simply allowed to air dry for 15 minutes; the uninvolved skin site was cleansed with an alcohol patch and allowed to air dry for 5 minutes. After air-drying, and visual grading, 3 water and 3 adjacent uninvolved skin sites were tape-stripped with tape 413-92-1 four times each (4 new tapes per site). The remaining 3 water and 3 uninvolved skin sites were similarly harvested with tape 413-92-3.

Results and Discussion:

In this experiment two different adhesive formulations were tested for the ability to recover RNA by tape harvesting the surface of the skin.

TABLE 8 Average mass of total RNA recovered per site from normal and water treated skin in 7 subjects. Average RNA Yield by Tape and Skin Treatment Tape 92-1 (rubber) Tape 92-3 (acrylic) Uninvolved Water Uninvolved Water Subject skin¹ Occluded¹ skin¹ Occluded¹ 1 3.6 0.77 0.076 0.16 2 62 14.9 ND ND 3 6.3 3.2 0.069 ND 4 0.54 0.14 ND ND 5 12.1 8.5 0.026*  0.78* 6 5.9 10 0.50* ND 7 1.2 2.1 1.06 1.11 Subject average ± 13.1 ± 8.3 5.7 ± 2.1 0.35 ± 0.2 0.68 ± 0.28 SEM ¹The average mass of total RNA recovered per site is shown in nanograms; unless otherwise noted, each value is the average of 3 sub-sites; ND indicates that no RNA was detected; *indicates that the value is an average of less than 3 sites because RNA was not detected at all sites

Table 8 clearly reveals that tape 92-1 is superior at recovering RNA from normal and water-occluded skin. In conclusion, a prototype rubber adhesive film (Product 90068) (Adhesive Research, Inc., Glen Rock, Pa.) was tested against an acrylic adhesive for the ability to recover RNA from the surface of the skin. The results conclusively demonstrate that the prototype rubber-based film is better than the acrylic film at recovering RNA from normal and water-occluded skin sites.

Example 2 The Use of RT-PCR and DNA Microarrays to Characterize RNA Recovered by Non-Invasive Tape-Harvesting of Normal and Inflamed Skin

This example illustrates a non-invasive approach for recovering messenger RNA from the surface of skin via a simple tape stripping procedure that permits a direct quantitative and qualitative assessment of pathologic and physiologic biomarkers. Tape harvested RNA is shown to be comparable in quality and utility to RNA recovered by biopsy. Using SLS irritation as a model system, the utility of assaying changes in IL-1β and IL-8 mRNA has been tested as an indication of irritant skin reactions and show that both sampling methods allow the recovery of RNA, the analysis of which reveals cutaneous irritation. Data is presented that biopsy and tape-harvested RNA are likely derived from different cell populations and that tape harvesting is an efficient method for sampling the epidermis and identifying select differentially regulated epidermal biomarkers. The successful amplification of tape-harvested RNA is reported, for hybridization to DNA microarrays. These experiments showed no significant gene expression level differences between replicate sites on a subject and minimal differences between a male and female subject. The array generated RNA profiles was also compared between normal and 24-hour 1% SLS-occluded skin and observed that SLS treatment resulted in statistically significant changes in the expression levels of more than 1,700 genes. These data establish the utility of tape harvesting as a non-invasive method for capturing RNA from human skin.

Contact dermatitis, a common skin reaction, involves several signaling pathways. Irritant contact dermatitis (ICD) predominantly involves keratinocyte activation (Freedberg, Tomic-Canic et al. 2001), whereas Langerhans cell presentation of antigen to T-cells in draining lymph nodes and recognition of the offending allergen in skin by memory T-cells control the initiation and expression of allergic contact dermatitis (ACD; (Feghali and Wright 1997)). Clinically, both contact dermatitides are characterized by pruritus, erythema and edema. This commonality of the clinical signs and symptoms makes distinguishing between ICD and ACD difficult at the clinical level, particularly when symptoms are subtle. By contrast, at the molecular level, ICD and ACD are believed to be characterized by unique mRNA patterns, although the published literature is conflicting (Hoefakker, Caubo et al. 1995; Flier, Boorsma et al. 1999; Morhenn, Chang et al. 1999; Ryan and Gerberick 1999; Ulfgren, Klareskog et al. 2000; Cumberbatch, Dearman et al. 2002). Documentation of simple and complex mRNA profiles is possible using reverse transcriptase polymerase chain reaction (RT-PCR) and DNA microarray technologies. Using the technique of tape stripping, RNA can be harvested from both normal and inflamed skin and by combining tape stripping and RNA profiling, it may be possible to non-invasively establish a diagnosis of ICD or ACD.

The study disclosed in this Example demonstrates that sufficient RNA can be recovered using sequential application of as few as 4 small tapes to a skin site. In order to document the use of tape harvesting as an accurate and reliable sampling method we performed a clinical trial in which occlusive patches containing either 1% SLS (irritant) or water (vehicle control) were applied to the mid-back of ten subjects for 24 hours. The sites were then clinically assessed and, along with normal control skin, surface cells were harvested with four applications of individual tapes and by shave biopsy. RNA was extracted from the tapes and biopsies and assayed semi-quantitatively for 1′-1β, IL-8, GAPDH and β-actin mRNA using fluorescent, quantitative RT-PCR. The results showed consistent increases in IL-1β and IL-8 mRNA in inflamed skin relative to untreated skin. Furthermore, experiments disclosed in this Example illustrate the successful use of tape-harvested RNA to profile normal and experimentally inflamed skin using DNA microarrays. This profile of SLS-irritated skin is an important step in the definition of RNA profiles designed to differentiate irritant from allergic skin reactions.

Materials and Methods

Clinical Protocols:

The study protocols were reviewed and approved by an independent IRB (BioMed IRB, San Diego) and all subjects signed informed consent. Ten healthy women, ages 21-55 were enrolled in the study. Regions of unblemished, normal appearing skin on the mid back were chosen for the application of 2 occlusive patches in the form of bandages approximately 4 cm×6.5 cm. The bandages were made using a clear, non-porous plastic hypoallergenic adhesive tape. In the center of this tape was a Webril (non-woven cotton) patch measuring approximately 2 cm×4.5 cm. One Webril patch contained 0.6 ml of 1% aqueous sodium lauryl sulfate and the other contained 0.6 ml of sterile water as the vehicle control. Patches were arranged such that the SLS patch was superior and directly adjacent to the water patch; the area of normal control skin was inferior to and adjacent to the water patch. At 24 hours post application, the SLS and water patches were removed and the skin allowed to air dry for 15 minutes before scoring. The sites were scored by a trained technician using the scale provided below. Patched sites were large enough that two areas could be tape harvested without overlap and room left for a shave biopsy (˜2×2 mm). Skin sites were tape stripped with 4 tapes each and then a shave biopsy taken under local anesthetic (lidocaine HCl 1% and epinephrine 1:100,000; Abbott Laboratories). The tapes were applied to the skin using 20 seconds of firm pressure with a circular motion. The tape used for tape stripping was a synthetic rubber-based adhesive on a polyurethane film (Product No. 90068, Adhesive Research, Glen Rock, Pa.). An area of uninvolved skin was tape harvested and shave biopsied in an identical manner. Tapes were stored in individual eppendorf tubes at −80 until extraction; biopsy samples were placed in buffer RLT and stored at −80 until extraction. Skin responses to each patch application were examined and graded under light supplied by a 100-watt incandescent blue bulb. The following grading scale was used: 0, no visible reaction; 1, slight, pink, patchy erythema; 2, mild confluent, pink erythema; 3, moderate erythema (definite redness) with edema; 4, strong erythema (very intense redness) with edema. In a second study, 3 subjects had 3 patches containing 1% SLS and 3 water patches applied to the mid back for 24 hours. Patches were removed, scored and tape stripped as above. In a third study, two individuals were tape stripped on uninvolved skin on the upper back at three adjacent sites as above. RNA harvested in these last two studies was used in the DNA microarray experiments described below.

Materials and Reagents:

Adhesive tape was purchased from Adhesives Research, Inc. (Product No. 90068) (Glen Rock, Pa.) in bulk rolls. These rolls were custom fabricated into small circular discs, 17 millimeters in diameter, by Diagnostic Laminations Engineering (Oceanside, Calif.). Total spleen RNA was purchased from Ambion. “RNeasy” RNA extraction kit and Sensiscript Reverse Transcriptase kit were purchased from Qiagen (Valencia, Calif.). PCR primers and probes (TaqMan™ Pre-Developed Assay Reagents) and TaqMan Universal Master Mix, which included all buffers and enzymes necessary for the amplification and fluorescent detection of specific cDNAs, were purchased from Applied Biosystems (Foster City, Calif.). Total mRNA was amplified using the MessageAmp aRNA kit purchased from Ambion Inc. (Austin, Tex.). Human Genome U133A DNA chips were purchased from Affymetrix Inc. (Santa Clara, Calif.).

Isolation of RNA:

The RNA within skin cells adherent to the 4 tapes used to harvest a site was pooled by simultaneously extracting the tapes in a volume of buffer RLT (supplied with RNeasy kit). Extraction was performed using the manufacturer's directions and included a Proteinase K digestion, sonication of tapes and “on-column” DNase I digestion. RNA was eluted in 100 microliters of sterile, RNase free water. Extraction of biopsies was performed with the same kit according to the manufacturer's instructions.

Quantitative RT-PCR:

10 μl of RNA was reverse transcribed (RT) into cDNA with the Sensiscript Reverse Transcriptase kit and random hexamers in a final volume of 20 μl according to the manufacturer's directions. The reaction was diluted 5-fold with sterile, nuclease-free water (Ambion) for use in the subsequent amplification/detection reaction. For each specific mRNA detection, 3 replicate RT⁺ reactions and one RT⁻ (no reverse transcriptase; negative control) reaction were performed. Two amplification/detection reactions were done on each RT⁺ reaction to yield a total of 6 independent determinations of the threshold value (C_(t); discussed below). All RT⁻ reactions were amplified using 2 replicates and were negative (data not shown).

Quantitation of RNA Mass Recovered with Adhesive Tape and Biopsy:

The amount of RNA recovered by tape is too small (in most samples) to detect by UV. We have also found that contaminants in the adhesive co-purify with the RNA and interfere with UV and fluorometric detection. We therefore estimated the RNA mass recovered from tapes by using quantitative RT-PCR with reference to a standard curve (C_(t, actin) vs. log[RNA]; (AppliedBiosystems 2001)) created from commercially purchased human spleen total RNA. Spleen RNA was treated with DNase I and purified with the Qiagen RNeasy kit following the manufacturer's instructions. Purified standard RNA was quantified spectroscopically using O.D. 260. The standard curve was constructed using 4 concentrations of RNA from 0.01 to 1 μgm/ml. Each RNA standard was reverse transcribed in triplicate and each RT reaction amplified once to yield 3 replicates per standard concentration. Amplification and detection of unknowns was accomplished as described below using β-actin mRNA as the quantified marker. Experimental samples were reverse transcribed in triplicate and each RT reaction amplified in duplicate to yield a total of 6 replicates. The average of these 6 replicates was used to calculate the concentration of RNA in the unknown with reference to the standard curve. Total RNA yields for all samples are reported in Table I. The accuracy of this method relies on the relative amount of β-actin mRNA to total RNA in the epidermis being similar to that in human spleen. If the relative amount of β-actin mRNA to total RNA is different between the two tissues then our mass data will be similarly affected. Therefore, we describe all tape-harvested RNA mass calculations as estimates to reflect this uncertainty. RNA recovered from biopsies was quantified fluorometrically with the RiboGreen RNA Quantitation Reagent (Molecular Probes, Eugene, Oreg.).

Amplification and Detection of Specific mRNA:

Specific mRNAs were converted to cDNA as described above. Specific cDNAs were semi-quantified using gene specific primer/probes (5′-nuclease assay) and fluorescence detection. Amplification and detection assays were performed using TaqMan Pre-Developed Assay Reagents (PDAR; Applied Biosystems) on an Applied Biosystems 7000 Sequence Detection System. β-actin, IL-1β and IL-8 mRNA assays were performed in the same tube (multiplex assay); these multiplex results were confirmed in repeat assays in single tube format (separate tube determination of β-actin and the mRNA of interest; data not shown) using 6 replicates; GAPDH mRNA assays were done in singleplex format. Thermal cycling conditions were: prior to cycling, two minutes at 50° C., then ten minutes at 95° C.; then 40 cycles at 95° C. for 15 seconds and 60° C. for 60 seconds. Threshold detection was set at 0.2 for all assays.

Semi-Quantitation of mRNA Using the ΔΔC_(t) Method:

In this Example, the comparative or ΔΔC_(t) method of calculating relative gene expression levels between two samples, was used. In the ΔΔC_(t) method the levels of IL-1β, IL-8 and GAPDH mRNAs are assayed semi-quantitatively by normalization to β-actin mRNA to create a ratio of (mRNA_(x))/(β-actin) mRNA for each RNA sample. This ratio is then further normalized to a control sample (a process called “calibration”; (AppliedBiosystems 2001)). When comparing the ratio of mRNA, to β-actin mRNA between two different samples, it is implicitly assumed that the level of β-actin mRNA to total RNA is constant between the two samples (i.e., it is an unchanging housekeeping gene). In the comparative method, the relative fold-increase of the mRNA of interest (“mRNA_(x)”) between 2 samples is given by the equation:

$\frac{\left( \frac{{mRNA}_{x}}{{mRNA}_{actin}} \right)_{Exp}}{\left( \frac{{mRNA}_{x}}{{mRNA}_{actin}} \right)_{Cal}} = 2^{{- {\Delta\Delta}}\; C_{t}}$

where “Exp” indicates the experimental sample (in this case SLS or water samples); “Cal” indicates the calibrator sample (uninvolved skin); and ΔΔC_(t, x)=[ΔC_(t, Exp)−ΔC_(t, Cal)]_(x); where ΔC_(t, Exp) and ΔC_(t, Cal) are calculated as (mean C_(t, RNAx))−(mean C_(t, actin)) for the respective samples. The C_(t) values are the experimentally determined number of PCR cycles required to achieve a threshold fluorescence (statistically significant increase in fluorescence over background) for mRNA_(x) and β-actin mRNA (Gibson, Heid et al. 1996; Heid, Stevens et al. 1996).

Calculation of Fold-Increase and Data Analysis:

Key to the method used to measure mRNA is the fact that the quantity of specific mRNA directly correlates with the number of cycles needed to reach threshold fluorescence, thus the fewer the number of cycles (the lower the C_(t)), the more mRNA is initially present. As described above, experimental data is reported as the number of cycles (C_(t)) required to reach a threshold fluorescence. Each reported C_(t) is the mean of 6 replicate measurements. Calibrated fold-change calculations are made using the equations above. A mRNA_(x)/β-actin mRNA ratio was considered to have a significant (with >95% confidence interval) fold-increase relative to its calibrator if the range of fold-change given by 2^(−(ΔΔCt±2 SEM)) did not include the value of 1, which is the defined value of the calibrator because the ΔΔC_(t) for the calibrator is equal to 0. The significance of ΔC_(t) values (Tables I and IV) was determined by applying a two-sided, paired t-test.

It is our experience that the practical limit of detection for real time PCR is 37 cycles. When the threshold number of PCR cycles (C_(t)) extends beyond 37, these values become highly variable or fluorescence does not achieve a threshold value. To interpret combinations of replicate measurements of undetectable and >37, we applied the rule that if 3 or more of the 6 replicates have any combination of C_(t) values equal to or greater than 37 (edge of detection) or are undetectable (no C_(t) value recorded), that mRNA is defined as undetectable and assigned a C_(t)=37. This assignment of a threshold equal to 37 typically occurs when total RNA is low or when a message is not present (for instance IL-1β and IL-8 mRNA in uninvolved skin). The assignment of C_(t)=37 to mRNAs that are undetectable is useful because it allows a calculation of the minimum fold-change of a mRNA_(x)/actin mRNA ratio between two samples.

T7 Linear RNA Amplification:

mRNA was amplified and biotin labeled using a MessageAmp™ aRNA kit purchased from Ambion Inc. according to the manufacturer's instructions. Typical yields of aRNA obtained from two rounds of amplification ranged from 30-80 μg.

Hybridization of Biotinylated mRNA Targets to Affymetrix GeneChips, Staining, Data Acquisition and Data Analysis:

Hybridization and staining were performed according to the manufacturer's instructions. Data Aquisition: Gene expression values from Affymetrix GeneChips are based on the average difference (AD) between hybridization signals of perfect match (PM) and mismatch (MM) oligonucleotide probe sets for each gene as described in the expression analysis technical manual from Affymetrix. The AD value of each probe set is calculated as AD=Σ(PM−MM)/# probe pairs. In initial iterations, Affymetrix software removed probe pairs that were out of a given range when calculating AD values for each probe set. In this process, the mean and standard deviation were calculated for intensity differences (PM-MM) across the entire probe set (excluding the highest and lowest values), and values within a set number of standard deviations (3 as default) were not included in the calculation. The advantage was that this process minimized the variance introduced by experimental or biological error by removing the outliers present in each probe set. The disadvantage was that this process didn't always remove the same probe pairs for the calculation of the AD values among GeneChips. This led to the misinterpretation of the gene expression profiles obtained from GeneChip experiments. To alleviate this problem, a model-based method incorporated into a program called dChip was developed by Li & Wong (Li and Wong 2001). This method maintains constant probe pair set identities across all GeneChips while excluding outliers due to cross hybridization, contamination during hybridization, or manufacturing defects that affect probe set measurements. For all of the GeneChip experiments reported here, each probe pair set from the *.cel files were modeled by the dChip software prior to statistical analysis. The dChip-modeled expression measurement of each gene was normalized to the total signal of each chip. For any given measurement, a value greater than zero (indicating an expression level) or a zero (indicating an expression level lower than background) was obtained. Only those genes exhibiting an expression level greater than zero in all experiments were used for statistical analysis.

Data Analysis:

Many experimental designs and applications of gene expression profiling experiments are possible. However, no matter what the purpose of an experiment, each experiment must be replicated a sufficient number of times for statistical analysis of the data. This is basically because each gene expression profiling experiment results in the measurement of the expression levels of thousands of genes. In such a high dimension experiment, the chance for erroneous measurements for any individual gene expression level is high. Thus, in the absence of high replication many genes will show large changes in expression levels between two experimental conditions purely by chance alone, even when the experimental conditions are the same. A simple t-test evaluates the distance between the means of two groups normalized in terms of the within-group standard deviations. The result is that large differences between genotypes for any given gene will be declared non-significant if the expression level of that gene is unreplicable within experimental treatments. Conversely, small differences in expression will be determined to be statistically significant for a given gene if expression levels for that gene are replicable within treatments. In short, the t-test statistic is constructed by scaling the difference in gene expression levels between genotypes relative to the observed variances within genotypes. p-values based on the t-test statistic range from 1.0 for gene expression levels with identical values associated with the null hypothesis to very small p-values for differential gene expression levels that are highly significant. It must be noted, however, that the simple t-test does not perform well with a small number of replicates. With a limited number of replicate measurements, often in the range of two to five for DNA microarray experiments, poor estimates of means, standard deviations, and p-values are obtained.

We have shown that the confidence in the interpretation of DNA microarray data with a low number of replicates can be improved by using a Bayesian statistical approach that incorporates information of within treatment measurements (Baldi and Long 2001; Long, Mangalam et al. 2001). This results in a more consistent set of differentially expressed genes identified with fewer replicates. The Bayesian approach is based on the observation that genes of similar expression levels exhibit similar variance (Hatfield, Hung et al. 2003). Thus, more robust estimates of the variance of a gene can be derived by pooling neighboring genes with comparable expression levels. For the analysis of the data reported here we ranked the mean gene expression levels of each replicate experiment in ascending order, used a sliding window of 101 genes, and assigned the average standard deviation of the 50 genes ranked below and above each gene as the background standard deviation for that gene. The variance of any gene within any given treatment was estimated by the weighted average of the treatment-specific background variance and the treatment-specific empirical variance across experimental replicates. In the Bayesian approach employed in this study, the weight given to the within experiment gene variance estimate is a function of the number of experimental replicates. This leads to the desirable property that the Bayesian approach employing such a regularized t-test converges on the same set of differentially expressed genes as the simple t-test but with fewer replicates (Long, Mangalam et al. 2001).

While the Bayesian method provides more robust p-values, it must be kept in mind that these p-values represent the local confidence that can be placed in an individual gene measurement. They say nothing about the global probability that an individual gene is differentially expressed. This can only be evaluated if an estimate of the global false positive level of each experiment can be determined. In other words, to interpret the results of a high dimensional DNA array experiment it is necessary to determine the global false positive and negative levels inherent in the data set being analyzed. For this purpose we have implemented a mixture-model based method described by Allison et al. (Allison, Gadbury et al. 2002) for the computation of the global false positive and negative levels inherent in a DNA microarray experiment. The basic idea is to consider the p-values based on the regularized t-test described above as a new data set, and to build a probabilistic model for these new data. When control data sets are compared to one another (i.e., no differential gene expression) it is easy to see that the p-values will exhibit a uniform distribution between zero and one. In contrast, when data sets from different genotypes or treatment conditions are compared to one another (differential gene expression), a non-uniform distribution will be observed in which p-values will tend to cluster more closely to zero than one; that is, there will be a subset of differentially expressed genes with “significant” p-values. The computational method of Allison (Allison, Gadbury et al. 2002) is used to model this mixture of uniform and non-uniform distributions to determine the probability, PPDE(<p) ranging from 0 to 1, that any gene at any given p-value is differentially expressed; that is, that it is a member of the uniform (not differentially expressed) or the non-uniform (differentially expressed) distribution. With this method, we can estimate the rates of false positives and false negatives as well as true positives and true negatives at any given p-value threshold, PPDE(<p). In other words, we can obtain a posterior probability of differential expression PPDE(p) value for each gene measurement and a PPDE(<p) value at any given p-value threshold based on the experiment-wide global false positive level and the p-value exhibited by that gene. It should also be emphasized that this information allows us to infer the genome-wide number of genes that are differentially expressed; that is, the fraction of genes in the non-uniform distribution (differentially expressed) and the fraction of genes in the uniform distribution (not differentially expressed).

Commonly used software packages for microarray data analysis do not possess algorithms for implementing Bayesian statistical methods. However, our statistical program, Cyber-T (www.igb.uci.edu) does accommodate this approach as well as the PPDE analysis described above. For the experiments reported here, we used these statistical tools incorporated into Cyber-T.

Results Total RNA Yields

RNA was recovered from 27 of 30 skin sites using 4 tapes as described above. The amount of total RNA recovered was variable from site to site and subject to subject (data not shown). The average mass of RNA recovered from uninvolved skin sites was 0.92 nanograms (±0.35) with a range of 0 (2 samples) to 3.2 ng. The average mass of RNA recovered from water-occluded skin was 0.69 ng (±0.27) with a range of 0 (1 sample) to 2.7 ng. SLS inflamed skin produced the greatest average yield of RNA with an average of 185 ng (±76) and a range of 0.067 to 747 ng.

Relative Levels of Housekeeping Genes in Tape Strip Samples and Biopsies

Markers of the inflammatory process IL-1β and IL-8 mRNAs were chosen. Differential recovery of total RNA mass in a sample was accounted for by normalizing these mRNAs to an internal control, the β-actin transcript. We then calibrated the mRNA_(x)/actin ratio in SLS and water samples to that ratio in untreated skin samples. In this study, IL-1β and IL-8 mRNA are predicted to increase relative to β-actin in response to SLS treatment, while the level of housekeeping mRNAs, such as β-actin and GAPDH are predicted to remain constant. We have tested this assumption by measuring the relative ratio of two housekeeping mRNAs, GAPDH and β-actin, to determine if their ratio is indeed a constant in different skin samples.

The measure of the relative abundance of two mRNAs in a sample is given by the ΔC_(t) value, which is the difference between the experimentally determined threshold values. To investigate the possibility that ΔC_(t, GAPDH) (C_(t, GAPDH)−C_(t, actin)) may have unique values for differently treated skin samples, we determined these values for all samples. Data in Table I show that biopsy-harvested RNA samples from water and SLS-treated sites have significantly different ΔC_(t, GAPDH) values (2-sided, paired t-test; p<0.005) than biopsy-harvested uninvolved skin.

The data in Table I also demonstrate that tape-harvested RNA samples from SLS-treated sites have significantly different ΔC_(t, GAPDH) values than tape-harvested samples from water treated sites (p<0.005). A comparison of tape-harvested samples from SLS treated and uninvolved skin sites nears significance (p=0.087). Tape-harvested RNA samples from water-occluded sites do not have significantly different ΔC_(t, GAPDH) values than uninvolved skin (p=0.61).

Table I further compares the ΔC_(t, GAPDH) values between tape and biopsy harvested samples of identically treated skin sites. The data show that each sampling method produces an RNA sample with a different ΔC_(t, GAPDH), and that this difference is highly significant (p<0.005) for SLS-treated skin samples and uninvolved skin samples (p=0.014). Because biopsy and tape-harvested RNA samples have differing ΔC_(t, GAPDH) values (and therefore different GAPDH/β-actin mRNA ratios), we hypothesize that the sampling methods are recovering different cell populations.

The data in Table I can be used to calculate the fold-change in GAPDH/actin mRNA ratios relative to uninvolved skin (see Materials and Methods). The results of such calculations, shown in Table II, reveal that while there is some variation in the GAPDH/actin mRNA ratios for different samples, the average variation amongst subjects for a particular treatment is less than 2-fold. While some individual changes are greater than 2-fold, these differences are insufficient to explain the much larger fold-changes we observe for IL-1β and IL-8/actin mRNA ratios. Thus, while there are statistically significant changes in GAPDH/actin mRNA ratios due to water and SLS treatment of the skin, these differences do not explain the changes in IL-1β and IL-8/actin ratios discussed later.

IL-1β/β-actin mRNA Ratios in SLS-Irritated and Control Skin

Table III reveals the fold change of IL-1β/β-actin mRNA in water-occluded and SLS-occluded skin relative to (calibrated to) uninvolved skin, in tape and biopsy harvested RNA samples. In 9 of 10 biopsy samples of SLS-occluded skin, the IL-1β/β-actin mRNA ratio was significantly elevated. In 7 of 10 uninvolved skin biopsy samples, IL-1β mRNA was undetectable, while in the remaining 3 samples it was present at very low levels (within 3 C_(t) units of our detection limit; data not shown). In biopsy samples of water-occluded skin, IL-1β mRNA was not detectable in 2 samples and was significantly elevated in 3 samples (Table III). Thus SLS-occlusion produced the most consistent elevation of the IL-1β/actin mRNA ratio but water-occlusion could effect a similar albeit smaller response. When the effect of water-occlusion is taken into effect by calibration of the SLS sample to the water-treated site, we find that 7 SLS-treated samples have significant increases in the IL-1β/actin mRNA ratio (data from Table III; calculation not shown).

Data in Table III reveal the fold change of IL-1β/β-actin mRNA in tape-harvested samples of water-occluded and SLS-occluded skin relative to uninvolved skin. Tape-harvested samples of SLS-occluded sites showed significant increases in 5 of 10 samples. These 5 samples with IL-1β increases are in qualitative agreement with the biopsy data. Analysis of the remaining 5 samples was indeterminate due to low RNA recovery. Similar to biopsy samples, tape samples of uninvolved skin did not have detectable amounts of IL-1β with one exception. Tape-harvested samples of water-occluded skin also showed undetectable amounts of IL-1β mRNA in 9 of 10 samples, while one sample with detectable IL-1β displayed a significant increase in IL-1β/actin mRNA relative to uninvolved skin.

IL-8/β-actin mRNA Ratios in SLS-Irritated and Control Skin

Table III reveals the fold increase of the IL-8/β-actin mRNA ratio in water-occluded and SLS-occluded skin compared to uninvolved skin. The data demonstrate that 8 of 10 biopsy samples of SLS-occluded skin revealed significant increases in IL-8/actin mRNA ratios. Biopsy samples from 9 of 10 untreated skin sites had undetectable IL-8 mRNA levels. The one uninvolved skin biopsy sample with detectable IL-8 mRNA was close to the level of detection. Thus IL-8 mRNA was generally not detectable in a biopsy of uninvolved skin. Similarly 5 of 10 samples from biopsies of water-occluded sites also had undetectable IL-8 mRNA. In the remaining 5 water-treated samples, 2 had significantly increased IL-8/actin mRNA ratios although these increases were small in comparison to the respective SLS-occluded sites. Thus water-occlusion did not appreciably stimulate IL-8 mRNA appearance in the epidermis of most subjects. Table III further reveals that 8 of 10 tape-harvested samples from SLS-occluded sites displayed significantly increased IL-8/β-actin mRNA ratios. Of the 2 samples without significant increases, one did not have detectable IL-8 mRNA (the sample was low in RNA and the result is inconclusive) while the second sample (Subject 4) likely had increased IL-8 message (see Discussion) but this could not be confirmed because the control tape sample failed to recover RNA. Data in Table III show that tape-harvested samples of water-treated sites reveal significant increases in IL-8/actin mRNA ratios in 3 subjects. In the remaining subjects, IL-8 could not be detected at significantly elevated levels. Thus, the tape data is in good qualitative agreement with the biopsy data with a majority of inflamed sites revealing increases in IL-8 mRNA.

Table IV reveals ΔC_(t, IL-8) values for all samples. This data supports and extends the previous observation that biopsy and tape harvested samples of equivalently treated sites may produce significantly different ΔC_(t) values. Table IV reveals that the average ΔC_(t, IL-8) value from tape-harvested, SLS-treated sites was −0.89 while the average value from biopsy harvested SLS sites was 4.13. A paired t-test between the individual ΔC_(t) values has a p<0.005. A similar comparison of ΔC_(t, IL-8) values between biopsy and tape harvested RNA samples from the water-occluded sites also shows a highly significant difference (p<0.005). These observations extend to uninvolved skin as well. Table IV shows that 4 samples of tape-harvested uninvolved skin had ΔC_(t, IL-8) values with a range of 1.51 to 4.15 while the analogous biopsy samples had a range of 8.22 to >9.7, a clear difference. The ability to consistently detect higher amounts of IL-8 mRNA in normal, water and SLS treated skin samples recovered by tape reinforces the hypothesis that tape harvesting preferentially recovers a subset of cells (probably close to the surface) poorly represented in biopsies.

DNA Microarray Analysis of RNA Extracted from Uninvolved Skin Using Tape

The success in the above analysis of tape-harvested RNA from different skin sites suggested that this RNA might be amenable to amplification and hybridization to DNA microarrays. In order to assess the reproducibility and consistency of tape-harvested RNA samples for gene expression profiling experiments, three samples were collected from the upper back of each of two healthy individuals, one male (sample C1, C2, and C3) and one female (sample A5, A6, and A9). Approximately one nanogram of total RNA was isolated and the mRNA was amplified and biotin labeled using a MessageAmp™ aRNA kit as described in Materials and Methods. The resulting biotin-labeled aRNA from each sample was used for hybridization to an Affymetrix HG-U133A GeneChip.

The results in TABLE V show the differences observed when a matrix of pair-wise gene expression comparisons between two GeneChips was performed using Affymetrix Microarray Suite software. These data show an average of only 12% variance among gene measurements, regardless of whether data from different sites on the same individual or sites from different individuals are compared. Furthermore, comparing the data in quadrant three of TABLE V (A vs. C) to the data in quadrants one (A vs. A) and four (C vs. C) shows that about 15% of this variance is due to either gender difference (A vs. C) or inter-subject variation (A vs. A or C vs. C). Thus, amazingly little variance is contributed by samples obtained from different sites or from different individuals.

To compare these data in a more quantitative manner, the three Affymetrix GeneChips each hybridized with targets from RNA samples obtained from individual A were compared to three GeneChips hybridized with targets from the three RNA samples obtained from individual C. These data were analyzed with a regularized t-test implemented in the Cyber-T statistical program. This three-by-three comparison revealed 21,790 probe sets that exhibited gene expression levels above background for all three sites from each subject. Of these genes 1,117 (5%) were differentially expressed with p-value less than 0.0035, which based on the global false positive and negative levels of this data set corresponds to a posterior probability of differential expression (PPDE) value of 0.95. Thus, 56 of the 1,117 differentially expressed genes that exceed this p-value threshold are expected to be false positives. The source of these inter-subject gene expression differences remains to be determined, however at least one of these differences is gender based. For example, the gene with the smallest p-value and the highest PPDE value is the Y-linked ribosomal protein S4 (PRS4Y). It is likely that differences that are not gender based are a reflection of normal variation of gene expression between individuals. These data are available at www.igb.uci.edu.

DNA Microarray Analysis of Normal Versus Water-Occluded and SLS-Occluded Skin

In a separate experiment, a total of nine RNA samples ranging from 1-10 nanograms were isolated by tape harvesting from three untreated, three water-occluded, and three SLS-occluded sites of each of three individuals. mRNA from each of the nine samples was amplified, biotin labeled and used for hybridization to each of nine Affymetrix HG-U133A GeneChips as shown in FIG. 1.

Untreated vs. SLS Treated Samples. A comparison of gene expression levels between three untreated (A1, B1, C1) samples and three SLS treated (A2, B2, C2) samples revealed 21,031 genes that exhibited expression levels above background for all samples. To assess the confidence in global changes in gene expression, the p-values for all gene measurements were distributed into 100 bins ranging from 0 to 1.0 and plotted against the number of genes in each bin (FIG. 2A). The β-mixture modeling methods implemented in Cyber-T were used to model these p-value distributions of the uniform (not differentially expressed) and non-uniform (differentially expressed) data sets to determine the posterior probability of differential expression, PPDE, of each gene based on global false positive and negative gene measurement levels as described by Hung et al. (Hung, Baldi et al. 2002) and Baldi and Hatfield (Baldi and Hatfield 2002). When untreated vs. SLS occluded (FIG. 2A) data are compared, the p-values for the differentially expressed genes are low and cluster toward 0. This is consistent with highly statistically significant differences among measurement levels of some genes. In fact 1,771 genes that are differentially expressed with a threshold of p=0.003, which corresponds to a PPDE(p) value equal to or greater than 0.99. These data are available in Table VII and provided on each of the compact disks in a file called “DERM1120.2 Tables.txt”.

SLS vs. Water Treated Samples.

A comparison of gene expression levels between three SLS treated (A2, B2, C2) samples and three water treated (A3, B3, C3) samples revealed 21,307 genes that exhibited expression levels above background for all samples. The p-values for all of these gene measurements were also distributed into 100 bins ranging from 0 to 1.0 and plotted against the number of genes in each bin (FIG. 2B). It is evident from an examination of the p-value distribution that, similar to the comparison with untreated cells, about twenty percent of the genes are differentially expressed. Based on a threshold of p=0.003, 1,364 genes are differentially expressed with a PPDE(p) value of 0.99. Of these, 1,063 genes are also differentially expressed with a p-value of 0.003 and a PPDE value of 0.99 when SLS and untreated samples are compared. These data are available at www.igb.uci.edu.

Untreated vs. Water Treated Samples.

A comparison of gene expression levels between three untreated (A1, B1, C1) samples and three water treated (A3, B3, C3) samples revealed 21,164 genes that exhibited expression levels above background for all samples. The p-values for all these gene measurements were again distributed into 100 bins ranging from 0 to 1.0 and plotted against the number of genes in each bin (FIG. 2C). The fact that these p-values are uniformly distributed demonstrates that, at the levels of variance inherent in these experiments, there are no statistically significant differences between the gene expression levels of these two data sets. Nevertheless, based on a review of the genes assigned the lowest p-values, many of which are associated with inflammation, we believe that the water treatment does lead to some changes in gene expression compared to untreated control skin. These data are found in Tables VII (provided in the attached Appendix) and VIII (See attached Compact Disk).

For purposes of discussion, only the 100 genes differentially expressed with p-values less than 1.4×100 and PPDE(p) values greater than 0.99 are discussed here and in TABLE VI. An examination of these top 100 genes most significantly altered when the SLS treated skin samples were compared to untreated skin samples revealed that, as expected, most of these genes carry out functions related to tissue inflammation and injury (TABLE VI). These differentially expressed genes are proteinases, protease inhibitors, cytokines, chemokines, complement components, HLA factors, or receptors involved in immune regulation. These associations with inflammation and injury responses for many of these mostly up-regulated genes are documented in the literature (TABLE VI). These results demonstrate that the tape stripping method described here harvests RNA suitable for complete gene expression profiles of the skin that accurately reflect its pathological state.

Discussion

Recent advances in molecular medicine have made the possibility of molecular diagnosis a reality (Aitman 2001; Bertucci, Houlgatte et al. 2001; Galiegue and Casellas 2002; Lacroix, Zammatteo et al. 2002; Whipple and Kuo 2002; Satagopan and Panageas 2003). Through the use of microarrays and RNA profiling it is becoming increasingly clear that simple and complex cell populations can be monitored or “profiled” with the intent of understanding the physiologic state of those cells or tissues. This information is expected to lead to more accurate and possibly predictive diagnoses. This Example illustrates that the use of 4 small tape strips is an effective and non-invasive approach to capturing messenger RNA from the surface of skin and that this technique permits a direct quantitative and qualitative assessment of pathologic and physiologic biomarkers as a function of normal physiology.

The levels of IL-1β and IL-8 mRNA have been assayed semi-quantitatively relative to β-actin in normal, water and SLS-occluded skin sites and shown that RNA from tape and biopsy samples produce qualitatively similar results. In order to account for the possibility that changes in β-actin mRNA were responsible for observed changes in the interleukin/β-actin mRNA ratios, (Suzuki, Higgins et al. 2000; Bustin 2002; Tricarico, Pinzani et al. 2002) the levels of two housekeeping genes relative to each other were quantified. The resulting data (Tables I and II) showed that while the GAPDH/β-actin mRNA ratio is different in differently treated skin samples, the magnitude of this difference is not capable of explaining the observed changes in Il-1β and IL-8 mRNA levels. This fact is most clearly demonstrated by tape-harvest and biopsy data in which IL-1β and IL-8 mRNA are virtually undetectable in control samples but easily detected in SLS-treated samples, an observation that cannot be explained by minor changes in β-actin mRNA levels. In addition, IL-1β and IL-8 mRNAs and proteins have been well characterized in inflammation and are known to become elevated in response to SLS and other treatments (Paludan and Thestrup-Pedersen 1992; Grangsjo, Leijon-Kuligowski et al. 1996; Corsini and Galli 1998; Tomic-Canic, Komine et al. 1998; Freedberg, Tomic-Canic et al. 2001; Perkins, Osterhues et al. 2001; Cumberbatch, Dearman et al. 2002; Coquette, Berna et al. 2003). Thus data provided herein, from both tape and biopsy, are consistent with published observations.

Biopsy and tape harvesting are not equivalent sampling methods and therefore should not be expected to yield identical results. Tape harvest is restricted to the skin surface and therefore may preferentially recover vellus hair follicles and cells lining sebaceous, eccrine and sweat ducts as well as corneocytes (not predicted to contain RNA). Our method of using a single application of 4 individual tapes does not result in glistening of uninvolved skin and thus does not bare the viable epidermis. In contrast, a shave biopsy is expected to include not only cells of the epidermis (primarily keratinocytes and melanocytes and immune cells) but fibroblasts from the upper dermis. The potential enrichment of surface epidermis conveyed by our circular tape compared to a shave biopsy can be appreciated by considering that the surface area of a tape is 284 mm², while the surface area of a 2×2 mm shave biopsy is 4 mm². Thus we propose that tape-harvested cells represent an enrichment of a sub-population of cells found in a shave biopsy.

The data presented in Tables I and IV support the hypothesis that tape and biopsy-harvested RNA are derived from different cell populations. Table I shows highly significant p values when comparing ΔC_(t, GAPDH) values between tape and biopsy samples of SLS and uninvolved skin samples. Table IV demonstrates that ΔC_(t, IL-8) is highly significantly different (p<0.005) between tape and biopsy samples derived from normal, water or SLS-treated skin samples. In SLS-treated skin samples, the difference in average ΔC_(t, IL-8) values implies that IL-8/β-actin mRNA ratio is 2^(−(−0.89−4.13)) or 32-fold greater in tape versus biopsy-harvested RNA samples. In water-treated samples, the IL-8/β-actin mRNA ratio is on average 2^(−(1.54−9.22)) or at least 200-fold greater in tape-harvest RNA samples (data from Table IV). Similar, supportive data was also observed for ΔC_(t, IL-1β). This data implies that some differentially expressed biomarkers may be best detected in tape rather than biopsy-harvested epidermal samples.

Identification of biomarkers diagnostic of clinical irritation has been a long sought goal (Muller-Decker, Furstenberger et al. 1994; Boelsma, Gibbs et al. 1998; Muller-Decker, Heinzelmann et al. 1998; van Ruissen, Le et al. 1998; Komine, Rao et al. 2001; Perkins, Osterhues et al. 2001; Boxman, Hensbergen et al. 2002; Perkins, Cardin et al. 2002; Coquette, Berna et al. 2003). Changes in IL-1β and IL-8 mRNA are used herein as indicators of irritation and shown that most but not all irritated sites display increased levels of these normalized mRNA markers (Table III). The data also shows that tape-harvested and biopsy recovered RNA are qualitatively equal in their ability to reveal an irritant skin reaction. With respect to biopsy samples, it is clear that neither marker is 100% efficient at diagnosing irritation, a result observed for every biomarker proposed to be diagnostic of erythema and inflammation (Grangsjo, Leijon-Kuligowski et al. 1996; Muller-Decker, Heinzelmann et al. 1998; Chung, Marshall et al. 2001; Perkins, Osterhues et al. 2001; Boxman, Hensbergen et al. 2002). The current limitation of the tape harvest assay is the inefficiency in detecting certain markers in samples with limiting amounts of RNA, a subject discussed below. However, in comparison with the Sebutape assay (immunoassay of IL-8 protein; (Perkins, Osterhues et al. 2001) for irritation, which has a sensitivity (Hoffrage, Lindsey et al. 2000) of approximately 30%, mRNA biomarkers seem to possess superior potential. The observation that water occlusion produced increases of biomarker ratios in some subjects has been reported by others (Grangsjo, Leijon-Kuligowski et al. 1996; Howie, Aldridge et al. 1996; Perkins, Osterhues et al. 2001).

Results presented herein show that the tape stripping method harvests RNA suitable for DNA microarray experiments, and that these gene expression profiles reflect the pathological state of human skin, it should be possible to identify a subset of genes whose differential expression patterns can be correlated with different pathological states with a high degree of statistical accuracy. The fact that 1,700 differentially expressed genes have been identified with high statistical confidence sets the stage for the creation of small custom DNA arrays designed to identify patterns of gene expression diagnostic of irritant skin reactions, possibly diagnostic of different irritants and predictive of irritant reactions. The next step along this path is to identify the analogous set of genes expressed during an allergic skin response, identify genes unique to the irritant or allergic response and combine them into one DNA array, which could be used to determine if a mild reaction to a substance is irritant or allergic in nature. Such an array could also be used to test a variety of irritants and allergens for unique profiles.

Analysis of the top 100 genes differentially expressed in our SLS-treated samples shows that well over half of these genes have been implicated in injury and inflammation (TABLE VI), with most of these genes being up regulated. Interestingly, many of the down-regulated genes are hair keratins and keratin associated proteins selectively expressed in the hair during the anagen phase of the hair cycle. Either, the occlusive SLS treatment removes hair prior to the tape stripping or the treatment blocks anagen in the hair follicles.

It is shown in this example that RNA can be non-invasively and productively recovered from the surface of the skin using 4 small tape strips. The number of tape strips can be reduced, for example to two tape strippings, in conditions where the surface of the skin has been disrupted, such as SLS occlusion for 24 hours or in hyperproliferative skin conditions such as psoriasis (See Example 2). Furthermore, the limitation of capturing small amounts of RNA from some skin sites can be effectively overcome by obtaining replicate control samples and by the appropriate choice of mRNA biomarker (discussed below). Also presented herein, is data that the ΔC_(t) value, which is normally used to calculate a ΔΔC_(t) value (and thus a calibrated fold-change), is itself potentially useful for characterizing the physiologic state of the epidermis without reference to a calibration site.

The potential utility of ΔC_(t) values is illustrated by the ΔC_(t, IL-8) for subject 4's SLS-treated skin (tape-harvested sample; Table IV). That ΔC_(t) is −1.28, however it cannot be used to calculate a ΔΔC_(t) value (and therefore a fold-change) because insufficient RNA was recovered from the normal and water-occluded control sites. However, comparison of this ΔC_(t) value to the remaining subjects' average SLS ΔC_(t, IL-8) value of −0.89 and average values from tape-harvested water-occluded and uninvolved skin sites (>2.49 for normal or 1.54 for tape) is highly suggestive that the ΔC_(t) value of −1.28 is in fact indicative of irritated skin. For example, the value of −1.28 implies that, compared to the average value for the 10 subjects, subject 4's SLS-site IL-8/β-actin mRNA ratio is at least 2^(−(−1.28−2.49)) or 13.6-fold higher than the average value for uninvolved skin. A similar calculation using the average ΔC_(t, IL-8) for water-occluded samples as the calibrator suggests that the IL-8/actin mRNA ratio is 2^(−(−1.28−1.54)) or 7.1-fold elevated. These data lead to the hypothesis that establishment of a database of ΔC_(t) values for different mRNA biomarkers might be useful to identify a physiologic skin state without reference to an intrasubject control site. This utility of ΔC_(t) values is predicated upon the consistency of the PCR reaction conditions and the use of identical probes between samples. Given these prerequisites, our data support the potential for ΔC_(t) values being diagnostic indicators.

In this study the quantity of RNA recovered from different individuals and skin sites was variable, with significantly more RNA being recovered from SLS-treated sites than uninvolved skin sites. The large amount of RNA recovered from the SLS-irritated sites is consistent with the known effects of SLS, which effects invasion of inflammatory cells and creates a weakened barrier facilitating the removal of the inflamed epidermis. It has been found that RNA recovery is also a function of anatomical site and similar sites vary between individuals with respect to RNA yield.

While the variability of total RNA recovered does not affect the results of relative gene quantitation, the recovery of very small amounts of RNA did affect our ability to fully analyze some samples. In this respect, the choice of biomarkers may be as important as the amount of RNA recovered from a site. For instance, Table I shows that most tape-harvested samples could be assayed for β-actin and GAPDH mRNAs and thus calibrated GAPDH/actin ratios could be calculated. However, Table III reveals that some of these same samples do not have calibrated IL-1β/actin or IL-8/actin mRNA ratios, with the IL-1β assay being the most affected. The reason for this difference between biomarker assays lies in the relative abundance of the specific mRNA. Because GAPDH mRNA is approximately equal in abundance to β-actin mRNA, all samples with detectable actin mRNA were successfully assayed for GAPDH. Likewise, a high success rate was achieved at calibrating IL-8/actin mRNA ratios in water and SLS treated tape-harvested skin samples because IL-8 message is relatively abundant in these samples. Thus the biomarker mRNA that is the most abundant will make the most efficient use of RNA mass. Therefore, candidate biomarker mRNAs should be chosen for best sensitivity, positive predictive value and high relative abundance when RT-PCR is to be used for detection and tape harvesting is to be the sampling method.

The present Example demonstrates the utility of tape-harvested RNA for semi-quantitative RT-PCR and microarray applications for several reasons. Both methods have particular advantages and are appropriate in different circumstances. The use of microarrays is an invaluable tool for the discovery of diagnostic and prognostic biomarker candidates and may be essential for subcategorizing disease states, which may demand simultaneous assay of hundreds of biomarkers. However, the use of microarrays is expensive and technically laborious. Quantitative RT-PCR is less expensive and less technically demanding and is appropriate for studies where a limited number of known markers are being studied.

In summary, the data of this Example show that the tape stripping method collects skin samples from normal and inflamed skin that are suitable for RNA isolation and gene expression profiling experiments. This method can be used to profile expression of a large number of genes in different skin conditions to design custom arrays that allow molecular diagnoses of skin disorders.

TABLE I ΔC_(t, GAPDH) values in tape and biopsy-harvested RNA samples from treated and untreated skin. ΔC_(t, GAPDH) ^(a) Tape Biopsy Subject Normal Water SLS Normal Water SLS 1 3.27 ± 0.36 2.04 ± 0.33 2.78 ± 0.44   0.1 ± 0.0.06 0.94 ± 0.09 1.61 ± 0.11 2 1.23 ± 0.17 1.41 ± 0.12 2.56 ± 0.11 0.99 ± 0.07 1.79 ± 0.12 1.95 ± 0.08 3 0.86 ± 0.15 1.54 ± 0.18 3.02 ± 0.08 0.73 ± 0.10 1.41 ± 0.11 1.44 ± 0.11 4 — — 2.28 ± 0.10 0.46 ± 0.16 0.95 ± 0.11 1.68 ± 0.09 5 — 2.04 ± 0.23 3.15 ± 0.15 0.83 ± 0.10 1.69 ± 0.10 1.78 ± 0.10 6 2.97 ± 0.15 2.71 ± 0.23 2.87 ± 0.10 0.24 ± 0.07 1.48 ± 0.06 2.33 ± 0.07 7 0.91 ± 0.13 1.47 ± 0.10 2.68 ± 0.09 0.31 ± 0.10   1 ± 0.07 1.73 ± 0.09 8 1.83 ± 0.13 1.04 ± 0.15   3 ± 0.11 0.04 ± 0.04 1.38 ± 0.12 1.54 ± 0.10 9  0.7 ± 0.19 2.16 ± 0.34 2.85 ± 0.15 0.35 ± 0.08  1.6 ± 0.10 3.25 ± 0.08 10  3.47 ± 0.15 1.01 ± 0.12 2.46 ± 0.08 0.87 ± 0.09 1.77 ± 0.12 1.05 ± 0.07 Average 1.91 1.67 2.78 0.49 1.4  1.84 (SD) (1.35) (0.35) (0.04) (0.34) (0.33) (0.6)  p value^(b) — 0.61  0.087 — <0.005 <0.005 (vs. normal) p value^(c) 0.61 — <0.005 <0.005 — 0.06 (vs. water) p value^(d)  0.014 0.28 <0.005 — — — (biopsy vs. tape) ΔC_(t, GAPDH) is defined as [C_(t, GAPDH) − C_(t, actin)]; see Materials and Methods; mean ± SD; tape-harvested samples from uninvolved skin of subjects 4 and 5 and water-occluded skin (subject 4) did not have sufficient RNA for accurate β-actin assay. The p value (2-sided, paired t-test) for water vs. normal and SLS vs. normal for biopsy and tape-harvested samples. The p value for water vs. normal and water vs. SLS for biopsy and tape-harvested samples. The p value for tape-harvested versus biopsy samples for normal, water and SLS-occluded skin.

TABLE II GAPDH/actin mRNA ratios in EGIR and biopsy samples of normal, water and SLS-occluded skin. Relative GAPDH/β-actin mRNA change^(a) EGIR Biopsy Subject SLS Water SLS Water 1 [1] 1.41 2.35 0.35 0.56 2 [3] 0.4  0.88 0.51 0.58 3 [3] 0.22 0.62 0.61 0.62 4 [2] — — 0.43 0.72 5 [3] — — 0.52 0.55 6 [4] 1.07 1.19 0.24 0.42 7 [3] 0.29 0.68 0.38 0.62 8 [3] 0.44 1.72 0.35 0.4 9 [3] 0.22 0.36 0.13 0.42 10 [4]  2.02 5.48 0.88 0.54 Average 0.55 1.18 0.44 0.54 ^(a)Fold-increase of GAPDH/β-actin mRNA in the indicated sample relative to uninvolved skin; individual fold-changes calculated from data in Table I and average changes calculated from average values in Table I as described in Materials and Methods.

TABLE III Summary of fold-changes in IL-1β/β-actin and IL-8/β-actin mRNA ratios relative to uninvolved skin. IL-1β/β-actin IL-8/β-actin Tape^(b) Biopsy^(b) Tape^(b) Biopsy^(b) Subject^(a) Water SLS Water SLS Water SLS Water SLS 1 [1] ND ND   3.7** 1 ND ND ND  >1.1 2 [3] 4.5** >7.3**^(†) >1.4 >28**^(†)  0.85   6**^(†) ND  84**^(†) 3 [3] ND 18**^(†)   ND >15**^(†) 1.8  24**^(†) ND >171**^(†) 4 [2] — NC >2.7   >3.3** — NC ND  >12**^(†) 5 [3] — NC ND  >8**^(†) >1.1   >9.3**^(†) >1.5 >101**^(†) 6 [4] ND >0.44    >6.7** >34**^(†)  >6.3**  >6.8** >10**  >778**^(†) 7 [3] ND >8.1**^(†) >3.1 >11**^(†) >24**  >235**^(†)   >1.4  >42**^(†) 8 [3] ND >1.9**   2.3  56**^(†) >1.4  >41**^(†)   >1.9 >594**^(†) 9 [3] ND >5**   >2   >53**^(†) 22**  18**  >5.2** >368**^(†) 10 [4]  ND >1.4     2.2**   2.2** 1.3 >3** ND  >1.1 ^(b)Subject identification followed by clinical score in brackets, score definitions are discussed in Materials and Methods. c. Fold-change is calculated from mean Ct values (IL-1β data not shown and IL-8 data in Table IV) as described in Materials and Methods. The following abbreviations are used; “—” indicates insufficient RNA recovered to accurately assay β-actin mRNA; “ND” indicates IL-1β or IL-8 mRNA was not detected in the indicated sample (water or SLS); NC indicates that the mRNA could be detected in the indicated sample but a calculation of fold-change could not be made due to low RNA recovery in the uninvolved skin sample; a “**” signifies that the fold-change is significant at greater than 95% confidence; a ^(†) designates that the fold-change is also significant when calculated relative to the water sample (data not shown); a > symbol indicates that IL-1β or IL-8 mRNA could not be detected in the control sample, thus a minimum estimate of fold-change was calculated as described in Materials and Methods.

TABLE IV ΔC_(t) values for IL-8 mRNA in normal, water-occluded and SLS-occluded skin. ΔC_(t, IL-8) ^(b) Normal Water SLS Subject^(a) Tape Biopsy Tape Biopsy Tape Biopsy 1 [1] 1.51 ± 0.37  >9.26 ± 0.06 >1.28 ± 0.11   >9.68 ± 0.13 >1.51 ± 0.17 9.15 ± 0.15 2 [3] 2.23 ± 0.17  8.22 ± 0.22 2.46 ± 0.19 >11.30 ± 0.07 −0.36 ± 0.05 1.82 ± 0.05 3 [3] 2.08 ± 0.16  >9.71 ± 0.06 1.26 ± 0.28 >10.76 ± 0.11 −2.59 ± 0.07 2.29 ± 0.13 4 [2] — >10.16 ± 0.10 — >10.53 ± 0.10 −1.28 ± 0.11 6.56 ± 0.10 5 [3] —  >9.72 ± 0.05 0.03 ± 0.27  9.09 ± 0.31 −3.05 ± 0.15 3.06 ± 0.11 6 [4] >2.7 ± 0.08 >10.36 ± 0.09 0.05 ± 0.13  7.00 ± 0.27 −0.05 ± 0.11 0.76 ± 0.13 7 [3] >7.20 ± 0.13  >10.52 ± 0.06 2.62 ± 0.14  10.06 ± 0.28 −0.68 ± 0.08 5.11 ± 0.06 8 [3] >4.91 ± 0.18  >10.89 ± 0.08 4.46 ± 0.32 10.00 ± 0.4 −0.44 ± 0.06 1.67 ± 0.08 9 [3] 4.15 ± 0.28  >9.58 ± 0.09 −0.30 ± 0.18   9.94 ± 0.28  0.02 ± 0.17 1.06 ± 0.07 10 [4]  >2.12 ± 0.11  >10.00 ± 0.07 1.70 ± 0.29 >10.31 ± 0.12  0.56 ± 0.07 9.81 ± 0.26 Average 2.49 >9.84 1.54 9.22 −0.89 4.13 p value — <0.005 — <0.005 (tape vs. (n = 5) (n = 9) biopsy)^(c) d. Subject ID and clinical score of SLS site in brackets; scoring is described in Materials and Methods. e. ΔC_(t) and minimum ΔC_(t) calculations are described in Materials and Methods; an entry of “—” indicated that insufficient RNA was recovered to provide a meaningful estimate of the indicated ΔC_(t). A value preceded by “>” indicates that the mRNA for IL-1β or IL-8 was not detected in the sample, therefore the respective C_(t) was assigned a value of 37 and a minimum ΔC_(t) is given (i.e., ΔC_(t) = 37 − C_(t, actin)). f. Two-way, paired t-test comparing ΔC_(t) for tape versus biopsy for a given skin treatment.

TABLE V Percentage of the measurement of gene expression level unchanged for each of all possible pair-wise comparisons among GeneChips (A5, A6, A9, C1, C2, and C3) hybridized with aRNA obtained from three different locations on the upper back of two subjects (A and C). Gene Chip/Subject ID A5 A6 A9 C1 C2 C3 A5  100% A6 88.90%  100% A9 90.80% 86.10%  100% C1 89.80% 88.20% 87.40%  100% C2 85.00% 85.30% 83.10% 89.60%  100% C3 88.00% 88.00% 87.30% 88.90% 83.70% 100%

TABLE VI Functional grouping of top 100 differentially expressed genes between untreated and SLS treated conditions with p-values less than 1.4 × 10⁻¹⁰ and PPDE(p) values greater than 0.99. Reference if Known Involvement in Injury/ Accession Number Gene Name Fold Inflammation Structural proteins: X99142.1 Hair keratin, hHb6 −167.9 AJ406939.1 Keratin associated protein 4.7 −51.9 (KRTAP4.7) BF740152 Myosin IE 26.2 NM_000381.1 Midline 1 (OpitzBBB syndrome) −32.9 (MID1) NM_030966.1 Keratin associated protein 1.3 −42.6 (KRTAP1.3) Z24727.1 Tropomyosin 1 (alpha) −17.8 NM_002275.1 Keratin 15 (KRT15) −26.2 (Raval, Bharadwaj et al. 2003) NM_030975.1 Keratin associated protein 9.9 −859.3 (KRTAP9.9) Proteinases and protease inhibitors: L10343 Elafin/skin derived protease inhibitor 57.8 (Molhuizen and 3 (SKALP) Schalkwijk 1995) NM_002422.2 Metalloproteinase 3 (Stromelysin 1) 109.9 (Pilcher, Wang et al. 1999; Fray, Dickinson et al. 2003) NM_003254.1 Tissue inhibitor of metalloproteinase 35.1 (Lobmann, Ambrosch et 1 (TIMP1) al. 2002) NM_001109.1 Disintegrin and metalloproteinase 97.1 (Kahari and Saarialho- domain 8 (ADAM8) Kere 1997) NM_000362.2 Tissue inhibitor of metalloproteinase −29.7 (Lobmann, Ambrosch et 3 (TIMP3) al. 2002) U08839.1 Urokinase-type plasminogen 19.3 (Chung, Lee et al. 1996) activator receptor NM_004994.1 Matrix metalloproteinase 9 24.2 (Kahari and Saarialho- (gelatinase B) Kere 1997; Herouy 2001) NM_001912.1 Cathépsin L (CTSL) 18.5 (Kawada, Hara et al. 1997; Benavides, Starost et al. 2002; Welss, Sun et al. 2003) NM_000129.2 Coagulation factor XIII, A1 20.4 (Chung, Lee et al. 1996; polypeptide (F13A1) Ichinose 2001) NM_001150.1 Alanyl (membrane) aminopeptidase 35.3 (Lendeckel, Arndt et al. (aminopeptidase N/CD13) 2003) Cytokines, chemokines and their receptors: NM_002984.1 Small inducible cytokine A4 136.3 (Asadullah, Sterry et al. (SCYA4) 2002; Dong, McDermott et al. 2003) NM_003856.1 Interleukin 1 receptor-like 1 89.4 (Asadullah, Sterry et al. (IL1RL1) 2002; Dong, McDermott et al. 2003) AI421071 Chemokine (C-C motif) receptor 1 334.7 (Asadullah, Sterry et al. 2002; Dong, McDermott et al. 2003) NM_002090.1 GRO3 oncogene 74.2 (Asadullah, Sterry et al. 2002; Dong, McDermott et al. 2003) NM_000640.1 Interleukin 13 receptor, alpha 2 53.6 (Asadullah, Sterry et al. (IL13RA2) 2002; Dong, McDermott et al. 2003) R64130 Pro-platelet basic protein 66.6 (Asadullah, Sterry et al. 2002; Dong, McDermott et al. 2003) NM_001511.1 GRO1 oncogene (melanoma growth 26.7 (Asadullah, Sterry et al. stimulating activity, alpha) 2002; Dong, McDermott et al. 2003) NM_001838.1 Chemokine (C-C motif) receptor 7 25.5 (Asadullah, Sterry et al. (CCR7) 2002; Dong, McDermott et al. 2003) NM_001558.1 Interleukin 10 receptor, alpha 171.1 (Asadullah, Sterry et al. (IL10RA) 2002; Dong, McDermott et al. 2003) NM_001562.1 Interleukin 18 −13.8 (Asadullah, Sterry et al. 2002; Dong, McDermott et al. 2003) NM_006850.1 Suppression of tumorigenicity 16/Il- 65.7 (Asadullah, Sterry et al. 24 2002; Dong, McDermott et al. 2003) NM_000576.1 Interleukin 1, beta (IL1B) 17.2 (Asadullah, Sterry et al. 2002; Dong, McDermott et al. 2003) NM_006273.2 Small inducible cytokine A7 44 (Asadullah, Sterry et al. (SCYA7) 2002; Dong, McDermott et al. 2003) Complement and complement receptors: NM_012072.2 Complement component C1q 78.7 (Verhoef 1991; Bayon, receptor (C1QR) Alonso et al. 1998) NM_001736.1 Complement component 5 receptor 1 121.5 (Verhoef 1991; Bayon, (C5R1) Alonso et al. 1998) U62027.1 Anaphylatoxin C3a receptor 51.5 (Verhoef 1991; Bayon, Alonso et al. 1998) Histocompatibility complex: NM_021983.2 Major histocompatibility complex, 26.7 (Alberts, Bray et al. 1994) class II, DR beta 4 (HLA-DRB4) AJ297586.1 MHC class II antigen (HLA-DRB1 37.1 (Alberts, Bray et al. 1994) gene) X76775 Major histocompatibility complex, 42 (Alberts, Bray et al. 1994) class II, DM alpha (HLA-DMA) M27487.1 MHC class II DPw3-alpha-1 chain 32.8 (Alberts, Bray et al. 1994) M60334.1 MHC class II HLA-DR-alpha 23.7 (Alberts, Bray et al. 1994) NM_002118.1 Major histocompatibility complex, 18.3 (Alberts, Bray et al. 1994) class II, DM beta (HLA-DMB) AA807056 Major histocompatibility complex, 24.4 (Alberts, Bray et al. 1994) class II, DR beta 3 AF005487.1 MHC class II antigen (DRB6) 22.4 (Alberts, Bray et al. 1994) Growth factors: NM_003862.1 Fibroblast growth factor 18 (FGF18) −21.8 NM_013959.1 Neuregulin 1 (NRG1) 23.3 (Vermeer, Einwalter et al. 2003) Receptors and cell surface ligands: NM_013252.1 C-type lectin, superfamily member 5 75.4 (Kilpatrick 2002) (CLECSF5) NM_000560.1 CD53 antigen 94.6 (Alberts, Bray et al. 1994) Z22969.1 CD163 antigen/M130 antigen 63.4 (Alberts, Bray et al. 1994) NM_018643.1 Triggering receptor expressed on 55.2 (Colonna 2003) myeloid cells 1 (TREM1) Y00062.1 CD45/T200 leukocyte common 61.9 (Alberts, Bray et al. 1994) antigen NM_002438.1 Mannose receptor, C type 1 (MRC1) 69.8 (Baker, Ovigne et al. 2003) NM_004106.1 Fc fragment of IgE, high affinity I, 51 (Alberts, Bray et al. 1994) receptor (FCER1G) NM_005849.1 Immunoglobulin superfamily, 44.5 (Alberts, Bray et al. 1994) member 6 (IGSF6) NM_004951.1 Epstein-Barr virus induced gene 2 34.9 (Alberts, Bray et al. 1994) (lymphocyte-specific G protein- coupled receptor) (EBI2) BG236280 CD86 antigen 23.9 (Alberts, Bray et al. 1994) AF313468.1 Dendritic cell-associated C-type 25.6 (Kilpatrick 2002) lectin-1 NM_003264.1 Toll-like receptor 2 (TLR2) 28.5 (Alberts, Bray et al. 1994) NM_016184.1 C-type lectin, superfamily member 6 19.9 (Kilpatrick 2002) (CLECSF6) NM_005211.1 Colony stimulating factor 1 receptor 37.4 (Alberts, Bray et al. 1994) NM_001828.3 Charcot-Leyden crystal 117.2 (Ackerman, Liu et al. protein/Galectin-10 2002) NM_002003.2 Ficolin 1 (FCN1) 17.6 (Alberts, Bray et al. 1994) M98399.1 CD36 81.7 (Alberts, Bray et al. 1994) Membrane transport: NM_022003.1 FXYD domain-containing ion −42.3 transport regulator 6 (FXYD6) NM_006931.1 Solute carrier family 2 (facilitated 48.3 glucose transporter), member 3 (SLC2A3) Intracellular signal transduction: NM_005335.1 Cell-specific Lyn substrate 1 35.8 (HCLS1) NM_003332.1 TYRO protein tyrosine kinase 219.3 (Lucas, Daniel et al. binding protein (TYROBP) 2002) NM_002463.1 Myxovirus (influenza) resistance 2 30.1 (Melen, Keskinen et al. 1996) AI123251 Lymphocyte cytosolic protein 2 140.1 NM_002048.1 Growth arrest-specific 1 (GAS1) −76.6 AF183421.1 Small GTP-binding protein rab22b 22.9 AI356412 v-yes-1 Yamaguchi sarcoma viral 27.3 related oncogene homolog AF039555.1 Visinin-like protein 1 (VSNL1) −12.5 BC002671.1 Dual specificity phosphatase 4 41.8 NM_014380.1 p75NTR-associated cell death −8.1 executor Enzymes: NM_003364.1 Uridine phosphorylase (UP) 46.3 NM_002933.1 Ribonuclease, RNase A family, 1 86.7 (RNASE1) NM_005746.1 Pre-B-cell colony-enhancing factor 35.5 (Samal, Sun et al. 1994) (PBEF) NM_000382.1 Aldehyde dehydrogenase 3 family, −17.2 member A2 (ALDH3A2) NM_021615.1 Carbohydrate (N-acetylglucosamine 68.3 6-O) sulfotransferase 6 (CHST6) W46388 Superoxide dismutase 2, 15.6 mitochondria Extracellular matrix associated proteins: NM_002727.1 Proteoglycan 1, secretory granule 65.3 (PRG1) NM_004385.1 Chondroitin sulfate proteoglycan 2 30.8 (Syrokou, Dobra et al. (versican) 2002) X77598.1 Laminin alpha 3 chain (LAM A3) 18.7 BF055462 Thrombospondin 1 55.5 (Vallejo, Mugge et al. 2000) Transcription factors: AU145890 Forkhead box C1 −18.8 BC001283.1 Nuclear factor IB −11.5 Others: AF245505.1 Adlican −65.4 U03891.2 Phorbolin 1 52.7 NM_020987.1 Ankyrin 3, node of Ranvier (ankyrin −42.3 G) (ANK3) NM_006762.1 Lysosomal-associated multispanning 41.2 membrane protein-5 (LAPTM5) U56725.1 Heat shock 70 kD protein 2 −26.2 NM_001442.1 Fatty acid binding protein 4, 29 adipocyte (FABP4), NM_014583.1 LIM and cysteine-rich domains 1 −25.4 (LMCD1) NM_015714.1 Putative lymphocyte G0G1 switch 52.8 gene (G0S2) NM_005410.1 Selenoprotein P (SEPP1) −16 NM_002965.2 S100 calcium-binding protein A9 21.8 (Kerkhoff, Eue et al. (calgranulin B) 1999; Thorey, Roth et al. 2001) BC006471.1 ALL1-fused gene from chromosome −14.8 1q NM_006332.1 Interferon, gamma-inducible protein 31.4 (Phan, Lackman et al. 30 (IFI30) 2002) AF063606.1 Brain my048 protein −63.1 NM_006851.1 Glioma pathogenesis-related protein 78.2 (RTVP1) AA149745 Tripartite motif protein TRIM2 −15.4

Example 3 Non-Invasive Isolation of Epidermal RNA from Psoriatic Patients Using Tape Stripping Method Provided Herein

This example illustrates the isolation and detection of nucleic acids from psoriatic lesions and the identification of genes whose expression is associated with psoriatic lesions. This example summarizes the results of tape harvesting lesional and non-lesional skin in 24 psoriatic patients in various treatment stages. The goal of this investigational work was to determine if DermTech's Epidermal Genetic Information Retrieval Technology (EGIR), which is a tape disc used with a synthetic rubber-based adhesive (Adhesive Research, Glen Rock, Pa.) on a polyurethane film (Product No. 90068), could successfully recover RNA from the surface of lesional and non-involved skin from psoriatic patients; and to semi-quantitate recovered RNA for specific mRNA molecules known to be elevated in psoriatic lesions. The data generated from these patients demonstrates that RNA can be recovered and that mRNAs for TNFα, IFNγ, CD2, GAPDH, and β-actin can be detected and semi-quantitated in tape harvested epidermal samples. Nanogram quantities of RNA were recovered from 92% of tape harvested psoriatic plaques. Recovery of RNA from non-involved control skin was less successful with a 31% success rate. The recovery of RNA from non-lesional skin was not random because some subjects could be tape harvested with repeated success while others could not. The recovery of RNA from non-lesional psoriatic skin contrasts with the success of tape harvesting normal skin of healthy individuals, which has an 85% success rate. Semi-quantitative RT-PCR analysis demonstrated that at least 6 patients had significantly elevated TNFα mRNA levels in psoriatic plaques, 4 patients had elevated IFNγ mRNA and 3 had increased CD2 message relative to β-actin. 18 patients could not have the relative change of any marker assayed in psoriatic lesions because of insufficient RNA collection from control skin. However, analysis of ΔC_(t) values in 21 patient's lesions demonstrated a highly significant difference between TNFα and CD2 mRNA levels relative to β-actin in psoriatic versus control skin. These data suggest that TNFα and CD2 mRNA were in fact elevated in most patients and that patients could be categorized into two groups, those with elevated TNFα and CD2 mRNA and those with elevated TNFα, CD2 and IFNγ mRNAs. The data demonstrate that there are distinct relative abundances of the 3 mRNAs with respect to β-actin in psoriatic versus non-lesional skin, differences which are common across subjects. These preliminary results are very encouraging and demand confirmation with additional patients.

Materials and Methods

Clinical: Sample collection was done at the University of Utah in collaboration with Dr. Gerald Krueger. For each body site a total of 4 fresh tapes were sequentially applied once to a single site and removed. Tapes were put into individual eppendorf tubes, frozen at −80 and express mailed on dry ice to DermTech International where all subsequent analysis was performed. The tape used for tape stripping was a synthetic rubber-based adhesive MA70 (Adhesive Research) on a polyurethane film.

Isolation of RNA:

Total RNA was isolated using our standard method and the RNeasy fibrous tissue kit (Qiagen). The 4 tapes used to harvest each site were combined in buffer RLT and extracted together according to the manufacturer's guidelines using our standard adaptations.

Quantitation of RNA Mass:

Samples were quantified by non-competitive semi-quantitative RT-PCR using a fluorescence-based 5′-nuclease assay (“Real-time” PCR) on an ABI 7000 or 7900. Each sample was reverse transcribed in triplicate and each cDNA amplified and quantified in duplicate; the resulting 6 C_(t) values were converted to RNA masses, which were averaged to yield the data in Table 1. C_(t) values were converted to RNA masses using the standard curve method. A standard curve was generated with total RNA from human spleen. The accuracy of this method assumes that the relative amount of β-actin in human spleen RNA is identical to that in skin samples recovered by tape stripping. All assays were performed using Predeveloped Assay Reagents purchased from Applied Biosystems. The data from the first 11 subjects (Sample Sets 1 and 2) was gathered using multiplex assays (same tube assay of actin and the mRNA of interest). Thereafter, all analyses have been done in a single tube single analysis format. All ΔC1 and ΔΔC_(t) calculations are done with C_(t) values determined during the same experiment (i.e., simultaneous amplification/detection).

Semi-Quantitation of mRNA Levels:

Messenger RNA (mRNA) levels were semi-quantified for GAPDH, TNFα, IFNγ, and CD2 using non-competitive RT-PCR and the comparative (AΔC_(t) method; 5′-nuclease assay). In the ΔΔC_(t) method individual mRNAs (“mRNA_(x)” i.e., the RNA-of-interest) are semi-quantified by normalization to β-actin mRNA (mRNA_(a)) and this ratio is divided by the similar ratio from an uninvolved skin site, a step referred to as “calibration”. The resulting number is an indication of the change of (mRNA_(x)/mRNA_(a)) in lesional versus non-lesional skin.

Background of the ΔΔC_(t) Method

(Parts of the following discussion and additional information not discussed here can be found in ABI User Bulletin #2, which can be found at: http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf): During amplification of a sample using fluorescence detection and the 5′-nuclease assay, the net (background corrected) fluorescence of a sample is directly related to the amount of PCR product synthesized, which is related to the initial amount of specific mRNA in the sample. This fluorescence, called ΔR_(n), is related to the amount of PCR product by the equation:

ΔR _(n) ∝X _(T) =X ₀2^(C)  1]

where X_(T) is the amount of total PCR product at cycle C and X₀ is the initial amount of mRNA_(x). During the PCR reaction, ΔR_(n) rises exponentially (under non-competitive conditions in the early stages of the reaction); when ΔR_(n) rises significantly above background, it is said to have reached a threshold value and equation 1] becomes:

ΔR _(N,x) =K _(X) X ₀2^(Ct,x)  2]

where K_(x) is a spectroscopic constant specific to the fluorescent probe and the reaction conditions and C_(t,x) (the threshold value) is the number of PCR cycles required to reach the threshold fluorescence ΔR_(n). A similar equation can be written for the normalization mRNA, which in this case is β-actin:

ΔR _(N,A) =K _(A) A ₀2^(Ct,A)  3]

where K_(A) is an actin specific constant and A_(o) is the initial number of actin mRNA molecules. By dividing equation 2 by 3 and rearranging, we obtain an equation relating the fraction of mRNA_(x) to β-actin mRNA in our unknown or “experimental” sample:

$\begin{matrix} \left( {\frac{X_{0}}{A_{0}} = {\frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}}K_{AX}2^{{- \Delta}\; C_{T,{Exp}}}}} \right)_{Exp} & \left. 4 \right\rbrack \end{matrix}$

where K_(AX)=K_(A)/K_(X) and ΔC_(t,Exp)=C_(t,X)−C_(t,A). This equation relates the initial (unknown) number of mRNA molecules to the experimentally determined threshold cycle number. From the equation, we can see that the ratio of the two mRNAs is not only a function of the experimentally derived C_(t) values but also a function of the constant K_(AX) (an unknown), and the two ΔR_(n) values, which are determined and reported by the instrument. Thus without knowledge of K_(AX), the comparative method does not reveal the absolute ratio of two mRNAs in a single sample. However, by writing a similar equation for a second “calibrator” sample

$\begin{matrix} \left( {\frac{X_{o}^{Cal}}{A_{o}^{Cal}} = {\frac{\Delta \; R_{n,X}^{Cal}}{\Delta \; R_{n,A}^{Cal}}K_{AX}2^{{- \Delta}\; C_{T}^{Cal}}}} \right)_{Cal} & \left. 5 \right\rbrack \end{matrix}$

and dividing equation 4 by 5 we obtain:

$\begin{matrix} {{\frac{X_{0}}{A_{0}}/\frac{X_{0}^{Cal}}{A_{0}^{Cal}}} = {\left( \frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}} \right)K_{AX}{2^{{- \Delta}\; C_{t,{Exp}}}/\left( \frac{\Delta \; R_{n,X}^{Cal}}{\Delta \; R_{n,A}^{Cal}} \right)}K_{AX}2^{{- \Delta}\; C_{t,{Cal}}}}} & \left. 6 \right\rbrack \end{matrix}$

If the experimental and calibrator samples are analyzed during the same experiment, the threshold values are equal ΔR_(n,x)=ΔR_(n,x) ^(Cal) and ΔR_(n,A)=ΔR_(n,A) ^(Cal), and because K_(AX) is identical for both samples, equation 6 simplifies to:

$\begin{matrix} {{\left( \frac{X_{0}}{A_{0}} \right)\left( \frac{A_{0}^{Cal}}{X_{0}^{Cal}} \right)} = 2^{{- {\Delta\Delta}}\; C_{t}}} & \left. 7 \right\rbrack \end{matrix}$

where ΔΔC_(t)=ΔC_(t,exp)−ΔC_(t, cal), recalling that ΔC_(t, exp) is C_(t,x)−C_(t,actin) for the experimental sample and ΔC_(t,cal) is the analogous difference for the calibrator sample. Thus equation 7 allows us to infer a change of mRNA_(x)/mRNA_(a) between the sample of interest (psoriatic tissue) and a calibrator sample (non-lesional skin) directly from C_(t) measurements. Note that if one adds the further assumption that the “housekeeping” gene does not change its expression relative to total RNA then equation 7 simplifies to:

$\begin{matrix} {\left( \frac{X_{0}}{X_{0}^{Cal}} \right) = 2^{{- {\Delta\Delta}}\; C_{t}}} & \left. 8 \right\rbrack \end{matrix}$

It should be noted that this final simplification is not necessary to draw significance from C_(t) values for diagnostic purposes.

Analysis of ΔC_(t) Values without Calibration:

The ΔΔC₁ method requires the use of a calibrator sample to eliminate unknown constants in Equation 4 and relate the ΔC_(t) values directly to mRNA levels in the two samples. It would be advantageous to be able to analyze ΔC_(t) values without the necessity of a calibrator sample. Equation 4 seems to offer several means of doing this. Equation 4 relates X₀/A₀ to ΔC_(t); if one could experimentally change this ratio (for instance by using in vitro transcribed RNA) then a graph of ΔC_(t) vs. log [X₀/A₀] should have a slope related to the known ΔR_(n)'s and the unknown K_(AX), which could be solved for K_(AX), which in turn could be used to directly relate ΔC_(t) to mRNA_(x)/mRNA_(a) in a sample without calibration.

An alternative strategy is to inspect equation 4 for the variables which contribute to the observed ΔC_(t) and assess their contributions to it. By taking the log of equation 4 we obtain:

$\begin{matrix} {{\log \left( \frac{X_{0}}{A_{0}} \right)} = {{\log \left( {\frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}}K_{AX}2^{{- \Delta}\; C_{T,{Exp}}}} \right)} = {{{\log \left( \frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}} \right)} + {\log \; K_{AX}} + {\log \; 2^{{- \Delta}\; C_{T,{Exp}}}}} = {{\log \left( \frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}} \right)} + {\log \; K_{AX}} - {\Delta \; C_{T,{Exp}}\log \; 2}}}}} & \left. 9 \right\rbrack \end{matrix}$

solving equation 9 for ΔC_(t) yields

$\begin{matrix} {{\Delta \; C_{T,{Exp}}} = \frac{{- {\log \left( \frac{X_{0}}{A_{0}} \right)}} + {\log \left( \frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}} \right)} + {\log \; K_{AX}}}{\log \; 2}} & \left. 10 \right\rbrack \end{matrix}$

We can see that ΔC_(t,Exp) depends on 3 factors; X₀/A₀; ΔR_(n,X)/ΔR_(n,A); and K_(AX). If we compare two samples analyzed during the same experiment, the ΔR_(n) values will be identical and cannot contribute to changes in the ΔC_(t). Likewise, since the K_(AX) values are identical we can see that ΔC_(t) values will only change if X₀/A₀ changes. Therefore, under same plate measurements, it is valid to compare ΔC_(t) values without a calibration step.

A logical extension is to ask if ΔC_(t) measurements from separate experiments can be compared. In such an event it is likely that ΔR_(n)'s will be different, however equation 10 allows one to calculate an adjusted ΔC_(t) that will reflect the effect of differing ΔR_(n) values.

Rearrangement of equation 10 gives:

$\begin{matrix} {{{\Delta \; C_{T,{Exp}}} - \frac{\log \left( \frac{\Delta \; R_{n,X}}{\Delta \; R_{n,A}} \right)}{\log \; 2}} = \frac{{- {\log \left( \frac{X_{0}}{A_{0}} \right)}} + {\log \; K_{AX}}}{\log \; 2}} & \left. 11 \right\rbrack \end{matrix}$

The expression to the left of the equality in equation 11 is an “adjusted” ΔC_(t) which accounts for differing ΔR_(n)'s. We can see that the adjusted ΔC_(t) only depends on A₀/X₀ and K_(AX). In this case K_(AX) will be constant for both samples—given identical reaction conditions and probes—and any differences between adjusted ΔC_(C)'s will be a consequence of differences in X₀/A₀.

Data Handling and Statistical Analysis:

For each mRNA assay we have 6 replicate measurements of the C_(t). The average of these C_(t) values is used to calculate the ΔC_(t,x) for the sample and calibrator. It is our experience that as C_(t) values approach 37 cycles, individual assays can produce undetectable readings or C_(t) values >37 with high variability. In order to deal with combinations of undetectable and readings greater than 37 with high standard deviations, we have adopted the following data management rules.

Rule 1] if there are 4 or more readings (out of 6 replicates) of undetectable, a C_(t) value of 37 (our limit of detection) is assigned to the sample; Rule 2] if an average C_(t) is greater than or equal to 37 and the standard deviation is greater than or equal to 1, a value of C_(t)=37 is assigned to the mRNA being measured. This last rule simply states that if an mRNA is at our limit of detection or reliable quantitation, we simply define it as undetectable in order to estimate its maximum value. Calculations performed with C_(t)≡37, where that value has been assigned by the above rules, are indicated by enclosing the resulting data in parentheses. Outlier measurements are defined as outside the average of remaining measurements ±3 standard deviations. If a single measurement lies outside this boundary it is eliminated from the calculations. An mRNA_(x)/mRNA_(a) ratio is considered statistically different than the control value (at 95% confidence) if the fold-change given by 2^(−ΔΔC±2std dev) does not overlap the control range given by 2^(±2std dev).

Results RNA Yield

Table 1 shows the yields of total RNA from non-lesional and lesional skin in 24 patients. It is our experience with tape harvesting that yields of less than 200 picograms are not useful for quantitating mRNA levels 8-fold less abundant than β-actin. By applying this standard of at least 200 picograms, we can categorize RNA recovery as successful or not successful. Table 2 summarizes the results of categorizing the mass data by the 200-picogram criterion. We can see that tape harvesting lesional skin was very successful with 91% of samples having sufficient RNA for analysis. However, tape harvesting of non-lesional skin was less successful (31% success).

Because analysis of the second sample set suggested that non-lesional skin might present recovery problems, subsequent sample sets included 2 non-lesional skin sites as controls. A total of 12 patients each had 2 control sites tape harvested. Of these 12 pairs of sites, 9 pairs produced insufficient RNA and 3 pairs produced nanogram quantities of RNA (Table 1). There were no pairs of mixed sites. This data strongly suggests that the recovery of RNA from uninvolved skin is not a random occurrence but that some patients may in fact yield less RNA. A similar observation applies to the skin of subjects with no psoriasis. However, the frequency of successful recovery from healthy subjects' normal skin is 84%. This contrasts quite strongly with the 31% recovery from non-lesional psoriatic skin. We conclude that 1] the uninvolved skin of psoriatic patients is different at the level of ability to recover RNA from the surface of the skin; and 2] that these 12 psoriatic patients can be divided into two categories based on the ability to recover RNA from non-lesional skin. A caveat to this second conclusion is that body location may be an important factor and the particular sites harvested have not yet been reported. It will be of interest to understand the differences between psoriatic patients who either do or do not yield RNA from non-lesional skin using EGIR adhesive films.

Relative Cytokine Levels

Table 3 reveals the relative increases in mRNAs for TNFα, IFNγ, and CD2 in lesional compared to non-lesional skin. Table 3 shows that 6 patients had significantly elevated TNFα/β-actin mRNA ratios compared to non-lesional skin. In 15 patients we were unable to classify the TNF/actin mRNA ratio as elevated or not because of poor RNA recovery from the control site.

The data for IFNγ shows 3 patients having elevated IFNγ/actin mRNA ratios and 18 patients having no conclusion because of inadequate control data. Data for CD2 reveals that 3 patients had elevated CD2/actin mRNA levels, 2-had normal or borderline elevated levels (possible 2.4-fold increases) and 16 samples were indeterminate.

Discussion

In this work we have analyzed the results of tape harvesting psoriatic and non-lesional skin on 24 patients. We have quantified the RNA recovered and shown that when sufficient RNA is recovered, it can be productively analyzed. We have found that RNA can be recovered with high frequency from psoriatic plaques, while RNA is recovered with below average frequency (compared to healthy subjects) from non-lesional skin. While it seems clear that recovery of RNA from non-lesional skin is patient specific, we have not eliminated the possibility that body site plays a major role in RNA recovery. The inability to efficiently collect non-lesional skin data from psoriatic patients would seem to be an obstacle to the analysis of lesions (Table 3). However, the ultimate goal of this work is to devise an assay which requires only a lesion sample and no control skin (discussed below). Because such a goal requires a foundational database of ΔC_(t) values from non-lesional skin, or at the very least normal skin, we will continue to pursue ideas to increase the isolation of RNA from non-lesional skin.

Several strategies can possibly be used for increasing the yield of RNA from non-lesional skin sites on psoriatic patients or devising a method of calibrating ΔC_(t)'s from lesions without using non-lesional controls. These strategies are:

-   -   1. Optimization of tape usage: It is probable that different         techniques of applying tape to the skin could affect the         recovery of RNA. In particular, aggressive application to the         skin is necessary. Two physicians have been trained in the         method. The consensus was that the training was highly         instructive and will make a difference in how efficiently         non-lesional skin is sampled.     -   2. In principle, only one non-lesional (i.e., unaffected)         control is needed, since that data could be used to calibrate         lesional samples taken at later time points. Thus a non-lesional         sample could involve the one time use of up to 10 applications         of tape to a single site to insure obtaining a sample.     -   3. There is anecdotal evidence that body location is a         significant factor for RNA recovery. This hypothesis is being         tested in healthy individuals. Preliminary data suggests that         the upper arm, over the deltoid, the upper back over the         scapular spine and the periauricular (mastoid) region may be         superior RNA yielding sites.     -   4. A single shave biopsy could act as a control for all         subsequent analysis.     -   5. It is possible, perhaps desirable to use commercially         available RNA as a “universal” calibrator.

It is relatively common in medical diagnostics to analyze tissue samples and draw conclusions—without reference to a control sample—based on population data. For instance, blood is routinely analyzed and conclusions based on whether the value of a given parameter falls within a normal or abnormal range. In this example there is no “control” sample, the patient only has one blood source; the control is based on the range of values found in normal samples. Likewise, we should be able to evaluate psoriatic plaques without reference to a control sample from that individual. While the most obvious candidate for a diagnostic parameter is the mRNA_(x)/reference mRNA ratio, we have seen that without absolute quantification of mRNA, we cannot use C_(t) values to calculate the absolute ratio of 2 mRNAs. This does not mean that we cannot use uncalibrated ΔC_(t)'s to compare and classify lesions.

When the ΔΔC_(t) method is used to semi-quantitate mRNA a calibrator sample is required that allows the cancellation of unknown constants and consequent direct relation of ΔΔC_(t) to relative mRNA_(x)/mRNA_(a) levels in the unknown and calibrator samples (formula 6; Materials and Methods Section). If one were to compare ΔC_(t) values amongst samples (i.e., an uncalibrated sample comparison), it would be necessary to account for the variables other than X₀/A₀ that contribute to the observed ΔC_(t).

Equation 4 relates the ΔC_(t) value to the mRNA_(x)/mRNA_(a) ratio in the sample. Rearrangement of equation 4 (Materials and Methods) shows that ΔC_(t) is a function of 1] the mRNA_(x)/mRNA_(a) ratio in the sample; 2] the ΔR_(n) values for the message of interest and normalization mRNA; and 3] the spectroscopic constant K. If the samples to be compared are assayed during the same experiment, then the ΔR_(n) values will be identical and will not contribute to any differences in ΔC_(t). The use of the same sample volumes, and probes will likewise assure that K_(AX) is the same for all samples. Therefore, it should be possible to compare uncalibrated ΔC_(t) values—knowing that they are only a function of X₀/A₀—and evaluate the hypothesis that the mRNA_(x)/mRNA_(a) ratio is different in psoriatic versus non-psoriatic skin and that this difference extends across individuals in a population.

The data in Table 4 can be used to test this hypothesis. Table 4 contains the ΔC_(t) values for all samples. Under each mRNA-of-interest, the ΔC_(t) values for lesions are sorted into one of three columns. The first column on the left (signified by ⇑) contains ΔC_(t) values from lesion samples with significant increases in the mRNA_(x)/mRNA_(a) ratio compared to control skin (Table 3). The second column contains ΔC_(t) values from lesions with no significant change from control skin. The third column contains ΔC_(t) values from unclassified lesions. The typical reason for a lesion being unclassified is due to insufficient RNA collection from the control sample (non-lesional skin). A fourth column contains ΔC_(t) values from non-lesional skin.

By sorting ΔC_(t) values into known and unknown categories, we can use statistical tests to determine if the categories define unique ranges. In Table 4 the average ΔC_(t,TNF) in samples with increased TNFα mRNA levels is 5.18. In contrast, the average ΔC_(t,TNF) for control skin samples is 9.53. A t-test shows that the difference between ΔC_(t) values for lesional vs. non-lesional skin is highly significant (p=0.0007). A similar analysis done on the unclassified ΔC_(t,TNF) data show that the unclassified lesion samples have ΔC_(t,TNF) values significantly different than control values (Table 4; p<0.0005). Thus it appears that the unclassified lesion samples consist largely of samples with elevated TNFα/β-actin mRNA ratios.

The same analysis can be applied to the ΔC_(t,CD2) data. Table 4 shows that the ΔC_(t,CD2) values for samples with elevated CD2 mRNA is significantly different than control samples (p=0.001) and that ΔC_(t,CD2) values for unclassified lesion samples are also different than control values (p<0.005). It therefore appears that our unclassified lesional samples represent mostly samples with increased CD2 mRNA levels.

Similar analysis of IFNγ mRNA reveals that ΔC_(t,IFN) in lesions with elevated IFNγ/actin mRNA ratios have significantly different ΔC_(t,IFN) values than control skin (Table 4; p=0.02). When the ΔC_(t,IFN) values for unclassified lesion samples are compared to control skin, there is not as high a confidence that they are different than non-lesional skin (p=0.12). Our interpretation of this data is that the unclassified category contains a mixture of samples, some of which have elevated IFNγ levels and some of which do not. Indeed, inspection of the unclassified ΔC_(t,IFN) values shows a range of values from a low of 2.01 (almost certainly abnormally high) to a high of 11.14 (probably normal). From this data we can conclude that most of the samples have elevated TNFα and CD2 mRNA levels and that some proportion of patients have elevated IFNγ mRNA levels. This suggests that we have 2 classes of patients, those with high levels of all 3 markers and those with high levels of TNF and CD2 and normal levels of IFNγ. It is of high interest to define the clinical differences that create these categories.

The above analysis of ΔC_(t) values establishes the likelihood that there is a range of values for lesional psoriatic skin and non-lesional skin unique to the skin type (Table 4). The heterogeneity in the unclassified ΔC_(t,IFNγ data highlights the larger question of how to categorize lesional ΔC) _(t) data for which we have no control samples. It is clear that in order to classify ΔC_(t)'s we need a database of calibrated ΔC_(t) values from lesional and non lesional (or normal skin from healthy individuals) skin. At our current rate of success obtaining RNA from non-lesional skin, we will need approximately 100 patients to get 25-30 calibrated ΔC_(t)'s from which we can define normal and abnormal ranges. The fact that a subset of patients seems to be good RNA yielders raises an interesting question. If in fact these individuals have “different” normal skin then they may not be appropriate controls (for some markers, which by definition would be interesting). In fact, normal healthy people may be the best control group.

TABLE 1 Total RNA yield summary. Skin Type and Yield* Non-lesional Lesional ID Yield Std dev Yield Std dev  1 (W.S.)¹ 5.1 1.2 44 8  2 (J.C.)¹ 4.6 0.8 11 2.9  3 (J.S.)¹ — 1.7 0.49  4 (D.C.)¹ 29 9.1 18 1.8  5 (J.P.)¹ 138 2.7 1.2 0.45  C1² 0.031 0.011 8.6 1.4  2² 0.045 0.016 12.6 1.5  3² 0.15 0.017 5.12 0.58  4² 3.94 0.63 0.053 0.006  5² 0.0063 0.85 0.13  6^(2,3) ND ND  60 (70)⁴ 0.02 0.018 8.1 0.86 100 (105)⁴ 0.16 0.044 18 1.2 100 (110)⁴ 0.027 0.025 115 (120)⁴ 0.027 0.012 14 1.2 115 (125)⁴ 0.099 0.027 130 (135)⁴ 18 1.6 40 4.9 130 (140)⁴ 38 3.9 150 (160)⁴ 12 1.2 9.3 0.66 150 (170)⁴ 1.8 0.26 180 (190)⁵ 0.053 0.018 11.6 0.7 180 (200)⁵ ND 210 (220)⁵ ND 2.32 0.06 210 (230)⁵ ND 250 (260)⁵ ND 0.31 0.04 250 (260)⁵ ND 270 (280)⁵ 0.017 0.024 1.37 0.08 270 (290)⁵ ND 300 (310)⁵ 0.02 0.015 1.4 0.12 300 (320)⁵ ND 340 (350)⁵ 0.022 0.021 5.92 0.64 340 (360)⁵ 0.09 0.029 370 (380)⁵ 24.5 1.3 15.3 2.82 370 (390)⁵ 7.33 0.44 400^(5,6) 0.027 0.024 410^(5,6) ND 420^(5,6) 0.1 0.059 *Yield reported in nanograms total RNA; ND = none detected ¹University of Utah Round 1 ²University of Utah Round 2 ³Subject consented to one tape application ⁴University of Utah Round 3; one patient had a single control (sample ID 70) and lesion (ID 60) sampled, the remaining 4 patients had 2 controls and 1 lesion sampled; the control ID is in parenthesis ⁵University of Utah Round 4; 2 controls and 1 lesion sampled; control ID is in parenthesis ⁶These samples have not been assigned sample/lesion designations and may have been transported on ice an undefined amount of time before freezing

TABLE 2 Summary of mass recovery in sample sets 1-4. Lesional¹ Control¹ Patient Total 21/23 (91%) 11/35 (31%) 24 ¹The fraction of samples with ≧200 picograms RNA; from a total of 23 patients, subject 6 from Round 2 is not included in these data (but is included in the patient total).

TABLE 3 Relative levels of TNFα, IFNγ and CD2 in psoriatic lesions. Relative mRNA/β-actin mRNA levels¹ Sample# TNFα IFNγ CD2  1²   (3.23)  (0.06)  (0.83)  2²  10** ND  (1.9)  3² — — —  4²  8.9** ND  3.9  5²  42** (513)** 20**  1³ — — —  2³ — — —  3³ — — —  4³ — — —  5³ — — —  60⁴ — — — 100⁴ — — — 115⁴ — — — 130⁴  11.3**  (1.7)  2.38**  8.3**  (4.3)**  2.42 150⁴  (37)**  558** 19**  (11)**  (5.7)** 180⁵ — — — 210⁵ — — — 250⁵ — — — 270⁵ — — — 300⁵ — — — 340⁵ — — — 370⁵ 331**   38** 11.1** 400^(5,6) — — — ¹The fold-induction relative to uninvolved skin is shown; Numbers in parentheses are lower limit estimates calculated by assigning a C_(t) = 37 to the mRNA of interest (TNFα, IFNγ or CD2), this estimate is used because the mRNA of interest was not detectable in the control site; values with ** are considered statistically different than the control site at the 95% confidence interval as described in Materials and Methods; a “—” indicates that insufficient RNA was recovered from the control (typical) or lesional site; ND indicates no mRNA for gene of interest detected in either lesion or control sample (but RNA present); Samples 130 and 150 have 2 different fold-increases corresponding to calibration to two different non-lesional skin sites. ²University of Utah Round 1 ³University of Utah Round 2 ⁴University of Utah Round 3; 1 patient had a single control and lesion sampled, the remaining 4 had 2 controls and 1 lesion sampled; the control ID is in parenthesis ⁵University of Utah Round 4; 2 controls and 1 lesion sampled; control ID is in parenthesis ⁶These samples have not been assigned sample/lesion ID and were transported on ice an undefined amount of time before freezing

TABLE 4 Categorization and comparison of ΔC_(t) values. ΔCt (C_(t, gene) − C_(t, actin))¹ TNFα IFNγ CD2 Psoriatic Psoriatic Psoriatic ID ↑

UK Control ↑

UK Control ↑

UK Control  1 (W.S.)² 6.45 (8.14) 11.16 7.12 8.17 (7.89)  2 (J.C.)² 5.28 8.59 (8.21) (7.6) 6.91 (7.84)  3 (J.S.)² 5.04 NRNA 4.25 NRNA 4.64 NRNA  4 (D.C.)² 7.84 10.99 (8.32) (9.43) 7.59 9.54  5 (J.P.)² 4.41 9.81 2.96 (11.96) 4.47 8.81  1³ 4.1 NRNA (8.19) NRNA 7.8 NRNA  2³ 2.84 NRNA 9.19 NRNA 5.25 NRNA  3³ 4.02 NRNA 7.96 NRNA 5.58 NRNA  4³ NRNA 6.79 NRNA 9.91 NRNA 6.84  5³ 3.07 NRNA (8.24) NRNA (5.33) NRNA  60 (70)⁴ 8.29 NRNA 9.98 NRNA 7.72 NRNA 100 (105)⁴ 6.22 NRNA 10.09 NRNA 7.06 NRNA 100 (110)⁴ NRNA NRNA NRNA 115 (120)⁴ 5.07 NRNA 11.14 NRNA 8.5 NRNA 115 (125)⁴ NRNA NRNA NRNA 130 (135)⁴ 7.11 10.6 10.2 (10.96) 8.67 9.92 130 (140)⁴ 10.16 (12.3) 9.94 150 (160)⁴ 5.13 (10.35) 3.49 12.62 4.48 8.72 150 (170)⁴ (6.99) (6.99) (6.99) 180 (190)⁵ 4.03 NRNA 4.68 NRNA 4.23 NRNA 180 (200)⁵ NRNA NRNA NRNA 210 (220)⁵ 6.86 NRNA (8.18) NRNA 7.8 NRNA 210 (230)⁵ NRNA NRNA NRNA 250 (240)⁵ 3.91 NRNA (4.98) NRNA (4.98) NRNA 250 (260)⁵ NRNA NRNA NRNA 270 (280)⁵ 3.7 NRNA 3.47 NRNA 5.54 NRNA 270 (290)⁵ NRNA NRNA NRNA 300 (310)⁵ 3.23 NRNA 2.01 NRNA 4.84 NRNA 300 (320)⁵ NRNA NRNA NRNA 340 (350)⁵ 2.65 NRNA 4.6 NRNA 5.51 NRNA 340 (360)⁵ NRNA NRNA NRNA 370 (380)⁵ 1.28 9.66 6.67 11.93 6.63 10.09  370 (390)⁵ 9.64 (10.13) (10.13)  400^(5,6) NRNA NRNA NRNA 410^(5,6) NRNA NRNA NRNA 420^(5,6) NRNA NRNA NRNA Average* 5.18 4.63 9.53 4.37 7.39 10.40 5.19 8.13 6.4 9.12 p-value^(†) 0.0007 <0.0005 0.02 0.12 0.001 0.3 <0.005 ¹The ΔC_(t) value is defined as the C_(t) value for the mRNA of interest minus the C_(t) value for β-actin (C_(t, mRNA) − C_(t, actin)). In some samples the mRNA of interest cannot be detected, in which case the C_(t) is defined as 37 cycles, our limit of detection; in such cases an estimated ΔC_(t) is calculated from the formula 37 − C_(t, actin) and is reported in parenthesis. A column headed by a ↑ contains data from lesions with statistically elevated (95% confidence interval) cytokine levels; a column headed with

 contains data from lesions showing no significant change; a column headed by UK contains unclassified data (calibrator unavailable); NRNA indicates insufficient RNA recovered. ²University of Utah Round 1. ³University of Utah Round 2. ⁴University of Utah Round 3; 1 patient had a single control and lesion sampled, the remaining 4 had 2 controls and 1 lesion sampled; the control ID is in parenthesis. ⁵University of Utah Round 4; 2 controls and 1 lesion sampled; control ID is in parenthesis. ⁶These samples have not been assigned sample/lesion ID and may have been transported on ice an undefined amount of time before freezing. *Averages and standard deviations do not include estimated data (# in parentheses). ^(†)Two tailed t-test compared to non-lesional skin; ΔC_(t) values in parentheses are not included in the calculation.

Example 4 Relative Levels of mRNA as Indicated by Δc_(t) Values in Lesional and Non-Lesional Skin of Psoriatic Patients

This example illustrates the use of the tape stripping method disclosed herein and ΔC_(t) values, to characterize genomic expression in the stratum corneum of psoriasis lesional and non-lesional skin. More specifically, this study determines if ΔC_(t) values for various mRNAs known to be upregulated in psoriatic lesions could be characterized using RNA recovered by tape stripping.

Methods

The tape stripping procedure and tape are identical to those disclosed in Example 3. One lesion was sampled and 3 independent uninvolved skin (UIS) sites were sampled per patient. The 3 uninvolved skin site samples were combined to produce one “global” control sample. Each site was sampled with 4 individual tapes, each sequentially applied and removed once. mRNA was semi-quantitated using the comparative or ΔC_(t) method using β-actin as the normalizing message.

Results and Discussion

In this tape stripping study a total of 72 subjects lesions and 163 normal skin sites were sampled. Some patients with less severe disease were only sampled on uninvolved skin sites. Each sample was semi-quantitated for GAPDH, TNFα, IFNγ, CD2, Krt-16, IL-12B, and IL-23A mRNA which were normalized to β-actin mRNA. The results of these assays are shown in Table 9.

TABLE 9 Population average ΔC_(t) values of select biomarker mRNAs in lesional and uninvolved skin of psoriatic patients Biomarker mRNA and Average ΔC_(t) ^(b) GAPDH TNFα IFNγ Krt-16 CD2 IL-12B IL-23A Site^(a) ΔC_(t) SEM ΔC_(t) SEM ΔC_(t) SEM ΔC_(t) SEM ΔC_(t) SEM ΔC_(t) SEM ΔC_(t) SEM UIS (N) 2.07 (163) 0.06 8.32 (97) 0.16 10.5 (9)  0.72 −1.33 (137) 0.12 8.43 (34) 0.3 11.5 (3)  1.8 9.03 (10) 0.63 Lesion (N) 0.72 (72)  0.19 4.87 (72) 0.21 7.79 (66) 0.35 −2.57 (45)  0.23 6.56 (69) 0.18 8.55 (44) 0.28  5.7 (45) 0.31 ^(a)Tape stripped site, lesional or uninvolved skin (UIS); the number of observations is listed below in parenthesis. ^(b)ΔC_(t) is defined as C_(t, mRNAx) − C_(t, actin mRNA) where C_(t) is the respective number of PCR cycles required to achieve threshold fluorescence. In some samples the threshold could not be determined (i.e., the mRNA was not detectable) or was not assayed, thus the number of observations is different for each mRNA. SEM is standard error of the mean calculated as standard deviation divided by N^(1/2).

The data in Table 9 clearly demonstrates that there are different relative levels of all the mRNAs listed in lesional and control skin. For TNFα, IFNγ, CD2, IL-12B, Krt-16 and IL-23A the ΔC_(t) values all indicate a relative increase in mRNA expression in lesional skin, in agreement with published data. Thus we conclude that RNA recovered from tape stripped skin can accurately reflect the molecular events known to be active in lesional psoriatic skin compared to uninvolved skin.

Example 5 A Comparison of Δc_(t) Values in Psoriatic Lesions with Clinical Assessment (NPF Score) Over Time and Treatment

This Example illustrates that tape harvested RNA and −C_(t) values can be used to monitor changes in psoriasis.

Methods

Patients were treated with Enbrel™ (Etanercept) over a period of months. Both before treatment commenced (week 0) and at various time points during treatment, a lesion was tape stripped using the synthetic rubber-based adhesive MA70 (Adhesives Research) on a polyurethane film. Adhesive strips were manufactured as circles of 17 mm diameter. Skin sites were sequentially stripped with 4 individual tapes, with each tape applied and removed once. The RNA isolated from the adherent cells on all 4 tapes (from one site) was pooled into one sample. Total RNA recovered from tapes was semi-quantified for the mRNAs listed in Table 1. Quantitation was by quantitative RT-PCR using the comparative method with β-actin mRNA as the internal normalizing mRNA standard and calibration achieved by using population average values for ΔC_(t) in uninvolved skin of psoriatic subjects (Table 1).

Results and Discussion

Table 10 shows the results of assaying GAPDH, TNFα, IFNγ, IL-12B and IL-23A mRNAs relative to β-actin mRNA as well as the clinical assessment of disease as characterized by NPF Score, both before and after 8 weeks of treatment. Rather than calibrate the lesion samples to uninvolved skin of each patient, we have chosen to calibrate to population average values to gain a fold-change relative to non-psoriatic skin. The results of calibrating to each patient's uninvolved skin values were virtually identical (data not shown). Table 10 also shows that the change from baseline to week 8 for almost all ΔC_(t) values in lesion samples was positive, while the change in NPF score was negative (indicating improvement in disease) over this same time period. Thus, positive changes in ΔC_(t) values of these specific mRNAs are negatively correlated with the change from baseline at week 8 in NPF scores. This negative correlation suggests that decreases in levels of TNFα, IFNγ, IL-12B and IL-23A mRNAs correlate with improvement in clinical symptoms. This is most clearly demonstrated by inspecting the fold-change data in Table 10. In order to assess the significance this observation, the ΔC_(t) and NPF data in Table 10 was analyzed. The results of this analysis are shown in Table 11.

TABLE 10 ΔC_(t) values, fold change and NPF score before treatment and at week 8 of treatment in psoriatic lesions of 6 patients Fold Change ΔC_(t,) (Lesion)^(a) (Pop-UIS)^(b) NPF Score^(c) Pa- Week Week Week mRNA tient # 0 8 0 8 0 8 GAPDH P2 −3.11 1.02 36.25 2.07 22 12 P3 −2.83 1.04 29.86 2.04 14.7 10.7 P4 −0.38 1.31 5.46 1.69 10.7 10.3 P5 −2.58 1.4 25.11 1.59 24.7 16.7 P6 0.95 1.58 2.17 1.40 20 18.7 P7 0.84 1.25 2.35 1.77 18.3 11.7 TNFα P2 0.52 4.99 222.86 10.06 22 12 P3 1.41 4.27 120.26 16.56 14.7 10.7 P4 4.86 5.82 11.00 5.66 10.7 10.3 P5 1.05 5.15 154.34 9.00 24.7 16.7 P6 6.58 4.8 3.34 11.47 20 18.7 P7 3.9 4.21 21.41 17.27 18.3 11.7 INFγ P2 4.19 11.27 79.34 0.59 22 12 P3 0.95 4.91 749.61 48.17 14.7 10.7 P4 9.09 9.92 2.66 1.49 10.7 10.3 P5 2.53 7.47 250.73 8.17 24.7 16.7 P6 10.83 9.13 0.80 2.58 20 18.7 P7 7.03 8.8 11.08 3.25 18.3 11.7 IL-12B P2 7.19 12.48 19.84 0.51 22 12 P3 4.65 7.35 79.34 9.45 14.7 10.7 P4 >9.3 9.09 4.59 5.31 10.7 10.3 P5 6.24 >8.01 38.32 11.24 24.7 16.7 P6 11.26 6.7 1.18 27.86 20 18.7 P7 4.23 4.78 154.34 105.42 18.3 11.7 IL-23A P2 2.81 6.59 74.54 5.43 22 12 P3 0.77 4.85 212.31 24.25 14.7 10.7 P4 8.24 6.52 1.73 5.70 10.7 10.3 P5 2.69 5.71 81.01 9.99 24.7 16.7 P6 5.17 4.94 14.52 17.03 20 18.7 P7 4.32 4.81 26.17 18.64 18.3 11.7 ^(a)ΔC_(t) for a sample is calculated as the C_(t, mRNAx) − C_(t, mRNA actin) where C_(t, mRNAx) is the number of PCR cycles required to achieve threshold fluorescence for gene “X” and C_(t, mRNA actin) is the analogous value for β-actin. Threshold values for the mRNA of interest and β-actin for a given sample were assayed simultaneously (i.e., during the same experiment). ^(b)The fold-change of the mRNA/β-actin mRNA ratio relative to the population average value ΔC_(t) for uninvolved skin. The fold-change is calculated as 2^(−(ΔΔCt)) where ΔΔC_(t) (comparative method) is equal to ΔC_(t, lesion) − ΔC_(t, population ave). ^(c)National Psoriasis Foundation (NPF) Score at week 0 and week 8.

The data in Table 11 shows the correlation coefficient and p-value for a one sided t-test as well as the exact p-value for a permutation test for a comparison of change in NPF score and ΔC_(t) value between week 0 and week 8 of treatment. The data show a significant correlation between ΔC_(t) values for TNFα, IFNγ, IL-12B and NPF Score, with the negative correlation confirming that an improvement (decrease) in NPF Score corresponds with a decrease (increase in ΔC_(t)) in mRNA levels. The table also shows that the correlation for IL-23B nears significance while the correlation of the housekeeping gene GAPDH is not significant. We suspect that with higher numbers of patients in the study the data would be even more significant. Similar data for CD2 and Krt-16 was not significant but trended towards significance (data not shown). We conclude that RNA recovered by the non-invasive tape stripping of psoriatic lesions can accurately portray clinical improvement. This data suggests that if molecular profiles exist that precede clinical improvement (i.e., predict outcome), that RNA recovered by tape stripping can reveal these profiles.

TABLE 11 Summary of correlation coefficients between change from week 0 and week 8 in NPF Score and ΔC_(t) value for various mRNAs in psoriatic lesions mRNA in Correlation Exact P value: lesion Observations Coefficient: R T_((N−2)) ^(a) One sided t test Permutation Test^(b) GAPDH 6 −0.56 −1.35 P > 0.10 0.097 TNFα 6 −0.74 −2.18 0.025 < P < 0.05 0.047 IFNγ 6 −0.85 −3.23 0.01 < P < 0.025 0.018 IL-12B 6 −0.76 −2.32 0.025 < P < 0.05 0.044 IL23-A 6 −0.73 −2.14 0.025 < P < 0.05 0.057 ^(a)A t-statistic with 4 degrees of freedom has been calculated to test the significance of the observed correlation coefficient using the formula; T_((N−2)) = R * (N − 2)^(0.5)/(1 − R²)^(0.5) ^(b)Since the number of observations used in the calculation of the correlation coefficient is only 6, calculation of T statistic, based on asymptotic normality may not be appropriate. Therefore we have used permutation test and exact probabilities of observing a correlation coefficient <= observed value have been calculated using bootstrap sampling. The software used for calculating these p values was “RESAMPLING STATS” in EXCEL.

The uninvolved skin data in Table 9 can be used to classify the lesional skin of patients in Table 2 by ΔC_(t) value. That is the ΔC_(t) value for different mRNAs in a lesion at time 0 can be classified as “normal” or “abnormal” by comparison with the population average ΔC_(t)'s for uninvolved skin. We have chosen as normal any value that falls within 3 SEMs of the average ΔC_(t) for uninvolved skin using the data in Table 9. The result of classifying lesions before treatment is shown in Table 12.

TABLE 12 Characterization of psoriatic lesions by comparison to population average values for uninvolved skin. Patient Molecular Phenotype of Lesion Before Treatment^(a) # GAPDH TNFα IFNγ IL-12B IL-23A Krt-16 CD2 2 − − − + − − − 3 − − − − − − − 4 − − + + + − − 5 − − − + − − − 6 − − + + − + + 7 − − − − − − − ^(a)classification of normal is indicated by “+”, while abnormal is indicated by “−”. The designation of normal is given if the lesion ΔC_(t) value (Table 10) approaches within 3 standard errors of the mean (SEM) of the population average value for uninvolved skin (Table 1). This criteria means that to be classified as normal, the ΔC_(t) values in the lesion must be greater than or equal to: 1.89 (GAPDH); 7.84 (TNFα); 8.34 (IFNγ); 6.1 (IL-12B); 7.14 (IL-23A); −1.69 (Krt-16); 7.53 (CD2). ΔC_(t) data is taken from Tables 1 and 3 with the exception of Krt-16 and CD2 patient data, which is not shown.

Table 12 shows that even this limited set of patients with similar clinical disease can be categorized into several sub-groups depending on the normal/abnormal profile of mRNA in the lesion. The most striking categories are patients 3 and 7 who have high levels of all mRNA in lesional skin and patients 4 and 6 who have normal levels of IFN and IL-12B in the lesion. The observation of very low IFNγ mRNA is surprising given the current dogma that IFNγ protein is elevated in all lesions. While the low mRNA level of IFNγ does not preclude high proteins levels, the fact that some lesions are low in IFNγ mRNA while others are high is surprising. While the significance of these differing lesional profiles has yet to be determined, we have confirmed that such profiling can be done using tape stripped mRNA. It is likely that with the addition of more patients in such studies and the use of DNA arrays to analyze RNA, significant multi-gene profiles will emerge that will be clinically useful.

Example 6 An Analysis of Keratin Gene Expression in SLS-IRRITATED AND CONTROL SKIN

This Example provides expression data of keratin 10, 16 and 17 in samples of SLS-irritated and control skin as recovered by tape harvesting and biopsy. The keratins are a family of cytoskeletal proteins found prominently in keratinocytes. The basal layer of the epidermis expresses Krt-5 and Krt-14, while the differentiating suprabasal layer expresses Krt-1 and Krt-10. When keratinocytes become inflammatory they are activated and express Krt-6, 16 and 17, while down-regulating transcription of Krt-10 (Komine, Freedberg et al. 1996; Freedberg, Tomic-Canic et al. 2001). Thus skin that has become inflamed by SLS would be predicted to express K16 and K17 and repress transcription of K10. In a continuing effort to define the ability of tape strip recovered RNA to reliably reveal quantitative changes in gene expression the expression of genes known to be induced by inflammation in tape stripped and biopsy samples of inflamed and control skin, were compared.

The samples analyzed in this study are those described in the protocol performed by Wong et al (Wong, Tran et al. 2004). Briefly, 10 subjects were occlusively patched (2 duplicate patches) with 1% SLS (aqueous) and water on the mid-back for 24 hours. Patches were removed and equivalent skin sites were biopsied and tape stripped as described in the Examples above. As an additional control, normal skin was also biopsied and tape stripped. Samples were processed for total RNA and assayed for keratin-10, keratin-16, keratin-17 and β-actin mRNA. The keratin mRNAs were normalized to β-actin mRNA in each sample. The semi-quantitative RT-PCR assay has been previously described (Wong, Tran et al. 2004).

Tables 13, 14 and 15 show the ΔC_(t) for Krt-10, Krt-16, and Krt-17 mRNA relative to β-actin mRNA. In addition, the tables also show the calculated fold-change of the mRNA/actin ratio in SLS and water treated skin relative to untreated skin. The tape and biopsy data for average K10 expression is virtually identical and reveals an approximate 20-fold average decrease in expression with SLS treatment, while water treatment has little effect (Table 13). Thus, for K10 expression, tape and biopsy data agree.

Table 14 shows biopsy data and tape data for K16 expression in SLS and water treated skin. As expected, K16 mRNA expression is increased in biopsy samples of SLS-treated skin. The table reveals an average 39-fold-increase with SLS treatment. Surprisingly, tape samples reveal an average 9-fold decrease in K16 expression in SLS treated samples. In order to confirm this difference between biopsy and tape data, we assayed the expression of K17, which is known to be induced with K16 during inflammation.

Table 15 shows the K17 data for tape and biopsy samples of SLS and water treated samples. The average fold-increase of K17 in biopsy samples of SLS-treated skin is 42-fold, virtually identical to the K16 data. Again, in contrast to biopsy samples, tape samples revealed the K17/actin mRNA ratio being 8-fold decreased in tape harvested samples of SLS-treated skin. Thus K16 and K17/actin mRNA ratios are consistently elevated in biopsy samples, as predicted, and decreased in tape harvested samples. This leads to the surprising conclusion that when irritated skin is sampled with tape, a decrease in K16 or K17 expression is diagnostic of inflammation.

The significance of the ΔC_(t) data in Tables 13, 14, and 15 was tested by a 2-way full, repeated measures ANOVA. The results showed significant overall effects for all the keratins (p<0.0001). Table 16 reveals some of the significant pair-wise comparisons. Table 16 reveals that not only are the fold-changes due to SLS-treatment highly significantly different, as expected, but that the ΔC_(t) values are also highly significantly different between tape and biopsy methods. This difference in ΔC_(t) values within a treatment and the fact that tape shows a decrease in Krt-16 and Krt-17 expression while biopsy shows an increase confirms previous data suggesting that tape harvesting and biopsy recover distinctly different cell populations.

LITERATURE CITED IN THIS EXAMPLE

-   Freedberg, I. M., M. Tomic-Canic, et al. (2001). “Keratins and the     keratinocyte activation cycle.” J Invest Dermatol 116(5): 633-40. -   Komine, M., I. M. Freedberg, et al. (1996). “Regulation of epidermal     expression of keratin K17 in inflammatory skin diseases.” J Invest     Dermatol 107(4): 569-75. -   Wong, R., V. Tran, et al. (2004). “The use of RT-PCR and DNA     microarrays to characterize RNA recovered by non-invasive     tape-harvesting of normal and inflamed skin.” J Invest Dermatol     123:159-167.

TABLE 13 Changes in ΔC_(t, Krt-10) in SLS treated, water-treated and untreated skin and resulting fold-change in Krt-10/β-actin mRNA ratio relative to untreated skin in RNA samples recovered by tape stripping and biopsy. ΔC_(t, Krt-10) ^(a) Fold Increase Krt-10/β-actin Tape Biopsy mRNA vs. normal^(b) Normal Normal Tape Biopsy ID Skin Water SLS Skin Water SLS Water SLS Water SLS 1 −2.13 −1.41 −2.76 −6.99 −7.06 −4.28 0.61 1.55 1.05 0.15 2 −1.45 −1.01 3.68 −7.22 −6.69 −0.24 0.74 0.03 0.69 0.01 3 −2.28 −3.09 8.19 −7.10 −7.26 −3.09 1.74 <0.001 1.11 0.06 4 — — −0.3 −6.98 −7.31 −6.35 — — 1.26 0.65 5 — −1.56 0.93 −7.38 −7.23 −4 — — 0.9 0.1 6 −2.08 0.97 5.1 −6.47 −6.45 0.4 0.12 0.01 0.99 0.01 7 −0.67 −0.87 1.03 −7.01 −7.17 −2 1.15 0.31 1.12 0.03 8 −2.29 −1.92 4.17 −6.65 −6.17 −2.7 0.77 0.01 0.72 0.06 9 −2.99 1.38 3.81 −6.51 −6.32 1.91 0.05 0.01 0.88 0.001 10  −0.53 −4.09 −0.81 −6.8 −6.03 −5.97 11.91 1.22 0.59 0.57 Average −1.80 −1.29 2.30 −6.91 −6.77 −2.63 0.70 0.06 0.91 0.05 ^(a)ΔC_(t, Krt-10) is defined as C_(t, Krt-10) − C_(t, actin) where C_(t, Krt-10) is the number of PCR cycles required to reach threshold fluorescence for Krt-10 detection and C_(t, actin) is the analogous number for β-actin detection in the same sample. ^(b)Fold-increase is calculated as 2^(−(ΔΔCT)) where ΔΔC_(t) is equal to ΔC_(t, condition) − ΔC_(t, normal); ΔC_(t, condition) is defined above where “condition” refers to either water or SLS treatment; ΔC_(t, normal) is the ΔC_(t) value in the normal (untreated skin) sample. Fold-increases were calculated using the data in the columns to the left. The method is described in detail in Wong et al (Wong, Tran et al. 2004).

TABLE 14 Changes in ΔC_(t, Krt-16) in SLS treated, water-treated and untreated skin and resulting fold-change in Krt-16/β-actin mRNA ratio relative to untreated skin in RNA samples recovered by tape stripping and biopsy. ΔC_(t, Krt-16) ^(a) Fold Increase Krt-16/actin Tape Biopsy mRNA ratio vs. normal^(a) Normal Normal Tape Biopsy ID Skin Water SLS Skin Water SLS Water SLS Water SLS 1 −4.18 −3.55 −4.51 4.85 5.33 0.97 0.64 1.25 0.72 14.73 2 −0.15 0.75 3.04 3.83 3.98 −2.43 0.54 0.11 0.90 76.61 3 −1.05 −2.42 3.96 3.57 3.14 −2.21 2.59 0.03 1.35 55.14 4 — — −2.87 5.61 3.62 1.41 — — 3.97 18.4 5 — −3.11 0.53 3.83 5 −1.12 — — 0.44 30.85 6 −3.57 −0.09 3.1 5.08 3.08 −1.75 0.09 0.01 4 113.69 7 −1.8 −1.29 0.53 4.76 4.81 −2.01 0.7 0.2 0.96 108.78 8 −1.48 −1.01 4.32 4.59 0.88 −1.79 0.72 0.02 13.04 82.98 9 −1.8 −2.13 2.87 3.84 3.88 0.74 1.26 0.04 0.97 8.57 10  −3.54 −1.69 −0.97 4.31 3.74 −0.32 0.28 0.17 1.48 24.78 Average −2.20 −1.62 1.00 4.43 3.75 −0.85 0.67 0.11 1.60 38.80 ^(a)See footnotes to Table 13 for a description of calculations.

TABLE 15 Changes in ΔC_(t, Krt-17) in SLS treated, water-treated and untreated skin and resulting fold-change in Krt-17/β-actin mRNA ratio relative to untreated skin in RNA samples recovered by tape stripping and biopsy. ΔC_(t, Krt-17) ^(a) Fold Increase Krt-17/β-actin Tape Biopsy mRNA ratio vs. normal^(a) Normal Normal Tape Biopsy ID Skin Water SLS Skin Water SLS Water SLS Water SLS 1 −4.38 −5.04 −5.12 4.45 3.4 0.71 1.58 1.67 2.06 13.31 2 −4.01 −3.63 1.64 4.27 2.89 −2.29 0.77 0.02 2.61 94.54 3 −3.84 −4.55 1.5 2.99 3.27 −2.5 1.63 0.02 0.82 44.95 4 — — −4.87 3.31 2.4 1.13 — — 1.87 4.51 5 — −5.1 −1.79 2.8 1.37 −1.97 — — 2.69 27.19 6 −5.26 −2.47 1.11 2.32 2.39 −1.63 0.14 0.01 0.95 15.44 7 −4.4 −4.62 −1.84 5.93 7.26 −2.91 1.16 0.17 0.4 459.45 8 −2.99 −3.53 1.38 5.86 1.96 −1.75 1.46 0.05 14.76 195.94 9 −4.35 −3.3 0.21 3.74 3.11 −1.86 0.48 0.04 1.55 48.35 10  −3.1 −4.01 −2.12 5.25 3.97 −0.11 1.87 0.5 2.43 41.13 Average −4.04 −4.03 −0.99 4.09 3.20 −1.32 0.99 0.12 1.85 42.52 d. See footnotes to Table 13 for a description of calculations.

TABLE 16 Significant pair-wise comparisons of ΔC_(t) values between sampling method and treatment. p-value by treatment^(b) mRNA Sampling method^(a) Untreated Water-treated SLS-treated Krt-10 Biopsy — 0.87 <0.0001 Tape — 0.58 <0.0001 Tape vs. biopsy <0.0001 <0.0001 0.0001 Krt-16 Biopsy — 0.37 <0.0001 Tape — 0.68 0.0002 Tape vs. biopsy <0.0001 <0.0001 0.017 Krt-17 Biopsy — 0.21 <0.0001 Tape — 0.8 0.0003 Tape vs. biopsy <0.0001 <0.0001 0.64 ^(a)When a single method is shown, the comparison is between that sampling method on normal skin versus the same sampling method on water or SLS treated skin. ^(b)Resulting p-values from pair-wise comparison of a 2-way full measures ANOVA. ΔC_(t) values are compared within a sampling method for normal versus SLS or water treated skin (i.e., biopsy of SLS-treated skin vs. biopsy of normal skin) and between methods for a given treatment (i.e., biopsy vs. tape for SLS treated skin).

Example 7 Differentiation of Irritant and Allergic Reactions by mRNA Profiling

This Example provides experiments to identify of RNA profiles that can differentiate irritant contact dermatitis (ICD) from allergic contact dermatitis (ACD). Current obstacles to differentiating irritant from allergic skin reactions are the clinical similarity of these different dermatitides. Molecular and histological analysis have shown that these reactions share many similar features but are known to have distinct identifying histologically features. To date there has been no demonstration of an RNA assay that can reliably differentiate between these two classes of dermatitides for broad classes of substances.

Method:

A clinical trial is conducted with up to 20 subjects. Each subject is patched occlusively with Finn chambers containing different irritants and allergens. Irritants such as: Triton X100, sodium lauryl sulfate, 8% formaldehyde, Tween 80, benzalkonium chloride, benzoic acid, CTAB, resorcinol, or phenol are applied at concentrations known to produce irritant skin reactions for up to 24 hours with the appropriate vehicle, with vehicle controls. Allergens such as poison ivy (rhus), 1% formaldehyde, nickel sulphate, coumarin, neomycin, Balsam of Peru, Kathon CG, epoxy resin, Carbamix, methyldibromoglutaronitril, imidazolidinyl urea or sequiterpene lactone mix are used at the appropriate concentrations in the standard vehicles. After up to 24 hours of exposure, chambers are removed and skin reactions scored. The sites are then tape harvested with up to 4 tapes sequentially applied and removed, using skin harvesting tape (Product No. 90068) (Adhesives Research, Glen Rock, Pa.). RNA is extracted from the tapes, amplified by the standard T7 linear method and amplified RNA hybridized to DNA arrays. From this data, distinct RNA differential expression profiles are identified; these profiles are confirmed in a second experiment.

A second protocol is performed to confirm that the profiles identified above can be used to reproducibly differentiate ACD from ICD. This second study is similar in design to the first, with the exception that at least one half the subjects will be different than the first study.

A core group of differentially regulated RNAs are expected to be identified that are unique, or expressed at different levels, in an irritant skin reaction compared to an allergic skin reaction. These RNAs will constitute a profile to be used to differentiate allergic from irritant skin reactions.

Example 8 Prediction of Irritant Skin Reactions Prior to Clinical Symptoms or with Slight Clinical Presentation

This Example provides experiments to identify RNA expression profiles that predict the onset of clinical irritation or toxic or corrosive skin reactions. In order to demonstrate an irritant or toxic/corrosive skin reaction it is necessary to apply the compound to the skin and leave it until a reaction becomes clinically apparent or a suitable amount of time has passed without any reaction (typically 2-3 weeks). The introduction of an assay that could reliably predict the probability that a substance would create a irritant or toxic/corrosive skin reaction after 1-3 hours of application to the skin represents a significant advancement.

Method:

A clinical protocol with up to 20 subjects is performed. Occlusive patches are applied to the skin for 1-3 hours. The patches contain strong irritants or known corrosive/toxic materials at concentrations known in advance not to cause more than a slight irritant skin reaction (defined as patchy light pink erythema) under the conditions of the trial. Vehicle controls such as dilutions of the test materials or water are applied. Examples of such strong irritants are: 20% sodium lauryl sulfate; 100% octanol; 10% acetic acid; 100% decanol. After 1-3 hours of exposure, patches (or Finn chambers) are removed and skin clinically scored. The sites are then tape harvested with up to 4 tapes sequentially applied and removed. RNA is extracted from the tapes, amplified by the standard T7 linear method and amplified RNA hybridized to DNA arrays. From this data, distinct RNA differential expression profiles are identified; these profiles will be confirmed in a second experiment with the same chemicals and different subjects.

It is likely that 1 to 3 hours of occlusive exposure to a diluted irritant or toxic/corrosive chemical is sufficient to induce transcriptional changes predictive of a strong irritant or toxic potential without actually inducing severe clinical irritation or toxicity. Thus, using the RNA profile it will be possible to deduce a substance's potential to create a strong irritant or toxic/corrosive skin reaction without actually effecting that reaction.

Example 9 Analysis of Psoriatic Lesions and Uninvolved Skin Before Treatment to Identify RNA Profiles Correlated with Specific Treatment Outcome

This Example provides experiments to identify, by microarray analysis, specific RNA profiles of psoriatic lesions—using RNA captured by tape stripping—that are predictive of success using a particular treatment(s). As illustrated in the Examples above, tape harvested RNA samples are reflective of pathological and/or normal skin physiology. Furthermore, as illustrated herein, psoriatic lesions can be sorted into different groups depending on the RNA profile revealed in tape strip samples. Thus, with different treatments, higher numbers of patients and the use of nucleic acid arrays to sift through large numbers of genes (human genome scan), it is expected that unique profiles will be identified that predict the effectiveness of a particular therapy.

Method:

In this study, psoriatic patients are tape stripped between 1 and 10 times using adhesive tape Prod. No. 90068 from Adhesive Research (Glen Rock, Pa.) on lesional and non-lesional skin before they undergo treatment. Patients that have received treatment previously undergo a standard “washout” period before being tape stripped and initiating treatment. During treatment, patients are tape stripped at weeks 1, 2, 4, 8, 12 and 24; NPF scores are generated at those visits. RNA is isolated, amplified, and hybridized to nucleic acid arrays as previously described. Statistical is performed to correlate RNA profile with NPF score at different weeks.

It is expected that RNA profiles of either lesions and/or uninvolved skin—previous to treatment—exist that correlate with lowering of NPF score (i.e., successful clinical outcome) after treatment with a particular therapy. This will allow the predetermination of the most efficacious therapy for a particular patient.

Example 10 Prediction of Treatment Efficacy Before Clinical Indication by Analysis of RNA Early in the Treatment Process

This example provides experiments aimed at identifying RNA profiles that are predictive of ultimate treatment efficacy early in the treatment program. It is illustrated herein that tape sampling of psoriatic lesions can be used to monitor the progress of treatment by RNA profiling. Preliminary data have also shown that some mRNA levels do not restore to normal levels and that some patients with this profile fail to ultimately respond to treatment. It is hypothesized that additional RNAs will be identified and that through multivariate analysis RNA expression profiles will be identified that correlate highly with response to treatment early in the treatment process.

Method:

Patients are tape stripped on lesional and non-lesional skin before and during therapy. Tape strip samples and NPF scores are generated at times 0, 1 week, 2 week, 3 week, 4 week and 6 weeks. RNA is isolated, amplified and hybridized to DNA arrays as previously disclosed herein. Data is analyzed and RNA profiles correlated with NPF scores.

It is anticipated that RNA profiles generated early in the treatment regime (weeks 1 through 6) that are highly correlated with a reduction of ultimate NPF score (at week 16 or greater), will be generated. Identification of such profiles will allow the identification of patients ultimately destined not to respond to treatment, thus allowing a change in treatment early in the process. Such screening will allow greater cost and time efficiency, and probably speed time to recovery.

BIBLIOGRAPHY

-   Ackerman, S. J., L. Liu, et al. (2002). “Charcot-Leyden crystal     protein (galectin-10) is not a dual function galectin with     lysophospholipase activity but binds a lysophospholipase inhibitor     in a novel structural fashion.” J Biol Chem 277(17): 14859-68. -   Aitman, T. J. (2001). “DNA microarrays in medical practice.” Bmj     323(7313): 611-5. -   Alberts, B., D. Bray, et al. (1994). The immune system. Molecular     Biology of The Cell. New York, N.Y., Garland Publishing, Inc.:     1229-1235. -   Allison, D. B., G. L. Gadbury, et al. (2002). “A mixture model     approach for the analysis of microarray gene expression data.”     Computational Statistics and Data Analysis 39: 1-20. -   Applied Biosystems (2001). User Bulletin #2: Relative quantitation     of gene expression. -   Asadullah, K., W. Sterry, et al. (2002). “Cytokines: interleukin and     interferon therapy in dermatology.” Clin Exp Dermatol 27(7): 578-84. -   Baker, B. S., J. M. Ovigne, et al. (2003). “Normal keratinocytes     express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR     expression in chronic plaque psoriasis.” Br J Dermatol 148(4):     670-9. -   Baldi, P. and G. W. Hatfield (2002). DNA microarrays and gene     expression: From experiments to data analysis and modeling.     Cambridge, UK, Cambridge University Press. -   Baldi, P. and A. D. Long (2001). “A Bayesian framework for the     analysis of microarray expression data: regularized t-test and     statistical inferences of gene changes.” Bioinformatics 17(6):     509-519. -   Bayon, Y., A. Alonso, et al. (1998). “Mechanisms of cell signaling     in immune-mediated inflammation.” Cytokines Cell Mol Ther 4(4):     275-86. -   Benavides, F., M. F. Starost, et al. (2002). “Impaired hair follicle     morphogenesis and cycling with abnormal epidermal differentiation in     nackt mice, a cathepsin L-deficient mutation.” Am J Pathol 161(2):     693-703. -   Bertucci, F., R. Houlgatte, et al. (2001). “Gene expression     profiling of cancer by use of DNA arrays: how far from the clinic?”     Lancet Oncol 2(11): 674-82. -   Boelsma, E., S. Gibbs, et al. (1998). “Expression of skin-derived     antileukoproteinase (SKALP) in reconstructed human epidermis and its     value as a marker for skin irritation.” Acta Derm Venereol 78(2):     107-13. -   Boxman, I. L., P. J. Hensbergen, et al. (2002). “Proteomic analysis     of skin irritation reveals the induction of HSP27 by sodium lauryl     sulphate in human skin.” Br J Dermatol 146(5): 777-85. -   Bustin, S. A. (2002). “Quantification of mRNA using real-time     reverse transcription PCR(RT-PCR): trends and problems.” J Mol     Endocrinol 29(1): 23-39. -   Chung, N. M., C. M. Marshall, et al. (2001). “Sodium dodecyl sulfate     induces plasminogen activator inhibitor type 2 expression in     epidermal keratinocytes in vivo and in vitro.” J Invest Dermatol     117(3): 647-53. -   Chung, S. I., S. Y. Lee, et al. (1996). “Factors that control     extravascular fibrinolysis.” Semin Thromb Hemost 22(6): 479-88. -   Colonna, M. (2003). “TREMs in the immune system and beyond.” Nat Rev     Immunol 3(6): 445-53. -   Coquette, A., N. Berna, et al. (2003). “Analysis of     interleukin-1alpha (IL-1alpha) and interleukin-8 (IL-8) expression     and release in in vitro reconstructed human epidermis for the     prediction of in vivo skin irritation and/or sensitization.” Toxicol     In Vitro 17(3): 311-21. -   Corsini, E. and C. L. Galli (1998). “Cytokines and irritant contact     dermatitis.” Toxicol Lett 102-103: 277-82. -   Cumberbatch, M., R. J. Dearman, et al. (2002). “Differential     regulation of epidermal langerhans cell migration by interleukins     (IL)-1 alpha and IL-1beta during irritant- and allergen-induced     cutaneous immune responses.” Toxicol Appl Pharmacol 182(2): 126-35. -   Dong, V. M., D. H. McDermott, et al. (2003). “Chemokines and     diseases.” Eur J Dermatol 13(3): 224-30. -   Feghali, C. A. and T. M. Wright (1997). “Cytokines in acute and     chronic inflammation.” Front Biosci 2: d12-26. -   Flier, J., D. M. Boorsma, et al. (1999). “The CXCR3 activating     chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in     irritant patch test reactions.” J Invest Dermatol 113(4): 574-8. -   Fray, M. J., R. P. Dickinson, et al. (2003). “A potent, selective     inhibitor of matrix metalloproteinase-3 for the topical treatment of     chronic dermal ulcers.” J Med Chem 46(16): 3514-25. -   Freedberg, I. M., M. Tomic-Canic, et al. (2001). “Keratins and the     keratinocyte activation cycle.” J Invest Dermatol 116(5): 633-40. -   Galiegue, S, and P. Casellas (2002). “[Exploitation of expression     profiles: examples in oncology].” J Soc Biol 196(4): 313-5. -   Gibson, U. E., C. A. Heid, et al. (1996). “A novel method for real     time quantitative RT-PCR.” Genome Res 6(10): 995-1001. -   Grangsjo, A., A. Leijon-Kuligowski, et al. (1996). “Different     pathways in irritant contact eczema? Early differences in the     epidermal elemental content and expression of cytokines after     application of 2 different irritants.” Contact Dermatitis 35(6):     355-60. -   Hatfield, G. W., S. P. Hung, et al. (2003). “Differential analysis     of DNA microarray gene expression data.” Mol. Microbiol. 47(4):     871-877. -   Heid, C. A., J. Stevens, et al. (1996). “Real time quantitative     PCR.” Genome Res 6(10): 986-94. -   Herouy, Y. (2001). “Matrix metalloproteinases in skin pathology     (Review).” Int J Mol Med 7(1): 3-12. -   Hoefakker, S., M. Caubo, et al. (1995). “In vivo cytokine profiles     in allergic and irritant contact dermatitis.” Contact Dermatitis     33(4): 258-66. -   Hoffrage, U., S. Lindsey, et al. (2000). “Communicating Statistical     Information.” Science 290(5500): 2261-2262. -   Howie, S. E., R. D. Aldridge, et al. (1996). “Epidermal keratinocyte     production of interferon-gamma immunoreactive protein and mRNA is an     early event in allergic contact dermatitis.” J Invest Dermatol     106(6): 1218-23. -   Hung, S.-P., P. Baldi, et al. (2002). “Global gene expression     profiling in Escherichia coli K12: The effects of leucine-responsive     regulatory protein.” J. Biol. Chem. 277(43): 40309-40323. -   Ichinose, A. (2001). “Physiopathology and regulation of factor     XIII.” Thromb Haemost 86(1): 57-65. -   Kahari, V. M. and U. Saarialho-Kere (1997). “Matrix     metalloproteinases in skin.” Exp Dermatol 6(5): 199-213. -   Kawada, A., K. Hara, et al. (1997). “Processing of cathepsins L, B     and D in psoriatic epidermis.” Arch Dermatol Res 289(2): 87-93. -   Kerkhoff, C., I. Eue, et al. (1999). “The regulatory role of MRP8     (S100A8) and MRP14 (S100A9) in the transendothelial migration of     human leukocytes.” Pathobiology 67(5-6): 230-2. -   Kilpatrick, D.C. (2002). “Animal lectins: a historical introduction     and overview.” Biochim Biophys Acta 1572(2-3): 187-97. -   Komine, M., L. S. Rao, et al. (2001). “Interleukin-1 induces     transcription of keratin K6 in human epidermal keratinocytes.” J     Invest Dermatol 116(2): 330-8. -   Lacroix, M., N. Zammatteo, et al. (2002). “A low-density DNA     microarray for analysis of markers in breast cancer.” Int J Biol     Markers 17(1): 5-23. -   Lendeckel, U., M. Arndt, et al. (2003). “Synergistic action of DPIV     and APN in the regulation of T cell function.” Adv Exp Med Biol 524:     123-31. -   Li, C. and W. H. Wong (2001). “Model-based analysis of     oligonucleotide arrays: expression index computation and outlier     detection.” Proc. Natl. Acad. Sci. U.S.A. 98(1): 31-36. -   Lobmann, R., A. Ambrosch, et al. (2002). “Expression of     matrix-metalloproteinases and their inhibitors in the wounds of     diabetic and non-diabetic patients.” Diabetologia 45(7): 1011-6. -   Long, A. D., H. J. Mangalam, et al. (2001). “Improved statistical     inference from DNA microarray data using analysis of variance and a     Bayesian statistical framework. Analysis of global gene expression     in Escherichia coli K12.” J. Biol. Chem. 276(23): 19937-19944. -   Lucas, M., L. Daniel, et al. (2002). “Massive inflammatory syndrome     and lymphocytic immunodeficiency in KARAP/DAP12-transgenic mice.”     Eur J Immunol 32(9): 2653-63. -   Melen, K., P. Keskinen, et al. (1996). “Human MxB protein, an     interferon-alpha-inducible GTPase, contains a nuclear targeting     signal and is localized in the heterochromatin region beneath the     nuclear envelope.” J Biol Chem 271(38): 23478-86. -   Molhuizen, H. O. and J. Schalkwijk (1995). “Structural, biochemical,     and cell biological aspects of the serine proteinase inhibitor     SKALP/elafin/ESI.” Biol Chem Hoppe Seyler 376(1): 1-7. -   Morhenn, V. B., E. Y. Chang, et al. (1999). “A noninvasive method     for quantifying and distinguishing inflammatory skin reactions.” J     Am Acad Dermatol 41(5 Pt 1): 687-92. -   Muller-Decker, K., G. Furstenberger, et al. (1994).     “Keratinocyte-derived proinflammatory key mediators and cell     viability as in vitro parameters of irritancy: a possible     alternative to the Draize skin irritation test.” Toxicol Appl     Pharmacol 127(1): 99-108. -   Muller-Decker, K., T. Heinzelmann, et al. (1998). “Arachidonic acid     metabolism in primary irritant dermatitis produced by patch testing     of human skin with surfactants.” Toxicol Appl Pharmacol 153(1):     59-67. -   Paludan, K. and K. Thestrup-Pedersen (1992). “Use of the polymerase     chain reaction in quantification of interleukin 8 mRNA in minute     epidermal samples.” J Invest Dermatol 99(6): 830-5. -   Perkins, M. A., C. W. Cardin, et al. (2002). “A non-invasive tape     absorption method for recovery of inflammatory mediators to     differentiate normal from compromised scalp conditions.” Skin Res     Technol 8(3): 187-93. -   Perkins, M. A., M. A. Osterhues, et al. (2001). “A noninvasive     method to assess skin irritation and compromised skin conditions     using simple tape adsorption of molecular markers of inflammation.”     Skin Res Technol 7(4): 227-37. -   Phan, U. T., R. L. Lackman, et al. (2002). “Role of the C-terminal     propeptide in the activity and maturation of     gamma-interferon-inducible lysosomal thiol reductase (GILT).” Proc     Natl Acad Sci USA 99(19): 12298-303. -   Pilcher, B. K., M. Wang, et al. (1999). “Role of matrix     metalloproteinases and their inhibition in cutaneous wound healing     and allergic contact hypersensitivity.” Ann N Y Acad Sci 878: 12-24. -   Raval, G. N., S. Bharadwaj, et al. (2003). “Loss of expression of     tropomyosin-1, a novel class II tumor suppressor that induces     anoikis, in primary breast tumors.” Oncogene 22(40): 6194-203. -   Ryan, C. A. and G. F. Gerberick (1999). “Cytokine mRNA expression in     human epidermis after patch treatment with rhus and sodium lauryl     sulfate.” Am J Contact Dermat 10(3): 127-35. -   Samal, B., Y. Sun, et al. (1994). “Cloning and characterization of     the cDNA encoding a novel human pre-B-cell colony-enhancing factor.”     Mol Cell Biol 14(2): 1431-7. -   Satagopan, J. M. and K. S. Panageas (2003). “A statistical     perspective on gene expression data analysis.” Stat Med 22(3):     481-99. -   Suzuki, T., P. J. Higgins, et al. (2000). “Control selection for RNA     quantitation.” Biotechniques 29(2): 332-7. -   Syrokou, A., K. Dobra, et al. (2002). “Synthesis and expression of     mRNA encoding for different versican splice variants is related to     the aggregation of human epithelial mesothelioma cells.” Anticancer     Res 22(6C): 4157-62. -   Thorey, I. S., J. Roth, et al. (2001). “The Ca²⁺-binding proteins     S100A8 and S100A9 are encoded by novel injury-regulated genes.” J     Biol Chem 276(38): 35818-25. -   Tomic-Canic, M., M. Komine, et al. (1998). “Epidermal signal     transduction and transcription factor activation in activated     keratinocytes.” J Dermatol Sci 17(3): 167-81. -   Tricarico, C., P. Pinzani, et al. (2002). “Quantitative real-time     reverse transcription polymerase chain reaction: normalization to     rRNA or single housekeeping genes is inappropriate for human tissue     biopsies.” Anal Biochem 309(2): 293-300. -   Ulfgren, A. K., L. Klareskog, et al. (2000). “An immunohistochemical     analysis of cytokine expression in allergic and irritant contact     dermatitis.” Acta Derm Venereol 80(3): 167-70. -   Vallejo, A. N., L. O. Mugge, et al. (2000). “Central role of     thrombospondin-1 in the activation and clonal expansion of     inflammatory T cells.” J Immunol 164(6): 2947-54. -   van Ruissen, F., M. Le, et al. (1998). “Differential effects of     detergents on keratinocyte gene expression.” J Invest Dermatol     110(4): 358-63. -   Verhoef, J. (1991). “The phagocytic process and the role of     complement in host defense.” J Chemother 3 Suppl 1: 93-7. -   Vermeer, P. D., L. A. Einwalter, et al. (2003). “Segregation of     receptor and ligand regulates activation of epithelial growth factor     receptor.” Nature 422(6929): 322-6. -   Weiss, T., J. Sun, et al. (2003). “Hurpin is a selective inhibitor     of lysosomal cathepsin L and protects keratinocytes from     ultraviolet-induced apoptosis.” Biochemistry 42(24): 7381-9. -   Whipple, M. E. and W. P. Kuo (2002). “DNA microarrays in     otolaryngology-head and neck surgery.” Otolaryngol Head Neck Surg     127(3): 196-204.

Although the invention has been described with reference to the above example, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

APPENDIX Affymetrix gene expression data for the 1771 genes expressed at a PPDE value equal to or greater than 0.99 For replicate experiments comparing RNA extracted from three normal and three SLS-treated skin samples. Affy Probe_ID Sequence Description 215189_at Consensus includes gb: X99142.1 /DEF = H. sapiens mRNA for hair keratin, hHb6. /FEA = mRNA /GEN = hHb6 /PROD = type II intermediate filament of hair keratin /DB_XREF = gi: 1903219 /UG = Hs.278658 keratin, hair, basic, 6 (monilethrix) 41469_at Cluster Incl. L10343: Huma elafin gene, complete cds /cds = (516, 869) /gb = L10343 /gi = 190337 /ug = Hs.112341 /len = 871 204103_at gb: NM_002984.1 /DEF = Homo sapiens small inducible cytokine A4 (homologous to mouse Mip-1b) (SCYA4), mRNA. /FEA = mRNA /GEN = SCYA4 /PROD = small inducible cytokine A4 (homologous to mouseMip-1b) /DB_XREF = gi: 4506844 /UG = Hs.75703 small inducible cytokine A4 (homologous to mouse Mip-1b) /FL = gb: J04130.1 gb: NM_002984.1 gb: M23502.1 gb: M25316.1 219890_at gb: NM_013252.1 /DEF = Homo sapiens C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5 (CLECSF5), mRNA. /FEA = mRNA /GEN = CLECSF5 /PROD = C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 5 /DB_XREF = gi: 10281668 /UG = Hs.126355 C- type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 5 /FL = gb: NM_013252.1 gb: AF139768.1 203416_at gb: NM_000560.1 /DEF = Homo sapiens CD53 antigen (CD53), mRNA. /FEA = mRNA /GEN = CD53 /PROD = CD53 antigen /DB_XREF = gi: 10834971 /UG = Hs.82212 CD53 antigen /FL = gb: NM_000560.1 gb: M60871.1 gb: M37033.1 201859_at gb: NM_002727.1 /DEF = Homo sapiens proteoglycan 1, secretory granule (PRG1), mRNA. /FEA = mRNA /GEN = PRG1 /PROD = proteoglycan 1, secretory granule /DB_XREF = gi: 4506044 /UG = Hs.1908 proteoglycan 1, secretory granule /FL = gb: J03223.1 gb: NM_002727.1 205828_at gb: NM_002422.2 /DEF = Homo sapiens matrix metalloproteinase 3 (stromelysin 1, progelatinase) (MMP3), mRNA. /FEA = mRNA /GEN = MMP3 /PROD = matrix metalloproteinase 3 preproprotein /DB_XREF = gi: 13027803 /UG = Hs.83326 matrix metalloproteinase 3 (stromelysin 1, progelatinase) /FL = gb: NM_002422.2 gb: J03209.1 216810_at Consensus includes gb: AJ406939.1 /DEF = Homo sapiens mRNA for keratin associated protein 4.7 (KRTAP4.7 gene). /FEA = mRNA /GEN = KRTAP4.7 /PROD = keratin associated protein 4.7 /DB_XREF = gi: 12655451 /UG = Hs.307020 Homo sapiens mRNA for keratin associated protein 4.7 (KRTAP4.7 gene) 202878_s_at gb: NM_012072.2 /DEF = Homo sapiens complement component C1q receptor (C1QR), mRNA. /FEA = mRNA /GEN = C1QR /PROD = complement component C1q receptor /DB_XREF = gi: 11496985 /UG = Hs.97199 complement component C1q receptor /FL = gb: NM_012072.2 gb: U94333.1 217897_at gb: NM_022003.1 /DEF = Homo sapiens FXYD domain-containing ion transport regulator 6 (FXYD6), mRNA. /FEA = mRNA /GEN = FXYD6 /PROD = FXYD domain-containing ion transport regulator6 /DB_XREF = gi: 11612654 /UG = Hs.3807 FXYD domain-containing ion transport regulator 6 /FL = gb: NM_022003.1 gb: AL136699.1 203691_at gb: NM_002638.1 /DEF = Homo sapiens protease inhibitor 3, skin-derived (SKALP) (PI3), mRNA. /FEA = mRNA /GEN = PI3 /PROD = protease inhibitor 3, skin-derived (SKALP) /DB_XREF = gi: 4505786 /UG = Hs.112341 protease inhibitor 3, skin-derived (SKALP) /FL = gb: NM_002638.1 207526_s_at gb: NM_003856.1 /DEF = Homo sapiens interleukin 1 receptor-like 1 (IL1RL1), mRNA. /FEA = mRNA /GEN = IL1RL1 /PROD = interleukin 1 receptor-like 1 /DB_XREF = gi: 4507244 /UG = Hs.66 interleukin 1 receptor-like 1 /FL = gb: NM_003856.1 209596_at gb: AF245505.1 /DEF = Homo sapiens adlican mRNA, complete cds. /FEA = mRNA /PROD = adlican /DB_XREF = gi: 9280404 /UG = Hs.72157 DKFZP564I1922 protein /FL = gb: AF245505.1 210873_x_at gb: U03891.2 /DEF = Homo sapiens phorbolin I mRNA, complete cds. /FEA = mRNA /PROD = phorbolin I /DB_XREF = gi: 4895107 /UG = Hs.226307 phorbolin (similar to apolipoprotein B mRNA editing protein) /FL = gb: U03891.2 212646_at Consensus includes gb: D42043.1 /DEF = Human mRNA for KIAA0084 gene, partial cds. /FEA = mRNA /GEN = KIAA0084 /DB_XREF = gi: 577298 /UG = Hs.79123 KIAA0084 protein 215049_x_at Consensus includes gb: Z22969.1 /DEF = H. sapiens mRNA for M130 antigen cytoplasmic variant 1. /FEA = mRNA /PROD = M130 antigen cytoplasmic variant 1 /DB_XREF = gi: 312143 /UG = Hs.74076 CD163 antigen 202957_at gb: NM_005335.1 /DEF = Homo sapiens hematopoietic cell-specific Lyn substrate 1 (HCLS1), mRNA. /FEA = mRNA /GEN = HCLS1 /PROD = hematopoietic cell-specific Lyn substrate 1 /DB_XREF = gi: 4885404 /UG = Hs.14601 hematopoietic cell-specific Lyn substrate 1 /FL = gb: NM_005335.1 203234_at gb: NM_003364.1 /DEF = Homo sapiens uridine phosphorylase (UP), mRNA. /FEA = mRNA /GEN = UP /PROD = uridine phosphorylase /DB_XREF = gi: 4507838 /UG = Hs.77573 uridine phosphorylase /FL = gb: BC001405.1 gb: NM_003364.1 219434_at gb: NM_018643.1 /DEF = Homo sapiens triggering receptor expressed on myeloid cells 1 (TREM1), mRNA. /FEA = mRNA /GEN = TREM1 /PROD = triggering receptor expressed on myeloid cells 1 /DB_XREF = gi: 8924261 /UG = Hs.283022 triggering receptor expressed on myeloid cells 1 /FL = gb: AF196329.1 gb: NM_018643.1 gb: AF287008.1 204620_s_at gb: NM_004385.1 /DEF = Homo sapiens chondroitin sulfate proteoglycan 2 (versican) (CSPG2), mRNA. /FEA = mRNA /GEN = CSPG2 /PROD = chondroitin sulfate proteoglycan 2 (versican) /DB_XREF = gi: 4758081 /UG = Hs.81800 chondroitin sulfate proteoglycan 2 (versican) /FL = gb: NM_004385.1 212588_at Consensus includes gb: Y00062.1 /DEF = Human mRNA for T200 leukocyte common antigen (CD45, LC-A). /FEA = mRNA /DB_XREF = gi: 34275 /UG = Hs.170121 protein tyrosine phosphatase, receptor type, C 201785_at gb: NM_002933.1 /DEF = Homo sapiens ribonuclease, RNase A family, 1 (pancreatic) (RNASE1), mRNA. /FEA = mRNA /GEN = RNASE1 /PROD = ribonuclease, RNase A family, 1 (pancreatic) /DB_XREF = gi: 4506546 /UG = Hs.78224 ribonuclease, RNase A family, 1 (pancreatic) /FL = gb: BC005324.1 gb: NM_002933.1 gb: D26129.1 206385_s_at gb: NM_020987.1 /DEF = Homo sapiens ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript variant 1, mRNA. /FEA = mRNA /GEN = ANK3 /PROD = ankyrin 3, isoform 1 /DB_XREF = gi: 10947055 /UG = Hs.75893 ankyrin 3, node of Ranvier (ankyrin G) /FL = gb: NM_020987.1 gb: U13616.1 213733_at Consensus includes gb: BF740152 /FEA = EST /DB_XREF = gi: 12066828 /DB_XREF = est: 7n13g08.x1 /CLONE = IMAGE: 3564495 /UG = Hs.121555 myosin IE 204122_at gb: NM_003332.1 /DEF = Homo sapiens TYRO protein tyrosine kinase binding protein (TYROBP), mRNA. /FEA = mRNA /GEN = TYROBP /PROD = TYRO protein tyrosine kinase binding protein /DB_XREF = gi: 4507754 /UG = Hs.9963 TYRO protein tyrosine kinase binding protein /FL = gb: AF019562.1 gb: NM_003332.1 201721_s_at gb: NM_006762.1 /DEF = Homo sapiens Lysosomal-associated multispanning membrane protein-5 (LAPTM5), mRNA. /FEA = mRNA /GEN = LAPTM5 /PROD = Lysosomal-associated multispanning membrane protein-5 /DB_XREF = gi: 5803055 /UG = Hs.79356 Lysosomal-associated multispanning membrane protein-5 /FL = gb: U51240.1 gb: NM_006762.1 gb: U30498.1 211538_s_at gb: U56725.1 /DEF = Human heat shock protein mRNA, complete cds. /FEA = mRNA /PROD = heat shock protein /DB_XREF = gi: 4204879 /UG = Hs.75452 heat shock 70 kD protein 2 /FL = gb: U56725.1 204438_at gb: NM_002438.1 /DEF = Homo sapiens mannose receptor, C type 1 (MRC1), mRNA. /FEA = mRNA /GEN = MRC1 /PROD = mannose receptor, C type 1 /DB_XREF = gi: 4505244 /UG = Hs.75182 mannose receptor, C type 1 /FL = gb: J05550.1 gb: NM_002438.1 201666_at gb: NM_003254.1 /DEF = Homo sapiens tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) (TIMP1), mRNA. /FEA = mRNA /GEN = TIMP1 /PROD = tissue inhibitor of metalloproteinase 1precursor /DB_XREF = gi: 4507508 /UG = Hs.5831 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) /FL = gb: BC000866.1 gb: M12670.1 gb: M59906.1 gb: NM_003254.1 205098_at Consensus includes gb: AI421071 /FEA = EST /DB_XREF = gi: 4267002 /DB_XREF = est: tf24a02.x1 /CLONE = IMAGE: 2097098 /UG = Hs.301921 chemokine (C-C motif) receptor 1 /FL = gb: L09230.1 gb: L10918.1 gb: NM_001295.1 203637_s_at gb: NM_000381.1 /DEF = Homo sapiens midline 1 (OpitzBBB syndrome) (MID1), mRNA. /FEA = mRNA /GEN = MID1 /PROD = midline 1 /DB_XREF = gi: 4557752 /UG = Hs.27695 midline 1 (OpitzBBB syndrome) /FL = gb: AF269101.1 gb: AF230976.1 gb: AF035360.1 gb: NM_000381.1 205180_s_at gb: NM_001109.1 /DEF = Homo sapiens a disintegrin and metalloproteinase domain 8 (ADAM8), mRNA. /FEA = mRNA /GEN = ADAM8 /PROD = a disintegrin and metalloproteinase domain 8precursor /DB_XREF = gi: 4557252 /UG = Hs.86947 a disintegrin and metalloproteinase domain 8 /FL = gb: D26579.1 gb: NM_001109.1 207850_at gb: NM_002090.1 /DEF = Homo sapiens GRO3 oncogene (GRO3), mRNA. /FEA = mRNA /GEN = GRO3 /PROD = GRO3 oncogene /DB_XREF = gi: 4504156 /UG = Hs.89690 GRO3 oncogene /FL = gb: M36821.1 gb: NM_002090.1 204232_at gb: NM_004106.1 /DEF = Homo sapiens Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide (FCER1G), mRNA. /FEA = mRNA /GEN = FCER1G /PROD = Fc fragment of IgE, high affinity I, receptor for, gamma polypeptide precursor /DB_XREF = gi: 4758343 /UG = Hs.743 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide /FL = gb: M33195.1 gb: NM_004106.1 217678_at Consensus includes gb: AA488687 /FEA = EST /DB_XREF = gi: 2216118 /DB_XREF = est: ab38f03.s1 /CLONE = IMAGE: 843101 /UG = Hs.284235 ESTs 217739_s_at gb: NM_005746.1 /DEF = Homo sapiens pre-B-cell colony-enhancing factor (PBEF), mRNA. /FEA = mRNA /GEN = PBEF /PROD = pre-B-cell colony-enhancing factor /DB_XREF = gi: 5031976 /UG = Hs.239138 pre-B-cell colony-enhancing factor /FL = gb: U02020.1 gb: NM_005746.1 204994_at gb: NM_002463.1 /DEF = Homo sapiens myxovirus (influenza) resistance 2, homolog of murine (MX2), mRNA. /FEA = mRNA /GEN = MX2 /PROD = myxovirus (influenza) resistance 2, homolog of murine /DB_XREF = gi: 11342663 /UG = Hs.926 myxovirus (influenza) resistance 2, homolog of murine /FL = gb: NM_002463.1 gb: M30818.1 gb: M33883.1 212915_at Consensus includes gb: AL569804 /FEA = EST /DB_XREF = gi: 12925507 /DB_XREF = est: AL569804 /CLONE = CS0DI002YJ15 (3 prime) /UG = Hs.177635 KIAA1095 protein 206172_at gb: NM_000640.1 /DEF = Homo sapiens interleukin 13 receptor, alpha 2 (IL13RA2), mRNA. /FEA = mRNA /GEN = IL13RA2 /PROD = interleukin 13 receptor, alpha 2 /DB_XREF = gi: 10834991 /UG = Hs.25954 interleukin 13 receptor, alpha 2 /FL = gb: NM_000640.1 gb: U70981.1 214146_s_at Consensus includes gb: R64130 /FEA = EST /DB_XREF = gi: 836009 /DB_XREF = est: yi18h03.s1 /CLONE = IMAGE: 139637 /UG = Hs.2164 pro-platelet basic protein (includes platelet basic protein, beta- thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) 220088_at gb: NM_001736.1 /DEF = Homo sapiens complement component 5 receptor 1 (C5a ligand) (C5R1), mRNA. /FEA = mRNA /GEN = C5R1 /PROD = complement component 5 receptor 1 (C5a ligand) /DB_XREF = gi: 4502508 /UG = Hs.2161 complement component 5 receptor 1 (C5a ligand) /FL = gb: M62505.1 gb: NM_001736.1 213603_s_at Consensus includes gb: BE138888 /FEA = EST /DB_XREF = gi: 8601388 /DB_XREF = est: xw97c06.x1 /CLONE = IMAGE: 2835946 /UG = Hs.301175 HSPC022 protein 206420_at gb: NM_005849.1 /DEF = Homo sapiens immunoglobulin superfamily, member 6 (IGSF6), mRNA. /FEA = mRNA /GEN = IGSF6 /PROD = immunoglobulin superfamily, member 6 /DB_XREF = gi: 5031672 /UG = Hs.135194 immunoglobulin superfamily, member 6 /FL = gb: NM_005849.1 221731_x_at Consensus includes gb: BF218922 /FEA = EST /DB_XREF = gi: 11112418 /DB_XREF = est: 601885091F1 /CLONE = IMAGE: 4103447 /UG = Hs.81800 chondroitin sulfate proteoglycan 2 (versican) 220978_at gb: NM_030966.1 /DEF = Homo sapiens keratin associated protein 1.3 (KRTAP1.3), mRNA. /FEA = mRNA /GEN = KRTAP1.3 /PROD = keratin associated protein 1.3 /DB_XREF = gi: 13569939 /FL = gb: NM_030966.1 206987_x_at gb: NM_003862.1 /DEF = Homo sapiens fibroblast growth factor 18 (FGF18), mRNA. /FEA = mRNA /GEN = FGF18 /PROD = fibroblast growth factor 18 /DB_XREF = gi: 4503694 /UG = Hs.49585 fibroblast growth factor 18 /FL = gb: AB007422.1 gb: AF075292.1 gb: NM_003862.1 208306_x_at gb: NM_021983.2 /DEF = Homo sapiens major histocompatibility complex, class II, DR beta 4 (HLA-DRB4), mRNA. /FEA = mRNA /GEN = HLA-DRB4 /PROD = major histocompatibility complex, class II, DRbeta 4 /DB_XREF = gi: 11875206 /UG = Hs.293934 major histocompatibility complex, class II, DR beta 4 /FL = gb: NM_021983.2 204470_at gb: NM_001511.1 /DEF = Homo sapiens GRO1 oncogene (melanoma growth stimulating activity, alpha) (GRO1), mRNA. /FEA = mRNA /GEN = GRO1 /PROD = GRO1 oncogene (melanoma growth stimulating activity, alpha) /DB_XREF = gi: 4504152 /UG = Hs.789 GRO1 oncogene (melanoma growth stimulating activity, alpha) /FL = gb: NM_001511.1 205419_at gb: NM_004951.1 /DEF = Homo sapiens Epstein-Barr virus induced gene 2 (lymphocyte-specific G protein-coupled receptor) (EBI2), mRNA. /FEA = mRNA /GEN = EBI2 /PROD = Epstein-Barr virus induced gene 2(lymphocyte-specific G protein-coupled receptor) /DB_XREF = gi: 4826705 /UG = Hs.784 Epstein-Barr virus induced gene 2 (lymphocyte-specific G protein-coupled receptor) /FL = gb: L08177.1 gb: NM_004951.1 220272_at gb: NM_017637.1 /DEF = Homo sapiens hypothetical protein FLJ20043 (FLJ20043), mRNA. /FEA = mRNA /GEN = FLJ20043 /PROD = hypothetical protein FLJ20043 /DB_XREF = gi: 8923050 /UG = Hs.103853 hypothetical protein FLJ20043 /FL = gb: NM_017637.1 203980_at gb: NM_001442.1 /DEF = Homo sapiens fatty acid binding protein 4, adipocyte (FABP4), mRNA. /FEA = mRNA /GEN = FABP4 /PROD = fatty acid binding protein 4, adipocyte /DB_XREF = gi: 4557578 /UG = Hs.83213 fatty acid binding protein 4, adipocyte /FL = gb: BC003672.1 gb: J02874.1 gb: NM_001442.1 218574_s_at gb: NM_014583.1 /DEF = Homo sapiens LIM and cysteine-rich domains 1 (LMCD1), mRNA. /FEA = mRNA /GEN = LMCD1 /PROD = LIM and cysteine-rich domains 1 /DB_XREF = gi: 7657308 /UG = Hs.279943 LIM and cysteine- rich domains 1 /FL = gb: AF216709.1 gb: BC000646.1 gb: AF169284.1 gb: NM_014583.1 210986_s_at gb: Z24727.1 /DEF = H. sapiens tropomyosin isoform mRNA, complete CDS. /FEA = mRNA /PROD = tropomyosin isoform /DB_XREF = gi: 854188 /UG = Hs.77899 tropomyosin 1 (alpha) /FL = gb: Z24727.1 213524_s_at Consensus includes gb: NM_015714.1 /DEF = Homo sapiens putative lymphocyte G0G1 switch gene (G0S2), mRNA. /FEA = CDS /GEN = G0S2 /PROD = putative lymphocyte G0G1 switch gene /DB_XREF = gi: 7657103 /UG = Hs.95910 putative lymphocyte G0G1 switch gene /FL = gb: NM_015714.1 205685_at Consensus includes gb: BG236280 /FEA = EST /DB_XREF = gi: 12750052 /DB_XREF = est: naf24d07.x1 /CLONE = IMAGE: 4141884 /UG = Hs.27954 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) /FL = gb: U04343.1 gb: NM_006889.1 201150_s_at gb: NM_000362.2 /DEF = Homo sapiens tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3), mRNA. /FEA = mRNA /GEN = TIMP3 /PROD = tissue inhibitor of metalloproteinase 3precursor /DB_XREF = gi: 9257248 /UG = Hs.245188 tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) /FL = gb: U67195.1 gb: U02571.1 gb: U14394.1 gb: NM_000362.2 215193_x_at Consensus includes gb: AJ297586.1 /DEF = Homo sapiens mRNA for MHC class II antigen (HLA-DRB1 gene), DRB1*0402 allele. /FEA = CDS /GEN = HLA-DRB1 /PROD = MHC class II antigen /DB_XREF = gi: 10185079 /UG = Hs.279930 major histocompatibility complex, class II, DR beta 3 217478_s_at Consensus includes gb: X76775 /DEF = H. sapiens HLA-DMA gene /FEA = mRNA_1 /DB_XREF = gi: 512468 /UG = Hs.77522 major histocompatibility complex, class II, DM alpha 202499_s_at gb: NM_006931.1 /DEF = Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 3 (SLC2A3), mRNA. /FEA = mRNA /GEN = SLC2A3 /PROD = solute carrier family 2 (facilitated glucose transporter), member 3 /DB_XREF = gi: 5902089 /UG = Hs.7594 solute carrier family 2 (facilitated glucose transporter), member 3 /FL = gb: M20681.1 gb: NM_006931.1 221698_s_at gb: AF313468.1 /DEF = Homo sapiens dendritic cell-associated C-type lectin-1 mRNA, complete cds. /FEA = mRNA /PROD = dendritic cell-associated C-type lectin-1 /DB_XREF = gi: 13649707 /FL = gb: AF313468.1 210845_s_at gb: U08839.1 /DEF = Human urokinase-type plasminogen activator receptor mRNA, complete cds. /FEA = mRNA /PROD = urokinase-type plasminogen activator receptor /DB_XREF = gi: 517197 /UG = Hs.179657 plasminogen activator, urokinase receptor /FL = gb: U08839.1 204924_at gb: NM_003264.1 /DEF = Homo sapiens toll-like receptor 2 (TLR2), mRNA. /FEA = mRNA /GEN = TLR2 /PROD = toll- like receptor2 /DB_XREF = gi: 4507528 /UG = Hs.63668 toll-like receptor 2 /FL = gb: U88878.1 gb: AF051152.1 gb: NM_003264.1 205269_at Consensus includes gb: AI123251 /FEA = EST /DB_XREF = gi: 3539017 /DB_XREF = est: qa47g03.x1 /CLONE = IMAGE: 1689940 /UG = Hs.2488 lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76 kD) /FL = gb: NM_005565.2 gb: U20158.1 201427_s_at gb: NM_005410.1 /DEF = Homo sapiens selenoprotein P, plasma, 1 (SEPP1), mRNA. /FEA = mRNA /GEN = SEPP1 /PROD = selenoprotein P precursor /DB_XREF = gi: 4885590 /UG = Hs.3314 selenoprotein P, plasma, 1 /FL = gb: NM_005410.1 219947_at gb: NM_016184.1 /DEF = Homo sapiens C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 6 (CLECSF6), mRNA. /FEA = mRNA /GEN = CLECSF6 /PROD = C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 6 /DB_XREF = gi: 7705337 /UG = Hs.115515 C- type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 6 /FL = gb: AF109146.1 gb: NM_016184.1 gb: AF067800.1 203535_at gb: NM_002965.2 /DEF = Homo sapiens S100 calcium-binding protein A9 (calgranulin B) (S100A9), mRNA. /FEA = mRNA /GEN = S100A9 /PROD = S100 calcium-binding protein A9 /DB_XREF = gi: 9845520 /UG = Hs.112405 S100 calcium-binding protein A9 (calgranulin B) /FL = gb: M26311.1 gb: NM_002965.2 213260_at Consensus includes gb: AU145890 /FEA = EST /DB_XREF = gi: 11007411 /DB_XREF = est: AU145890 /CLONE = HEMBA1006158 /UG = Hs.284186 forkhead box C1 /FL = gb: NM_001453.1 211991_s_at Consensus includes gb: M27487.1 /DEF = Homo sapiens MHC class II DPw3-alpha-1 chain mRNA, complete cds. /FEA = CDS /GEN = HLA-DPA1 /PROD = MHC class II DP3-alpha /DB_XREF = gi: 703088 /UG = Hs.914 Human mRNA for SB classII histocompatibility antigen alpha-chain /FL = gb: M27487.1 204457_s_at gb: NM_002048.1 /DEF = Homo sapiens growth arrest-specific 1 (GAS1), mRNA. /FEA = mRNA /GEN = GAS1 /PROD = growth arrest-specific 1 /DB_XREF = gi: 4503918 /UG = Hs.65029 growth arrest-specific 1 /FL = gb: NM_002048.1 gb: L13698.1 203104_at gb: NM_005211.1 /DEF = Homo sapiens colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog (CSF1R), mRNA. /FEA = mRNA /GEN = CSF1R /PROD = colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog /DB_XREF = gi: 4885158 /UG = Hs.174142 colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog /FL = gb: NM_005211.1 211071_s_at gb: BC006471.1 /DEF = Homo sapiens, ALL1-fused gene from chromosome 1q, clone MGC: 4013, mRNA, complete cds. /FEA = mRNA /PROD = ALL1-fused gene from chromosome 1q /DB_XREF = gi: 13623686 /FL = gb: BC006471.1 217764_s_at gb: AF183421.1 /DEF = Homo sapiens small GTP-binding protein rab22b mRNA, complete cds. /FEA = mRNA /PROD = small GTP-binding protein rab22b /DB_XREF = gi: 9963780 /UG = Hs.223025 RAB31, member RAS oncogene family /FL = gb: AF234995.1 gb: BC001148.1 gb: U59877.1 gb: U57091.1 gb: NM_006868.1 gb: AF183421.1 209312_x_at gb: U65585.1 /DEF = Homo sapiens MHC class II antigen (HLA-DRB1) mRNA, HLA-DRB1*PBL allele, complete cds. /FEA = mRNA /GEN = HLA-DRB1 /PROD = MHC class II antigen /DB_XREF = gi: 5478215 /UG = Hs.180255 major histocompatibility complex, class II, DR beta 1 /FL = gb: M33600.1 gb: NM_002124.1 gb: M28583.1 gb: U65585.1 208894_at gb: M60334.1 /DEF = Human MHC class II HLA-DR-alpha mRNA, complete cds. /FEA = mRNA /GEN = HLA-DRA /PROD = cell surface glycoprotein /DB_XREF = gi: 188255 /UG = Hs.76807 major histocompatibility complex, class II, DR alpha /FL = gb: M60334.1 gb: NM_019111.1 201422_at gb: NM_006332.1 /DEF = Homo sapiens interferon, gamma-inducible protein 30 (IFI30), mRNA. /FEA = mRNA /GEN = IFI30 /PROD = interferon, gamma-inducible protein 30 /DB_XREF = gi: 5453695 /UG = Hs.14623 interferon, gamma-inducible protein 30 /FL = gb: J03909.1 gb: NM_006332.1 gb: AF097362.1 203932_at gb: NM_002118.1 /DEF = Homo sapiens major histocompatibility complex, class II, DM beta (HLA-DMB), mRNA. /FEA = mRNA /GEN = HLA-DMB /PROD = major histocompatibility complex, class II, DMbeta /DB_XREF = gi: 4504398 /UG = Hs.1162 major histocompatibility complex, class II, DM beta /FL = gb: NM_002118.1 gb: U15085.1 216250_s_at Consensus includes gb: X77598.1 /DEF = H. sapiens LAM A3 mRNA for laminin alpha 3 chain. /FEA = mRNA /DB_XREF = gi: 9716101 /UG = Hs.83450 laminin, alpha 3 (nicein (150 kD), kalinin (165 kD), BM600 (150 kD), epilegrin) 204734_at gb: NM_002275.1 /DEF = Homo sapiens keratin 15 (KRT15), mRNA. /FEA = mRNA /GEN = KRT15 /PROD = keratin 15 /DB_XREF = gi: 4504914 /UG = Hs.80342 keratin 15 /FL = gb: BC002641.1 gb: NM_002275.1 209906_at gb: U62027.1 /DEF = Human anaphylatoxin C3a receptor (HNFAG09) mRNA, complete cds. /FEA = mRNA /GEN = HNFAG09 /PROD = anaphylatoxin C3a receptor /DB_XREF = gi: 1511643 /UG = Hs.155935 complement component 3a receptor 1 /FL = gb: U28488.1 gb: U62027.1 gb: NM_004054.1 201108_s_at Consensus includes gb: BF055462 /FEA = EST /DB_XREF = gi: 10809358 /DB_XREF = est: 7j80e06.x1 /CLONE = IMAGE: 3392770 /UG = Hs.87409 thrombospondin 1 /FL = gb: NM_003246.1 202054_s_at gb: NM_000382.1 /DEF = Homo sapiens aldehyde dehydrogenase 3 family, member A2 (ALDH3A2), mRNA. /FEA = mRNA /GEN = ALDH3A2 /PROD = aldehyde dehydrogenase 3A2 /DB_XREF = gi: 4557302 /UG = Hs.159608 aldehyde dehydrogenase 3 family, member A2 /FL = gb: L47162.1 gb: U46689.1 gb: NM_000382.1 203936_s_at gb: NM_004994.1 /DEF = Homo sapiens matrix metalloproteinase 9 (gelatinase B, 92 kD gelatinase, 92 kD type IV collagenase) (MMP9), mRNA. /FEA = mRNA /GEN = MMP9 /PROD = matrix metalloproteinase 9 preproprotein /DB_XREF = gi: 4826835 /UG = Hs.151738 matrix metalloproteinase 9 (gelatinase B, 92 kD gelatinase, 92 kD type IV collagenase) /FL = gb: J05070.1 gb: NM_004994.1 211276_at gb: AF063606.1 /DEF = Homo sapiens brain my048 protein mRNA, complete cds. /FEA = mRNA /PROD = brain my048 protein /DB_XREF = gi: 12002041 /UG = Hs.17481 Homo sapiens clone 24606 mRNA sequence /FL = gb: AF063606.1 202625_at Consensus includes gb: AI356412 /FEA = EST /DB_XREF = gi: 4108033 /DB_XREF = est: qz26h02.x1 /CLONE = IMAGE: 2028051 /UG = Hs.80887 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog /FL = gb: NM_002350.1 203797_at gb: AF039555.1 /DEF = Homo sapiens visinin-like protein 1 (VSNL1) mRNA, complete cds. /FEA = mRNA /GEN = VSNL1 /PROD = visinin-like protein 1 /DB_XREF = gi: 4104813 /UG = Hs.2288 visinin-like 1 /FL = gb: AF039555.1 gb: NM_003385.1 gb: AB001104.1 gb: U14747.1 206337_at gb: NM_001838.1 /DEF = Homo sapiens chemokine (C-C motif) receptor 7 (CCR7), mRNA. /FEA = mRNA /GEN = CCR7 /PROD = chemokine (C-C motif) receptor 7 /DB_XREF = gi: 4502640 /UG = Hs.1652 chemokine (C-C motif) receptor 7 /FL = gb: L08176.1 gb: NM_001838.1 gb: L31581.1 205686_s_at gb: NM_006889.1 /DEF = Homo sapiens CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) (CD86), mRNA. /FEA = mRNA /GEN = CD86 /PROD = CD86 antigen (CD28 antigen ligand 2, B7-2antigen) /DB_XREF = gi: 5901919 /UG = Hs.27954 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) /FL = gb: U04343.1 gb: NM_006889.1 221059_s_at gb: NM_021615.1 /DEF = Homo sapiens carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 (CHST6), mRNA. /FEA = mRNA /GEN = CHST6 /PROD = carbohydrate (N-acetylglucosamine 6-O)sulfotransferase 6 /DB_XREF = gi: 11055975 /UG = Hs.157439 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 /FL = gb: AF219990.1 gb: NM_021615.1 220972_s_at gb: NM_030975.1 /DEF = Homo sapiens keratin associated protein 9.9 (KRTAP9.9), mRNA. /FEA = mRNA /GEN = KRTAP9.9 /PROD = keratin associated protein 9.9 /DB_XREF = gi: 13569951 /FL = gb: NM_030975.1 206207_at gb: NM_001828.3 /DEF = Homo sapiens Charot-Leyden crystal protein (CLC), mRNA. /FEA = mRNA /GEN = CLC /PROD = Charot-Leyden crystal protein /DB_XREF = gi: 6325464 /UG = Hs.889 Charot-Leyden crystal protein /FL = gb: L01664.1 gb: NM_001828.3 219093_at gb: NM_017933.1 /DEF = Homo sapiens hypothetical protein FLJ20701 (FLJ20701), mRNA. /FEA = mRNA /GEN = FLJ20701 /PROD = hypothetical protein FLJ20701 /DB_XREF = gi: 8923631 /UG = Hs.169764 hypothetical protein FLJ20701 /FL = gb: NM_017933.1 215223_s_at Consensus includes gb: W46388 /FEA = EST /DB_XREF = gi: 1331076 /DB_XREF = est: zc32c08.s1 /CLONE = IMAGE: 324014 /UG = Hs.318885 superoxide dismutase 2, mitochondrial 221491_x_at Consensus includes gb: AA807056 /FEA = EST /DB_XREF = gi: 2876632 /DB_XREF = est: oc35c12.s1 /CLONE = IMAGE: 1351702 /UG = Hs.279930 major histocompatibility complex, class II, DR beta 3 /FL = gb: M27635.1 gb: NM_022555.1 gb: M26038.1 gb: U95989.1 gb: U95819.1 gb: U66825.1 204912_at gb: NM_001558.1 /DEF = Homo sapiens interleukin 10 receptor, alpha (IL10RA), mRNA. /FEA = mRNA /GEN = IL10RA /PROD = interleukin 10 receptor, alpha /DB_XREF = gi: 4504632 /UG = Hs.327 interleukin 10 receptor, alpha /FL = gb: NM_001558.1 gb: U00672.1 204015_s_at gb: BC002671.1 /DEF = Homo sapiens, dual specificity phosphatase 4, clone MGC: 3713, mRNA, complete cds. /FEA = mRNA /PROD = dual specificity phosphatase 4 /DB_XREF = gi: 12803670 /UG = Hs.2359 dual specificity phosphatase 4 /FL = gb: U48807.1 gb: NM_001394.2 gb: BC002671.1 gb: U21108.1 202087_s_at gb: NM_001912.1 /DEF = Homo sapiens cathepsin L (CTSL), mRNA. /FEA = mRNA /GEN = CTSL /PROD = cathepsin L /DB_XREF = gi: 4503154 /UG = Hs.78056 cathepsin L /FL = gb: NM_001912.1 204222_s_at gb: NM_006851.1 /DEF = Homo sapiens glioma pathogenesis-related protein (RTVP1), mRNA. /FEA = mRNA /GEN = RTVP1 /PROD = glioma pathogenesis-related protein /DB_XREF = gi: 5803150 /UG = Hs.64639 glioma pathogenesis-related protein /FL = gb: U16307.1 gb: NM_006851.1 201148_s_at Consensus includes gb: AW338933 /FEA = EST /DB_XREF = gi: 6835559 /DB_XREF = est: ha68g07.x1 /CLONE = IMAGE: 2878908 /UG = Hs.245188 tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) /FL = gb: U67195.1 gb: U02571.1 gb: U14394.1 gb: NM_000362.2 217362_x_at Consensus includes gb: AF005487.1 /DEF = Homo sapiens MHC class II antigen (DRB6) mRNA, HLA-DRB6*0201 allele, sequence. /FEA = mRNA /DB_XREF = gi: 5915893 /UG = Hs.167385 Homo sapiens MHC class II antigen HLA- DRB6 mRNA, partial cds 203305_at gb: NM_000129.2 /DEF = Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1), mRNA. /FEA = mRNA /GEN = F13A1 /PROD = coagulation factor XIII A1 subunit precursor /DB_XREF = gi: 9961355 /UG = Hs.80424 coagulation factor XIII, A1 polypeptide /FL = gb: M14354.1 gb: NM_000129.2 209290_s_at gb: BC001283.1 /DEF = Homo sapiens, Similar to nuclear factor IB, clone MGC: 5146, mRNA, complete cds. /FEA = mRNA /PROD = Similar to nuclear factor IB /DB_XREF = gi: 12654878 /UG = Hs.33287 nuclear factor IB /FL = gb: BC001283.1 gb: U85193.1 gb: NM_005596.1 202888_s_at gb: NM_001150.1 /DEF = Homo sapiens alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) (ANPEP), mRNA. /FEA = mRNA /GEN = ANPEP /PROD = membrane alanine aminopeptidase precursor /DB_XREF = gi: 4502094 /UG = Hs.1239 alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) /FL = gb: M22324.1 gb: NM_001150.1 206295_at gb: NM_001562.1 /DEF = Homo sapiens interleukin 18 (interferon-gamma-inducing factor) (IL18), mRNA. /FEA = mRNA /GEN = IL18 /PROD = interleukin 18 /DB_XREF = gi: 4504652 /UG = Hs.83077 interleukin 18 (interferon- gamma-inducing factor) /FL = gb: D49950.1 gb: AF077611.1 gb: NM_001562.1 217963_s_at gb: NM_014380.1 /DEF = Homo sapiens p75NTR-associated cell death executor; ovarian granulosa cell protein (13 kD) (DXS6984E), mRNA. /FEA = mRNA /GEN = DXS6984E /PROD = p75NTR-associated cell death executor; ovarian granulosa cell protein (13 kD) /DB_XREF = gi: 7657043 /UG = Hs.17775 p75NTR-associated cell death executor; ovarian granulosa cell protein (13 kD) /FL = gb: NM_014380.1 gb: AF187064.1 205237_at gb: NM_002003.2 /DEF = Homo sapiens ficolin (collagenfibrinogen domain-containing) 1 (FCN1), mRNA. /FEA = mRNA /GEN = FCN1 /PROD = ficolin 1 precursor /DB_XREF = gi: 8051583 /UG = Hs.252136 ficolin (collagenfibrinogen domain-containing) 1 /FL = gb: D83920.1 gb: NM_002003.2 206343_s_at gb: NM_013959.1 /DEF = Homo sapiens neuregulin 1 (NRG1), transcript variant SMDF, mRNA. /FEA = mRNA /GEN = NRG1 /PROD = neuregulin 1 isoform SMDF /DB_XREF = gi: 7669517 /UG = Hs.172816 neuregulin 1 /FL = gb: NM_013959.1 gb: L41827.1 209555_s_at gb: M98399.1 /DEF = Human antigen CD36 (clone 21) mRNA, complete cds. /FEA = mRNA /GEN = CD36 /PROD = antigen CD36 /DB_XREF = gi: 180112 /UG = Hs.75613 CD36 antigen (collagen type I receptor, thrombospondin receptor) /FL = gb: M98399.1 206569_at gb: NM_006850.1 /DEF = Homo sapiens suppression of tumorigenicity 16 (melanoma differentiation) (ST16), mRNA. /FEA = mRNA /GEN = ST16 /PROD = suppression of tumorigenicity 16 (melanoma differentiation) /DB_XREF = gi: 5803085 /UG = Hs.315463 suppression of tumorigenicity 16 (melanoma differentiation) /FL = gb: U16261.1 gb: NM_006850.1 202341_s_at Consensus includes gb: AA149745 /FEA = EST /DB_XREF = gi: 1720818 /DB_XREF = est: zo02h04.s1 /CLONE = IMAGE: 566551 /UG = Hs.12372 tripartite motif protein TRIM2 /FL = gb: AF220018.1 gb: NM_015271.1 205067_at gb: NM_000576.1 /DEF = Homo sapiens interleukin 1, beta (IL1B), mRNA. /FEA = mRNA /GEN = IL1B /PROD = interleukin 1, beta /DB_XREF = gi: 10835144 /UG = Hs.126256 interleukin 1, beta /FL = gb: NM_000576.1 gb: K02770.1 gb: M15330.1 gb: M54933.1 208075_s_at gb: NM_006273.2 /DEF = Homo sapiens small inducible cytokine A7 (monocyte chemotactic protein 3) (SCYA7), mRNA. /FEA = mRNA /GEN = SCYA7 /PROD = monocyte chemotactic protein 3 precursor /DB_XREF = gi: 13435401 /FL = gb: NM_006273.2 219371_s_at gb: NM_016270.1 /DEF = Homo sapiens Kruppel-like factor (LOC51713), mRNA. /FEA = mRNA /GEN = LOC51713 /PROD = Kruppel-like factor /DB_XREF = gi: 7706468 /UG = Hs.107740 Kruppel-like factor 2 (lung) /FL = gb: AF134053.1 gb: AF205849.1 gb: NM_016270.1 212998_x_at Consensus includes gb: AI583173 /FEA = EST /DB_XREF = gi: 4569070 /DB_XREF = est: tq64e04.x1 /CLONE = IMAGE: 2213598 /UG = Hs.73931 major histocompatibility complex, class II, DQ beta 1 205185_at gb: NM_006846.1 /DEF = Homo sapiens serine protease inhibitor, Kazal type, 5 (SPINK5), mRNA. /FEA = mRNA /GEN = SPINK5 /PROD = serine protease inhibitor, Kazal type, 5 /DB_XREF = gi: 5803218 /UG = Hs.331555 serine protease inhibitor, Kazal type, 5 /FL = gb: NM_006846.1 204619_s_at Consensus includes gb: BF590263 /FEA = EST /DB_XREF = gi: 11682587 /DB_XREF = est: nab22b12.x1 /CLONE = IMAGE: 3266638 /UG = Hs.81800 chondroitin sulfate proteoglycan 2 (versican) /FL = gb: NM_004385.1 202901_x_at gb: BC002642.1 /DEF = Homo sapiens, cathepsin S, clone MGC: 3886, mRNA, complete cds. /FEA = mRNA /PROD = cathepsin S /DB_XREF = gi: 12803614 /UG = Hs.181301 cathepsin S /FL = gb: BC002642.1 gb: M86553.1 gb: NM_004079.1 gb: M90696.1 204588_s_at gb: NM_003982.1 /DEF = Homo sapiens solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 (SLC7A7), mRNA. /FEA = mRNA /GEN = SLC7A7 /PROD = solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 /DB_XREF = gi: 4507054 /UG = Hs.194693 solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 /FL = gb: BC003062.1 gb: AF092032.1 gb: NM_003982.1 gb: AB011263.1 204446_s_at gb: NM_000698.1 /DEF = Homo sapiens arachidonate 5-lipoxygenase (ALOX5), mRNA. /FEA = mRNA /GEN = ALOX5 /PROD = arachidonate 5-lipoxygenase /DB_XREF = gi: 4502056 /UG = Hs.89499 arachidonate 5-lipoxygenase /FL = gb: J03600.1 gb: J03571.1 gb: NM_000698.1 204670_x_at gb: NM_002125.1 /DEF = Homo sapiens major histocompatibility complex, class II, DR beta 5 (HLA-DRB5), mRNA. /FEA = mRNA /GEN = HLA-DRB5 /PROD = major histocompatibility complex, class II, DRbeta 5 /DB_XREF = gi: 4504412 /UG = Hs.308026 major histocompatibility complex, class II, DR beta 5 /FL = gb: M11867.1 gb: M20430.1 gb: NM_002125.1 209606_at gb: L06633.1 /DEF = Human transcription factor mRNA, complete cds. /FEA = mRNA /PROD = transcription factor /DB_XREF = gi: 431327 /UG = Hs.270 pleckstrin homology, Sec7 and coiledcoil domains, binding protein /FL = gb: AF068836.1 gb: L06633.1 gb: NM_004288.2 214467_at Consensus includes gb: NM_003608.1 /DEF = Homo sapiens G protein-coupled receptor 65 (GPR65), mRNA. /FEA = CDS /GEN = GPR65 /PROD = G protein-coupled receptor 65 /DB_XREF = gi: 4507420 /UG = Hs.131924 G protein- coupled receptor 65 /FL = gb: NM_003608.1 211742_s_at gb: BC005926.1 /DEF = Homo sapiens, ecotropic viral integration site 2B, clone MGC: 14529, mRNA, complete cds. /FEA = mRNA /PROD = ecotropic viral integration site 2B /DB_XREF = gi: 13543535 /FL = gb: BC005926.1 221477_s_at Consensus includes gb: BF575213 /FEA = EST /DB_XREF = gi: 11648925 /DB_XREF = est: 602133624F1 /CLONE = IMAGE: 4288756 /UG = Hs.177781 Homo sapiens, clone MGC: 5618, mRNA, complete cds /FL = gb: BC001980.1 203961_at Consensus includes gb: AL157398 /DEF = Human DNA sequence from clone RP11-56H7 on chromosome 10. Contains ESTs, STSs and GSSs. Contains the gene for the nebulette protein (NEBL, actin-binding Z-disc protein) /FEA = mRNA_1 /DB_XREF = gi: 10045326 /UG = Hs.5025 nebulette /FL = gb: NM_006393.1 204735_at gb: NM_006202.1 /DEF = Homo sapiens phosphodiesterase 4A, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E2) (PDE4A), mRNA. /FEA = mRNA /GEN = PDE4A /PROD = phosphodiesterase 4A, cAMP-specific (dunce(Drosophila)-homolog phosphodiesterase E2) /DB_XREF = gi: 5453861 /UG = Hs.89901 phosphodiesterase 4A, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E2) /FL = gb: U97584.1 gb: U68532.1 gb: NM_006202.1 204057_at Consensus includes gb: AI073984 /FEA = EST /DB_XREF = gi: 3400628 /DB_XREF = est: oy66c05.x1 /CLONE = IMAGE: 1670792 /UG = Hs.14453 interferon consensus sequence binding protein 1 /FL = gb: M91196.1 gb: NM_002163.1 214036_at Consensus includes gb: BE464799 /FEA = EST /DB_XREF = gi: 9510493 /DB_XREF = est: hs87a06.x1 /CLONE = IMAGE: 3144178 /UG = Hs.27342 ESTs 204661_at gb: NM_001803.1 /DEF = Homo sapiens CDW52 antigen (CAMPATH-1 antigen) (CDW52), mRNA. /FEA = mRNA /GEN = CDW52 /PROD = CDW52 antigen (CAMPATH-1 antigen) /DB_XREF = gi: 4502760 /UG = Hs.276770 CDW52 antigen (CAMPATH-1 antigen) /FL = gb: BC000644.1 gb: NM_001803.1 204992_s_at gb: NM_002628.1 /DEF = Homo sapiens profilin 2 (PFN2), mRNA. /FEA = mRNA /GEN = PFN2 /PROD = profilin 2 /DB_XREF = gi: 4505750 /UG = Hs.91747 profilin 2 /FL = gb: L10678.1 gb: NM_002628.1 201278_at Consensus includes gb: N21202 /FEA = EST /DB_XREF = gi: 1126372 /DB_XREF = est: yx41e12.s1 /CLONE = IMAGE: 264334 /UG = Hs.81988 disabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) /FL = gb: U39050.1 gb: U53446.1 gb: BC003064.1 gb: NM_001343.1 210895_s_at gb: L25259.1 /DEF = Human CTLA4 counter-receptor (B7-2) mRNA, complete cds. /FEA = mRNA /GEN = B7-2 /PROD = CTLA4 counter-receptor /DB_XREF = gi: 416368 /UG = Hs.27954 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) /FL = gb: L25259.1 202910_s_at gb: NM_001784.1 /DEF = Homo sapiens CD97 antigen (CD97), mRNA. /FEA = mRNA /GEN = CD97 /PROD = CD97 antigen /DB_XREF = gi: 4502690 /UG = Hs.3107 CD97 antigen /FL = gb: NM_001784.1 216834_at Consensus includes gb: S59049.1 /DEF = BL34 = B cell activation gene human, mRNA, 1398 nt. /FEA = mRNA /GEN = BL34 /DB_XREF = gi: 299704 /UG = Hs.75256 regulator of G-protein signalling 1 207067_s_at gb: NM_002112.1 /DEF = Homo sapiens histidine decarboxylase (HDC), mRNA. /FEA = mRNA /GEN = HDC /PROD = histidine decarboxylase /DB_XREF = gi: 4504364 /UG = Hs.1481 histidine decarboxylase /FL = gb: M60445.1 gb: NM_002112.1 208981_at Consensus includes gb: AA702701 /FEA = EST /DB_XREF = gi: 2705814 /DB_XREF = est: zi90h02.s1 /CLONE = IMAGE: 448083 /UG = Hs.78146 platelet endothelial cell adhesion molecule (CD31 antigen) /FL = gb: M37780.1 gb: M28526.1 gb: NM_000442.1 204173_at gb: NM_002475.1 /DEF = Homo sapiens myosin, light polypeptide 1, alkali; skeletal, fast (MYL1), mRNA. /FEA = mRNA /GEN = MYL1 /PROD = myosin, light polypeptide 1, alkali; skeletal, fast /DB_XREF = gi: 4505302 /UG = Hs.90318 myosin, light polypeptide 1, alkali; skeletal, fast /FL = gb: M31211.1 gb: NM_002475.1 213029_at Consensus includes gb: BG478428 /FEA = EST /DB_XREF = gi: 13410807 /DB_XREF = est: 602523839F1 /CLONE = IMAGE: 4642353 /UG = Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (from clone DKFZp564H1916) 209921_at gb: AB040875.1 /DEF = Homo sapiens hxCT mRNA for cystine glutamate exchanger, complete cds. /FEA = mRNA /GEN = hxCT /PROD = cystine glutamate exchanger /DB_XREF = gi: 13516845 /UG = Hs.6682 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 /FL = gb: AB040875.1 203474_at gb: NM_006633.1 /DEF = Homo sapiens IQ motif containing GTPase activating protein 2 (IQGAP2), mRNA. /FEA = mRNA /GEN = IQGAP2 /PROD = IQ motif containing GTPase activating protein 2 /DB_XREF = gi: 5729886 /UG = Hs.78993 IQ motif containing GTPase activating protein 2 /FL = gb: U51903.1 gb: NM_006633.1 205372_at gb: NM_002655.1 /DEF = Homo sapiens pleiomorphic adenoma gene 1 (PLAG1), mRNA. /FEA = mRNA /GEN = PLAG1 /PROD = pleiomorphic adenoma gene 1 /DB_XREF = gi: 4505854 /UG = Hs.14968 pleiomorphic adenoma gene 1 /FL = gb: U65002.1 gb: NM_002655.1 211429_s_at gb: AF119873.1 /DEF = Homo sapiens PRO2275 mRNA, complete cds. /FEA = mRNA /PROD = PRO2275 /DB_XREF = gi: 7770182 /UG = Hs.297681 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 /FL = gb: AF119873.1 216841_s_at Consensus includes gb: X15132.1 /DEF = Human mRNA for manganese containing superoxide dismutase (EC 1.15.1.1). /FEA = mRNA /DB_XREF = gi: 34794 /UG = Hs.318885 superoxide dismutase 2, mitochondrial 219142_at gb: NM_023940.1 /DEF = Homo sapiens hypothetical protein MGC2827 (MGC2827), mRNA. /FEA = mRNA /GEN = MGC2827 /PROD = hypothetical protein MGC2827 /DB_XREF = gi: 13027611 /UG = Hs.8035 hypothetical protein MGC2827 /FL = gb: BC001087.1 gb: BC001846.1 gb: NM_023940.1 209723_at gb: BC002538.1 /DEF = Homo sapiens, serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9, clone MGC: 2131, mRNA, complete cds. /FEA = mRNA /PROD = serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9 /DB_XREF = gi: 12803428 /UG = Hs.104879 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9 /FL = gb: L40378.1 gb: BC002538.1 gb: U71364.1 gb: NM_004155.1 204475_at gb: NM_002421.2 /DEF = Homo sapiens matrix metalloproteinase 1 (interstitial collagenase) (MMP1), mRNA. /FEA = mRNA /GEN = MMP1 /PROD = matrix metalloproteinase 1 preproprotein /DB_XREF = gi: 13027798 /UG = Hs.83169 matrix metalloproteinase 1 (interstitial collagenase) /FL = gb: NM_002421.2 gb: M13509.1 205987_at gb: NM_001765.1 /DEF = Homo sapiens CD1C antigen, c polypeptide (CD1C), mRNA. /FEA = mRNA /GEN = CD1C /PROD = CD1C antigen, c polypeptide /DB_XREF = gi: 4502646 /UG = Hs.1311 CD1C antigen, c polypeptide /FL = gb: M28827.1 gb: NM_001765.1 206488_s_at gb: NM_000072.1 /DEF = Homo sapiens CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36), mRNA. /FEA = mRNA /GEN = CD36 /PROD = CD36 antigen (collagen type I receptor, thrombospondin receptor) /DB_XREF = gi: 4557418 /UG = Hs.75613 CD36 antigen (collagen type I receptor, thrombospondin receptor) /FL = gb: M24795.1 gb: M98398.1 gb: L06850.1 gb: NM_000072.1 203153_at gb: NM_001548.1 /DEF = Homo sapiens interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), mRNA. /FEA = mRNA /GEN = IFIT1 /PROD = interferon-induced protein with tetratricopeptide repeats 1 /DB_XREF = gi: 4504584 /UG = Hs.20315 interferon-induced protein with tetratricopeptide repeats 1 /FL = gb: M24594.1 gb: NM_001548.1 205003_at gb: NM_014705.1 /DEF = Homo sapiens KIAA0716 gene product (KIAA0716), mRNA. /FEA = mRNA /GEN = KIAA0716 /PROD = KIAA0716 gene product /DB_XREF = gi: 7662263 /UG = Hs.118140 KIAA0716 gene product /FL = gb: AB018259.1 gb: NM_014705.1 204440_at gb: NM_004233.1 /DEF = Homo sapiens CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) (CD83), mRNA. /FEA = mRNA /GEN = CD83 /PROD = CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) /DB_XREF = gi: 4757945 /UG = Hs.79197 CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) /FL = gb: NM_004233.1 213988_s_at Consensus includes gb: BE971383 /FEA = EST /DB_XREF = gi: 10584719 /DB_XREF = est: 601651561F1 /CLONE = IMAGE: 3934935 /UG = Hs.28491 spermidine spermine N1-acetyltransferase 205986_at gb: NM_004920.1 /DEF = Homo sapiens apoptosis-associated tyrosine kinase (AATK), mRNA. /FEA = mRNA /GEN = AATK /PROD = apoptosis-associated tyrosine kinase /DB_XREF = gi: 4758641 /UG = Hs.128316 apoptosis- associated tyrosine kinase /FL = gb: AB014541.1 gb: NM_004920.1 212992_at Consensus includes gb: AI935123 /FEA = EST /DB_XREF = gi: 5673993 /DB_XREF = est: wp13h09.x1 /CLONE = IMAGE: 2464769 /UG = Hs.57548 ESTs 211002_s_at gb: AF230389.1 /DEF = Homo sapiens tripartite motif protein TRIM29 beta mRNA, complete cds. /FEA = mRNA /PROD = tripartite motif protein TRIM29 beta /DB_XREF = gi: 12275865 /UG = Hs.82237 ataxia-telangiectasia group D- associated protein /FL = gb: AF230389.1 213924_at Consensus includes gb: BF476502 /FEA = EST /DB_XREF = gi: 11547329 /DB_XREF = est: naa27a03.x1 /CLONE = IMAGE: 3255844 /UG = Hs.154145 hypothetical protein FLJ11585 209619_at gb: K01144.1 /DEF = Human major histocompatibility class II antigen gamma chain mRNA, complete cds. /FEA = mRNA /PROD = class II antigen gamma chain /DB_XREF = gi: 188469 /UG = Hs.84298 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) /FL = gb: NM_004355.1 gb: K01144.1 200648_s_at gb: NM_002065.1 /DEF = Homo sapiens glutamate-ammonia ligase (glutamine synthase) (GLUL), mRNA. /FEA = mRNA /GEN = GLUL /PROD = glutamate-ammonia ligase (glutamine synthase) /DB_XREF = gi: 4504026 /UG = Hs.170171 glutamate-ammonia ligase (glutamine synthase) /FL = gb: NM_002065.1 203038_at gb: NM_002844.1 /DEF = Homo sapiens protein tyrosine phosphatase, receptor type, K (PTPRK), mRNA. /FEA = mRNA /GEN = PTPRK /PROD = protein tyrosine phosphatase, receptor type, K /DB_XREF = gi: 4506316 /UG = Hs.79005 protein tyrosine phosphatase, receptor type, K /FL = gb: L77886.1 gb: NM_002844.1 207710_at gb: NM_014357.1 /DEF = Homo sapiens skin-specific protein (XP5), mRNA. /FEA = mRNA /GEN = XP5 /PROD = skin- specific protein /DB_XREF = gi: 7657684 /UG = Hs.234766 skin-specific protein /FL = gb: AF005080.1 gb: NM_014357.1 205400_at gb: NM_000377.1 /DEF = Homo sapiens Wiskott-Aldrich syndrome (eczema-thrombocytopenia) (WAS), mRNA. /FEA = mRNA /GEN = WAS /PROD = Wiskott-Aldrich syndrome protein /DB_XREF = gi: 4507908 /UG = Hs.2157 Wiskott- Aldrich syndrome (eczema-thrombocytopenia) /FL = gb: NM_000377.1 gb: U12707.1 gb: U19927.1 222088_s_at Consensus includes gb: AA778684 /FEA = EST /DB_XREF = gi: 2838015 /DB_XREF = est: af87g07.s1 /CLONE = 1049052 /UG = Hs.7594 solute carrier family 2 (facilitated glucose transporter), member 3 205863_at gb: NM_005621.1 /DEF = Homo sapiens S100 calcium-binding protein A12 (calgranulin C) (S100A12), mRNA. /FEA = mRNA /GEN = S100A12 /PROD = S100 calcium-binding protein A12 /DB_XREF = gi: 5032058 /UG = Hs.19413 S100 calcium-binding protein A12 (calgranulin C) /FL = gb: D83664.1 gb: D49549.1 gb: NM_005621.1 210020_x_at gb: M58026.1 /DEF = Human NB-1 mRNA, complete cds. /FEA = mRNA /GEN = NB-1 /DB_XREF = gi: 189080 /UG = Hs.239600 calmodulin-like 3 /FL = gb: M36707.1 gb: M58026.1 gb: NM_005185.1 204724_s_at gb: NM_001853.1 /DEF = Homo sapiens collagen, type IX, alpha 3 (COL9A3), mRNA. /FEA = mRNA /GEN = COL9A3 /PROD = collagen, type IX, alpha 3 /DB_XREF = gi: 4502966 /UG = Hs.53563 collagen, type IX, alpha 3 /FL = gb: L41162.1 gb: NM_001853.1 220016_at gb: NM_024060.1 /DEF = Homo sapiens hypothetical protein MGC5395 (MGC5395), mRNA. /FEA = mRNA /GEN = MGC5395 /PROD = hypothetical protein MGC5395 /DB_XREF = gi: 13129033 /UG = Hs.165215 hypothetical protein MGC5395 /FL = gb: BC000926.1 gb: NM_024060.1 212154_at Consensus includes gb: AI380298 /FEA = EST /DB_XREF = gi: 4190151 /DB_XREF = est: tf99h06.x1 /CLONE = IMAGE: 2107451 /UG = Hs.1501 syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan) 217762_s_at Consensus includes gb: BE789881 /FEA = EST /DB_XREF = gi: 10211079 /DB_XREF = est: 601476750F1 /CLONE = IMAGE: 3879493 /UG = Hs.223025 RAB31, member RAS oncogene family /FL = gb: AF234995.1 gb: BC001148.1 gb: U59877.1 gb: U57091.1 gb: NM_006868.1 gb: AF183421.1 206214_at gb: NM_005084.1 /DEF = Homo sapiens phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), mRNA. /FEA = mRNA /GEN = PLA2G7 /PROD = phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) /DB_XREF = gi: 4826883 /UG = Hs.93304 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) /FL = gb: U24577.1 gb: NM_005084.1 gb: U20157.1 202037_s_at gb: NM_003012.2 /DEF = Homo sapiens secreted frizzled-related protein 1 (SFRP1), mRNA. /FEA = mRNA /GEN = SFRP1 /PROD = secreted frizzled-related protein 1 /DB_XREF = gi: 8400731 /UG = Hs.7306 secreted frizzled- related protein 1 /FL = gb: AF001900.1 gb: AF017987.1 gb: AF056087.1 gb: NM_003012.2 209289_at Consensus includes gb: AI700518 /FEA = EST /DB_XREF = gi: 4988418 /DB_XREF = est: we37d09.x1 /CLONE = IMAGE: 2343281 /UG = Hs.33287 nuclear factor IB /FL = gb: BC001283.1 gb: U85193.1 gb: NM_005596.1 209949_at gb: BC001606.1 /DEF = Homo sapiens, Similar to neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2), clone MGC: 2275, mRNA, complete cds. /FEA = mRNA /PROD = Similar to neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /DB_XREF = gi: 12804408 /UG = Hs.949 neutrophil cytosolic factor 2 (65 kD, chronic granulomatous disease, autosomal 2) /FL = gb: BC001606.1 gb: M32011.1 gb: NM_000433.1 203233_at gb: NM_000418.1 /DEF = Homo sapiens interleukin 4 receptor (IL4R), mRNA. /FEA = mRNA /GEN = IL4R /PROD = interleukin 4 receptor precursor /DB_XREF = gi: 4557668 /UG = Hs.75545 interleukin 4 receptor /FL = gb: NM_000418.1 201426_s_at Consensus includes gb: AI922599 /FEA = EST /DB_XREF = gi: 5658563 /DB_XREF = est: wm90b11.x1 /CLONE = IMAGE: 2443197 /UG = Hs.297753 vimentin /FL = gb: BC000163.2 gb: NM_003380.1 203561_at gb: NM_021642.1 /DEF = Homo sapiens Fc fragment of IgG, low affinity IIa, receptor for (CD32) (FCGR2A), mRNA. /FEA = mRNA /GEN = FCGR2A /PROD = Fc fragment of IgG, low affinity IIa, receptor for (CD32) /DB_XREF = gi: 11056051 /UG = Hs.78864 Fc fragment of IgG, low affinity IIa, receptor for (CD32) /FL = gb: NM_021642.1 gb: M31932.1 gb: J03619.1 gb: M28697.1 201675_at gb: NM_003488.1 /DEF = Homo sapiens A kinase (PRKA) anchor protein 1 (AKAP1), mRNA. /FEA = mRNA /GEN = AKAP1 /PROD = A kinase (PRKA) anchor protein 1 /DB_XREF = gi: 4502014 /UG = Hs.78921 A kinase (PRKA) anchor protein 1 /FL = gb: BC000729.1 gb: NM_003488.1 217989_at gb: NM_016245.1 /DEF = Homo sapiens retinal short-chain dehydrogenase reductase retSDR2 (LOC51170), mRNA. /FEA = mRNA /GEN = LOC51170 /PROD = retinal short-chain dehydrogenase reductase retSDR2 /DB_XREF = gi: 7705904 /UG = Hs.12150 retinal short-chain dehydrogenase reductase retSDR2 /FL = gb: AF126780.1 gb: NM_016245.1 219403_s_at gb: NM_006665.1 /DEF = Homo sapiens heparanase (HPSE), mRNA. /FEA = mRNA /GEN = HPSE /PROD = heparanase /DB_XREF = gi: 5729872 /UG = Hs.44227 heparanase /FL = gb: AF165154.1 gb: AF152376.1 gb: NM_006665.1 gb: AF084467.1 gb: AF155510.1 214382_at Consensus includes gb: AL021331 /DEF = Human DNA sequence from clone 366N23 on chromosome 6q27. Contains two genes similar to consecutive parts of the C. elegans UNC-93 (protein 1, C46F11.1) gene, a KIAA0173 and Tubulin- Tyrosine Ligase LIKE gene, a Mitotic Feedback Control Protein MADP . . . /FEA = mRNA_2 /DB_XREF = gi: 3355532 /UG = Hs.22033 Human DNA sequence from clone 366N23 on chromosome 6q27. Contains two genes similar to consecutive parts of the C. elegans UNC-93 (protein 1, C46F11.1) gene, a KIAA0173 and Tubulin-Tyrosine Ligase LIKE gene, a Mitotic Feedback Control Protein MADP2 Homolo 210987_x_at gb: M19267.1 /DEF = Human tropomyosin mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 339943 /UG = Hs.77899 tropomyosin 1 (alpha) /FL = gb: M19267.1 209685_s_at gb: M13975.1 /DEF = Homo sapiens protein kinase C beta-II type (PRKCB1) mRNA, complete cds. /FEA = mRNA /GEN = PRKCB1 /PROD = protein kinase C beta-II type /DB_XREF = gi: 189968 /UG = Hs.77202 protein kinase C, beta 1 /FL = gb: M13975.1 208018_s_at gb: NM_002110.1 /DEF = Homo sapiens hemopoietic cell kinase (HCK), mRNA. /FEA = mRNA /GEN = HCK /PROD = hemopoietic cell kinase /DB_XREF = gi: 4504356 /UG = Hs.89555 hemopoietic cell kinase /FL = gb: M16591.1 gb: NM_002110.1 201667_at gb: NM_000165.2 /DEF = Homo sapiens gap junction protein, alpha 1, 43 kD (connexin 43) (GJA1), mRNA. /FEA = mRNA /GEN = GJA1 /PROD = connexin 43 /DB_XREF = gi: 4755136 /UG = Hs.74471 gap junction protein, alpha 1, 43 kD (connexin 43) /FL = gb: M65188.1 gb: NM_000165.2 211361_s_at Consensus includes gb: AJ001696.2 /DEF = Homo sapiens mRNA for hurpin, clone R7-1.1. /FEA = mRNA /GEN = PI13 /PROD = hurpin /DB_XREF = gi: 6018505 /UG = Hs.241407 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 13 /FL = gb: AF169949.1 gb: NM_012397.1 204949_at gb: NM_002162.2 /DEF = Homo sapiens intercellular adhesion molecule 3 (ICAM3), mRNA. /FEA = mRNA /GEN = ICAM3 /PROD = intercellular adhesion molecule 3 precursor /DB_XREF = gi: 12545399 /UG = Hs.99995 intercellular adhesion molecule 3 /FL = gb: NM_002162.2 212975_at Consensus includes gb: AB020677.2 /DEF = Homo sapiens mRNA for KIAA0870 protein, partial cds. /FEA = mRNA /GEN = KIAA0870 /PROD = KIAA0870 protein /DB_XREF = gi: 6635136 /UG = Hs.18166 KIAA0870 protein 201842_s_at Consensus includes gb: AI826799 /FEA = EST /DB_XREF = gi: 5447470 /DB_XREF = est: wk56d07.x1 /CLONE = IMAGE: 2419405 /UG = Hs.76224 EGF-containing fibulin-like extracellular matrix protein 1 /FL = gb: U03877.1 gb: NM_004105.2 210644_s_at gb: AF109683.1 /DEF = Homo sapiens leukocyte-associated Ig-like receptor 1b mRNA, complete cds. /FEA = mRNA /PROD = leukocyte-associated Ig-like receptor 1b /DB_XREF = gi: 6563041 /UG = Hs.115808 leukocyte-associated Ig-like receptor 1 /FL = gb: AF251509.2 gb: NM_021706.1 gb: AF109683.1 218002_s_at gb: NM_004887.1 /DEF = Homo sapiens small inducible cytokine subfamily B (Cys-X-Cys), member 14 (BRAK) (SCYB14), mRNA. /FEA = mRNA /GEN = SCYB14 /PROD = small inducible cytokine subfamily B(Cys-X-Cys), member 14 (BRAK) /DB_XREF = gi: 4757869 /UG = Hs.24395 small inducible cytokine subfamily B (Cys-X-Cys), member 14 (BRAK) /FL = gb: BC003513.1 gb: AF073957.1 gb: NM_004887.1 gb: AF144103.1 gb: AF106911.1 205270_s_at gb: NM_005565.2 /DEF = Homo sapiens lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76 kD) (LCP2), mRNA. /FEA = mRNA /GEN = LCP2 /PROD = lymphocyte cytosolic protein 2 /DB_XREF = gi: 7382491 /UG = Hs.2488 lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76 kD) /FL = gb: NM_005565.2 gb: U20158.1 222242_s_at Consensus includes gb: AF243527 /DEF = Homo sapiens serine protease gene cluster, complete sequence /FEA = CDS_12 /DB_XREF = gi: 11244757 /UG = Hs.50915 kallikrein 5 210757_x_at gb: AF188298.1 /DEF = Homo sapiens disabled 2 p93 (DAB2) mRNA, alternatively spliced, complete cds. /FEA = mRNA /GEN = DAB2 /PROD = disabled 2 p93 /DB_XREF = gi: 6176335 /UG = Hs.81988 disabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) /FL = gb: AF188298.1 203903_s_at gb: NM_014799.1 /DEF = Homo sapiens hephaestin (HEPH), mRNA. /FEA = mRNA /GEN = HEPH /PROD = hephaestin /DB_XREF = gi: 7662253 /UG = Hs.31720 hephaestin /FL = gb: AB014598.1 gb: NM_014799.1 201790_s_at Consensus includes gb: AW150953 /FEA = EST /DB_XREF = gi: 6198851 /DB_XREF = est: xg42f09.x1 /CLONE = IMAGE: 2630249 /UG = Hs.11806 7-dehydrocholesterol reductase /FL = gb: BC000054.1 gb: AF034544.1 gb: AF067127.1 gb: AF096305.1 gb: NM_001360.1 209879_at Consensus includes gb: AI741056 /FEA = EST /DB_XREF = gi: 5109344 /DB_XREF = est: wg25h08.x1 /CLONE = IMAGE: 2366175 /UG = Hs.79283 selectin P ligand /FL = gb: U02297.1 gb: NM_003006.2 201910_at Consensus includes gb: BF213279 /FEA = EST /DB_XREF = gi: 11106865 /DB_XREF = est: 601844779F1 /CLONE = IMAGE: 4070203 /UG = Hs.183738 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) /FL = gb: AB008430.1 gb: NM_005766.1 215704_at Consensus includes gb: AL356504 /DEF = Human DNA sequence from clone RP1-14N1 on chromosome 1q21.1-21.3 Contains ESTs, GSSs and STSs. Contains the FLG gene for profilaggrin and part of a gene for a novel S-100ICaBP type calcium binding domain protein similar to trichohyalin.n /FEA = mRNA /DB_XREF = gi: 9588237 /UG = Hs.73995 filaggrin 201858_s_at gb: J03223.1 /DEF = Human secretory granule proteoglycan peptide core mRNA, complete cds. /FEA = mRNA /GEN = PRG1 /DB_XREF = gi: 190419 /UG = Hs.1908 proteoglycan 1, secretory granule /FL = gb: J03223.1 gb: NM_002727.1 210095_s_at gb: M31159.1 /DEF = Human growth hormone-dependent insulin-like growth factor-binding protein mRNA, complete cds. /FEA = mRNA /GEN = IGFBP1 /DB_XREF = gi: 183115 /UG = Hs.77326 insulin-like growth factor binding protein 3 /FL = gb: BC000013.1 gb: M31159.1 203320_at gb: NM_005475.1 /DEF = Homo sapiens lymphocyte adaptor protein (LNK), mRNA. /FEA = mRNA /GEN = LNK /PROD = lymphocyte adaptor protein /DB_XREF = gi: 4885454 /UG = Hs.13131 lymphocyte adaptor protein /FL = gb: AF055581.1 gb: NM_005475.1 201487_at gb: NM_001814.1 /DEF = Homo sapiens cathepsin C (CTSC), mRNA. /FEA = mRNA /GEN = CTSC /PROD = cathepsin C /DB_XREF = gi: 4503140 /UG = Hs.10029 cathepsin C /FL = gb: NM_001814.1 205147_x_at gb: NM_000631.2 /DEF = Homo sapiens neutrophil cytosolic factor 4 (40 kD) (NCF4), transcript variant 1, mRNA. /FEA = mRNA /GEN = NCF4 /PROD = neutrophil cytosolic factor 4 (40 kD), isoform 1 /DB_XREF = gi: 7382494 /UG = Hs.196352 neutrophil cytosolic factor 4 (40 kD) /FL = gb: AB025220.1 gb: NM_000631.2 202672_s_at gb: NM_001674.1 /DEF = Homo sapiens activating transcription factor 3 (ATF3), mRNA. /FEA = mRNA /GEN = ATF3 /PROD = activating transcription factor 3 long isoform /DB_XREF = gi: 4502262 /UG = Hs.460 activating transcription factor 3 /FL = gb: L19871.1 gb: NM_001674.1 201791_s_at gb: NM_001360.1 /DEF = Homo sapiens 7-dehydrocholesterol reductase (DHCR7), mRNA. /FEA = mRNA /GEN = DHCR7 /PROD = 7-dehydrocholesterol reductase /DB_XREF = gi: 4503320 /UG = Hs.11806 7-dehydrocholesterol reductase /FL = gb: BC000054.1 gb: AF034544.1 gb: AF067127.1 gb: AF096305.1 gb: NM_001360.1 202856_s_at gb: NM_004207.1 /DEF = Homo sapiens solute carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA. /FEA = mRNA /GEN = SLC16A3 /PROD = solute carrier family 16 (monocarboxylic acid transporters), member 3 /DB_XREF = gi: 4759111 /UG = Hs.85838 solute carrier family 16 (monocarboxylic acid transporters), member 3 /FL = gb: U81800.1 gb: NM_004207.1 213587_s_at Consensus includes gb: AI884867 /FEA = EST /DB_XREF = gi: 5590031 /DB_XREF = est: wl85g03.x1 /CLONE = IMAGE: 2431732 /UG = Hs.91379 ribosomal protein L26 214598_at Consensus includes gb: AL049977.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564C122 (from clone DKFZp564C122). /FEA = mRNA /DB_XREF = gi: 4884227 /UG = Hs.162209 claudin 8 /FL = gb: NM_012132.1 218959_at gb: NM_017409.1 /DEF = Homo sapiens homeo box C10 (HOXC10), mRNA. /FEA = mRNA /GEN = HOXC10 /PROD = homeo box C10 /DB_XREF = gi: 8393550 /UG = Hs.44276 homeo box C10 /FL = gb: BC001293.1 gb: AF255675.1 gb: NM_017409.1 202391_at gb: NM_006317.1 /DEF = Homo sapiens brain acid-soluble protein 1 (BASF1), mRNA. /FEA = mRNA /GEN = BASP1 /PROD = brain acid-soluble protein 1 /DB_XREF = gi: 5453749 /UG = Hs.79516 brain abundant, membrane attached signal protein 1 /FL = gb: BC000518.1 gb: AF039656.1 gb: NM_006317.1 219607_s_at gb: NM_024021.1 /DEF = Homo sapiens membrane-spanning 4-domains, subfamily A, member 4 (MS4A4), mRNA. /FEA = mRNA /GEN = MS4A4 /PROD = membrane-spanning 4-domains, subfamily A, member4 /DB_XREF = gi: 13430865 /UG = Hs.325960 membrane-spanning 4-domains, subfamily A, member 4 /FL = gb: AB013102.1 gb: NM_024021.1 gb: AF068288.1 gb: NM_016650.1 202086_at gb: NM_002462.1 /DEF = Homo sapiens myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) (MX1), mRNA. /FEA = mRNA /GEN = MX1 /PROD = myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) /DB_XREF = gi: 4505290 /UG = Hs.76391 myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) /FL = gb: M30817.1 gb: M33882.1 gb: NM_002462.1 213032_at Consensus includes gb: AI186739 /FEA = EST /DB_XREF = gi: 3737377 /DB_XREF = est: qe79c01.x1 /CLONE = IMAGE: 1745184 /UG = Hs.326416 Homo sapiens mRNA; cDNA DKFZp564H1916 (from clone DKFZp564H1916) 210785_s_at gb: AB035482.1 /DEF = Homo sapiens mRNA for ICB-1beta, complete cds. /FEA = mRNA /PROD = ICB-1beta /DB_XREF = gi: 8272423 /UG = Hs.10649 basement membrane-induced gene /FL = gb: AB035482.1 220413_at gb: NM_014579.1 /DEF = Homo sapiens zinc transporter (ZIP2), mRNA. /FEA = mRNA /GEN = ZIP2 /PROD = zinc transporter /DB_XREF = gi: 7657698 /UG = Hs.175783 zinc transporter /FL = gb: AF186081.1 gb: D83039.1 gb: NM_014579.1 202158_s_at gb: NM_006561.1 /DEF = Homo sapiens CUG triplet repeat, RNA-binding protein 2 (CUGBP2), mRNA. /FEA = mRNA /GEN = CUGBP2 /PROD = CUG triplet repeat, RNA-binding protein 2 /DB_XREF = gi: 5729815 /UG = Hs.211610 CUG triplet repeat, RNA-binding protein 2 /FL = gb: U69546.1 gb: AF036956.1 gb: AF090694.1 gb: NM_006561.1 218736_s_at gb: NM_017734.1 /DEF = Homo sapiens hypothetical protein FLJ20271 (FLJ20271), mRNA. /FEA = mRNA /GEN = FLJ20271 /PROD = hypothetical protein FLJ20271 /DB_XREF = gi: 8923242 /UG = Hs.14606 hypothetical protein FLJ20271 /FL = gb: NM_017734.1 219247_s_at gb: NM_024630.1 /DEF = Homo sapiens hypothetical protein FLJ20984 (FLJ20984), mRNA. /FEA = mRNA /GEN = FLJ20984 /PROD = hypothetical protein FLJ20984 /DB_XREF = gi: 13375857 /UG = Hs.38270 hypothetical protein FLJ20984 /FL = gb: NM_024630.1 206380_s_at gb: NM_002621.1 /DEF = Homo sapiens properdin P factor, complement (PFC), mRNA. /FEA = mRNA /GEN = PFC /PROD = properdin P factor, complement /DB_XREF = gi: 4505736 /UG = Hs.53155 properdin P factor, complement /FL = gb: NM_002621.1 gb: M83652.1 208438_s_at gb: NM_005248.1 /DEF = Homo sapiens Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog (FGR), mRNA. /FEA = mRNA /GEN = FGR /PROD = Gardner-Rasheed feline sarcoma viral (v-fgr)oncogene homolog /DB_XREF = gi: 4885234 /UG = Hs.1422 Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog /FL = gb: M19722.1 gb: NM_005248.1 213241_at Consensus includes gb: AF035307.1 /DEF = Homo sapiens clone 23785 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 2661068 /UG = Hs.184697 Homo sapiens clone 23785 mRNA sequence 210065_s_at gb: AB002155.1 /DEF = Homo sapiens mRNA for human uroplakin Ib, complete cds. /FEA = mRNA /PROD = human uroplakin Ib /DB_XREF = gi: 6682736 /UG = Hs.271580 uroplakin 1B /FL = gb: AB015234.1 gb: AF042331.1 gb: NM_006952.1 gb: AB002155.1 214866_at Consensus includes gb: X74039.1 /DEF = H. sapiens mRNA for urokinase plasminogen activator receptor. /FEA = mRNA /PROD = urokinase plasminogen activator receptor /DB_XREF = gi: 456192 /UG = Hs.179657 plasminogen activator, urokinase receptor 204436_at gb: NM_025201.1 /DEF = Homo sapiens hypothetical protein PP1628 (PP1628), mRNA. /FEA = mRNA /GEN = PP1628 /PROD = hypothetical protein PP1628 /DB_XREF = gi: 13376795 /UG = Hs.7159 hypothetical protein PP1628 /FL = gb: NM_025201.1 214438_at Consensus includes gb: M60721.1 /DEF = Human homeobox gene, complete cds. /FEA = mRNA /DB_XREF = gi: 183789 /UG = Hs.74870 H2.0 (Drosophila)-like homeo box 1 /FL = gb: NM_021958.1 gb: M60721.1 219511_s_at gb: NM_005460.1 /DEF = Homo sapiens synuclein, alpha interacting protein (synphilin) (SNCAIP), mRNA. /FEA = mRNA /GEN = SNCAIP /PROD = synuclein alpha interacting protein /DB_XREF = gi: 4885602 /UG = Hs.24948 synuclein, alpha interacting protein (synphilin) /FL = gb: AF076929.1 gb: NM_005460.1 209969_s_at gb: BC002704.1 /DEF = Homo sapiens, Similar to signal transducer and activator of transcription 1, 91 kD, clone MGC: 3493, mRNA, complete cds. /FEA = mRNA /PROD = Similar to signal transducer and activator of transcription 1, 91 kD /DB_XREF = gi: 12803734 /UG = Hs.21486 signal transducer and activator of transcription 1, 91 kD /FL = gb: BC002704.1 218854_at gb: NM_013352.1 /DEF = Homo sapiens squamous cell carcinoma antigen recognized by T cell (SART-2), mRNA. /FEA = mRNA /GEN = SART-2 /PROD = squamous cell carcinoma antigen recognized by Tcell /DB_XREF = gi: 7019520 /UG = Hs.58636 squamous cell carcinoma antigen recognized by T cell /FL = gb: AF098066.1 gb: NM_013352.1 204858_s_at gb: NM_001953.2 /DEF = Homo sapiens endothelial cell growth factor 1 (platelet-derived) (ECGF1), mRNA. /FEA = mRNA /GEN = ECGF1 /PROD = endothelial cell growth factor 1(platelet-derived) /DB_XREF = gi: 7669488 /UG = Hs.73946 endothelial cell growth factor 1 (platelet-derived) /FL = gb: NM_001953.2 211936_at Consensus includes gb: AF216292.1 /DEF = Homo sapiens endoplasmic reticulum lumenal Ca2+ binding protein grp78 mRNA, complete cds. /FEA = CDS /PROD = endoplasmic reticulum lumenal Ca2+ binding protein grp78 /DB_XREF = gi: 7229461 /UG = Hs.75410 heat shock 70 kD protein 5 (glucose-regulated protein, 78 kD) /FL = gb: AF216292.1 211756_at gb: BC005961.1 /DEF = Homo sapiens, parathyroid hormone-like hormone, clone MGC: 14611, mRNA, complete cds. /FEA = mRNA /PROD = parathyroid hormone-like hormone /DB_XREF = gi: 13543620 /FL = gb: BC005961.1 218532_s_at gb: NM_019000.1 /DEF = Homo sapiens hypothetical protein (FLJ20152), mRNA. /FEA = mRNA /GEN = FLJ20152 /PROD = hypothetical protein /DB_XREF = gi: 9506660 /UG = Hs.82273 hypothetical protein /FL = gb: NM_019000.1 203339_at Consensus includes gb: AI887457 /FEA = EST /DB_XREF = gi: 5592621 /DB_XREF = est: wm05f07.x1 /CLONE = IMAGE: 2435077 /UG = Hs.179866 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 /FL = gb: NM_003705.1 211133_x_at gb: AF009643.1 /DEF = Homo sapiens clone 6 immunoglobulin-like transcript 5 protein mRNA, complete cds. /FEA = mRNA /PROD = immunoglobulin-like transcript 5 protein /DB_XREF = gi: 2662445 /UG = Hs.105928 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 /FL = gb: AF009643.1 217967_s_at gb: AF288391.1 /DEF = Homo sapiens C1orf24 mRNA, complete cds. /FEA = mRNA /PROD = C1orf24 /DB_XREF = gi: 12620191 /UG = Hs.48778 niban protein /FL = gb: AB050477.1 gb: NM_022083.1 gb: AF288391.1 207571_x_at gb: NM_004848.1 /DEF = Homo sapiens basement membrane-induced gene (ICB-1), mRNA. /FEA = mRNA /GEN = ICB-1 /PROD = basement membrane-induced gene /DB_XREF = gi: 4758579 /UG = Hs.10649 basement membrane-induced gene /FL = gb: AF044896.1 gb: NM_004848.1 204493_at gb: NM_001196.1 /DEF = Homo sapiens BH3 interacting domain death agonist (BID), mRNA. /FEA = mRNA /GEN = BID /PROD = BH3 interacting domain death agonist /DB_XREF = gi: 4557360 /UG = Hs.172894 BH3 interacting domain death agonist /FL = gb: AF042083.1 gb: NM_001196.1 214247_s_at Consensus includes gb: AU148057 /FEA = EST /DB_XREF = gi: 11009578 /DB_XREF = est: AU148057 /CLONE = MAMMA1002489 /UG = Hs.278503 regulated in glioma 204580_at gb: NM_002426.1 /DEF = Homo sapiens matrix metalloproteinase 12 (macrophage elastase) (MMP12), mRNA. /FEA = mRNA /GEN = MMP12 /PROD = matrix metalloproteinase 12 preproprotein /DB_XREF = gi: 4505206 /UG = Hs.1695 matrix metalloproteinase 12 (macrophage elastase) /FL = gb: L23808.1 gb: NM_002426.1 218009_s_at gb: NM_003981.1 /DEF = Homo sapiens protein regulator of cytokinesis 1 (PRC1), mRNA. /FEA = mRNA /GEN = PRC1 /PROD = protein regulator of cytokinesis 1 /DB_XREF = gi: 4506038 /UG = Hs.5101 protein regulator of cytokinesis 1 /FL = gb: BC003138.1 gb: AF044588.1 gb: NM_003981.1 203645_s_at gb: NM_004244.1 /DEF = Homo sapiens CD163 antigen (CD163), mRNA. /FEA = mRNA /GEN = CD163 /PROD = CD163 antigen /DB_XREF = gi: 4758721 /UG = Hs.74076 CD163 antigen /FL = gb: NM_004244.1 207339_s_at gb: NM_002341.1 /DEF = Homo sapiens lymphotoxin beta (TNF superfamily, member 3) (LTB), transcript variant 1, mRNA. /FEA = mRNA /GEN = LTB /PROD = lymphotoxin-beta isoform a /DB_XREF = gi: 4505034 /UG = Hs.890 lymphotoxin beta (TNF superfamily, member 3) /FL = gb: L11015.1 gb: NM_002341.1 204464_s_at gb: NM_001957.1 /DEF = Homo sapiens endothelin receptor type A (EDNRA), mRNA. /FEA = mRNA /GEN = EDNRA /PROD = endothelin receptor type A /DB_XREF = gi: 4503464 /UG = Hs.76252 endothelin receptor type A /FL = gb: L06622.1 gb: NM_001957.1 205466_s_at gb: NM_005114.1 /DEF = Homo sapiens heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (HS3ST1), mRNA. /FEA = mRNA /GEN = HS3ST1 /PROD = heparan sulfate D-glucosaminyl3-O-sulfotransferase 1 precursor /DB_XREF = gi: 4826763 /UG = Hs.40968 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 /FL = gb: AF019386.1 gb: NM_005114.1 222218_s_at Consensus includes gb: AJ400843.1 /DEF = Homo sapiens partial mRNA for immunoglobulin-like cell surface receptor FDF03-M14, soluble alternative form. /FEA = mRNA /GEN = FDF03-M14 /PROD = cell surface receptor FDF03-M14 /DB_XREF = gi: 9715838 /UG = Hs.122591 paired immunoglobulin-like receptor alpha 206707_x_at gb: NM_015864.1 /DEF = Homo sapiens chromosome 6 open reading frame 32 (C6ORF32), mRNA. /FEA = mRNA /GEN = C6ORF32 /PROD = PL48 /DB_XREF = gi: 7705341 /UG = Hs.101359 chromosome 6 open reading frame 32 /FL = gb: BC001232.1 gb: U49187.1 gb: NM_015864.1 200635_s_at Consensus includes gb: AU145351 /FEA = EST /DB_XREF = gi: 11006872 /DB_XREF = est: AU145351 /CLONE = HEMBA1004591 /UG = Hs.75216 protein tyrosine phosphatase, receptor type, F /FL = gb: NM_002840.1 211434_s_at gb: AF015524.1 /DEF = Homo sapiens putative chemokine receptor (CRAM-A) mRNA, complete cds. /FEA = mRNA /GEN = CRAM-A /PROD = putative chemokine receptor /DB_XREF = gi: 3550066 /UG = Hs.302043 chemokine (C-C motif) receptor-like 2 /FL = gb: AF015524.1 216565_x_at Consensus includes gb: AL121994 /DEF = Human DNA sequence from clone RP4-781L3 on chromosome 1p34.3-36.11 Contains a pseudogene similar to IFITM3 (interferon induced ntransmembrane protein 3 (1-8U)), STSs and GSSs /FEA = CDS /DB_XREF = gi: 8648917 /UG = Hs.302117 Human DNA sequence from clone RP4-781L3 on chromosome 1p34.3-36.11 Contains a pseudogene similar to IFITM3 (interferon induced ntransmembrane protein 3 (1-8U)), STSs and GSSs 204174_at gb: NM_001629.1 /DEF = Homo sapiens arachidonate 5-lipoxygenase-activating protein (ALOX5AP), mRNA. /FEA = mRNA /GEN = ALOX5AP /PROD = arachidonate 5-lipoxygenase-activating protein /DB_XREF = gi: 4502058 /UG = Hs.100194 arachidonate 5-lipoxygenase-activating protein /FL = gb: NM_001629.1 205483_s_at gb: NM_005101.1 /DEF = Homo sapiens interferon-stimulated protein, 15 kDa (ISG15), mRNA. /FEA = mRNA /GEN = ISG15 /PROD = interferon-stimulated protein, 15 kDa /DB_XREF = gi: 4826773 /UG = Hs.833 interferon-stimulated protein, 15 kDa /FL = gb: M13755.1 gb: NM_005101.1 213036_x_at Consensus includes gb: Y15724 /DEF = Homo sapiens SERCA3 gene, exons 1-7 (and joined CDS) /FEA = mRNA /DB_XREF = gi: 3021395 /UG = Hs.5541 ATPase, Ca++ transporting, ubiquitous 201417_at Consensus includes gb: AL136179 /DEF = Human DNA sequence from clone RP3-322L4 on chromosome 6. Contains the SOX4 gene for SRY (sex determining region Y)-box 4, a pseudogene similar to predicted fly, worm and yeast genes, ESTs, STSs, GSSs and four CpG islands /FEA = mRNA /DB_XREF = gi: 8649149 /UG = Hs.83484 SRY (sex determining region Y)-box 4 /FL = gb: NM_003107.1 210946_at gb: AF014403.1 /DEF = Homo sapiens type-2 phosphatidic acid phosphatase alpha-2 (PAP2-a2) mRNA, complete cds. /FEA = mRNA /GEN = PAP2-a2 /PROD = type-2 phosphatidic acid phosphatase alpha-2 /DB_XREF = gi: 3123849 /UG = Hs.41569 phosphatidic acid phosphatase type 2A /FL = gb: AF014403.1 202053_s_at gb: L47162.1 /DEF = Human fatty aldehyde dehydrogenase (FALDH) mRNA, complete cds. /FEA = mRNA /GEN = FALDH /PROD = fatty aldehyde dehydrogenase /DB_XREF = gi: 1082035 /UG = Hs.159608 aldehyde dehydrogenase 3 family, member A2 /FL = gb: L47162.1 gb: U46689.1 gb: NM_000382.1 205114_s_at gb: NM_002983.1 /DEF = Homo sapiens small inducible cytokine A3 (homologous to mouse Mip-1a) (SCYA3), mRNA. /FEA = mRNA /GEN = SCYA3 /PROD = small inducible cytokine A3 (homologous to mouseMip-1a) /DB_XREF = gi: 4506842 /UG = Hs.73817 small inducible cytokine A3 (homologous to mouse Mip-1a) /FL = gb: M23452.1 gb: D00044.1 gb: NM_002983.1 gb: M25315.1 209173_at gb: AF088867.1 /DEF = Homo sapiens putative secreted protein XAG mRNA, complete cds. /FEA = mRNA /PROD = putative secreted protein XAG /DB_XREF = gi: 6652811 /UG = Hs.91011 anterior gradient 2 (Xenepus laevis) homolog /FL = gb: AF007791.1 gb: AF038451.1 gb: NM_006408.1 gb: AF088867.1 204400_at gb: NM_005864.1 /DEF = Homo sapiens signal transduction protein (SH3 containing) (EFS2), mRNA. /FEA = mRNA /GEN = EFS2 /PROD = signal transduction protein (SH3 containing) /DB_XREF = gi: 5031680 /UG = Hs.24587 signal transduction protein (SH3 containing) /FL = gb: AB001466.1 gb: NM_005864.1 203700_s_at gb: NM_013989.1 /DEF = Homo sapiens deiodinase, iodothyronine, type II (DIO2), transcript variant 1, mRNA. /FEA = mRNA /GEN = DIO2 /PROD = deiodinase, iodothyronine, type II /DB_XREF = gi: 7549802 /UG = Hs.154424 deiodinase, iodothyronine, type II /FL = gb: U53506.1 gb: AF093774.1 gb: NM_013989.1 203922_s_at Consensus includes gb: AI308863 /FEA = EST /DB_XREF = gi: 4003734 /DB_XREF = est: qo78d02.x1 /CLONE = IMAGE: 1914627 /UG = Hs.88974 cytochrome b-245, beta polypeptide (chronic granulomatous disease) /FL = gb: NM_000397.2 210724_at gb: AF239764.1 /DEF = Homo sapiens EGF-like module-containing mucin-like receptor EMR3 mRNA, complete cds. /FEA = mRNA /PROD = EGF-like module-containing mucin-like receptor EMR3 /DB_XREF = gi: 13183148 /UG = Hs.326777 Homo sapiens EGF-like module-containing mucin-like receptor EMR3 mRNA, complete cds /FL = gb: AF239764.1 214085_x_at Consensus includes gb: AI912583 /FEA = EST /DB_XREF = gi: 5632438 /DB_XREF = est: we11d05.x1 /CLONE = IMAGE: 2340777 /UG = Hs.154762 HIV-1 rev binding protein 2 202289_s_at gb: NM_006997.1 /DEF = Homo sapiens transforming, acidic coiled-coil containing protein 2 (TACC2), mRNA. /FEA = mRNA /GEN = TACC2 /PROD = transforming, acidic coiled-coil containing protein 2 /DB_XREF = gi: 11119413 /UG = Hs.272023 transforming, acidic coiled-coil containing protein 2 /FL = gb: AF095791.2 gb: NM_006997.1 213380_x_at Consensus includes gb: AA911235 /FEA = EST /DB_XREF = gi: 3050525 /DB_XREF = est: ol49d02.s1 /CLONE = IMAGE: 1526787 /UG = Hs.278657 macrophage stimulating 1 (hepatocyte growth factor-like) 205159_at Consensus includes gb: AV756141 /FEA = EST /DB_XREF = gi: 10913989 /DB_XREF = est: AV756141 /CLONE = BMFAKF10 /UG = Hs.285401 colony stimulating factor 2 receptor, beta, low-affinity (granulocyte- macrophage) /FL = gb: NM_000395.1 gb: M59941.1 215966_x_at Consensus includes gb: AA292874 /FEA = EST /DB_XREF = gi: 1941855 /DB_XREF = est: zt66a07.r1 /CLONE = IMAGE: 727284 /UG = Hs.1466 glycerol kinase 219282_s_at gb: NM_015930.1 /DEF = Homo sapiens vanilloid receptor-like protein 1 (VRL-1), mRNA. /FEA = mRNA /GEN = VRL-1 /PROD = vanilloid receptor-like protein 1 /DB_XREF = gi: 7706764 /UG = Hs.279746 vanilloid receptor-like protein 1 /FL = gb: AF129112.1 gb: NM_015930.1 206932_at gb: NM_003956.1 /DEF = Homo sapiens cholesterol 25-hydroxylase (CH25H), mRNA. /FEA = mRNA /GEN = CH25H /PROD = cholesterol 25-hydroxylase /DB_XREF = gi: 4502498 /UG = Hs.194687 cholesterol 25-hydroxylase /FL = gb: AF059214.1 gb: NM_003956.1 201195_s_at gb: AB018009.1 /DEF = Homo sapiens mRNA for L-type amino acid transporter 1, complete cds. /FEA = mRNA /GEN = hLAT1 /PROD = L-type amino acid transporter 1 /DB_XREF = gi: 5926731 /UG = Hs.184601 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 /FL = gb: AF077866.1 gb: AB018542.1 gb: AF104032.1 gb: NM_003486.1 gb: AB017908.1 gb: AB018009.1 39402_at Cluster Incl. M15330: Human interleukin 1-beta (IL1B) mRNA, complete cds /cds = (86, 895) /gb = M15330 /gi = 186283 /ug = Hs.126256 /len = 1497 205786_s_at gb: NM_000632.2 /DEF = Homo sapiens integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) (ITGAM), mRNA. /FEA = mRNA /GEN = ITGAM /PROD = integrin alpha M precursor /DB_XREF = gi: 6006013 /UG = Hs.172631 integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) /FL = gb: J03925.1 gb: NM_000632.2 48031_r_at Cluster Incl. H93077: yv05a04.s1 Homo sapiens cDNA, 3 end /clone = IMAGE-241806 /clone_end = 3 /gb = H93077 /gi = 1099405 /ug = Hs.10235 /len = 604 215679_at Consensus includes gb: AL109706.1 /DEF = Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 362430. /FEA = mRNA /DB_XREF = gi: 5689823 /UG = Hs.32769 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 362430 204014_at gb: NM_001394.2 /DEF = Homo sapiens dual specificity phosphatase 4 (DUSP4), mRNA. /FEA = mRNA /GEN = DUSP4 /PROD = dual specificity phosphatase 4 /DB_XREF = gi: 12707552 /UG = Hs.2359 dual specificity phosphatase 4 /FL = gb: U48807.1 gb: NM_001394.2 gb: BC002671.1 gb: U21108.1 203761_at gb: NM_006748.1 /DEF = Homo sapiens Src-like-adapter (SLA), mRNA. /FEA = mRNA /GEN = SLA /PROD = Src-like- adapter /DB_XREF = gi: 5803170 /UG = Hs.75367 Src-like-adapter /FL = gb: U30473.1 gb: D89077.1 gb: U44403.1 gb: NM_006748.1 201125_s_at gb: NM_002213.1 /DEF = Homo sapiens integrin, beta 5 (ITGB5), mRNA. /FEA = mRNA /GEN = ITGB5 /PROD = integrin, beta 5 /DB_XREF = gi: 4504772 /UG = Hs.149846 integrin, beta 5 /FL = gb: M35011.1 gb: J05633.1 gb: NM_002213.1 208146_s_at gb: NM_031311.1 /DEF = Homo sapiens serine carboxypeptidase vitellogenic-like (LOC54504), mRNA. /FEA = mRNA /GEN = LOC54504 /PROD = serine carboxypeptidase vitellogenic-like /DB_XREF = gi: 13786124 /FL = gb: NM_031311.1 203756_at gb: NM_014786.1 /DEF = Homo sapiens KIAA0337 gene product (KIAA0337), mRNA. /FEA = mRNA /GEN = KIAA0337 /PROD = KIAA0337 gene product /DB_XREF = gi: 7662063 /UG = Hs.45180 KIAA0337 gene product /FL = gb: AB002335.1 gb: NM_014786.1 217028_at Consensus includes gb: AJ224869 /DEF = Homo sapiens CXCR4 gene encoding receptor CXCR4 /FEA = mRNA /DB_XREF = gi: 3059119 /UG = Hs.89414 chemokine (C-X-C motif), receptor 4 (fusin) 217272_s_at Consensus includes gb: AJ001698.1 /DEF = Homo sapiens mRNA for hurpin, clone R7-16.1. /FEA = mRNA /GEN = PI13 /PROD = hurpin /DB_XREF = gi: 6018509 /UG = Hs.241407 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 13 218975_at gb: NM_015719.1 /DEF = Homo sapiens collagen, type V, alpha 3 (COL5A3), mRNA. /FEA = mRNA /GEN = COL5A3 /PROD = procollagen, type V, alpha 3 /DB_XREF = gi: 7656988 /UG = Hs.235368 collagen, type V, alpha 3 /FL = gb: AF177941.1 gb: NM_015719.1 219572_at gb: NM_017954.1 /DEF = Homo sapiens hypothetical protein FLJ20761 (FLJ20761), mRNA. /FEA = mRNA /GEN = FLJ20761 /PROD = hypothetical protein FLJ20761 /DB_XREF = gi: 8923671 /UG = Hs.107872 hypothetical protein FLJ20761 /FL = gb: NM_017954.1 207720_at gb: NM_000427.1 /DEF = Homo sapiens loricrin (LOR), mRNA. /FEA = mRNA /GEN = LOR /PROD = loricrin /DB_XREF = gi: 4557724 /UG = Hs.251680 loricrin /FL = gb: M61120.1 gb: NM_000427.1 219666_at gb: NM_022349.1 /DEF = Homo sapiens CD20-like precusor (LOC64166), mRNA. /FEA = mRNA /GEN = LOC64166 /PROD = CD20-like precusor /DB_XREF = gi: 11641258 /UG = Hs.17914 membrane-spanning 4-domains, subfamily A, member6 /FL = gb: AF142409.1 gb: NM_022349.1 201279_s_at gb: BC003064.1 /DEF = Homo sapiens, disabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein), clone MGC: 1764, mRNA, complete cds. /FEA = mRNA /PROD = disabled (Drosophila) homolog 2(mitogen-responsive phosphoprotein) /DB_XREF = gi: 13111753 /UG = Hs.81988 disabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) /FL = gb: U39050.1 gb: U53446.1 gb: BC003064.1 gb: NM_001343.1 204007_at gb: J04162.1 /DEF = Human leukocyte IgG receptor (Fc-gamma-R) mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 183036 /UG = Hs.176663 Fc fragment of IgG, low affinity IIIb, receptor for (CD16) /FL = gb: NM_000570.1 gb: J04162.1 gb: M24854.1 gb: AB025256.1 212727_at Consensus includes gb: AB033058.1 /DEF = Homo sapiens mRNA for KIAA1232 protein, partial cds. /FEA = mRNA /GEN = KIAA1232 /PROD = KIAA1232 protein /DB_XREF = gi: 6330721 /UG = Hs.11101 KIAA1232 protein 200712_s_at Consensus includes gb: AI633566 /FEA = EST /DB_XREF = gi: 4684896 /DB_XREF = est: th68f09.x1 /CLONE = IMAGE: 2123849 /UG = Hs.234279 microtubule-associated protein, RPEB family, member 1 /FL = gb: NM_012325.1 gb: U24166.1 206969_at gb: NM_021013.2 /DEF = Homo sapiens keratin, hair, acidic, 4 (KRTHA4), mRNA. /FEA = mRNA /GEN = KRTHA4 /PROD = type I hair keratin 4 /DB_XREF = gi: 11641406 /UG = Hs.296942 keratin, hair, acidic, 4 /FL = gb: NM_021013.2 219561_at gb: NM_016429.1 /DEF = Homo sapiens COPZ2 for nonclathrin coat protein zeta-COP (LOC51226), mRNA. /FEA = mRNA /GEN = LOC51226 /PROD = COPZ2 for nonclathrin coat protein zeta-COP /DB_XREF = gi: 7705982 /UG = Hs.37482 COPZ2 for nonclathrin coat protein zeta-COP /FL = gb: AB047849.1 gb: AB037938.1 gb: NM_016429.1 201843_s_at gb: NM_004105.2 /DEF = Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), transcript variant 1, mRNA. /FEA = mRNA /GEN = EFEMP1 /PROD = EGF-containing fibulin-like extracellular matrixprotein 1 precursor, isoform a precursor /DB_XREF = gi: 9665261 /UG = Hs.76224 EGF-containing fibulin-like extracellular matrix protein 1 /FL = gb: U03877.1 gb: NM_004105.2 203881_s_at gb: NM_004010.1 /DEF = Homo sapiens dystrophin (muscular dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272 (DMD), transcript variant Dp427p2, mRNA. /FEA = mRNA /GEN = DMD /PROD = dystrophin Dp427p2 isoform /DB_XREF = gi: 5032314 /UG = Hs.169470 dystrophin (muscular dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272 /FL = gb: NM_004010.1 209774_x_at gb: M57731.1 /DEF = Human gro-beta mRNA, complete cds. /FEA = mRNA /GEN = gro-beta /PROD = cytokine gro-beta /DB_XREF = gi: 183626 /UG = Hs.75765 GRO2 oncogene /FL = gb: M57731.1 gb: M36820.1 gb: NM_002089.1 204774_at gb: NM_014210.1 /DEF = Homo sapiens ecotropic viral integration site 2A (EVI2A), mRNA. /FEA = mRNA /GEN = EVI2A /PROD = ecotropic viral integration site 2A /DB_XREF = gi: 7657074 /UG = Hs.70499 ecotropic viral integration site 2A /FL = gb: NM_014210.1 203910_at gb: NM_004815.1 /DEF = Homo sapiens PTPL1-associated RhoGAP 1 (PARG1), mRNA. /FEA = mRNA /GEN = PARG1 /PROD = PTPL1-associated RhoGAP 1 /DB_XREF = gi: 4758881 /UG = Hs.70983 PTPL1-associated RhoGAP 1 /FL = gb: U90920.1 gb: NM_004815.1 215726_s_at Consensus includes gb: M22976.1 /DEF = Human cytochrome b5 mRNA, 3 end. /FEA = mRNA /GEN = CYB5 /PROD = cytochrome b5 /DB_XREF = gi: 181228 /UG = Hs.83834 cytochrome b-5 207677_s_at gb: NM_013416.1 /DEF = Homo sapiens neutrophil cytosolic factor 4 (40 kD) (NCF4), transcript variant 2, mRNA. /FEA = mRNA /GEN = NCF4 /PROD = neutrophil cytosolic factor 4 (40 kD), isoform 2 /DB_XREF = gi: 7382492 /UG = Hs.196352 neutrophil cytosolic factor 4 (40 kD) /FL = gb: BC002798.1 gb: AB025219.1 gb: NM_013416.1 220412_x_at gb: NM_005714.1 /DEF = Homo sapiens potassium channel, subfamily K, member 7 (KCNK7), mRNA. /FEA = mRNA /GEN = KCNK7 /PROD = potassium channel, subfamily K, member 7 /DB_XREF = gi: 5031820 /UG = Hs.175218 potassium channel, subfamily K, member 7 /FL = gb: AF110524.1 gb: NM_005714.1 218477_at gb: NM_014051.1 /DEF = Homo sapiens PTD011 protein (PTD011), mRNA. /FEA = mRNA /GEN = PTD011 /PROD = PTD011 protein /DB_XREF = gi: 7662638 /UG = Hs.94896 PTD011 protein /FL = gb: AF078864.1 gb: AF239771.1 gb: NM_014051.1 202643_s_at Consensus includes gb: AI738896 /FEA = EST /DB_XREF = gi: 5100877 /DB_XREF = est: wi22g02.x1 /CLONE = IMAGE: 2391026 /UG = Hs.211600 tumor necrosis factor, alpha-induced protein 3 /FL = gb: M59465.1 gb: NM_006290.1 212365_at Consensus includes gb: BF215996 /FEA = EST /DB_XREF = gi: 11109582 /DB_XREF = est: 601881549F1 /CLONE = IMAGE: 4093740 /UG = Hs.121576 Homo sapiens cDNA FLJ20153 fis, clone COL08656, highly similar to AJ001381 Homo sapiens incomplete cDNA for a mutated allele 204183_s_at Consensus includes gb: AI478542 /FEA = EST /DB_XREF = gi: 4371768 /DB_XREF = est: tm53c11.x1 /CLONE = IMAGE: 2161844 /UG = Hs.13944 adrenergic, beta, receptor kinase 2 /FL = gb: NM_005160.2 203603_s_at gb: NM_014795.1 /DEF = Homo sapiens zinc finger homeobox 1B (ZFHX1B), mRNA. /FEA = mRNA /GEN = ZFHX1B /PROD = zinc finger homeobox 1B /DB_XREF = gi: 7662183 /UG = Hs.34871 zinc finger homeobox 1B /FL = gb: AB011141.1 gb: NM_014795.1 203786_s_at gb: NM_003287.1 /DEF = Homo sapiens tumor protein D52-like 1 (TPD52L1), mRNA. /FEA = mRNA /GEN = TPD52L1 /PROD = tumor protein D52-like 1 /DB_XREF = gi: 4507640 /UG = Hs.16611 tumor protein D52-like 1 /FL = gb: U44427.1 gb: NM_003287.1 219620_x_at gb: NM_017723.1 /DEF = Homo sapiens hypothetical protein FLJ20245 (FLJ20245), mRNA. /FEA = mRNA /GEN = FLJ20245 /PROD = hypothetical protein FLJ20245 /DB_XREF = gi: 8923220 /UG = Hs.169758 hypothetical protein FLJ20245 /FL = gb: NM_017723.1 202430_s_at gb: NM_021105.1 /DEF = Homo sapiens phospholipid scramblase 1 (PLSCR1), mRNA. /FEA = mRNA /GEN = PLSCR1 /PROD = phospholipid scramblase 1 /DB_XREF = gi: 10863876 /UG = Hs.198282 phospholipid scramblase 1 /FL = gb: NM_021105.1 gb: AB006746.1 gb: AF098642.1 217865_at gb: NM_018434.1 /DEF = Homo sapiens goliath protein (LOC55819), mRNA. /FEA = mRNA /GEN = LOC55819 /PROD = goliath protein /DB_XREF = gi: 10092650 /UG = Hs.102737 goliath protein /FL = gb: NM_018434.1 209530_at gb: U07139.1 /DEF = Human voltage-gated calcium channel beta subunit mRNA, complete cds. /FEA = mRNA /PROD = voltage-gated calcium channel beta subunit /DB_XREF = gi: 463890 /UG = Hs.250712 calcium channel, voltage- dependent, beta 3 subunit /FL = gb: NM_000725.1 gb: U07139.1 202555_s_at gb: NM_005965.1 /DEF = Homo sapiens myosin, light polypeptide kinase (MYLK), mRNA. /FEA = mRNA /GEN = MYLK /PROD = myosin, light polypeptide kinase /DB_XREF = gi: 5174600 /UG = Hs.211582 myosin, light polypeptide kinase /FL = gb: AB037663.1 gb: NM_005965.1 gb: AF069601.2 207857_at gb: NM_006866.1 /DEF = Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 (LILRA2), mRNA. /FEA = mRNA /GEN = LILRA2 /PROD = leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 /DB_XREF = gi: 5803067 /UG = Hs.94498 leukocyte immunoglobulin- like receptor, subfamily A (with TM domain), member 2 /FL = gb: U82275.1 gb: NM_006866.1 212012_at Consensus includes gb: BF342851 /FEA = EST /DB_XREF = gi: 11289878 /DB_XREF = est: 602015135F1 /CLONE = IMAGE: 4150664 /UG = Hs.118893 Melanoma associated gene 209696_at gb: D26054.1 /DEF = Human mRNA for fructose-1,6-bisphosphatase, complete cds. /FEA = mRNA /PROD = fructose-1,6- bisphosphatase /DB_XREF = gi: 439225 /UG = Hs.574 fructose-1,6-bisphosphatase 1 /FL = gb: M19922.1 gb: L10320.1 gb: D26054.1 gb: D26055.1 gb: D26056.1 gb: NM_000507.1 202510_s_at gb: NM_006291.1 /DEF = Homo sapiens tumor necrosis factor, alpha-induced protein 2 (TNFAIP2), mRNA. /FEA = mRNA /GEN = TNFAIP2 /PROD = tumor necrosis factor, alpha-induced protein 2 /DB_XREF = gi: 5454133 /UG = Hs.101382 tumor necrosis factor, alpha-induced protein 2 /FL = gb: M92357.1 gb: NM_006291.1 214927_at Consensus includes gb: AL359052.1 /DEF = Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422. /FEA = mRNA /PROD = ITGBL1, integrin beta-like 1 /DB_XREF = gi: 8518175 /UG = Hs.311054 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422 218614_at gb: NM_018169.1 /DEF = Homo sapiens hypothetical protein FLJ10652 (FLJ10652), mRNA. /FEA = mRNA /GEN = FLJ10652 /PROD = hypothetical protein FLJ10652 /DB_XREF = gi: 8922572 /UG = Hs.236844 hypothetical protein FLJ10652 /FL = gb: NM_018169.1 210592_s_at gb: M55580.1 /DEF = Human spermidinespermine N1-acetyltransferase mRNA, complete cds. /FEA = mRNA /GEN = spermidinespermine N1-acetyltransferase /PROD = spermidinespermine N1-acetyltransferase /DB_XREF = gi: 338335 /UG = Hs.28491 spermidinespermine N1-acetyltransferase /FL = gb: M55580.1 200636_s_at gb: NM_002840.1 /DEF = Homo sapiens protein tyrosine phosphatase, receptor type, F (PTPRF), mRNA. /FEA = mRNA /GEN = PTPRF /PROD = protein tyrosine phosphatase, receptor type, fpolypeptide /DB_XREF = gi: 4506310 /UG = Hs.75216 protein tyrosine phosphatase, receptor type, F /FL = gb: NM_002840.1 211075_s_at gb: Z25521.1 /DEF = H. sapiens integrin associated protein mRNA, complete CDS,. /FEA = mRNA /PROD = integrin associated protein /DB_XREF = gi: 396704 /FL = gb: Z25521.1 205640_at gb: NM_000694.1 /DEF = Homo sapiens aldehyde dehydrogenase 3 family, member B1 (ALDH3B1), mRNA. /FEA = mRNA /GEN = ALDH3B1 /PROD = aldehyde dehydrogenase 3B1 /DB_XREF = gi: 4502042 /UG = Hs.83155 aldehyde dehydrogenase 3 family, member B1 /FL = gb: NM_000694.1 gb: U10868.1 211138_s_at gb: BC005297.1 /DEF = Homo sapiens, Similar to kynurenine 3-monooxygenase (kynurenine 3-hydroxylase), clone MGC: 12362, mRNA, complete cds. /FEA = mRNA /PROD = Similar to kynurenine 3-monooxygenase(kynurenine 3- hydroxylase) /DB_XREF = gi: 13529016 /UG = Hs.107318 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) /FL = gb: BC005297.1 204575_s_at gb: U38321.1 /DEF = Homo sapiens clone rasi-11 matrix metalloproteinase RASI-1 mRNA, complete cds. /FEA = mRNA /PROD = matrix metalloproteinase RASI-1 /DB_XREF = gi: 2228243 /UG = Hs.154057 matrix metalloproteinase 19 /FL = gb: NM_002429.2 gb: U38321.1 gb: U37791.1 222237_s_at Consensus includes gb: AC084239 /DEF = Homo sapiens chromosome 19, BAC CTC-512J12 (BC347040), complete sequence /FEA = mRNA_2 /DB_XREF = gi: 10864171 /UG = Hs.48589 zinc finger protein 228 202664_at Consensus includes gb: AW058622 /FEA = EST /DB_XREF = gi: 5934261 /DB_XREF = est: wy59c01.x1 /CLONE = IMAGE: 2552832 /UG = Hs.24143 Wiskott-Aldrich syndrome protein interacting protein /FL = gb: NM_003387.2 210241_s_at gb: AB007458.1 /DEF = Homo sapiens mRNA for P53TG1-D, complete cds. /FEA = mRNA /GEN = P53TG1 /PROD = P53TG1-D /DB_XREF = gi: 5006272 /UG = Hs.306301 Homo sapiens mRNA for P53TG1-D, complete cds /FL = gb: AB007458.1 219183_s_at gb: NM_013385.2 /DEF = Homo sapiens pleckstrin homology, Sec7 and coiledcoil domains 4 (PSCD4), mRNA. /FEA = mRNA /GEN = PSCD4 /PROD = pleckstrin homology, Sec7 and coiledcoildomains 4 /DB_XREF = gi: 8670549 /UG = Hs.7189 pleckstrin homology, Sec7 and coiledcoil domains 4 /FL = gb: AF075458.1 gb: NM_013385.2 206022_at gb: NM_000266.1 /DEF = Homo sapiens Norrie disease (pseudoglioma) (NDP), mRNA. /FEA = mRNA /GEN = NDP /PROD = Norrie disease protein /DB_XREF = gi: 4557788 /UG = Hs.2839 Norrie disease (pseudoglioma) /FL = gb: NM_000266.1 216136_at Consensus includes gb: AF113683.1 /DEF = Homo sapiens clone FLB3521. /FEA = mRNA /DB_XREF = gi: 6855610 /UG = Hs.306569 Homo sapiens clone FLB3521 219059_s_at Consensus includes gb: AL574194 /FEA = EST /DB_XREF = gi: 12934166 /DB_XREF = est: AL574194 /CLONE = CS0DI039YJ06 (3 prime) /UG = Hs.17917 extracellular link domain-containing 1 /FL = gb: AF118108.1 gb: NM_006691.1 211135_x_at gb: AF009644.1 /DEF = Homo sapiens clone 41 immunoglobulin-like transcript 5 protein mRNA, complete cds. /FEA = mRNA /PROD = immunoglobulin-like transcript 5 protein /DB_XREF = gi: 2662447 /UG = Hs.105928 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 /FL = gb: AF009644.1 203060_s_at gb: AF074331.1 /DEF = Homo sapiens PAPS synthetase-2 (PAPSS2) mRNA, complete cds. /FEA = mRNA /GEN = PAPSS2 /PROD = PAPS synthetase-2 /DB_XREF = gi: 5052074 /UG = Hs.274230 3-phosphoadenosine 5- phosphosulfate synthase 2 /FL = gb: AF150754.2 gb: AF313907.1 gb: AF091242.1 gb: NM_004670.1 gb: AF074331.1 gb: AF173365.1 34726_at Cluster Incl. U07139: Human voltage-gated calcium channel beta subunit mRNA, complete cds /cds = (34, 1488) /gb = U07139 /gi = 463890 /ug = Hs.239447 /len = 2532 208370_s_at gb: NM_004414.2 /DEF = Homo sapiens Down syndrome critical region gene 1 (DSCR1), mRNA. /FEA = mRNA /GEN = DSCR1 /PROD = Down syndrome critical region protein 1 /DB_XREF = gi: 7657042 /UG = Hs.184222 Down syndrome critical region gene 1 /FL = gb: U28833.2 gb: NM_004414.2 210132_at Consensus includes gb: AW189015 /FEA = EST /DB_XREF = gi: 6463451 /DB_XREF = est: xk98d10.x1 /CLONE = IMAGE: 2674771 /UG = Hs.37054 ephrin-A3 /FL = gb: NM_004952.1 gb: L37360.1 gb: U14187.1 209147_s_at gb: AB000888.1 /DEF = Homo sapiens mRNA for phosphatidic acid phosphatase 2a, complete cds. /FEA = mRNA /PROD = phosphatidic acid phosphatase 2a /DB_XREF = gi: 2467297 /UG = Hs.41569 phosphatidic acid phosphatase type 2A /FL = gb: AB000888.1 gb: AF017116.1 gb: AF014402.1 gb: NM_003711.1 212268_at Consensus includes gb: NM_030666.1 /DEF = Homo sapiens serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 (SERPINB1), mRNA. /FEA = CDS /GEN = SERPINB1 /PROD = serine (or cysteine) proteinase inhibitor, cladeB (ovalbumin), member 1 /DB_XREF = gi: 13489086 /UG = Hs.183583 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 /FL = gb: NM_030666.1 220197_at gb: NM_020632.1 /DEF = Homo sapiens ATPase, H(+)-transporting, lysosomal, noncatalytic accessory protein 1B (ATP6N1B), mRNA. /FEA = mRNA /GEN = ATP6N1B /PROD = ATPase, H(+)-transporting, lysosomal, noncatalytic accessory protein 1B /DB_XREF = gi: 10190665 /UG = Hs.98967 ATPase, H(+)-transporting, lysosomal, noncatalytic accessory protein 1B /FL = gb: NM_020632.1 gb: AF245517.1 205614_x_at gb: NM_020998.1 /DEF = Homo sapiens macrophage stimulating 1 (hepatocyte growth factor-like) (MST1), mRNA. /FEA = mRNA /GEN = MST1 /PROD = macrophage stimulating 1 (hepatocyte growth factor-like) /DB_XREF = gi: 10337614 /UG = Hs.278657 macrophage stimulating 1 (hepatocyte growth factor-like) /FL = gb: NM_020998.1 gb: M74178.1 gb: L11924.1 213695_at Consensus includes gb: L48516.1 /DEF = Homo sapiens paraoxonase 3 (PON3) mRNA, 3 end of cds. /FEA = mRNA /GEN = PON3 /PROD = paraoxonase-3 /DB_XREF = gi: 1333633 /UG = Hs.296259 paraoxonase 3 208578_at gb: NM_006514.1 /DEF = Homo sapiens sodium channel, voltage-gated, type X, alpha polypeptide (SCN10A), mRNA. /FEA = CDS /GEN = SCN10A /PROD = sodium channel, voltage-gated, type X, alphapolypeptide /DB_XREF = gi: 5730032 /UG = Hs.250443 sodium channel, voltage-gated, type X, alpha polypeptide /FL = gb: AF117907.1 gb: NM_006514.1 212848_s_at Consensus includes gb: BG036668 /FEA = EST /DB_XREF = gi: 12432092 /DB_XREF = est: 602326882F1 /CLONE = IMAGE: 4428237 /UG = Hs.18075 chromosome 9 open reading frame 3 210889_s_at gb: M31933.1 /DEF = Human IgG low affinity Fc fragment receptor (FcRIIb3) mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 182598 /UG = Hs.278443 Fc fragment of IgG, low affinity IIb, receptor for (CD32) /FL = gb: M31933.1 210225_x_at gb: AF009635.1 /DEF = Homo sapiens clone 17.7 immunoglobulin-like transcript 5 protein mRNA, complete cds. /FEA = mRNA /PROD = immunoglobulin-like transcript 5 protein /DB_XREF = gi: 2662429 /UG = Hs.105928 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 /FL = gb: AF000575.1 gb: U91928.1 gb: AF025533.1 gb: AF009632.1 gb: AF009633.1 gb: AF009635.1 gb: AF009638.1 gb: AF009639.1 gb: AF009641.1 gb: AF009642.1 gb: AF031553.1 gb: AF031554.1 gb: AF031555.1 gb: AF031556.1 gb: NM_006864.1 203705_s_at Consensus includes gb: AI333651 /FEA = EST /DB_XREF = gi: 4070210 /DB_XREF = est: qq08e12.x1 /CLONE = IMAGE: 1931950 /UG = Hs.173859 frizzled (Drosophila) homolog 7 /FL = gb: AB010881.1 gb: AB017365.1 gb: NM_003507.1 205660_at gb: NM_003733.1 /DEF = Homo sapiens 2-5oligoadenylate synthetase-like (OASL), mRNA. /FEA = mRNA /GEN = OASL /PROD = 2-5oligoadenylate synthetase-like /DB_XREF = gi: 11321576 /UG = Hs.118633 2-5oligoadenylate synthetase-like /FL = gb: NM_003733.1 gb: AF063611.1 200906_s_at Consensus includes gb: AK025843.1 /DEF = Homo sapiens cDNA: FLJ22190 fis, clone HRC01053. /FEA = mRNA /DB_XREF = gi: 10438481 /UG = Hs.194431 palladin /FL = gb: AF077041.1 gb: AF151909.1 gb: NM_016081.1 204336_s_at gb: NM_005873.1 /DEF = Homo sapiens regulator of G-protein signalling 19 (RGS19), mRNA. /FEA = mRNA /GEN = RGS19 /PROD = G protein signalling regulator 19 /DB_XREF = gi: 5031704 /UG = Hs.22698 regulator of G-protein signalling 19 /FL = gb: NM_005873.1 216248_s_at Consensus includes gb: S77154.1 /DEF = TINUR = NGFI-Bnur77 beta-type transcription factor homolog human, T lymphoid cell line, PEER, mRNA, 2469 nt. /FEA = mRNA /GEN = TINUR /DB_XREF = gi: 913966 /UG = Hs.82120 nuclear receptor subfamily 4, group A, member 2 217738_at Consensus includes gb: BF575514 /FEA = EST /DB_XREF = gi: 11649318 /DB_XREF = est: 602133090F1 /CLONE = IMAGE: 4288079 /UG = Hs.239138 pre-B-cell colony-enhancing factor /FL = gb: U02020.1 gb: NM_005746.1 209292_at Consensus includes gb: AL022726 /DEF = Human DNA sequence from clone 625H18 on chromosome 6p22.2-23. Contains the gene for ID4 Helix-loop-helix DNA binding protein and part of an alternatively spliced novel gene. Contains ESTs, STSs, GSSs and putative CpG islands /FEA = mRNA /DB_XREF = gi: 3676217 /UG = Hs.34853 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein /FL = gb: NM_001546.1 gb: U16153.1 gb: U28368.1 216236_s_at Consensus includes gb: AL110298.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564K1672 (from clone DKFZp564K1672); partial cds. /FEA = mRNA /GEN = DKFZp564K1672 /PROD = hypothetical protein /DB_XREF = gi: 5817258 /UG = Hs.7594 solute carrier family 2 (facilitated glucose transporter), member 3 211990_at Consensus includes gb: M27487.1 /DEF = Homo sapiens MHC class II DPw3-alpha-1 chain mRNA, complete cds. /FEA = CDS /GEN = HLA-DPA1 /PROD = MHC class II DP3-alpha /DB_XREF = gi: 703088 /UG = Hs.914 Human mRNA for SB classII histocompatibility antigen alpha-chain /FL = gb: M27487.1 209309_at gb: D90427.1 /DEF = Human mRNA for zinc-alpha2-glycoprotein, complete cds. /FEA = mRNA /PROD = zinc-alpha2- glycoprotein precursor /DB_XREF = gi: 220150 /UG = Hs.71 alpha-2-glycoprotein 1, zinc /FL = gb: D90427.1 gb: M76707.1 gb: NM_001185.1 208303_s_at gb: NM_022148.1 /DEF = Homo sapiens cytokine receptor-like factor 2 (CRLF2), mRNA. /FEA = mRNA /GEN = CRLF2 /PROD = cytokine receptor-like factor 2 /DB_XREF = gi: 13375623 /UG = Hs.287729 cytokine receptor-like factor 2 /FL = gb: NM_022148.1 204759_at gb: NM_001268.1 /DEF = Homo sapiens chromosome condensation 1-like (CHC1L), mRNA. /FEA = mRNA /GEN = CHC1L /PROD = RCC1-like G exchanging factor RLG /DB_XREF = gi: 4557444 /UG = Hs.27007 chromosome condensation 1-like /FL = gb: AF060219.1 gb: NM_001268.1 204256_at gb: NM_024090.1 /DEF = Homo sapiens hypothetical protein MGC5487 (MGC5487), mRNA. /FEA = mRNA /GEN = MGC5487 /PROD = hypothetical protein MGC5487 /DB_XREF = gi: 13129087 /UG = Hs.211556 hypothetical protein MGC5487 /FL = gb: NM_024090.1 214974_x_at Consensus includes gb: AK026546.1 /DEF = Homo sapiens cDNA: FLJ22893 fis, clone KAT04792. /FEA = mRNA /DB_XREF = gi: 10439427 /UG = Hs.287716 Homo sapiens cDNA: FLJ22893 fis, clone KAT04792 205479_s_at gb: NM_002658.1 /DEF = Homo sapiens plasminogen activator, urokinase (PLAU), mRNA. /FEA = mRNA /GEN = PLAU /PROD = plasminogen activator, urokinase /DB_XREF = gi: 4505862 /UG = Hs.77274 plasminogen activator, urokinase /FL = gb: M15476.1 gb: NM_002658.1 209815_at Consensus includes gb: BG054916 /FEA = EST /DB_XREF = gi: 12512119 /DB_XREF = est: nac92b02.x1 /CLONE = IMAGE: 3441723 /UG = Hs.159526 patched (Drosophila) homolog /FL = gb: U43148.1 201818_at gb: NM_024830.1 /DEF = Homo sapiens hypothetical protein FLJ12443 (FLJ12443), mRNA. /FEA = mRNA /GEN = FLJ12443 /PROD = hypothetical protein FLJ12443 /DB_XREF = gi: 13376233 /UG = Hs.179882 hypothetical protein FLJ12443 /FL = gb: NM_024830.1 203678_at gb: NM_014967.1 /DEF = Homo sapiens KIAA1018 protein (KIAA1018), mRNA. /FEA = mRNA /GEN = KIAA1018 /PROD = KIAA1018 protein /DB_XREF = gi: 7662449 /UG = Hs.5400 KIAA1018 protein /FL = gb: AB023235.1 gb: NM_014967.1 218326_s_at gb: NM_018490.1 /DEF = Homo sapiens G protein-coupled receptor 48 (GPR48), mRNA. /FEA = mRNA /GEN = GPR48 /PROD = G protein-coupled receptor 48 /DB_XREF = gi: 8923700 /UG = Hs.160271 G protein-coupled receptor 48 /FL = gb: AF257182.1 gb: NM_018490.1 211248_s_at gb: AF283325.1 /DEF = Homo sapiens chordin variant 3 (CHRD) mRNA, complete cds, alternatively spliced. /FEA = mRNA /GEN = CHRD /PROD = chordin variant 3 /DB_XREF = gi: 11494372 /UG = Hs.166186 chordin /FL = gb: AF283325.1 206247_at gb: NM_005931.1 /DEF = Homo sapiens MHC class I polypeptide-related sequence B (MICB), mRNA. /FEA = mRNA /GEN = MICB /PROD = MHC class I polypeptide-related sequence B /DB_XREF = gi: 5174564 /UG = Hs.211580 MHC class I polypeptide-related sequence B /FL = gb: NM_005931.1 214284_s_at Consensus includes gb: AA022949 /FEA = EST /DB_XREF = gi: 1487039 /DB_XREF = est: ze72h02.s1 /CLONE = IMAGE: 364563 /UG = Hs.49585 fibroblast growth factor 18 216347_s_at Consensus includes gb: AK023188.1 /DEF = Homo sapiens cDNA FLJ13126 fis, clone NT2RP3002909, weakly similar to P53-BINDING PROTEIN 2. /FEA = mRNA /DB_XREF = gi: 10435002 /UG = Hs.6162 KIAA0771 protein 208309_s_at gb: NM_006785.1 /DEF = Homo sapiens mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1), mRNA. /FEA = mRNA /GEN = MALT1 /PROD = mucosa associated lymphoid tissue lymphomatranslocation gene 1 /DB_XREF = gi: 5803077 /UG = Hs.180566 mucosa associated lymphoid tissue lymphoma translocation gene 1 /FL = gb: AF316597.1 gb: AF130356.2 gb: NM_006785.1 207367_at gb: NM_001676.2 /DEF = Homo sapiens ATPase, H+K+ transporting, nongastric, alpha polypeptide (ATP12A), mRNA. /FEA = mRNA /GEN = ATP12A /PROD = ATPase, H+K+ transporting, nongastric, alphapolypeptide /DB_XREF = gi: 10280617 /UG = Hs.1165 ATPase, H+K+ transporting, nongastric, alpha polypeptide /FL = gb: NM_001676.2 gb: U02076.1 201911_s_at gb: NM_005766.1 /DEF = Homo sapiens FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte- derived) (FARP1), mRNA. /FEA = mRNA /GEN = FARP1 /PROD = FERM, RhoGEF, and pleckstrin domain protein 1 /DB_XREF = gi: 5031632 /UG = Hs.183738 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte- derived) /FL = gb: AB008430.1 gb: NM_005766.1 205101_at gb: NM_000246.1 /DEF = Homo sapiens MHC class II transactivator (MHC2TA), mRNA. /FEA = mRNA /GEN = MHC2TA /PROD = MHC class II transactivator /DB_XREF = gi: 4557748 /UG = Hs.3076 MHC class II transactivator /FL = gb: NM_000246.1 gb: U18259.1 204730_at gb: NM_014747.1 /DEF = Homo sapiens KIAA0237 gene product (KIAA0237), mRNA. /FEA = mRNA /GEN = KIAA0237 /PROD = KIAA0237 gene product /DB_XREF = gi: 7662015 /UG = Hs.78748 KIAA0237 gene product /FL = gb: D87074.1 gb: NM_014747.1 204197_s_at gb: NM_004350.1 /DEF = Homo sapiens runt-related transcription factor 3 (RUNX3), mRNA. /FEA = mRNA /GEN = RUNX3 /PROD = runt-related transcription factor 3 /DB_XREF = gi: 4757917 /UG = Hs.170019 runt-related transcription factor 3 /FL = gb: NM_004350.1 204975_at gb: NM_001424.1 /DEF = Homo sapiens epithelial membrane protein 2 (EMP2), mRNA. /FEA = mRNA /GEN = EMP2 /PROD = epithelial membrane protein 2 /DB_XREF = gi: 4503560 /UG = Hs.29191 epithelial membrane protein 2 /FL = gb: U52100.1 gb: NM_001424.1 204622_x_at gb: NM_006186.1 /DEF = Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), mRNA. /FEA = mRNA /GEN = NR4A2 /PROD = nuclear receptor subfamily 4, group A, member 2 /DB_XREF = gi: 5453821 /UG = Hs.82120 nuclear receptor subfamily 4, group A, member 2 /FL = gb: NM_006186.1 212657_s_at Consensus includes gb: U65590 /DEF = Homo sapiens IL-1 receptor antagonist IL-1Ra (IL-1RN) gene, alternatively spliced forms, complete cds /FEA = mRNA_2 /DB_XREF = gi: 2707374 /UG = Hs.81134 interleukin 1 receptor antagonist 211654_x_at gb: M17565.1 /DEF = Human MHC class II DQ-beta associated with DRw6, DQw1 protein, complete cds. /FEA = mRNA /GEN = HLA-DQB1 /DB_XREF = gi: 188188 /FL = gb: M17565.1 219920_s_at gb: NM_021971.1 /DEF = Homo sapiens GDP-mannose pyrophosphorylase B (GMPPB), transcript variant 2, mRNA. /FEA = mRNA /GEN = GMPPB /PROD = GDP-mannose pyrophosphorylase B, isoform 2 /DB_XREF = gi: 11761620 /UG = Hs.28077 GDP-mannose pyrophosphorylase B /FL = gb: NM_021971.1 gb: BC001141.1 gb: AF135421.1 204923_at Consensus includes gb: AL023653 /DEF = Human DNA sequence from clone 753P9 on chromosome Xq25-26.1. Contains the gene coding for Aminopeptidase P (EC 3.4.11.9, XAA-ProX-ProProlineAminoacylproline Aminopeptidase) and a novel gene. Contains ESTs, STSs, GSSs and a gaaa repeat polymorphism /FEA = mRNA_1 /DB_XREF = gi: 3550108 /UG = Hs.61469 hypothetical protein /FL = gb: NM_018990.1 211744_s_at gb: BC005930.1 /DEF = Homo sapiens, Similar to CD58 antigen, (lymphocyte function-associated antigen 3), clone MGC: 14538, mRNA, complete cds. /FEA = mRNA /PROD = Similar to CD58 antigen, (lymphocytefunction-associated antigen 3) /DB_XREF = gi: 13543544 /FL = gb: BC005930.1 209473_at Consensus includes gb: AV717590 /FEA = EST /DB_XREF = gi: 10814742 /DB_XREF = est: AV717590 /CLONE = DCBCFE01 /UG = Hs.205353 ectonucleoside triphosphate diphosphohydrolase 1 /FL = gb: U87967.1 205031_at gb: NM_001406.1 /DEF = Homo sapiens ephrin-B3 (EFNB3), mRNA. /FEA = mRNA /GEN = EFNB3 /PROD = ephrin-B3 precursor /DB_XREF = gi: 4503488 /UG = Hs.26988 ephrin-B3 /FL = gb: U62775.1 gb: U66406.1 gb: NM_001406.1 218704_at gb: NM_017763.1 /DEF = Homo sapiens hypothetical protein FLJ20315 (FLJ20315), mRNA. /FEA = mRNA /GEN = FLJ20315 /PROD = hypothetical protein FLJ20315 /DB_XREF = gi: 8923298 /UG = Hs.18457 hypothetical protein FLJ20315 /FL = gb: NM_017763.1 214453_s_at Consensus includes gb: NM_006417.1 /DEF = Homo sapiens interferon-induced, hepatitis C-associated microtubular aggregate protein (44 kD) (MTAP44), mRNA. /FEA = CDS /GEN = MTAP44 /PROD = interferon-induced, hepatitis C- associated microtubular aggregate protein (44 kD) /DB_XREF = gi: 5453743 /UG = Hs.82316 interferon-induced, hepatitis C-associated microtubular aggregate protein (44 kD) /FL = gb: NM_006417.1 202388_at gb: NM_002923.1 /DEF = Homo sapiens regulator of G-protein signalling 2, 24 kD (RGS2), mRNA. /FEA = mRNA /GEN = RGS2 /PROD = regulator of G-protein signalling 2, 24 kD /DB_XREF = gi: 4506516 /UG = Hs.78944 regulator of G- protein signalling 2, 24 kD /FL = gb: L13463.1 gb: NM_002923.1 218285_s_at gb: NM_020139.1 /DEF = Homo sapiens oxidoreductase UCPA (LOC56898), mRNA. /FEA = mRNA /GEN = LOC56898 /PROD = oxidoreductase UCPA /DB_XREF = gi: 10047131 /UG = Hs.124696 oxidoreductase UCPA /FL = gb: NM_020139.1 gb: AF164790.1 200905_x_at gb: NM_005516.1 /DEF = Homo sapiens major histocompatibility complex, class I, E (HLA-E), mRNA. /FEA = mRNA /GEN = HLA-E /PROD = major histocompatibility complex, class I, E /DB_XREF = gi: 5031744 /UG = Hs.181392 major histocompatibility complex, class I, E /FL = gb: BC002578.1 gb: NM_005516.1 200897_s_at gb: NM_016081.1 /DEF = Homo sapiens palladin (KIAA0992), mRNA. /FEA = mRNA /GEN = KIAA0992 /PROD = palladin /DB_XREF = gi: 7706354 /UG = Hs.194431 palladin /FL = gb: AF077041.1 gb: AF151909.1 gb: NM_016081.1 217456_x_at Consensus includes gb: M31183.1 /DEF = Homo sapiens (cosmid clone cd3.3) MHC class I HLA-B51 mRNA, 3 end of cds. /FEA = mRNA /GEN = HLA-B /PROD = MHC class I lymphocyte antigen /DB_XREF = gi: 601851 /UG = Hs.181392 major histocompatibility complex, class I, E 210886_x_at gb: AB007457.1 /DEF = Homo sapiens mRNA for P53TG1-C, complete cds. /FEA = mRNA /GEN = P53TG1 /PROD = P53TG1-C /DB_XREF = gi: 5006270 /UG = Hs.274329 TP53 target gene 1 /FL = gb: AB007457.1 221737_at Consensus includes gb: AK024696.1 /DEF = Homo sapiens cDNA: FLJ21043 fis, clone CAE11633. /FEA = mRNA /DB_XREF = gi: 10437043 /UG = Hs.182874 guanine nucleotide binding protein (G protein) alpha 12 /FL = gb: L01694.1 gb: NM_007353.1 201012_at gb: NM_000700.1 /DEF = Homo sapiens annexin A1 (ANXA1), mRNA. /FEA = mRNA /GEN = ANXA1 /PROD = annexin I /DB_XREF = gi: 4502100 /UG = Hs.78225 annexin A1 /FL = gb: BC001275.1 gb: NM_000700.1 212062_at Consensus includes gb: AB014511.1 /DEF = Homo sapiens mRNA for KIAA0611 protein, partial cds. /FEA = mRNA /GEN = KIAA0611 /PROD = KIAA0611 protein /DB_XREF = gi: 3327035 /UG = Hs.70604 ATPase, Class II, type 9A 205833_s_at Consensus includes gb: AI770098 /FEA = EST /DB_XREF = gi: 5236553 /DB_XREF = est: wj30h12.x1 /CLONE = IMAGE: 2404391 /UG = Hs.96744 prostate androgen-regulated transcript 1 /FL = gb: NM_016590.2 gb: AF163475.1 204972_at gb: NM_016817.1 /DEF = Homo sapiens 2-5oligoadenylate synthetase 2 (OAS2), transcript variant 1, mRNA. /FEA = mRNA /GEN = OAS2 /PROD = 2-5oligoadenylate synthetase 2, isoform p71 /DB_XREF = gi: 8051624 /UG = Hs.264981 2-5oligoadenylate synthetase 2 /FL = gb: M87434.1 gb: NM_016817.1 217966_s_at gb: NM_022083.1 /DEF = Homo sapiens niban protein (NIBAN), mRNA. /FEA = mRNA /GEN = NIBAN /PROD = niban protein /DB_XREF = gi: 11545796 /UG = Hs.48778 niban protein /FL = gb: AB050477.1 gb: NM_022083.1 gb: AF288391.1 208158_s_at gb: NM_018030.1 /DEF = Homo sapiens oxysterol-binding protein-related protein 1 (FLJ10217), mRNA. /FEA = mRNA /GEN = FLJ10217 /PROD = oxysterol-binding protein-related protein 1 /DB_XREF = gi: 13877169 /FL = gb: NM_018030.1 202156_s_at Consensus includes gb: N36839 /FEA = EST /DB_XREF = gi: 1157981 /DB_XREF = est: yy35f07.s1 /CLONE = IMAGE: 273253 /UG = Hs.211610 CUG triplet repeat, RNA-binding protein 2 /FL = gb: U69546.1 gb: AF036956.1 gb: AF090694.1 gb: NM_006561.1 211506_s_at gb: AF043337.1 /DEF = Homo sapiens interleukin 8 C-terminal variant (IL8) mRNA, complete cds. /FEA = mRNA /GEN = IL8 /PROD = interleukin 8 C-terminal variant /DB_XREF = gi: 12641914 /UG = Hs.624 interleukin 8 /FL = gb: AF043337.1 209153_s_at gb: M31523.1 /DEF = Human transcription factor (E2A) mRNA, complete cds. /FEA = mRNA /GEN = TCF3 /DB_XREF = gi: 339477 /UG = Hs.101047 transcription factor 3 (E2A immunoglobulin enhancer binding factors E12E47) /FL = gb: M31523.1 212730_at Consensus includes gb: AK026420.1 /DEF = Homo sapiens cDNA: FLJ22767 fis, clone KAIA1191. /FEA = mRNA /DB_XREF = gi: 10439281 /UG = Hs.10587 KIAA0353 protein 211404_s_at gb: BC004371.1 /DEF = Homo sapiens, clone MGC: 10449, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 10449) /DB_XREF = gi: 13325115 /UG = Hs.279518 amyloid beta (A4) precursor-like protein 2 /FL = gb: BC004371.1 215017_s_at Consensus includes gb: AW270932 /FEA = EST /DB_XREF = gi: 6657962 /DB_XREF = est: xs06c12.x1 /CLONE = IMAGE: 2768854 /UG = Hs.239681 hypothetical protein FLJ20275 1007_s_at U48705 /FEATURE = mRNA /DEFINITION = HSU48705 Human receptor tyrosine kinase DDR gene, complete cds 221900_at Consensus includes gb: AI806793 /FEA = EST /DB_XREF = gi: 5393359 /DB_XREF = est: wf15d05.x1 /CLONE = IMAGE: 2350665 /UG = Hs.249239 collagen, type VIII, alpha 2 205872_x_at gb: NM_022359.1 /DEF = Homo sapiens similar to rat myomegalin (LOC64182), mRNA. /FEA = mRNA /GEN = LOC64182 /PROD = similar to rat myomegalin /DB_XREF = gi: 11641276 /UG = Hs.265848 similar to rat myomegalin /FL = gb: AB042558.1 gb: NM_022359.1 210517_s_at gb: AB003476.1 /DEF = Homo sapiens mRNA for gravin, complete cds. /FEA = mRNA /PROD = gravin /DB_XREF = gi: 2081606 /UG = Hs.788 A kinase (PRKA) anchor protein (gravin) 12 /FL = gb: AB003476.1 214574_x_at Consensus includes gb: NM_007161.1 /DEF = Homo sapiens DNA segment on chromosome 6 (unique) 49 expressed sequence, NK cell triggering receptor, p30 (D6S49E), mRNA. /FEA = CDS /GEN = D6S49E /PROD = leukocyte-specific transcript 1 /DB_XREF = gi: 6005740 /UG = Hs.88411 lymphocyte antigen 117 /FL = gb: NM_007161.1 202944_at gb: NM_000262.1 /DEF = Homo sapiens N-acetylgalactosaminidase, alpha-(NAGA), mRNA. /FEA = mRNA /GEN = NAGA /PROD = alpha-N-acetylgalactosaminidase precursor /DB_XREF = gi: 4557780 /UG = Hs.75372 N- acetylgalactosaminidase, alpha- /FL = gb: BC000095.1 gb: M62783.1 gb: M38083.1 gb: NM_000262.1 210146_x_at gb: AF004231.1 /DEF = Homo sapiens monocytemacrophage Ig-related receptor MIR-10 (MIR cl-10) mRNA, complete cds. /FEA = mRNA /GEN = MIR cl-10 /PROD = MIR-10 /DB_XREF = gi: 2343110 /UG = Hs.22405 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2 /FL = gb: AF000574.1 gb: AF004231.1 gb: AF011565.1 217997_at Consensus includes gb: AI795908 /FEA = EST /DB_XREF = gi: 5361371 /DB_XREF = est: wh40a05.x1 /CLONE = IMAGE: 2383184 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 220330_s_at gb: NM_022136.1 /DEF = Homo sapiens SAM domain, SH3 domain and nuclear localisation signals, 1 (SAMSN1), mRNA. /FEA = mRNA /GEN = SAMSN1 /PROD = SAM domain, SH3 domain and nuclear localisation signals, 1 /DB_XREF = gi: 11545870 /UG = Hs.24633 SAM domain, SH3 domain and nuclear localisation signals, 1 /FL = gb: AF222927.1 gb: NM_022136.1 206114_at gb: NM_004438.1 /DEF = Homo sapiens EphA4 (EPHA4), mRNA. /FEA = mRNA /GEN = EPHA4 /PROD = EphA4 /DB_XREF = gi: 4758279 /UG = Hs.73964 EphA4 /FL = gb: NM_004438.1 gb: L36645.1 200907_s_at Consensus includes gb: AU157932 /FEA = EST /DB_XREF = gi: 11019453 /DB_XREF = est: AU157932 /CLONE = PLACE1010217 /UG = Hs.194431 palladin /FL = gb: AF077041.1 gb: AF151909.1 gb: NM_016081.1 214068_at Consensus includes gb: AF070610.1 /DEF = Homo sapiens clone 24505 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 3387992 /UG = Hs.100543 Homo sapiens clone 24505 mRNA sequence 212372_at Consensus includes gb: AK026977.1 /DEF = Homo sapiens cDNA: FLJ23324 fis, clone HEP12482, highly similar to HUMMYOHCB Human nonmuscle myosin heavy chain-B (MYH10) mRNA. /FEA = mRNA /DB_XREF = gi: 10439970 /UG = Hs.296842 Homo sapiens, clone IMAGE: 3357927, mRNA, partial cds 202504_at gb: NM_012101.1 /DEF = Homo sapiens ataxia-telangiectasia group D-associated protein (ATDC), mRNA. /FEA = mRNA /GEN = ATDC /PROD = ataxia-telangiectasia group D-associated protein /DB_XREF = gi: 6912249 /UG = Hs.82237 ataxia-telangiectasia group D-associated protein /FL = gb: AF230388.1 gb: L24203.1 gb: NM_012101.1 213187_x_at Consensus includes gb: BG538564 /FEA = EST /DB_XREF = gi: 13530797 /DB_XREF = est: 602567289F1 /CLONE = IMAGE: 4691639 /UG = Hs.324746 alpha-2-HS-glycoprotein 206873_at gb: NM_001215.1 /DEF = Homo sapiens carbonic anhydrase VI (CA6), mRNA. /FEA = mRNA /GEN = CA6 /PROD = carbonic anhydrase VI precursor /DB_XREF = gi: 4557396 /UG = Hs.100322 carbonic anhydrase VI /FL = gb: M57892.1 gb: NM_001215.1 200798_x_at gb: NM_021960.1 /DEF = Homo sapiens myeloid cell leukemia sequence 1 (BCL2-related) (MCL1), mRNA. /FEA = mRNA /GEN = MCL1 /PROD = myeloid cell leukemia sequence 1 (BCL2-related) /DB_XREF = gi: 11386164 /UG = Hs.86386 myeloid cell leukemia sequence 1 (BCL2-related) /FL = gb: NM_021960.1 gb: AF118124.1 213418_at Consensus includes gb: NM_002155.1 /DEF = Homo sapiens heat shock 70 kD protein 6 (HSP70B) (HSPA6), mRNA. /FEA = CDS /GEN = HSPA6/PROD = heat shock 70 kD protein 6 (HSP70B) /DB_XREF = gi: 4504514 /UG = Hs.3268 heat shock 70 kD protein 6 (HSP70B) /FL = gb: NM_002155.1 205896_at gb: NM_003059.1 /DEF = Homo sapiens solute carrier family 22 (organic cation transporter), member 4 (SLC22A4), mRNA. /FEA = mRNA /GEN = SLC22A4 /PROD = solute carrier family 22 (organic cation transporter), member 4 /DB_XREF = gi: 4507002 /UG = Hs.77239 solute carrier family 22 (organic cation transporter), member 4 /FL = gb: AB007448.1 gb: NM_003059.1 214607_at Consensus includes gb: AW085556 /FEA = EST /DB_XREF = gi: 6040708 /DB_XREF = est: wy67b11.x1 /CLONE = IMAGE: 2553597 /UG = Hs.152663 p21 (CDKN1A)-activated kinase 3 /FL = gb: AF068864.1 gb: NM_002578.1 213100_at Consensus includes gb: AA127885 /FEA = EST /DB_XREF = gi: 1687192 /DB_XREF = est: zl13b04.s1 /CLONE = IMAGE: 501775 /UG = Hs.13350 Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918) 212509_s_at Consensus includes gb: BF968134 /FEA = EST /DB_XREF = gi: 12335349 /DB_XREF = est: 602269121F1 /CLONE = IMAGE: 4357349 /UG = Hs.250723 FK506 binding protein 12-rapamycin associated protein 1 207826_s_at gb: NM_002167.1 /DEF = Homo sapiens inhibitor of DNA binding 3, dominant negative helix-loop-helix protein (ID3), mRNA. /FEA = mRNA /GEN = ID3 /PROD = inhibitor of DNA binding 3, dominant negative helix-loop-helix protein /DB_XREF = gi: 10835060 /UG = Hs.76884 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein /FL = gb: NM_002167.1 209757_s_at gb: BC002712.1 /DEF = Homo sapiens, v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived, clone MGC: 3962, mRNA, complete cds. /FEA = mRNA /PROD = v-myc avian myelocytomatosis viral relatedoncogene, neuroblastoma derived /DB_XREF = gi: 12803748 /UG = Hs.25960 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived /FL = gb: BC002712.1 gb: NM_005378.1 205151_s_at gb: NM_014817.1 /DEF = Homo sapiens KIAA0644 gene product (KIAA0644), mRNA. /FEA = mRNA /GEN = KIAA0644 /PROD = KIAA0644 gene product /DB_XREF = gi: 7662219 /UG = Hs.21572 KIAA0644 gene product /FL = gb: AB014544.1 gb: NM_014817.1 212286_at Consensus includes gb: AW572909 /FEA = EST /DB_XREF = gi: 7237642 /DB_XREF = est: hf17d03.x1 /CLONE = IMAGE: 2932133 /UG = Hs.27973 KIAA0874 protein /FL = gb: AF317425.1 215076_s_at Consensus includes gb: AU144167 /FEA = EST /DB_XREF = gi: 11005688 /DB_XREF = est: AU144167 /CLONE = HEMBA1001071 /UG = Hs.297909 Homo sapiens cDNA FLJ11428 fis, clone HEMBA1001071, highly similar to PROCOLLAGEN ALPHA 1(III) CHAIN PRECURSOR 201298_s_at gb: BC003398.1 /DEF = Homo sapiens, hypothetical protein FLJ10788, clone MGC: 4929, mRNA, complete cds. /FEA = mRNA /PROD = hypothetical protein FLJ10788 /DB_XREF = gi: 13097287 /UG = Hs.196437 hypothetical protein FLJ10788 /FL = gb: AB016839.1 gb: BC003398.1 gb: NM_018221.1 216988_s_at Consensus includes gb: L48722 /DEF = Homo sapiens (clone hh18) protein tyrosine phosphatase (ptp-IV1r) gene, 5 end of cds /FEA = CDS /DB_XREF = gi: 1246237 /UG = Hs.82911 protein tyrosine phosphatase type IVA, member 2 221903_s_at Consensus includes gb: BE046443 /FEA = EST /DB_XREF = gi: 8363496 /DB_XREF = est: hn47d10.x2 /CLONE = IMAGE: 3026803 /UG = Hs.18827 KIAA0849 protein 213797_at Consensus includes gb: AI337069 /FEA = EST /DB_XREF = gi: 4073996 /DB_XREF = est: qx82h04.x1 /CLONE = IMAGE: 2009047 /UG = Hs.17518 Homo sapiens cig5 mRNA, partial sequence 204393_s_at gb: NM_001099.2 /DEF = Homo sapiens acid phosphatase, prostate (ACPP), mRNA. /FEA = mRNA /GEN = ACPP /PROD = prostatic acid phosphatase precursor /DB_XREF = gi: 6382063 /UG = Hs.1852 acid phosphatase, prostate /FL = gb: M24902.1 gb: M34840.1 gb: NM_001099.2 212681_at Consensus includes gb: AI770004 /FEA = EST /DB_XREF = gi: 5236513 /DB_XREF = est: wh66d06.x1 /CLONE = IMAGE: 2385707 /UG = Hs.103839 erythrocyte membrane protein band 4.1-like 3 205119_s_at gb: NM_002029.1 /DEF = Homo sapiens formyl peptide receptor 1 (FPR1), mRNA. /FEA = mRNA /GEN = FPR1 /PROD = formyl peptide receptor 1 /DB_XREF = gi: 4503778 /UG = Hs.753 formyl peptide receptor 1 /FL = gb: BC005315.1 gb: M60626.1 gb: M60627.1 gb: NM_002029.1 205329_s_at gb: NM_003794.1 /DEF = Homo sapiens sorting nexin 4 (SNX4), mRNA. /FEA = mRNA /GEN = SNX4 /PROD = sorting nexin 4 /DB_XREF = gi: 4507144 /UG = Hs.267812 sorting nexin 4 /FL = gb: AF130078.1 gb: AF065485.1 gb: NM_003794.1 212013_at Consensus includes gb: D86983.1 /DEF = Human mRNA for KIAA0230 gene, partial cds. /FEA = mRNA /GEN = KIAA0230 /DB_XREF = gi: 1504039 /UG = Hs.118893 Melanoma associated gene 207114_at gb: NM_025261.1 /DEF = Homo sapiens G6C protein (G6C), mRNA. /FEA = mRNA /GEN = G6C /PROD = G6C protein /DB_XREF = gi: 13376873 /UG = Hs.241586 G6C protein /FL = gb: NM_025261.1 204806_x_at gb: NM_018950.1 /DEF = Homo sapiens major histocompatibility complex, class I, F (HLA-F), mRNA. /FEA = mRNA /GEN = HLA-F /PROD = major histocompatibility complex, class I, F /DB_XREF = gi: 9665231 /UG = Hs.110309 major histocompatibility complex, class I, F /FL = gb: NM_018950.1 210880_s_at gb: AB001467.1 /DEF = Homo sapiens mRNA for Efs2, complete cds. /FEA = mRNA /PROD = Efs2 /DB_XREF = gi: 2829303 /UG = Hs.24587 signal transduction protein (SH3 containing) /FL = gb: AB001467.1 221127_s_at gb: NM_006394.1 /DEF = Homo sapiens regulated in glioma (RIG), mRNA. /FEA = mRNA /GEN = RIG /PROD = regulated in glioma /DB_XREF = gi: 5454007 /UG = Hs.278503 regulated in glioma /FL = gb: NM_006394.1 gb: U32331.1 212913_at Consensus includes gb: BE674960 /FEA = EST /DB_XREF = gi: 10035501 /DB_XREF = est: 7f11a09.x1 /CLONE = IMAGE: 3294328 /UG = Hs.112193 mutS (E. coli) homolog 5 209890_at gb: AF065389.1 /DEF = Homo sapiens tetraspan NET-4 mRNA, complete cds. /FEA = mRNA /PROD = tetraspan NET-4 /DB_XREF = gi: 3152702 /UG = Hs.20709 tetraspan 5 /FL = gb: AF065389.1 gb: NM_005723.1 212820_at Consensus includes gb: AB020663.1 /DEF = Homo sapiens mRNA for KIAA0856 protein, partial cds. /FEA = mRNA /GEN = KIAA0856 /PROD = KIAA0856 protein /DB_XREF = gi: 4240200 /UG = Hs.13264 KIAA0856 protein 210749_x_at gb: L11315.1 /DEF = Homo sapiens receptor tyrosine kinase mRNA, complete cds. /FEA = mRNA /PROD = receptor tyrosine kinase /DB_XREF = gi: 403386 /UG = Hs.75562 discoidin domain receptor family, member 1 /FL = gb: L11315.1 211535_s_at gb: M60485.1 /DEF = Human fibroblast growth factor receptor mRNA, complete cds. /FEA = mRNA /PROD = fibroblast growth factor receptor /DB_XREF = gi: 182560 /UG = Hs.748 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) /FL = gb: M60485.1 203373_at gb: NM_003877.1 /DEF = Homo sapiens STAT induced STAT inhibitor-2 (STATI2), mRNA. /FEA = mRNA /GEN = STATI2 /PROD = STAT induced STAT inhibitor-2 /DB_XREF = gi: 4507262 /UG = Hs.110776 STAT induced STAT inhibitor-2 /FL = gb: AB004903.1 gb: AB006966.1 gb: AF037989.1 gb: AF020590.1 gb: NM_003877.1 203413_at gb: NM_006159.1 /DEF = Homo sapiens nel (chicken)-like 2 (NELL2), mRNA. /FEA = mRNA /GEN = NELL2 /PROD = nel (chicken)-like 2 /DB_XREF = gi: 5453765 /UG = Hs.79389 nel (chicken)-like 2 /FL = gb: D83018.1 gb: NM_006159.1 204547_at gb: NM_006822.1 /DEF = Homo sapiens GTP-binding protein homologous to Saccharomyces cerevisiae SEC4 (SEC4L), mRNA. /FEA = mRNA /GEN = SEC4L /PROD = GTP-binding protein homologous to Saccharomyces cerevisiae SEC4 /DB_XREF = gi: 5803162 /UG = Hs.302498 GTP-binding protein homologous to Saccharomyces cerevisiae SEC4 /FL = gb: U05227.1 gb: NM_006822.1 217755_at gb: NM_016185.1 /DEF = Homo sapiens hematological and neurological expressed 1 (HN1), mRNA. /FEA = mRNA /GEN = HN1 /PROD = hematological and neurological expressed 1 /DB_XREF = gi: 7705876 /UG = Hs.109706 hematological and neurological expressed 1 /FL = gb: AF060925.1 gb: BC001420.1 gb: AF177862.1 gb: NM_016185.1 216320_x_at Consensus includes gb: U37055 /DEF = Human hepatocyte growth factor-like protein gene, complete cds /FEA = mRNA /DB_XREF = gi: 1311660 /UG = Hs.278657 macrophage stimulating 1 (hepatocyte growth factor-like) 204134_at gb: NM_002599.1 /DEF = Homo sapiens phosphodiesterase 2A, cGMP-stimulated (PDE2A), mRNA. /FEA = mRNA /GEN = PDE2A /PROD = phosphodiesterase 2A, cGMP-stimulated /DB_XREF = gi: 4505656 /UG = Hs.154437 phosphodiesterase 2A, cGMP-stimulated /FL = gb: U67733.1 gb: NM_002599.1 212593_s_at Consensus includes gb: N92498 /FEA = EST /DB_XREF = gi: 1264807 /DB_XREF = est: zb28a04.s1 /CLONE = IMAGE: 304878 /UG = Hs.326248 Homo sapiens cDNA: FLJ22071 fis, clone HEP11691 203455_s_at gb: NM_002970.1 /DEF = Homo sapiens spermidinespermine N1-acetyltransferase (SAT), mRNA. /FEA = mRNA /GEN = SAT /PROD = spermidinespermine N1-acetyltransferase /DB_XREF = gi: 4506788 /UG = Hs.28491 spermidinespermine N1-acetyltransferase /FL = gb: BC002503.1 gb: M77693.1 gb: NM_002970.1 203765_at gb: NM_012198.1 /DEF = Homo sapiens grancalcin (GCL), mRNA. /FEA = mRNA /GEN = GCL /PROD = grancalcin /DB_XREF = gi: 6912387 /UG = Hs.79381 grancalcin /FL = gb: BC005214.1 gb: M81637.1 gb: NM_012198.1 212594_at Consensus includes gb: AI185160 /FEA = EST /DB_XREF = gi: 3735798 /DB_XREF = est: qe30g10.s1 /CLONE = IMAGE: 1740546 /UG = Hs.326248 Homo sapiens cDNA: FLJ22071 fis, clone HEP11691 205933_at gb: NM_015559.1 /DEF = Homo sapiens KIAA0437 protein (KIAA0437), mRNA. /FEA = mRNA /GEN = KIAA0437 /PROD = KIAA0437 protein /DB_XREF = gi: 7662121 /UG = Hs.151717 KIAA0437 protein /FL = gb: AB022660.1 gb: NM_015559.1 207169_x_at gb: NM_001954.2 /DEF = Homo sapiens discoidin domain receptor family, member 1 (DDR1), transcript variant 2, mRNA. /FEA = mRNA /GEN = DDR1 /PROD = discoidin receptor tyrosine kinase isoform b /DB_XREF = gi: 7669486 /UG = Hs.75562 discoidin domain receptor family, member 1 /FL = gb: NM_001954.2 212761_at Consensus includes gb: AI949687 /FEA = EST /DB_XREF = gi: 5741997 /DB_XREF = est: wq13g04.x1 /CLONE = IMAGE: 2471190 /UG = Hs.173638 transcription factor 7-like 2 (T-cell specific, HMG-box) 222368_at Consensus includes gb: AW972351 /FEA = EST /DB_XREF = gi: 8162197 /DB_XREF = est: EST384442 /UG = Hs.293451 ESTs 202551_s_at Consensus includes gb: BG546884 /FEA = EST /DB_XREF = gi: 13545549 /DB_XREF = est: 602574066F1 /CLONE = IMAGE: 4702049 /UG = Hs.19280 cysteine-rich motor neuron 1 /FL = gb: NM_016441.1 gb: AF167706.1 206749_at gb: NM_001764.1 /DEF = Homo sapiens CD1B antigen, b polypeptide (CD1B), mRNA. /FEA = mRNA /GEN = CD1B /PROD = CD1B antigen, b polypeptide /DB_XREF = gi: 4502644 /UG = Hs.1310 CD1B antigen, b polypeptide /FL = gb: M28826.1 gb: NM_001764.1 207808_s_at gb: NM_000313.1 /DEF = Homo sapiens protein S (alpha) (PROS1), mRNA. /FEA = mRNA /GEN = PROS1 /PROD = protein S (alpha) /DB_XREF = gi: 4506116 /UG = Hs.64016 protein S (alpha) /FL = gb: M15036.1 gb: NM_000313.1 203964_at gb: NM_004688.1 /DEF = Homo sapiens N-myc (and STAT) interactor (NMI), mRNA. /FEA = mRNA /GEN = NMI /PROD = N-myc and STAT interactor /DB_XREF = gi: 4758813 /UG = Hs.54483 N-myc (and STAT) interactor /FL = gb: BC001268.1 gb: U32849.1 gb: NM_004688.1 207528_s_at gb: NM_014331.1 /DEF = Homo sapiens solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 (SLC7A11), mRNA. /FEA = mRNA /GEN = SLC7A11 /PROD = solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 /DB_XREF = gi: 7657682 /UG = Hs.6682 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 /FL = gb: AF200708.1 gb: AB026891.1 gb: NM_014331.1 203408_s_at gb: NM_002971.1 /DEF = Homo sapiens special AT-rich sequence binding protein 1 (binds to nuclear matrixscaffold- associating DNAs) (SATB1), mRNA. /FEA = mRNA /GEN = SATB1 /PROD = special AT-rich sequence binding protein 1(binds to nuclear matrixscaffold-associating DNAs) /DB_XREF = gi: 4506790 /UG = Hs.74592 special AT-rich sequence binding protein 1 (binds to nuclear matrixscaffold-associating DNAs) /FL = gb: M97287.1 gb: NM_002971.1 207387_s_at gb: NM_000167.1 /DEF = Homo sapiens glycerol kinase (GK), mRNA. /FEA = mRNA /GEN = GK /PROD = glycerol kinase /DB_XREF = gi: 4504006 /UG = Hs.1466 glycerol kinase /FL = gb: L13943.1 gb: NM_000167.1 207843_x_at gb: NM_001914.1 /DEF = Homo sapiens cytochrome b-5 (CYB5), nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = CYB5 /PROD = cytochrome b-5 /DB_XREF = gi: 4503182 /UG = Hs.83834 cytochrome b-5 /FL = gb: M60174.1 gb: NM_001914.1 217996_at Consensus includes gb: AA576961 /FEA = EST /DB_XREF = gi: 2354435 /DB_XREF = est: nm82d08.s1 /CLONE = IMAGE: 1074735 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 203657_s_at gb: NM_003793.2 /DEF = Homo sapiens cathepsin F (CTSF), mRNA. /FEA = mRNA /GEN = CTSF /PROD = cathepsin F /DB_XREF = gi: 6042195 /UG = Hs.11590 cathepsin F /FL = gb: AF071748.1 gb: AF071749.1 gb: AF088886.2 gb: NM_003793.2 gb: AF136279.1 208763_s_at gb: AL110191.1 /DEF = Homo sapiens mRNA; cDNA DKFZp566A093 (from clone DKFZp566A093); complete cds. /FEA = mRNA /GEN = DKFZp566A093 /PROD = hypothetical protein /DB_XREF = gi: 5817105 /UG = Hs.75450 delta sleep inducing peptide, immunoreactor /FL = gb: AF228339.1 gb: AF153603.1 gb: AL110191.1 gb: AF183393.1 220403_s_at gb: NM_022112.1 /DEF = Homo sapiens p53-regulated apoptosis-inducing protein 1 (P53AIP1), mRNA. /FEA = mRNA /GEN = P53AIP1 /PROD = p53-regulated apoptosis-inducing protein 1 /DB_XREF = gi: 11545826 /UG = Hs.160953 p53- regulated apoptosis-inducing protein 1 /FL = gb: AB045832.1 gb: NM_022112.1 201876_at gb: NM_000305.1 /DEF = Homo sapiens paraoxonase 2 (PON2), mRNA. /FEA = mRNA /GEN = PON2 /PROD = paraoxonase 2 /DB_XREF = gi: 4505952 /UG = Hs.169857 paraoxonase 2 /FL = gb: L48513.1 gb: AF001601.1 gb: NM_000305.1 221011_s_at gb: NM_030915.1 /DEF = Homo sapiens hypothetical protein DKFZp566J091 (DKFZP566J091), mRNA. /FEA = mRNA /GEN = DKFZP566J091 /PROD = hypothetical protein DKFZp566J091 /DB_XREF = gi: 13569871 /FL = gb: NM_030915.1 208702_x_at Consensus includes gb: AI525212 /FEA = EST /DB_XREF = gi: 4439347 /DB_XREF = est: pt1.1-2.A08.r /UG = Hs.279518 amyloid beta (A4) precursor-like protein 2 /FL = gb: BC000373.1 61734_at Cluster Incl. AI797684: we90d02.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2348355 /clone_end = 3 /gb = AI797684 /gi = 5363156 /ug = Hs.39619 /len = 708 209656_s_at gb: AL136550.1 /DEF = Homo sapiens mRNA; cDNA DKFZp761J17121 (from clone DKFZp761J17121); complete cds. /FEA = mRNA /GEN = DKFZp761J17121 /PROD = hypothetical protein /DB_XREF = gi: 13276606 /UG = Hs.8769 Homo sapiens mRNA; cDNA DKFZp761J17121 (from clone DKFZp761J17121); complete cds /FL = gb: AL136550.1 219983_at gb: NM_020386.1 /DEF = Homo sapiens H-REV107 protein-related protein (LOC57110), mRNA. /FEA = mRNA /GEN = LOC57110 /PROD = H-REV107 protein-related protein /DB_XREF = gi: 9966858 /UG = Hs.36761 H-REV107 protein-related protein /FL = gb: AB030816.1 gb: NM_020386.1 202722_s_at gb: NM_002056.1 /DEF = Homo sapiens glutamine-fructose-6-phosphate transaminase 1 (GFPT1), mRNA. /FEA = mRNA /GEN = GFPT1 /PROD = glucosamine-fructose-6-phosphateaminotransferase /DB_XREF = gi: 4503980 /UG = Hs.1674 glutamine-fructose-6-phosphate transaminase 1 /FL = gb: M90516.1 gb: NM_002056.1 221641_s_at gb: AF241787.1 /DEF = Homo sapiens CGI16-iso mRNA, complete cds. /FEA = mRNA /PROD = CGI16-iso /DB_XREF = gi: 12005490 /UG = Hs.18625 Mitochondrial Acyl-CoA Thioesterase /FL = gb: AF241787.1 210955_at gb: U86214.1 /DEF = Human Fas-associated death domain protein interleukin-1b-converting enzyme 2 mRNA, complete cds. /FEA = mRNA /PROD = Fas-associated death domain proteininterleukin-1b-converting enzyme 2 /DB_XREF = gi: 1835778 /UG = Hs.5353 caspase 10, apoptosis-related cysteine protease /FL = gb: U86214.1 206465_at Consensus includes gb: BE856376 /FEA = EST /DB_XREF = gi: 10369339 /DB_XREF = est: 7f93f09.x1 /CLONE = IMAGE: 3304553 /UG = Hs.277543 very long-chain acyl-CoA synthetase; lipidosin /FL = gb: NM_015162.1 gb: AF179481.1 205417_s_at gb: NM_004393.1 /DEF = Homo sapiens dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), mRNA. /FEA = mRNA /GEN = DAG1 /PROD = dystroglycan 1 precursor /DB_XREF = gi: 4758115 /UG = Hs.76111 dystroglycan 1 (dystrophin-associated glycoprotein 1) /FL = gb: L19711.1 gb: NM_004393.1 221773_at Consensus includes gb: AW575374 /FEA = EST /DB_XREF = gi: 7246913 /DB_XREF = est: UI-HF-BL0-adc-c-12-0-UI.s1 /CLONE = IMAGE: 3060887 /UG = Hs.288555 Homo sapiens cDNA: FLJ22425 fis, clone HRC08686 216704_at Consensus includes gb: AL353949.1 /DEF = Homo sapiens mRNA; cDNA DKFZp761P1114 (from clone DKFZp761P1114). /FEA = mRNA /DB_XREF = gi: 7669990 /UG = Hs.306506 Homo sapiens mRNA; cDNA DKFZp761P1114 (from clone DKFZp761P1114) 213258_at Consensus includes gb: BF511231 /FEA = EST /DB_XREF = gi: 11594529 /DB_XREF = est: UI-H-BI4-aoi-g-11-0-UI.s1 /CLONE = IMAGE: 3085244 /UG = Hs.288582 ESTs, Weakly similar to ubiquitous TPR motif, Y isoform H. sapiens 201525_at gb: NM_001647.1 /DEF = Homo sapiens apolipoprotein D (APOD), mRNA. /FEA-mRNA /GEN = APOD /PROD = apolipoprotein D precursor /DB_XREF = gi: 4502162 /UG = Hs.75736 apolipoprotein D /FL = gb: J02611.1 gb: NM_001647.1 201137_s_at gb: NM_002121.1 /DEF = Homo sapiens major histocompatibility complex, class II, DP beta 1 (HLA-DPB1), mRNA. /FEA = mRNA /GEN = HLA-DPB1 /PROD = major histocompatibility complex, class II, DPbeta 1 /DB_XREF = gi: 4504404 /UG = Hs.814 major histocompatibility complex, class II, DP beta 1 /FL = gb: J03041.1 gb: M57466.1 gb: M83664.1 gb: NM_002121.1 gb: M28200.1 gb: M28202.1 205968_at gb: NM_002252.1 /DEF = Homo sapiens potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 (KCNS3), mRNA. /FEA = mRNA /GEN = KCNS3 /PROD = potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 /DB_XREF = gi: 4504862 /UG = Hs.47584 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 /FL = gb: BC004148.1 gb: BC004987.1 gb: AF043472.1 gb: NM_002252.1 205569_at gb: NM_014398.1 /DEF = Homo sapiens similar to lysosome-associated membrane glycoprotein (TSC403), mRNA. /FEA = mRNA /GEN = TSC403 /PROD = similar to lysosome-associated membraneglycoprotein /DB_XREF = gi: 7657660 /UG = Hs.10887 similar to lysosome-associated membrane glycoprotein /FL = gb: AB013924.1 gb: NM_014398.1 203355_s_at gb: NM_015310.1 /DEF = Homo sapiens KIAA0942 protein (KIAA0942), mRNA. /FEA = mRNA /GEN = KIAA0942 /PROD = KIAA0942 protein /DB_XREF = gi: 7662395 /UG = Hs.6763 KIAA0942 protein /FL = gb: AF243495.2 gb: NM_015310.1 206595_at gb: NM_001323.1 /DEF = Homo sapiens cystatin EM (CST6), mRNA. /FEA = mRNA /GEN = CST6 /PROD = cystatin M /DB_XREF = gi: 4503112 /UG = Hs.83393 cystatin EM /FL = gb: U62800.1 gb: U81233.1 gb: NM_001323.1 212186_at Consensus includes gb: BE855983 /FEA = EST /DB_XREF = gi: 10368561 /DB_XREF = est: 7f85g11.x1 /CLONE = IMAGE: 3303812 /UG = Hs.7232 acetyl-Coenzyme A carboxylase alpha /FL = gb: NM_000664.1 gb: U19822.1 214259_s_at Consensus includes gb: AI144075 /FEA = EST /DB_XREF = gi: 3665884 /DB_XREF = est: qi63e12.x1 /CLONE = IMAGE: 1861198 /UG = Hs.6980 aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) 204787_at gb: NM_007268.1 /DEF = Homo sapiens Ig superfamily protein (Z39IG), mRNA. /FEA = mRNA /GEN = Z39IG /PROD = Ig superfamily protein /DB_XREF = gi: 6005957 /UG = Hs.8904 Ig superfamily protein /FL = gb: NM_007268.1 209014_at gb: AF217963.1 /DEF = Homo sapiens NRAGE mRNA, complete cds. /FEA = mRNA /PROD = NRAGE /DB_XREF = gi: 9963809 /UG = Hs.177556 melanoma antigen, family D, 1 /FL = gb: AF132205.1 gb: AF124440.1 gb: NM_006986.1 gb: AF217963.1 214875_x_at Consensus includes gb: AW001847 /FEA = EST /DB_XREF = gi: 5848763 /DB_XREF = est: wt81a04.x1 /CLONE = IMAGE: 2513838 /UG = Hs.279518 amyloid beta (A4) precursor-like protein 2 211372_s_at gb: U64094.1 /DEF = Human soluble type II interleukin-1 receptor mRNA, complete cds. /FEA = mRNA /PROD = soluble type II interleukin-1 receptor /DB_XREF = gi: 1488065 /UG = Hs.25333 interleukin 1 receptor, type II /FL = gb: U64094.1 205013_s_at gb: NM_000675.2 /DEF = Homo sapiens adenosine A2a receptor (ADORA2A), mRNA. /FEA = mRNA /GEN = ADORA2A /PROD = adenosine A2a receptor /DB_XREF = gi: 5921991 /UG = Hs.1613 adenosine A2a receptor /FL = gb: M97370.1 gb: NM_000675.2 212658_at Consensus includes gb: N66633 /FEA = EST /DB_XREF = gi: 1218758 /DB_XREF = est: yy70f02.s1 /CLONE = IMAGE: 278907 /UG = Hs.79299 lipoma HMGIC fusion partner-like 2 220161_s_at gb: NM_019114.1 /DEF = Homo sapiens EHM2 gene (EHM2), mRNA. /FEA = mRNA /GEN = EHM2 /PROD = EHM2 gene /DB_XREF = gi: 9506568 /UG = Hs.267997 EHM2 gene /FL = gb: NM_019114.1 202194_at Consensus includes gb: AL117354 /DEF = Human DNA sequence from clone RP5-976O13 on chromosome 1p21.2-22.2 Contains part of the gene for CGI-100 protein, 3 isoforms of the gene for M96 protein, ESTs, STSs, GSSs and a CpG Island /FEA = mRNA_1 /DB_XREF = gi: 6822199 /UG = Hs.296155 CGI-100 protein /FL = gb: AF151858.1 gb: NM_016040.1 213358_at Consensus includes gb: AB018345.1 /DEF = Homo sapiens mRNA for KIAA0802 protein, partial cds. /FEA = mRNA /GEN = KIAA0802 /PROD = KIAA0802 protein /DB_XREF = gi: 3882324 /UG = Hs.27657 KIAA0802 protein 212262_at Consensus includes gb: AA149639 /FEA = EST /DB_XREF = gi: 1720440 /DB_XREF = est: z139c06.s1 /CLONE = IMAGE: 504298 /UG = Hs.15020 homolog of mouse quaking QKI (KH domain RNA binding protein) /FL = gb: AF142419.1 gb: AF142422.1 202729_s_at gb: NM_000627.1 /DEF = Homo sapiens latent transforming growth factor beta binding protein 1 (LTBP1), mRNA. /FEA = mRNA /GEN = LTBP1 /PROD = latent transforming growth factor beta bindingprotein 1 precursor /DB_XREF = gi: 4557730 /UG = Hs.241257 latent transforming growth factor beta binding protein 1 /FL = gb: M34057.1 gb: NM_000627.1 211105_s_at gb: U80918.1 /DEF = Homo sapiens transcription factor (NF-ATcC) mRNA, complete cds. /FEA = mRNA /GEN = NF- ATcC /PROD = transcription factor /DB_XREF = gi: 4098860 /UG = Hs.96149 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 /FL = gb: U80918.1 206219_s_at gb: NM_005428.2 /DEF = Homo sapiens vav 1 oncogene (VAV1), mRNA. /FEA = mRNA /GEN = VAV1 /PROD = vav 1 oncogene /DB_XREF = gi: 7108366 /UG = Hs.116237 vav 1 oncogene /FL = gb: NM_005428.2 210074_at gb: AF070448.1 /DEF = Homo sapiens cathepsin U (CTSU) mRNA, complete cds. /FEA = mRNA /GEN = CTSU /PROD = cathepsin U /DB_XREF = gi: 3228671 /UG = Hs.87417 cathepsin L2 /FL = gb: AB001928.1 gb: AF076448.1 gb: NM_001333.1 203471_s_at gb: NM_002664.1 /DEF = Homo sapiens pleckstrin (PLEK), mRNA. /FEA = mRNA /GEN = PLEK /PROD = pleckstrin /DB_XREF = gi: 4505878 /UG = Hs.77436 pleckstrin /FL = gb: NM_002664.1 203741_s_at gb: NM_001114.1 /DEF = Homo sapiens adenylate cyclase 7 (ADCY7), mRNA. /FEA = mRNA /GEN = ADCY7 /PROD = adenylate cyclase 7 /DB_XREF = gi: 4557254 /UG = Hs.172199 adenylate cyclase 7 /FL = gb: D25538.1 gb: NM_001114.1 214054_at Consensus includes gb: AI828929 /FEA = EST /DB_XREF = gi: 5449600 /DB_XREF = est: wj37g10.x1 /CLONE = IMAGE: 2405058 /UG = Hs.71215 docking protein 2, 56 kD /FL = gb: AF034970.1 gb: NM_003974.1 91826_at Cluster Incl. AI219073: qg16e08.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-1759718 /clone_end = 3 /gb = AI219073 /gi = 3801276 /ug = Hs.126062 /len = 555 204415_at gb: NM_022873.1 /DEF = Homo sapiens interferon, alpha-inducible protein (clone IFI-6-16) (G1P3), transcript variant 3, mRNA. /FEA = mRNA /GEN = G1P3 /PROD = interferon induced 6-16 protein, isoform c /DB_XREF = gi: 13259549 /UG = Hs.265827 interferon, alpha-inducible protein (clone IFI-6-16) /FL = gb: NM_022872.1 gb: NM_022873.1 gb: NM_002038.2 209291_at Consensus includes gb: AW157094 /FEA = EST /DB_XREF = gi: 6228495 /DB_XREF = est: au91g11.x1 /CLONE = IMAGE: 2783684 /UG = Hs.34853 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein /FL = gb: NM_001546.1 gb: U16153.1 gb: U28368.1 219560_at gb: NM_024627.1 /DEF = Homo sapiens hypothetical protein FLJ21125 (FLJ21125), mRNA. /FEA = mRNA /GEN = FLJ21125 /PROD = hypothetical protein FLJ21125 /DB_XREF = gi: 13375851 /UG = Hs.36574 hypothetical protein FLJ21125 /FL = gb: NM_024627.1 214521_at Consensus includes gb: NM_019089.1 /DEF = Homo sapiens hairy and enhancer of split (Drosophila) homolog 2 (HES2), mRNA. /FEA = CDS /GEN = HES2 /PROD = hairy and enhancer of split (Drosophila) homolog2 /DB_XREF = gi: 10092644 /UG = Hs.156042 hairy and enhancer of split (Drosophila) homolog 2 /FL = gb: NM_019089.1 202036_s_at gb: AF017987.1 /DEF = Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /FEA = mRNA /GEN = SARP2 /PROD = secreted apoptosis related protein 2 /DB_XREF = gi: 2415416 /UG = Hs.7306 secreted frizzled-related protein 1 /FL = gb: AF001900.1 gb: AF017987.1 gb: AF056087.1 gb: NM_003012.2 208096_s_at gb: NM_030820.1 /DEF = Homo sapiens hypothetical protein DKFZp564B052 (DKFZp564B052), mRNA. /FEA = mRNA /GEN = DKFZp564B052 /PROD = hypothetical protein DKFZp564B052 /DB_XREF = gi: 13540617 /FL = gb: NM_030820.1 213572_s_at Consensus includes gb: AI554300 /FEA = EST /DB_XREF = gi: 4486663 /DB_XREF = est: tq05e07.x1 /CLONE = IMAGE: 2207940 /UG = Hs.183583 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1 219764_at gb: NM_007197.1 /DEF = Homo sapiens frizzled (Drosophila) homolog 10 (FZD10), mRNA. /FEA = mRNA /GEN = FZD10 /PROD = frizzled (Drosophila) homolog 10 /DB_XREF = gi: 6005761 /UG = Hs.31664 frizzled (Drosophila) homolog 10 /FL = gb: AB027464.1 gb: NM_007197.1 218330_s_at gb: NM_018162.1 /DEF = Homo sapiens hypothetical protein FLJ10633 (FLJ10633), mRNA. /FEA = mRNA /GEN = FLJ10633 /PROD = hypothetical protein FLJ10633 /DB_XREF = gi: 9506612 /UG = Hs.23467 hypothetical protein FLJ10633 /FL = gb: NM_018162.1 208616_s_at gb: U48297.1 /DEF = Homo sapiens protein tyrosine phosphatase PTPCAAX2 (hPTPCAAX2) mRNA, complete cds. /FEA = mRNA /GEN = hPTPCAAX2 /PROD = protein tyrosine phosphatase PTPCAAX2 /DB_XREF = gi: 1777756 /UG = Hs.82911 protein tyrosine phosphatase type IVA, member 2 /FL = gb: U48297.1 gb: NM_003479.1 gb: AF208850.1 204754_at Consensus includes gb: W60800 /FEA = EST /DB_XREF = gi: 1367644 /DB_XREF = est: zd27d08.s1 /CLONE = IMAGE: 341871 /UG = Hs.250692 hepatic leukemia factor /FL = gb: M95585.1 gb: NM_002126.1 211795_s_at gb: AF198052.1 /DEF = Homo sapiens EVH1 domain binding protein mRNA, complete cds. /FEA = CDS /PROD = EVH1 domain binding protein /DB_XREF = gi: 7416992 /UG = Hs.58435 FYN-binding protein (FYB-120130) /FL = gb: AF198052.1 203927_at gb: NM_004556.1 /DEF = Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon (NFKBIE), mRNA. /FEA = mRNA /GEN = NFKBIE /PROD = nuclear factor of kappa light polypeptide geneenhancer in B-cells inhibitor, epsilon /DB_XREF = gi: 4758805 /UG = Hs.91640 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon /FL = gb: U91616.1 gb: NM_004556.1 202917_s_at gb: NM_002964.2 /DEF = Homo sapiens S100 calcium-binding protein A8 (calgranulin A) (S100A8), mRNA. /FEA = mRNA /GEN = S100A8 /PROD = S100 calcium-binding protein A8 /DB_XREF = gi: 9845519 /UG = Hs.100000 S100 calcium-binding protein A8 (calgranulin A) /FL = gb: NM_002964.2 212788_x_at Consensus includes gb: BG537190 /FEA = EST /DB_XREF = gi: 13528922 /DB_XREF = est: 602565589F1 /CLONE = IMAGE: 4690079 /UG = Hs.111334 ferritin, light polypeptide 205606_at gb: NM_002336.1 /DEF = Homo sapiens low density lipoprotein receptor-related protein 6 (LRP6), mRNA. /FEA = mRNA /GEN = LRP6 /PROD = low density lipoprotein receptor-related protein6 /DB_XREF = gi: 4505016 /UG = Hs.23672 low density lipoprotein receptor-related protein 6 /FL = gb: AF074264.1 gb: NM_002336.1 209521_s_at gb: AF286598.1 /DEF = Homo sapiens angiomotin mRNA, complete cds. /FEA = mRNA /PROD = angiomotin /DB_XREF = gi: 9887325 /UG = Hs.9271 KIAA1071 protein /FL = gb: AF286598.1 52255_s_at Cluster Incl. AI984221: wz57c09.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2562160 /clone_end = 3 /gb = AI984221 /gi = 5811440 /ug = Hs.235368 /len = 515 214056_at Consensus includes gb: BF981280 /FEA = EST /DB_XREF = gi: 12384092 /DB_XREF = est: 602308517F1 /CLONE = IMAGE: 4399756 /UG = Hs.86386 myeloid cell leukemia sequence 1 (BCL2-related) 36499_at Cluster Incl. D87469: Human mRNA for KIAA0279 gene, partial cds /cds = (0, 7226) /gb = D87469 /gi = 1665820 /ug = Hs.57652 /len = 8924 203300_x_at gb: NM_003916.1 /DEF = Homo sapiens adaptor-related protein complex 1, sigma 2 subunit (AP1S2), mRNA. /FEA = mRNA /GEN = AP1S2 /PROD = adaptor-related protein complex 1, sigma 2subunit /DB_XREF = gi: 4506956 /UG = Hs.40368 adaptor-related protein complex 1, sigma 2 subunit /FL = gb: AF251295.1 gb: BC001117.1 gb: AB015320.1 gb: NM_003916.1 205290_s_at gb: NM_001200.1 /DEF = Homo sapiens bone morphogenetic protein 2 (BMP2), mRNA. /FEA = mRNA /GEN = BMP2 /PROD = bone morphogenetic protein 2 precursor /DB_XREF = gi: 4557368 /UG = Hs.73853 bone morphogenetic protein 2 /FL = gb: NM_001200.1 202195_s_at gb: NM_016040.1 /DEF = Homo sapiens CGI-100 protein (LOC50999), mRNA. /FEA = mRNA /GEN = LOC50999 /PROD = CGI-100 protein /DB_XREF = gi: 7705583 /UG = Hs.296155 CGI-100 protein /FL = gb: AF151858.1 gb: NM_016040.1 218125_s_at gb: NM_018246.1 /DEF = Homo sapiens hypothetical protein FLJ10853 (FLJ10853), mRNA. /FEA = mRNA /GEN = FLJ10853 /PROD = hypothetical protein FLJ10853 /DB_XREF = gi: 8922717 /UG = Hs.72085 hypothetical protein FLJ10853 /FL = gb: NM_018246.1 203185_at gb: NM_014737.1 /DEF = Homo sapiens Ras association (RalGDSAF-6) domain family 2 (RASSF2), mRNA. /FEA = mRNA /GEN = RASSF2 /PROD = Ras association (RalGDSAF-6) domain family 2 /DB_XREF = gi: 7661963 /UG = Hs.80905 Ras association (RalGDSAF-6) domain family 2 /FL = gb: D79990.1 gb: NM_014737.1 208539_x_at gb: NM_006945.1 /DEF = Homo sapiens small proline-rich protein 2B (SPRR2B), mRNA. /FEA = CDS /GEN = SPRR2B /PROD = small proline-rich protein 2B /DB_XREF = gi: 5902119 /UG = Hs.231622 small proline-rich protein 2B /FL = gb: NM_006945.1 201852_x_at Consensus includes gb: AI813758 /FEA = EST /DB_XREF = gi: 5424973 /DB_XREF = est: wk79b04.x1 /CLONE = IMAGE: 2421583 /UG = Hs.119571 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) /FL = gb: NM_000090.1 204576_s_at Consensus includes gb: AA207013 /FEA = EST /DB_XREF = gi: 1802425 /DB_XREF = est: zr87c08.s1 /CLONE = IMAGE: 682670 /UG = Hs.155995 KIAA0643 protein /FL = gb: NM_024793.1 213256_at Consensus includes gb: AW593996 /FEA = EST /DB_XREF = gi: 7281254 /DB_XREF = est: hg41g06.x1 /CLONE = IMAGE: 2948218 /UG = Hs.124969 Homo sapiens clone 24707 mRNA sequence 204041_at gb: NM_000898.1 /DEF = Homo sapiens monoamine oxidase B (MAOB), nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = MAOB /PROD = monoamine oxidase B /DB_XREF = gi: 4505092 /UG = Hs.82163 monoamine oxidase B /FL = gb: M69177.1 gb: NM_000898.1 202558_s_at gb: NM_006948.1 /DEF = Homo sapiens stress 70 protein chaperone, microsome-associated, 60 kD (STCH), mRNA. /FEA = mRNA /GEN = STCH /PROD = stress 70 protein chaperone, microsome-associated, 60 kD /DB_XREF = gi: 5902125 /UG = Hs.288799 stress 70 protein chaperone, microsome-associated, 60 kD /FL = gb: U04735.1 gb: NM_006948.1 216891_at Consensus includes gb: U00956.1 /DEF = Human clone KDB5.1 (CAC)n(GTG)n repeat-containing mRNA. /FEA = mRNA /DB_XREF = gi: 405058 /UG = Hs.104112 Human clone KDB5.1 (CAC)n(GTG)n repeat-containing mRNA 206571_s_at gb: NM_004834.1 /DEF = Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), mRNA. /FEA = mRNA /GEN = MAP4K4 /PROD = mitogen-activated protein kinase kinase kinasekinase 4 /DB_XREF = gi: 4758523 /UG = Hs.3628 mitogen-activated protein kinase kinase kinase kinase 4 /FL = gb: AF096300.1 gb: NM_004834.1 208992_s_at gb: BC000627.1 /DEF = Homo sapiens, Signal transducer and activator of transcription 3, clone MGC: 1607, mRNA, complete cds. /FEA = mRNA /PROD = Signal transducer and, activator of transcription3 /DB_XREF = gi: 12653684 /UG = Hs.321677 signal transducer and activator of transcription 3 (acute-phase response factor) /FL = gb: BC000627.1 gb: NM_003150.1 gb: L29277.1 207861_at gb: NM_002990.1 /DEF = Homo sapiens small inducible cytokine subfamily A (Cys-Cys), member 22 (SCYA22), mRNA. /FEA = mRNA /GEN = SCYA22 /PROD = small inducible cytokine subfamily A (Cys-Cys), member 22 /DB_XREF = gi: 4506836 /UG = Hs.97203 small inducible cytokine subfamily A (Cys-Cys), member 22 /FL = gb: U83171.1 gb: U83239.1 gb: NM_002990.1 218322_s_at gb: NM_016234.2 /DEF = Homo sapiens long-chain fatty acid coenzyme A ligase 5 (FACL5), mRNA. /FEA = mRNA /GEN = FACL5 /PROD = long-chain fatty acid coenzyme A ligase 5 /DB_XREF = gi: 12669912 /UG = Hs.11638 long-chain fatty acid coenzyme A ligase 5 /FL = gb: NM_016234.2 gb: AB033899.1 202016_at gb: NM_002402.1 /DEF = Homo sapiens mesoderm specific transcript (mouse) homolog (MEST), mRNA. /FEA = mRNA /GEN = MEST /PROD = mesoderm specific transcript (mouse) homolog /DB_XREF = gi: 4505154 /UG = Hs.79284 mesoderm specific transcript (mouse) homolog /FL = gb: BC002413.1 gb: D78611.1 gb: D87367.1 gb: NM_002402.1 41856_at Cluster Incl. AL049370: Homo sapiens mRNA; cDNA DKFZp586D0918 (from clone DKFZp586D0918) /cds = UNKNOWN /gb = AL049370 /gi = 4500162 /ug = Hs.13350 /len = 2705 34697_at Cluster Incl. AF074264: Homo sapiens LDL receptor-related protein 6 (LRP6) mRNA, complete cds /cds = (77, 4918) /gb = F074264 /gi = 3462526 /ug = Hs.23672 /len = 5288 222361_at Consensus includes gb: AI433261 /FEA = EST /DB_XREF = gi: 4287937 /DB_XREF = est: ti32f08.x1 /CLONE = IMAGE: 2132199 /UG = Hs.23189 ESTs, Moderately similar to TBB2_HUMAN TUBULIN BETA-2 CHAIN H. sapiens 210335_at gb: AF056209.1 /DEF = Homo sapiens PAM COOH-terminal interactor protein 1 (PCIP1) mRNA, complete cds. /FEA = mRNA /GEN = PCIP1 /PROD = PAM COOH-terminal interactor protein 1 /DB_XREF = gi: 3560562 /UG = Hs.159396 peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor protein-1 /FL = gb: NM_005447.2 gb: AF056209.1 206416_at gb: NM_003456.1 /DEF = Homo sapiens zinc finger protein 205 (ZNF205), mRNA, /FEA = mRNA /GEN = ZNF205 /PROD = zinc finger protein 205 /DB_XREF = gi: 4508014 /UG = Hs.13128 zinc finger protein 205 /FL = gb: BC002810.1 gb: AF060865.1 gb: NM_003456.1 206400_at gb: NM_002307.1 /DEF = Homo sapiens lectin, galactoside-binding, soluble, 7 (galectin 7) (LGALS7), mRNA. /FEA = mRNA /GEN = LGALS7 /PROD = galectin 7 /DB_XREF = gi: 4504984 /UG = Hs.99923 lectin, galactoside-binding, soluble, 7 (galectin 7) /FL = gb: L07769.1 gb: NM_002307.1 gb: U06643.1 219696_at gb: NM_019049.1 /DEF = Homo sapiens hypothetical protein (FLJ20054), mRNA. /FEA = mRNA /GEN = FLJ20054 /PROD = hypothetical protein /DB_XREF = gi: 9506654 /UG = Hs.101590 hypothetical protein /FL = gb: NM_019049.1 209366_x_at gb: M22865.1 /DEF = Human cytochrome b5 mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 181226 /UG = Hs.83834 cytochrome b-5 /FL = gb: M22865.1 208499_s_at gb: NM_006260.1 /DEF = Homo sapiens protein-kinase, interferon-inducible double stranded RNA dependent inhibitor (PRKRI), mRNA. /FEA = CDS /GEN = PRKRI /PROD = protein-kinase, interferon-inducible double stranded RNA dependent inhibitor /DB_XREF = gi: 5453979 /UG = Hs.9683 DnaJ (Hsp40) homolog, subfamily C, member 3 /FL = gb: U28424.1 gb: NM_006260.1 207076_s_at gb: NM_000050.1 /DEF = Homo sapiens argininosuccinate synthetase (ASS), mRNA. /FEA = mRNA /GEN = ASS /PROD = argininosuccinate synthetase /DB_XREF = gi: 4557336 /UG = Hs.160786 argininosuccinate synthetase /FL = gb: NM_000050.1 209732_at gb: BC005254.1 /DEF = Homo sapiens, Similar to C-type (calcium dependent, carbohydrate-recognition domain) lectin, super family member 2 (activation-induced), clone MGC: 12289, mRNA, complete cds. /FEA = mRNA /PROD = Similar to C-type (calcium dependent, carbohydrate-recognition domain) lectin, super family member 2 (activation-induced) /DB_XREF = gi: 13528920 /UG = Hs.85201 C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 2 (activation-induced) /FL = gb: BC005254.1 gb: AB015628.1 gb: NM_005127.1 201140_s_at gb: NM_004583.1 /DEF = Homo sapiens RAB5C, member RAS oncogene family (RAB5C), mRNA. /FEA = mRNA /GEN = RAB5C /PROD = RAB5C, member RAS oncogene family /DB_XREF = gi: 4759019 /UG = Hs.479 RAB5C, member RAS oncogene family /FL = gb: NM_004583.1 gb: U11293.1 gb: U18420.1 gb: AF141304.1 212687_at Consensus includes gb: AL110164.1 /DEF = Homo sapiens mRNA; cDNA DKFZp586I0324 (from clone DKFZp586I0324). /FEA = mRNA /DB_XREF = gi: 5817069 /UG = Hs.193700 Homo sapiens mRNA; cDNA DKFZp586I0324 (from clone DKFZp586I0324) 222303_at Consensus includes gb: AV700891 /FEA = EST /DB_XREF = gi: 10302862 /DB_XREF = est: AV700891 /CLONE = GKCBQD03 /UG = Hs.292477 ESTs 200644_at gb: NM_023009.1 /DEF = Homo sapiens macrophage myristoylated alanine-rich C kinase substrate (MACMARCKS), mRNA. /FEA = mRNA /GEN = MACMARCKS /PROD = macrophage myristoylated alanine-rich C kinase substrate /DB_XREF = gi: 13491173 /UG = Hs.75061 macrophage myristoylated alanine-rich C kinase substrate /FL = gb: NM_023009.1 220528_at gb: NM_018399.1 /DEF = Homo sapiens VNN3 protein (HSA238982), mRNA. /FEA = mRNA /GEN = HSA238982 /PROD = VNN3 protein /DB_XREF = gi: 9055235 /UG = Hs.183656 VNN3 protein /FL = gb: NM_018399.1 209917_s_at gb: BC002709.1 /DEF = Homo sapiens, TP53 target gene 1, clone MGC: 3578, mRNA, complete cds. /FEA = mRNA /PROD = TP53 target gene 1 /DB_XREF = gi: 12803742 /UG = Hs.274329 TP53 target gene 1 /FL = gb: BC002709.1 gb: AB007455.1 gb: NM_007233.1 202157_s_at gb: U69546.1 /DEF = Homo sapiens RNA-binding protein BRUNOL3 (BRUNOL3) mRNA, complete cds. /FEA = mRNA /GEN = BRUNOL3 /PROD = RNA-binding protein BRUNOL3 /DB_XREF = gi: 1568642 /UG = Hs.211610 CUG triplet repeat, RNA-binding protein 2 /FL = gb: U69546.1 gb: AF036956.1 gb: AF090694.1 gb: NM_006561.1 214582_at Consensus includes gb: NM_000753.1 /DEF = Homo sapiens 2,3-cyclic nucleotide 3 phosphodiesterase (CNP), mRNA. /FEA = CDS /GEN = CNP /PROD = 2,3-cyclic nucleotide 3 phosphodiesterase /DB_XREF = gi: 4502924 /UG = Hs.150741 2,3-cyclic nucleotide 3 phosphodiesterase /FL = gb: NM_0.00753.1 204589_at gb: NM_014840.1 /DEF = Homo sapiens KIAA0537 gene product (KIAA0537), mRNA. /FEA = mRNA /GEN = KIAA0537 /PROD = KIAA0537 gene product /DB_XREF = gi: 7662169 /UG = Hs.200598 KIAA0537 gene product /FL = gb: AB011109.1 gb: NM_014840.1 210413_x_at gb: U19557.1 /DEF = Human squamous cell carcinoma antigen 2 (SCCA2) mRNA, complete cds. /FEA = mRNA /GEN = SCCA2 /PROD = squamous cell carcinoma antigen 2 /DB_XREF = gi: 1052870 /UG = Hs.123035 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 4 /FL = gb: U19557.1 220548_at gb: NM_006071.1 /DEF = Homo sapiens polycystic kidney disease (polycystin) and REJ (sperm receptor for egg jelly, sea urchin homolog)-like (PKDREJ), mRNA. /FEA = mRNA /GEN = PKDREJ /PROD = polycystic kidney disease (polycystin) and REJ(sperm receptor for egg jelly, sea urchin homolog)-like /DB_XREF = gi: 5174632 /UG = Hs.241383 polycystic kidney disease (polycystin) and REJ (sperm receptor for egg jelly, sea urchin homolog)-like /FL = gb: AF116458.1 gb: NM_006071.1 203450_at gb: NM_015373.1 /DEF = Homo sapiens chromosome 22 open reading frame 2 (C22ORF2), mRNA. /FEA = mRNA /GEN = C22ORF2 /PROD = chromosome 22 open reading frame 2 /DB_XREF = gi: 7656941 /UG = Hs.227637 chromosome 22 open reading frame 2 /FL = gb: AL136686.1 gb: NM_015373.1 205730_s_at gb: NM_014945.1 /DEF = Homo sapiens KIAA0843 protein (KIAA0843), mRNA. /FEA = mRNA /GEN = KIAA0843 /PROD = KIAA0843 protein /DB_XREF = gi: 7662329 /UG = Hs.26777 KIAA0843 protein /FL = gb: AB020650.1 gb: NM_014945.1 218913_s_at gb: NM_016573.1 /DEF = Homo sapiens Gem-interacting protein (LOC51291), mRNA. /FEA = mRNA /GEN = LOC51291 /PROD = Gem-interacting protein /DB_XREF = gi: 7706106 /UG = Hs.49427 Gem-interacting protein /FL = gb: AF132541.1 gb: NM_016573.1 208322_s_at gb: NM_003033.1 /DEF = Homo sapiens sialyltransferase 4A (beta-galactosidase alpha-2,3-sialytransferase) (SIAT4A), mRNA. /FEA = mRNA /GEN = SIAT4A /PROD = sialyltransferase 4A (beta-galactosidasealpha-2,3-sialytransferase) /DB_XREF = gi: 4506950 /UG = Hs.301698 sialyltransferase 4A (beta-galactosidase alpha-2,3-sialytransferase) /FL = gb: L13972.1 gb: NM_003033.1 gb: L29555.1 203473_at gb: NM_007256.1 /DEF = Homo sapiens solute carrier family 21 (organic anion transporter), member 9 (SLC21A9), mRNA. /FEA = mRNA /GEN = SLC21A9 /PROD = solute carrier family 21 (organic aniontransporter), member 9 /DB_XREF = gi: 6005819 /UG = Hs.7884 solute carrier family 21 (organic anion transporter), member 9 /FL = gb: AB020687.1 gb: AB026256.1 gb: NM_007256.1 212326_at Consensus includes gb: AB007922.2 /DEF = Homo sapiens mRNA for KIAA0453 protein, partial cds. /FEA = mRNA /GEN = KIAA0453 /PROD = KIAA0453 protein /DB_XREF = gi: 6634036 /UG = Hs.194737 KIAA0453 protein 219760_at gb: NM_022165.1 /DEF = Homo sapiens Lin-7b protein (LIN-7B), mRNA. /FEA = mRNA /GEN = LIN-7B /PROD = Lin-7b protein /DB_XREF = gi: 11545919 /UG = Hs.293686 Lin-7b protein; likely ortholog of mouse LIN-7B; mammalian LIN-7 protein 2 /FL = gb: AF311862.1 gb: NM_022165.1 204321_at gb: NM_002499.1 /DEF = Homo sapiens neogenin (chicken) homolog 1 (NEO1), mRNA. /FEA = mRNA /GEN = NEO1 /PROD = neogenin (chicken) homolog 1 /DB_XREF = gi: 4505374 /UG = Hs.90408 neogenin (chicken) homolog 1 /FL = gb: U61262.1 gb: U72391.1 gb: NM_002499.1 211704_s_at gb: AF356353.1 /DEF = Homo sapiens spindlin-like protein 2 (SPIN2) mRNA, complete cds. /FEA = mRNA /GEN = SPIN2 /PROD = spindlin-like protein 2 /DB_XREF = gi: 13650143 /FL = gb: AF356353.1 205832_at gb: NM_016352.1 /DEF = Homo sapiens carboxypeptidase A3 (LOC51200), mRNA. /FEA = mRNA /GEN = LOC51200 /PROD = carboxypeptidase A3 /DB_XREF = gi: 10047105 /UG = Hs.93764 carboxypeptidase A3 /FL = gb: NM_016352.1 gb: AF095719.1 219694_at gb: NM_019018.1 /DEF = Homo sapiens hypothetical protein (FLJ11127), mRNA. /FEA = mRNA /GEN = FLJ11127 /PROD = hypothetical protein /DB_XREF = gi: 9506640 /UG = Hs.91165 hypothetical protein /FL = gb: NM_019018.1 203733_at gb: NM_014015.2 /DEF = Homo sapiens MYLE protein (MYLE), mRNA. /FEA = mRNA /GEN = MYLE /PROD = MYLE protein /DB_XREF = gi: 13384596 /UG = Hs.11902 MYLE protein /FL = gb: BC001083.1 gb: AF108145.2 gb: NM_014015.2 213932_x_at Consensus includes gb: AI923492 /FEA = EST /DB_XREF = gi: 5659456 /DB_XREF = est: wn86a02.x1 /CLONE = IMAGE: 2452682 /UG = Hs.181244 major histocompatibility complex, class I, A 203453_at gb: NM_001038.1 /DEF = Homo sapiens sodium channel, nonvoltage-gated 1 alpha (SCNN1A), mRNA. /FEA = mRNA /GEN = SCNN1A /PROD = sodium channel, nonvoltage-gated 1 alpha /DB_XREF = gi: 4506814 /UG = Hs.2794 sodium channel, nonvoltage-gated 1 alpha /FL = gb: NM_001038.1 210164_at gb: J03189.1 /DEF = Human proteolytic serine esterase-like protein (SECT) gene, complete cds. /FEA = mRNA /DB_XREF = gi: 338010 /UG = Hs.1051 granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) /FL = gb: J04071.1 gb: J03189.1 gb: M17016.1 gb: NM_004131.2 205220_at gb: NM_006018.1 /DEF = Homo sapiens putative chemokine receptor; GTP-binding protein (HM74), mRNA. /FEA = mRNA /GEN = HM74 /PROD = putative chemokine receptor; GTP-binding protein /DB_XREF = gi: 5174460 /UG = Hs.137555 putative chemokine receptor; GTP-binding protein /FL = gb: NM_006018.1 213891_s_at Consensus includes gb: AI927067 /FEA = EST /DB_XREF = gi: 5663031 /DB_XREF = est: wo87f01.x1 /CLONE = IMAGE: 2462329 /UG = Hs.289068 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272 204269_at gb: NM_006875.1 /DEF = Homo sapiens pim-2 oncogene (PIM2), mRNA. /FEA = mRNA /GEN = PIM2 /PROD = pim-2 oncogene /DB_XREF = gi: 5803124 /UG = Hs.80205 pim-2 oncogene /FL = gb: U77735.1 gb: NM_006875.1 213050_at Consensus includes gb: AA594937 /FEA = EST /DB_XREF = gi: 2410287 /DB_XREF = est: no40b03.s1 /CLONE = IMAGE: 1103117 /UG = Hs.33010 KIAA0633 protein 222293_at Consensus includes gb: AW204383 /FEA = EST /DB_XREF = gi: 6503855 /DB_XREF = est: UI-H-BI1-adv-c-03-0-UI.s1 /CLONE = IMAGE: 2717957 /UG = Hs.312723 ESTs, Highly similar to F22162 1 H. sapiens 211725_s_at gb: BC005884.1 /DEF = Homo sapiens, clone MGC: 4736, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 4736) /DB_XREF = gi: 13543452 /FL = gb: BC005884.1 204967_at gb: NM_001649.1 /DEF = Homo sapiens apical protein, Xenopus laevis-like (APXL), mRNA. /FEA = mRNA /GEN = APXL /PROD = apical protein, Xenopus laevis-like /DB_XREF = gi: 4502174 /UG = Hs.2391 apical protein, Xenopus laevis-like /FL = gb: NM_001649.1 204284_at Consensus includes gb: N26005 /FEA = EST /DB_XREF = gi: 1140353 /DB_XREF = est: yx88f04.s1 /CLONE = IMAGE: 268831 /UG = Hs.303090 protein phosphatase 1, regulatory (inhibitor) subunit 5 /FL = gb: NM_005398.1 203127_s_at gb: BC005123.1 /DEF = Homo sapiens, serine palmitoyltransferase, long chain base subunit 2, clone MGC: 10362, mRNA, complete cds. /FEA = mRNA /PROD = serine palmitoyltransferase, long chain base subunit 2 /DB_XREF = gi: 13477298 /UG = Hs.59403 serine palmitoyltransferase, long chain base subunit 2 /FL = gb: BC005123.1 gb: AB011098.1 gb: NM_004863.1 209708_at gb: AY007239.1 /DEF = Homo sapiens monooxygenase X mRNA, complete cds. /FEA = mRNA /PROD = monooxygenase X /DB_XREF = gi: 9988949 /UG = Hs.6909 DKFZP564G202 protein /FL = gb: AY007239.1 210150_s_at gb: BC003355.1 /DEF = Homo sapiens, clone MGC: 5311, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 5311) /DB_XREF = gi: 13097167 /UG = Hs.312953 Homo sapiens, clone MGC: 5311, mRNA, complete cds /FL = gb: BC003355.1 207480_s_at gb: NM_020149.1 /DEF = Homo sapiens TALE homeobox protein Meis2e (LOC56908), mRNA. /FEA = mRNA /GEN = LOC56908 /PROD = TALE homeobox protein Meis2e /DB_XREF = gi: 9910355 /UG = Hs.283312 TALE homeobox protein Meis2e /FL = gb: AF179899.1 gb: NM_020149.1 202330_s_at gb: NM_003362.1 /DEF = Homo sapiens uracil-DNA glycosylase (UNG), mRNA. /FEA = mRNA /GEN = UNG /PROD = uracil-DNA glycosylase /DB_XREF = gi: 6224978 /UG = Hs.78853 uracil-DNA glycosylase /FL = gb: NM_003362.1 220425_x_at gb: NM_017578.1 /DEF = Homo sapiens AKAP-binding sperm protein ropporin (DKFZp434B1222), mRNA. /FEA = mRNA /GEN = DKFZp434B1222 /PROD = AKAP-binding sperm protein ropporin /DB_XREF = gi: 13487901 /UG = Hs.194093 AKAP-binding sperm protein ropporin /FL = gb: AF231410.1 gb: NM_017578.1 219836_at gb: NM_024508.1 /DEF = Homo sapiens hypothetical protein MGC10796 (MGC10796), mRNA. /FEA = mRNA /GEN = MGC10796 /PROD = hypothetical protein MGC10796 /DB_XREF = gi: 13375643 /UG = Hs.136912 hypothetical protein MGC10796 /FL = gb: BC003536.1 gb: NM_024508.1 220416_at gb: NM_024837.1 /DEF = Homo sapiens hypothetical protein FLJ21472 (FLJ21472), mRNA. /FEA = mRNA /GEN = FLJ21472 /PROD = hypothetical protein FLJ21472 /DB_XREF = gi: 13376248 /UG = Hs.182738 hypothetical protein FLJ21472 /FL = gb: NM_024837.1 210422_x_at gb: D50402.1 /DEF = Human mRNA for NRAMP1, complete cds. /FEA = mRNA /PROD = Nramp /DB_XREF = gi: 1000996 /UG = Hs.182611 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 /FL = gb: D50402.1 gb: D50403.1 gb: NM_000578.1 gb: L32185.1 213812_s_at Consensus includes gb: AK024748.1 /DEF = Homo sapiens cDNA: FLJ21095 fis, clone CAS03846. /FEA = mRNA /DB_XREF = gi: 10437113 /UG = Hs.108708 calciumcalmodulin-dependent protein kinase kinase 2, beta 213392_at Consensus includes gb: AW070229 /FEA = EST /DB_XREF = gi: 6025227 /DB_XREF = est: xa09e01.x1 /CLONE = IMAGE: 2567832 /UG = Hs.242407 G protein-coupled receptor, family C, group 5, member B 209893_s_at gb: M58596.1 /DEF = Human ELAM-1 ligand fucosyltransferase (ELFT) mRNA, complete cds. /FEA = mRNA /PROD = ELAM-1 ligand fucosyltransferase /DB_XREF = gi: 182068 /UG = Hs.2173 fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific) /FL = gb: M58596.1 gb: M58597.1 gb: NM_002033.1 200838_at gb: NM_001908.1 /DEF = Homo sapiens cathepsin B (CTSB), mRNA. /FEA = mRNA /GEN = CTSB /PROD = cathepsin B /DB_XREF = gi: 4503138 /UG = Hs.297939 cathepsin B /FL = gb: M14221.1 gb: L16510.1 gb: NM_001908.1 218018_at Consensus includes gb: AW449022 /FEA = EST /DB_XREF = gi: 6989798 /DB_XREF = est: UI-H-BI3-ake-f-11-0-UI.s1 /CLONE = IMAGE: 2734220 /UG = Hs.4746 hypothetical protein FLJ21324 /FL = gb: NM_021941.1 gb: BC003651.1 203724_s_at gb: NM_014961.1 /DEF = Homo sapiens KIAA0871 protein (KIAA0871), mRNA. /FEA = mRNA /GEN = KIAA0871 /PROD = KIAA0871 protein /DB_XREF = gi: 7662351 /UG = Hs.7972 KIAA0871 protein /FL = gb: AB020678.1 gb: NM_014961.1 202789_at Consensus includes gb: AL022394 /DEF = Human DNA sequence from clone RP3-511B24 on chromosome 20q11.2-12. Contains the 3 end of the TOP1 gene for topoisomerase (DNA) I, the PLCG1 gene for phospholipase C gamma 1, gene KIAA0395 for a possible homeobox protein, a 60S Ribosomal Protein L . . . /FEA = mRNA_1 /DB_XREF = gi: 11345540 /UG = Hs.268177 phospholipase C, gamma 1 (formerly subtype 148) /FL = gb: M34667.1 gb: NM_602660.1 204135_at gb: NM_014890.1 /DEF = Homo sapiens downregulated in ovarian cancer 1 (DOC1), mRNA. /FEA = mRNA /GEN = DOC1 /PROD = downregulated in ovarian cancer 1 /DB_XREF = gi: 7657036 /UG = Hs.15432 downregulated in ovarian cancer 1 /FL = gb: U53445.1 gb: NM_014890.1 211959_at Consensus includes gb: AW007532 /FEA = EST /DB_XREF = gi: 5856310 /DB_XREF = est: ws52h07.x1 /CLONE = IMAGE: 2500861 /UG = Hs.103391 Human insulin-like growth factor binding protein 5 (IGFBP5) mRNA 201764_at gb: NM_024056.1 /DEF = Homo sapiens hypothetical protein MGC5576 (MGC5576), mRNA. /FEA = mRNA /GEN = MGC5576 /PROD = hypothetical protein MGC5576 /DB_XREF = gi: 13129025 /UG = Hs.103834 hypothetical protein MGC5576 /FL = gb: BC000854.1 gb: NM_024056.1 200748_s_at gb: NM_002032.1 /DEF = Homo sapiens ferritin, heavy polypeptide 1 (FTH1), mRNA. /FEA = mRNA /GEN = FTH1 /PROD = ferritin, heavy polypeptide 1 /DB_XREF = gi: 4503794 /UG = Hs.62954 ferritin, heavy polypeptide 1 /FL = gb: BC000857.1 gb: BC001399.1 gb: M11146.1 gb: M12937.1 gb: M97164.1 gb: NM_002032.1 gb: L20941.1 220049_s_at gb: NM_025239.1 /DEF = Homo sapiens programmed death ligand 2 (PDL2), mRNA. /FEA = mRNA /GEN = PDL2 /PROD = programmed death ligand 2 /DB_XREF = gi: 13376849 /UG = Hs.61929 programmed death ligand 2 /FL = gb: AF344424.1 gb: NM_025239.1 218510_x_at Consensus includes gb: AI816291 /FEA = EST /DB_XREF = gi: 5431837 /DB_XREF = est: au46f08.x1 /CLONE = IMAGE: 2517831 /UG = Hs.82273 hypothetical protein /FL = gb: NM_019000.1 206306_at gb: NM_001036.1 /DEF = Homo sapiens ryanodine receptor 3 (RYR3), mRNA. /FEA = mRNA /GEN = RYR3 /PROD = ryanodine receptor 3 /DB_XREF = gi: 4506758 /UG = Hs.9349 ryanodine receptor 3 /FL = gb: AB001025.1 gb: AJ001515.1 gb: NM_001036.1 202935_s_at Consensus includes gb: AI382146 /FEA = EST /DB_XREF = gi: 4194927 /DB_XREF = est: te30c10.x1 /CLONE = IMAGE: 2087442 /UG = Hs.2316 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) /FL = gb: NM_000346.1 201325_s_at gb: NM_001423.1 /DEF = Homo sapiens epithelial membrane protein 1 (EMP1), mRNA. /FEA = mRNA /GEN = EMP1 /PROD = epithelial membrane protein 1 /DB_XREF = gi: 4563558 /UG = Hs.79368 epithelial membrane protein 1 /FL = gb: U77085.1 gb: U43916.1 gb: NM_001423.1 220856_x_at gb: NM_014128.1 /DEF = Homo sapiens PRO0470 protein (PRO0470), mRNA. /FEA = mRNA /GEN = PRO0470 /PROD = PRO0470 protein /DB_XREF = gi: 7662555 /UG = Hs.278937 PRO0470 protein /FL = gb: AF090928.1 gb: NM_014128.1 209242_at Consensus includes gb: AL042588 /FEA = EST /DB_XREF = gi: 5935496 /DB_XREF = est: DKFZp434K2121_r1 /CLONE = DKFZp434K2121 /UG = Hs.139033 paternally expressed 3 /FL = gb: AF208967.1 219615_s_at gb: NM_003740.1 /DEF = Homo sapiens potassium channel, subfamily K, member 5 (TASK-2) (KCNK5), mRNA. /FEA = mRNA /GEN = KCNK5 /PROD = potassium channel, subfamily K, member 5(TASK-2) /DB_XREF = gi: 4504850 /UG = Hs.127007 potassium channel, subfamily K, member 5 (TASK-2) /FL = gb: AF084830.1 gb: NM_003740.1 208961_s_at gb: AB017493.1 /DEF = Homo sapiens mRNA for DNA-binding zinc finger(GBF), complete cds. /FEA = mRNA /PROD = DNA-binding zinc finger(GBF) /DB_XREF = gi: 3582142 /UG = Hs.285313 core promoter element binding protein /FL = gb: BC000311.1 gb: BC004301.1 gb: AF001461.1 gb: AB017493.1 gb: NM_001300.2 211382_s_at gb: AF220152.2 /DEF = Homo sapiens TACC2 mRNA, complete cds. /FEA = mRNA /PROD = TACC2 /DB_XREF = gi: 7934571 /UG = Hs.272023 transforming, acidic coiled-coil containing protein 2 /FL = gb: AF220152.2 203640_at Consensus includes gb: BE328496 /FEA = EST /DB_XREF = gi: 9202272 /DB_XREF = est: hs98f09.x1 /CLONE = IMAGE: 3145289 /UG = Hs.283609 hypothetical protein PRO2032 /FL = gb: AF116683.1 gb: NM_018615.1 206453_s_at gb: NM_016250.1 /DEF = Homo sapiens N-myc downstream-regulated gene 2 (NDRG2), mRNA. /FEA = mRNA /GEN = NDRG2 /PROD = KIAA1248 protein /DB_XREF = gi: 10280619 /UG = Hs.243960 N-myc downstream-regulated gene 2 /FL = gb: NM_016250.1 gb: AF159092.3 219066_at gb: NM_021823.1 /DEF = Homo sapiens hypothetical protein MDS018 (MDS018), mRNA. /FEA = mRNA /GEN = MDS018 /PROD = hypothetical protein MDS018 /DB_XREF = gi: 11141896 /UG = Hs.24647 hypothetical protein MDS018 /FL = gb: AF182419.1 gb: NM_021823.1 201328_at Consensus includes gb: AL575509 /FEA = EST /DB_XREF = gi: 12936742 /DB_XREF = est: AL575509 /CLONE = CS0DI059YP21 (3 prime) /UG = Hs.85146 v-ets avian erythroblastosis virus E26 oncogene homolog 2 /FL = gb: J04102.1 gb: NM_005239.1 221655_x_at gb: AF282167.1 /DEF = Homo sapiens DRC3 mRNA, complete cds. /FEA = mRNA /PROD = DRC3 /DB_XREF = gi: 9944939 /UG = Hs.28907 hypothetical protein FLJ20258 /FL = gb: AF282167.1 218779_x_at gb: NM_017729.1 /DEF = Homo sapiens hypothetical protein FLJ20258 (FLJ20258), mRNA. /FEA = mRNA /GEN = FLJ20258 /PROD = hypothetical protein FLJ20258 /DB_XREF = gi: 8923231 /UG = Hs.28907 hypothetical protein FLJ20258 /FL = gb: NM_017729.1 222236_s_at Consensus includes gb: AK000253.1 /DEF = Homo sapiens cDNA FLJ20246 fis, clone COLF6458. /FEA = mRNA /DB_XREF = gi: 7020209 /UG = Hs.44579 hypothetical protein FLJ20199 212071_s_at Consensus includes gb: BE968833 /FEA = EST /DB_XREF = gi: 10579538 /DB_XREF = est: 601649861F1 /CLONE = IMAGE: 3933782 /UG = Hs.324648 Homo sapiens cDNA FLJ13700 fis, clone PLACE2000216, highly similar to SPECTRIN BETA CHAIN, BRAIN 221872_at Consensus includes gb: AI669229 /FEA = EST /DB_XREF = gi: 4834003 /DB_XREF = est: wc13e06.x1 /CLONE = IMAGE: 2315074 /UG = Hs.82547 retinoic acid receptor responder (tazarotene induced) 1 209719_x_at gb: U19556.1 /DEF = Human squamous cell carcinoma antigen 1 (SCCA1) mRNA, complete cds. /FEA = mRNA /GEN = SCCA1 /PROD = squamous cell carcinoma antigen 1 /DB_XREF = gi: 1276435 /UG = Hs.227948 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3 /FL = gb: U19556.1 gb: BC005224.1 gb: NM_006919.1 201124_at Consensus includes gb: AL048423 /FEA = EST /DB_XREF = gi: 5936493 /DB_XREF = est: DKFZp586H2324_s1 /CLONE = DKFZp586H2324 /UG = Hs.149846 integrin, beta 5 /FL = gb: M35011.1 gb: J05633.1 gb: NM_002213.1 213455_at Consensus includes gb: W87466 /FEA = EST /DB_XREF = gi: 1401521 /DB_XREF = est: zh67c05.s1 /CLONE = IMAGE: 417128 /UG = Hs.246885 hypothetical protein FLJ20783 206336_at gb: NM_002993.1 /DEF = Homo sapiens Small inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) (SCYB6), mRNA. /FEA = mRNA /GEN = SCYB6 /PROD = small inducible cytokine subfamily B(Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) /DB_XREF = gi: 4506850 /UG = Hs.164021 small inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) /FL = gb: U81234.1 gb: NM_002993.1 211312_s_at gb: AB034725.1 /DEF = Homo sapiens mRNA for WISP-1 variant, complete cds. /FEA = mRNA /PROD = WISP-1 variant /DB_XREF = gi: 11176998 /UG = Hs.194680 WNT1 inducible signaling pathway protein 1 /FL = gb: AB034725.1 220178_at gb: NM_021731.1 /DEF = Homo sapiens hypothetical protein PP3501 (PP3501), mRNA. /FEA = mRNA /GEN = PP3501 /PROD = hypothetical protein PP3501 /DB_XREF = gi: 11119425 /UG = Hs.301406 hypothetical protein PP3501 /FL = gb: NM_021731.1 205859_at gb: NM_004271.1 /DEF = Homo sapiens MD-1, RP105-associated (MD-1), mRNA. /FEA = mRNA /GEN = MD-1 /PROD = MD-1, RP105-associated /DB_XREF = gi: 4758707 /UG = Hs.184018 MD-1, RP105-associated /FL = gb: AF057178.2 gb: AB020499.1 gb: NM_004271.1 205464_at gb: NM_000336.1 /DEF = Homo sapiens sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) (SCNN1B), mRNA. /FEA = mRNA /GEN = SCNN1B /PROD = sodium channel, nonvoltage-gated 1, beta /DB_XREF = gi: 4506816 /UG = Hs.37129 sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) /FL = gb: NM_000336.1 gb: L36593.1 206388_at gb: U36798.1 /DEF = Homo sapiens platelet cGI-PDE mRNA, complete cds. /FEA = mRNA /PROD = platelet cGI-PDE /DB_XREF = gi: 1039473 /UG = Hs.777 phosphodiesterase 3A, cGMP-inhibited /FL = gb: U36798.1 gb: M91667.1 gb: NM_000921.1 35671_at Cluster Incl. U02619: Human TFIIIC Box B-binding subunit mRNA, complete cds /cds = (60, 6389) /gb = U02619 /gi = 414932 /ug = Hs.331 /len = 6996 210793_s_at gb: U41815.1 /DEF = Human nucleoporin 98 (NUP98) mRNA, complete cds. /FEA = mRNA /GEN = NUP98 /PROD = nucleoporin 98 /DB_XREF = gi: 1184172 /UG = Hs.112255 nucleoporin 98 kD /FL = gb: U41815.1 208779_x_at gb: L20817.1 /DEF = Homo sapiens tyrosine protein kinase (CAK) gene, complete cds. /FEA = mRNA /GEN = CAK /PROD = tyrosine protein kinase /DB_XREF = gi: 306474 /UG = Hs.75562 discoidin domain receptor family, member 1 /FL = gb: L20817.1 205888_s_at Consensus includes gb: AI962693 /FEA = EST /DB_XREF = gi: 5755406 /DB_XREF = est: wq55a09.x1 /CLONE = IMAGE: 2475160 /UG = Hs.43107 KIAA0555 gene product /FL = gb: AB011127.1 gb: NM_014790.1 220535_at gb: NM_018088.1 /DEF = Homo sapiens hypothetical protein FLJ10408 (FLJ10408), mRNA. /FEA = mRNA /GEN = FLJ10408 /PROD = hypothetical protein FLJ10408 /DB_XREF = gi: 8922410 /UG = Hs.196086 hypothetical protein FLJ10408 /FL = gb: NM_018088.1 206321_at gb: NM_002918.1 /DEF = Homo sapiens regulatory factor X, 1 (influences HLA class II expression) (RFX1), mRNA. /FEA = mRNA /GEN = RFX1 /PROD = regulatory factor X, 1 (influences HLA class II expression) /DB_XREF = gi: 4506492 /UG = Hs.123638 regulatory factor X, 1 (influences HLA class II expression) /FL = gb: NM_002918.1 213293_s_at Consensus includes gb: AA083478 /FEA = EST /DB_XREF = gi: 1625564 /DB_XREF = est: zn32e02.s1 /CLONE = IMAGE: 549146 /UG = Hs.295978 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 746039 205109_s_at gb: NM_015320.1 /DEF = Homo sapiens Rho guanine nucleotide exchange factor (GEF) 4 (ARHGEF4), mRNA. /FEA = mRNA /GEN = ARHGEF4 /PROD = KIAA1112 protein /DB_XREF = gi: 9558722 /UG = Hs.6066 Rho guanine nucleotide exchange factor (GEF) 4 /FL = gb: AF249745.1 gb: NM_015320.1 212414_s_at Consensus includes gb: D50918.1 /DEF = Human mRNA for KIAA0128 gene, partial cds. /FEA = mRNA /GEN = KIAA0128 /DB_XREF = gi: 1469178 /UG = Hs.90998 KIAA0128 protein; septin 2 219228_at gb: NM_018555.2 /DEF = Homo sapiens C2H2-like zinc finger protein (ZNF361), mRNA. /FEA = mRNA /GEN = ZNF361 /PROD = C2H2-like zinc finger protein /DB_XREF = gi: 10092612 /UG = Hs.147644 zinc finger protein 331 /FL = gb: AF251515.2 gb: NM_018555.2 gb: AF272148.1 220414_at gb: NM_017422.2 /DEF = Homo sapiens calmodulin-like skin protein (CLSP), mRNA. /FEA = mRNA /GEN = CLSP /PROD = calmodulin-like skin protein /DB_XREF = gi: 13699870 /UG = Hs.180142 calmodulin-like skin protein /FL = gb: NM_017422.2 gb: AF172852.1 218548_x_at gb: NM_015926.1 /DEF = Homo sapiens putative secreted protein (SIG11), mRNA. /FEA = mRNA /GEN = SIG11 /PROD = putative secreted protein /DB_XREF = gi: 7706707 /UG = Hs.279785 putative secreted protein /FL = gb: AF072733.1 gb: NM_015926.1 206170_at gb: NM_000024.2 /DEF = Homo sapiens adrenergic, beta-2-, receptor, surface (ADRB2), mRNA. /FEA = mRNA /GEN = ADRB2 /PROD = adrenergic, beta-2-, receptor, surface /DB_XREF = gi: 13162366 /UG = Hs.2551 adrenergic, beta- 2-, receptor, surface /FL = gb: NM_000024.2 gb: M15169.1 200800_s_at gb: NM_005345.3 /DEF = Homo sapiens heat shock 70 kD protein 1A (HSPA1A), mRNA. /FEA = mRNA /GEN = HSPA1A /PROD = heat shock 70 kD protein 1A /DB_XREF = gi: 5579469 /UG = Hs.8997 heat shock 70 kD protein 1A /FL = gb: BC002453.1 gb: NM_005345.3 202534_x_at gb: NM_000791.2 /DEF = Homo sapiens dihydrofolate reductase (DHFR), mRNA. /FEA = mRNA /GEN = DHFR /PROD = dihydrofolate reductase /DB_XREF = gi: 7262376 /UG = Hs.83765 dihydrofolate reductase /FL = gb: BC000192.1 gb: BC003584.1 gb: NM_000791.2 202637_s_at Consensus includes gb: AI608725 /FEA = EST /DB_XREF = gi: 4617892 /DB_XREF = est: tw90b01.x1 /CLONE = IMAGE: 2266921 /UG = Hs.168383 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor /FL = gb: M24283.1 gb: J03132.1 gb: NM_000201.1 212169_at Consensus includes gb: AL050187.1 /DEF = Homo sapiens mRNA; cDNA DKFZp586B1723 (from clone DKFZp586B1723). /FEA = mRNA /DB_XREF = gi: 4884402 /UG = Hs.302749 FK506-binding protein 9 (63 kD) 209737_at gb: AB014605.1 /DEF = Homo sapiens mRNA for KIAA0705 protein, complete cds. /FEA = mRNA /GEN = KIAA0705 /PROD = KIAA0705 protein /DB_XREF = gi: 3327223 /UG = Hs.22599 atrophin-1 interacting protein 1; activin receptor interacting protein 1 /FL = gb: AB014605.1 204747_at gb: NM_001549.1 /DEF = Homo sapiens interferon-induced protein with tetratricopeptide repeats 4 (IFIT4), mRNA. /FEA = mRNA /GEN = IFIT4 /PROD = interferon-induced protein with tetratricopeptide repeats 4 /DB_XREF = gi: 4504586 /UG = Hs.181874 interferon-induced protein with tetratricopeptide repeats 4 /FL = gb: BC001383.1 gb: BC004977.1 gb: U52513.1 gb: AF026939.1 gb: AF083470.1 gb: NM_001549.1 222339_x_at Consensus includes gb: AI054381 /FEA = EST /DB_XREF = gi: 3322168 /DB_XREF = est: qi64d09.x1 /CLONE = IMAGE: 1861265 /UG = Hs.176139 ESTs 206584_at gb: NM_015364.1 /DEF = Homo sapiens MD-2 protein (MD-2), mRNA. /FEA = mRNA /GEN = MD-2 /PROD = MD-2 protein/DB_XREF = gi: 7662503 /UG = Hs.69328 MD-2 protein /FL = gb: AB018549.1 gb: NM_015364.1 gb: AF168121.1 218469_at gb: NM_013372.1 /DEF = Homo sapiens cysteine knot superfamily 1, BMP antagonist 1 (CKTSF1B1), mRNA. /FEA = mRNA /GEN = CKTSF1B1 /PROD = cysteine knot superfamily 1, BMP antagonist 1 /DB_XREF = gi: 7019348 /UG = Hs.40098 cysteine knot superfamily 1, BMP antagonist 1 /FL = gb: AF154054.1 gb: AF045800.1 gb: AF110137.2 gb: NM_013372.1 212188_at Consensus includes gb: AA551075 /FEA = EST /DB_XREF = gi: 2321327 /DB_XREF = est: nk74h06.s1 /CLONE = IMAGE: 1019291 /UG = Hs.109438 Homo sapiens clone 24775 mRNA sequence 209859_at gb: AF220036.1 /DEF = Homo sapiens tripartite motif protein TRIM9 isoform alpha (TRIM9) mRNA, complete cds; alternatively spliced. /FEA = mRNA /GEN = TRIM9 /PROD = tripartite motif protein TRIM9 isoform alpha /DB_XREF = gi: 12407402 /UG = Hs.75090 KIAA0282 protein /FL = gb: AF220036.1 gb: AF220037.1 gb: AF220038.1 211208_s_at gb: AB039327.2 /DEF = Homo sapiens CASK mRNA for calciumcalmodulin-dependent serine protein kinase, complete cds. /FEA = mRNA /GEN = CASK /PROD = calciumcalmodulin-dependent serine proteinkinase /DB_XREF = gi: 13359270 /UG = Hs.151469 calciumcalmodulin-dependent serine protein kinase (MAGUK family) /FL = gb: AB039327.2 212158_at Consensus includes gb: AL577322 /FEA = EST /DB_XREF = gi: 12940338 /DB_XREF = est: AL577322 /CLONE = CS0DI085YI06 (3 prime) /UG = Hs.1501 syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan) 214000_s_at Consensus includes gb: AI744627 /FEA = EST /DB_XREF = gi: 5113004 /DB_XREF = est: wg04g05.x1 /CLONE = IMAGE: 2364152 /UG = Hs.82280 regulator of G-protein signalling 10 209583_s_at gb: AF063591.1 /DEF = Homo sapiens brain my033 protein mRNA, complete cds. /FEA = mRNA /PROD = brain my033 protein /DB_XREF = gi: 12002013 /UG = Hs.79015 antigen identified by monoclonal antibody MRC OX-2 /FL = gb: AF063591.1 214255_at Consensus includes gb: N35112 /FEA = EST /DB_XREF = gi: 1156254 /DB_XREF = est: yy19h05.s1 /CLONE = IMAGE: 271737 /UG = Hs.44697 ATPase, Class V, type 10C 221828_s_at Consensus includes gb: AK024432.1 /DEF = Homo sapiens mRNA for FLJ00022 protein, partial cds. /FEA = mRNA /GEN = FLJ00022 /PROD = FLJ00022 protein /DB_XREF = gi: 10440372 /UG = Hs.4914 Homo sapiens mRNA for FLJ00031 protein, partial cds 203315_at gb: BC000103.1 /DEF = Homo sapiens, NCK adaptor protein 2, clone MGC: 1698, mRNA, complete cds. /FEA = mRNA /PROD = NCK adaptor protein 2 /DB_XREF = gi: 12652708 /UG = Hs.101695 NCK adaptor protein 2 /FL = gb: BC000103.1 gb: AF043119.1 gb: AF047487.1 gb: NM_003581.1 219861_at gb: NM_018163.1 /DEF = Homo sapiens hypothetical protein FLJ10634 (FLJ10634), mRNA. /FEA = mRNA /GEN = FLJ10634 /PROD = hypothetical protein FLJ10634 /DB_XREF = gi: 8922562 /UG = Hs.24989 hypothetical protein FLJ10634 /FL = gb: BC000048.1 gb: NM_018163.1 213540_at Consensus includes gb: AL031228 /DEF = Human DNA sequence from clone 1033B10 on chromosome 6p21.2-21.31. Contains the BING5 gene, exons 11 to 15 of the BING4 gene, the gene for GalT3 (beta3-Galactosyltransferase), the RPS18 (40S ribosomal protein S18) gene, the SACM2L (suppressor of ac . . . /FEA = mRNA_1 /DB_XREF = gi: 3646023 /UG = Hs.288354 FabG (beta-ketoacyl-acyl-carrier-protein reductase, E coli) like 221238_at gb: NM_030763.1 /DEF = Homo sapiens nucleosomal binding protein 1 (NSBP1), mRNA. /FEA = mRNA /GEN = NSBP1 /PROD = nucleosomal binding protein 1 /DB_XREF = gi: 13540522 /FL = gb: NM_030763.1 217506_at Consensus includes gb: H49382 /FEA = EST /DB_XREF = gi: 989223 /DB_XREF = est: yq19b06.s1 /CLONE = IMAGE: 274115 /UG = Hs.124984 ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION WARNING ENTRY H. sapiens 218145_at gb: NM_021158.1 /DEF = Homo sapiens protein kinase domains containing protein similar to phosphoprotein C8FW (LOC57761), mRNA. /FEA = mRNA /GEN = LOC57761 /PROD = protein kinase domains containing protein similar to phosphoprotein C8FW /DB_XREF = gi: 11056039 /UG = Hs.26802 protein kinase domains containing protein similar to phosphoprotein C8FW /FL = gb: NM_021158.1 214051_at Consensus includes gb: BF677486 /FEA = EST /DB_XREF = gi: 11951381 /DB_XREF = est: 602085745F1 /CLONE = IMAGE: 4249834 /UG = Hs.56145 thymosin, beta, identified in neuroblastoma cells 211776_s_at gb: BC006141.1 /DEF = Homo sapiens, Similar to erythrocyte protein band 4.1-like 3, clone MGC: 13087, mRNA, complete cds. /FEA = mRNA /PROD = Similar to erythrocyte protein band 4.1-like 3 /DB_XREF = gi: 13544008 /FL = gb: BC006141.1 203874_s_at gb: NM_003069.1 /DEF = Homo sapiens SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (SMARCA1), mRNA. /FEA = mRNA /GEN = SMARCA1 /PROD = SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 /DB_XREF = gi: 4507066 /UG = Hs.152292 SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 /FL = gb: M88163.1 gb: NM_003069.1 202552_s_at gb: NM_016441.1 /DEF = Homo sapiens cysteine-rich motor neuron 1 (CRIM1), mRNA. /FEA = mRNA /GEN = CRIM1 /PROD = cysteine-rich motor neuron 1 /DB_XREF = gi: 10092638 /UG = Hs.19280 cysteine-rich motor neuron 1 /FL = gb: NM_016441.1 gb: AF167706.1 213578_at Consensus includes gb: AI678679 /FEA = EST /DB_XREF = gi: 4888861 /DB_XREF = est: tu58f02.x1 /CLONE = IMAGE: 2255259 /UG = Hs.2534 bone morphogenetic protein receptor, type IA 204362_at gb: NM_003930.1 /DEF = Homo sapiens SKAP55 homologue (SKAP-HOM), mRNA. /FEA = mRNA /GEN = SKAP-HOM /PROD = SKAP55 homologue /DB_XREF = gi: 4506962 /UG = Hs.52644 SKAP55 homologue /FL = gb: BC002893.1 gb: AF072166.1 gb: AB014486.1 gb: AF051323.1 gb: NM_003930.1 209094_at Consensus includes gb: AL078459 /DEF = Human DNA sequence from clone RP4-621F18 on chromosome 1p11.4-21.3. Contains the 3 end of the gene for ng, ng dimethylarginine dimethylaminohydrolase (EC 3.5.3.18), ESTs, STSs and GSSs /FEA = mRNA /DB_XREF = gi: 5791502 /UG = Hs.303180 dimethylarginine dimethylaminohydrolase 1 /FL = gb: AB001915.1 gb: NM_012137.1 219477_s_at gb: NM_018676.1 /DEF = Homo sapiens TMTSP for transmembrane molecule with thrombospondin module (LOC55901), mRNA. /FEA = mRNA /GEN = LOC55901 /PROD = TMTSP for transmembrane molecule with thrombospondin module /DB_XREF = gi: 8923893 /UG = Hs.325667 TMTSP for transmembrane molecule with thrombospondin module /FL = gb: AB044385.1 gb: NM_018676.1 218035_s_at gb: NM_019027.1 /DEF = Homo sapiens hypothetical protein (FLJ20273), mRNA. /FEA = mRNA /GEN = FLJ20273 /PROD = hypothetical protein /DB_XREF = gi: 9506670 /UG = Hs.95549 hypothetical protein /FL = gb: NM_019027.1 204420_at Consensus includes gb: BG251266 /FEA = EST /DB_XREF = gi: 12761082 /DB_XREF = est: 602365892F1 /CLONE = IMAGE: 4474055 /UG = Hs.283565 FOS-like antigen-1 /FL = gb: NM_005438.1 213857_s_at Consensus includes gb: BG230614 /FEA = EST /DB_XREF = gi: 12725656 /DB_XREF = est: naf41b12.x1 /CLONE = IMAGE: 4143335 /UG = Hs.82685 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) 209863_s_at gb: AF091627.1 /DEF = Homo sapiens CUSP mRNA, complete cds. /FEA = mRNA /PROD = CUSP /DB_XREF = gi: 3644039 /UG = Hs.137569 tumor protein 63 kDa with strong homology to p53 /FL = gb: AF091627.1 gb: AF075431.1 gb: AF075433.1 206173_x_at gb: NM_002041.2 /DEF = Homo sapiens GA-binding protein transcription factor, beta subunit 2 (47 kD) (GABPB2), transcript variant gamma, mRNA. /FEA = mRNA /GEN = GABPB2 /PROD = GA-binding protein transcription factor, beta subunit 2 (47 kD), isoform gamma 1 /DB_XREF = gi: 8051596 /UG = Hs.278238 GA-binding protein transcription factor, beta subunit 2 (47 kD) /FL = gb: U13047.1 gb: NM_002041.2 219161_s_at gb: NM_016951.2 /DEF = Homo sapiens transmembrane proteolipid (HSPC224), mRNA. /FEA = mRNA /GEN = HSPC224 /PROD = transmembrane proteolipid /DB_XREF = gi: 10092593 /UG = Hs.15159 chemokine-like factor, alternatively spliced /FL = gb: NM_016951.2 gb: BC004380.1 gb: AF057306.1 gb: AF151058.1 gb: AF135380.2 220146_at gb: NM_016562.1 /DEF = Homo sapiens toll-like receptor 7 (LOC51284), mRNA. /FEA = mRNA /GEN = LOC51284 /PROD = toll-like receptor 7 /DB_XREF = gi: 7706092 /UG = Hs.179152 toll-like receptor 7 /FL = gb: AF240467.1 gb: NM_016562.1 gb: AF245702.1 202266_at gb: NM_016614.1 /DEF = Homo sapiens TRAF and TNF receptor-associated protein (AD022), mRNA. /FEA = mRNA /GEN = AD022 /PROD = TRAF and TNF receptor-associated protein /DB_XREF = gi: 7705261 /UG = Hs.46847 TRAF and TNF receptor-associated protein /FL = gb: AF201687.1 gb: AF223469.1 gb: NM_016614.1 204834_at gb: NM_006682.1 /DEF = Homo sapiens fibrinogen-like 2 (FGL2), mRNA. /FEA = mRNA /GEN = FGL2 /PROD = fibrinogen-like 2 /DB_XREF = gi: 5730074 /UG = Hs.2659 fibrinogen-like 2 /FL = gb: NM_006682.1 204401_at gb: NM_002250.1 /DEF = Homo sapiens potassium intermediatesmall conductance calcium-activated channel, subfamily N, member 4 (KCNN4), mRNA. /FEA = mRNA /GEN = KCNN4 /PROD = potassium intermediatesmall conductance calcium-activated channel, subfamily N, member 4 /DB_XREF = gi: 4504858 /UG = Hs.10082 potassium intermediatesmall conductance calcium-activated channel, subfamily N, member 4 /FL = gb: AF000972.1 gb: AF033021.1 gb: AF022150.1 gb: AF022797.1 gb: NM_002250.1 220894_x_at gb: NM_021619.1 /DEF = Homo sapiens PR domain containing 12 (PRDM12), mRNA. /FEA = mRNA /GEN = PRDM12 /PROD = PR domain containing 12 /DB_XREF = gi: 11055979 /UG = Hs.287385 PR domain containing 12 /FL = gb: AY004252.1 gb: NM_021619.1 215075_s_at Consensus includes gb: L29511.1 /DEF = Human GRB2 isoform mRNA. /FEA = mRNA /PROD = growth factor receptor- bound protein 3 /DB_XREF = gi: 460667 /UG = Hs.296381 growth factor receptor-bound protein 2 201983_s_at Consensus includes gb: AW157070 /FEA = EST /DB_XREF = gi: 6228471 /DB_XREF = est: au91e07.x1 /CLONE = IMAGE: 2783652 /UG = Hs.77432 epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb- b) oncogene homolog) /FL = gb: NM_005228.1 208436_s_at gb: NM_004030.1 /DEF = Homo sapiens interferon regulatory factor 7 (IRF7), transcript variant c, mRNA. /FEA = mRNA /GEN = IRF7 /PROD = interferon regulatory factor 7, transcriptvariant c /DB_XREF = gi: 4809285 /UG = Hs.166120 interferon regulatory factor 7 /FL = gb: NM_004030.1 219622_at gb: NM_017817.1 /DEF = Homo sapiens hypothetical protein FLJ20429 (FLJ20429), mRNA. /FEA = mRNA /GEN = FLJ20429 /PROD = hypothetical protein FLJ20429 /DB_XREF = gi: 8923400 /UG = Hs.179791 hypothetical protein FLJ20429 /FL = gb: NM_017817.1 207232_s_at gb: NM_014648.1 /DEF = Homo sapiens KIAA0675 gene product (KIAA0675), mRNA. /FEA = mRNA /GEN = KIAA0675 /PROD = KIAA0675 gene product /DB_XREF = gi: 7662243 /UG = Hs.165662 KIAA0675 gene product /FL = gb: AB014575.1 gb: NM_014648.1 203105_s_at gb: NM_012062.1 /DEF = Homo sapiens dynamin 1-like (DNM1L), transcript variant 1, mRNA. /FEA = mRNA /GEN = DNM1L /PROD = dynamin 1-like protein, isoform 1 /DB_XREF = gi: 6996004 /UG = Hs.180628 dynamin 1-like /FL = gb: AF000430.1 gb: AB006965.1 gb: NM_012062.1 215440_s_at Consensus includes gb: AL523320 /FEA = EST /DB_XREF = gi: 12786813 /DB_XREF = est: AL523320 /CLONE = CS0DC001YD02 (5 prime) /UG = Hs.184736 hypothetical protein FLJ10097 203778_at gb: NM_005908.1 /DEF = Homo sapiens mannosidase, beta A, lysosomal (MANBA), mRNA. /FEA = mRNA /GEN = MANBA /PROD = Mannosidase, beta A, lysosomal /DB_XREF = gi: 5174522 /UG = Hs.115945 mannosidase, beta A, lysosomal /FL = gb: U60337.1 gb: NM_005908.1 204614_at gb: NM_002575.1 /DEF = Homo sapiens serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), mRNA. /FEA = mRNA /GEN = SERPINB2 /PROD = serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 /DB_XREF = gi: 4505594 /UG = Hs.75716 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 /FL = gb: J02685.1 gb: J03603.1 gb: M18082.1 gb: NM_002575.1 209590_at Consensus includes gb: AL157414 /DEF = Human DNA sequence from clone RP11-560A15 on chromosome 20 Contains part of a novel gene, the 3 part of the BMP7 (bone morphogenetic protein 7 (osteogenic protein 1)) gene, ESTs, STSs, GSSs and a CpG island /FEA = mRNA_1 /DB_XREF = gi: 9581576 /UG = Hs.170195 bone morphogenetic protein 7 (osteogenic protein 1) /FL = gb: M60316.1 gb: NM_001719.1 204621_s_at Consensus includes gb: AI935096 /FEA = EST /DB_XREF = gi: 5673966 /DB_XREF = est: wp13e10.x1 /CLONE = IMAGE: 2464746 /UG = Hs.82120 nuclear receptor subfamily 4, group A, member 2 /FL = gb: NM_006186.1 204998_s_at gb: NM_012068.2 /DEF = Homo sapiens activating transcription factor 5 (ATF5), mRNA. /FEA = mRNA /GEN = ATF5 /PROD = activating transcription factor 5 /DB_XREF = gi: 12597624 /UG = Hs.9754 activating transcription factor 5 /FL = gb: AF305687.1 gb: AB021663.2 gb: NM_012068.2 gb: BC005174.1 204881_s_at gb: NM_003358.1 /DEF = Homo sapiens UDP-glucose ceramide glucosyltransferase (UGCG), mRNA. /FEA = mRNA /GEN = UGCG /PROD = ceramide glucosyltransferase /DB_XREF = gi: 4507810 /UG = Hs.152601 UDP-glucose ceramide glucosyltransferase /FL = gb: D50840.1 gb: NM_003358.1 37892_at Cluster Incl. J04177: Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds /cds = (161, 5581) /gb = J04177 /gi = 179729 /ug = Hs.82772 /len = 6158 201669_s_at gb: NM_002356.4 /DEF = Homo sapiens myristoylated alanine-rich protein kinase C substrate (MARCKS, 80K-L) (MACS), mRNA. /FEA = mRNA /GEN = MACS /PROD = myristoylated alanine-rich protein kinase C substrate /DB_XREF = gi: 11125771 /UG = Hs.75607 myristoylated alanine-rich protein kinase C substrate (MARCKS, 80K-L) /FL = gb: NM_002356.4 gb: M68956.1 gb: D10522.1 219517_at gb: NM_025165.1 /DEF = Homo sapiens hypothetical protein FLJ22637 (FLJ22637), mRNA. /FEA = mRNA /GEN = FLJ22637 /PROD = hypothetical protein FLJ22637 /DB_XREF = gi: 13376767 /UG = Hs.296178 hypothetical protein FLJ22637 /FL = gb: NM_025165.1 202562_s_at gb: AL136658.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564H0664 (from clone DKFZp564H0664); complete cds. /FEA = mRNA /GEN = DKFZp564H0664 /PROD = hypothetical protein /DB_XREF = gi: 12052839 /UG = Hs.15106 chromosome 14 open reading frame 1 /FL = gb: AL136658.1 gb: AF136971.1 gb: BC002444.1 gb: AF134159.2 gb: NM_007176.1 201416_at Consensus includes gb: BG528420 /FEA = EST /DB_XREF = gi: 13519957 /DB_XREF = est: 602579853F1 /CLONE = IMAGE: 4719060 /UG = Hs.83484 SRY (sex determining region Y)-box 4 /FL = gb: NM_003107.1 219210_s_at gb: NM_016530.1 /DEF = Homo sapiens RAB-8b protein (LOC51762), mRNA. /FEA = mRNA /GEN = LOC51762 /PROD = RAB-8b protein /DB_XREF = gi: 7706562 /UG = Hs.321245 RAB-8b protein /FL = gb: AB038995.1 gb: NM_016530.1 208875_s_at Consensus includes gb: BF796470 /FEA = EST /DB_XREF = gi: 12101524 /DB_XREF = est: 602259926F1 /CLONE = IMAGE: 4342999 /UG = Hs.284275 Homo sapiens PAK2 mRNA, complete cds /FL = gb: AF092132.1 202073_at Consensus includes gb: AV757675 /FEA = EST /DB_XREF = gi: 10915523 /DB_XREF = est: AV757675 /CLONE = BMFAVB12 /UG = Hs.278898 tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains; Huntingtin interacting protein L; transcrption factor IIIA-interacting protein /FL = gb: NM_021980.1 221991_at Consensus includes gb: AI937333 /FEA = EST /DB_XREF = gi: 5676203 /DB_XREF = est: wp75h10.x1 /CLONE = IMAGE: 2467651 /UG = Hs.55069 neurexophilin 3 201847_at gb: NM_000235.1 /DEF = Homo sapiens lipase A, lysosomal acid, cholesterol esterase (Wolman disease) (LIPA), mRNA. /FEA = mRNA /GEN = LIPA /PROD = lipase A precursor /DB_XREF = gi: 4557720 /UG = Hs.85226 lipase A, lysosomal acid, cholesterol esterase (Wolman disease) /FL = gb: M74775.1 gb: NM_000235.1 gb: U08464.1 203178_at gb: NM_001482.1 /DEF = Homo sapiens glycine amidinotransferase (L-arginine:glycine amidinotransferase) (GATM), mRNA. /FEA = mRNA /GEN = GATM /PROD = glycine amidinotransferase (L-arginine:glycineamidinotransferase) /DB_XREF = gi: 4503932 /UG = Hs.75335 glycine amidinotransferase (L-arginine:glycine amidinotransferase) /FL = gb: BC004141.1 gb: NM_001482.1 221009_s_at gb: NM_016109.1 /DEF = Homo sapiens PPAR(gamma) angiopoietin related protein (PGAR), mRNA. /FEA = mRNA /GEN = PGAR /PROD = PPAR(gamma) angiopoietin related protein /DB_XREF = gi: 7705828 /UG = Hs.9613 PPAR(gamma) angiopoietin related protein /FL = gb: AF153606.1 gb: NM_016109.1 216935_at Consensus includes gb: AF005082.1 /DEF = Homo sapiens skin-specific protein (xp33) mRNA, partial cds. /FEA = mRNA /GEN = xp33 /PROD = skin-specific protein /DB_XREF = gi: 2589191 /UG = Hs.113261 Homo sapiens skin-specific protein (xp33) mRNA, partial cds 210041_s_at gb: BC001258.1 /DEF = Homo sapiens, N-acetylglucosamine-phosphate mutase, clone MGC: 5002, mRNA, complete cds. /FEA = mRNA /PROD = N-acetylglucosamine-phosphate mutase /DB_XREF = gi: 12654830 /UG = Hs.237323 N- acetylglucosamine-phosphate mutase /FL = gb: BC001258.1 gb: AF102265.1 gb: AF180371.1 gb: AB032081.1 218788_s_at gb: NM_022743.1 /DEF = Homo sapiens hypothetical protein FLJ21080 (FLJ21080), mRNA. /FEA = mRNA /GEN = FLJ21080 /PROD = hypothetical protein FLJ21080 /DB_XREF = gi: 12232400 /UG = Hs.8109 hypothetical protein FLJ21080 /FL = gb: NM_022743.1 202647_s_at gb: NM_002524.2 /DEF = Homo sapiens neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), mRNA. /FEA = mRNA /GEN = NRAS /PROD = neuroblastoma RAS viral (v-ras) oncogenehomolog /DB_XREF = gi: 6006027 /UG = Hs.260523 neuroblastoma RAS viral (v-ras) oncogene homolog /FL = gb: BC005219.1 gb: NM_002524.2 217585_at Consensus includes gb: BE502910 /FEA = EST /DB_XREF = gi: 9705318 /DB_XREF = est: hz81a09.x1 /CLONE = IMAGE: 3214360 /UG = Hs.166449 ESTs, Weakly similar to S55024 nebulin, skeletal muscle H. sapiens 207719_x_at gb: NM_014812.1 /DEF = Homo sapiens KIAA0470 gene product (KIAA0470), mRNA. /FEA = mRNA /GEN = KIAA0470 /PROD = KARP-1-binding protein /DB_XREF = gi: 7662141 /UG = Hs.25132 KIAA0470 gene product /FL = gb: AB022657.1 gb: NM_014812.1 207038_at gb: NM_004694.1 /DEF = Homo sapiens solute carrier family 16 (monocarboxylic acid transporters), member 6 (SLC16A6), mRNA. /FEA = mRNA /GEN = SLC16A6 /PROD = solute carrier family 16 (monocarboxylic acid transporters), member 6 /DB_XREF = gi: 4759117 /UG = Hs.114924 solute carrier family 16 (monocarboxylic acid transporters), member 6 /FL = gb: U79745.1 gb: NM_004694.1 201904_s_at Consensus includes gb: BF031714 /FEA = EST /DB_XREF = gi: 10739426 /DB_XREF = est: 601558023F1 /CLONE = IMAGE: 3827909 /UG = Hs.147189 HYA22 protein /FL = gb: D88153.1 gb: NM_005808.1 219076_s_at gb: NM_018663.1 /DEF = Homo sapiens 22 kDa peroxisomal membrane protein-like (LOC55895), mRNA. /FEA = mRNA /GEN = LOC55895 /PROD = 22 kDa peroxisomal membrane protein-like /DB_XREF = gi: 8923891 /UG = Hs.49912 22 kDa peroxisomal membrane protein-like /FL = gb: AF250136.1 gb: NM_018663.1 221133_s_at gb: NM_016369.1 /DEF = Homo sapiens claudin 18 (CLDN18), mRNA. /FEA = mRNA /GEN = CLDN18 /PROD = claudin 18 /DB_XREF = gi: 7705960 /UG = Hs.278966 Claudin-18 /FL = gb: AF221069.1 gb: NM_016369.1 203693_s_at gb: NM_001949.2 /DEF = Homo sapiens E2F transcription factor 3 (E2F3) mRNA, complete cds. /FEA = mRNA /GEN = E2F3 /PROD = E2F transcription factor 3 /DB_XREF = gi: 12669913 /UG = Hs.1189 E2F transcription factor 3 /FL = gb: NM_001949.2 212077_at Consensus includes gb: AL583520 /FEA = EST /DB_XREF = gi: 12952562 /DB_XREF = est: AL583520 /CLONE = CS0DC024YE13 (5 prime) /UG = Hs.182183 Homo sapiens mRNA for caldesmon, 3 UTR 212297_at Consensus includes gb: BF218804 /FEA = EST /DB_XREF = gi: 11112494 /DB_XREF = est: 601882315F1 /CLONE = IMAGE: 4094786 /UG = Hs.4934 H. sapiens polyA site DNA 219587_at gb: NM_017868.1 /DEF = Homo sapiens hypothetical protein FLJ20535 (FLJ20535), mRNA. /FEA = mRNA /GEN = FLJ20535 /PROD = hypothetical protein FLJ20535 /DB_XREF = gi: 8923504 /UG = Hs.183362 hypothetical protein FLJ20535 /FL = gb: NM_017868.1 218610_s_at gb: NM_018340.1 /DEF = Homo sapiens hypothetical protein FLJ11151 (FLJ11151), mRNA. /FEA = mRNA /GEN = FLJ11151 /PROD = hypothetical protein FLJ11151 /DB_XREF = gi: 8922900 /UG = Hs.14992 hypothetical protein FLJ11151 /FL = gb: NM_018340.1 200889_s_at Consensus includes gb: AI016620 /FEA = EST /DB_XREF = gi: 3230956 /DB_XREF = est: ov30e10.x1 /CLONE = IMAGE: 1638858 /UG = Hs.250773 signal sequence receptor, alpha (translocon-associated protein alpha) /FL = gb: AF156965.1 gb: NM_003144.2 204319_s_at gb: NM_002925.2 /DEF = Homo sapiens regulator of G-protein signalling 10 (RGS10), mRNA. /FEA = mRNA /GEN = RGS10 /PROD = regulator of G-protein signaling 10 /DB_XREF = gi: 11184225 /UG = Hs.82280 regulator of G- protein signalling 10 /FL = gb: NM_002925.2 gb: AF045229.1 205531_s_at gb: NM_013267.1 /DEF = Homo sapiens breast cell glutaminase (GA), mRNA. /FEA = mRNA /GEN = GA /PROD = breast cell glutaminase /DB_XREF = gi: 7019388 /UG = Hs.325443 breast cell glutaminase /FL = gb: AF110330.1 gb: AF110331.1 gb: AF223944.1 gb: NM_013267.1 213413_at Consensus includes gb: BG434174 /FEA = EST /DB_XREF = gi: 13340680 /DB_XREF = est: 602506106F1 /CLONE = IMAGE: 4603513 /UG = Hs.23437 Homo sapiens cDNA FLJ13555 fis, clone PLACE1007677 219867_at gb: NM_024944.1 /DEF = Homo sapiens hypothetical protein FLJ12627 (FLJ12627), mRNA. /FEA = mRNA /GEN = FLJ12627 /PROD = hypothetical protein FLJ12627 /DB_XREF = gi: 13376424 /UG = Hs.283725 hypothetical protein FLJ12627 /FL = gb: NM_024944.1 202422_s_at gb: NM_022977.1 /DEF = Homo sapiens fatty-acid-Coenzyme A ligase, long-chain 4 (FACL4), transcript variant 2, mRNA. /FEA = mRNA /GEN = FACL4 /PROD = long-chain fatty-acid-Coenzyme A ligase 4, isoform 2 /DB_XREF = gi: 12669908 /UG = Hs.81452 fatty-acid-Coenzyme A ligase, long-chain 4 /FL = gb: NM_022977.1 216640_s_at Consensus includes gb: AK026926.1 /DEF = Homo sapiens cDNA: FLJ23273 fis, clone HEP02611, highly similar to HSU79278 Human protein disulfide isomerase-related protein P5 mRNA. /FEA = mRNA /DB_XREF = gi: 10439898 /UG = Hs.182429 protein disulfide isomerase-related protein 201286_at Consensus includes gb: Z48199 /DEF = H. sapiens syndecan-1 gene (exons 2-5) /FEA = mRNA /DB_XREF = gi: 666051 /UG = Hs.82109 syndecan 1 /FL = gb: J05392.1 gb: NM_002997.1 36030_at Cluster Incl. AL080214: Homo sapiens mRNA; cDNA DKFZp586I2223 (from clone DKFZp586I2223) /cds = (0.318) /gb = AL080214 /gi = 5262704 /ug = Hs.46659 /len = 1272 202936_s_at gb: NM_000346.1 /DEF = Homo sapiens SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex- reversal) (SOX9), mRNA. /FEA = mRNA /GEN = SOX9 /PROD = transcription factor SOX9 /DB_XREF = gi: 4557852 /UG = Hs.2316 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) /FL = gb: NM_000346.1 206924_at gb: NM_000641.1 /DEF = Homo sapiens interleukin 11 (IL11), mRNA. /FEA = mRNA /GEN = IL11 /PROD = interleukin 11 /DB_XREF = gi: 10834993 /UG = Hs.1721 interleukin 11 /FL = gb: NM_000641.1 gb: M57765.1 204454_at gb: NM_012317.1 /DEF = Homo sapiens leucine zipper, down-regulated in cancer 1 (LDOC1), mRNA. /FEA = mRNA /GEN = LDOC1 /PROD = leucine zipper, down-regulated in cancer 1 /DB_XREF = gi: 6912479 /UG = Hs.45231 leucine zipper, down-regulated in cancer 1 /FL = gb: BC003104.1 gb: AB019527.1 gb: NM_012317.1 202906_s_at Consensus includes gb: AF049895 /DEF = Homo sapiens 8q21.3: Nibrin (NBS1), 2,4-dienoyl-CoA reductase (DECR), and calbindin 1 (CALB1) genes /FEA = mRNA_5 /DB_XREF = gi: 4126312 /UG = Hs.25812 Nijmegen breakage syndrome 1 (nibrin) /FL = gb: AF058696.1 gb: AF051334.1 gb: NM_002485.2 200743_s_at gb: NM_000391.2 /DEF = Homo sapiens ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease) (CLN2), mRNA. /FEA = mRNA /GEN = CLN2 /PROD = ceroid-lipofuscinosis, neuronal 2, lateinfantile (Jansky- Bielschowsky disease) /DB_XREF = gi: 5597012 /UG = Hs.20478 ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky- Bielschowsky disease) /FL = gb: AF017456.1 gb: NM_000391.2 213620_s_at Consensus includes gb: AA126728 /FEA = EST /DB_XREF = gi: 1686292 /DB_XREF = est: zk95d07.s1 /CLONE = IMAGE: 490573 /UG = Hs.83733 intercellular adhesion molecule 2 208729_x_at gb: D83043.1 /DEF = Human HLA-B mRNA, allele A*2711, complete cds. /FEA = mRNA /GEN = HLA-B /DB_XREF = gi: 1871135 /UG = Hs.77961 major histocompatibility complex, class I, B /FL = gb: U36492.1 gb: U35431.1 gb: L37881.1 gb: U31971.1 gb: L42345.1 gb: U50710.1 gb: L41925.1 gb: L41214.1 gb: U27608.1 gb: U35734.1 gb: U70528.1 gb: U70529.1 gb: U80945.1 gb: U64801.1 gb: U09864.1 gb: M77776.1 gb: M77775.1 gb: L04696.1 gb: D83043.1 gb: M12678.1 gb: L09736.1 gb: L09735.1 gb: M75138.1 gb: M84381.1 gb: M84382.1 gb: M84383.1 gb: M84384.1 gb: M84385.1 gb: M32318.1 gb: M32319.1 gb: M32320.1 gb: M81798.1 gb: L04695.1 gb: M84694.1 gb: U30936.1 gb: AF016641.1 gb: U36392.1 gb: AB008102.1 gb: U75533.1 gb: U57966.1 gb: AF026218.1 gb: L07743.1 gb: U01848.1 gb: U38800.1 gb: U40498.1 gb: U03027.1 gb: U03859.1 gb: L22028.1 gb: U04243.1 gb: U06862.1 gb: L32862.1 gb: L15005.1 gb: L22027.1 gb: L19923.1 gb: L11666.1 gb: L11604.1 gb: L11603.1 gb: L19937.1 gb: L33923.1 gb: AF170577.1 gb: M28205.1 gb: U17107.1 gb: U14943.1 gb: AF130734.1 gb: D25275.1 gb: D50290.1 gb: D50291.1 gb: D50299.1 gb: D50300.1 gb: L38504.1 gb: L36591.1 gb: U30904.1 205347_s_at gb: NM_021992.1 /DEF = Homo sapiens thymosin, beta, identified in neuroblastoma cells (TMSNB), mRNA. /FEA = mRNA /GEN = TMSNB /PROD = thymosin, beta, identified in neuroblastomacells /DB_XREF = gi: 11496272 /UG = Hs.56145 thymosin, beta, identified in neuroblastoma cells /FL = gb: NM_021992.1 gb: BC000183.1 gb: D82345.1 203504_s_at gb: NM_005502.1 /DEF = Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), mRNA. /FEA = mRNA /GEN = ABCA1 /PROD = ATP-binding cassette, sub-family A member 1 /DB_XREF = gi: 5915657 /UG = Hs.211562 ATP-binding cassette, sub-family A (ABC1), member 1 /FL = gb: AF165281.1 gb: NM_005502.1 gb: AF285167.1 202489_s_at gb: BC005238.1 /DEF = Homo sapiens, FXYD domain-containing ion transport regulator 3, clone MGC: 12265, mRNA, complete cds. /FEA = mRNA /PROD = FXYD domain-containing ion transport regulator3 /DB_XREF = gi: 13528881 /UG = Hs.301350 FXYD domain-containing ion transport regulator 3 /FL = gb: NM_005971.2 gb: BC005238.1 221601_s_at Consensus includes gb: AI084226 /FEA = EST /DB_XREF = gi: 3422649 /DB_XREF = est: oy72g09.x1 /CLONE = IMAGE: 1671424 /UG = Hs.58831 regulator of Fas-induced apoptosis /FL = gb: AF057557.1 gb: NM_005449.1 221875_x_at Consensus includes gb: AW514210 /FEA = EST /DB_XREF = gi: 7152378 /DB_XREF = est: hd75b05.x1 /CLONE = IMAGE: 2915313 /UG = Hs.110309 major histocompatibility complex, class I, F 219415_at gb: NM_020659.1 /DEF = Homo sapiens tweety (Drosophila) homolog 1 (TTYH1), mRNA. /FEA = mRNA /GEN = TTYH1 /PROD = tweety (Drosophila) homolog 1 /DB_XREF = gi: 10257436 /UG = Hs.12828 tweety (Drosophila) homolog 1 /FL = gb: NM_020659.1 gb: AF177909.1 207072_at gb: NM_003853.1 /DEF = Homo sapiens interleukin 18 receptor accessory protein (IL18RAP), mRNA. /FEA = mRNA /GEN = IL18RAP /PROD = interleukin 18 receptor accessory protein /DB_XREF = gi: 4504656 /UG = Hs.158315 interleukin 18 receptor accessory protein /FL = gb: AF077346.1 gb: NM_003853.1 214020_x_at Consensus includes gb: BE138575 /FEA = EST /DB_XREF = gi: 8601075 /DB_XREF = est: xr77e12.x2 /CLONE = IMAGE: 2766190 /UG = Hs.149846 integrin, beta 5 219115_s_at gb: NM_014432.1 /DEF = Homo sapiens interleukin 20 receptor, alpha (IL20RA), mRNA. /FEA = mRNA /GEN = IL20RA /PROD = interleukin 20 receptor, alpha /DB_XREF = gi: 7657690 /UG = Hs.21814 interleukin 20 receptor, alpha /FL = gb: AF184971.1 gb: NM_014432.1 204316_at Consensus includes gb: W19676 /FEA = EST /DB_XREF = gi: 1295644 /DB_XREF = est: zb36h07.r1 /CLONE = IMAGE: 305725 /UG = Hs.82280 regulator of G-protein signalling 10 /FL = gb: NM_002925.2 gb: AF045229.1 213075_at Consensus includes gb: AL050002.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564O222 (from clone DKFZp564O222). /FEA = mRNA /DB_XREF = gi: 4884256 /UG = Hs.94795 Homo sapiens mRNA; cDNA DKFZp564O222 (from clone DKFZp564O222) 213272_s_at Consensus includes gb: AF070596.1 /DEF = Homo sapiens clone 24796 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 3387973 /UG = Hs.27191 hypothetical protein from clone 24796 214368_at Consensus includes gb: AI688812 /FEA = EST /DB_XREF = gi: 4900106 /DB_XREF = est: wd41c03.x1 /CLONE = IMAGE: 2330692 /UG = Hs.99491 RAS guanyl releasing protein 2 (calcium and DAG-regulated) 219032_x_at gb: NM_014322.1 /DEF = Homo sapiens opsin 3 (encephalopsin) (OPN3), mRNA. /FEA = mRNA /GEN = OPN3 /PROD = opsin 3 (encephalopsin) /DB_XREF = gi: 7657070 /UG = Hs.279926 opsin 3 (encephalopsin) /FL = gb: AF140242.1 gb: NM_014322.1 209344_at gb: BC002827.1 /DEF = Homo sapiens, tropomyosin 4, clone MGC: 3641, mRNA, complete cds. /FEA = mRNA /PROD = tropomyosin 4 /DB_XREF = gi: 12803958 /UG = Hs.250641 tropomyosin 4 /FL = gb: BC002827.1 gb: NM_003290.1 218833_at gb: NM_016653.1 /DEF = Homo sapiens sterile-alpha motif and leucine zipper containing kinase AZK (ZAK), mRNA. /FEA = mRNA /GEN = ZAK /PROD = sterile-alpha motif and leucine zipper containing kinase AZK /DB_XREF = gi: 7706600 /UG = Hs.115175 sterile-alpha motif and leucine zipper containing kinase AZK /FL = gb: AB049733.1 gb: AF238255.1 gb: AF251441.1 gb: NM_016653.1 gb: AB030034.1 204789_at gb: NM_005892.1 /DEF = Homo sapiens formin-like (FMNL), mRNA. /FEA = mRNA /GEN = FMNL /PROD = formin-like /DB_XREF = gi: 5174400 /UG = Hs.100217 formin-like /FL = gb: BC001710.1 gb: NM_005892.1 218723_s_at gb: NM_014059.1 /DEF = Homo sapiens RGC32 protein (RGC32), mRNA. /FEA = mRNA /GEN = RGC32 /PROD = RGC32 protein /DB_XREF = gi: 7662650 /UG = Hs.76640 RGC32 protein /FL = gb: AF036549.1 gb: NM_014059.1 214071_at Consensus includes gb: AI082827 /FEA = EST /DB_XREF = gi: 3417803 /DB_XREF = est: ox78b09.x1 /CLONE = IMAGE: 1662425 /UG = Hs.154145 hypothetical protein FLJ11585 205514_at gb: NM_018355.1 /DEF = Homo sapiens hypothetical protein FLJ11191 (FLJ11191), mRNA. /FEA = mRNA /GEN = FLJ11191 /PROD = hypothetical protein FLJ11191 /DB_XREF = gi: 8922928 /UG = Hs.21838 hypothetical protein FLJ11191 /FL = gb: NM_018355.1 210176_at gb: AL050262.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564I0682 (from clone DKFZp564I0682); complete cds. /FEA = mRNA /GEN = DKFZp564I0682 /PROD = hypothetical protein /DB_XREF = gi: 4886482 /UG = Hs.2474 toll-like receptor 1 /FL = gb: U88540.1 gb: D13637.1 gb: NM_003263.1 gb: AL050262.1 213158_at Consensus includes gb: AA045174 /FEA = EST /DB_XREF = gi: 1523376 /DB_XREF = est: zk66a07.s1 /CLONE = IMAGE: 487764 /UG = Hs.16193 Homo sapiens mRNA; cDNA DKFZp586B211 (from clone DKFZp586B211) 220780_at gb: NM_015715.1 /DEF = Homo sapiens group III secreted phospholipase A2 (GIII-SPLA2), mRNA. /FEA = mRNA /GEN = GIII-SPLA2 /PROD = group III secreted phospholipase A2 /DB_XREF = gi: 7657125 /UG = Hs.149623 group III secreted phospholipase A2 /FL = gb: AF220490.1 gb: NM_015715.1 212185_x_at Consensus includes gb: NM_005953.1 /DEF = Homo sapiens metallothionein 2A (MT2A), mRNA. /FEA = CDS /GEN = MT2A /PROD = metallothionein 2A /DB_XREF = gi: 5174763 /UG = Hs.118786 metallothionein 2A /FL = gb: NM_005953.1 219799_s_at gb: NM_005771.1 /DEF = Homo sapiens retinol dehydrogenase homolog (RDHL), mRNA. /FEA = mRNA /GEN = RDHL /PROD = retinol dehydrogenase homolog /DB_XREF = gi: 5032034 /UG = Hs.179608 retinol dehydrogenase homolog /FL = gb: AF067174.1 gb: NM_005771.1 209397_at gb: BC000147.1 /DEF = Homo sapiens, Similar to malic enzyme 2, NAD(+)-dependent, mitochondrial, clone MGC: 5187, mRNA, complete cds. /FEA = mRNA /PROD = Similar to malic enzyme 2, NAD(+)-dependent, mitochondrial /DB_XREF = gi: 12652790 /UG = Hs.75342 malic enzyme 2, NAD(+)-dependent, mitochondrial /FL = gb: BC000147.1 218531_at gb: NM_025124.1 /DEF = Homo sapiens hypothetical protein FLJ21749 (FLJ21749), mRNA. /FEA = mRNA /GEN = FLJ21749 /PROD = hypothetical protein FLJ21749 /DB_XREF = gi: 13376700 /UG = Hs.288761 hypothetical protein FLJ21749 /FL = gb: NM_025124.1 202747_s_at gb: NM_004867.1 /DEF = Homo sapiens integral membrane protein 2A (ITM2A), mRNA. /FEA = mRNA /GEN = ITM2A /PROD = integral membrane protein 2A /DB_XREF = gi: 4758223 /UG = Hs.17109 integral membrane protein 2A /FL = gb: AF038953.1 gb: NM_004867.1 204573_at gb: NM_021151.1 /DEF = Homo sapiens carnitine octanoyltransferase (COT), mRNA. /FEA = mRNA /GEN = COT /PROD = carnitine octanoyltransferase /DB_XREF = gi: 10863952 /UG = Hs.12743 carnitine O-octanoyltransferase /FL = gb: NM_021151.1 gb: AF073770.1 gb: AF168793.1 209083_at gb: U34690.1 /DEF = Human coronin-like protein (HCORO1) mRNA, complete cds. /FEA = mRNA /GEN = HCORO1 /PROD = coronin-like protein /DB_XREF = gi: 1002922 /UG = Hs.109606 coronin, actin-binding protein, 1A /FL = gb: U34690.1 gb: NM_007074.1 gb: D44497.1 220625_s_at gb: AF115403.1 /DEF = Homo sapiens Ets transcription factor ESE-2b mRNA, complete cds. /FEA = mRNA /PROD = Ets transcription factor ESE-2b /DB_XREF = gi: 4559274 /UG = Hs.11713 E74-like factor 5 (ets domain transcription factor) /FL = gb: AF049703.1 gb: NM_001422.1 gb: AF115403.1 57532_at Cluster Incl. AW016304: UI-H-BI0p-abl-h-10-0-UI.s1 Homo sapiens cDNA, 3 end /clone = IMAGE-2712427 /clone_end = 3 /gb = AW016304 /gi = 5865061 /ug = Hs.118640 /len = 591 222235_s_at Consensus includes gb: AL139812 /DEF = Human DNA sequence from clone RP1-19N1 on chromosome Xq21.33-22.3 Contains a gene for a novel protein. Contains ESTs, STSs and GSSs /FEA = mRNA /DB_XREF = gi: 9187185 /UG = Hs.287761 Human DNA sequence from clone RP1-19N1 on chromosome Xq21.33-22.3 Contains a gene for a novel protein. Contains ESTs, STSs and GSSs 208121_s_at gb: NM_002848.2 /DEF = Homo sapiens protein tyrosine phosphatase, receptor type, O (PTPRO), transcript variant 2, mRNA. /FEA = mRNA /GEN = PTPRO /PROD = receptor-type protein tyrosine phosphatase O, isoform b precursor /DB_XREF = gi: 13677212 /FL = gb: NM_002848.2 208986_at Consensus includes gb: AL559478 /FEA = EST /DB_XREF = gi: 12905019 /DB_XREF = est: AL559478 /CLONE = CS0DJ013YM17 (5 prime) /UG = Hs.21704 transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) /FL = gb: M80627.1 gb: M83233.1 gb: NM_003205.2 203490_at gb: NM_001421.1 /DEF = Homo sapiens E74-like factor 4 (ets domain transcription factor) (ELF4), mRNA. /FEA = mRNA /GEN = ELF4 /PROD = E74-like factor 4 (ets domain transcription factor) /DB_XREF = gi: 4503554 /UG = Hs.151139 E74-like factor 4 (ets domain transcription factor) /FL = gb: U32645.1 gb: AF000670.1 gb: NM_001421.1 213119_at Consensus includes gb: AW058600 /FEA = EST /DB_XREF = gi: 5934239 /DB_XREF = est: wx23h08.x1 /CLONE = IMAGE: 2544543 /UG = Hs.18593 Homo sapiens cDNA: FLJ21449 fis, clone COL04483, highly similar to AF010235 Homo sapiens mRNA from chromosome 5q31-33 region 212314_at Consensus includes gb: AB018289.1 /DEF = Homo sapiens mRNA for KIAA0746 protein, partial cds. /FEA = mRNA /GEN = KIAA0746 /PROD = KIAA0746 protein /DB_XREF = gi: 3882212 /UG = Hs.49500 KIAA0746 protein 203246_s_at gb: NM_006545.1 /DEF = Homo sapiens homologous to yeast nitrogen permease (candidate tumor suppressor) (NPR2L), mRNA. /FEA = mRNA /GEN = NPR2L /PROD = homologous to yeast nitrogen permease (candidate tumor suppressor) /DB_XREF = gi: 5729948 /UG = Hs.169780 homologous to yeast nitrogen permease (candidate tumor suppressor) /FL = gb: BC002791.1 gb: AF040707.1 gb: NM_006545.1 205068_s_at Consensus includes gb: BE671084 /FEA = EST /DB_XREF = gi: 10031625 /DB_XREF = est: 7e45g09.x1 /CLONE = IMAGE: 3285472 /UG = Hs.132942 GTPase regulator associated with the focal adhesion kinase pp125(FAK); KIAA0621 protein /FL = gb: AF141884.1 gb: NM_015071.1 210790_s_at gb: BC003658.1 /DEF = Homo sapiens, SAR1 protein, clone MGC: 4824, mRNA, complete cds. /FEA = mRNA /PROD = SAR1 protein /DB_XREF = gi: 13177777 /UG = Hs.110796 SAR1 protein /FL = gb: BC003658.1 204793_at gb: NM_014710.1 /DEF = Homo sapiens KIAA0443 gene product (KIAA0443), mRNA. /FEA = mRNA /GEN = KIAA0443 /PROD = KIAA0443 gene product /DB_XREF = gi: 7662129 /UG = Hs.113082 KIAA0443 gene product /FL = gb: AB007903.1 gb: NM_014710.1 205475_at gb: NM_007281.1 /DEF = Homo sapiens scrapie responsive protein 1 (SCRG1), mRNA. /FEA = mRNA /GEN = SCRG1 /PROD = scrapie responsive protein 1 /DB_XREF = gi: 6005869 /UG = Hs.7122 scrapie responsive protein 1 /FL = gb: NM_007281.1 203074_at gb: NM_001630.1 /DEF = Homo sapiens annexin A8 (ANXA8), mRNA. /FEA = mRNA /GEN = ANXA8 /PROD = annexin VIII /DB_XREF = gi: 4502112 /UG = Hs.87268 annexin A8 /FL = gb: BC004376.1 gb: M81844.1 gb: NM_001630.1 204140_at gb: NM_003596.1 /DEF = Homo sapiens tyrosylprotein sulfotransferase 1 (TPST1), mRNA. /FEA = mRNA /GEN = TPST1 /PROD = tyrosylprotein sulfotransferase 1 /DB_XREF = gi: 4507664 /UG = Hs.17279 tyrosylprotein sulfotransferase 1 /FL = gb: AF038009.1 gb: NM_003596.1 214435_x_at Consensus includes gb: NM_005402.1 /DEF = Homo sapiens v-ral simian leukemia viral oncogene homolog A (ras related) (RALA), mRNA. /FEA = CDS /GEN = RALA /PROD = v-ral simian leukemia viral oncogene homolog A (ras related) /DB_XREF = gi: 4885568 /UG = Hs.288757 v-ral simian leukemia viral oncogene homolog A (ras related) /FL = gb: M29893.1 gb: NM_005402.1 200967_at gb: NM_000942.1 /DEF = Homo sapiens peptidylprolyl isomerase B (cyclophilin B) (PPIB), mRNA. /FEA = mRNA /GEN = PPIB /PROD = peptidylprolyl isomerase B (cyclophilin B) /DB_XREF = gi: 4758949 /UG = Hs.699 peptidylprolyl isomerase B (cyclophilin B) /FL = gb: BC001125.1 gb: M60857.1 gb: M63573.1 gb: NM_000942.1 202304_at gb: NM_014923.1 /DEF = Homo sapiens KIAA0970 protein (KIAA0970), mRNA. /FEA = mRNA /GEN = KIAA0970 /PROD = KIAA0970 protein /DB_XREF = gi: 7662419 /UG = Hs.103329 KIAA0970 protein /FL = gb: AB023187.1 gb: NM_014923.1 216742_at Consensus includes gb: AK024561.1 /DEF = Homo sapiens cDNA: FLJ20908 fis, clone ADSE00417. /FEA = mRNA /DB_XREF = gi: 10436870 /UG = Hs.306689 Homo sapiens cDNA: FLJ20908 fis, clone ADSE00417 204150_at gb: NM_015136.1 /DEF = Homo sapiens KIAA0246 protein (KIAA0246), mRNA. /FEA = mRNA /GEN = KIAA0246 /PROD = KIAA0246 protein /DB_XREF = gi: 12225239 /UG = Hs.301989 KIAA0246 protein /FL = gb: NM_015136.1 204897_at Consensus includes gb: AA897516 /FEA = EST /DB_XREF = gi: 3034136 /DB_XREF = est: aj62c04.s1 /CLONE = IMAGE: 1394886 /UG = Hs.199248 prostaglandin E receptor 4 (subtype EP4) /FL = gb: D28472.1 gb: L25124.1 gb: NM_000958.1 gb: L28175.1 202669_s_at gb: U16797.1 /DEF = Human LERK-5 (EPLG5) mRNA, complete cds. /FEA = mRNA /GEN = EPLG5 /PROD = LERK-5 /DB_XREF = gi: 902370 /UG = Hs.30942 ephrin-B2 /FL = gb: U81262.1 gb: NM_004093.1 gb: L38734.1 gb: U16797.1 212909_at Consensus includes gb: AL567376 /FEA = EST /DB_XREF = gi: 12920672 /DB_XREF = est: AL567376 /CLONE = CS0DF024YO04 (3 prime) /UG = Hs.85339 G protein-coupled receptor 39 211163_s_at gb: AF012536.1 /DEF = Homo sapiens decoy receptor 1 (DcR1) mRNA, complete cds. /FEA = mRNA /GEN = DcR1 /PROD = decoy receptor 1 /DB_XREF = gi: 2338421 /UG = Hs.119684 tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain /FL = gb: AF012536.1 212531_at Consensus includes gb: NM_005564.1 /DEF = Homo sapiens lipocalin 2 (oncogene 24p3) (LCN2), mRNA. /FEA = CDS /GEN = LCN2 /PROD = lipocalin 2 (oncogene 24p3) /DB_XREF = gi: 5031852 /UG = Hs.204238 lipocalin 2 (oncogene 24p3) /FL = gb: NM_005564.1 205639_at gb: NM_001637.1 /DEF = Homo sapiens acyloxyacyl hydrolase (neutrophil) (AOAH), mRNA. /FEA = mRNA /GEN = AOAH /PROD = acyloxyacyl hydrolase precursor /DB_XREF = gi: 4502114 /UG = Hs.82542 acyloxyacyl hydrolase (neutrophil) /FL = gb: M62840.1 gb: NM_001637.1 214175_x_at Consensus includes gb: AI254547 /FEA = EST /DB_XREF = gi: 3862072 /DB_XREF = est: qv48h06.x1 /CLONE = IMAGE: 1984859 /UG = Hs.79691 LIM domain protein 201674_s_at gb: BC000729.1 /DEF = Homo sapiens, A kinase (PRKA) anchor protein 1, clone MGC: 1807, mRNA, complete cds. /FEA = mRNA /PROD = A kinase (PRKA) anchor protein 1 /DB_XREF = gi: 12653874 /UG = Hs.78921 A kinase (PRKA) anchor protein 1 /FL = gb: BC000729.1 gb: NM_003488.1 205795_at gb: NM_004796.1 /DEF = Homo sapiens neurexin 3 (NRXN3), mRNA. /FEA = mRNA /GEN = NRXN3 /PROD = neurexin 3 /DB_XREF = gi: 4758827 /UG = Hs.22269 neurexin 3 /FL = gb: AB018286.1 gb: NM_004796.1 203066_at gb: NM_014863.1 /DEF = Homo sapiens B cell RAG associated protein (BRAG), mRNA. /FEA = mRNA /GEN = BRAG /PROD = KIAA0598 gene product /DB_XREF = gi: 7662195 /UG = Hs.6079 B cell RAG associated protein /FL = gb: AB011170.1 gb: AF026477.1 gb: NM_014863.1 gb: NM_015892.1 219401_at gb: NM_022167.1 /DEF = Homo sapiens xylosyltransferase II (XT2), mRNA. /FEA = mRNA /GEN = XT2 /PROD = xylosyltransferase II /DB_XREF = gi: 11545913 /UG = Hs.32117 xylosyltransferase II /FL = gb: NM_022167.1 205401_at gb: NM_003659.1 /DEF = Homo sapiens alkylglycerone phosphate synthase (AGPS), mRNA. /FEA = mRNA /GEN = AGPS /PROD = alkylglycerone phosphate synthase precursor /DB_XREF = gi: 4501992 /UG = Hs.22580 alkylglycerone phosphate synthase /FL = gb: NM_003659.1 202756_s_at gb: NM_002081.1 /DEF = Homo sapiens glypican 1 (GPC1), mRNA. /FEA = mRNA /GEN = GPC1 /PROD = glypican 1 precursor /DB_XREF = gi: 4504080 /UG = Hs.2699 glypican 1 /FL = gb: NM_002081.1 213874_at Consensus includes gb: NM_006215.1 /DEF = Homo sapiens serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 (SERPINA4), mRNA. /FEA = CDS /GEN = SERPINA4 /PROD = serine (or cysteine) proteinase inhibitor, cladeA (alpha-1 antiproteinase, antitrypsin), member 4 /DB_XREF = gi: 5453887 /UG = Hs.159628 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 /FL = gb: L19684.1 gb: NM_006215.1 219100_at gb: NM_024928.1 /DEF = Homo sapiens hypothetical protein FLJ22559 (FLJ22559), mRNA. /FEA = mRNA /GEN = FLJ22559 /PROD = hypothetical protein FLJ22559 /DB_XREF = gi: 13487922 /UG = Hs.273387 hypothetical protein FLJ22559 /FL = gb: NM_024928.1 205388_at gb: NM_003279.1 /DEF = Homo sapiens troponin C2, fast (TNNC2), mRNA. /FEA = mRNA /GEN = TNNC2 /PROD = troponin C2, fast /DB_XREF = gi: 4507616 /UG = Hs.182421 troponin C2, fast /FL = gb: M22307.1 gb: BC005323.1 gb: NM_003279.1 206039_at gb: NM_004794.1 /DEF = Homo sapiens RAB33A, member RAS oncogene family (RAB33A), mRNA. /FEA = mRNA /GEN = RAB33A /PROD = RAB33A, member RAS oncogene family /DB_XREF = gi: 4758995 /UG = Hs.56294 RAB33A, member RAS oncogene family /FL = gb: BC001157.1 gb: D14889.1 gb: NM_004794.1 202061_s_at Consensus includes gb: AI927770 /FEA = EST /DB_XREF = gi: 5663734 /DB_XREF = est: wo08h07.x1 /CLONE = IMAGE: 2454781 /UG = Hs.181300 sel-1 (suppressor of lin-12, C. elegans)-like /FL = gb: NM_005065.1 gb: AB020335.1 gb: AF052059.1 gb: U11037.1 220664_at gb: NM_006518.1 /DEF = Homo sapiens small proline-rich protein 2C (SPRR2C), mRNA. /FEA = mRNA /GEN = SPRR2C /PROD = small proline-rich protein 2C /DB_XREF = gi: 10835253 /UG = Hs.2421 small proline-rich protein 2C /FL = gb: NM_006518.1 207705_s_at gb: NM_025176.1 /DEF = Homo sapiens KIAA0980 protein (KIAA0980), mRNA. /FEA = mRNA /GEN = KIAA0980 /PROD = hypothetical protein FLJ11792 /DB_XREF = gi: 13378150 /UG = Hs.227743 KIAA0980 protein /FL = gb: NM_025176.1 212829_at Consensus includes gb: BE878277 /FEA = EST /DB_XREF = gi: 10327053 /DB_XREF = est: 601488188F1 /CLONE = IMAGE: 3890564 /UG = Hs.57079 Homo sapiens cDNA FLJ13267 fis, clone OVARC1000964 209140_x_at gb: L42024.1 /DEF = Homo sapiens MHC HLA-B39 mRNA, complete cds. /FEA = mRNA /GEN = HLA-B39 /PROD = major histocompatibility complex /DB_XREF = gi: 804748 /UG = Hs.77961 major histocompatibility complex, class I, B /FL = gb: L37880.1 gb: U29057.1 gb: U29480.1 gb: U63653.1 gb: D85761.1 gb: D85762.1 gb: M77774.1 gb: M77778.1 gb: M77777.1 gb: M16102.1 gb: M84380.1 gb: M32317.1 gb: M24033.1 gb: L17005.1 gb: U88407.1 gb: U29083.1 gb: L24373.1 gb: U03698.1 gb: U04787.1 gb: U04244.1 gb: U04245.1 gb: NM_005514.1 gb: L33922.1 gb: AF189017.1 gb: U21052.1 gb: U21053.1 gb: L36318.1 gb: U09912.1 gb: L42024.1 203595_s_at Consensus includes gb: N47725 /FEA = EST /DB_XREF = gi: 1188891 /DB_XREF = est: yy92h11.s1 /CLONE = IMAGE: 281061 /UG = Hs.27610 retinoic acid- and interferon-inducible protein (58 kD) /FL = gb: U34605.1 gb: NM_012420.1 204780_s_at Consensus includes gb: AA164751 /FEA = EST /DB_XREF = gi: 1740929 /DB_XREF = est: zo93g12.s1 /CLONE = IMAGE: 594502 /UG = Hs.82359 tumor necrosis factor receptor superfamily, member 6 /FL = gb: M67454.1 gb: NM_000043.1 202481_at gb: NM_004753.1 /DEF = Homo sapiens short-chain dehydrogenasereductase 1 (SDR1), mRNA. /FEA = mRNA /GEN = SDR1 /PROD = short-chain dehydrogenasereductase 1 /DB_XREF = gi: 4759083 /UG = Hs.17144 short-chain dehydrogenasereductase 1 /FL = gb: BC002730.1 gb: AF061741.1 gb: NM_004753.1 208072_s_at gb: NM_003648.1 /DEF = Homo sapiens diacylglycerol kinase, delta (130 kD) (DGKD), mRNA. /FEA = mRNA /GEN = DGKD /PROD = diacylglycerol kinase, delta (130 kD) /DB_XREF = gi: 4503310 /UG = Hs.115907 diacylglycerol kinase, delta (130 kD) /FL = gb: D73409.1 gb: NM_003648.1 217502_at Consensus includes gb: BE888744 /FEA = EST /DB_XREF = gi: 10345354 /DB_XREF = est: 601513656F1 /CLONE = IMAGE: 3915133 /UG = Hs.169274 ESTs, Highly similar to IFT2_HUMAN INTERFERON-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 2 H. sapiens 205637_s_at gb: NM_003027.1 /DEF = Homo sapiens SH3-domain GRB2-like 3 (SH3GL3), mRNA. /FEA = mRNA /GEN = SH3GL3 /PROD = SH3-domain GRB2-like 3 /DB_XREF = gi: 4506932 /UG = Hs.80315 SH3-domain GRB2-like 3 /FL = gb: AF036269.1 gb: AF036270.1 gb: AF036271.1 gb: NM_003027.1 219732_at gb: NM_017753.1 /DEF = Homo sapiens hypothetical protein FLJ20300 (FLJ20300), mRNA. /FEA = mRNA /GEN = FLJ20300 /PROD = hypothetical protein FLJ20300 /DB_XREF = gi: 8923280 /UG = Hs.106825 hypothetical protein FLJ20300 /FL = gb: NM_017753.1 202877_s_at Consensus includes gb: W72082 /FEA = EST /DB_XREF = gi: 1382588 /DB_XREF = est: zd70c06.s1 /CLONE = IMAGE: 345994 /UG = Hs.97199 complement component C1q receptor /FL = gb: NM_012072.2 gb: U94333.1 215790_at Consensus includes gb: AA835004 /FEA = EST /DB_XREF = gi: 2908732 /DB_XREF = est: aj39d06.s1 /CLONE = IMAGE: 1392683 /UG = Hs.25924 hypothetical protein 214459_x_at Consensus includes gb: M12679.1 /DEF = Human Cw1 antigen mRNA, complete cds. /FEA = mRNA /GEN = HLA-C /DB_XREF = gi: 187911 /UG = Hs.274485 Cw1 antigen /FL = gb: M12679.1 202458_at gb: NM_007173.1 /DEF = Homo sapiens protease, serine, 23 (SPUVE), mRNA. /FEA = mRNA /GEN = SPUVE /PROD = protease, serine, 23 /DB_XREF = gi: 6005881 /UG = Hs.325820 protease, serine, 23 /FL = gb: AL136914.1 gb: BC001278.1 gb: AF015287.1 gb: NM_007173.1 gb: AF193611.1 204675_at gb: NM_001047.1 /DEF = Homo sapiens steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4- dehydrogenase alpha 1) (SRD5A1), mRNA. /FEA = mRNA /GEN = SRD5A1 /PROD = steroid-5-alpha-reductase, alpha polypeptide 1(3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) /DB_XREF = gi: 4507200 /UG = Hs.552 steroid-5- alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) /FL = gb: M32313.1 gb: AF052126.1 gb: NM_001047.1 203764_at gb: NM_014750.1 /DEF = Homo sapiens KIAA0008 gene product (KIAA0008), mRNA. /FEA = mRNA /GEN = KIAA0008 /PROD = KIAA0008 gene product /DB_XREF = gi: 7661851 /UG = Hs.77695 KIAA0008 gene product /FL = gb: D13633.1 gb: NM_014750.1 202557_at Consensus includes gb: AI718418 /FEA = EST /DB_XREF = gi: 5035674 /DB_XREF = est: as43b01.x1 /CLONE = IMAGE: 2319913 /UG = Hs.288799 stress 70 protein chaperone, microsome-associated, 60 kD /FL = gb: U04735.1 gb: NM_006948.1 220104_at gb: NM_020119.1 /DEF = Homo sapiens hypothetical protein FLB6421 (FLB6421), mRNA. /FEA = mRNA /GEN = FLB6421 /PROD = hypothetical protein FLB6421 /DB_XREF = gi: 9910221 /UG = Hs.35254 hypothetical protein FLB6421 /FL = gb: NM_020119.1 205259_at gb: NM_000901.1 /DEF = Homo sapiens nuclear receptor subfamily 3, group C, member 2 (NR3C2), mRNA. /FEA = mRNA /GEN = NR3C2 /PROD = nuclear receptor subfamily 3, group C, member 2 /DB_XREF = gi: 4505198 /UG = Hs.1790 nuclear receptor subfamily 3, group C, member 2 /FL = gb: M16801.1 gb: NM_000901.1 206167_s_at gb: NM_001174.2 /DEF = Homo sapiens Rho GTPase activating protein 6 (ARHGAP6), transcript variant 2, mRNA. /FEA = mRNA /GEN = ARHGAP6 /PROD = Rho GTPase activating protein 6 isoform 2 /DB_XREF = gi: 7382476 /UG = Hs.250830 Rho GTPase activating protein 6 /FL = gb: AF022212.2 gb: NM_001174.2 217567_at Consensus includes gb: BF222018 /FEA = EST /DB_XREF = gi: 11129195 /DB_XREF = est: 7p41a04.x1 /CLONE = IMAGE: 3648271 /UG = Hs.289803 ESTs, Moderately similar to S71105 protein-glutamine gamma- glutamyltransferase H. sapiens 208712_at gb: M73554.1 /DEF = Human bcl-1 mRNA, complete CDS. /FEA = mRNA /GEN = bcl-1 /PROD = bcl-1 /DB_XREF = gi: 179364 /UG = Hs.82932 cyclin D1 (PRAD1: parathyroid adenomatosis 1) /FL = gb: BC000076.1 gb: M73554.1 219429_at gb: NM_024306.1 /DEF = Homo sapiens fatty acid hydroxylase (FAAH), mRNA. /FEA = mRNA /GEN = FAAH /PROD = fatty acid hydroxylase /DB_XREF = gi: 13236537 /UG = Hs.249163 fatty acid hydroxylase /FL = gb: BC002679.1 gb: NM_024306.1 gb: BC004263.1 205844_at gb: NM_004666.1 /DEF = Homo sapiens vanin 1 (VNN1), mRNA. /FEA = mRNA /GEN = VNN1 /PROD = vanin 1 /DB_XREF = gi: 4759311 /UG = Hs.12114 vanin 1 /FL = gb: NM_004666.1 gb: U39664.1 203642_s_at gb: NM_014900.1 /DEF = Homo sapiens KIAA0977 protein (KIAA0977), mRNA. /FEA = mRNA /GEN = KIAA0977 /PROD = KIAA0977 protein /DB_XREF = gi: 7662427 /UG = Hs.300855 KIAA0977 protein /FL = gb: AB023194.1 gb: NM_014900.1 205126_at gb: NM_006296.1 /DEF = Homo sapiens vaccinia related kinase 2 (VRK2), mRNA. /FEA = mRNA /GEN = VRK2 /PROD = vaccinia related kinase 2 /DB_XREF = gi: 5454163 /UG = Hs.82771 vaccinia related kinase 2 /FL = gb: AB000450.1 gb: NM_006296.1 203921_at gb: NM_004267.1 /DEF = Homo sapiens carbohydrate (chondroitin 6keratan) sulfotransferase 2 (CHST2), mRNA. /FEA = mRNA /GEN = CHST2 /PROD = carbohydrate (chondroitin 6keratan)sulfotransferase 2 /DB_XREF = gi: 4757983 /UG = Hs.8786 carbohydrate (chondroitin 6keratan) sulfotransferase 2 /FL = gb: AB021124.1 gb: AB014679.1 gb: AB014680.1 gb: AF083066.1 gb: NM_004267.1 213274_s_at Consensus includes gb: AA020826 /FEA = EST /DB_XREF = gi: 1484570 /DB_XREF = est: ze64b04.s1 /CLONE = IMAGE: 363727 /UG = Hs.297939 cathepsin B 221058_s_at gb: NM_016326.2 /DEF = Homo sapiens chemokine-like factor 3, alternatively spliced (LOC51192), mRNA. /FEA = mRNA /GEN = LOC51192 /PROD = chemokine-like factor 3, alternatively spliced /DB_XREF = gi: 10092611 /UG = Hs.15159 chemokine-like factor, alternatively spliced /FL = gb: NM_016326.2 gb: AF135381.2 214451_at Consensus includes gb: NM_003221.1 /DEF = Homo sapiens transcription factor AP-2 beta (activating enhancer-binding protein 2 beta) (TFAP2B), mRNA. /FEA = CDS /GEN = TFAP2B /PROD = transcription factor AP-2 beta (activating enhancer-binding protein 2 beta) /DB_XREF = gi: 4507442 /UG = Hs.33102 transcription factor AP-2 beta (activating enhancer-binding protein 2 beta) /FL = gb: NM_003221.1 207254_at gb: NM_005073.1 /DEF = Homo sapiens solute carrier family 15 (oligopeptide transporter), member 1 (SLC15A1), mRNA. /FEA = mRNA /GEN = SLC15A1 /PROD = solute carrier family 15 (oligopeptide transporter), member 1 /DB_XREF = gi: 4827007 /UG = Hs.2217 solute carrier family 15 (oligopeptide transporter), member 1 /FL = gb: AF043233.1 gb: NM_005073.1 gb: U21936.1 gb: U13173.1 207565_s_at gb: NM_001531.1 /DEF = Homo sapiens major histocompatibility complex, class I-like sequence (HLALS), mRNA. /FEA = mRNA /GEN = HLALS /PROD = major histocompatibility complex, class I-like sequence /DB_XREF = gi: 4504416 /UG = Hs.101840 major histocompatibility complex, class I-like sequence /FL = gb: NM_001531.1 gb: U22963.1 213939_s_at Consensus includes gb: AI871641 /FEA = EST /DB_XREF = gi: 5545690 /DB_XREF = est: we28f04.x1 /CLONE = IMAGE: 2342431 /UG = Hs.306623 Homo sapiens cDNA FLJ12012 fis, clone HEMBB1001668 208998_at gb: U94592.1 /DEF = Human uncoupling protein homolog (UCPH) mRNA, complete cds. /FEA = mRNA /GEN = UCPH /PROD = uncoupling protein homolog /DB_XREF = gi: 2052354 /UG = Hs.80658 uncoupling protein 2 (mitochondrial, proton carrier) /FL = gb: NM_003355.2 gb: U76367.1 gb: U82819.1 gb: U94592.1 221665_s_at gb: BC004907.1 /DEF = Homo sapiens, Similar to RIKEN cDNA 4632407K17 gene, clone MGC: 4642, mRNA, complete cds. /FEA = mRNA /PROD = Similar to RIKEN cDNA 4632407K17 gene /DB_XREF = gi: 13436193 /UG = Hs.28907 hypothetical protein FLJ20258 /FL = gb: BC004907.1 216231_s_at Consensus includes gb: AW188940 /FEA = EST /DB_XREF = gi: 6463376 /DB_XREF = est: xk90f09.x1 /CLONE = IMAGE: 2674025 /UG = Hs.75415 beta-2-microglobulin 200958_s_at gb: NM_005625.1 /DEF = Homo sapiens syndecan binding protein (syntenin) (SDCBP), mRNA. /FEA = mRNA /GEN = SDCBP /PROD = syndecan binding protein (syntenin) /DB_XREF = gi: 5032082 /UG = Hs.8180 syndecan binding protein (syntenin) /FL = gb: AF000652.1 gb: NM_005625.1 202644_s_at gb: NM_006290.1 /DEF = Homo sapiens tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), mRNA. /FEA = mRNA /GEN = TNFAIP3 /PROD = tumor necrosis factor, alpha-induced protein 3 /DB_XREF = gi: 5454131 /UG = Hs.211600 tumor necrosis factor, alpha-induced protein 3 /FL = gb: M59465.1 gb: NM_006290.1 206995_x_at gb: NM_003693.1 /DEF = Homo sapiens acetyl LDL receptor; SREC = scavenger receptor expressed by endothelial cells (SREC), mRNA. /FEA = mRNA /GEN = SREC /PROD = acetyl LDL receptor; SREC = scavenger receptor expressed by endothelial cells /DB_XREF = gi: 4507202 /UG = Hs.57735 acetyl LDL receptor; SREC /FL = gb: D63483.1 gb: D86864.1 gb: NM_003693.1 218935_at gb: NM_014600.1 /DEF = Homo sapiens EH-domain containing 3 (EHD3), mRNA. /FEA = mRNA /GEN = EHD3 /PROD = EH-domain containing 3 /DB_XREF = gi: 7657055 /UG = Hs.87125 EH-domain containing 3 /FL = gb: AF214736.1 gb: AF181264.1 gb: NM_014600.1 210314_x_at gb: AF114013.1 /DEF = Homo sapiens tumor necrosis factor-related death ligand-1gamma mRNA, complete cds. /FEA = mRNA /PROD = tumor necrosis factor-related death ligand-1gamma /DB_XREF = gi: 7328557 /UG = Hs.54673 tumor necrosis factor (ligand) superfamily, member 13 /FL = gb: AF136294.1 gb: AF114013.1 219334_s_at gb: NM_022837.1 /DEF = Homo sapiens hypothetical protein FLJ22833 (FLJ22833), mRNA. /FEA = mRNA /GEN = FLJ22833 /PROD = hypothetical protein FLJ22833 /DB_XREF = gi: 12383083 /UG = Hs.118183 hypothetical protein FLJ22833 /FL = gb: NM_022837.1 205005_s_at Consensus includes gb: AW293531 /FEA = EST /DB_XREF = gi: 6700167 /DB_XREF = est: UI-H-BI2-ahq-d-03-0-UI.s1 /CLONE = IMAGE: 2727604 /UG = Hs.122647 N-myristoyltransferase 2 /FL = gb: AF043325.1 gb: NM_004808.1 209762_x_at gb: AF280094.1 /DEF = Homo sapiens transcriptional coactivator Sp110b mRNA, complete cds. /FEA = mRNA /PROD = transcriptional coactivator Sp110b /DB_XREF = gi: 9800493 /UG = Hs.38125 interferon-induced protein 75, 52 kD /FL = gb: AF280094.1 217648_at Consensus includes gb: AW295367 /FEA = EST /DB_XREF = gi: 6702003 /DB_XREF = est: UI-H-BI2-ahv-e-04-0-UI.s1 /CLONE = IMAGE: 2728039 /UG = Hs.196585 ESTs, Weakly similar to Pro-Pol-dUTPase polyprotein M. musculus 201329_s_at gb: NM_005239.1 /DEF = Homo sapiens v-ets avian erythroblastosis virus E26 oncogene homolog 2 (ETS2), mRNA. /FEA = mRNA /GEN = ETS2 /PROD = v-ets avian erythroblastosis virus E26 oncogene homolog 2 /DB_XREF = gi: 4885220 /UG = Hs.85146 v-ets avian erythroblastosis virus E26 oncogene homolog 2 /FL = gb: J04102.1 gb: NM_005239.1 202270_at gb: NM_002053.1 /DEF = Homo sapiens guanylate binding protein 1, interferon-inducible, 67 kD (GBP1), mRNA. /FEA = mRNA /GEN = GBP1 /PROD = guanylate binding protein 1, interferon-inducible, 67 kD /DB_XREF = gi: 4503938 /UG = Hs.62661 guanylate binding protein 1, interferon-inducible, 67 kD /FL = gb: BC002666.1 gb: M55542.1 gb: NM_002053.1 215908_at Consensus includes gb: AF009267.1 /DEF = Homo sapiens clone FBA1 Cri-du-chat region mRNA. /FEA = mRNA /DB_XREF = gi: 2331069 /UG = Hs.102238 Homo sapiens clone FBA1 Cri-du-chat region mRNA 215146_s_at Consensus includes gb: AB028966.1 /DEF = Homo sapiens mRNA for KIAA1043 protein, partial cds. /FEA = mRNA /GEN = KIAA1043 /PROD = KIAA1043 protein /DB_XREF = gi: 5689422 /UG = Hs.11390 KIAA1043 protein 218259_at gb: NM_014048.1 /DEF = Homo sapiens KIAA1243 protein (KIAA1243), mRNA. /FEA = mRNA /GEN = KIAA1243 /PROD = NPD001 protein /DB_XREF = gi: 7662513 /UG = Hs.151076 KIAA1243 protein /FL = gb: AF078853.1 gb: NM_014048.1 209759_s_at gb: BC002746.1 /DEF = Homo sapiens, Similar to dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A isomerase), clone MGC: 3903, mRNA, complete cds. /FEA = mRNA /PROD = Similar to dodecenoyl-Coenzyme A delta isomerase(3,2 trans-enoyl-Coenzyme A isomerase) /DB_XREF = gi: 12803812 /UG = Hs.322824 Homo sapiens, Similar to dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A isomerase), clone MGC: 3903, mRNA, complete cds /FL = gb: BC002746.1 218440_at gb: NM_020166.2 /DEF = Homo sapiens methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) (MCCC1), mRNA. /FEA = mRNA /GEN = MCCC1 /PROD = methylcrotonoyl-Coenzyme A carboxylase 1(alpha) /DB_XREF = gi: 13518227 /UG = Hs.47649 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) /FL = gb: AF310339.1 gb: AF310972.1 gb: BC004187.1 gb: BC004214.1 gb: NM_020166.2 gb: AB029826.1 209392_at gb: L35594.1 /DEF = Human autotaxin mRNA, complete cds. /FEA = mRNA /PROD = autotaxin /DB_XREF = gi: 537905 /UG = Hs.174185 ectonucleotide pyrophosphatasephos phodiesterase 2 (autotaxin) /FL = gb: L35594.1 202803_s_at gb: NM_000211.1 /DEF = Homo sapiens integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) (ITGB2), mRNA. /FEA = mRNA /GEN = ITGB2 /PROD = integrin beta chain, beta 2 precursor /DB_XREF = gi: 4557885 /UG = Hs.83968 integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) /FL = gb: NM_000211.1 219377_at gb: NM_022751.1 /DEF = Homo sapiens hypothetical protein FLJ21610 (FLJ21610), mRNA. /FEA = mRNA /GEN = FLJ21610 /PROD = hypothetical protein FLJ21610 /DB_XREF = gi: 12232414 /UG = Hs.12727 hypothetical protein FLJ21610 /FL = gb: NM_022751.1 218671_s_at gb: NM_016311.1 /DEF = Homo sapiens ATPase inhibitor precursor (LOC51189), mRNA. /FEA = mRNA /GEN = LOC51189 /PROD = ATPase inhibitor precursor /DB_XREF = gi: 7705926 /UG = Hs.241336 ATPase inhibitor precursor /FL = gb: BC004955.1 gb: AB029042.1 gb: NM_016311.1 201337_s_at gb: NM_004781.2 /DEF = Homo sapiens vesicle-associated membrane protein 3 (cellubrevin) (VAMP3), mRNA. /FEA = mRNA /GEN = VAMP3 /PROD = vesicle-associated membrane protein 3 /DB_XREF = gi: 9257252 /UG = Hs.66708 vesicle-associated membrane protein 3 (cellubrevin) /FL = gb: BC003570.1 gb: NM_004781.2 204786_s_at gb: L41944.1 /DEF = Homo sapiens interferon receptor ifnar2-1 (splice variant IFNAR2-1) mRNA, complete cds. /FEA = mRNA /GEN = IFNAR2 /PROD = interferon receptor /DB_XREF = gi: 995296 /UG = Hs.86958 interferon (alpha, beta and omega) receptor 2 /FL = gb: NM_000874.1 gb: L41944.1 203021_at gb: NM_003064.1 /DEF = Homo sapiens secretory leukocyte protease inhibitor (antileukoproteinase) (SLPI), mRNA. /FEA = mRNA /GEN = SLPI /PROD = secretory leukocyte protease inhibitor(antileukoproteinase) /DB_XREF = gi: 4507064 /UG = Hs.251754 secretory leukocyte protease inhibitor (antileukoproteinase) /FL = gb: NM_003066.1 gb: AF114471.1 gb: NM_003064.1 214211_at Consensus includes gb: AA083483 /FEA = EST /DB_XREF = gi: 1625544 /DB_XREF = est: zn32a06.s1 /CLONE = IMAGE: 549106 /UG = Hs.62954 ferritin, heavy polypeptide 1 218876_at gb: NM_016140.1 /DEF = Homo sapiens brain specific protein (LOC51673), mRNA. /FEA = mRNA /GEN = LOC51673 /PROD = brain specific protein /DB_XREF = gi: 7706392 /UG = Hs.279772 brain specific protein /FL = gb: BC000691.1 gb: AF132972.1 gb: AF078846.1 gb: NM_015964.1 gb: NM_016140.1 201089_at gb: NM_001693.1 /DEF = Homo sapiens ATPase, H+ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 5658 kD, isoform 2 (ATP6B2), mRNA. /FEA = mRNA /GEN = ATP6B2 /PROD = ATPase, H+ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 5658 kD, isoform 2 /DB_XREF = gi: 4502310 /UG = Hs.1697 ATPase, H+ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 5658 kD, isoform 2 /FL = gb: BC003100.1 gb: NM_001693.1 gb: L35249.1 213638_at Consensus includes gb: AW054711 /FEA = EST /DB_XREF = gi: 5920414 /DB_XREF = est: wz96g08.x1 /CLONE = IMAGE: 2566718 /UG = Hs.121591 Human DNA sequence from PAC 257A7 on chromosome 6p24. Contains two unknown genes and ESTs, STSs and a GSS 206130_s_at gb: NM_001181.1 /DEF = Homo sapiens asialoglycoprotein receptor 2 (ASGR2), mRNA. /FEA = mRNA /GEN = ASGR2 /PROD = asialoglycoprotein receptor 2 /DB_XREF = gi: 4502252 /UG = Hs.1259 asialoglycoprotein receptor 2 /FL = gb: M11025.1 gb: NM_001181.1 205014_at gb: NM_005130.1 /DEF = Homo sapiens heparin-binding growth factor binding protein (HBP17), mRNA. /FEA = mRNA /GEN = HBP17 /PROD = heparin-binding growth factor binding protein /DB_XREF = gi: 4826753 /UG = Hs.1690 heparin- binding growth factor binding protein /FL = gb: BC003628.1 gb: M60047.1 gb: NM_005130.1 221713_s_at gb: BC006434.1 /DEF = Homo sapiens, hypothetical protein FLJ12748, clone MGC: 13089, mRNA, complete cds. /FEA = mRNA /PROD = hypothetical protein FLJ12748 /DB_XREF = gi: 13623628 /FL = gb: BC006434.1 206683_at gb: NM_003447.1 /DEF = Homo sapiens zinc finger protein 165 (ZNF165), mRNA. /FEA = mRNA /GEN = ZNF165 /PROD = zinc finger protein 165 /DB_XREF = gi: 4508000 /UG = Hs.55481 zinc finger protein 165 /FL = gb: U78722.1 gb: NM_003447.1 202084_s_at gb: NM_003003.1 /DEF = Homo sapiens SEC14 (S. cerevisiae)-like 1 (SEC14L1), mRNA. /FEA = mRNA /GEN = SEC14L1 /PROD = SEC14 (S. cerevisiae)-like 1 /DB_XREF = gi: 4506866 /UG = Hs.75232 SEC14 (S. cerevisiae)- like 1 /FL = gb: D67029.1 gb: NM_003003.1 211694_at gb: AF348076.1 /DEF = Homo sapiens serinethreonine kinase FKSG81 (FKSG81) mRNA, complete cds. /FEA = mRNA /GEN = FKSG81 /PROD = serinethreonine kinase FKSG81 /DB_XREF = gi: 13540323 /FL = gb: AF348076.1 212481_s_at Consensus includes gb: AI214061 /FEA = EST /DB_XREF = gi: 3777662 /DB_XREF = est: ap29d10.x1 /CLONE = IMAGE: 1956787 /UG = Hs.250641 tropomyosin 4 205796_at gb: NM_018393.1 /DEF = Homo sapiens hypothetical protein FLJ11336 (FLJ11336), mRNA. /FEA = mRNA /GEN = FLJ11336 /PROD = hypothetical protein FLJ11336 /DB_XREF = gi: 8922998 /UG = Hs.22383 hypothetical protein FLJ11336 /FL = gb: NM_018393.1 209731_at gb: U79718.1 /DEF = Human endonuclease III homolog 1 (OCTS3) mRNA, complete cds. /FEA = mRNA /GEN = OCTS3 /PROD = endonuclease III homolog 1, hNTH1 /DB_XREF = gi: 1800270 /UG = Hs.66196 nth (E. coli endonuclease III)-like 1 /FL = gb: BC000391.1 gb: BC003014.1 gb: U81285.1 gb: U79718.1 gb: AB001575.1 gb: NM_002528.3 212104_s_at Consensus includes gb: N95026 /FEA = EST /DB_XREF = gi: 1267308 /DB_XREF = est: zb45d12.s1 /CLONE = IMAGE: 306551 /UG = Hs.5011 RNA binding motif protein 9 205801_s_at gb: NM_015376.1 /DEF = Homo sapiens KIAA0846 protein (KIAA0846), mRNA. /FEA = mRNA /GEN = KIAA0846 /PROD = KIAA0846 protein /DB_XREF = gi: 7662333 /UG = Hs.24024 KIAA0846 protein /FL = gb: AB020653.1 gb: NM_015376.1 211064_at gb: BC006408.1 /DEF = Homo sapiens, Similar to zinc finger protein 254, clone MGC: 10544, mRNA, complete cds. /FEA = mRNA /PROD = Similar to zinc finger protein 254 /DB_XREF = gi: 13623586 /FL = gb: BC006408.1 209502_s_at gb: BC002495.1 /DEF = Homo sapiens, Similar to BAI1-associated protein 2, clone MGC: 1836, mRNA, complete cds. /FEA = mRNA /PROD = Similar to BAI1-associated protein 2 /DB_XREF = gi: 12803352 /UG = Hs.7936 BAI1-associated protein 2 /FL = gb: BC002495.1 216158_at Consensus includes gb: AK024123.1 /DEF = Homo sapiens cDNA FLJ14061 fis, clone HEMBB1000749. /FEA = mRNA /DB_XREF = gi: 10436427 /UG = Hs.306664 Homo sapiens cDNA FLJ14061 fis, clone HEMBB1000749 210017_at Consensus includes gb: AF070528.1 /DEF = Homo sapiens clone 24631 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 3387883 /UG = Hs.180566 mucosa associated lymphoid tissue lymphoma translocation gene 1 /FL = gb: AB026118.1 212014_x_at Consensus includes gb: AI493245 /FEA = EST /DB_XREF = gi: 4394248 /DB_XREF = est: ti30d08.x1 /CLONE = IMAGE: 2131983 /UG = Hs.169610 CD44 antigen (homing function and Indian blood group system) 209875_s_at gb: M83248.1 /DEF = Human nephropontin mRNA, complete cds. /FEA = mRNA /GEN = nephropontin /PROD = nephropontin /DB_XREF = gi: 189150 /UG = Hs.313 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) /FL = gb: M83248.1 207945_s_at gb: NM_001893.1 /DEF = Homo sapiens casein kinase 1, delta (CSNK1D), mRNA. /FEA = mRNA /GEN = CSNK1D /PROD = casein kinase 1, delta /DB_XREF = gi: 4503090 /UG = Hs.75852 casein kinase 1, delta /FL = gb: NM_001893.1 gb: U29171.1 219874_at gb: NM_024628.1 /DEF = Homo sapiens hypothetical protein FLJ23188 (FLJ23188), mRNA. /FEA = mRNA /GEN = FLJ23188 /PROD = hypothetical protein FLJ23188 /DB_XREF = gi: 13375853 /UG = Hs.36793 hypothetical protein FLJ23188 /FL = gb: NM_024628.1 206715_at gb: NM_012252.1 /DEF = Homo sapiens transcription factor EC (TFEC), mRNA. /FEA = mRNA /GEN = TFEC /PROD = transcription factor EC /DB_XREF = gi: 6912701 /UG = Hs.113274 transcription factor EC /FL = gb: D43945.1 gb: NM_012252.1 200727_s_at Consensus includes gb: AA699583 /FEA = EST /DB_XREF = gi: 2703730 /DB_XREF = est: zi42g07.s1 /CLONE = IMAGE: 433500 /UG = Hs.42915 ARP2 (actin-related protein 2, yeast) homolog /FL = gb: AF006082.1 gb: NM_005722.1 220034_at gb: NM_007199.1 /DEF = Homo sapiens interleukin-1 receptor-associated kinase M (IRAK-M), mRNA. /FEA = mRNA /GEN = IRAK-M /PROD = interleukin-1 receptor-associated kinase M /DB_XREF = gi: 6005791 /UG = Hs.268552 interleukin-1 receptor-associated kinase M /FL = gb: AF113136.1 gb: NM_007199.1 212577_at Consensus includes gb: AA868754 /FEA = EST /DB_XREF = gi: 2964199 /DB_XREF = est: ak52e09.s1 /CLONE = IMAGE: 1409608 /UG = Hs.8118 KIAA0650 protein 205038_at Consensus includes gb: BG540504 /FEA = EST /DB_XREF = gi: 13532737 /DB_XREF = est: 602569230F1 /CLONE = IMAGE: 4693783 /UG = Hs.54452 zinc finger protein, subfamily 1A, 1 (Ikaros) /FL = gb: U40462.1 gb: NM_006060.1 219298_at gb: NM_024693.1 /DEF = Homo sapiens hypothetical protein FLJ20909 (FLJ20909), mRNA. /FEA = mRNA /GEN = FLJ20909 /PROD = hypothetical protein FLJ20909 /DB_XREF = gi: 13375972 /UG = Hs.98855 hypothetical protein FLJ20909 /FL = gb: NM_024693.1 219718_at gb: NM_018291.1 /DEF = Homo sapiens hypothetical protein FLJ10986 (FLJ10986), mRNA. /FEA = mRNA /GEN = FLJ10986 /PROD = hypothetical protein FLJ10986 /DB_XREF = gi: 8922805 /UG = Hs.273333 hypothetical protein FLJ10986 /FL = gb: BC000610.1 gb: NM_018291.1 204753_s_at Consensus includes gb: AI810712 /FEA = EST /DB_XREF = gi: 5397278 /DB_XREF = est: tt86f08.x1 /CLONE = IMAGE: 2248455 /UG = Hs.250692 hepatic leukemia factor /FL = gb: M95585.1 gb: NM_002126.1 202052_s_at gb: NM_015577.1 /DEF = Homo sapiens novel retinal pigment epithelial gene (NORPEG), mRNA. /FEA = mRNA /GEN = NORPEG /PROD = DKFZP564G013 protein /DB_XREF = gi: 13470085 /UG = Hs.15165 novel retinal pigment epithelial gene /FL = gb: NM_015577.1 gb: AF155135.1 215716_s_at Consensus includes gb: L14561 /DEF = Homo sapiens plasma membrane calcium ATPase isoform 1 (ATP2B1) gene, alternative splice products, partial cds /FEA = mRNA_2 /DB_XREF = gi: 4165324 /UG = Hs.78546 ATPase, Ca++ transporting, plasma membrane 1 211911_x_at gb: L07950.1 /DEF = Homo sapiens MHC class I HLA B71 mRNA, complete cds. /FEA = CDS /GEN = HLA-B /PROD = MHC HLA B71 /DB_XREF = gi: 307236 /FL = gb: L07950.1 203439_s_at gb: BC000658.1 /DEF = Homo sapiens, stanniocalcin 2, clone MGC: 1881, mRNA, complete cds. /FEA = mRNA /PROD = stanniocalcin 2 /DB_XREF = gi: 12653744 /UG = Hs.155223 stanniocalcin 2 /FL = gb: BC000658.1 gb: AF055460.1 gb: AB012664.1 gb: AF098462.1 gb: AF031036.1 gb: NM_003714.1 210136_at Consensus includes gb: AW070431 /FEA = EST /DB_XREF = gi: 6025429 /DB_XREF = est: xa11b04.x1 /CLONE = IMAGE: 2567983 /UG = Hs.69547 myelin basic protein /FL = gb: L18865.1 201189_s_at gb: NM_002224.1 /DEF = Homo sapiens inositol 1,4,5-triphosphate receptor, type 3 (ITPR3), mRNA. /FEA = mRNA /GEN = ITPR3 /PROD = inositol 1,4,5-triphosphate receptor, type 3 /DB_XREF = gi: 4504794 /UG = Hs.77515 inositol 1,4,5- triphosphate receptor, type 3 /FL = gb: D26351.1 gb: NM_002224.1 gb: U01062.1 202014_at gb: NM_014330.2 /DEF = Homo sapiens growth arrest and DNA-damage-inducible 34 (GADD34), mRNA. /FEA = mRNA /GEN = GADD34 /PROD = growth arrest and DNA-damage-inducible 34 /DB_XREF = gi: 9790902 /UG = Hs.76556 growth arrest and DNA-damage-inducible 34 /FL = gb: BC003067.1 gb: U83981.1 gb: NM_014330.2 200634_at gb: NM_005022.1 /DEF = Homo sapiens profilin 1 (PFN1), mRNA. /FEA = mRNA /GEN = PFN1 /PROD = profilin 1 /DB_XREF = gi: 4826897 /UG = Hs.75721 profilin 1 /FL = gb: BC002475.1 gb: J03191.1 gb: NM_005022.1 203675_at gb: NM_005013.1 /DEF = Homo sapiens nucleobindin 2 (NUCB2), mRNA. /FEA = mRNA /GEN = NUCB2 /PROD = nucleobindin 2 /DB_XREF = gi: 4826869 /UG = Hs.3164 nucleobindin 2 /FL = gb: AF052642.1 gb: AF052643.1 gb: AF052644.1 gb: NM_005013.1 221124_s_at gb: NM_014588.2 /DEF = Homo sapiens visual system homeobox 1 (zebrafish) homolog (CHX10-like) (VSX1), mRNA. /FEA = mRNA /GEN = VSX1 /PROD = visual system homeobox 1 (zebrafish) homolog(CHX10-like) /DB_XREF = gi: 11056037 /UG = Hs.274264 visual system homeobox 1 (zebrafish) homolog (CHX10-like) /FL = gb: AF176797.2 gb: NM_014588.2 gb: AF251033.1 214251_s_at Consensus includes gb: AI337584 /FEA = EST /DB_XREF = gi: 4074511 /DB_XREF = est: qw91a01.x1 /CLONE = IMAGE: 1998408 /UG = Hs.301512 nuclear mitotic apparatus protein 1 210868_s_at gb: BC001305.1 /DEF = Homo sapiens, clone MGC: 5487, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 5487) /DB_XREF = gi: 12654918 /UG = Hs.211556 hypothetical protein MGC5487 /FL = gb: BC001305.1 201179_s_at gb: J03005.1 /DEF = Human alternative guanine nucleotide-binding regulatory protein (G) alpha-inhibitory-subunit mRNA, complete cds. /FEA = mRNA /GEN = GNAI1 /DB_XREF = gi: 183183 /UG = Hs.73799 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 /FL = gb: J03005.1 gb: J03198.1 gb: M27543.1 gb: J03238.1 gb: NM_006496.1 205289_at Consensus includes gb: AA583044 /FEA = EST /DB_XREF = gi: 2360404 /DB_XREF = est: nn80f11.s1 /CLONE = IMAGE: 1090221 /UG = Hs.73853 bone morphogenetic protein 2 /FL = gb: NM_001200.1 217894_at gb: NM_016121.1 /DEF = Homo sapiens NY-REN-45 antigen (LOC51133), mRNA. /FEA = mRNA /GEN = LOC51133 /PROD = NY-REN-45 antigen /DB_XREF = gi: 7705836 /UG = Hs.239155 NY-REN-45 antigen /FL = gb: AF155110.1 gb: NM_016121.1 213486_at Consensus includes gb: BF435376 /FEA = EST /DB_XREF = gi: 11447664 /DB_XREF = est: nab38h02.x1 /CLONE = IMAGE: 3268442 /UG = Hs.6421 hypothetical protein DKFZp761N09121 208955_at gb: AB049113.1 /DEF = Homo sapiens DUT mRNA for dUTP pyrophosphatase, complete cds. /FEA = mRNA /GEN = DUT /PROD = dUTP pyrophosphatase /DB_XREF = gi: 10257384 /UG = Hs.82113 dUTP pyrophosphatase /FL = gb: AB049113.1 gb: U31930.1 gb: U62891.1 gb: M89913.1 gb: NM_001948.1 202020_s_at gb: NM_006055.1 /DEF = Homo sapiens LanC (bacterial lantibiotic synthetase component C)-like 1 (LANCL1), mRNA. /FEA = mRNA /GEN = LANCL1 /PROD = lanthionine synthetase C-like protein 1 /DB_XREF = gi: 5174444 /UG = Hs.13351 LanC (bacterial lantibiotic synthetase component C)-like 1 /FL = gb: NM_006055.1 214209_s_at Consensus includes gb: BE504895 /FEA = EST /DB_XREF = gi: 9707303 /DB_XREF = est: hz32b07.x1 /CLONE = IMAGE: 3209653 /UG = Hs.6129 ATP-binding cassette, sub-family B (MDRTAP), member 9 202364_at gb: NM_005962.1 /DEF = Homo sapiens MAX-interacting protein 1 (MXI1), mRNA. /FEA = mRNA /GEN = MXI1 /PROD = MAX-interacting protein 1 /DB_XREF = gi: 5174596 /UG = Hs.118630 MAX-interacting protein 1 /FL = gb: L07648.1 gb: NM_005962.1 gb: D63940.1 207660_at gb: NM_004019.1 /DEF = Homo sapiens dystrophin (muscular, dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272 (DMD), transcript variant Dp40, mRNA. /FEA = mRNA /GEN = DMD /PROD = dystrophin Dp40 isoform /DB_XREF = gi: 5032304 /UG = Hs.169470 dystrophin (muscular dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272 /FL = gb: NM_004019.1 209627_s_at gb: AY008372.1 /DEF = Homo sapiens oxysterol binding protein-related protein 3 (ORP3) mRNA, complete cds. /FEA = mRNA /GEN = ORP3 /PROD = oxysterol binding protein-related protein 3 /DB_XREF = gi: 10880972 /UG = Hs.197955 KIAA0704 protein /FL = gb: AY008372.1 204733_at gb: NM_002774.1 /DEF = Homo sapiens kallikrein 6 (neurosin, zyme) (KLK6), mRNA. /FEA = mRNA /GEN = KLK6 /PROD = kallikrein 6 (neurosin, zyme) /DB_XREF = gi: 4506154 /UG = Hs.79361 kallikrein 6 (neurosin, zyme) /FL = gb: U62801.1 gb: D78203.1 gb: AF013988.1 gb: NM_002774.1 201335_s_at gb: NM_015313.1 /DEF = Homo sapiens KIAA0382 protein; leukemia-associated rho guanine nucleotide exchange factor (GEF) (ARHGEF12), mRNA. /FEA = mRNA /GEN = ARHGEF12 /PROD = KIAA0382 protein; leukemia-associated rhoguanine nucleotide exchange factor (GEF) /DB_XREF = gi: 7662087 /UG = Hs.6582 Rho guanine exchange factor (GEF) 12 /FL = gb: AF180681.1 gb: NM_015313.1 204357_s_at gb: NM_002314.2 /DEF = Homo sapiens LIM domain kinase 1 (LIMK1), transcript variant 1, mRNA. /FEA = mRNA /GEN = LIMK1 /PROD = LIM domain kinase 1 isoform 1 /DB_XREF = gi: 8051616 /UG = Hs.36566 LIM domain kinase 1 /FL = gb: D26309.1 gb: NM_002314.2 209721_s_at gb: BC002857.1 /DEF = Homo sapiens, clone MGC: 3442, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 3442) /DB_XREF = gi: 12804008 /UG = Hs.46659 DKFZP586I2223 protein /FL = gb: BC002857.1 gb: BC001790.1 gb: NM_015438.1 gb: BC004384.1 217998_at Consensus includes gb: NM_007350.1 /DEF = Homo sapiens pleckstrin homology-like domain, family A, member 1 (PHLDA1), mRNA. /FEA = mRNA /GEN = PHLDA1 /PROD = pleckstrin homology-like domain, family A, member 1 /DB_XREF = gi: 6679302 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 208228_s_at gb: M87771.1 /DEF = Human secreted fibroblast growth factor receptor (K-sam-III) mRNA, complete cds. /FEA = mRNA /GEN = K-sam-III /PROD = fibroblast growth factor receptor /DB_XREF = gi: 186781 /UG = Hs.278581 fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) /FL = gb: NM_022970.1 gb: M87771.1 215313_x_at Consensus includes gb: AA573862 /FEA = EST /DB_XREF = gi: 2348377 /DB_XREF = est: nk08f01.s1 /CLONE = IMAGE: 1012921 /UG = Hs.181244 major histocompatibility complex, class I, A 220005_at gb: NM_023914.1 /DEF = Homo sapiens G protein-coupled receptor 86 (GPR86), mRNA. /FEA = mRNA /GEN = GPR86 /PROD = G protein-coupled receptor 86 /DB_XREF = gi: 13194202 /UG = Hs.13040 G protein-coupled receptor 86 /FL = gb: AF295368.1 gb: NM_023914.1 gb: AF178982.1 gb: AF345565.1 217916_s_at gb: NM_016623.1 /DEF = Homo sapiens hypothetical protein (BM-009), mRNA. /FEA = mRNA /GEN = BM-009 /PROD = hypothetical protein /DB_XREF = gi: 7705303 /UG = Hs.92918 hypothetical protein /FL = gb: BC003599.1 gb: AF208851.1 gb: NM_016623.1 216718_at Consensus includes gb: AF005082.1 /DEF = Homo sapiens skin-specific protein (xp33) mRNA, partial cds. /FEA = mRNA /GEN = xp33 /PROD = skin-specific protein /DB_XREF = gi: 2589191 /UG = Hs.113261 Homo sapiens skin-specific protein (xp33) mRNA, partial cds 217794_at gb: NM_018457.1 /DEF = Homo sapiens DKFZp564J157 protein (DKFZP564J157), mRNA. /FEA = mRNA /GEN = DKFZP564J157 /PROD = DKFZp564J157 protein /DB_XREF = gi: 8922156 /UG = Hs.63042 DKFZp564J157 protein /FL = gb: AF217517.1 gb: NM_018457.1 204867_at gb: NM_005258.2 /DEF = Homo sapiens GTP cyclohydrolase I feedback regulatory protein (GCHFR), mRNA. /FEA = mRNA /GEN = GCHFR /PROD = GTP cyclohydrolase I feedback regulatory protein /DB_XREF = gi: 6382072 /UG = Hs.83081 GTP cyclohydrolase I feedback regulatory protein /FL = gb: NM_005258.2 218189_s_at gb: NM_018946.2 /DEF = Homo sapiens N-acetylneuraminic acid phosphate synthase; sialic acid synthase (SAS), mRNA. /FEA = mRNA /GEN = SAS /PROD = N-acetylneuraminic acid phosphate synthase /DB_XREF = gi: 12056472 /UG = Hs.274424 N-acetylneuraminic acid phosphate synthase; sialic acid synthase /FL = gb: NM_018946.2 gb: BC000008.1 gb: AF257466.1 201042_at Consensus includes gb: AL031651 /DEF = Human DNA sequence from clone RP5-1054A22 on chromosome 20q11.22-12 Contains two isoforms of the gene for TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma- glutamyltransferase), ESTs, STSs, GSSs and a CpG island /FEA = mRNA_1 /DB_XREF = gi: 6065866 /UG = Hs.8265 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) /FL = gb: M55153.1 gb: NM_004613.1 218502_s_at gb: NM_014112.1 /DEF = Homo sapiens trichorhinophalangeal syndrome I gene (TRPS1), mRNA. /FEA = mRNA /GEN = TRPS1 /PROD = trichorhinophalangeal syndrome I gene /DB_XREF = gi: 7657658 /UG = Hs.26102 trichorhinophalangeal syndrome I /FL = gb: AF183810.1 gb: NM_014112.1 201906_s_at gb: NM_005808.1 /DEF = Homo sapiens HYA22 protein (HYA22), mRNA. /FEA = mRNA /GEN = HYA22 /PROD = HYA22 protein /DB_XREF = gi: 5031774 /UG = Hs.147189 HYA22 protein /FL = gb: D88153.1 gb: NM_005808.1 207173_x_at gb: D21254.1 /DEF = Human mRNA for OB-cadherin-1, complete cds. /FEA = mRNA /GEN = osf-4 /PROD = OB-cadherin- 1 /DB_XREF = gi: 575577 /UG = Hs.75929 cadherin 11, type 2, OB-cadherin (osteoblast) /FL = gb: NM_001797.1 gb: L34056.1 gb: D21254.1 200825_s_at gb: NM_006389.2 /DEF = Homo sapiens oxygen regulated protein (150 kD) (ORP150), mRNA. /FEA = mRNA /GEN = ORP150 /PROD = oxygen regulated protein precursor /DB_XREF = gi: 13699861 /UG = Hs.277704 oxygen regulated protein (150 kD) /FL = gb: NM_006389.2 gb: U65785.1 212068_s_at Consensus includes gb: AB011087.1 /DEF = Homo sapiens mRNA for KIAA0515 protein, partial cds. /FEA = mRNA /GEN = KIAA0515 /PROD = KIAA0515 protein /DB_XREF = gi: 3043553 /UG = Hs.108945 KIAA0515 protein 221485_at Consensus includes gb: AL035683 /DEF = Human DNA sequence from clone RP5-1063B2 on chromosome 20q13.1-13.2. Contains the 3 part of the gene for Beta-1,4-galactosyltransferase, ESTs, STSs and GSSs /FEA = mRNA /DB_XREF = gi: 7288039 /UG = Hs.107526 UDP-Gal: betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 /FL = gb: AB004550.1 gb: AF038663.1 gb: NM_004776.1 209834_at gb: AB017915.1 /DEF = Homo sapiens mRNA for chondroitin 6-sulfotransferase, complete cds. /FEA = mRNA /PROD = chondroitin 6-sulfotransferase /DB_XREF = gi: 4115403 /UG = Hs.158304 carbohydrate (chondroitin 6keratan) sulfotransferase 3 /FL = gb: AB017915.1 219540_at Consensus includes gb: AU150728 /FEA = EST /DB_XREF = gi: 11012249 /DB_XREF = est: AU150728 /CLONE = NT2RP2003470 /UG = Hs.145498 zinc finger protein 267 /FL = gb: NM_003414.2 gb: AF220492.1 217473_x_at Consensus includes gb: AF229163 /DEF = Homo sapiens natural resistance-associated macrophage protein 1 (SLC11A1) gene, complete cds, alternatively spliced; and nuclear LIM interactor-interacting factor (NLI-IF) gene, complete cds /FEA = mRNA_3 /DB_XREF = gi: 10257408 /UG = Hs.182611 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 220751_s_at gb: NM_016348.1 /DEF = Homo sapiens chromosome 5 open reading frame 4 (C5ORF4), mRNA. /FEA = mRNA /GEN = C5ORF4 /PROD = putative tumor suppressor /DB_XREF = gi: 7705942 /UG = Hs.10235 chromosome 5 open reading frame 4 /FL = gb: AF159165.1 gb: NM_016348.1 213523_at Consensus includes gb: AI671049 /FEA = EST /DB_XREF = gi: 4850780 /DB_XREF = est: tz17d11.x1 /CLONE = IMAGE: 2288853 /UG = Hs.9700 cyclin E1 204922_at gb: NM_024650.1 /DEF = Homo sapiens hypothetical protein FLJ22531 (FLJ22531), mRNA. /FEA = mRNA /GEN = FLJ22531 /PROD = hypothetical protein FLJ22531 /DB_XREF = gi: 13375894 /UG = Hs.55613 hypothetical protein FLJ22531 /FL = gb: NM_024650.1 212364_at Consensus includes gb: BF432550 /FEA = EST /DB_XREF = gi: 11444700 /DB_XREF = est: nac56e10.x1 /CLONE = IMAGE: 3406555 /UG = Hs.121576 Homo sapiens cDNA FLJ20153 fis, clone COL08656, highly similar to AJ001381 Homo sapiens incomplete cDNA for a mutated allele 202724_s_at gb: NM_002015.2 /DEF = Homo sapiens forkhead box O1A (rhabdomyosarcoma) (FOXO1A), mRNA. /FEA = mRNA /GEN = FOXO1A /PROD = forkhead box O1A /DB_XREF = gi: 9257221 /UG = Hs.170133 forkhead box O1A (rhabdomyosarcoma) /FL = gb: AF032885.1 gb: U02310.1 gb: NM_002015.2 212636_at Consensus includes gb: AL031781 /DEF = Human DNA sequence from clone 51J12 on chromosome 6q26-27. Contains the 3 part of the alternatively spliced gene for the human orthologs of mouse QKI-7 and QKI-7B (KH Domain RNA Binding proteins) and zebrafish ZKQ-1 (Quaking protein homolog). Con . . . /FEA = mRNA_2 /DB_XREF = gi: 4038570 /UG = Hs.15020 homolog of mouse quaking QKI (KH domain RNA binding protein) /FL = gb: AF142417.1 215078_at Consensus includes gb: AL050388.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564M2422 (from clone DKFZp564M2422); partial cds. /FEA = mRNA /GEN = DKFZp564M2422 /PROD = hypothetical protein /DB_XREF = gi: 4914612 /UG = Hs.306320 Homo sapiens mRNA; cDNA DKFZp564M2422 (from clone DKFZp564M2422); partial cds 203697_at gb: U91903.1 /DEF = Human Fritz mRNA, complete cds. /FEA = mRNA /PROD = Fritz /DB_XREF = gi: 1917006 /UG = Hs.153684 frizzled-related protein /FL = gb: U24163.1 gb: U68057.1 gb: U91903.1 gb: NM_0014631 203620_s_at gb: NM_014824.1 /DEF = Homo sapiens KIAA0769 gene product (KIAA0769), mRNA. /FEA = mRNA /GEN = KIAA0769 /PROD = KIAA0769 gene product /DB_XREF = gi: 7662295 /UG = Hs.19056 KIAA0769 gene product /FL = gb: AB018312.1 gb: NM_014824.1 201502_s_at Consensus includes gb: AI078167 /FEA = EST /DB_XREF = gi: 3412575 /DB_XREF = est: oz30d08.x1 /CLONE = IMAGE: 1676847 /UG = Hs.81328 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha /FL = gb: NM_020529.1 gb: BC002601.1 gb: BC004983.1 gb: M69043.1 205568_at gb: NM_020980.2 /DEF = Homo sapiens aquaporin 9 (AQP9), mRNA. /FEA = mRNA /GEN = AQP9 /PROD = aquaporin 9 /DB_XREF = gi: 11038652 /UG = Hs.104624 aquaporin 9 /FL = gb: NM_020980.2 gb: AB008775.1 gb: AF016495.1 210118_s_at gb: M15329.1 /DEF = Human interleukin 1-alpha (IL1A) mRNA, complete cds. /FEA = mRNA /GEN = IL1A /PROD = interleukin 1-alpha /DB_XREF = gi: 186277 /UG = Hs.1722 interleukin 1, alpha /FL = gb: M15329.1 219664_s_at gb: NM_020664.1 /DEF = Homo sapiens 2,4-dienoyl CoA reductase 2, peroxisomal (DECR2), mRNA. /FEA = mRNA. /GEN = DECR2 /PROD = peroxisomal 2,4-dienoyl-CoA reductase /DB_XREF = gi: 10190703 /UG = Hs.15898 2,4-dienoyl CoA reductase 2, peroxisomal /FL = gb: NM_020664.1 216215_s_at Consensus includes gb: AL049748 /DEF = Human DNA sequence from clone RP1-41P2 on chromosome 22 Contains the 3 part of the RBM9 gene for RNA binding motif protein 9 and the 3 part of the gene for a novel protein similar to part of APOL (apolipoprotein L) and TNF-inducible protein CG12 . . . /FEA = mRNA_2 /DB_XREF = gi: 6572235 /UG = Hs.5011 RNA binding motif protein 9 202450_s_at gb: NM_000396.1 /DEF = Homo sapiens cathepsin K (pycnodysostosis) (CTSK), mRNA. /FEA = mRNA /GEN = CTSK /PROD = cathepsin K (pycnodysostosis) /DB_XREF = gi: 4503150 /UG = Hs.83942 cathepsin K (pycnodysostosis) /FL = gb: NM_000396.1 gb: U13665.1 219869_s_at gb: NM_022154.1 /DEF = Homo sapiens up-regulated by BCG-CWS (LOC64116), mRNA. /FEA = mRNA /GEN = LOC64116 /PROD = up-regulated by BCG-CWS /DB_XREF = gi: 11545899 /UG = Hs.284205 up-regulated by BCG-CWS /FL = gb: NM_022154.1 200736_s_at gb: NM_000581.1 /DEF = Homo sapiens glutathione peroxidase 1 (GPX1), mRNA. /FEA = mRNA /GEN = GPX1 /PROD = glutathione peroxidase 1 /DB_XREF = gi: 10834975 /UG = Hs.76686 glutathione peroxidase 1 /FL = gb: NM_000581.1 gb: BC000742.1 gb: M21304.1 204646_at gb: NM_000110.2 /DEF = Homo sapiens dihydropyrimidine dehydrogenase (DPYD), mRNA. /FEA = mRNA /GEN = DPYD /PROD = dihydropyrimidine dehydrogenase /DB_XREF = gi: 4557874 /UG = Hs.1602 dihydropyrimidine dehydrogenase /FL = gb: U20938.1 gb: NM_000110.2 gb: U09178.1 gb: AB003063.1 204029_at gb: NM_001408.1 /DEF = Homo sapiens cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog (CELSR2), mRNA. /FEA = mRNA /GEN = CELSR2 /PROD = cadherin EGF LAG seven-pass G-type receptor 2 /DB_XREF = gi: 13325063 /UG = Hs.57652 cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog /FL = gb: NM_001408.1 200871_s_at gb: NM_002778.1 /DEF = Homo sapiens prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) (PSAP), mRNA. /FEA = mRNA /GEN = PSAP /PROD = prosaposin (variant Gaucher disease and variantmetachromatic leukodystrophy) /DB_XREF = gi: 11386146 /UG = Hs.78575 prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) /FL = gb: NM_002778.1 gb: BC004275.1 gb: J03077.1 gb: D00422.1 gb: M60255.1 gb: M32221.1 gb: M60257.1 gb: M60258.1 gb: M81355.1 211670_x_at gb: S82471.1 /DEF = Homo sapiens Kruppel-associated box containing gene product SSX3 (SSX3) mRNA, complete cds. /FEA = mRNA /GEN = SSX3 /PROD = Kruppel-associated box containing gene product SSX3 /DB_XREF = gi: 1699271 /FL = gb: S82471.1 218613_at gb: NM_018422.1 /DEF = Homo sapiens hypothetical protein DKFZp761K1423 (DKFZp761K1423), mRNA. /FEA = mRNA /GEN = DKFZp761K1423 /PROD = hypothetical protein DKFZp761K1423 /DB_XREF = gi: 8922171 /UG = Hs.236438 hypothetical protein DKFZp761K1423 /FL = gb: NM_018422.1 200629_at gb: NM_004184.2 /DEF = Homo sapiens tryptophanyl-tRNA synthetase (WARS), mRNA. /FEA = mRNA /GEN = WARS /PROD = tryptophanyl-tRNA synthetase /DB_XREF = gi: 7710155 /UG = Hs.82030 tryptophanyl-tRNA synthetase /FL = gb: M77804.1 gb: M61715.1 gb: NM_004184.2 202307_s_at gb: NM_000593.2 /DEF = Homo sapiens ATP-binding cassette, sub-family B (MDRTAP), member 2 (ABCB2), mRNA. /FEA = mRNA /GEN = ABCB2 /PROD = ATP-binding cassette, sub-family B, member 2 /DB_XREF = gi: 9665247 /UG = Hs.158164 ATP-binding cassette, sub-family B (MDRTAP), member 2 /FL = gb: L21204.1 gb: L21205.1 gb: L21206.1 gb: L21207.1 gb: L21208.1 gb: NM_000593.2 203175_at gb: NM_001665.1 /DEF = Homo sapiens ras homolog gene family, member G (rho G) (ARHG), mRNA. /FEA = mRNA /GEN = ARHG /PROD = ras homolog gene family, member G (rho G) /DB_XREF = gi: 4502218 /UG = Hs.75082 ras homolog gene family, member G (rho G) /FL = gb: NM_001665.1 203382_s_at gb: NM_000041.1 /DEF = Homo sapiens apolipoprotein E (APOE), mRNA. /FEA = mRNA /GEN = APOE /PROD = apolipoprotein E /DB_XREF = gi: 4557324 /UG = Hs.169401 apolipoprotein E /FL = gb: BC003557.1 gb: M12529.1 gb: K00396.1 gb: NM_000041.1 209281_s_at gb: M95541.1 /DEF = Homo sapiens adenosine triphosphatase mRNA, complete cds. /FEA = mRNA /PROD = adenosine triphosphatase /DB_XREF = gi: 184269 /UG = Hs.78546 ATPase, Ca++ transporting, plasma membrane 1 /FL = gb: M95541.1 gb: NM_001682.1 gb: J04027.1 201313_at gb: NM_001975.1 /DEF = Homo sapiens enolase 2, (gamma, neuronal) (ENO2), mRNA. /FEA = mRNA /GEN = ENO2 /PROD = enolase 2, (gamma, neuronal) /DB_XREF = gi: 5803010 /UG = Hs.146580 enolase 2, (gamma, neuronal) /FL = gb: BC002745.1 gb: NM_001975.1 gb: M22349.1 208012_x_at gb: NM_004509.1 /DEF = Homo sapiens interferon-induced protein 41, 30 kD (IFI41), mRNA. /FEA = mRNA /GEN = IFI41 /PROD = interferon-induced protein 41, 30 kD /DB_XREF = gi: 4758585 /UG = Hs.241510 interferon-induced protein 41, 30 kD /FL = gb: L22342.1 gb: NM_004509.1 203028_s_at gb: NM_000101.1 /DEF = Homo sapiens cytochrome b-245, alpha polypeptide (CYBA), mRNA. /FEA = mRNA /GEN = CYBA /PROD = flavocytochrome b-558 alpha polypeptide /DB_XREF = gi: 4557504 /UG = Hs.68877 cytochrome b- 245, alpha polypeptide /FL = gb: M21186.1 gb: NM_000101.1 207277_at gb: AF290886.1 /DEF = Homo sapiens DC-SIGN mRNA, complete cds. /FEA = mRNA /PROD = DC-SIGN /DB_XREF = gi: 13383467 /UG = Hs.278694 CD209 antigen /FL = gb: NM_021155.1 gb: AF290886.1 gb: M98457.1 212235_at Consensus includes gb: AL575403 /FEA = EST /DB_XREF = gi: 12936533 /DB_XREF = est: AL575403 /CLONE = CS0DI060YL02 (3 prime) /UG = Hs.301685 KIAA0620 protein 209537_at gb: AF000416.1 /DEF = Homo sapiens EXT-like protein 2 (EXTL2) mRNA, complete cds. /FEA = mRNA /GEN = EXTL2 /PROD = EXT-like protein 2 /DB_XREF = gi: 2895061 /UG = Hs.61152 exostoses (multiple)-like 2 /FL = gb: AB009284.1 gb: AF000416.1 213935_at Consensus includes gb: AF007132.1 /DEF = Homo sapiens clone 23551 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 2852606 /UG = Hs.184019 Homo sapiens clone 23551 mRNA sequence 220615_s_at gb: NM_018099.1 /DEF = Homo sapiens hypothetical protein FLJ10462 (FLJ10462), mRNA. /FEA = mRNA /GEN = FLJ10462 /PROD = hypothetical protein FLJ10462 /DB_XREF = gi: 8922433 /UG = Hs.100895 hypothetical protein FLJ10462 /FL = gb: AL136843.1 gb: NM_018099.1 221527_s_at gb: AF196185.1 /DEF = Homo sapiens atypical PKC isotype-specific interacting protein long variant mRNA, complete cds. /FEA = mRNA /PROD = atypical PKC isotype-specific interacting protein long variant /DB_XREF = gi: 13491609 /UG = Hs.72249 three-PDZ containing protein similar to C. elegans PAR3 (partitioning defect) /FL = gb: AF196185.1 209500_x_at gb: AF114012.1 /DEF = Homo sapiens tumor necrosis factor-related death ligand-1beta mRNA, complete cds. /FEA = mRNA /PROD = tumor necrosis factor-related death ligand-1beta /DB_XREF = gi: 7328555 /UG = Hs.54673 tumor necrosis factor (ligand) superfamily, member 13 /FL = gb: AF114012.1 221833_at Consensus includes gb: AI971258 /FEA = EST /DB_XREF = gi: 5768084 /DB_XREF = est: wr27b08.x1 /CLONE = IMAGE: 2488887 /UG = Hs.295923 seven in absentia (Drosophila) homolog 1 209189_at gb: BC004490.1 /DEF = Homo sapiens, v-fos FBJ murine osteosarcoma viral oncogene homolog, clone MGC: 11074, mRNA, complete cds. /FEA = mRNA /PROD = v-fos FBJ murine osteosarcoma viral oncogene homolog /DB_XREF = gi: 13325363 /UG = Hs.25647 v-fos FBJ murine osteosarcoma viral oncogene homolog /FL = gb: BC004490.1 gb: NM_005252.2 201780_s_at gb: NM_007282.1 /DEF = Homo sapiens ring finger protein 13 (RNF13), mRNA. /FEA = mRNA /GEN = RNF13 /PROD = ring finger protein 13 /DB_XREF = gi: 6005863 /UG = Hs.6900 ring finger protein 13 /FL = gb: AF037204.1 gb: AF070558.1 gb: NM_007282.1 203019_x_at gb: NM_014021.1 /DEF = Homo sapiens KIAA0923 protein (KIAA0923), mRNA. /FEA = mRNA /GEN = KIAA0923 /PROD = KIAA0923 protein /DB_XREF = gi: 7662381 /UG = Hs.22587 KIAA0923 protein /FL = gb: AB023140.1 gb: NM_014021.1 212533_at Consensus includes gb: X62048.1 /DEF = H. sapiens Wee1 hu gene. /FEA = mRNA /GEN = Wee1 Hu /DB_XREF = gi: 499071 /UG = Hs.75188 wee1+ (S. pombe) homolog /FL = gb: NM_003390.1 gb: U10564.1 205107_s_at gb: NM_005227.1 /DEF = Homo sapiens ephrin-A4 (EFNA4), mRNA. /FEA = mRNA /GEN = EFNA4 /PROD = ephrin-A4 /DB_XREF = gi: 4885196 /UG = Hs.42331 ephrin-A4 /FL = gb: NM_005227.1 gb: U14188.1 218257_s_at gb: NM_020120.1 /DEF = Homo sapiens UDP-glucose:glycoprotein glucosyltransferase 1 (HUGT1), mRNA. /FEA = mRNA /GEN = HUGT1 /PROD = UDP-glucose:glycoprotein glucosyltransferase 1 /DB_XREF = gi: 9910279 /UG = Hs.105794 UDP-glucose:glycoprotein glucosyltransferase 1 /FL = gb: AF227905.1 gb: NM_020120.1 203923_s_at gb: NM_000397.2 /DEF = Homo sapiens cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB), mRNA. /FEA = mRNA /GEN = CYBB /PROD = cytochrome b-245, beta polypeptide (chronicgranulomatous disease) /DB_XREF = gi: 6996020 /UG = Hs.88974 cytochrome b-245, beta polypeptide (chronic granulomatous disease) /FL = gb: NM_000397.2 204698_at gb: NM_002201.2 /DEF = Homo sapiens interferon stimulated gene (20 kD) (ISG20), mRNA. /FEA = mRNA /GEN = ISG20 /PROD = interferon stimulated gene (20 kD) /DB_XREF = gi: 6857799 /UG = Hs.183487 interferon stimulated gene (20 kD) /FL = gb: U88964.1 gb: NM_002201.2 202587_s_at gb: BC001116.1 /DEF = Homo sapiens, adenylate kinase 1, clone MGC: 1808, mRNA, complete cds. /FEA = mRNA /PROD = adenylate kinase 1 /DB_XREF = gi: 12654562 /UG = Hs.76240 adenylate kinase 1 /FL = gb: BC001116.1 gb: NM_000476.1 gb: AB021871.1 205082_s_at gb: AB046692.1 /DEF = Homo sapiens hAO mRNA for aldeyde oxidase, complete cds. /FEA = mRNA /GEN = hAO /PROD = aldeyde oxidase /DB_XREF = gi: 13516378 /UG = Hs.174151 aldehyde oxidase 1 /FL = gb: AB046692.1 gb: L11005.1 gb: NM_001159.2 207016_s_at gb: AB015228.1 /DEF = Homo sapiens mRNA for RALDH2-T, complete cds. /FEA = mRNA /GEN = RALDH2 /PROD = RALDH2-T /DB_XREF = gi: 3970845 /UG = Hs.95197 aldehyde dehydrogenase 1 family, member A2 /FL = gb: NM_003888.1 gb: AB015226.1 gb: AB015227.1 gb: AB015228.1 206978_at gb: NM_000647.2 /DEF = Homo sapiens chemokine (C-C motif) receptor 2 (CCR2), mRNA. /FEA = mRNA /GEN = CCR2 /PROD = chemokine (C-C motif) receptor 2 /DB_XREF = gi: 4827072 /UG = Hs.395 chemokine (C-C motif) receptor 2 /FL = gb: U03882.1 gb: NM_000647.2 205176_s_at gb: NM_014288.1 /DEF = Homo sapiens integrin beta 3 binding protein (beta3-endonexin) (ITGB3BP), mRNA. /FEA = mRNA /GEN = ITGB3BP /PROD = integrin beta 3 binding protein(beta3-endonexin) /DB_XREF = gi: 7657205 /UG = Hs.82084 integrin beta 3 binding protein (beta3-endonexin) /FL = gb: BC005301.1 gb: AF175306.1 gb: NM_014288.1 202887_s_at gb: NM_019058.1 /DEF = Homo sapiens hypothetical protein (FLJ20500), mRNA. /FEA = mRNA /GEN = FLJ20500 /PROD = hypothetical protein /DB_XREF = gi: 9506686 /UG = Hs.111244 hypothetical protein /FL = gb: AL136668.1 gb: NM_019058.1 214452_at Consensus includes gb: NM_005504.1 /DEF = Homo sapiens branched chain aminotransferase 1, cytosolic (BCAT1), mRNA. /FEA = CDS /GEN = BCAT1 /PROD = branched chain aminotransferase 1, cytosolic /DB_XREF = gi: 5031606 /UG = Hs.157205 branched chain aminotransferase 1, cytosolic /FL = gb: U21551.1 gb: NM_005504.1 209108_at gb: AF053453.1 /DEF = Homo sapiens tetraspan TM4SF (TSPAN-6) mRNA, complete cds. /FEA = mRNA /GEN = TSPAN 6 /PROD = tetraspan TM4SF /DB_XREF = gi: 2995860 /UG = Hs.121068 transmembrane 4 superfamily member 6 /FL = gb: AF043906.1 gb: AF053453.1 gb: U84895.1 gb: NM_003270.1 gb: AF133426.1 213385_at Consensus includes gb: AK026415.1 /DEF = Homo sapiens cDNA: FLJ22762 fis, clone KAIA0960, highly similar to HUMB2CHIM Homo sapiens beta2-chimaerin mRNA. /FEA = mRNA /DB_XREF = gi: 10439275 /UG = Hs.286055 chimerin (chimaerin) 2 204755_x_at gb: M95585.1 /DEF = Human hepatic leukemia factor (HLF) mRNA, complete cds. /FEA = mRNA /GEN = HLF /PROD = hepatic leukemia factor /DB_XREF = gi: 184223 /UG = Hs.250692 hepatic leukemia factor /FL = gb: M95585.1 gb: NM_002126.1 212775_at Consensus includes gb: AI978623 /FEA = EST /DB_XREF = gi: 5803653 /DB_XREF = est: wr57d03.x1 /CLONE = IMAGE: 2491781 /UG = Hs.6654 KIAA0657 protein 213482_at Consensus includes gb: BF593175 /FEA = EST /DB_XREF = gi: 11685499 /DB_XREF = est: 7o57g10.x1 /CLONE = IMAGE: 3578322 /UG = Hs.7022 dedicator of cyto-kinesis 3 205191_at gb: NM_006915.1 /DEF = Homo sapiens retinitis pigmentosa 2 (X-linked recessive) (RP2), mRNA. /FEA = mRNA /GEN = RP2 /PROD = XRP2 protein /DB_XREF = gi: 5902059 /UG = Hs.44766 retinitis pigmentosa 2 (X-linked recessive) /FL = gb: NM_006915.1 217867_x_at gb: NM_012105.1 /DEF = Homo sapiens beta-site APP-cleaving enzyme 2 (BACE2), mRNA. /FEA = mRNA /GEN = BACE2 /PROD = beta-site APP-cleaving enzyme 2 /DB_XREF = gi: 6912263 /UG = Hs.271411 beta-site APP- cleaving enzyme 2 /FL = gb: AF117892.1 gb: AF050171.1 gb: AF200192.1 gb: AF200342.1 gb: AF204944.1 gb: AF178532.1 gb: NM_012105.1 216464_x_at Consensus includes gb: AF118265 /DEF = Homo sapiens orphan G protein-coupled receptor GPR44 (GPR44) gene, complete cds /FEA = CDS /DB_XREF = gi: 4455060 /UG = Hs.299567 G protein-coupled receptor 44 215239_x_at Consensus includes gb: AU132789 /FEA = EST /DB_XREF = gi: 10993328 /DB_XREF = est: AU132789 /CLONE = NT2RP4000545 /UG = Hs.89732 zinc finger protein 273 205554_s_at gb: NM_004944.1 /DEF = Homo sapiens deoxyribonuclease I-like 3 (DNASE1L3), mRNA. /FEA = mRNA /GEN = DNASE1L3 /PROD = deoxyribonuclease I-like 3 /DB_XREF = gi: 4826697 /UG = Hs.88646 deoxyribonuclease I- like 3 /FL = gb: U56814.1 gb: AF047354.1 gb: NM_004944.1 218627_at gb: NM_018370.1 /DEF = Homo sapiens hypothetical protein FLJ11259 (FLJ11259), mRNA. /FEA = mRNA /GEN = FLJ11259 /PROD = hypothetical protein FLJ11259 /DB_XREF = gi: 8922957 /UG = Hs.184465 hypothetical protein FLJ11259 /FL = gb: NM_018370.1 217901_at Consensus includes gb: BF031829 /FEA = EST /DB_XREF = gi: 10739541 /DB_XREF = est: 601557983F1 /CLONE = IMAGE: 3827709 /UG = Hs.2631 desmoglein 2 /FL = gb: NM_001943.1 209073_s_at gb: AF015040.1 /DEF = Homo sapiens NUMB protein (NUMB) mRNA, complete cds. /FEA = mRNA /GEN = NUMB /PROD = NUMB protein /DB_XREF = gi: 4102704 /UG = Hs.78890 numb (Drosophila) homolog /FL = gb: AF015040.1 gb: AF108092.1 gb: AF171939.1 204950_at gb: NM_014959.1 /DEF = Homo sapiens KIAA0955 protein (KIAA0955), mRNA. /FEA = mRNA /GEN = KIAA0955 /PROD = KIAA0955 protein /DB_XREF = gi: 7662403 /UG = Hs.10031 KIAA0955 protein /FL = gb: AF322184.1 gb: AF331519.1 gb: AY026322.1 gb: AB023172.1 gb: NM_014959.1 203340_s_at gb: NM_003705.1 /DEF = Homo sapiens solute carrier family 25 (mitochondrial carrier, Aralar), member 12 (SLC25A12), mRNA. /FEA = mRNA /GEN = SLC25A12 /PROD = solute carrier family 25 (mitochondrial carrier, Aralar), member 12 /DB_XREF = gi: 4507006 /UG = Hs.179866 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 /FL = gb: NM_003705.1 211423_s_at gb: D85181.1 /DEF = Homo sapiens mRNA for fungal sterol-C5-desaturase homolog, complete cds. /FEA = mRNA /PROD = fungal sterol-C5-desaturase homolog /DB_XREF = gi: 1906795 /UG = Hs.288031 sterol-C5-desaturase (fungal ERGS, delta-5-desaturase)-like /FL = gb: D85181.1 212561_at Consensus includes gb: AA349595 /FEA = EST /DB_XREF = gi: 2001934 /DB_XREF = est: EST56429 /UG = Hs.26797 KIAA1091 protein 210660_at gb: AF025529.1 /DEF = Homo sapiens leucocyte immunoglobulin-like receptor-6b (LIR-6) mRNA, complete cds. /FEA = mRNA /GEN = LIR-6 /PROD = leucocyte immunoglobulin-like receptor-6b /DB_XREF = gi: 2653864 /UG = Hs.166156 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 /FL = gb: AF025529.1 210313_at gb: AF041261.1 /DEF = Homo sapiens immunoglobulin-like transcript 7 mRNA, complete cds. /FEA = mRNA /PROD = immunoglobulin-like transcript 7 /DB_XREF = gi: 4104890 /UG = Hs.48647 immunoglobulin-like transcript 7 /FL = gb: AF041261.1 217807_s_at gb: NM_015710.1 /DEF = Homo sapiens glioma tumor suppressor candidate region gene 2 (GLTSCR2), mRNA /FEA = mRNA /GEN = GLTSCR2 /PROD = glioma tumor suppressor candidate region gene 2 /DB_XREF = gi: 7657129 /UG = Hs.2237 glioma tumor suppressor candidate region gene 2 /FL = gb: AF182076.1 gb: NM_015710.1 212930_at Consensus includes gb: AW576457 /FEA = EST /DB_XREF = gi: 7247996 /DB_XREF = est: UI-HF-BR0p-aji-a-01-0-UI.s1 /CLONE = IMAGE: 3074568 /UG = Hs.20952 Homo sapiens clone 24411 mRNA sequence 213212_x_at Consensus includes gb: AI632181 /FEA = EST /DB_XREF = gi: 4683511 /DB_XREF = est: ts85h05.x1 /CLONE = IMAGE: 2238105 /UG = Hs.182982 golgin-67 203567_s_at Consensus includes gb: AU157590 /FEA = EST /DB_XREF = gi: 11019111 /DB_XREF = est: AU157590 /CLONE = PLACE1008438 /UG = Hs.59545 ring finger protein 15 /FL = gb: U90547.1 gb: NM_006355.1 219342_at gb: NM_022900.1 /DEF = Homo sapiens hypothetical protein FLJ21213 (FLJ21213), mRNA. /FEA = mRNA /GEN = FLJ21213 /PROD = hypothetical protein FLJ21213 /DB_XREF = gi: 12597638 /UG = Hs.128003 hypothetical protein FLJ21213 /FL = gb: NM_022900.1 212702_s_at Consensus includes gb: N45111 /FEA = EST /DB_XREF = gi: 1186277 /DB_XREF = est: yz12f12.s1 /CLONE = IMAGE: 282863 /UG = Hs.330988 Homo sapiens, Similar to Bicaudal D (Drosophila) homolog 1, clone IMAGE: 3622452, mRNA, partial cds 209340_at gb: S73498.1 /DEF = Homo sapiens AgX-1 antigen mRNA, complete cds. /FEA = mRNA /PROD = AgX-1 antigen /DB_XREF = gi: 688010 /UG = Hs.21293 UDP-N-acteylglucosamine pyrophosphorylase 1 /FL = gb: AB011004.1 gb: NM_003115.1 gb: S73498.1 202943_s_at gb: M38083.1 /DEF = Human alpha-N-acetylgalactosaminidase mRNA, complete cds. /FEA = mRNA /PROD = alpha-N- acetylgalactosaminidase /DB_XREF = gi: 189054 /UG = Hs.75372 N-acetylgalactosaminidase, alpha- /FL = gb: BC000095.1 gb: M62783.1 gb: M38083.1 gb: NM_000262.1 202894_at gb: NM_004444.1 /DEF = Homo sapiens EphB4 (EPHB4) mRNA. /FEA = mRNA /GEN = HTK /PROD = EphB4 /DB_XREF = gi: 4758289 /UG = Hs.155227 EphB4 /FL = gb: NM_004444.1 gb: U07695.1 207670_at gb: NM_002283.1 /DEF = Homo sapiens keratin, hair, basic, 5 (KRTHB5), mRNA. /FEA = mRNA /GEN = KRTHB5 /PROD = keratin, hair, basic, 5 /DB_XREF = gi: 4504934 /UG = Hs.182507 keratin, hair, basic, 5 /FL = gb: NM_002283.1 202375_at gb: NM_014822.1 /DEF = Homo sapiens SEC24 (S. cerevisiae) related gene family, member D (SEC24D), mRNA. /FEA = mRNA /GEN = SEC24D /PROD = SEC24 (S. cerevisiae) related gene family, member D /DB_XREF = gi: 7662658 /UG = Hs.19822 SEC24 (S. cerevisiae) related gene family, member D /FL = gb: AB018298.1 gb: AF130464.2 gb: NM_014822.1 39318_at Cluster Incl. X82240: H. sapiens mRNA for Tcell leukemia/lymphoma 1 /cds = (45, 389) /gb = X82240 /gi = 624960 /ug = Hs.2484 /len = 1312 221765_at Consensus includes gb: AI378044 /FEA = EST /DB_XREF = gi: 4187897 /DB_XREF = est: te67h09.x1 /CLONE = IMAGE: 2091809 /UG = Hs.23703 ESTs 202746_at Consensus includes gb: AL021786 /DEF = Human DNA sequence from PAC 696H22 on chromosome Xq21.1-21.2. Contains a mouse E25 like gene, a Kinesin like pseudogene and ESTs /FEA = mRNA /DB_XREF = gi: 2853186 /UG = Hs.17109 integral membrane protein 2A /FL = gb: AF038953.1 gb: NM_004867.1 216960_s_at Consensus includes gb: AL049646 /DEF = Human DNA sequence from clone RP4-568F9 on chromosome 20 Contains the ZNF133 (zinc finger protein 133 (clone pHZ-13)) gene, part of a gene for a novel protein, ESTs, STSs, GSSs and CpG islands /FEA = mRNA_2 /DB_XREF = gi: 11121205 /UG = Hs.78434 zinc finger protein 133 (clone pHZ-13) 213110_s_at Consensus includes gb: AW052179 /FEA = EST /DB_XREF = gi: 5914538 /DB_XREF = est: wx26h09.x1 /CLONE = IMAGE: 2544833 /UG = Hs.169825 collagen, type IV, alpha 5 (Alport syndrome) /FL = gb: NM_000495.2 200918_s_at gb: NM_003139.1 /DEF = Homo sapiens signal recognition particle receptor (docking protein) (SRPR), mRNA. /FEA = mRNA /GEN = SRPR /PROD = signal recognition particle receptor (docking protein) /DB_XREF = gi: 4507222 /UG = Hs.75730 signal recognition particle receptor (docking protein) /FL = gb: BC001162.1 gb: NM_003139.1 209438_at Consensus includes gb: AL096700 /DEF = Human DNA sequence from clone RP3-499B10 on chromosome Xp22.31-22.13. Contains the 3 end of the gene for serine threonine protein phosphatase PPEF, the 3 end of the PHKA2 gene for liver phosphorylase kinase alpha 2, ESTs, STSs and GSSs /FEA = mRNA_2 /DB_XREF = gi: 7077104 /UG = Hs.54941 phosphorylase kinase, alpha 2 (liver) /FL = gb: D38616.1 gb: NM_000292.1 200700_s_at gb: NM_006854.2 /DEF = Homo sapiens KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 (KDELR2), mRNA. /FEA = mRNA /GEN = KDELR2 /PROD = KDEL receptor 2 /DB_XREF = gi: 8051609 /UG = Hs.118778 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 /FL = gb: NM_006854.2 202833_s_at gb: NM_000295.1 /DEF = Homo sapiens serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (SERPINA1), mRNA. /FEA = mRNA /GEN = SERPINA1 /PROD = serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 /DB_XREF = gi: 4505792 /UG = Hs.297681 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 /FL = gb: AF130068.1 gb: M11465.1 gb: K01396.1 gb: NM_000295.1 202607_at Consensus includes gb: AL526632 /FEA = EST /DB_XREF = gi: 12790125 /DB_XREF = est: AL526632 /CLONE = CS0DC020YC21 (3 prime) /UG = Hs.20894 N-deacetylaseN-sulfotransferase (heparan glucosaminyl) 1 /FL = gb: U36600.1 gb: NM_001543.1 gb: U17970.1 gb: U18918.1 221103_s_at gb: NM_018338.1 /DEF = Homo sapiens hypothetical protein FLJ11142 (FLJ11142), mRNA. /FEA = mRNA /GEN = FLJ11142 /PROD = hypothetical protein FLJ11142 /DB_XREF = gi: 8922896 /UG = Hs.272244 hypothetical protein FLJ11142 /FL = gb: NM_018338.1 210544_s_at gb: BC002430.1 /DEF = Homo sapiens, aldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase), clone MGC: 2136, mRNA, complete cds. /FEA = mRNA /PROD = aldehyde dehydrogenase 10 (fatty aldehydedehydrogenase) /DB_XREF = gi: 12803234 /UG = Hs.159608 aldehyde dehydrogenase 3 family, member A2 /FL = gb: BC002430.1 221581_s_at gb: AF257135.1 /DEF = Homo sapiens WBSCR15 protein (WBSCR15) mRNA, complete cds. /FEA = mRNA /GEN = WBSCR15 /PROD = WBSCR15 protein /DB_XREF = gi: 9651998 /UG = Hs.56607 Williams-Beuren syndrome chromosome region 5 /FL = gb: NM_022040.1 gb: BC001609.1 gb: AF257135.1 219482_at gb: NM_017438.1 /DEF = Homo sapiens chromosome 21 open reading frame 18 (C21ORF18), mRNA. /FEA = mRNA /GEN = C21ORF18 /PROD = chromosome 21 open reading frame 18 /DB_XREF = gi: 8393012 /UG = Hs.50748 chromosome 21 open reading frame 18 /FL = gb: NM_017438.1 218950_at gb: NM_022481.1 /DEF = Homo sapiens hypothetical protein FLJ21065 (FLJ21065), mRNA. /FEA = mRNA /GEN = FLJ21065 /PROD = hypothetical protein FLJ21065 /DB_XREF = gi: 11968032 /UG = Hs.25277 hypothetical protein FLJ21065 /FL = gb: NM_022481.1 212399_s_at Consensus includes gb: D50911.2 /DEF = Homo sapiens mRNA for KIAA0121 protein, partial cds. /FEA = mRNA /GEN = KIAA0121 /PROD = KIAA0121 protein /DB_XREF = gi: 6633996 /UG = Hs.155584 KIAA0121 gene product 219274_at gb: NM_012338.1 /DEF = Homo sapiens transmembrane 4 superfamily member (tetraspan NET-2) (NET-2), mRNA. /FEA = mRNA /GEN = NET-2 /PROD = transmembrane 4 superfamily member (tetraspanNET-2) /DB_XREF = gi: 6912527 /UG = Hs.16529 transmembrane 4 superfamily member (tetraspan NET-2) /FL = gb: AF124522.1 gb: NM_012338.1 202498_s_at Consensus includes gb: BE550486 /FEA = EST /DB_XREF = gi: 9792178 /DB_XREF = est: 7a27c01.x1 /CLONE = IMAGE: 3219936 /UG = Hs.7594 solute carrier family 2 (facilitated glucose transporter), member 3 /FL = gb: M20681.1 gb: NM_006931.1 221234_s_at gb: NM_021813.1 /DEF = Homo sapiens BTB and CNC homology 1, basic leucine zipper transcription factor 2 (BACH2), mRNA. /FEA = mRNA /GEN = BACH2 /PROD = BTB and CNC homology 1, basic leucine zipper transcription factor 2 /DB_XREF = gi: 13540489 /FL = gb: NM_021813.1 219968_at gb: NM_016089.1 /DEF = Homo sapiens KRAB-zinc finger protein SZF1-1 (SZF1), mRNA. /FEA = mRNA /GEN = SZF1 /PROD = KRAB-zinc finger protein SZF1-1 /DB_XREF = gi: 7706726 /UG = Hs.19585 KRAB-zinc finger protein SZF1-1 /FL = gb: AF114816.1 gb: NM_016089.1 201506_at gb: NM_000358.1 /DEF = Homo sapiens transforming growth factor, beta-induced, 68 kD (TGFBI), mRNA. /FEA = mRNA /GEN = TGFBI /PROD = transforming growth factor, beta-induced, 68 kD /DB_XREF = gi: 4507466 /UG = Hs.118787 transforming growth factor, beta-induced, 68 kD /FL = gb: BC000097.1 gb: BC004972.1 gb: M77349.1 gb: NM_000358.1 203420_at gb: NM_016255.1 /DEF = Homo sapiens Autosomal Highly Conserved Protein (AHCP), mRNA. /FEA = mRNA /GEN = AHCP /PROD = Autosomal Highly Conserved Protein /DB_XREF = gi: 7705267 /UG = Hs.95260 Autosomal Highly Conserved Protein /FL = gb: AF097027.1 gb: NM_016255.1 222171_s_at Consensus includes gb: AK023792.1 /DEF = Homo sapiens cDNA FLJ13730 fis, clone PLACE3000136. /FEA = mRNA /DB_XREF = gi: 10435834 /UG = Hs.10043 hypothetical protein FLJ13074 221488_s_at gb: AF230924.1 /DEF = Homo sapiens brain acetylcholinesterase putative membrane anchor mRNA, complete cds. /FEA = mRNA /PROD = brain acetylcholinesterase putative membraneanchor /DB_XREF = gi: 7341254 /UG = Hs.107187 divalent cation tolerant protein CUTA /FL = gb: AF230924.1 213178_s_at Consensus includes gb: AB028989.1 /DEF = Homo sapiens mRNA for KIAA1066 protein, partial cds. /FEA = mRNA /GEN = KIAA1066 /PROD = KIAA1066 protein /DB_XREF = gi: 5689468 /UG = Hs.88500 mitogen-activated protein kinase 8 interacting protein 3 205239_at gb: NM_001657.1 /DEF = Homo sapiens amphiregulin (schwannoma-derived growth factor) (AREG), mRNA. /FEA = mRNA /GEN = AREG /PROD = amphiregulin (schwannoma-derived growth factor) /DB_XREF = gi: 4502198 /UG = Hs.270833 amphiregulin (schwannoma-derived growth factor) /FL = gb: M30704.1 gb: NM_001657.1 212463_at Consensus includes gb: BE379006 /FEA = EST /DB_XREF = gi: 9324371 /DB_XREF = est: 601236272F1 /CLONE = IMAGE: 3608680 /UG = Hs.99766 Homo sapiens mRNA; cDNA DKFZp564J0323 (from clone DKFZp564J0323) 202059_s_at gb: NM_002264.1 /DEF = Homo sapiens karyopherin alpha 1 (importin alpha 5) (KPNA1), mRNA. /FEA = mRNA /GEN = KPNA1 /PROD = karyopherin alpha 1 /DB_XREF = gi: 4504894 /UG = Hs.169149 karyopherin alpha 1 (importin alpha 5) /FL = gb: BC002374.1 gb: BC003009.1 gb: NM_002264.1 214483_s_at Consensus includes gb: AF124489.1 /DEF = Homo sapiens arfaptin-1b mRNA, alternatively spliced, complete cds. /FEA = CDS /PROD = arfaptin-1b /DB_XREF = gi: 4761515 /UG = Hs.301064 arfaptin 1 /FL = gb: AF124489.1 203327_at Consensus includes gb: N22903 /FEA = EST /DB_XREF = gi: 1137053 /DB_XREF = est: yx66e04.s1 /CLONE = IMAGE: 266718 /UG = Hs.1508 insulin-degrading enzyme /FL = gb: M21188.1 gb: NM_004969.1 214022_s_at Consensus includes gb: AA749101 /FEA = EST /DB_XREF = gi: 2789059 /DB_XREF = est: ny11d02.s1 /CLONE = IMAGE: 1271427 /UG = Hs.146360 interferon induced transmembrane protein 1 (9-27) 202912_at gb: NM_001124.1 /DEF = Homo sapiens adrenomedullin (ADM), mRNA. /FEA = mRNA /GEN = ADM /PROD = adrenomedullin /DB_XREF = gi: 4501944 /UG = Hs.394 adrenomedullin /FL = gb: NM_001124.1 gb: D14874.1 210385_s_at gb: AF106037.1 /DEF = Homo sapiens adipocyte-derived leucine aminopeptidase mRNA, complete cds. /FEA = mRNA /PROD = adipocyte-derived leucine aminopeptidase /DB_XREF = gi: 6381988 /UG = Hs.247043 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator /FL = gb: AF106037.1 203017_s_at Consensus includes gb: R52678 /FEA = EST /DB_XREF = gi: 814580 /DB_XREF = est: yg99c07.s1 /CLONE = IMAGE: 41738 /UG = Hs.22587 KIAA0923 protein /FL = gb: AB023140.1 gb: NM_014021.1 202668_at Consensus includes gb: BF001670 /FEA = EST /DB_XREF = gi: 10701945 /DB_XREF = est: 7g91e06.x1 /CLONE = IMAGE: 3313858 /UG = Hs.30942 ephrin-B2 /FL = gb: U81262.1 gb: NM_004093.1 gb: L38734.1 gb: U16797.1 209496_at gb: BC000069.1 /DEF = Homo sapiens, retinoic acid receptor responder (tazarotene induced) 2, clone MGC: 1544, mRNA, complete cds. /FEA = mRNA /PROD = retinoic acid receptor responder (tazaroteneinduced) 2 /DB_XREF = gi: 12652642 /UG = Hs.37682 retinoic acid receptor responder (tazarotene induced) 2 /FL = gb: BC000069.1 gb: U77594.1 gb: AB015632.1 gb: NM_002889.2 204157_s_at gb: NM_025164.1 /DEF = Homo sapiens KIAA0999 protein (KIAA0999), mRNA. /FEA = mRNA /GEN = KIAA0999 /PROD = hypothetical protein FLJ12240 /DB_XREF = gi: 13386467 /UG = Hs.4278 KIAA0999 protein /FL = gb: NM_025164.1 200806_s_at Consensus includes gb: BE256479 /FEA = EST /DB_XREF = gi: 9126938 /DB_XREF = est: 601111293F1 /CLONE = IMAGE: 3352631 /UG = Hs.79037 heat shock 60 kD protein 1 (chaperonin) /FL = gb: BC002676.1 gb: BC003030.1 gb: M34664.1 gb: M22382.1 gb: NM_002156.1 213923_at Consensus includes gb: AW005535 /FEA = EST /DB_XREF = gi: 5854313 /DB_XREF = est: wz87d04.x1 /CLONE = IMAGE: 2565799 /UG = Hs.155218 E1B-55 kDa-associated protein 5 206522_at gb: NM_004668.1 /DEF = Homo sapiens maltase-glucoamylase (alpha-glucosidase) (MGAM), mRNA. /FEA = mRNA /GEN = MGAM /PROD = alpha-glucosidase /DB_XREF = gi: 4758711 /UG = Hs.122785 maltase-glucoamylase (alpha- glucosidase) /FL = gb: AF016833.1 gb: NM_004668.1 201041_s_at gb: NM_004417.2 /DEF = Homo sapiens dual specificity phosphatase 1 (DUSP1), mRNA. /FEA = mRNA /GEN = DUSP1 /PROD = dual specificity phosphatase 1 /DB_XREF = gi: 7108342 /UG = Hs.171695 dual specificity phosphatase 1 /FL = gb: NM_004417.2 208002_s_at gb: NM_007274.1 /DEF = Homo sapiens cytosolic acyl coenzyme A thioester hydrolase (HBACH), mRNA. /FEA = mRNA /GEN = HBACH /PROD = cytosolic acyl coenzyme A thioester hydrolase /DB_XREF = gi: 6857796 /UG = Hs.8679 cytosolic acyl coenzyme A thioester hydrolase /FL = gb: U91316.1 gb: NM_007274.1 200660_at gb: NM_005620.1 /DEF = Homo sapiens S100 calcium-binding protein A11 (calgizzarin) (S100A11), mRNA. /FEA = mRNA /GEN = S100A11 /PROD = S100 calcium-binding protein A11 /DB_XREF = gi: 5032056 /UG = Hs.256290 S100 calcium-binding protein A11 (calgizzarin) /FL = gb: D49355.1 gb: BC001410.1 gb: D50374.1 gb: NM_005620.1 gb: D38583.1 201532_at gb: NM_002788.1 /DEF = Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3), mRNA. /FEA = mRNA /GEN = PSMA3 /PROD = proteasome (prosome, macropain) subunit, alphatype, 3 /DB_XREF = gi: 4506182 /UG = Hs.167106 proteasome (prosome, macropain) subunit, alpha type, 3 /FL = gb: BC005265.1 gb: NM_002788.1 208944_at gb: D50683.1 /DEF = Homo sapiens mRNA for TGF-betaIIR alpha, complete cds. /FEA = mRNA /PROD = TGF-betaIIR alpha /DB_XREF = gi: 1827474 /UG = Hs.82028 transforming growth factor, beta receptor II (70-80 kD) /FL = gb: D50683.1 212415_at Consensus includes gb: AW150913 /FEA = EST /DB_XREF = gi: 6198811 /DB_XREF = est: xg42a01.x1 /CLONE = IMAGE: 2630184 /UG = Hs.90998 KIAA0128 protein; septin 2 206118_at gb: NM_003151.1 /DEF = Homo sapiens signal transducer and activator of transcription 4 (STAT4), mRNA. /FEA = mRNA /GEN = STAT4 /PROD = signal transducer and activator of transcription 4 /DB_XREF = gi: 4507254 /UG = Hs.80642 signal transducer and activator of transcription 4 /FL = gb: L78440.1 gb: NM_003151.1 201543_s_at gb: NM_020150.1 /DEF = Homo sapiens SAR1 protein (SAR1), mRNA. /FEA = mRNA /GEN = SAR1 /PROD = SAR1 protein /DB_XREF = gi: 9910541 /UG = Hs.110796 SAR1 protein /FL = gb: AY008268.1 gb: AL136724.1 gb: AF261717.1 gb: NM_020150.1 212157_at Consensus includes gb: BE048514 /FEA = EST /DB_XREF = gi: 8365567 /DB_XREF = est: hr50a03.x1 /CLONE = IMAGE: 3131884 /UG = Hs.1501 syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan) 219558_at gb: NM_024524.1 /DEF = Homo sapiens hypothetical protein FLJ20986 (FLJ20986), mRNA. /FEA = mRNA /GEN = FLJ20986 /PROD = hypothetical protein FLJ20986 /DB_XREF = gi: 13375667 /UG = Hs.324507 hypothetical protein FLJ20986 /FL = gb: NM_024524.1 221603_at gb: BC000467.1 /DEF = Homo sapiens, Similar to peroxisomal biogenesis factor 16, clone MGC: 8550, mRNA, complete cds. /FEA = mRNA /PROD = Similar to peroxisomal biogenesis factor 16 /DB_XREF = gi: 12653394 /UG = Hs.100915 peroxisomal biogenesis factor 16 /FL = gb: BC000467.1 212552_at Consensus includes gb: BE617588 /FEA = EST /DB_XREF = gi: 9888526 /DB_XREF = est: 601441509T1 /CLONE = IMAGE: 3845643 /UG = Hs.3618 hippocalcin-like 1 205945_at gb: NM_000565.1 /DEF = Homo sapiens interleukin 6 receptor (IL6R), mRNA. /FEA = mRNA /GEN = IL6R /PROD = interleukin 6 receptor /DB_XREF = gi: 4504672 /UG = Hs.193400 interleukin 6 receptor /FL = gb: NM_000565.1 209124_at gb: U70451.1 /DEF = Human myleoid differentiation primary response protein MyD88 mRNA, complete cds. /FEA = mRNA /PROD = MyD88 /DB_XREF = gi: 1763090 /UG = Hs.82116 myeloid differentiation primary response gene (88) /FL = gb: U70451.1 gb: U84408.1 gb: NM_002468.1 205778_at gb: NM_005046.1 /DEF = Homo sapiens kallikrein 7 (chymotryptic, stratum corneum) (KLK7), mRNA. /FEA = mRNA /GEN = KLK7 /PROD = kallikrein 7 (chymotryptic, stratum corneum) /DB_XREF = gi: 4826949 /UG = Hs.151254 kallikrein 7 (chymotryptic, stratum corneum) /FL = gb: NM_005046.1 gb: L33404.1 200807_s_at gb: NM_002156.1 /DEF = Homo sapiens heat shock 60 kD protein 1 (chaperonin) (HSPD1), mRNA. /FEA = mRNA /GEN = HSPD1 /PROD = heat shock 60 kD protein 1 (chaperonin) /DB_XREF = gi: 4504520 /UG = Hs.79037 heat shock 60 kD protein 1 (chaperonin) /FL = gb: BC002676.1 gb: BC003030.1 gb: M34664.1 gb: M22382.1 gb: NM_002156.1 219956_at gb: NM_007210.2 /DEF = Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- acetylgalactosaminyltransferase 6 (GalNAc-T6) (GALNT6), mRNA. /FEA = mRNA /GEN = GALNT6 /PROD = polypeptide N-acetylgalactosaminyltransferase 6 /DB_XREF = gi: 13124893 /UG = Hs.151678 UDP-N-acetyl- alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) /FL = gb: NM_007210.2 200803_s_at gb: AF033095.1 /DEF = Homo sapiens testis enhanced gene transcript protein (TEGT) mRNA, complete cds. /FEA = mRNA /GEN = TEGT /PROD = testis enhanced gene transcript protein /DB_XREF = gi: 2645728 /UG = Hs.74637 testis enhanced gene transcript (BAX inhibitor 1) /FL = gb: BC000916.1 gb: AF033095.1 gb: NM_003217.1 219174_at gb: NM_025103.1 /DEF = Homo sapiens hypothetical protein FLJ22621 (FLJ22621), mRNA. /FEA = mRNA /GEN = FLJ22621 /PROD = hypothetical protein FLJ22621 /DB_XREF = gi: 13376668 /UG = Hs.288617 hypothetical protein FLJ22621 /FL = gb: NM_025103.1 218815_s_at gb: NM_018022.1 /DEF = Homo sapiens hypothetical protein FLJ10199 (FLJ10199), mRNA. /FEA = mRNA /GEN = FLJ10199 /PROD = hypothetical protein FLJ10199 /DB_XREF = gi: 8922276 /UG = Hs.30925 hypothetical protein FLJ10199 /FL = gb: BC000202.1 gb: BC000593.1 gb: NM_018022.1 209013_x_at gb: AF091395.1 /DEF = Homo sapiens Trio isoform mRNA, complete cds. /FEA = mRNA /PROD = Trio isoform /DB_XREF = gi: 3644047 /UG = Hs.171957 triple functional domain (PTPRF interacting) /FL = gb: AF091395.1 209933_s_at gb: AF020314.1 /DEF = Homo sapiens CMRF-35-H9 mRNA, complete cds. /FEA = mRNA /PROD = CMRF-35-H9 /DB_XREF = gi: 4103065 /UG = Hs.9688 leukocyte membrane antigen /FL = gb: AF020314.1 220126_at gb: NM_013270.1 /DEF = Homo sapiens testes-specific protease 50 (TSP50), mRNA. /FEA = mRNA /GEN = TSP50 /PROD = testes-specific protease 50 /DB_XREF = gi: 7019562 /UG = Hs.120365 testes-specific protease 50 /FL = gb: AF100707.1 gb: NM_013270.1 221266_s_at gb: NM_030788.1 /DEF = Homo sapiens DC-specific transmembrane protein (LOC81501), mRNA. /FEA = mRNA /GEN = LOC81501 /PROD = DC-specific transmembrane protein /DB_XREF = gi: 13540564 /FL = gb: NM_030788.1 218194_at gb: NM_015523.1 /DEF = Homo sapiens small fragment nuclease (DKFZP566E144), mRNA. /FEA = mRNA /GEN = DKFZP566E144 /PROD = small fragment nuclease /DB_XREF = gi: 7661645 /UG = Hs.7527 small fragment nuclease /FL = gb: AF151872.1 gb: AL110239.1 gb: NM_015523.1 203860_at gb: NM_000282.1 /DEF = Homo sapiens propionyl Coenzyme A carboxylase, alpha polypeptide (PCCA), nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = PCCA /PROD = Propionyl-Coenzyme A carboxylase, alphapolypeptide precursor /DB_XREF = gi: 4557832 /UG = Hs.80741 propionyl Coenzyme A carboxylase, alpha polypeptide /FL = gb: BC000140.1 gb: NM_000282.1 205500_at gb: NM_001735.1 /DEF = Homo sapiens complement component 5 (C5), mRNA. /FEA = mRNA /GEN = C5 /PROD = complement component 5 /DB_XREF = gi: 4502506 /UG = Hs.1281 complement component 5 /FL = gb: M57729.1 gb: NM_001735.1 201192_s_at gb: NM_006224.1 /DEF = Homo sapiens phosphotidylinositol transfer protein (PITPN), mRNA. /FEA = mRNA /GEN = PITPN /PROD = phosphotidylinositol transfer protein /DB_XREF = gi: 5453907 /UG = Hs.79709 phosphotidylinositol transfer protein /FL = gb: D30036.1 gb: M73704.1 gb: NM_006224.1 217591_at Consensus includes gb: BF725121 /FEA = EST /DB_XREF = gi: 12041032 /DB_XREF = est: bx12e01.x1 /CLONE = bx12e01 /UG = Hs.272108 ESTs 203515_s_at gb: NM_006556.1 /DEF = Homo sapiens phosphomevalonate kinase (PMVK), mRNA. /FEA = mRNA /GEN = PMVK /PROD = phosphomevalonate kinase /DB_XREF = gi: 5729979 /UG = Hs.30954 phosphomevalonate kinase /FL = gb: L77213.1 gb: NM_006556.1 210976_s_at gb: U24183.1 /DEF = Human phosphofructokinase (PFKM) mRNA, complete cds. /FEA = mRNA /GEN = PFKM /PROD = phosphofructokinase /DB_XREF = gi: 975289 /UG = Hs.75160 phosphofructokinase, muscle /FL = gb: U24183.1 210115_at gb: L05096.1 /DEF = Homo sapiens ribosomal protein L39 mRNA, complete cds. /FEA = mRNA /PROD = ribosomal protein L39 /DB_XREF = gi: 388035 /UG = Hs.132748 Homo sapiens ribosomal protein L39 mRNA, complete cds /FL = gb: L05096.1 209653_at gb: U93240.1 /DEF = Human importin alpha 3 mRNA, complete cds. /FEA = mRNA /PROD = importin alpha 3 /DB_XREF = gi: 1928974 /UG = Hs.302499 karyopherin alpha 4 (importin alpha 3) /FL = gb: AB002533.2 gb: NM_002268.2 gb: U93240.1 208878_s_at gb: AF092132.1 /DEF = Homo sapiens PAK2 mRNA, complete cds. /FEA = mRNA /PROD = PAK2 /DB_XREF = gi: 5138913 /UG = Hs.284275 Homo sapiens PAK2 mRNA, complete cds /FL = gb: AF092132.1 216526_x_at Consensus includes gb: AK024836.1 /DEF = Homo sapiens cDNA: FLJ21183 fis, clone CAS11634, highly similar to HSHLACW07 Homo sapiens mRNA for human leukocyte antigen C alpha chain. /FEA = mRNA /DB_XREF = gi: 10437242 /UG = Hs.277477 major histocompatibility complex, class I, C 213556_at Consensus includes gb: BE673445 /FEA = EST /DB_XREF = gi: 10033986 /DB_XREF = est: 7d35d10.x1 /CLONE = IMAGE: 3249235 /UG = Hs.22049 Homo sapiens chromosome 19, cosmid R28379 218966_at gb: NM_018728.1 /DEF = Homo sapiens myosin 5C (MYO5C), mRNA. /FEA = mRNA /GEN = MYO5C /PROD = myosin 5C /DB_XREF = gi: 9055283 /UG = Hs.111782 myosin 5C /FL = gb: AF272390.1 gb: NM_018728.1 205564_at gb: NM_007003.1 /DEF = Homo sapiens JM27 protein (JM27), mRNA. /FEA = mRNA /GEN = JM27 /PROD = JM27 protein /DB_XREF = gi: 5901985 /UG = Hs.95420 JM27 protein /FL = gb: AJ005894.1 gb: NM_007003.1 gb: AF275258.1 215646_s_at Consensus includes gb: R94644 /FEA = EST /DB_XREF = gi: 970039 /DB_XREF = est: yq42a12.r1 /CLONE = IMAGE: 198430 /UG = Hs.306542 Homo sapiens versican Vint isoform, mRNA, partial cds 219358_s_at gb: NM_018404.1 /DEF = Homo sapiens centaurin-alpha 2 protein (HSA272195), mRNA. /FEA = mRNA /GEN = HSA272195 /PROD = centaurin-alpha 2 protein /DB_XREF = gi: 8923762 /UG = Hs.28802 centaurin-alpha 2 protein /FL = gb: NM_618404.1 219439_at gb: NM_020156.1 /DEF = Homo sapiens core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3- galactosyltransferase (C1GALT1), mRNA. /FEA = mRNA /GEN = C1GALT1 /PROD = core1UDP-galactose:N- acetylgalactosamine-alpha-R beta1,3-galactosyltransferase /DB_XREF = gi: 9910143 /UG = Hs.46744 core1 UDP- galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase /FL = gb: AF155582.1 gb: NM_020156.1 204818_at gb: NM_002153.1 /DEF = Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 (HSD17B2), mRNA. /FEA = mRNA /GEN = HSD17B2 /PROD = hydroxysteroid (17-beta) dehydrogenase 2 /DB_XREF = gi: 4504502 /UG = Hs.155109 hydroxysteroid (17-beta) dehydrogenase 2 /FL = gb: L11708.1 gb: NM_002153.1 207813_s_at gb: NM_004110.2 /DEF = Homo sapiens ferredoxin reductase (FDXR), transcript variant 2, nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = FDXR /PROD = ferredoxin reductase isoform 2 precursor /DB_XREF = gi: 13435351 /UG = Hs.69745 ferredoxin reductase /FL = gb: NM_004110.2 gb: J03826.1 217971_at gb: NM_021970.1 /DEF = Homo sapiens MEK partner 1 (MP1), mRNA. /FEA = mRNA /GEN = MP1 /PROD = MEK partner 1 /DB_XREF = gi: 11496276 /UG = Hs.6361 MEK partner 1 /FL = gb: AF130115.1 gb: NM_021970.1 gb: AF201947.1 210570_x_at gb: U35002.1 /DEF = Human JNK2 beta1 protein kinase (JNK2B1) mRNA, complete cds. /FEA = mRNA /GEN = JNK2B1 /PROD = JNK2 beta1 protein kinase /DB_XREF = gi: 1463132 /UG = Hs.246857 mitogen-activated protein kinase 9 /FL = gb: U35002.1 gb: U35003.1 201647_s_at gb: NM_005506.1 /DEF = Homo sapiens CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II) (CD36L2), mRNA. /FEA = mRNA /GEN = CD36L2 /PROD = CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integralmembrane protein II) /DB_XREF = gi: 5031630 /UG = Hs.323567 CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II) /FL = gb: D12676.1 gb: NM_005506.1 218109_s_at gb: NM_022736.1 /DEF = Homo sapiens hypothetical protein FLJ14153 (FLJ14153), mRNA. /FEA = mRNA /GEN = FLJ14153 /PROD = hypothetical protein FLJ14153 /DB_XREF = gi: 12232392 /UG = Hs.7503 hypothetical protein FLJ14153 /FL = gb: NM_022736.1 gb: AB014732.1 205470_s_at gb: NM_006853.1 /DEF = Homo sapiens kallikrein 11 (KLK11), mRNA. /FEA = mRNA /GEN = KLK11 /PROD = kallikrein 11 /DB_XREF = gi: 5803198 /UG = Hs.57771 kallikrein 11 /FL = gb: AB012917.1 gb: NM_006853.1 gb: AB041036.1 208893_s_at gb: BC005047.1 /DEF = Homo sapiens, clone MGC: 12852, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 12852) /DB_XREF = gi: 13477170 /UG = Hs.180383 dual specificity phosphatase 6 /FL = gb: BC003562.1 gb: BC003143.1 gb: BC005047.1 gb: AB013382.1 gb: NM_001946.1 212771_at Consensus includes gb: AU150943 /FEA = EST /DB_XREF = gi: 11012464 /DB_XREF = est: AU150943 /CLONE = NT2RP2003984 /UG = Hs.66762 Homo sapiens mRNA; cDNA DKFZp564A026 (from clone DKFZp564A026) 203821_at gb: NM_001945.1 /DEF = Homo sapiens diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) (DTR), mRNA. /FEA = mRNA /GEN = DTR /PROD = diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) /DB_XREF = gi: 4503412 /UG = Hs.799 diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) /FL = gb: M60278.1 gb: NM_001945.1 202620_s_at gb: NM_000935.1 /DEF = Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 (PLOD2), mRNA. /FEA = mRNA /GEN = PLOD2 /PROD = procollagen-lysine, 2-oxoglutarate 5-dioxygenase(lysine hydroxylase) 2 /DB_XREF = gi: 4505888 /UG = Hs.41270 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 /FL = gb: U84573.1 gb: NM_000935.1 203973_s_at gb: NM_005195.1 /DEF = Homo sapiens CCAATenhancer binding protein (CEBP), delta (CEBPD), mRNA. /FEA = mRNA /GEN = CEBPD /PROD = CCAATenhancer binding protein (CEBP), delta /DB_XREF = gi: 4885130 /UG = Hs.76722 CCAATenhancer binding protein (CEBP), delta /FL = gb: M83667.1 gb: NM_005195.1 202133_at Consensus includes gb: BF674349 /FEA = EST /DB_XREF = gi: 11948244 /DB_XREF = est: 602137094F1 /CLONE = IMAGE: 4273679 /UG = Hs.24341 transcriptional co-activator with PDZ-binding motif (TAZ) /FL = gb: NM_015472.1 213001_at Consensus includes gb: AF007150.1 /DEF = Homo sapiens clone 23767 and 23782 mRNA sequences. /FEA = mRNA /DB_XREF = gi: 2852628 /UG = Hs.8025 Homo sapiens clone 23767 and 23782 mRNA sequences 211564_s_at gb: BC003096.1 /DEF = Homo sapiens, Similar to LIM domain protein, clone MGC: 1645, mRNA, complete cds. /FEA = mRNA /PROD = Similar to LIM domain protein /DB_XREF = gi: 13111856 /UG = Hs.79691 LIM domain protein /FL = gb: BC003096.1 210122_at gb: BC005303.1 /DEF = Homo sapiens, Similar to protamine 2, clone MGC: 12373, mRNA, complete cds. /FEA = mRNA /PROD = Similar to protamine 2 /DB_XREF = gi: 13529034 /UG = Hs.2324 protamine 2 /FL = gb: BC005303.1 gb: NM_002762.1 222369_at Consensus includes gb: AW971254 /FEA = EST /DB_XREF = gi: 8161099 /DB_XREF = est: EST383343 /UG = Hs.178433 ESTs 214651_s_at Consensus includes gb: U41813.1 /DEF = Human class I homeoprotein (HOXA9) mRNA, partial cds. /FEA = mRNA /GEN = HOXA9 /PROD = HOXA9 /DB_XREF = gi: 1184168 /UG = Hs.127428 homeo box A9 /FL = gb: NM_002142.1 211528_x_at gb: M90685.1 /DEF = Human lymphocyte antigen (HLA-G2.2) mRNA, complete cds. /FEA = mRNA /GEN = HLA-G2.2 /PROD = b2 microglobulin /DB_XREF = gi: 184211 /UG = Hs.73885 HLA-G histocompatibility antigen, class I, G /FL = gb: M90685.1 201431_s_at gb: NM_001387.1 /DEF = Homo sapiens dihydropyrimidinase-like 3 (DPYSL3), mRNA. /FEA = mRNA /GEN = DPYSL3 /PROD = dihydropyrimidinase-like 3 /DB_XREF = gi: 4503378 /UG = Hs.74566 dihydropyrimidinase-like 3 /FL = gb: D78014.1 gb: NM_001387.1 222062_at Consensus includes gb: AI983115 /FEA = EST /DB_XREF = gi: 5810334 /DB_XREF = est: wu18b02.x1 /CLONE = IMAGE: 2517291 /UG = Hs.132781 class I cytokine receptor 213479_at Consensus includes gb: U26662.1 /DEF = Human neuronal pentraxin II (NPTX2) mRNA, partial cds. /FEA = mRNA /GEN = NPTX2 /PROD = neuronal pentraxin II /DB_XREF = gi: 881933 /UG = Hs.3281 neuronal pentraxin II 219683_at gb: NM_017412.1 /DEF = Homo sapiens frizzled (Drosophila) homolog 3 (FZD3), mRNA. /FEA = mRNA /GEN = FZD3 /PROD = frizzled (Drosophila) homolog 3 /DB_XREF = gi: 8393377 /UG = Hs.40735 frizzled (Drosophila) homolog 3 /FL = gb: AY005130.3 gb: AB039723.1 gb: NM_017412.1 202890_at Consensus includes gb: AW242297 /FEA = EST /DB_XREF = gi: 6576051 /DB_XREF = est: xm96b11.x1 /CLONE = IMAGE: 2692029 /UG = Hs.146388 microtubule-associated protein 7 /FL = gb: NM_003980.1 201147_s_at Consensus includes gb: BF347089 /FEA = EST /DB_XREF = gi: 11294684 /DB_XREF = est: 602020842F1 /CLONE = IMAGE: 4156354 /UG = Hs.245188 tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) /FL = gb: U67195.1 gb: U02571.1 gb: U14394.1 gb: NM_000362.2 214721_x_at Consensus includes gb: AL162074.1 /DEF = Homo sapiens mRNA: cDNA DKFZp762L106 (from clone DKFZp762L106), partial cds. /FEA = mRNA /GEN = DKFZp762L106 /PROD = hypothetical protein /DB_XREF = gi: 7328153 /UG = Hs.3903 Cdc42 effector protein 4: binder of Rho GTPases 4 200968_s_at gb: NM_000942.1 /DEF = Homo sapiens peptidylprolyl isomerase B (cyclophilin B) (PPIB), mRNA. /FEA = mRNA /GEN = PPIB /PROD = peptidylprolyl isomerase B (cyclophilin B) /DB_XREF = gi: 4758949 /UG = Hs.699 peptidylprolyl isomerase B (cyclophilin B) /FL = gb: BC001125.1 gb: M60857.1 gb: M63573.1 gb: NM_000942.1 212430_at Consensus includes gb: AL109955 /DEF = Human DNA sequence from clone RP4-800J21 on chromosome 20 Contains ESTs, STSs, GSSs and CpG islands. Contains the 3 part of the RAE1 gene for a homolog to RNA export protein 1 from S. pombe and the gene for the ssDNA binding protein SEB4D.n /FEA = mRNA_1 /DB_XREF = gi: 11558768 /UG = Hs.236361 seb4D 59644_at Cluster Incl. AI735391: at10e09.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2354728 /clone_end = 3 /gb = AI735391 /gi = 5056915 /ug = Hs.20137 /len = 567 214912_at Consensus includes gb: AK022067.1 /DEF = Homo sapiens cDNA FLJ12005 fis, clone HEMBB1001565. /FEA = mRNA /DB_XREF = gi: 10433387 /UG = Hs.287477 Homo sapiens cDNA FLJ12005 fis, clone HEMBB1001565 203894_at gb: NM_016437.1 /DEF = Homo sapiens tubulin, gamma 2 (TUBG2), mRNA. /FEA = mRNA /GEN = TUBG2 /PROD = tubulin, gamma 2 /DB_XREF = gi: 7706750 /UG = Hs.279669 tubulin, gamma 2 /FL = gb: AF225971.1 gb: NM_016437.1 211530_x_at gb: M90686.1 /DEF = Human lymphocyte antigen (HLA-G3) mRNA, complete cds. /FEA = mRNA /GEN = HLA-G3 /PROD = b2 microglobulin /DB_XREF = gi: 184213 /UG = Hs.73885 HLA-G histocompatibility antigen, class I, G /FL = gb: M90686.1 222056_s_at Consensus includes gb: AA723370 /FEA = EST /DB_XREF = gi: 2741077 /DB_XREF = est: zg73a01.s1 /CLONE = IMAGE: 398952 /UG = Hs.279932 CGI-105 protein 209099_x_at gb: U73936.1 /DEF = Homo sapiens Jagged 1 (HJ1) mRNA, complete cds. /FEA = mRNA /GEN = HJ1 /PROD = Jagged 1 /DB_XREF = gi: 1695273 /UG = Hs.91143 jagged 1 (Alagille syndrome) /FL = gb: U61276.1 gb: U73936.1 gb: AF003837.1 gb: AF028593.1 gb: NM_000214.1 218193_s_at gb: NM_016072.1 /DEF = Homo sapiens CGI-141 protein (LOC51026), mRNA. /FEA = mRNA /GEN = LOC51026 /PROD = CGI-141 protein /DB_XREF = gi: 7705635 /UG = Hs.62275 CGI-141 protein /FL = gb: AF151899.1 gb: AL136571.1 gb: NM_016072.1 205066_s_at gb: NM_006208.1 /DEF = Homo sapiens ectonucleotide pyrophosphatasephosphodiesterase 1 (ENPP1), mRNA. /FEA = mRNA /GEN = ENPP1 /PROD = ectonucleotide pyrophosphatasephosphodiesterase1 /DB_XREF = gi: 13324676 /UG = Hs.11951 ectonucleotide pyrophosphatasephosphodiesterase 1 /FL = gb: NM_006208.1 gb: M57736.1 209710_at Consensus includes gb: AL563460 /FEA = EST /DB_XREF = gi: 12912874 /DB_XREF = est: AL563460 /CLONE = CS0DD006YG06 (3 prime) /UG = Hs.760 GATA-binding protein 2 /FL = gb: M68891.1 220402_at gb: NM_022112.1 /DEF = Homo sapiens p53-regulated apoptosis-inducing protein 1 (P53AIP1), mRNA. /FEA = mRNA /GEN = P53AIP1 /PROD = p53-regulated apoptosis-inducing protein 1 /DB_XREF = gi: 11545826 /UG = Hs.160953 p53- regulated apoptosis-inducing protein 1 /FL = gb: AB045832.1 gb: NM_022112.1 209295_at gb: AF016266.1 /DEF = Homo sapiens TRAIL receptor 2 mRNA, complete cds. /FEA = mRNA /PROD = TRAIL receptor 2 /DB_XREF = gi: 2529562 /UG = Hs.51233 tumor necrosis factor receptor superfamily, member 10b /FL = gb: BC001281.1 gb: AF018658.1 gb: AF016849.1 gb: AF016266.1 203395_s_at gb: NM_005524.2 /DEF = Homo sapiens hairy (Drosophila)-homolog (HRY), mRNA. /FEA = mRNA /GEN = HRY /PROD = hairy (Drosophila)-homolog /DB_XREF = gi: 8400709 /UG = Hs.250666 hairy (Drosophila)-homolog /FL = gb: AF264785.1 gb: NM_005524.2 222116_s_at Consensus includes gb: AL157485.1 /DEF = Homo sapiens mRNA; cDNA DKFZp762O207 (from clone DKFZp762O207). /FEA = mRNA /DB_XREF = gi: 7018528 /UG = Hs.91973 hypothetical protein 202723_s_at Consensus includes gb: AW117498 /FEA = EST /DB_XREF = gi: 6086082 /DB_XREF = est: xd92e10.x1 /CLONE = IMAGE: 2605098 /UG = Hs.170133 forkhead box O1A (rhabdomyosarcoma) /FL = gb: AF032885.1 gb: U02310.1 gb: NM_002015.2 203687_at gb: NM_002996.1 /DEF = Homo sapiens small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine, neurotactin) (SCYD1), mRNA. /FEA = mRNA /GEN = SCYD1 /PROD = small inducible cytokine subfamily D(Cys-X3- Cys), member 1 (fractalkine, neurotactin) /DB_XREF = gi: 4506856 /UG = Hs.80420 small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine, neurotactin) /FL = gb: BC001163.1 gb: U84487.1 gb: U91835.1 gb: NM_002996.1 220782_x_at gb: NM_019598.1 /DEF = Homo sapiens kallikrein 12 (KLK12), mRNA. /FEA = mRNA /GEN = KLK12 /PROD = kallikrein 12 /DB_XREF = gi: 9665235 /UG = Hs.159679 kallikrein 12 /FL = gb: NM_019598.1 204714_s_at gb: NM_000130.2 /DEF = Homo sapiens coagulation factor V (proaccelerin, labile factor) (F5), mRNA. /FEA = mRNA /GEN = F5 /PROD = coagulation factor V precursor /DB_XREF = gi: 10518500 /UG = Hs.30054 coagulation factor V (proaccelerin, labile factor) /FL = gb: NM_000130.2 gb: M16967.1 gb: M14335.1 214512_s_at Consensus includes gb: NM_006713.1 /DEF = Homo sapiens activated RNA polymerase II transcription cofactor 4 (PC4), mRNA. /FEA = CDS /GEN = PC4 /PROD = activated RNA polymerase II transcriptioncofactor 4 /DB_XREF = gi: 5729967 /UG = Hs.74861 activated RNA polymerase II transcription cofactor 4 /FL = gb: U12979.1 gb: NM_006713.1 221558_s_at gb: AF288571.1 /DEF = Homo sapiens lymphoid enhancer factor-1 (LEF1) mRNA, complete cds. /FEA = mRNA /GEN = LEF1 /PROD = lymphoid enhancer factor-1 /DB_XREF = gi: 9858157 /UG = Hs.44865 lymphoid enhancer binding factor-1 /FL = gb: AF198532.1 gb: NM_016269.1 gb: AF288571.1 207828_s_at gb: NM_005196.1 /DEF = Homo sapiens centromere protein F (350400 kD, mitosin) (CENPF), mRNA. /FEA = mRNA /GEN = CENPF /PROD = centromere protein F (350400 kD, mitosin) /DB_XREF = gi: 4885132 /UG = Hs.77204 centromere protein F (350400 kD, mitosin) /FL = gb: NM_005196.1 gb: U19769.1 215016_x_at Consensus includes gb: BC004912.1 /DEF = Homo sapiens, clone IMAGE: 3534745, mRNA, partial cds. /FEA = mRNA /PROD = Unknown (protein for IMAGE: 3534745) /DB_XREF = gi: 13436208 /UG = Hs.198689 KIAA0728 protein 221878_at Consensus includes gb: BF110411 /FEA = EST /DB_XREF = gi: 10940101 /DB_XREF = est: 7n52f02.x1 /CLONE = IMAGE: 3568274 /UG = Hs.16959 ESTs 219209_at gb: NM_022168.1 /DEF = Homo sapiens melanoma differentiation associated protein-5 (MDA5), mRNA. /FEA = mRNA /GEN = MDA5 /PROD = melanoma differentiation associated protein-5 /DB_XREF = gi: 11545921 /UG = Hs.293591 melanoma differentiation associated protein-5 /FL = gb: AF095844.1 gb: NM_022168.1 gb: AY017378.1 219489_s_at gb: NM_017821.1 /DEF = Homo sapiens hypothetical protein FLJ20435 (FLJ20435), mRNA. /FEA = mRNA /GEN = FLJ20435 /PROD = hypothetical protein FLJ20435 /DB_XREF = gi: 8923408 /UG = Hs.11408 hypothetical protein FLJ20435 /FL = gb: NM_017821.1 207352_s_at gb: NM_021911.1 /DEF = Homo sapiens gamma-aminobutyric acid (GABA) A receptor, beta 2 (GABRB2), transcript variant 1, mRNA. /FEA = mRNA /GEN = GABRB2 /PROD = gamma-aminobutyric acid (GABA) A receptor, beta2, isoform 1 /DB_XREF = gi: 12548784 /UG = Hs.103998 gamma-aminobutyric acid (GABA) A receptor, beta 2 /FL = gb: NM_021911.1 206605_at gb: NM_006025.1 /DEF = Homo sapiens protease, serine, 22 (P11), mRNA. /FEA = mRNA /GEN = P11 /PROD = protease, serine, 22 /DB_XREF = gi: 5174622 /UG = Hs.997 protease, serine, 22 /FL = gb: M32402.1 gb: NM_006025.1 203753_at gb: NM_003199.1 /DEF = Homo sapiens transcription factor 4 (TCF4), mRNA. /FEA = mRNA /GEN = TCF4 /PROD = transcription factor 4, isoform b /DB_XREF = gi: 4507398 /UG = Hs.326198 transcription factor 4 /FL = gb: M74719.1 gb: NM_003199.1 217999_s_at Consensus includes gb: NM_007350.1 /DEF = Homo sapiens pleckstrin homology-like domain, family A, member 1 (PHLDA1), mRNA. /FEA = mRNA /GEN = PHLDA1 /PROD = pleckstrin homology-like domain, family A, member 1 /DB_XREF = gi: 6679302 /UG = Hs.82101 pleckstrin homology-like domain, family A, member 1 /FL = gb: NM_007350.1 208188_at gb: NM_000226.1 /DEF = Homo sapiens keratin 9 (epidermolytic palmoplantar keratoderma) (KRT9), mRNA. /FEA = mRNA /GEN = KRT9 /PROD = keratin 9 /DB_XREF = gi: 4557704 /UG = Hs.2783 keratin 9 (epidermolytic palmoplantar keratoderma) /FL = gb: NM_000226.1 211685_s_at gb: AF251061.1 /DEF = Homo sapiens neurocalcin mRNA, complete cds. /FEA = mRNA /PROD = neurocalcin /DB_XREF = gi: 13625183 /FL = gb: AF251061.1 209691_s_at gb: BC003541.1 /DEF = Homo sapiens, hypothetical protein FLJ10488, clone MGC: 10806, mRNA, complete cds. /FEA = mRNA /PROD = hypothetical protein FLJ10488 /DB_XREF = gi: 13097653 /UG = Hs.279832 hypothetical protein FLJ10488 /FL = gb: BC003541.1 213362_at Consensus includes gb: N73931 /FEA = EST /DB_XREF = gi: 1231216 /DB_XREF = est: za74a07.s1 /CLONE = IMAGE: 298260 /UG = Hs.323079 Homo sapiens mRNA; cDNA DKFZp564P116 (from clone DKFZp564P116) 203179_at gb: NM_000155.1 /DEF = Homo sapiens galactose-1-phosphate uridylyltransferase (GALT), mRNA. /FEA = mRNA /GEN = GALT /PROD = galactose-1-phosphate uridylyltransferase /DB_XREF = gi: 4557614 /UG = Hs.75641 galactose-1- phosphate uridylyltransferase /FL = gb: M60091.1 gb: NM_000155.1 208812_x_at gb: BC004489.1 /DEF = Homo sapiens, major histocompatibility complex, class I, C, clone MGC: 11039, mRNA, complete cds. /FEA = mRNA /PROD = major histocompatibility complex, class I, C /DB_XREF = gi: 13325360 /UG = Hs.277477 major histocompatibility complex, class I, C /FL = gb: NM_002117.1 gb: M99388.1 gb: U06487.1 gb: BC002463.1 gb: BC004489.1 gb: D64145.1 gb: D38526.1 gb: D49552.1 gb: D49819.1 gb: M24097.1 gb: M84171.1 gb: M84172.1 gb: M84173.1 gb: M84174.1 gb: M26429.1 gb: M26430.1 gb: M26431.1 gb: U41420.1 gb: U41386.1 gb: D50852.1 gb: D50853.1 gb: D50854.1 gb: D83031.1 gb: U57028.1 gb: U06695.1 gb: U06696.1 gb: M99389.1 gb: M99390.1 gb: M28160.1 gb: U09853.1 gb: AF168611.1 gb: L38251.1 gb: D31817.1 213909_at Consensus includes gb: AU147799 /FEA = EST /DB_XREF = gi: 11009320 /DB_XREF = est: AU147799 /CLONE = MAMMA1001744 /UG = Hs.288467 Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744 216449_x_at Consensus includes gb: AK025862.1 /DEF = Homo sapiens cDNA: FLJ22209 fis, clone HRC01496. /FEA = mRNA /DB_XREF = gi: 10438505 /UG = Hs.288528 Homo sapiens cDNA: FLJ22209 fis, clone HRC01496 204118_at gb: NM_001778.1 /DEF = Homo sapiens CD48 antigen (B-cell membrane protein) (CD48), mRNA. /FEA = mRNA /GEN = CD48 /PROD = CD48 antigen (B-cell membrane protein) /DB_XREF = gi: 4502674 /UG = Hs.901 CD48 antigen (B- cell membrane protein) /FL = gb: M59904.1 gb: M37766.1 gb: NM_001778.1 205030_at gb: NM_001446.1 /DEF = Homo sapiens fatty acid binding protein 7, brain (FABP7), mRNA. /FEA = mRNA /GEN = ABP7 /PROD = fatty acid binding protein 7, brain /DB_XREF = gi: 4557584 /UG = Hs.26770 fatty acid binding protein 7, brain /FL = gb: D50373.1 gb: U51338.1 gb: D88648.1 gb: U81235.1 gb: NM_001446.1 215358_x_at Consensus includes gb: AK026980.1 /DEF = Homo sapiens cDNA: FLJ23327 fis, clone HEP12630, highly similar to HSZNF37 Homo sapiens ZNF37A mRNA for zinc finger protein. /FEA = mRNA /DB_XREF = gi: 10439974 /UG = Hs.278064 Homo sapiens cDNA: FLJ23327 fis, clone HEP12630, highly similar to HSZNF37 Homo sapiens ZNF37A mRNA for zinc finger protein 218557_at gb: NM_020202.1 /DEF = Homo sapiens Nit protein 2 (NIT2), mRNA. /FEA = mRNA /GEN = NIT2 /PROD = Nit protein 2 /DB_XREF = gi: 9910459 /UG = Hs.15627 Nit protein 2 /FL = gb: AF260334.1 gb: AF284574.1 gb: NM_020202.1 203124_s_at gb: NM_000617.1 /DEF = Homo sapiens solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 (SLC11A2), mRNA. /FEA = mRNA /GEN = SLC11A2 /PROD = solute carrier family 11 (proton- coupleddivalent metal ion transporters), member 2 /DB_XREF = gi: 10835168 /UG = Hs.57435 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 /FL = gb: NM_000617.1 gb: BC002592.1 gb: AB004857.1 gb: AF046997.1 219305_x_at gb: NM_012168.1 /DEF = Homo sapiens F-box only protein 2 (FBXO2), mRNA. /FEA = mRNA /GEN = FBXO2 /PROD = F-box only protein 2 /DB_XREF = gi: 6912363 /UG = Hs.132753 F-box only protein 2 /FL = gb: NM_012168.1 205807_s_at gb: NM_020127.1 /DEF = Homo sapiens tuftelin 1 (TUFT1), mRNA. /FEA = mRNA /GEN = TUFT1 /PROD = tuftelin 1 /DB_XREF = gi: 9910595 /UG = Hs.283009 tuftelin 1 /FL = gb: AL136917.1 gb: AF254260.1 gb: NM_020127.1 42361_g_at Cluster Incl. AI588986: tk15g03.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2151124 /clone_end = 3 /gb = AI588986 /gi = 4598034 /ug = Hs.236209 /len = 499 213224_s_at Consensus includes gb: AK025724.1 /DEF = Homo sapiens cDNA: FLJ22071 fis, clone HEP11691. /FEA = mRNA /DB_XREF = gi: 10438333 /UG = Hs.326248 Homo sapiens cDNA: FLJ22071 fis, clone HEP11691 210142_x_at gb: AF117234.1 /DEF = Homo sapiens flotillin mRNA, complete cds. /FEA = mRNA /PROD = flotillin /DB_XREF = gi: 6563241 /UG = Hs.179986 flotillin 1 /FL = gb: AF117234.1 214297_at Consensus includes gb: BE857703 /FEA = EST /DB_XREF = gi: 10371993 /DB_XREF = est: 7g46a02.x1 /CLONE = IMAGE: 3309482 /UG = Hs.9004 chondroitin sulfate proteoglycan 4 (melanoma-associated) 203555_at gb: NM_014369.1 /DEF = Homo sapiens protein tyrosine phosphatase, non-receptor type 18 (brain-derived) (PTPN18), mRNA. /FEA = mRNA /GEN = PTPN18 /PROD = protein tyrosine phosphatase, non-receptor type18 (brain-derived) /DB_XREF = gi: 7657483 /UG = Hs.278597 protein tyrosine phosphatase, non-receptor type 18 (brain-derived) /FL = gb: NM_014369.1 211464_x_at gb: U20537.1 /DEF = Human cysteine protease Mch2 isoform beta (Mch2) mRNA, complete cds. /FEA = mRNA /GEN = Mch2 /PROD = cysteine protease Mch2 isoform beta /DB_XREF = gi: 882255 /UG = Hs.3280 caspase 6, apoptosis- related cysteine protease /FL = gb: U20537.1 221521_s_at gb: BC003186.1 /DEF = Homo sapiens, HSPC037 protein, clone MGC: 673, mRNA, complete cds. /FEA = mRNA /PROD = HSPC037 protein /DB_XREF = gi: 13112024 /UG = Hs.108196 HSPC037 protein /FL = gb: BC003186.1 gb: AF201939.1 207146_at gb: NM_002278.1 /DEF = Homo sapiens keratin, hair, acidic, 2 (KRTHA2), mRNA. /FEA = mRNA /GEN = KRTHA2 /PROD = type I hair keratin 2 /DB_XREF = gi: 4504922 /UG = Hs.41752 keratin, hair, acidic, 2 /FL = gb: NM_002278.1 219880_at gb: NM_022907.1 /DEF = Homo sapiens hypothetical protein FLJ23053 (FLJ23053), mRNA. /FEA = mRNA /GEN = FLJ23053 /PROD = hypothetical protein FLJ23053 /DB_XREF = gi: 12597650 /UG = Hs.94037 hypothetical protein FLJ23053 /FL = gb: NM_022907.1 212298_at Consensus includes gb: BE620457 /FEA = EST /DB_XREF = gi: 9891395 /DB_XREF = est: 601483690F1 /CLONE = IMAGE: 3886055 /UG = Hs.69285 neuropilin 1 /FL = gb: AF018956.1 gb: AF016050.1 gb: NM_003873.1 212990_at Consensus includes gb: AB020717.1 /DEF = Homo sapiens mRNA for KIAA0910 protein, partial cds. /FEA = mRNA /GEN = KIAA0910 /PROD = KIAA0910 protein /DB_XREF = gi: 4240308 /UG = Hs.127416 synaptojanin 1 210305_at gb: AB042557.1 /DEF = Homo sapiens mRNA, similar to rat myomegalin, complete cds. /FEA = mRNA /DB_XREF = gi: 11138039 /UG = Hs.265848 similar to rat myomegalin /FL = gb: AB042557.1 217311_at Consensus includes gb: AF086790.1 /DEF = Homo sapiens aconitase precursor (ACON) mRNA, nuclear gene encoding mitochondrial protein, partial cds. /FEA = mRNA /GEN = ACON /PROD = aconitase precursor /DB_XREF = gi: 3600097 /UG = Hs.166002 Homo sapiens aconitase precursor (ACON) mRNA, nuclear gene encoding mitochondrial protein, partial cds 209539_at Consensus includes gb: D25304.1 /DEF = Human mRNA for KIAA0006 gene, partial cds. /FEA = mRNA /GEN = KIAA0006 /DB_XREF = gi: 435445 /UG = Hs.79307 RacCdc42 guanine exchange factor (GEF) 6 /FL = gb: D13631.1 200776_s_at Consensus includes gb: AL518328 /FEA = EST /DB_XREF = gi: 12781821 /DB_XREF = est: AL518328 /CLONE = CS0DA009YK18 (3 prime) /UG = Hs.155291 KIAA0005 gene product /FL = gb: D13630.1 gb: NM_014670.1 217699_at Consensus includes gb: AV700338 /FEA = EST /DB_XREF = gi: 10302309 /DB_XREF = est: AV700338 /CLONE = GKCAMH12 /UG = Hs.286243 ESTs 202716_at gb: NM_002827.1 /DEF = Homo sapiens protein tyrosine phosphatase, non-receptor type 1 (PTPN1), mRNA. /FEA = mRNA /GEN = PTPN1 /PROD = protein tyrosine phosphatase, non-receptor type1 /DB_XREF = gi: 4506288 /UG = Hs.155894 protein tyrosine phosphatase, non-receptor type 1 /FL = gb: M33689.1 gb: M31724.1 gb: NM_002827.1 211787_s_at gb: BC006210.1 /DEF = Homo sapiens, Similar to eukaryotic translation initiation factor 4A, isoform 1, clone MGC: 8484, mRNA, complete cds. /FEA = mRNA /PROD = Similar to eukaryotic translation initiationfactor 4A, isoform 1 /DB_XREF = gi: 13623224 /FL = gb: BC006210.1 215985_at Consensus includes gb: X92110.1 /DEF = H. sapiens mRNA for hcgVIII protein. /FEA = mRNA /DB_XREF = gi: 1216163 /UG = Hs.153618 HCGVIII-1 protein 216442_x_at Consensus includes gb: AK026737.1 /DEF = Homo sapiens cDNA: FLJ23084 fis, clone LNG06602, highly similar to HSFIB1 Human mRNA for fibronectin (FN precursor). /FEA = mRNA /DB_XREF = gi: 10439658 /UG = Hs.287820 fibronectin 1 206111_at gb: NM_002934.1 /DEF = Homo sapiens ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) (RNASE2), mRNA. /FEA = mRNA /GEN = RNASE2 /PROD = ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) /DB_XREF = gi: 4506548 /UG = Hs.728 ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) /FL = gb: M24157.1 gb: M30510.1 gb: NM_002934.1 gb: M28129.1 208044_s_at gb: NM_006238.1 /DEF = Homo sapiens peroxisome proliferative activated receptor, delta (PPARD), mRNA. /FEA = mRNA /GEN = PPARD /PROD = peroxisome proliferative activated receptor, delta /DB_XREF = gi: 5453939 /UG = Hs.106415 peroxisome proliferative activated receptor, delta /FL = gb: L07592.1 gb: NM_006238.1 202579_x_at gb: NM_006353.1 /DEF = Homo sapiens high-mobility group (nonhistone chromosomal) protein 17-like 3 (HMG17L3), mRNA. /FEA = mRNA /GEN = HMG17L3 /PROD = high-mobility group (nonhistone chromosomal)protein 17-like 3 /DB_XREF = gi: 10835239 /UG = Hs.236774 high-mobility group (nonhistone chromosomal) protein 17-like 3 /FL = gb: NM_006353.1 gb: U90549.1 218853_s_at gb: NM_019556.1 /DEF = Homo sapiens hypothetical protein dJ473B4 (DJ473B4), mRNA. /FEA = mRNA /GEN = DJ473B4 /PROD = hypothetical protein dJ473B4 /DB_XREF = gi: 9506542 /UG = Hs.57549 hypothetical protein dJ473B4 /FL = gb: NM_019556.1 218245_at gb: NM_015516.1 /DEF = Homo sapiens hypothetical protein, estradiol-induced (E2IG4), mRNA. /FEA = mRNA /GEN = E2IG4 /PROD = hypothetical protein, estradiol-induced /DB_XREF = gi: 7661667 /UG = Hs.8361 hypothetical protein, estradiol-induced /FL = gb: AF191019.1 gb: NM_015516.1 202974_at gb: NM_002436.2 /DEF = Homo sapiens membrane protein, palmitoylated 1 (55 kD) (MPP1), mRNA. /FEA = mRNA /GEN = MPP1 /PROD = palmitoylated membrane protein 1 /DB_XREF = gi: 6006024 /UG = Hs.1861 membrane protein, palmitoylated 1 (55 kD) /FL = gb: BC002392.1 gb: M64925.1 gb: NM_002436.2 212127_at Consensus includes gb: BE379408 /FEA = EST /DB_XREF = gi: 9324773 /DB_XREF = est: 601237213F1 /CLONE = IMAGE: 3609315 /UG = Hs.183800 Ran GTPase activating protein 1 /FL = gb: NM_002883.1 201798_s_at gb: NM_013451.1 /DEF = Homo sapiens fer-1 (C. elegans)-like 3 (myoferlin) (FER1L3), mRNA. /FEA = mRNA /GEN = FER1L3 /PROD = fer-1 (C. elegans)-like 3 (myoferlin) /DB_XREF = gi: 7305052 /UG = Hs.234680 fer-1 (C. elegans). like 3 (myoferlin) /FL = gb: AF182316.1 gb: NM_013451.1 205680_at gb: NM_002425.1 /DEF = Homo sapiens matrix metalloproteinase 10 (stromelysin 2) (MMP10), mRNA. /FEA = mRNA /GEN = MMP10 /PROD = matrix metalloproteinase 10 preproprotein /DB_XREF = gi: 4505204 /UG = Hs.2258 matrix metalloproteinase 10 (stromelysin 2) /FL = gb: BC002591.1 gb: NM_002425.1 214316_x_at Consensus includes gb: AI378706 /FEA = EST /DB_XREF = gi: 4188559 /DB_XREF = est: tb91f09.x1 /CLONE = IMAGE: 2061737 /UG = Hs.16488 calreticulin 212919_at Consensus includes gb: AV715578 /FEA = EST /DB_XREF = gi: 10797095 /DB_XREF = est: AV715578 /CLONE = DCBBJG09 /UG = Hs.21056 Homo sapiens cDNA: FLJ21366 fis, clone COL03012, highly similar to AB002445 Homo sapiens mRNA from chromosome 5q21-22 203917_at gb: NM_001338.1 /DEF = Homo sapiens coxsackie virus and adenovirus receptor (CXADR), mRNA. /FEA = mRNA /GEN = CXADR /PROD = coxsackie virus and adenovirus receptor /DB_XREF = gi: 4503172 /UG = Hs.79187 coxsackie virus and adenovirus receptor /FL = gb: BC003684.1 gb: U90716.1 gb: NM_001338.1 214014_at Consensus includes gb: W81196 /FEA = EST /DB_XREF = gi: 1392235 /DB_XREF = est: zd85d03.s1 /CLONE = IMAGE: 347429 /UG = Hs.12289 Cdc42 effector protein 2 219051_x_at gb: NM_024042.1 /DEF = Homo sapiens hypothetical protein MGC2601 (MGC2601), mRNA. /FEA = mRNA /GEN = MGC2601 /PROD = hypothetical protein MGC2601 /DB_XREF = gi: 13128999 /UG = Hs.124915 hypothetical protein MGC2601 /FL = gb: BC000662.1 gb: NM_024042.1 219135_s_at Consensus includes gb: AL515916 /FEA = EST /DB_XREF = gi: 12779409 /DB_XREF = est: AL515916 /CLONE = CS0DA001YH18 (3 prime) /UG = Hs.58362 hypothetical protein FLJ12681 /FL = gb: NM_022773.1 211143_x_at gb: D49728.1 /DEF = Human NAK1 mRNA for DNA binding protein, complete cds. /FEA = mRNA /GEN = NAK1 /PROD = DNA binding protein /DB_XREF = gi: 1813881 /UG = Hs.1119 nuclear receptor subfamily 4, group A, member 1 /FL = gb: D49728.1 203188_at gb: NM_006876.1 /DEF = Homo sapiens i-beta-1,3-N-acetylglucosaminyltransferase (BETA3GNTI), mRNA. /FEA = mRNA /GEN = BETA3GNTI /PROD = i-beta-1,3-N-acetylglucosaminyltransferase /DB_XREF = gi: 5802983 /UG = Hs.8526 i-beta-1,3-N-acetylglucosaminyltransferase /FL = gb: AF029893.1 gb: NM_006876.1 205839_s_at gb: NM_004758.1 /DEF = Homo sapiens peripheral benzodiazepine receptor-associated protein 1 (PRAX-1), mRNA. /FEA = mRNA /GEN = PRAX-1 /PROD = peripheral benzodiazepine receptor-associatedprotein 1 /DB_XREF = gi: 4758955 /UG = Hs.112499 peripheral benzodiazepine receptor-associated protein 1 /FL = gb: AF039571.1 gb: NM_004758.1 200890_s_at Consensus includes gb: AW006345 /FEA = EST /DB_XREF = gi: 5855123 /DB_XREF = est: wt04d05.x1 /CLONE = IMAGE: 2506473 /UG = Hs.250773 signal sequence receptor, alpha (translocon-associated protein alpha) /FL = gb: AF156965.1 gb: NM_003144.2 202967_at gb: NM_001512.1 /DEF = Homo sapiens glutathione S-transferase A4 (GSTA4), mRNA. /FEA = mRNA /GEN = GSTA4 /PROD = glutathione S-transferase A4 /DB_XREF = gi: 4504172 /UG = Hs.169907 glutathione S-transferase A4 /FL = gb: AF020918.1 gb: AF025887.1 gb: NM_001512.1 gb: AF125271.1 gb: AF125272.1 gb: AF125273.1 37170_at Cluster Incl. AB015331: Homo sapiens HRIHFB2017 mRNA, partial cds /cds = (0, 650) /gb = AB015331 /gi = 3970851 /ug = Hs.108903 /len = 1064 201830_s_at gb: NM_005863.1 /DEF = Homo sapiens neuroepithelial cell transforming gene 1 (NET1), mRNA. /FEA = mRNA /GEN = NET1 /PROD = neuroepithelial cell transforming gene 1 /DB_XREF = gi: 5031938 /UG = Hs.25155 neuroepithelial cell transforming gene 1 /FL = gb: NM_005863.1 gb: U02081.1 213825_at Consensus includes gb: AA757419 /FEA = EST /DB_XREF = gi: 2805282 /DB_XREF = est: zg36b11.s1 /CLONE = IMAGE: 395421 /UG = Hs.176977 protein kinase C binding protein 2 207540_s_at gb: NM_003177.1 /DEF = Homo sapiens spleen tyrosine kinase (SYK), mRNA. /FEA = mRNA /GEN = SYK /PROD = spleen tyrosine kinase /DB_XREF = gi: 4507328 /UG = Hs.74101 spleen tyrosine kinase /FL = gb: NM_003177.1 207008_at gb: NM_001557.1 /DEF = Homo sapiens interleukin 8 receptor, beta (IL8RB), mRNA. /FEA = mRNA /GEN = IL8RB /PROD = interleukin 8 receptor, beta /DB_XREF = gi: 4504682 /UG = Hs.846 interleukin 8 receptor, beta /FL = gb: M94582.1 gb: M73969.1 gb: NM_001557.1 gb: L19593.1 212671_s_at Consensus includes gb: BG397856 /FEA = EST /DB_XREF = gi: 13291304 /DB_XREF = est: 602438950F1 /CLONE = IMAGE: 4564956 /UG = Hs.198253 major histocompatibility complex, class II, DQ alpha 1 200962_at Consensus includes gb: AI348010 /FEA = EST /DB_XREF = gi: 4085216 /DB_XREF = est: qp61b10.x1 /CLONE = IMAGE: 1927483 /UG = Hs.184014 ribosomal protein L31 /FL = gb: NM_000993.1 205379_at gb: NM_001236.2 /DEF = Homo sapiens carbonyl reductase 3 (CBR3), mRNA. /FEA = mRNA /GEN = CBR3 /PROD = carbonyl reductase 3 /DB_XREF = gi: 7108334 /UG = Hs.154510 carbonyl reductase 3 /FL = gb: BC002812.1 gb: AB004854.1 gb: NM_001236.2 205599_at gb: NM_005658.1 /DEF = Homo sapiens TNF receptor-associated factor 1 (TRAF1), mRNA. /FEA = mRNA /GEN = TRAF1 /PROD = TNF receptor-associated factor 1 /DB_XREF = gi: 5032192 /UG = Hs.2134 TNF receptor- associated factor 1 /FL = gb: NM_005658.1 gb: U19261.1 206382_s_at gb: NM_001709.1 /DEF = Homo sapiens brain-derived neurotrophic factor (BDNF), mRNA. /FEA = mRNA /GEN = BDNF /PROD = brain-derived neurotrophic factor /DB_XREF = gi: 4502392 /UG = Hs.56023 brain-derived neurotrophic factor /FL = gb: NM_001709.1 215097_at Consensus includes gb: BG420053 /FEA = EST /DB_XREF = gi: 13326559 /DB_XREF = est: 602453740F1 /CLONE = IMAGE: 4592120 /UG = Hs.76368 capping protein (actin filament) muscle Z-line, beta 205130_at gb: NM_014226.1 /DEF = Homo sapiens renal tumor antigen (RAGE), mRNA. /FEA = mRNA /GEN = RAGE /PROD = renal tumor antigen /DB_XREF = gi: 7657497 /UG = Hs.104119 renal tumor antigen /FL = gb: AB022694.1 gb: NM_014226.1 217497_at Consensus includes gb: AW613387 /FEA = EST /DB_XREF = gi: 7318573 /DB_XREF = est: hh71e04.x1 /CLONE = IMAGE: 2968254 /UG = Hs.278541 ESTs, Moderately similar to TYPH_HUMAN THYMIDINE PHOSPHORYLASE PRECURSOR H. sapiens 221589_s_at Consensus includes gb: AW612403 /FEA = EST /DB_XREF = gi: 7317589 /DB_XREF = est: hh01b05.x1 /CLONE = IMAGE: 2953809 /UG = Hs.293970 methylmalonate-semialdehyde dehydrogenase /FL = gb: AF130089.1 213437_at Consensus includes gb: AA861784 /FEA = EST /DB_XREF = gi: 2953924 /DB_XREF = est: ak35d05.s1 /CLONE = IMAGE: 1407945 /UG = Hs.7972 KIAA0871 protein 210891_s_at gb: AF035737.1 /DEF = Homo sapiens general transcription factor 2-I (GTF2I) mRNA, complete cds. /FEA = mRNA /GEN = GTF2I /PROD = general transcription factor 2-I; alternativesplice product /DB_XREF = gi: 2827179 /UG = Hs.278589 general transcription factor II, i /FL = gb: AF035737.1 216942_s_at Consensus includes gb: D28586.1 /DEF = Human mRNA for LFA-3(delta D2), partial cds. /FEA = mRNA /PROD = LFA- 3(delta D2) /DB_XREF = gi: 466540 /UG = Hs.75626 CD58 antigen, (lymphocyte function-associated antigen 3) 203154_s_at gb: NM_005884.2 /DEF = Homo sapiens protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs (PAK4), mRNA. /FEA = mRNA /GEN = PAK4 /PROD = protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs /DB_XREF = gi: 7382497 /UG = Hs.20447 protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs /FL = gb: AF005046.1 gb: NM_005884.2 218852_at gb: NM_017917.1 /DEF = Homo sapiens hypothetical protein FLJ20644 (FLJ20644), mRNA. /FEA = mRNA /GEN = FLJ20644 /PROD = hypothetical protein FLJ20644 /DB_XREF = gi: 8923599 /UG = Hs.49376 hypothetical protein FLJ20644 /FL = gb: NM_017917.1 201315_x_at gb: NM_006435.1 /DEF = Homo sapiens interferon induced transmembrane protein 2 (1-8D) (IFITM2), mRNA. /FEA = mRNA /GEN = IFITM2 /PROD = interferon induced transmembrane protein 2(1-8D) /DB_XREF = gi: 10835237 /UG = Hs.174195 interferon induced transmembrane protein 2 (1-8D) /FL = gb: NM_006435.1 46665_at Cluster Incl. AI949392: wq11a04.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2470926 /clone_end = 3 /gb = AI949392 /gi = 5741790 /ug = Hs.7188 /len = 596 201616_s_at Consensus includes gb: AL577531 /FEA = EST /DB_XREF = gi: 12940753 /DB_XREF = est: AL577531 /CLONE = CS0DI087YP20 (3 prime) /UG = Hs.325474 caldesmon 1 /FL = gb: NM_004342.2 gb: M64110.1 219165_at gb: NM_021630.1 /DEF_Homo sapiens PDZ-LIM protein mystique (LOC59346), mRNA. /FEA = mRNA /GEN = LOC59346 /PROD = PDZ-LIM protein mystique /DB_XREF = gi: 11055999 /UG = Hs.19447 PDZ-LIM protein mystique /FL = gb: AY007729.1 gb: NM_021630.1 59625_at Cluster Incl. AI912351: tz24d02.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2289507 /clone_end = 3 /gb = AI912351 /gi = 5632206 /ug = Hs.198793 /len = 507 216037_x_at Consensus includes gb: AA664011 /FEA = EST /DB_XREF = gi: 2618002 /DB_XREF = est: ac03f10.s1 /CLONE = IMAGE: 855403 /UG = Hs.173638 transcription factor 7-like 2 (T-cell specific, HMG-box) 210874_s_at gb: BC004483.1 /DEF = Homo sapiens, putative tumor suppressor, clone MGC: 10586, mRNA, complete cds. /FEA = mRNA /PROD = putative tumor suppressor /DB_XREF = gi: 13325345 /UG = Hs.22919 putative tumor suppressor /FL = gb: BC004483.1 201829_at Consensus includes gb: AW263232 /FEA = EST /DB_XREF = gi: 6640048 /DB_XREF = est: xn79e03.x1 /CLONE = IMAGE: 2700700 /UG = Hs.25155 neuroepithelial cell transforming gene 1 /FL = gb: NM_005863.1 gb: U02081.1 202627_s_at Consensus includes gb: AL574210 /FEA = EST /DB_XREF = gi: 12934198 /DB_XREF = est: AL574210 /CLONE = CS0DI039YB02 (3 prime) /UG = Hs.82085 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 /FL = gb: NM_000602.1 gb: M16006.1 202902_s_at gb: NM_004079.1 /DEF = Homo sapiens cathepsin S (CTSS), mRNA. /FEA = mRNA /GEN = CTSS /PROD = cathepsin S /DB_XREF = gi: 4758097 /UG = Hs.181301 cathepsin S /FL = gb: BC002642.1 gb: M86553.1 gb: NM_004079.1 gb: M90696.1 218456_at gb: NM_023925.1 /DEF = Homo sapiens hypothetical protein FLJ22569 (FLJ22569), mRNA. /FEA = mRNA /GEN = FLJ22569 /PROD = hypothetical protein FLJ22569 /DB_XREF = gi: 12965192 /UG = Hs.234355 hypothetical protein FLJ22569 /FL = gb: NM_023925.1 217529_at Consensus includes gb: BE547674 /FEA = EST /DB_XREF = gi: 9776319 /DB_XREF = est: 601076255F1 /CLONE = IMAGE: 3462325 /UG = Hs.204169 ESTs 200833_s_at gb: NM_015646.1 /DEF = Homo sapiens RAP1B, member of RAS oncogene family (RAP1B), mRNA. /FEA = mRNA /GEN = RAP1B /PROD = DKFZP586H0723 protein /DB_XREF = gi: 7661677 /UG = Hs.156764 RAP1B, member of RAS oncogene family /FL = gb: BC000176.2 gb: NM_015646.1 218217_at gb: NM_021626.1 /DEF = Homo sapiens serine carboxypeptidase 1 precursor protein (HSCP1), mRNA. /FEA = mRNA /GEN = HSCP1 /PROD = serine carboxypeptidase 1 precursor protein /DB_XREF = gi: 11055991 /UG = Hs.106747 serine carboxypeptidase 1 precursor protein /FL = gb: AF282618.1 gb: NM_021626.1 gb: AF113214.1 gb: AF265441.1 209493_at gb: AF338650.1 /DEF = Homo sapiens PDZ domain-containing protein AIPC (AIPC) mRNA, complete cds. /FEA = mRNA /GEN = AIPC /PROD = PDZ domain-containing protein AIPC /DB_XREF = gi: 12751451 /UG = Hs.173035 KIAA0300 protein /FL = gb: AF338650.1 202937_x_at Consensus includes gb: AL022316 /DEF = Human DNA sequence from clone CTA-126B4 on chromosome 22q13.2-13.31 Contains two or three novel genes, ESTs, STSs, GSSs and a CpG Island /FEA = mRNA_3 /DB_XREF = gi: 4691242 /UG = Hs.239934 CGI-96 protein /FL = gb: AF151854.1 gb: NM_015703.1 207055_at gb: NM_004767.1 /DEF = Homo sapiens endothelin type b receptor-like protein 2 (ET(B)R-LP-2), mRNA. /FEA = mRNA /GEN = ET(B)R-LP-2 /PROD = endothelin type b receptor-like protein 2 /DB_XREF = gi: 4758309 /UG = Hs.132049 endothelin type b receptor-like protein 2 /FL = gb: NM_004767.1 212731_at Consensus includes gb: U79297.1 /DEF = Human clone 23589 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 1710280 /UG = Hs.11506 Human clone 23589 mRNA sequence 201772_at gb: NM_015878.1 /DEF = Homo sapiens antizyme inhibitor (LOC51582), mRNA. /FEA = mRNA /GEN = LOC51582 /PROD = antizyme inhibitor /DB_XREF = gi: 7706219 /UG = Hs.223014 antizyme inhibitor /FL = gb: D88674.1 gb: NM_015878.1 210871_x_at gb: AL133046.1 /DEF = Homo sapiens mRNA; cDNA DKFZp434C0515 (from clone DKFZp434C0515); complete cds. /FEA = mRNA /GEN = DKFZp434C0515 /PROD = hypothetical protein /DB_XREF = gi: 6453458 /UG = Hs.22587 KIAA0923 protein /FL = gb: AL133046.1 212386_at Consensus includes gb: BF592782 /FEA = EST /DB_XREF = gi: 11685106 /DB_XREF = est: 7j94d06.x1 /CLONE = IMAGE: 3442594 /UG = Hs.289068 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272 202575_at gb: NM_001878.2 /DEF = Homo sapiens cellular retinoic acid-binding protein 2 (CRABP2), mRNA. /FEA = mRNA /GEN = CRABP2 /PROD = cellular retinoic acid-binding protein 2 /DB_XREF = gi: 6382069 /UG = Hs.183650 cellular retinoic acid-binding protein 2 /FL = gb: BC001109.1 gb: M68867.1 gb: NM_001878.2

8_at gb: NM_024915.1 /DEF = Homo sapiens hypothetical protein FLJ13782 (FLJ13782), mRNA. /FEA = mRNA /GEN = FLJ13782 /PROD = hypothetical protein FLJ13782 /DB_XREF = gi: 13376381 /UG = Hs.257924 hypothetical protein FLJ13782 /FL = gb: NM_024915.1

0_at gb: NM_018075.1 /DEF = Homo sapiens hypothetical protein FLJ10375 (FLJ10375), mRNA. /FEA = mRNA /GEN = FLJ10375 /PROD = hypothetical protein FLJ10375 /DB_XREF = gi: 8922383 /UG = Hs.319088 hypothetical protein FLJ10375 /FL = gb: NM_018075.1 202308_at gb: NM_004176.1 /DEF = Homo sapiens sterol regulatory element binding transcription factor 1 (SREBF1), mRNA. /FEA = mRNA /GEN = SREBF1 /PROD = sterol regulatory element binding transcription factor 1 /DB_XREF = gi: 4759167 /UG = Hs.166 sterol regulatory element binding transcription factor 1 /FL = gb: U00968.1 gb: NM_004176.1 222146_s_at Consensus includes gb: AK026674.1 /DEF = Homo sapiens cDNA: FLJ23021 fis, clone LNG01014, highly similar to HUMSEF21B Human SEF2-1B protein (SEF2-1B) mRNA. /FEA = mRNA /DB_XREF = gi: 10439577 /UG = Hs.326198 transcription factor 4 212953_x_at Consensus includes gb: BE251303 /FEA = EST /DB_XREF = gi: 9121413 /DB_XREF = est: 601107814F1 /CLONE = IMAGE: 3344018 /UG = Hs.16488 calreticulin 213306_at Consensus includes gb: AA917899 /FEA = EST /DB_XREF = gi: 3057789 /DB_XREF = est: ol76e05.s1 /CLONE = IMAGE: 1535552 /UG = Hs.169378 multiple PDZ domain protein 213309_at Consensus includes gb: AL117515.1 /DEF = Homo sapiens mRNA; cDNA DKFZp434L0735 (from clone DKFZp434L0735); partial cds. /FEA = mRNA /GEN = DKFZp434L0735 /PROD = hypothetical protein /DB_XREF = gi: 5912029 /UG = Hs.54886 phospholipase C, epsilon 2 204115_at gb: NM_004126.1 /DEF = Homo sapiens guanine nucleotide binding protein 11 (GNG11), mRNA. /FEA = mRNA /GEN = GNG11 /PROD = guanine nucleotide binding protein 11 /DB_XREF = gi: 4758447 /UG = Hs.83381 guanine nucleotide binding protein 11 /FL = gb: NM_004126.1 gb: U31384.1 212850_s_at Consensus includes gb: AA584297 /FEA = EST /DB_XREF = gi: 2368906 /DB_XREF = est: nn79e08.s1 /CLONE = IMAGE: 1090118 /UG = Hs.4930 low density lipoprotein receptor-related protein 4 218943_s_at gb: NM_014314.1 /DEF = Homo sapiens RNA helicase (RIG-I), mRNA. /FEA = mRNA /GEN = RIG-I /PROD = RNA helicase /DB_XREF = gi: 7657515 /UG = Hs.145612 RNA helicase /FL = gb: AF038963.1 gb: NM_014314.1 210119_at gb: U73191.1 /DEF = Human inward rectifier potassium channel (Kir1.3), complete cds. /FEA = mRNA /GEN = Kir1.3 /PROD = inward rectifier potassium channel /DB_XREF = gi: 1765984 /UG = Hs.17287 potassium inwardly-rectifying channel, subfamily J, member 15 /FL = gb: U73191.1 gb: NM_002243.1 202731_at gb: NM_014456.1 /DEF = Homo sapiens programmed cell death 4 (PDCD4), mRNA. /FEA = mRNA /GEN = PDCD4 /PROD = programmed cell death 4 /DB_XREF = gi: 7657448 /UG = Hs.296251 programmed cell death 4 /FL = gb: U96628.1 gb: NM_014456.1 212573_at Consensus includes gb: AF131747.1 /DEF = Homo sapiens clone 24951 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 4406562 /UG = Hs.167115 KIAA0830 protein 218999_at gb: NM_018295.1 /DEF = Homo sapiens hypothetical protein FLJ11000 (FLJ11000), mRNA. /FEA = mRNA /GEN = FLJ11000 /PROD = hypothetical protein FLJ11000 /DB_XREF = gi: 8922813 /UG = Hs.302981 hypothetical protein FLJ11000 /FL = gb: NM_018295.1 212095_s_at Consensus includes gb: BE552421 /FEA = EST /DB_XREF = gi: 9794113 /DB_XREF = est: hw26b02.x1 /CLONE = IMAGE: 3184011 /UG = Hs.7946 KIAA1288 protein 203608_at Consensus includes gb: AL031230 /DEF = Human DNA sequence from clone 73M23 on chromosome 6p22.2-22.3. Contains the 5 part of the possibly alternatively spliced gene for Phosphatidylinositol-glycan-specific Phospholipase D 1 precursor (EC 3.1.4.50, PIGPLD1, Glycoprotein Phospholipase D . . . /FEA = mRNA_5 /DB_XREF = gi: 3947845 /UG = Hs.5299 aldehyde dehydrogenase 5 family, member A1 (succinate-semialdehyde dehydrogenase) /FL = gb: NM_001080.1 202733_at gb: NM_004199.1 /DEF = Homo sapiens procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II (P4HA2), mRNA. /FEA = mRNA /GEN = P4HA2 /PROD = procollagen-proline, 2-oxoglutarate4- dioxygenase (proline 4-hydroxylase), alpha polypeptide II /DB_XREF = gi: 4758867 /UG = Hs.3622 procollagen-proline, 2- oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II /FL = gb: U90441.1 gb: NM_004199.1 218087_s_at gb: NM_015385.1 /DEF = Homo sapiens SH3-domain protein 5 (ponsin) (SH3D5), mRNA. /FEA = mRNA /GEN = SH3D5 /PROD = ponsin /DB_XREF = gi: 7661699 /UG = Hs.108924 SH3-domain protein 5 (ponsin) /FL = gb: AL117472.1 gb: NM_015385.1 217047_s_at Consensus includes gb: AK027138.1 /DEF = Homo sapiens cDNA: FLJ23485 fis, clone KAIA05211. /FEA = mRNA /DB_XREF = gi: 10440190 /UG = Hs.177664 KIAA0914 gene product 220524_at gb: NM_024823.1 /DEF = Homo sapiens hypothetical protein FLJ21596 (FLJ21596), mRNA. /FEA = mRNA /GEN = FLJ21596 /PROD = hypothetical protein FLJ21596 /DB_XREF = gi: 13376219 /UG = Hs.171537 hypothetical protein FLJ21596 /FL = gb: NM_024823.1 202872_at Consensus includes gb: AW024925 /FEA = EST /DB_XREF = gi: 5878455 /DB_XREF = est: wu92g09.x1 /CLONE = IMAGE: 2527552 /UG = Hs.86905 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42 kD /FL = gb: NM_001695.1 209979_at gb: AF001042.1 /DEF = Homo sapiens RNA editase (RED1) mRNA, complete cds. /FEA = mRNA /GEN = RED1 /PROD = RNA editase /DB_XREF = gi: 2114492 /UG = Hs.85302 adenosine deaminase, RNA-specific, B1 (homolog of rat RED1) /FL = gb: AF001042.1 205651_x_at gb: NM_007023.1 /DEF = Homo sapiens cAMP-regulated guanine nucleotide exchange factor II (CAMP-GEFII), mRNA. /FEA = mRNA /GEN = CAMP-GEFII /PROD = cAMP-regulated guanine nucleotide exchange factor II /DB_XREF = gi: 5901913 /UG = Hs.91971 cAMP-regulated guanine nucleotide exchange factor II /FL = gb: U78516.1 gb: NM_007023.1 202531_at gb: NM_002198.1 /DEF = Homo sapiens interferon regulatory factor 1 (IRF1), mRNA. /FEA = mRNA /GEN = IRF1 /PROD = interferon regulatory factor 1 /DB_XREF = gi: 4504720 /UG = Hs.80645 interferon regulatory factor 1 /FL = gb: NM_002198.1 200731_s_at Consensus includes gb: AW165960 /FEA = EST /DB_XREF = gi: 6397485 /DB_XREF = est: xf43a12.x1 /CLONE = IMAGE: 2620798 /UG = Hs.227777 protein tyrosine phosphatase type IVA, member 1 /FL = gb: U48296.1 gb: NM_003463.1 213058_at Consensus includes gb: AL033538 /DEF = Human DNA sequence from clone RP3-477H23 on chromosome 22q12.1-12.2 Contains parts of one or two novel genes, ESTs, STSs and GSSs /FEA = mRNA /DB_XREF = gi: 4165236 /UG = Hs.11390 KIAA1043 protein 215253_s_at Consensus includes gb: AL049369.1 /DEF = Homo sapiens mRNA; cDNA DKFZp586D0518 (from clone DKFZp586D0518). /FEA = mRNA /DB_XREF = gi: 4500160 /UG = Hs.250724 Homo sapiens mRNA; cDNA DKFZp586D0518 (from clone DKFZp586D0518) 200628_s_at gb: M61715.1 /DEF = Human tryptophanyl-tRNA synthetase (WRS) mRNA, complete cds. /FEA = mRNA /GEN = WARS /PROD = transfer RNA-Trp synthetase /DB_XREF = gi: 340367 /UG = Hs.82030 tryptophanyl-tRNA synthetase /FL = gb: M77804.1 gb: M61715.1 gb: NM_004184.2 218638_s_at gb: NM_012445.1 /DEF = Homo sapiens spondin 2, extracellular matrix protein (SPON2), mRNA. /FEA = mRNA /GEN = SPON2 /PROD = spondin 2, extracellular matrix protein /DB_XREF = gi: 6912681 /UG = Hs.288126 spondin 2, extracellular matrix protein /FL = gb: BC002707.1 gb: AB027466.1 gb: NM_012445.1 206393_at gb: NM_003282.1 /DEF = Homo sapiens troponin I, skeletal, fast (TNNI2), mRNA. /FEA = mRNA /GEN = TNNI2 /PROD = troponin I, skeletal, fast /DB_XREF = gi: 4507620 /UG = Hs.83760 troponin I, skeletal, fast /FL = gb: NM_003282.1 gb: L21715.1 218062_x_at gb: NM_012121.2 /DEF = Homo sapiens Cdc42 effector protein 4; binder of Rho GTPases 4 (CEP4), mRNA. /FEA = mRNA /GEN = CEP4 /PROD = Cdc42 effector protein 4; binder of Rho GTPases4 /DB_XREF = gi: 13786126 /UG = Hs.3903 Cdc42 effector protein 4; binder of Rho GTPases 4 /FL = gb: AB042237.1 gb: NM_012121.2 gb: AF099664.1 203298_s_at gb: NM_004973.2 /DEF = Homo sapiens jumonji (mouse) homolog (JMJ), mRNA. /FEA = mRNA /GEN = JMJ /PROD_jumonji /DB_XREF = gi: 11863151 /UG = Hs.40154 jumonji (mouse) homolog /FL = gb: NM_004973.2 gb: U57592.1 213324_at Consensus includes gb: AK024281.1 /DEF = Homo sapiens cDNA FLJ14219 fis, clone NT2RP3003800, highly similar to Rattus norvegicus tyrosine protein kinase pp60-c-src mRNA. /FEA = mRNA /DB_XREF = gi: 10436622 /UG = Hs.198298 v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 213591_at Consensus includes gb: AU149534 /FEA = EST /DB_XREF = gi: 11011055 /DB_XREF = est: AU149534 /CLONE = NT2RM4002512 /UG = Hs.74294 aldehyde dehydrogenase 7 family, member A1 205047_s_at gb: NM_001673.1 /DEF = Homo sapiens asparagine synthetase (ASNS), mRNA. /FEA = mRNA /GEN = ASNS /PROD = asparagine synthetase /DB_XREF = gi: 4502258 /UG = Hs.75692 asparagine synthetase /FL = gb: M27396.1 gb: NM_001673.1 220066_at gb: NM_022162.1 /DEF = Homo sapiens NOD2 protein (NOD2), mRNA. /FEA = mRNA /GEN = NOD2 /PROD = NOD2 protein /DB_XREF = gi: 11545911 /UG = Hs.135201 NOD2 protein /FL = gb: AF178930.1 gb: NM_022162.1 217906_at gb: NM_014315.1 /DEF = Homo sapiens host cell factor homolog (LCP), mRNA. /FEA = mRNA /GEN = LCP /PROD = host cell factor homolog /DB_XREF = gi: 7657300 /UG = Hs.20597 host cell factor homolog /FL = gb: BC002335.1 gb: AF113131.1 gb: NM_014315.1 gb: AF244137.1 202023_at gb: NM_004428.1 /DEF = Homo sapiens ephrin-A1 (EFNA1), mRNA. /FEA = mRNA /GEN = EFNA1 /PROD = ephrin A1 precursor /DB_XREF = gi: 4758245 /UG = Hs.1624 ephrin-A1 /FL = gb: M57730.1 gb: NM_004428.1 221751_at Consensus includes gb: AL565516 /FEA = EST /DB_XREF = gi: 12916970 /DB_XREF = est: AL565516 /CLONE = CS0DF004YF08 (3 prime) /UG = Hs.6986 Human glucose transporter pseudogene 201463_s_at gb: NM_006755.1 /DEF = Homo sapiens transaldolase 1 (TALDO1), mRNA. /FEA = mRNA /GEN = TALDO1 /PROD = transaldolase 1 /DB_XREF = gi: 5803186 /UG = Hs.77290 transaldolase 1 /FL = gb: L19437.2 gb: NM_006755.1 203763_at gb: NM_016008.1 /DEF = Homo sapiens CGI-60 protein (LOC51626), mRNA. /FEA = mRNA /GEN = LOC51626 /PROD = CGI-60 protein /DB_XREF = gi: 7706299 /UG = Hs.7627 CGI-60 protein /FL = gb: AF151818.1 gb: NM_016008.1 205383_s_at gb: NM_015642.1 /DEF = Homo sapiens zinc finger protein 288 (ZNF288), mRNA. /FEA = mRNA /GEN = ZNF288 /PROD = zinc finger protein 288 /DB_XREF = gi: 7661651 /UG = Hs.159456 zinc finger protein 288 /FL = gb: AL050276.1 gb: NM_015642.1 213373_s_at Consensus includes gb: BF439983 /FEA = EST /DB_XREF = gi: 11452500 /DB_XREF = est: nac51f11.x1 /CLONE = IMAGE: 3406220 /UG = Hs.19949 caspase 8, apoptosis-related cysteine protease /FL = gb: U58143.1 200707_at gb: NM_002743.1 /DEF = Homo sapiens protein kinase C substrate 80K-H (PRKCSH), mRNA. /FEA = mRNA /GEN = PRKCSH /PROD = protein kinase C substrate 80K-H /DB_XREF = gi: 4506076 /UG = Hs.1432 protein kinase C substrate 80K-H /FL = gb: J03075.1 gb: NM_002743.1 gb: AF144075.1 212427_at Consensus includes gb: AB002366.1 /DEF = Human mRNA for KIAA0368 gene, partial cds. /FEA = mRNA /GEN = KIAA0368 /DB_XREF = gi: 2224676 /UG = Hs.3852 KIAA0368 protein 216268_s_at Consensus includes gb: U77914.1 /DEF = Human soluble protein Jagged mRNA, partial cds. /FEA = mRNA /PROD = soluble protein Jagged /DB_XREF = gi: 1684889 /UG = Hs.91143 jagged 1 (Alagille syndrome) 210457_x_at gb: AF176039.1 /DEF = Homo sapiens high mobility group protein-R mRNA, complete cds. /FEA = mRNA /PROD = high mobility group protein-R /DB_XREF = gi: 5834272 /UG = Hs.139800 high-mobility group (nonhistone chromosomal) protein isoforms I and Y /FL = gb: AF176039.1 200924_s_at gb: NM_002394.1 /DEF = Homo sapiens solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 (SLC3A2), mRNA. /FEA = mRNA /GEN = SLC3A2 /PROD = antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 /DB_XREF = gi: 4505140 /UG = Hs.79748 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 /FL = gb: BC001061.1 gb: J02769.1 gb: J03569.1 gb: NM_002394.1 gb: AB018010.1 203409_at gb: NM_000107.1 /DEF = Homo sapiens damage-specific DNA binding protein 2 (48 kD) (DDB2), mRNA. /FEA = mRNA /GEN = DDB2 /PROD = damage-specific DNA binding protein 2 (48 kD) /DB_XREF = gi: 4557514 /UG = Hs.77602 damage-specific DNA binding protein 2 (48 kD) /FL = gb: BC000093.1 gb: U18300.1 gb: NM_000107.1 205715_at gb: NM_004334.1 /DEF = Homo sapiens bone marrow stromal cell antigen 1 (BST1), mRNA. /FEA = mRNA /GEN = BST1 /PROD = bone marrow stromal cell antigen 1 precursor /DB_XREF = gi: 4757873 /UG = Hs.169998 bone marrow stromal cell antigen 1 /FL = gb: NM_004334.1 gb: D21878.1 213609_s_at Consensus includes gb: AB023144.1 /DEF = Homo sapiens mRNA for KIAA0927 protein, partial cds. /FEA = mRNA /GEN = KIAA0927 /PROD = KIAA0927 protein /DB_XREF = gi: 4589485 /UG = Hs.194766 seizure related gene 6 (mouse)- like 212932_at Consensus includes gb: AK022494.1 /DEF = Homo sapiens cDNA FLJ12432 fis, clone NT2RM1000018, highly similar to Human mRNA for KIAA0066 gene. /FEA = mRNA /DB_XREF = gi: 10433912 /UG = Hs.227881 RAB3 GTPase- ACTIVATING PROTEIN 204632_at gb: NM_003942.1 /DEF = Homo sapiens ribosomal protein S6 kinase, 90 kD, polypeptide 4 (RPS6KA4), mRNA. /FEA = mRNA /GEN = RPS6KA4 /PROD = ribosomal protein S6 kinase, 90 kD, polypeptide4 /DB_XREF = gi: 4506734 /UG = Hs.105584 ribosomal protein S6 kinase, 90 kD, polypeptide 4 /FL = gb: NM_003942.1 201988_s_at Consensus includes gb: BF438056 /FEA = EST /DB_XREF = gi: 11450573 /DB_XREF = est: 7q66e01.x1 /CLONE = IMAGE: 3703369 /UG = Hs.13313 cAMP responsive element binding protein-like 2 /FL = gb: AF039081.1 gb: NM_001310.1 212117_at Consensus includes gb: BF978689 /FEA = EST /DB_XREF = gi: 12345904 /DB_XREF = est: 602149457F2 /CLONE = IMAGE: 4308014 /UG = Hs.166982 phosphatidylinositol glycan, class F 217496_s_at Consensus includes gb: AA918442 /FEA = EST /DB_XREF = gi: 3058332 /DB_XREF = est: om38b01.s1 /CLONE = IMAGE: 1543273 /UG = Hs.326641 Homo sapiens insulin-degrading enzyme (IDE), mRNA 203180_at gb: NM_000693.1 /DEF = Homo sapiens aldehyde dehydrogenase 1 family, member A3 (ALDH1A3), mRNA. /FEA = mRNA /GEN = ALDH1A3 /PROD = aldehyde dehydrogenase 1A3 /DB_XREF = gi: 4502040 /UG = Hs.75746 aldehyde dehydrogenase 1 family, member A3 /FL = gb: NM_000693.1 gb: U07919.1 203801_at Consensus includes gb: AA013164 /FEA = EST /DB_XREF = gi: 1474190 /DB_XREF = est: ze35e12.s1 /CLONE = IMAGE: 361006 /UG = Hs.247324 hypothetical protein LOC63931 /FL = gb: NM_022100.1 214494_s_at Consensus includes gb: NM_005200.1 /DEF = Homo sapiens cell matrix adhesion regulator (CMAR), mRNA. /FEA = CDS /GEN = CMAR /PROD = cell matrix adhesion regulator /DB_XREF = gi: 4885142 /UG = Hs.272480 cell matrix adhesion regulator /FL = gb: NM_005200.1 201196_s_at gb: M21154.1 /DEF = Human S-adenosylmethionine decarboxylase mRNA, complete cds. /FEA = mRNA /GEN = AMD2 /DB_XREF = gi: 178517 /UG = Hs.262476 S-adenosylmethionine decarboxylase 1 /FL = gb: BC000171.2 gb: M21154.1 gb: NM_001634.3 210325_at gb: M28825.1 /DEF = Human thymocyte antigen CD1a mRNA, complete cds. /FEA = mRNA /GEN = CD1A /DB_XREF = gi: 180035 /UG = Hs.1309 CD1A antigen, a polypeptide /FL = gb: M28825.1 200755_s_at Consensus includes gb: BF939365 /FEA = EST /DB_XREF = gi: 12356685 /DB_XREF = est: nad87h04.x1 /CLONE = IMAGE: 3410551 /UG = Hs.7753 calumenin /FL = gb: U67280.1 gb: AF013759.1 gb: NM_001219.2 206580_s_at gb: NM_016938.1 /DEF = Homo sapiens EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2), mRNA. /FEA = mRNA /GEN = EFEMP2 /PROD = EGF-containing fibulin-like extracellular matrixprotein 2 /DB_XREF = gi: 8393298 /UG = Hs.6059 EGF-containing fibulin-like extracellular matrix protein 2 /FL = gb: AF093119.1 gb: AF109121.1 gb: NM_016938.1 204379_s_at gb: NM_000142.2 /DEF = Homo sapiens fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) (FGFR3), transcript variant 1, mRNA. /FEA = mRNA /GEN = FGFR3 /PROD = fibroblast growth factor receptor 3, isoform 1precursor /DB_XREF = gi: 13112046 /UG = Hs.1420 fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) /FL = gb: NM_000142.2 gb: M58051.1 213805_at Consensus includes gb: AI692428 /FEA = EST /DB_XREF = gi: 4969768 /DB_XREF = est: wd69c12.x1 /CLONE = IMAGE: 2336854 /UG = Hs.184019 Homo sapiens clone 23551 mRNA sequence 207907_at gb: NM_003807.1 /DEF = Homo sapiens tumor necrosis factor (ligand) superfamily, member 14 (TNFSF14), mRNA. /FEA = mRNA /GEN = TNFSF14 /PROD = tumor necrosis factor (ligand) superfamily, member 14 /DB_XREF = gi: 4507600 /UG = Hs.129708 tumor necrosis factor (ligand) superfamily, member 14 /FL = gb: AF036581.1 gb: AF064090.1 gb: NM_003807.1 204045_at gb: NM_004780.1 /DEF = Homo sapiens transcription elongation factor A (SII)-like 1 (TCEAL1), mRNA. /FEA = mRNA /GEN = TCEAL1 /PROD = transcription elongation factor A (SII)-like 1 /DB_XREF = gi: 4759215 /UG = Hs.95243 transcription elongation factor A (SII)-like 1 /FL = gb: BC000809.1 gb: NM_004780.1 gb: M99701.1 210788_s_at gb: AF126782.1 /DEF = Homo sapiens retinal short-chain dehydrogenasereductase retSDR4 mRNA, complete cds. /FEA = mRNA /PROD = retinal short-chain dehydrogenasereductaseretSDR4 /DB_XREF = gi: 6318547 /UG = Hs.109201 CGI-86 protein /FL = gb: AF126782.1 204601_at gb: NM_014664.1 /DEF = Homo sapiens KIAA0615 gene product (KIAA0615), mRNA. /FEA = mRNA /GEN = KIAA0615 /PROD = KIAA0615 gene product /DB_XREF = gi: 7662203 /UG = Hs.323712 KIAA0615 gene product /FL = gb: AB014515.1 gb: NM_014664.1 219179_at gb: NM_016651.2 /DEF = Homo sapiens heptacellular carcinoma novel gene-3 protein (LOC51339), mRNA. /FEA = mRNA /GEN = LOC51339 /PROD = heptacellular carcinoma novel gene-3 protein /DB_XREF = gi: 8393715 /UG = Hs.48950 heptacellular carcinoma novel gene-3 protein /FL = gb: AF251079.2 gb: NM_016651.2 222241_at Consensus includes gb: AK000001.1 /DEF = Homo sapiens mRNA for FLJ00001 protein, partial cds. /FEA = mRNA /GEN = FLJ00001 /PROD = FLJ00001 protein /DB_XREF = gi: 7209302 /UG = Hs.4914 Homo sapiens mRNA for FLJ00031 protein, partial cds 221210_s_at gb: NM_030769.1 /DEF = Homo sapiens hypothetical protein similar to swine acylneuraminate lyase (C1ORF13), mRNA. /FEA = mRNA /GEN = C1ORF13 /PROD = hypothetical protein similar to swineacylneuraminate lyase /DB_XREF = gi: 13540532 /FL = gb: NM_030769.1 215990_s_at Consensus includes gb: S67779.1 /DEF = BCL5 = Cys2-His2 zinc-finger transcription factor human, liver, mRNA, 2600 nt. /FEA = mRNA /DB_XREF = gi: 459372 /UG = Hs.155024 B-cell CLLlymphoma 6 (zinc finger protein 51) 201650_at gb: NM_002276.1 /DEF = Homo sapiens keratin 19 (KRT19), mRNA. /FEA = mRNA /GEN = KRT19 /PROD = keratin 19 /DB_XREF = gi: 4504916 /UG = Hs.182265 keratin 19 /FL = gb: BC002539.1 gb: NM_002276.1 208736_at gb: AF004561.1 /DEF = Homo sapiens p21-Arc mRNA, complete cds. /FEA = mRNA /PROD = p21-Arc /DB_XREF = gi: 2209346 /UG = Hs.6895 actin related protein 23 complex, subunit 3 (21 kD) /FL = gb: AF004561.1 gb: AF006086.1 gb: NM_005719.1 202598_at gb: NM_005979.1 /DEF = Homo sapiens S100 calcium-binding protein A13 (S100A13), mRNA. /FEA = mRNA /GEN = S100A13 /PROD = S100 calcium-binding protein A13 /DB_XREF = gi: 5174658 /UG = Hs.14331 S100 calcium- binding protein A13 /FL = gb: BC000632.1 gb: NM_005979.1 203307_at gb: NM_005275.1 /DEF = Homo sapiens guanine nucleotide binding protein-like 1 (GNL1), mRNA. /FEA = mRNA /GEN = GNL1 /PROD = guanine nucleotide binding protein-like 1 /DB_XREF = gi: 4885288 /UG = Hs.83147 guanine nucleotide binding protein-like 1 /FL = gb: NM_005275.1 gb: L25665.1 205349_at gb: NM_002068.1 /DEF = Homo sapiens guanine nucleotide binding protein (G protein), alpha 15 (Gq class) (GNA15), mRNA. /FEA = mRNA /GEN = GNA15 /PROD = guanine nucleotide binding protein (G protein), alpha 15 (Gq class) /DB_XREF = gi: 4504038 /UG = Hs.73797 guanine nucleotide binding protein (G protein), alpha 15 (Gq class) /FL = gb: M63904.1 gb: NM_002068.1 201116_s_at Consensus includes gb: AI922855 /FEA = EST /DB_XREF = gi: 5658819 /DB_XREF = est: wo14h05.x1 /CLONE = IMAGE: 2455353 /UG = Hs.75360 carboxypeptidase E /FL = gb: NM_001873.1 200862_at gb: NM_014762.1 /DEF = Homo sapiens seladin-1 (KIAA0018), mRNA. /FEA = mRNA /GEN = KIAA0018 /PROD = seladin-1 /DB_XREF = gi: 13375617 /UG = Hs.75616 seladin-1 /FL = gb: AF261758.1 gb: BC004375.1 gb: NM_014762.1 218807_at gb: NM_006113.2 /DEF = Homo sapiens vav 3 oncogene (VAV3), mRNA. /FEA = mRNA /GEN = VAV3 /PROD = vav 3 oncogene /DB_XREF = gi: 7262390 /UG = Hs.267659 vav 3 oncogene /FL = gb: AF067817.1 gb: AF118887.1 gb: NM_006113.2 212514_x_at Consensus includes gb: R60068 /FEA = EST /DB_XREF = gi: 830763 /DB_XREF = est: yh12h07.s1 /CLONE = IMAGE: 43138 /UG = Hs.147916 DEADH (Asp-Glu-Ala-AspHis) box polypeptide 3 208315_x_at gb: NM_003300.1 /DEF = Homo sapiens TNF receptor-associated factor 3 (TRAF3), mRNA. /FEA = mRNA /GEN = TRAF3 /PROD = TNF receptor-associated factor 3 /DB_XREF = gi: 4507678 /UG = Hs.297660 TNF receptor- associated factor 3 /FL = gb: NM_003300.1 gb: U21092.1 201920_at gb: NM_005415.2 /DEF = Homo sapiens solute carrier family 20 (phosphate transporter), member 1 (SLC20A1), mRNA. /FEA = mRNA /GEN = SLC20A1 /PROD = solute carrier family 20 (phosphate transporter), member 1 /DB_XREF = gi: 7382462 /UG = Hs.78452 solute carrier family 20 (phosphate transporter), member 1 /FL = gb: L20859.1 gb: NM_005415.2 221974_at Consensus includes gb: AW770748 /FEA = EST /DB_XREF = gi: 7702795 /DB_XREF = est: hl90a07.x1 /CLONE = IMAGE: 3009204 /UG = Hs.5022 imprinted in Prader-Willi syndrome 201516_at gb: NM_003132.1 /DEF = Homo sapiens spermidine synthase (SRM), mRNA. /FEA = mRNA /GEN = SRM /PROD = spermidine synthase /DB_XREF = gi: 4507208 /UG = Hs.76244 spermidine synthase /FL = gb: BC000309.1 gb: NM_003132.1 gb: M34338.1 209395_at gb: M80927.1 /DEF = Human glycoprotein mRNA, complete cds. /FEA = mRNA /PROD = glycoprotein /DB_XREF = gi: 348911 /UG = Hs.75184 chitinase 3-like 1 (cartilage glycoprotein-39) /FL = gb: M80927.1 gb: NM_001276.1 213616_at Consensus includes gb: BF063896 /FEA = EST /DB_XREF = gi: 10822806 /DB_XREF = est: 7h90a05.x1 /CLONE = IMAGE: 3323216 /UG = Hs.22981 DKFZP586M1523 protein 204521_at gb: NM_013300.1 /DEF = Homo sapiens protein predicted by clone 23733 (HSU79274), mRNA. /FEA = mRNA /GEN = HSU79274 /PROD = protein predicted by clone 23733 /DB_XREF = gi: 9558740 /UG = Hs.150555 protein predicted by clone 23733 /FL = gb: U79274.1 gb: NM_013300.1 213900_at Consensus includes gb: AA524029 /FEA = EST /DB_XREF = gi: 2264957 /DB_XREF = est: ng32f02.s1 /CLONE = IMAGE: 936507 /UG = Hs.77889 Friedreich ataxia region gene X123 219682_s_at gb: NM_016569.1 /DEF = Homo sapiens TBX3-iso protein (TBX3-iso), mRNA. /FEA = mRNA /GEN = TBX3-iso /PROD = TBX3-iso protein /DB_XREF = gi: 7706728 /UG = Hs.332150 TBX3-iso protein /FL = gb: AF216750.1 gb: NM_016569.1 217513_at Consensus includes gb: BG334495 /FEA = EST /DB_XREF = gi: 13140933 /DB_XREF = est: 602461128F1 /CLONE = IMAGE: 4577718 /UG = Hs.228201 ESTs, Moderately similar to AF118094 25 PRO1992 H. sapiens 220432_s_at gb: NM_016593.1 /DEF = Homo sapiens oxysterol 7alpha-hydroxylase (CYP39A1), mRNA. /FEA = mRNA /GEN = CYP39A1 /PROD = oxysterol 7alpha-hydroxylase /DB_XREF = gi: 7706128 /UG = Hs.20766 oxysterol 7alpha- hydroxylase /FL = gb: AF237982.1 gb: NM_016593.1 202107_s_at gb: NM_004526.1 /DEF = Homo sapiens minichromosome maintenance deficient (S. cerevisiae) 2 (mitotin) (MCM2), mRNA. /FEA = mRNA /GEN = MCM2 /PROD = minichromosome maintenance deficient (S. cerevisiae) 2 (mitotin) /DB_XREF = gi: 4758705 /UG = Hs.57101 minichromosome maintenance deficient (S. cerevisiae) 2 (mitotin) /FL = gb: D83987.1 gb: NM_004526.1 204785_x_at gb: NM_000874.1 /DEF = Homo sapiens interferon (alpha, beta and omega) receptor 2 (IFNAR2), mRNA. /FEA = mRNA /GEN = IFNAR2 /PROD = interferon (alpha, beta and omega) receptor 2 /DB_XREF = gi: 4504600 /UG = Hs.86958 interferon (alpha, beta and omega) receptor 2 /FL = gb: NM_000874.1 gb: L41944.1 206134_at gb: NM_014479.1 /DEF = Homo sapiens disintegrin protease (M12.219), mRNA. /FEA = mRNA /GEN = M12.219 /PROD = disintegrin protease /DB_XREF = gi: 7657318 /UG = Hs.145296 disintegrin protease /FL = gb: NM_014479.1 213125_at Consensus includes gb: AW007573 /FEA = EST /DB_XREF = gi: 5856436 /DB_XREF = est: wt02e12.x1 /CLONE = IMAGE: 2506318 /UG = Hs.43658 DKFZP586L151 protein 216836_s_at Consensus includes gb: X03363.1 /DEF = Human c-erb-B-2 mRNA. /FEA = mRNA /DB_XREF = gi: 31197 /UG = Hs.323910 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuroglioblastoma derived oncogene homolog) 202796_at gb: NM_007286.1 /DEF = Homo sapiens synaptopodin (KIAA1029), mRNA. /FEA = mRNA /GEN = KIAA1029 /PROD = synaptopodin /DB_XREF = gi: 6005797 /UG = Hs.5307 synaptopodin /FL = gb: AB028952.1 gb: NM_007286.1 219270_at gb: NM_024111.1 /DEF = Homo sapiens hypothetical protein MGC4504 (MGC4504), mRNA. /FEA = mRNA /GEN = MGC4504 /PROD = hypothetical protein MGC4504 /DB_XREF = gi: 13129125 /UG = Hs.155569 hypothetical protein MGC4504 /FL = gb: BC001847.1 gb: NM_024111.1 216782_at Consensus includes gb: AK026679.1 /DEF = Homo sapiens cDNA: FLJ23026 fis, clone LNG01738. /FEA = mRNA /DB_XREF = gi: 10439585 /UG = Hs.306863 Homo sapiens cDNA: FLJ23026 fis, clone LNG01738 219265_at gb: NM_024761.1 /DEF = Homo sapiens hypothetical protein FLJ13204 (FLJ13204), mRNA. /FEA = mRNA /GEN = FLJ13204 /PROD = hypothetical protein FLJ13204 /DB_XREF = gi: 13376100 /UG = Hs.128905 hypothetical protein FLJ13204 /FL = gb: NM_024761.1 203726_s_at gb: NM_000227.1 /DEF = Homo sapiens laminin, alpha 3 (nicein (150 kD), kalinin (165 kD), BM600 (150 kD), epilegrin) (LAMA3), mRNA. /FEA = mRNA /GEN = LAMA3 /PROD = laminin alpha 3 subunit precursor /DB_XREF = gi: 4557710 /UG = Hs.83450 laminin, alpha 3 (nicein (150 kD), kalinin (165 kD), BM600 (150 kD), epilegrin) /FL = gb: NM_000227.1 gb: L34155.1 204824_at gb: NM_004435.1 /DEF = Homo sapiens endonuclease G (ENDOG), nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = ENDOG /PROD = endonuclease G precursor /DB_XREF = gi: 4758269 /UG = Hs.182418 endonuclease G /FL = gb: BC004922.1 gb: NM_004435.1 203049_s_at gb: NM_014639.1 /DEF = Homo sapiens KIAA0372 gene product (KIAA0372), mRNA. /FEA = mRNA /GEN = KIAA0372 /PROD = KIAA0372 gene product /DB_XREF = gi: 7662077 /UG = Hs.170098 KIAA0372 gene product /FL = gb: AB002370.1 gb: NM_014639.1 204641_at gb: NM_002497.1 /DEF = Homo sapiens NIMA (never in mitosis gene a)-related kinase 2 (NEK2), mRNA. /FEA = mRNA /GEN = NEK2 /PROD = NIMA (never in mitosis gene a)-related kinase 2 /DB_XREF = gi: 4505372 /UG = Hs.153704 NIMA (never in mitosis gene a)-related kinase 2 /FL = gb: NM_002497.1 gb: U11050.1 219410_at gb: NM_018004.1 /DEF = Homo sapiens hypothetical protein FLJ10134 (FLJ10134), mRNA. /FEA = mRNA /GEN = FLJ10134 /PROD = hypothetical protein FLJ10134 /DB_XREF = gi: 8922242 /UG = Hs.104800 hypothetical protein FLJ10134 /FL = gb: NM_018004.1 204417_at gb: NM_000153.1 /DEF = Homo sapiens galactosylceramidase (Krabbe disease) (GALC), mRNA. /FEA = mRNA /GEN = GALC /PROD = galactosylceramidase precursor /DB_XREF = gi: 4557612 /UG = Hs.273 galactosylceramidase (Krabbe disease) /FL = gb: L23116.1 gb: NM_000153.1 gb: D25283.1 220168_at gb: NM_018272.1 /DEF = Homo sapiens hypothetical protein FLJ10921 (FLJ10921), mRNA. /FEA = mRNA /GEN = FLJ10921 /PROD = hypothetical protein FLJ10921 /DB_XREF = gi: 8922767 /UG = Hs.279012 hypothetical protein FLJ10921 /FL = gb: NM_018272.1 209909_s_at gb: M19154.1 /DEF = Human transforming growth factor-beta-2 mRNA, complete cds. /FEA = mRNA /PROD = transforming growth factor beta 2 /DB_XREF = gi: 339549 /UG = Hs.169300 transforming growth factor, beta 2 /FL = gb: M19154.1 205805_s_at gb: NM_005012.1 /DEF = Homo sapiens receptor tyrosine kinase-like orphan receptor 1 (ROR1), mRNA. /FEA = mRNA /GEN = ROR1 /PROD = receptor tyrosine kinase-like orphan receptor 1 /DB_XREF = gi: 4826867 /UG = Hs.274243 receptor tyrosine kinase-like orphan receptor 1 /FL = gb: M97675.1 gb: NM_005012.1 214716_at Consensus includes gb: AW504018 /FEA = EST /DB_XREF = gi: 7141685 /DB_XREF = est: UI-HF-BN0-alh-f-03-0-UI.r1 /CLONE = IMAGE: 3079804 /UG = Hs.20137 hypothetical protein DKFZp434P0116 214925_s_at Consensus includes gb: AK026484.1 /DEF = Homo sapiens cDNA: FLJ22831 fis, clone KAIA4161. /FEA = mRNA /DB_XREF = gi: 10439356 /UG = Hs.321666 Homo sapiens cDNA: FLJ22831 fis, clone KAIA4161 205348_s_at gb: NM_004411.1 /DEF = Homo sapiens dynein, cytoplasmic, intermediate polypeptide 1 (DNCI1), mRNA. /FEA = mRNA /GEN = DNCI1 /PROD = dynein, cytoplasmic, intermediate polypeptide 1 /DB_XREF = gi: 4758177 /UG = Hs.65248 dynein, cytoplasmic, intermediate polypeptide 1 /FL = gb: AF063228.1 gb: NM_004411.1 219109_at gb: NM_024532.1 /DEF = Homo sapiens hypothetical protein FLJ22724 (FLJ22724), mRNA. /FEA = mRNA /GEN = FLJ22724 /PROD = hypothetical protein FLJ22724 /DB_XREF = gi: 13375683 /UG = Hs.6783 hypothetical protein FLJ22724 /FL = gb: NM_024532.1 203692_s_at Consensus includes gb: AI640363 /FEA = EST /DB_XREF = gi: 4703472 /DB_XREF = est: wa17d03.x1 /CLONE = IMAGE: 2298341 /UG = Hs.1189 E2F transcription factor 3 /FL = gb: NM_001949.2 211628_x_at gb: J04755.1 /DEF = Human ferritin H processed pseudogene, complete cds. /FEA = mRNA /GEN = FTHP1 /DB_XREF = gi: 182512 /FL = gb: J04755.1 209768_s_at Consensus includes gb: AI860917 /FEA = EST /DB_XREF = gi: 5514533 /DB_XREF = est: wl56b07.x1 /CLONE = IMAGE: 2428885 /UG = Hs.283743 glycoprotein Ib (platelet), beta polypeptide /FL = gb: L20860.1 211527_x_at gb: M27281.1 /DEF = Human vascular permeability factor mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 340300 /UG = Hs.73793 vascular endothelial growth factor /FL = gb: M27281.1 205241_at gb: NM_005138.1 /DEF = Homo sapiens SCO (cytochrome oxidase deficient, yeast) homolog 2 (SCO2), nuclear gene encoding mitochondrial protein, mRNA. /FEA = mRNA /GEN = SCO2 /PROD = SCO (cytochrome oxidase deficient, yeast)homolog 2 /DB_XREF = gi: 4826991 /UG = Hs.278431 SCO (cytochrome oxidase deficient, yeast) homolog 2 /FL = gb: NM_005138.1 219863_at gb: NM_016323.1 /DEF = Homo sapiens cyclin-E binding protein 1 (LOC51191), mRNA. /FEA = mRNA /GEN = LOC51191 /PROD = cyclin-E binding protein 1 /DB_XREF = gi: 7705930 /UG = Hs.26663 cyclin-E binding protein 1 /FL = gb: AB027289.1 gb: NM_016323.1 201091_s_at Consensus includes gb: BE748755 /FEA = EST /DB_XREF = gi: 10162747 /DB_XREF = est: 601571933T1 /CLONE = IMAGE: 3838737 /UG = Hs.278554 heterochromatin-like protein 1 /FL = gb: AF136630.1 gb: NM_016587.1 207433_at gb: NM_000572.1 /DEF = Homo sapiens interleukin 10 (IL10), mRNA. /FEA = mRNA /GEN = IL10 /PROD = interleukin 10 /DB_XREF = gi: 10835140 /UG = Hs.193717 interleukin 10 /FL = gb: NM_000572.1 gb: M57627.1 200622_x_at Consensus includes gb: AV685208 /FEA = EST /DB_XREF = gi: 10287071 /DB_XREF = est: AV685208 /CLONE = GKCCXA06 /UG = Hs.141011 calmodulin 3 (phosphorylase kinase, delta) /FL = gb: BC005137.1 gb: J04046.1 gb: NM_005184.1 203032_s_at Consensus includes gb: AI363836 /FEA = EST /DB_XREF = gi: 4123525 /DB_XREF = est: qy62g01.x1 /CLONE = IMAGE: 2016624 /UG = Hs.75653 fumarate hydratase /FL = gb: BC003108.1 gb: M15502.1 gb: U59309.1 gb: U48857.1 gb: NM_000143.1 204237_at gb: NM_016315.1 /DEF = Homo sapiens CED-6 protein (CED-6), mRNA. /FEA = mRNA /GEN = CED-6 /PROD = CED-6 protein /DB_XREF = gi: 7705317 /UG = Hs.107056 CED-6 protein /FL = gb: AF200715.1 gb: AF191771.1 gb: NM_016315.1 216264_s_at Consensus includes gb: X79683.1 /DEF = H. sapiens LAMB2 mRNA for beta2 laminin. /FEA = mRNA /GEN = LAMB2 /PROD = beta2S laminin chain /DB_XREF = gi: 663206 /UG = Hs.90291 laminin, beta 2 (laminin S) 208710_s_at Consensus includes gb: AI424923 /FEA = EST /DB_XREF = gi: 4270841 /DB_XREF = est: tg19a07.x1 /CLONE = IMAGE: 2109204 /UG = Hs.75056 adaptor-related protein complex 3, delta 1 subunit /FL = gb: AF002163.1 221541_at gb: AL136861.1 /DEF = Homo sapiens mRNA; cDNA DKFZp434B044 (from clone DKFZp434B044); complete cds. /FEA = mRNA /GEN = DKFZp434B044 /PROD = hypothetical protein /DB_XREF = gi: 12053226 /UG = Hs.262958 Homo sapiens mRNA; cDNA DKFZp434B044 (from clone DKFZp434B044); complete cds /FL = gb: AL136861.1 206059_at gb: NM_003430.1 /DEF = Homo sapiens zinc finger protein 91 (HPF7, HTF10) (ZNF91), mRNA. /FEA = mRNA /GEN = ZNF91 /PROD = zinc finger protein 91 (HPF7, HTF10) /DB_XREF = gi: 4508040 /UG = Hs.8597 zinc finger protein 91 (HPF7, HTF10) /FL = gb: L11672.1 gb: NM_003430.1 200872_at gb: NM_002966.1 /DEF = Homo sapiens S100 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) (S100A10), mRNA. /FEA = mRNA /GEN = S100A10 /PROD = S100 calcium-binding protein A10 /DB_XREF = gi: 4506760 /UG = Hs.119301 S100 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) /FL = gb: M81457.1 gb: M38591.1 gb: NM_002966.1 203962_s_at gb: NM_006393.1 /DEF = Homo sapiens nebulette (NEBL), mRNA. /FEA = mRNA /GEN = NEBL /PROD = nebulette /DB_XREF = gi: 5453757 /UG = Hs.5025 nebulette /FL = gb: NM_006393.1 209617_s_at gb: AF035302.1 /DEF = Homo sapiens clone 23717 mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 2661061 /UG = Hs.80220 catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein) /FL = gb: NM_001332.1 gb: U72665.1 gb: AF035302.1 gb: U96136.1 gb: AB013805.1 207920_x_at gb: NM_003410.1 /DEF = Homo sapiens zinc finger protein, X-linked (ZFX), mRNA. /FEA = mRNA /GEN = ZFX /PROD = zinc finger protein, X-linked /DB_XREF = gi: 4507964 /UG = Hs.2074 zinc finger protein, X-linked /FL = gb: M30608.1 gb: NM_003410.1 202207_at Consensus includes gb: BG435404 /FEA = EST /DB_XREF = gi: 13341910 /DB_XREF = est: 602507678F1 /CLONE = IMAGE: 4605066 /UG = Hs.111554 ADP-ribosylation factor-like 7 /FL = gb: BC001051.1 gb: AB016811.1 gb: NM_005737.2 203853_s_at gb: NM_012296.1 /DEF = Homo sapiens GRB2-associated binding protein 2 (GAB2), mRNA. /FEA = mRNA /GEN = GAB2 /PROD = GRB2-associated binding protein 2 /DB_XREF = gi: 6912459 /UG = Hs.30687 GRB2-associated binding protein 2 /FL = gb: AB011143.1 gb: NM_012296.1 205759_s_at gb: NM_004605.1 /DEF = Homo sapiens sulfotransferase family, cytosolic, 2B, member 1 (SULT2B1), mRNA. /FEA = mRNA /GEN = SULT2B1 /PROD = sulfotransferase family, cytosolic, 2B, member1 /DB_XREF = gi: 4759191 /UG = Hs.94581 sulfotransferase family, cytosolic, 2B, member 1 /FL = gb: U92314.1 gb: NM_004605.1 221811_at Consensus includes gb: BF033007 /FEA = EST /DB_XREF = gi: 10740719 /DB_XREF = est: 601455980F1 /CLONE = IMAGE: 3859819 /UG = Hs.91668 Homo sapiens clone PP1498 unknown mRNA 200704_at gb: AB034747.1 /DEF = Homo sapiens SIMPLE mRNA for small integral membrane protein of lysosomelate endosome, complete cds. /FEA = mRNA /GEN = SIMPLE /PROD = small integral membrane protein of lysosomelate endosome /DB_XREF = gi: 12862475 /UG = Hs.76507 LPS-induced TNF-alpha factor /FL = gb: AB034747.1 gb: U77396.1 gb: AF010312.1 gb: NM_004862.1 203484_at gb: NM_014302.1 /DEF = Homo sapiens Sec61 gamma (SEC61G), mRNA. /FEA = mRNA /GEN = SEC61G /PROD = Sec61 gamma /DB_XREF = gi: 7657545 /UG = Hs.9950 Sec61 gamma /FL = gb: AF054184.1 gb: NM_014302.1 200021_at gb: NM_005507.1 /DEF = Homo sapiens cofilin 1 (non-muscle) (CFL1), mRNA. /FEA = mRNA /GEN = CFL1 /PROD = cofilin 1 (non-muscle) /DB_XREF = gi: 5031634 /UG = Hs.180370 cofilin 1 (non-muscle) /FL = gb: NM_005507.1 218901_at gb: NM_020353.1 /DEF = Homo sapiens phospholipid scramblase 4 (LOC57088), mRNA. /FEA = mRNA /GEN = LOC57088 /PROD = phospholipid scramblase 4 /DB_XREF = gi: 9966818 /UG = Hs.182538 phospholipid scramblase 4 /FL = gb: AF199023.1 gb: NM_020353.1 207619_at gb: NM_001525.1 /DEF = Homo sapiens hypocretin (orexin) receptor 1 (HCRTR1), mRNA. /FEA = mRNA /GEN = HCRTR1 /PROD = orexin receptor 1 /DB_XREF = gi: 4557636 /UG = Hs.150968 hypocretin (orexin) receptor 1 /FL = gb: AF041243.1 gb: NM_001525.1 206157_at gb: NM_002852.1 /DEF = Homo sapiens pentaxin-related gene, rapidly induced by IL-1 beta (PTX3), mRNA. /FEA = mRNA /GEN = PTX3 /PROD = pentaxin-related gene, rapidly induced by IL-1beta /DB_XREF = gi: 4506332 /UG = Hs.2050 pentaxin-related gene, rapidly induced by IL-1 beta /FL = gb: M31166.1 gb: NM_002852.1 217902_s_at gb: NM_004667.2 /DEF = Homo sapiens hect domain and RLD 2 (HERC2), mRNA. /FEA = mRNA /GEN = HERC2 /PROD = hect domain and RLD 2 /DB_XREF = gi: 5729867 /UG = Hs.266933 hect domain and RLD 2 /FL = gb: AF071172.3 gb: NM_004667.2 200729_s_at gb: NM_005722.1 /DEF = Homo sapiens ARP2 (actin-related protein 2, yeast) homolog (ACTR2), mRNA. /FEA = mRNA /GEN = ACTR2 /PROD = ARP2 (actin-related protein 2, yeast) homolog /DB_XREF = gi: 5031570 /UG = Hs.42915 ARP2 (actin-related protein 2, yeast) homolog /FL = gb: AF006082.1 gb: NM_005722.1 213547_at Consensus includes gb: AB014567.1 /DEF = Homo sapiens mRNA for KIAA0667 protein, partial cds. /FEA = mRNA /GEN = KIAA0667 /PROD = KIAA0667 protein /DB_XREF = gi: 3327147 /UG = Hs.154740 TBP-interacting protein 209425_at Consensus includes gb: AA888589 /FEA = EST /DB_XREF = gi: 3004264 /DB_XREF = est: oe68e10.s1 /CLONE = IMAGE: 1416810 /UG = Hs.128749 alpha-methylacyl-CoA racemase /FL = gb: AF047020.1 gb: AF158378.1 gb: NM_014324.1 205525_at gb: NM_018495.3 /DEF = Homo sapiens NAG22 protein (LOC55873), mRNA. /FEA = mRNA /GEN = LOC55873 /PROD = NAG22 protein /DB_XREF = gi: 13236500 /UG = Hs.283080 NAG22 protein /FL = gb: AF247820.3 gb: NM_018495.3 219508_at gb: NM_004751.1 /DEF = Homo sapiens glucosaminyl (N-acetyl) transferase 3, mucin type (GCNT3), mRNA. /FEA = mRNA /GEN = GCNT3 /PROD = glucosaminyl (N-acetyl) transferase 3, mucintype /DB_XREF = gi: 4758421 /UG = Hs.194710 glucosaminyl (N-acetyl) transferase 3, mucin type /FL = gb: AF102542.1 gb: AF038650.1 gb: NM_004751.1 218916_at gb: NM_024671.1 /DEF = Homo sapiens hypothetical protein FLJ23436 (FLJ23436), mRNA. /FEA = mRNA /GEN = FLJ23436 /PROD = hypothetical protein FLJ23436 /DB_XREF = gi: 13375931 /UG = Hs.85658 hypothetical protein FLJ23436 /FL = gb: NM_024671.1 219811_at gb: NM_022720.1 /DEF = Homo sapiens DiGeorge syndrome critical region gene 8 (DGCR8), mRNA. /FEA = mRNA /GEN = DGCR8 /PROD = DiGeorge syndrome critical region gene 8 /DB_XREF = gi: 12225241 /UG = Hs.301855 DiGeorge syndrome critical region gene 8 /FL = gb: NM_022720.1 gb: AF165527.1 215129_at Consensus includes gb: AJ000008.1 /DEF = Homo sapiens mRNA for C2 domain containing PI3-kinase. /FEA = mRNA /PROD = PI3-kinase /DB_XREF = gi: 3288456 /UG = Hs.22500 phosphoinositide-3-kinase, class 2, gamma polypeptide 215169_at Consensus includes gb: BE885244 /FEA = EST /DB_XREF = gi: 10334020 /DB_XREF = est: 601506311F1 /CLONE = IMAGE: 3907947 /UG = Hs.214646 KIAA0447 gene product 212723_at Consensus includes gb: AK021780.1 /DEF = Homo sapiens cDNA FLJ11718 fis, clone HEMBA1005252, highly similar to Homo sapiens mRNA for KIAA0585 protein. /FEA = mRNA /DB_XREF = gi: 10433034 /UG = Hs.72660 phosphatidylserine receptor 210495_x_at gb: AF130095.1 /DEF = Homo sapiens clone FLC0562 PRO2841 mRNA, complete cds. /FEA = mRNA /PROD = PRO2841 /DB_XREF = gi: 11493493 /UG = Hs.287820 fibronectin 1 /FL = gb: AF130095.1 210916_s_at gb: AF098641.1 /DEF = Homo sapiens CD44 isoform RC (CD44) mRNA, complete cds. /FEA = mRNA /GEN = CD44 /PROD = CD44 isoform RC /DB_XREF = gi: 3832517 /UG = Hs.306278 Homo sapiens CD44 isoform RC (CD44) mRNA, complete cds /FL = gb: AF098641.1 220321_s_at gb: NM_024584.1 /DEF = Homo sapiens hypothetical protein FLJ13646 (FLJ13646), mRNA. /FEA = mRNA /GEN = FLJ13646 /PROD = hypothetical protein FLJ13646 /DB_XREF = gi: 13375767 /UG = Hs.21081 hypothetical protein FLJ13646 /FL = gb: NM_024584.1 207224_s_at gb: NM_016543.1 /DEF = Homo sapiens D-siglec precursor, (LOC51766), mRNA. /FEA = mRNA /GEN = LOC51766 /PROD = D-siglec precursor, /DB_XREF = gi: 7706570 /UG = Hs.149250 D-siglec precursor, /FL = gb: AF178981.1 gb: NM_016543.1 218025_s_at gb: NM_006117.1 /DEF = Homo sapiens peroxisomal D3,D2-enoyl-CoA isomerase (PECI), mRNA. /FEA = mRNA /GEN = PECI /PROD = peroxisomal D3,D2-enoyl-CoA isomerase /DB_XREF = gi = 5174624 /UG = Hs.15250 peroxisomal D3,D2-enoyl-CoA isomerase /FL = gb: AL136642.1 gb: BC002668.1 gb: AF069301.1 gb: AF153612.1 gb: NM_006117.1 gb: AF244138.1 212067_s_at Consensus includes gb: AL573058 /FEA = EST /DB_XREF = gi: 12931931 /DB_XREF = est: AL573058 /CLONE = CS0DI014YC05 (3 prime) /UG = Hs.1279 complement component 1, r subcomponent 200887_s_at gb: NM_007315.1 /DEF = Homo sapiens signal transducer and activator of transcription 1, 91 kD (STAT1), mRNA. /FEA = mRNA /GEN = STAT1 /PROD = signal transducer and activator of transcription1, 91 kD /DB_XREF = gi: 6274551 /UG = Hs.21486 signal transducer and activator of transcription 1, 91 kD /FL = gb: M97935.1 gb: NM_007315.1 214996_at Consensus includes gb: AL079294.1 /DEF = Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 362780. /FEA = mRNA /DB_XREF = gi: 5102751 /UG = Hs.29952 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 362780 211596_s_at gb: AB050468.1 /DEF = Homo sapiens mRNA for membrane glycoprotein LIG-1, complete cds. /FEA = mRNA /GEN = lig- 1 /PROD = membrane glycoprotein LIG-1 /DB_XREF = gi: 13537354 /FL = gb: AB050468.1 214967_at Consensus includes gb: AU146983 /FEA = EST /DB_XREF = gi: 11008504 /DB_XREF = est: AU146983 /CLONE = HEMBB1002049 /UG = Hs.262212 Homo sapiens cDNA FLJ12055 fis, clone HEMBB1002049 202874_s_at gb: NM_001695.1 /DEF = Homo sapiens ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42 kD (ATP6C), mRNA. /FEA = mRNA /GEN = ATP6C /PROD = ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42 kD /DB_XREF = gi: 4502314 /UG = Hs.86905 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42 kD /FL = gb: NM_001695.1 43427_at Cluster Incl. AI970898: wr21c03.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2488324 /clone_end = 3 /gb = AI970898 /gi = 5767724 /ug = Hs.234898 /len = 382 211862_x_at gb: AF015451.1 /DEF = Homo sapiens Usurpin-beta mRNA, complete cds. /FEA = CDS /PROD = Usurpin-beta /DB_XREF = gi: 3133282 /UG = Hs.195175 CASP8 and FADD-like apoptosis regulator /FL = gb: AF015451.1 202727_s_at gb: NM_000416.1 /DEF = Homo sapiens interferon gamma receptor 1 (IFNGR1), mRNA. /FEA = mRNA /GEN = IFNGR1 /PROD = interferon gamma receptor 1 /DB_XREF = gi: 4557879 /UG = Hs.180866 interferon gamma receptor 1 /FL = gb: BC005333.1 gb: J03143.1 gb: NM_000416.1 204563_at gb: NM_000655.2 /DEF = Homo sapiens selectin L (lymphocyte adhesion molecule 1) (SELL), mRNA. /FEA = mRNA /GEN = SELL /PROD = selectin L /DB_XREF = gi: 5713320 /UG = Hs.82848 selectin L (lymphocyte adhesion molecule 1) /FL = gb: M25280.1 gb: NM_000655.2 200733_s_at gb: U48296.1 /DEF = Homo sapiens protein tyrosine phosphatase PTPCAAX1 (hPTPCAAX1) mRNA, complete cds. /FEA = mRNA /GEN = hPTPCAAX1 /PROD = protein tyrosine phosphatase PTPCAAX1 /DB_XREF = gi: 1777754 /UG = Hs.227777 protein tyrosine phosphatase type IVA, member 1 /FL = gb: U48296.1 gb: NM_003463.1 204815_s_at Consensus includes gb: AI924903 /FEA = EST /DB_XREF = gi: 5660867 /DB_XREF = est: wn25e04.x1 /CLONE = IMAGE: 2446494 /UG = Hs.151706 KIAA0134 gene product /FL = gb: D50924.1 gb: NM_014681.1 212830_at Consensus includes gb: W68084 /FEA = EST /DB_XREF = gi: 1376954 /DB_XREF = est: zd42f12.s1 /CLONE = IMAGE: 343343 /UG = Hs.5599 EGF-like-domain, multiple 5 219895_at gb: NM_017938.1 /DEF = Homo sapiens hypothetical protein FLJ20716 (FLJ20716), mRNA. /FEA = mRNA /GEN = FLJ20716 /PROD = hypothetical protein FLJ20716 /DB_XREF = gi: 8923642 /UG = Hs.144517 hypothetical protein FLJ20716 /FL = gb: NM_017938.1 212070_at Consensus includes gb: AL554008 /FEA = EST /DB_XREF = gi: 12894377 /DB_XREF = est: AL554008 /CLONE = CS0DI079YN13 (5 prime) /UG = Hs.6527 G protein-coupled receptor 56 219013_at gb: NM_022087.1 /DEF = Homo sapiens hypothetical protein FLJ21634 (FLJ21634), mRNA. /FEA = mRNA /GEN = FLJ21634 /PROD = hypothetical protein FLJ21634 /DB_XREF = gi: 11545800 /UG = Hs.97056 hypothetical protein FLJ21634 /FL = gb: NM_022087.1 210569_s_at gb: AF247180.1 /DEF = Homo sapiens sialic acid-binding immunoglobulin-like lectin-9 mRNA, complete cds. /FEA = mRNA /PROD = sialic acid-binding immunoglobulin-likelectin-9 /DB_XREF = gi: 9392623 /UG = Hs.245828 sialic acid binding Ig-like lectin 9 /FL = gb: AF227924.1 gb: AF247180.1 202371_at gb: NM_024863.1 /DEF = Homo sapiens hypothetical protein FLJ21174 (FLJ21174), mRNA. /FEA = mRNA /GEN = FLJ21174 /PROD = hypothetical protein FLJ21174 /DB_XREF = gi: 13376293 /UG = Hs.194329 hypothetical protein FLJ21174 /FL = gb: AF271783.1 gb: NM_024863.1 207198_s_at gb: NM_004987.2 /DEF = Homo sapiens LIM and senescent cell antigen-like domains 1 (LIMS1), mRNA. /FEA = mRNA /GEN = LIMS1 /PROD = LIM and senescent cell antigen-like domains 1 /DB_XREF = gi: 13518025 /UG = Hs.112378 LIM and senescent cell antigen-like domains 1 /FL = gb: U09284.2 gb: NM_004987.2 209301_at gb: M36532.1 /DEF = Human carbonic anhydrase II mRNA, complete cds. /FEA = mRNA /GEN = CA2 /DB_XREF = gi: 179794 /UG = Hs.155097 carbonic anhydrase II /FL = gb: J03037.1 gb: M36532.1 gb: NM_000067.1 201522_x_at gb: NM_003097.2 /DEF = Homo sapiens small nuclear ribonucleoprotein polypeptide N (SNRPN), transcript variant 1, mRNA. /FEA = mRNA /GEN = SNRPN /PROD = small nuclear ribonucleoprotein polypeptide N /DB_XREF = gi: 13027651 /UG = Hs.48375 small nuclear ribonucleoprotein polypeptide N /FL = gb: U41303.1 gb: NM_003097.2 gb: BC003180.1 gb: J04615.1 202404_s_at gb: NM_000089.1 /DEF = Homo sapiens collagen, type I, alpha 2 (COL1A2), mRNA. /FEA = mRNA /GEN = COL1A2 /PROD = collagen, type I, alpha 2 /DB_XREF = gi: 4502946 /UG = Hs.179573 collagen, type I, alpha 2 /FL = gb: J03464.1 gb: NM_000089.1 211474_s_at gb: BC004948.1 /DEF = Homo sapiens, clone MGC: 10846, mRNA, complete cds. /FEA = mRNA /PROD = Unknown (protein for MGC: 10846) /DB_XREF = gi: 13436313 /UG = Hs.41072 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6 /FL = gb: BC004948.1 206045_s_at gb: NM_003787.1 /DEF = Homo sapiens nucleolar protein 4 (NOL4), mRNA. /FEA = mRNA /GEN = NOL4 /PROD = nucleolar protein 4 /DB_XREF = gi: 4505420 /UG = Hs.6414 nucleolar protein 4 /FL = gb: AB017800.1 gb: NM_003787.1 214978_s_at Consensus includes gb: AK023365.1 /DEF = Homo sapiens cDNA FLJ13303 fis, clone OVARC1001372, highly similar to Homo sapiens liprin-alpha4 mRNA. /FEA = mRNA /DB_XREF = gi: 10435269 /UG = Hs.300704 Homo sapiens cDNA FLJ13303 fis, clone OVARC1001372, highly similar to Homo sapiens liprin-alpha4 mRNA 210029_at gb: M34455.1 /DEF = Human interferon-gamma-inducible indoleamine 2,3-dioxygenase (IDO) mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 185790 /UG = Hs.840 indoleamine-pyrrole 2,3 dioxygenase /FL = gb: M34455.1 gb: NM_002164.1 200971_s_at gb: NM_014445.1 /DEF = Homo sapiens stress-associated endoplasmic reticulum protein 1; ribosome associated membrane protein 4 (SERP1), mRNA. /FEA = mRNA /GEN = SERP1 /PROD = stress-associated endoplasmic reticulum protein1; ribosome associated membrane protein 4 /DB_XREF = gi: 7657551 /UG = Hs.76698 stress-associated endoplasmic reticulum protein 1; ribosome associated membrane protein 4 /FL = gb: AL136807.1 gb: AF136975.1 gb: AB022427.1 gb: NM_014445.1 213713_s_at Consensus includes gb: R48779 /FEA = EST /DB_XREF = gi: 810805 /DB_XREF = est: yj69c07.s1 /CLONE = IMAGE: 153996 /UG = Hs.293845 ESTs, Weakly similar to B32688 beta-galactosidase-related protein H. sapiens 212946_at Consensus includes gb: AK025432.1 /DEF = Homo sapiens cDNA: FLJ21779 fis, clone HEP00210. /FEA = mRNA /DB_XREF = gi: 10437943 /UG = Hs.151385 KIAA0564 protein 203162_s_at gb: NM_005886.1 /DEF = Homo sapiens katanin p80 (WD40-containing) subunit B 1 (KATNB1), mRNA. /FEA = mRNA /GEN = KATNB1 /PROD = katanin p80 subunit B 1 /DB_XREF = gi: 5031816 /UG = Hs.275675 katanin p80 (WD40- containing) subunit B 1 /FL = gb: BC001353.1 gb: AF052432.1 gb: NM_005886.1 202064_s_at gb: AF052059.1 /DEF = Homo sapiens SEL1L (SEL1L) mRNA, complete cds. /FEA = mRNA /GEN = SEL1L /PROD = SEL1L /DB_XREF = gi: 6851088 /UG = Hs.181300 sel-1 (suppressor of lin-12, C. elegans)-like /FL = gb: NM_005065.1 gb: AB020335.1 gb: AF052059.1 gb: U11037.1 219735_s_at gb: NM_014553.1 /DEF = Homo sapiens LBP protein (LBP-9), mRNA. /FEA = mRNA /GEN = LBP-9 /PROD = LBP protein /DB_XREF = gi: 7657298 /UG = Hs.114747 LBP protein; likely ortholog of mouse CRTR-1 /FL = gb: AF198488.1 gb: NM_014553.1 212008_at Consensus includes gb: N29889 /FEA = EST /DB_XREF = gi: 1148409 /DB_XREF = est: yy11e11.s1 /CLONE = IMAGE: 270956 /UG = Hs.77495 UBX domain-containing 1 221795_at Consensus includes gb: AI346341 /FEA = EST /DB_XREF = gi: 4083547 /DB_XREF = est: qp50b09.x1 /CLONE = IMAGE: 1926425 /UG = Hs.298998 Homo sapiens, Similar to hypothetical protein FLJ20093, clone MGC: 1076, mRNA, complete cds 209821_at gb: AB024518.1 /DEF = Homo sapiens mRNA for DVS27-related protein, complete cds. /FEA = mRNA /GEN = DVS27 /PROD = DVS27-related protein /DB_XREF = gi: 4520327 /UG = Hs.58589 glycogenin 2 /FL = gb: AB024518.1 205602_x_at gb: NM_002783.1 /DEF = Homo sapiens pregnancy specific beta-1-glycoprotein 7 (PSG7), mRNA. /FEA = mRNA /GEN = PSG7 /PROD = pregnancy specific beta-1-glycoprotein 7 /DB_XREF = gi: 4506176 /UG = Hs.225932 pregnancy specific beta-1-glycoprotein 7 /FL = gb: NM_002783.1 gb: U18467.1 211144_x_at gb: M30894.1 /DEF = Human T-cell receptor Ti rearranged gamma-chain mRNA V-J-C region, complete cds. /FEA = mRNA /GEN = CD3G /DB_XREF = gi: 339406 /UG = Hs.112259 T cell receptor gamma locus /FL = gb: M30894.1 215231_at Consensus includes gb: AU144309 /FEA = EST /DB_XREF = gi: 11005830 /DB_XREF = est: AU144309 /CLONE = HEMBA1001533 /UG = Hs.55830 Homo sapiens cDNA FLJ10068 fis, clone HEMBA1001533 203245_s_at gb: BC002791.1 /DEF = Homo sapiens, homologous to yeast nitrogen permease (candidate tumor suppressor), clone MGC: 3527, mRNA, complete cds. /FEA = mRNA /PROD = homologous to yeast nitrogen permease (candidate tumor suppressor) /DB_XREF = gi: 12803888 /UG = Hs.169780 homologous to yeast nitrogen permease (candidate tumor suppressor) /FL = gb: BC002791.1 gb: AF040707.1 gb: NM_006545.1 205695_at gb: NM_006843.1 /DEF = Homo sapiens serine dehydratase (SDS), mRNA. /FEA = mRNA /GEN = SDS /PROD = serine dehydratase /DB_XREF = gi: 5803160 /UG = Hs.76751 serine dehydratase /FL = gb: J05037.1 gb: NM_006843.1 221928_at Consensus includes gb: AI057637 /FEA = EST /DB_XREF = gi: 3331503 /DB_XREF = est: oy31h06.x1 /CLONE = IMAGE: 1667483 /UG = Hs.234898 ESTs, Weakly similar to 2109260A B cell growth factor H. sapiens 211191_at gb: AF054818.1 /DEF = Homo sapiens leukocyte differentiation antigen CD84 isoform CD84s (CD84) mRNA, complete cds. /FEA = mRNA /GEN = CD84 /PROD = leukocyte differentiation antigen CD84 isoformCD84s /DB_XREF = gi: 6650111 /UG = Hs.137548 CD84 antigen (leukocyte antigen) /FL = gb: AF054818.1 201141_at gb: NM_002510.1 /DEF = Homo sapiens glycoprotein (transmembrane) nmb (GPNMB), mRNA. /FEA = mRNA /GEN = GPNMB /PROD = glycoprotein (transmembrane) nmb /DB_XREF = gi: 4505404 /UG = Hs.82226 glycoprotein (transmembrane) nmb /FL = gb: AF322909.1 gb: NM_002510.1 217299_s_at Consensus includes gb: AK001017.1 /DEF = Homo sapiens cDNA FLJ10155 fis, clone HEMBA1003433, highly similar to Homo sapiens gene for NBS1. /FEA = mRNA /DB_XREF = gi: 7022031 /UG = Hs.25812 Nijmegen breakage syndrome 1 (nibrin) 213338_at Consensus includes gb: BF062629 /FEA = EST /DB_XREF = gi: 10821539 /DB_XREF = est: 7h62h07.x1 /CLONE = IMAGE: 3320605 /UG = Hs.35861 DKFZP586E1621 protein 213416_at Consensus includes gb: BG532690 /FEA = EST /DB_XREF = gi: 13524229 /DB_XREF = est: 602580263F1 /CLONE = IMAGE: 4718390 /UG = Hs.40034 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 220349_s_at gb: NM_022759.1 /DEF = Homo sapiens hypothetical protein FLJ21865 (FLJ21865), mRNA. /FEA = mRNA /GEN = FLJ21865 /PROD = hypothetical protein FLJ21865 /DB_XREF = gi: 12232428 /UG = Hs.29288 hypothetical protein FLJ21865 /FL = gb: NM_022759.1 219807_x_at gb: NM_016154.1 /DEF = Homo sapiens ras-related GTP-binding protein 4b (RAB4B), mRNA. /FEA = mRNA /GEN = RAB4B /PROD = ras-related GTP-binding protein 4b /DB_XREF = gi: 7706672 /UG = Hs.279771 Homo sapiens TR00071289_m (RAB4B), mRNA /FL = gb: AF165522.1 gb: NM_016154.1 212566_at Consensus includes gb: AL523310 /FEA = EST /DB_XREF = gi: 12786803 /DB_XREF = est: AL523310 /CLONE = CS0DC001YN06 (3 prime) /UG = Hs.150580 putative translation initiation factor 212170_at Consensus includes gb: BF447705 /FEA = EST /DB_XREF = gi: 11512843 /DB_XREF = est: 7q94d07.x1 /CLONE = IMAGE: 3706021 /UG = Hs.180895 putative brain nuclearly-targeted protein 220007_at gb: NM_024770.1 /DEF = Homo sapiens hypothetical protein FLJ13984 (FLJ13984), mRNA. /FEA = mRNA /GEN = FLJ13984 /PROD = hypothetical protein FLJ13984 /DB_XREF = gi: 13376116 /UG = Hs.135146 hypothetical protein FLJ13984 /FL = gb: NM_024770.1 201489_at gb: BC005020.1 /DEF = Homo sapiens, peptidylprolyl isomerase F (cyclophilin F), clone MGC: 11022, mRNA, complete cds. /FEA = mRNA /PROD = peptidylprolyl isomerase F (cyclophilin F) /DB_XREF = gi: 13477126 /UG = Hs.173125 peptidylprolyl isomerase F (cyclophilin F) /FL = gb: BC005020.1 gb: M80254.1 gb: NM_005729.1 218820_at gb: NM_020215.1 /DEF = Homo sapiens hypothetical protein DKFZp761F2014 (DKFZp761F2014), mRNA. /FEA = mRNA /GEN = DKFZp761F2014 /PROD = hypothetical protein DKFZp761F2014 /DB_XREF = gi: 9910205 /UG = Hs.6434 hypothetical protein DKFZp761F2014 /FL = gb: NM_020215.1 212310_at Consensus includes gb: D87742.1 /DEF = Human mRNA for KIAA0268 gene, partial cds. /FEA = mRNA /GEN = KIAA0268 /DB_XREF = gi: 1665824 /UG = Hs.241552 KIAA0268 protein 216274_s_at Consensus includes gb: N99438 /FEA = EST /DB_XREF = gi: 1270864 /DB_XREF = est: yz96c06.r1 /CLONE = IMAGE: 290890 /UG = Hs.9534 signal peptidase complex (18 kD) 201118_at gb: NM_002631.1 /DEF = Homo sapiens phosphogluconate dehydrogenase (PGD), mRNA. /FEA = mRNA /GEN = PGD /PROD = phosphogluconate dehydrogenase /DB_XREF = gi: 4505758 /UG = Hs.75888 phosphogluconate dehydrogenase /FL = gb: BC000368.1 gb: NM_002631.1 gb: U30255.1 219885_at gb: NM_018042.1 /DEF = Homo sapiens hypothetical protein FLJ10260 (FLJ10260), mRNA. /FEA = mRNA /GEN = FLJ10260 /PROD = hypothetical protein FLJ10260 /DB_XREF = gi: 8922317 /UG = Hs.105859 hypothetical protein FLJ10260 /FL = gb: NM_018042.1 217597_x_at Consensus includes gb: AI344141 /FEA = EST /DB_XREF = gi: 4081347 /DB_XREF = est: tc02d09.x1 /CLONE = IMAGE: 2062673 /UG = Hs.229850 ESTs, Highly similar to G01251 Rar protein H. sapiens 202074_s_at gb: NM_021980.1 /DEF = Homo sapiens tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains; Huntingtin interacting protein L; transcrption factor IIIA-interacting protein (FIP2), mRNA. /FEA = mRNA /GEN = FIP2 /PROD = tumor necrosis factor alpha-inducible cellularprotein containing leucine zipper domains; Huntingtin interacting protein L; transcrption factor IIIA-interacting protein /DB_XREF = gi: 11415041 /UG = Hs.278898 tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains; Huntingtin interacting protein L; transcrption factor IIIA-interacting protein /FL = gb: NM_021980.1 209598_at gb: AB020690.1 /DEF = Homo sapiens mRNA for KIAA0883 protein, complete cds. /FEA = mRNA /GEN = KIAA0883 /PROD = KIAA0883 protein /DB_XREF = gi: 4240254 /UG = Hs.7782 paraneoplastic antigen MA2 /FL = gb: AF286487.1 gb: NM_007257.1 gb: AB020690.1 203549_s_at gb: NM_000237.1 /DEF = Homo sapiens lipoprotein lipase (LPL), mRNA. /FEA = mRNA /GEN = LPL /PROD = lipoprotein lipase precursor /DB_XREF = gi: 4557726 /UG = Hs.180878 lipoprotein lipase /FL = gb: M15856.1 gb: NM_000237.1 213089_at Consensus includes gb: AU158490 /FEA = EST /DB_XREF = gi: 11020011 /DB_XREF = est: AU158490 /CLONE = PLACE3000042 /UG = Hs.303632 Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene similar to GUSB (glucuronidase, beta), a gene for a membrane protein, ESTs, STSs, GSSs and CpG islands 209166_s_at gb: U68567.1 /DEF = Human lysosomal acid alpha-mannosidase mRNA, complete cds. /FEA = mRNA /PROD = lysosomal acid alpha-mannosidase /DB_XREF = gi: 1658373 /UG = Hs.279854 mannosidase, alpha, class 2B, member 1 /FL = gb: NM_000528.1 gb: BC000736.1 gb: U05572.1 gb: U68567.1 gb: U60266.1 203043_at gb: NM_004729.1 /DEF = Homo sapiens Ac-like transposable element (ALTE), mRNA. /FEA = mRNA /GEN = ALTE /PROD = Ac-like transposable element /DB_XREF = gi: 4759257 /UG = Hs.9933 Ac-like transposable element /FL = gb: AB018328.1 gb: NM_004729.1 217914_at gb: NM_017901.1 /DEF = Homo sapiens two-pore channel 1, homolog (KIAA1169), mRNA. /FEA = mRNA /GEN = KIAA1169 /PROD = two-pore channel 1, homolog /DB_XREF = gi: 8923566 /UG = Hs.26440 two-pore channel 1, homolog /FL = gb: NM_017901.1 204613_at gb: NM_002661.1 /DEF = Homo sapiens phospholipase C, gamma 2 (phosphatidylinositol-specific) (PLCG2), mRNA. /FEA = mRNA /GEN = PLCG2 /PROD = phospholipase C, gamma 2(phosphatidylinositol-specific) /DB_XREF = gi: 4505870 /UG = Hs.75648 phospholipase C, gamma 2 (phosphatidylinositol-specific) /FL = gb: M37238.1 gb: NM_002661.1 205866_at gb: NM_003665.1 /DEF = Homo sapiens ficolin (collagenfibrinogen domain-containing) 3 (Hakata antigen) (FCN3), mRNA. /FEA = mRNA /GEN = FCN3 /PROD = ficolin 3 precursor /DB_XREF = gi: 4504330 /UG = Hs.21415 ficolin (collagenfibrinogen domain-containing) 3 (Hakata antigen) /FL = gb: D88587.1 gb: NM_003665.1 221295_at gb: NM_001279.1 /DEF = Homo sapiens cell death-inducing DFFA-like effector a (CIDEA), mRNA. /FEA = CDS /GEN = CIDEA /PROD = cell death-inducing DFFA-like effector a /DB_XREF = gi: 4557464 /UG = Hs.249129 cell death- inducing DFFA-like effector a /FL = gb: AF041378.1 gb: NM_001279.1 212814_at Consensus includes gb: AB020635.1 /DEF = Homo sapiens mRNA for KIAA0828 protein, partial cds. /FEA = mRNA /GEN = KIAA0828 /PROD = KIAA0828 protein /DB_XREF = gi: 4240144 /UG = Hs.4984 KIAA0828 protein 219563_at gb: NM_024633.1 /DEF = Homo sapiens hypothetical protein FLJ21276 (FLJ21276), mRNA. /FEA = mRNA /GEN = FLJ21276 /PROD = hypothetical protein FLJ21276 /DB_XREF = gi: 13375863 /UG = Hs.41502 hypothetical protein FLJ21276 /FL = gb: NM_024633.1 209201_x_at gb: L01639.1 /DEF = Human (clone HSY3RR) neuropeptide Y receptor (NPYR) mRNA, complete cds. /FEA = mRNA /GEN = NPYR /PROD = neuropeptide Y receptor /DB_XREF = gi: 189313 /UG = Hs.89414 chemokine (C—X—C motif), receptor 4 (fusin) /FL = gb: L01639.1 gb: AF025375.1 gb: M99293.1 gb: L06797.1 gb: NM_003467.1 gb: AF147204.1 212511_at Consensus includes gb: AI766247 /FEA = EST /DB_XREF = gi: 5232756 /DB_XREF = est: wh68f03.x1 /CLONE = IMAGE: 2385917 /UG = Hs.7885 phosphatidylinositol binding clathrin assembly protein 207702_s_at gb: NM_012301.1 /DEF = Homo sapiens atrophin-1 interacting protein 1; activin receptor interacting protein 1 (KIAA0705), mRNA. /FEA = mRNA /GEN = KIAA0705 /PROD = atrophin-1 interacting protein 1; activin receptor interacting protein 1 /DB_XREF = gi: 6912461 /UG = Hs.22599 atrophin-1 interacting protein 1; activin receptor interacting protein 1 /FL = gb: AF038563.1 gb: NM_012301.1 207681_at gb: NM_001504.1 /DEF = Homo sapiens G protein-coupled receptor 9 (GPR9), mRNA. /FEA = mRNA /GEN = GPR9 /PROD = G protein-coupled receptor 9 /DB_XREF = gi: 4504098 /UG = Hs.198252 G protein-coupled receptor 9 /FL = gb: NM_001504.1 216322_at Consensus includes gb: D28586.1 /DEF = Human mRNA for LFA-3(delta D2), partial cds. /FEA = mRNA /PROD = LFA- 3(delta D2) /DB_XREF = gi: 466540 /UG = Hs.75626 CD58 antigen, (lymphocyte function-associated antigen 3) 221973_at Consensus includes gb: AI983904 /FEA = EST /DB_XREF = gi: 5811123 /DB_XREF = est: wz55d05.x1 /CLONE = IMAGE: 2561961 /UG = Hs.79732 fibulin 1 207092_at gb: NM_000230.1 /DEF = Homo sapiens leptin (murine obesity homolog) (LEP), mRNA. /FEA = mRNA /GEN = LEP /PROD = leptin precursor /DB_XREF = gi: 4557714 /UG = Hs.194236 leptin (murine obesity homolog) /FL = gb: U43653.1 gb: AF008123.1 gb: NM_000230.1 gb: U18915.1 gb: D49487.1 204019_s_at gb: NM_015677.1 /DEF = Homo sapiens hypothetical protein (DKFZP586F1318), mRNA. /FEA = mRNA /GEN = DKFZP586F1318 /PROD = hypothetical protein /DB_XREF = gi: 7661669 /UG = Hs.25213 hypothetical protein /FL = gb: NM_015677.1 212109_at Consensus includes gb: AI590869 /FEA = EST /DB_XREF = gi: 4599917 /DB_XREF = est: tw88g03.x1 /CLONE = IMAGE: 2266804 /UG = Hs.172035 hypothetical protein similar to mouse HN1 (Hematological and Neurological expressed sequence 1) 215563_s_at Consensus includes gb: U28055.1 /DEF = Homo sapiens hepatocyte growth factor-like protein homolog mRNA, partial cds. /FEA = mRNA /PROD = hepatocyte growth factor-like protein homolog /DB_XREF = gi: 1141776 /UG = Hs.278657 macrophage stimulating 1 (hepatocyte growth factor-like) 202696_at gb: NM_005109.1 /DEF = Homo sapiens oxidative-stress responsive 1 (OSR1), mRNA. /FEA = mRNA /GEN = OSR1 /PROD = oxidative-stress responsive 1 /DB_XREF = gi: 4826877 /UG = Hs.95220 oxidative-stress responsive 1 /FL = gb: AB017642.1 gb: NM_005109.1 gb: AB029024.1 222143_s_at Consensus includes gb: AY007098.1 /DEF = Homo sapiens clone TCCCIA00183 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 9955989 /UG = Hs.27556 hypothetical protein FLJ22405 208161_s_at gb: NM_020037.1 /DEF = Homo sapiens ATP-binding cassette, sub-family C (CFTRMRP), member 3 (ABCC3), transcript variant MRP3A, mRNA. /FEA = mRNA /GEN = ABCC3 /PROD = ATP-binding cassette, sub-family C, member 3, isoform MRP3A /DB_XREF = gi: 9955971 /UG = Hs.90786 ATP-binding cassette, sub-family C (CFTRMRP), member 3 /FL = gb: AF085691.1 gb: NM_020037.1 214353_at Consensus includes gb: AW241864 /FEA = EST /DB_XREF = gi: 6575618 /DB_XREF = est: xn76b12.x1 /CLONE = IMAGE: 2700383 /UG = Hs.252387 cadherin, EGF LAG seven-pass G-type receptor 1, flamingo (Drosophila) homolog 55616_at Cluster Incl. AI703342: wd93b03.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-2339117 /clone_end = 3 /gb = AI703342 /gi = 4991242 /ug = Hs.91668 /len = 494 208647_at Consensus includes gb: AA872727 /FEA = EST /DB_XREF = gi: 2968849 /DB_XREF = est: ob11c12.s1 /CLONE = IMAGE: 1323382 /UG = Hs.48876 farnesyl-diphosphate farnesyltransferase 1 /FL = gb: L06070.1 gb: L06105.1 gb: NM_004462.1 219659_at Consensus includes gb: AU146927 /FEA = EST /DB_XREF = gi: 11008448 /DB_XREF = est: AU146927 /CLONE = HEMBB1001906 /UG = Hs.130489 ATPase, aminophospholipid transporter-like, Class I, type 8A, member 2 /FL = gb: AF236871.1 gb: NM_016529.1 201470_at gb: NM_004832.1 /DEF = Homo sapiens glutathione-S-transferase like; glutathione transferase omega (GSTTLp28), mRNA. /FEA = mRNA /GEN = GSTTLp28 /PROD = glutathione-S-transferase like /DB_XREF = gi: 4758483 /UG = Hs.11465 glutathione-S-transferase like; glutathione transferase omega /FL = gb: BC000127.1 gb: U90313.1 gb: NM_004832.1 gb: AF212303.1 209561_at gb: L38969.1 /DEF = Homo sapiens thrombospondin 3 (THBS3) mRNA, complete cds. /FEA = mRNA /GEN = THBS3 /PROD = thrombospondin 3 /DB_XREF = gi: 886298 /UG = Hs.169875 thrombospondin 3 /FL = gb: NM_007112.1 gb: L38969.1 214162_at Consensus includes gb: AF070541.1 /DEF = Homo sapiens clones 24714 and 24715 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 3387900 /UG = Hs.4267 Homo sapiens clones 24714 and 24715 mRNA sequence 204681_s_at gb: NM_012294.1 /DEF = Homo sapiens guanine nucleotide exchange factor for Rap1; M-Ras-regulated GEF (KIAA0277), mRNA. /FEA = mRNA /GEN = KIAA0277 /PROD = guanine nucleotide exchange factor for Rap1; M-Ras- regulated GEF /DB_XREF = gi: 6912455 /UG = Hs.80620 guanine nucleotide exchange factor for Rap1; M-Ras-regulated GEF /FL = gb: D87467.1 gb: NM_012294.1 203132_at gb: NM_000321.1 /DEF = Homo sapiens retinoblastoma 1 (including osteosarcoma) (RB1), mRNA. /FEA = mRNA /GEN = RB1 /PROD = retinoblastoma 1 (including osteosarcoma) /DB_XREF = gi: 4506434 /UG = Hs.75770 retinoblastoma 1 (including osteosarcoma) /FL = gb: M33647.1 gb: M15400.1 gb: M28419.1 gb: NM_000321.1 202973_x_at gb: NM_014883.1 /DEF = Homo sapiens KIAA0914 gene product (KIAA0914), mRNA. /FEA = mRNA /GEN = KIAA0914 /PROD = KIAA0914 gene product /DB_XREF = gi: 7662375 /UG = Hs.177664 KIAA0914 gene product /FL = gb: AB020721.1 gb: NM_014883.1 214023_x_at Consensus includes gb: AL533838 /FEA = EST /DB_XREF = gi: 12797331 /DB_XREF = est: AL533838 /CLONE = CS0DF002YB07 (3 prime) /UG = Hs.179661 tubulin, beta polypeptide 212254_s_at Consensus includes gb: AI798790 /FEA = EST /DB_XREF = gi: 5364262 /DB_XREF = est: we92f11.x1 /CLONE = IMAGE: 2348589 /UG = Hs.198689 KIAA0728 protein 218028_at gb: NM_016031.1 /DEF = Homo sapiens elongation of very long chain fatty acids (FEN1Elo2, SUR4Elo3, yeast)-like 1 (ELOVL1), mRNA. /FEA = mRNA /GEN = ELOVL1 /PROD = elongation of very long chain fatty acids(FEN1Elo2, SUR4Elo3, yeast)-like 1 /DB_XREF = gi: 7705798 /UG = Hs.25597 elongation of very long chain fatty acids (FEN1Elo2, SUR4Elo3, yeast)-like 1 /FL = gb: BC000618.1 gb: NM_022821.1 gb: AF151846.1 gb: NM_016031.1 203263_s_at Consensus includes gb: AI625739 /FEA = EST /DB_XREF = gi: 4650670 /DB_XREF = est: ty65g05.x1 /CLONE = IMAGE: 2283992 /UG = Hs.54697 Cdc42 guanine exchange factor (GEF) 9 /FL = gb: NM_015185.1 212360_at Consensus includes gb: AI916249 /FEA = EST /DB_XREF = gi: 5636104 /DB_XREF = est: wg99c01.x1 /CLONE = IMAGE: 2379360 /UG = Hs.82927 adenosine monophosphate deaminase 2 (isoform L) /FL = gb: NM_004037.2 200732_s_at Consensus includes gb: AL578310 /FEA = EST /DB_XREF = gi: 12942259 /DB_XREF = est: AL578310 /CLONE = CS0DK010YM06 (3 prime) /UG = Hs.227777 protein tyrosine phosphatase type IVA, member 1 /FL = gb: U48296.1 gb: NM_003463.1 203912_s_at gb: NM_006730.1 /DEF = Homo sapiens deoxyribonuclease I-like 1 (DNASE1L1), mRNA. /FEA = mRNA /GEN = DNASE1L1 /PROD = deoxyribonuclease I-like 1 /DB_XREF = gi: 5803006 /UG = Hs.77091 deoxyribonuclease I- like 1 /FL = gb: U06846.1 gb: NM_006730.1 212246_at Consensus includes gb: BE880828 /FEA = EST /DB_XREF = gi: 10329604 /DB_XREF = est: 601493261F1 /CLONE = IMAGE: 3895407 /UG = Hs.84775 Human transposon-like element mRNA 214204_at Consensus includes gb: BF224076 /FEA = EST /DB_XREF = gi: 11131303 /DB_XREF = est: 7q83e08.x1 /CLONE = IMAGE: 3704942 /UG = Hs.307438 Human DNA sequence from clone 495O10 on chromosome 6q26-27. Contains an RPL37A (60S Ribosomal Protein L37A) pseudogene, the last exon of a gene for a novel protein similar to worm E04F6.2, ESTs, STSs and GSSs 207643_s_at gb: NM_001065.1 /DEF = Homo sapiens tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A), mRNA. /FEA = mRNA /GEN = TNFRSF1A /PROD = tumor necrosis factor receptor 1 (55 kD) /DB_XREF = gi: 4507574 /UG = Hs.159 tumor necrosis factor receptor superfamily, member 1A /FL = gb: NM_001065.1 200611_s_at gb: AB010427.2 /DEF = Homo sapiens mRNA for NORI-1, complete cds. /FEA = mRNA /PROD = NORI-1 /DB_XREF = gi: 5103672 /UG = Hs.85100 WD repeat domain 1 /FL = gb: BC000201.1 gb: BC002489.1 gb: AF020056.1 gb: AB010427.2 gb: NM_017491.1 218153_at gb: NM_024537.1 /DEF = Homo sapiens hypothetical protein FLJ12118 (FLJ12118), mRNA. /FEA = mRNA /GEN = FLJ12118 /PROD = hypothetical protein FLJ12118 /DB_XREF = gi: 13375694 /UG = Hs.7779 hypothetical protein FLJ12118 /FL = gb: NM_024537.1 219627_at gb: NM_024910.1 /DEF = Homo sapiens hypothetical protein FLJ12700 (FLJ12700), mRNA. /FEA = mRNA /GEN = FLJ12700 /PROD = hypothetical protein FLJ12700 /DB_XREF = gi: 13376370 /UG = Hs.250547 hypothetical protein FLJ12700 /FL = gb: NM_024910.1 204333_s_at gb: NM_000027.1 /DEF = Homo sapiens aspartylglucosaminidase (AGA), mRNA. /FEA = mRNA /GEN = AGA /PROD = aspartylglucosaminidase precursor /DB_XREF = gi: 4557272 /UG = Hs.207776 aspartylglucosaminidase /FL = gb: M64073.1 gb: NM_000027.1 203782_s_at gb: NM_005035.1 /DEF = Homo sapiens polymerase (RNA) mitochondrial (DNA directed) (POLRMT), mRNA. /FEA = mRNA /GEN = POLRMT /PROD = polymerase (RNA) mitochondrial (DNA directed) /DB_XREF = gi: 4826925 /UG = Hs.153880 polymerase (RNA) mitochondrial (DNA directed) /FL = gb: U75370.1 gb: NM_005035.1 203435_s_at gb: NM_007287.1 /DEF = Homo sapiens membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) (MME), transcript variant 1bis, mRNA. /FEA = mRNA /GEN = MME /PROD = membrane metallo- endopeptidase /DB_XREF = gi: 6042199 /UG = Hs.1298 membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) /FL = gb: J03779.1 gb: NM_007287.1 gb: NM_007288.1 205403_at gb: NM_004633.1 /DEF = Homo sapiens interleukin 1 receptor, type II (IL1R2), mRNA. /FEA = mRNA /GEN = IL1R2 /PROD = interleukin 1 receptor, type II /DB_XREF = gi: 4758597 /UG = Hs.25333 interleukin 1 receptor, type II /FL = gb: U74649.1 gb: NM_004633.1 202719_s_at gb: BC001451.1 /DEF = Homo sapiens, testin, clone MGC: 1146, mRNA, complete cds. /FEA = mRNA /PROD = testin /DB_XREF = gi: 12655188 /UG = Hs.165986 testin /FL = gb: AF245356.1 gb: AF245357.1 gb: BC001451.1 gb: NM_015641.1 200701_at gb: NM_006432.1 /DEF = Homo sapiens epididymal secretory protein (19.5 kD) (HE1), mRNA. /FEA = mRNA /GEN = HE1 /PROD = epididymal secretory protein (19.5 kD) /DB_XREF = gi: 5453677 /UG = Hs.119529 epididymal secretory protein (19.5 kD) /FL = gb: BC002532.1 gb: NM_006432.1 208749_x_at gb: AF085357.1 /DEF = Homo sapiens flotillin mRNA, complete cds. /FEA = mRNA /PROD = flotillin /DB_XREF = gi: 5114048 /UG = Hs.179986 flotillin 1 /FL = gb: BC001146.1 gb: AF085357.1 gb: AF089750.2 gb: NM_005803.2 220980_s_at gb: NM_031284.1 /DEF = Homo sapiens hypothetical protein DKFZp434B195 (DKFZP434B195), mRNA. /FEA = mRNA /GEN = DKFZP434B195 /PROD = hypothetical protein DKFZp434B195 /DB_XREF = gi: 13775193 /FL = gb: NM_031284.1 201126_s_at gb: NM_002406.2 /DEF = Homo sapiens mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1), mRNA. /FEA = mRNA /GEN = MGAT1 /PROD = mannosyl (alpha-1,3-)-glycoproteinbeta-1,2-N- acetylglucosaminyltransferase /DB_XREF = gi: 6031182 /UG = Hs.151513 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N- acetylglucosaminyltransferase /FL = gb: M55621.1 gb: NM_002406.2 202842_s_at gb: AL080081.1 /DEF = Homo sapiens mRNA; cDNA DKFZp564F1862 (from clone DKFZp564F1862); complete cds. /FEA = mRNA /GEN = DKFZp564F1862 /PROD = hypothetical protein /DB_XREF = gi: 5262493 /UG = Hs.6790 DnaJ (Hsp40) homolog, subfamily B, member 9 /FL = gb: AF083247.1 gb: AL080081.1 gb: AB026908.1 gb: NM_012328.1 220437_at gb: NM_018687.1 /DEF = Homo sapiens hepatocellular carcinoma-associated gene TD26 (LOC55908), mRNA. /FEA = mRNA /GEN = LOC55908 /PROD = hepatocellular carcinoma-associated gene TD26 /DB_XREF = gi: 8923901 /UG = Hs.224121 hepatocellular carcinoma-associated gene TD26 /FL = gb: NM_018687.1 205363_at gb: NM_003986.1 /DEF = Homo sapiens butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 (BBOX1), mRNA. /FEA = mRNA /GEN = BBOX1 /PROD = gamma-butyrobetaine hydroxylase /DB_XREF = gi: 4502368 /UG = Hs.9667 butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 /FL = gb: AF082868.1 gb: NM_003986.1 218865_at gb: NM_022746.1 /DEF = Homo sapiens hypothetical protein FLJ22390 (FLJ22390), mRNA. /FEA = mRNA /GEN = FLJ22390 /PROD = hypothetical protein FLJ22390 /DB_XREF = gi: 12232404 /UG = Hs.10974 hypothetical protein FLJ22390 /FL = gb: NM_022746.1 210662_at gb: BC000879.1 /DEF = Homo sapiens, Similar to kynureninase (L-kynurenine hydrolase), clone MGC: 5080, mRNA, complete cds. /FEA = mRNA /PROD = Similar to kynureninase (L-kynureninehydrolase) /DB_XREF = gi: 12654128 /UG = Hs.169139 kynureninase (L-kynurenine hydrolase) /FL = gb: BC000879.1 204531_s_at gb: NM_007295.1 /DEF = Homo sapiens breast cancer 1, early onset (BRCA1), transcript variant BRCA1b, mRNA. /FEA = mRNA /GEN = BRCA1 /PROD = breast cancer 1, early onset /DB_XREF = gi: 6552300 /UG = Hs.194143 breast cancer 1, early onset /FL = gb: NM_007295.1 202515_at Consensus includes gb: BG251175 /FEA = EST /DB_XREF = gi: 12760991 /DB_XREF = est: 602364982F1 /CLONE = IMAGE: 4473165 /UG = Hs.154294 discs, large (Drosophila) homolog 1 /FL = gb: NM_004087.1 gb: U13896.1 37152_at Cluster Incl. L07592: Human peroxisome proliferator activated receptor mRNA, complete cds /cds = (337, 1662) /gb = L07592 /gi = 190229 /ug = Hs.106415 /len = 3301 216381_x_at Consensus includes gb: AL035413 /DEF = Human DNA sequence from clone RP4-657E11 on chromosome 1p35.1-36.23 Contains 3 part of the CAPZB (capping protein (actin filament) muscle Z-line, beta) gene, genes for aldo-keto reductase family 7 (aflatoxin aldehyde reductase) members A2 (AKR7A2 . . . /FEA = mRNA_1 /DB_XREF = gi: 6010110 /UG = Hs.284236 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 220162_s_at gb: NM_022352.1 /DEF = Homo sapiens caspase recruitment domain protein 9 (LOC64170), mRNA. /FEA = mRNA /GEN = LOC64170 /PROD = caspase recruitment domain protein 9 /DB_XREF = gi: 11641262 /UG = Hs.271815 caspase recruitment domain protein 9 /FL = gb: NM_022352.1 219687_at gb: NM_018194.1 /DEF = Homo sapiens hypothetical protein FLJ10724 (FLJ10724), mRNA. /FEA = mRNA /GEN = FLJ10724 /PROD = hypothetical protein FLJ10724 /DB_XREF = gi: 8922620 /UG = Hs.58650 melanoma antigen recognized by T cells 2 /FL = gb: NM_018194.1 202214_s_at gb: NM_003588.1 /DEF = Homo sapiens cullin 4B (CUL4B), mRNA. /FEA = mRNA /GEN = CUL4B /PROD = cullin 4B /DB_XREF = gi: 13270466 /UG = Hs.155976 cullin 4B /FL = gb: NM_003588.1 gb: AB014595.1 215346_at Consensus includes gb: BF664114 /FEA = EST /DB_XREF = gi: 11938009 /DB_XREF = est: 602145911F1 /CLONE = IMAGE: 4309610 /UG = Hs.25648 tumor necrosis factor receptor superfamily, member 5 219768_at gb: NM_024626.1 /DEF = Homo sapiens hypothetical protein FLJ22418 (FLJ22418), mRNA. /FEA = mRNA /GEN = FLJ22418 /PROD = hypothetical protein FLJ22418 /DB_XREF = gi: 13375849 /UG = Hs.36563 hypothetical protein FLJ22418 /FL = gb: NM_024626.1 202464_s_at gb: NM_004566.1 /DEF = Homo sapiens 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 3 (PFKFB3), mRNA. /FEA = mRNA /GEN = PFKFB3 /PROD = 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 3 /DB_XREF = gi: 4758899 /UG = Hs.195471 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 3 /FL = gb: D49817.1 gb: AF109735.1 gb: NM_004566.1 212762_s_at Consensus includes gb: AI375916 /FEA = EST /DB_XREF = gi: 4175906 /DB_XREF = est: tc14c12.x1 /CLONE = IMAGE: 2063830 /UG = Hs.173638 transcription factor 7-like 2 (T-cell specific, HMG-box) 206487_at gb: NM_025154.1 /DEF = Homo sapiens KIAA0810 protein (KIAA0810), mRNA. /FEA = mRNA /GEN = KIAA0810 /PROD = hypothetical protein FLJ12407 /DB_XREF = gi: 13435158 /UG = Hs.7531 KIAA0810 protein /FL = gb: NM_025154.1 218817_at gb: NM_021928.1 /DEF = Homo sapiens hypothetical protein FLJ22649 similar to signal peptidase SPC2223 (FLJ22649), mRNA. /FEA = mRNA /GEN = FLJ22649 /PROD = hypothetical protein FLJ22649 similar to signalpeptidase SPC2223 /DB_XREF = gi: 11345461 /UG = Hs.42194 hypothetical protein FLJ22649 similar to signal peptidase SPC2223 /FL = gb: NM_021928.1 gb: AL136660.1 205227_at gb: NM_002182.1 /DEF = Homo sapiens interleukin 1 receptor accessory protein (IL1RAP), mRNA. /FEA = mRNA /GEN = IL1RAP /PROD = interleukin 1 receptor accessory protein /DB_XREF = gi: 4504660 /UG = Hs.173880 interleukin 1 receptor accessory protein /FL = gb: AF029213.1 gb: AB006537.1 gb: NM_002182.1 208795_s_at gb: D55716.1 /DEF = Human mRNA for P1cdc47, complete cds. /FEA = mRNA /GEN = P1cdc47 /PROD = P1cdc47 /DB_XREF = gi: 1255616 /UG = Hs.77152 minichromosome maintenance deficient (S. cerevisiae) 7 /FL = gb: D55716.1 36129_at Cluster Incl. AB007857: Homo sapiens KIAA0397 mRNA, complete cds /cds = (54, 1520) /gb = AB007857 /gi = 2662074 /ug = Hs.7416 /len = 6629 201827_at gb: AF113019.1 /DEF = Homo sapiens PRO2451 mRNA, complete cds. /FEA = mRNA /PROD = PRO2451 /DB_XREF = gi: 6642761 /UG = Hs.250581 SWISNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2 /FL = gb: U66618.1 gb: NM_003077.1 gb: AF113019.1 200599_s_at gb: NM_003299.1 /DEF = Homo sapiens tumor rejection antigen (gp96) 1 (TRA1), mRNA. /FEA = mRNA /GEN = TRA1 /PROD = tumor rejection antigen (gp96) 1 /DB_XREF = gi: 4507676 /UG = Hs.82689 tumor rejection antigen (gp96) 1 /FL = gb: NM_003299.1 210473_s_at gb: M37712.1 /DEF = Human p58GTA (galactosyltransferase associated protein kinase) mRNA, complete cds. /FEA = mRNA /PROD = p58GTA protein kinase /DB_XREF = gi: 189480 /UG = Hs.183418 cell division cycle 2-like 1 (PITSLRE proteins) /FL = gb: M37712.1 gb: U04819.1 207034_s_at gb: NM_030379.1 /DEF = Homo sapiens GLI-Kruppel family member GLI2 (GLI2), transcript variant 1, mRNA. /FEA = mRNA /GEN = GLI2 /PROD = GLI-Kruppel family member GLI2, isoform alpha /DB_XREF = gi: 13518230 /UG = Hs.111867 GLI-Kruppel family member GLI2 /FL = gb: NM_030379.1 gb: AB007295.1 212875_s_at Consensus includes gb: AP001745 /DEF = Homo sapiens genomic DNA, chromosome 21q, section 89105 /FEA = mRNA_3 /DB_XREF = gi: 7768737 /UG = Hs.16007 chromosome 21 open reading frame 25 201793_x_at Consensus includes gb: BF509099 /FEA = EST /DB_XREF = gi: 11592397 /DB_XREF = est: UI-H-BI4-aou-e-05-0-UI.s1 /CLONE = IMAGE: 3086288 /UG = Hs.15087 KIAA0250 gene product /FL = gb: D87437.1 gb: NM_014837.1 217992_s_at gb: NM_024329.1 /DEF = Homo sapiens hypothetical protein MGC4342 (MGC4342), mRNA. /FEA = mRNA /GEN = MGC4342 /PROD = hypothetical protein MGC4342 /DB_XREF = gi: 13443015 /UG = Hs.301342 hypothetical protein MGC4342 /FL = gb: BC003033.1 gb: NM_024329.1 211731_x_at gb: BC005904.1 /DEF = Homo sapiens, synovial sarcoma, X breakpoint 3, clone MGC: 14495, mRNA, complete cds. /FEA = mRNA /PROD = synovial sarcoma, X breakpoint 3 /DB_XREF = gi: 13543493 /FL = gb: BC005904.1 219408_at gb: NM_019023.1 /DEF = Homo sapiens hypothetical protein (FLJ10640), mRNA. /FEA = mRNA /GEN = FLJ10640 /PROD = hypothetical protein /DB_XREF = gi: 9506614 /UG = Hs.91753 hypothetical protein /FL = gb: BC000146.1 gb: NM_019023.1 218506_x_at gb: NM_018459.1 /DEF = Homo sapiens uncharacterized bone marrow protein BM045 (BM045), mRNA. /FEA = mRNA /GEN = BM045 /PROD = uncharacterized bone marrow protein BM045 /DB_XREF = gi: 8922103 /UG = Hs.8750 uncharacterized bone marrow protein BM045 /FL = gb: AF217521.1 gb: NM_018459.1 200742_s_at Consensus includes gb: BG231932 /FEA = EST /DB_XREF = gi: 12727071 /DB_XREF = est: naf34b12.x1 /CLONE = IMAGE: 4142926 /UG = Hs.20478 ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease) /FL = gb: AF017456.1 gb: NM_000391.2 218584_at gb: NM_024549.1 /DEF = Homo sapiens hypothetical protein FLJ21127 (FLJ21127), mRNA. /FEA = mRNA /GEN = FLJ21127 /PROD = hypothetical protein FLJ21127 /DB_XREF = gi: 13375712 /UG = Hs.11500 hypothetical protein FLJ21127 /FL = gb: NM_024549.1 205026_at gb: NM_012448.1 /DEF = Homo sapiens signal transducer and activator of transcription 5B (STAT5B), mRNA. /FEA = mRNA /GEN = STAT5B /PROD = signal transducer and activator of transcription5B /DB_XREF = gi: 6912687 /UG = Hs.244613 signal transducer and activator of transcription 5B /FL = gb: U47686.1 gb: NM_012448.1 gb: U48730.2 204861_s_at gb: NM_004536.1 /DEF = Homo sapiens baculoviral IAP repeat-containing 1 (BIRC1), mRNA. /FEA = mRNA /GEN = BIRC1 /PROD = baculoviral IAP repeat-containing 1 /DB_XREF = gi: 4758751 /UG = Hs.79019 baculoviral IAP repeat-containing 1 /FL = gb: U19251.1 gb: NM_004536.1 210512_s_at gb: AF022375.1 /DEF = Homo sapiens vascular endothelial growth factor mRNA, complete cds. /FEA = mRNA /PROD = vascular endothelial growth factor /DB_XREF = gi: 3719220 /UG = Hs.73793 vascular endothelial growth factor /FL = gb: M32977.1 gb: AF022375.1 gb: NM_003376.1 gb: AB021221.1 gb: AF091352.1 209019_s_at gb: AF316873.1 /DEF = Homo sapiens protein kinase BRPK mRNA, complete cds. /FEA = mRNA /PROD = protein kinase BRPK /DB_XREF = gi: 13492051 /UG = Hs.6163 Homo sapiens protein kinase BRPK mRNA, complete cds /FL = gb: AF316873.1 220936_s_at gb: NM_018267.1 /DEF = Homo sapiens hypothetical protein FLJ10903 (FLJ10903), mRNA. /FEA = mRNA /GEN = FLJ10903 /PROD = hypothetical protein FLJ10903 /DB_XREF = gi: 8922757 /UG = Hs.36727 hypothetical protein FLJ10903 /FL = gb: NM_018267.1 218729_at gb: NM_020169.1 /DEF = Homo sapiens latexin protein (LXN), mRNA. /FEA = mRNA /GEN = LXN /PROD = latexin protein /DB_XREF = gi: 9910395 /UG = Hs.109276 latexin protein /FL = gb: BC005346.1 gb: AF282626.1 gb: NM_020169.1 213940_s_at Consensus includes gb: AU145053 /FEA = EST /DB_XREF = gi: 11006574 /DB_XREF = est: AU145053 /CLONE = HEMBA1003755 /UG = Hs.301763 KIAA0554 protein 220453_at gb: NM_017765.1 /DEF = Homo sapiens hypothetical protein FLJ20320 (FLJ20320), mRNA. /FEA = mRNA /GEN = FLJ20320 /PROD = hypothetical protein FLJ20320 /DB_XREF = gi: 8923300 /UG = Hs.263081 hypothetical protein FLJ20320 /FL = gb: NM_017765.1 212976_at Consensus includes gb: R41498 /FEA = EST /DB_XREF = gi: 816800 /DB_XREF = est: yf86h08.s1 /CLONE = IMAGE: 29486 /UG = Hs.199243 KIAA0231 protein 222159_at Consensus includes gb: AK023058.1 /DEF = Homo sapiens cDNA FLJ12996 fis, clone NT2RP3000235. /FEA = mRNA /DB_XREF = gi: 10434801 /UG = Hs.287546 Homo sapiens cDNA FLJ12996 fis, clone NT2RP3000235 212055_at Consensus includes gb: BF689173 /FEA = EST /DB_XREF = gi: 11974581 /DB_XREF = est: 602184834T1 /CLONE = IMAGE: 4299201 /UG = Hs.22981 DKFZP586M1523 protein 219024_at gb: NM_021622.1 /DEF = Homo sapiens pleckstrin homology domain-containing, family A (phosphoinositide binding specific) member 1 (PLEKHA1), mRNA. /FEA = mRNA /GEN = PLEKHA1 /PROD = pleckstrin homology domain- containing, family A(phosphoinositide binding specific) member 1 /DB_XREF = gi: 11055985 /UG = Hs.17757 pleckstrin homology domain-containing, family A (phosphoinositide binding specific) member 1 /FL = gb: AF286160.1 gb: NM_021622.1 gb: BC001136.1 205595_at gb: NM_001944.1 /DEF = Homo sapiens desmoglein 3 (pemphigus vulgaris antigen) (DSG3), mRNA. /FEA = mRNA /GEN = DSG3 /PROD = desmoglein 3 preproprotein /DB_XREF = gi: 4503404 /UG = Hs.1925 desmoglein 3 (pemphigus vulgaris antigen) /FL = gb: M76482.1 gb: NM_001944.1 203509_at gb: NM_003105.2 /DEF = Homo sapiens sortilin-related receptor, L(DLR class) A repeats-containing (SORL1), mRNA. /FEA = mRNA /GEN = SORL1 /PROD = sortilin-related receptor, L(DLR class) Arepeats-containing /DB_XREF = gi: 6325473 /UG = Hs.278571 sortilin-related receptor, L(DLR class) A repeats-containing /FL = gb: U60975.2 gb: NM_003105.2 208877_at Consensus includes gb: W74494 /FEA = EST /DB_XREF = gi: 1384781 /DB_XREF = est: zd75f10.s1 /CLONE = IMAGE: 346507 /UG = Hs.284275 Homo sapiens PAK2 mRNA, complete cds /FL = gb: AF092132.1 212350_at Consensus includes gb: AB029031.1 /DEF = Homo sapiens mRNA for KIAA1108 protein, partial cds. /FEA = mRNA /GEN = KIAA1108 /PROD = KIAA1108 protein /DB_XREF = gi: 5689552 /UG = Hs.278586 KIAA1108 protein 222076_at Consensus includes gb: BE222436 /FEA = EST /DB_XREF = gi: 8909754 /DB_XREF = est: hv90h11.x1 /CLONE = IMAGE: 3180741 /UG = Hs.799 diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) 206628_at gb: NM_000343.1 /DEF = Homo sapiens solute carrier family 5 (sodiumglucose cotransporter), member 1 (SLC5A1), mRNA. /FEA = mRNA /GEN = SLC5A1 /PROD = solute carrier family 5 (sodiumglucosecotransporter), member 1 /DB_XREF = gi: 4507030 /UG = Hs.1964 solute carrier family 5 (sodiumglucose cotransporter), member 1 /FL = gb: M24847.1 gb: NM_000343.1 220148_at gb: NM_022568.1 /DEF = Homo sapiens aldehyde dehydrogenase 12 (ALDH12), mRNA. /FEA = mRNA /GEN = ALDH12 /PROD = aldehyde dehydrogenase 12 /DB_XREF = gi: 12007647 /UG = Hs.18443 aldehyde dehydrogenase 8 family, member A1 /FL = gb: AF303134.1 gb: NM_022568.1 218687_s_at gb: NM_017648.1 /DEF = Homo sapiens hypothetical protein FLJ20063 (FLJ20063), mRNA. /FEA = mRNA /GEN = FLJ20063 /PROD = hypothetical protein FLJ20063 /DB_XREF = gi: 8923068 /UG = Hs.5940 hypothetical protein FLJ20063 /FL = gb: AB035807.1 gb: NM_017648.1 202543_s_at gb: BC005359.1 /DEF = Homo sapiens, glia maturation factor, beta, clone MGC: 12462, mRNA, complete cds. /FEA = mRNA /PROD = glia maturation factor, beta /DB_XREF = gi: 13529184 /UG = Hs.151413 glia maturation factor, beta /FL = gb: BC005359.1 gb: M86492.1 gb: AB001106.1 gb: NM_004124.1 204491_at Consensus includes gb: R40917 /FEA = EST /DB_XREF = gi: 823119 /DB_XREF = est: yf75d09.s1 /CLONE = IMAGE: 28220 /UG = Hs.172081 phosphodiesterase 4D, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E3) /FL = gb: L20969.1 gb: U02882.1 gb: NM_006203.1 212503_s_at Consensus includes gb: N22859 /FEA = EST /DB_XREF = gi: 1137009 /DB_XREF = est: yx56d09.s1 /CLONE = IMAGE: 265745 /UG = Hs.227716 KIAA0934 protein 216921_s_at Consensus includes gb: X90763.1 /DEF = Homo sapiens mRNA for type I keratin. /FEA = mRNA /GEN = hHa5 /PROD = HHa5 hair keratin type I intermediate filament /DB_XREF = gi: 1668743 /UG = Hs.73082 keratin, hair, acidic, 5 217664_at Consensus includes gb: AA780524 /FEA = EST /DB_XREF = gi: 2839855 /DB_XREF = est: ac71f01.s1 /CLONE = IMAGE: 868057 /UG = Hs.294072 ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION WARNING ENTRY H. sapiens 211997_x_at Consensus includes gb: NM_005324.1 /DEF = Homo sapiens H3 histone, family 3B (H3.3B) (H3F3B), mRNA. /FEA = CDS /GEN = H3F3B /PROD = H3 histone, family 3B (H3.3B) /DB_XREF = gi: 4885384 /UG = Hs.180877 H3 histone, family 3B (H3.3B) /FL = gb: NM_005324.1 220233_at gb: NM_024907.1 /DEF = Homo sapiens hypothetical protein FLJ11798 (FLJ11798), mRNA. /FEA = mRNA /GEN = FLJ11798 /PROD = hypothetical protein FLJ11798 /DB_XREF = gi: 13376364 /UG = Hs.249727 hypothetical protein FLJ11798 /FL = gb: NM_024907.1 221297_at gb: NM_018654.1 /DEF = Homo sapiens G protein-coupled receptor, family C, group 5, member D (GPRC5D), mRNA. /FEA = CDS /GEN = GPRC5D /PROD = G protein-coupled receptor, family C, group 5, member D /DB_XREF = gi: 8923704 /UG = Hs.283073 G protein-coupled receptor, family C, group 5, member D /FL = gb: AF209923.1 gb: NM_018654.1 202864_s_at gb: NM_003113.1 /DEF = Homo sapiens nuclear antigen Sp100 (SP100), mRNA. /FEA = mRNA /GEN = SP100 /PROD = nuclear antigen Sp100 /DB_XREF = gi: 4507164 /UG = Hs.77617 nuclear antigen Sp100 /FL = gb: M60618.1 gb: NM_003113.1 218898_at gb: NM_024792.1 /DEF = Homo sapiens hypothetical protein FLJ22282 (FLJ22282), mRNA. /FEA = mRNA /GEN = FLJ22282 /PROD = hypothetical protein FLJ22282 /DB_XREF = gi: 13376161 /UG = Hs.154396 hypothetical protein FLJ22282 /FL = gb: NM_024792.1 209377_s_at gb: AF274949.1 /DEF = Homo sapiens PNAS-24 mRNA, complete cds. /FEA = mRNA /PROD = PNAS-24 /DB_XREF = gi: 12751062 /UG = Hs.77558 thyroid hormone receptor interactor 7 /FL = gb: AF274949.1 209485_s_at Consensus includes gb: W19983 /FEA = EST /DB_XREF = gi: 1295853 /DB_XREF = est: zb38d10.r1 /CLONE = IMAGE: 305875 /UG = Hs.252716 Homo sapiens oxysterol-binding protein-related protein (ORP1) mRNA, complete cds /FL = gb: AF274714.1 211612_s_at gb: U62858.1 /DEF = Human interleukin-13 receptor mRNA, complete cds. /FEA = mRNA /PROD = interleukin-13 receptor /DB_XREF = gi: 1695875 /FL = gb: U62858.1 210608_s_at gb: BC001899.1 /DEF = Homo sapiens, Similar to fucosyltransferase 2 (secretor status included), clone MGC: 2062, mRNA, complete cds. /FEA = mRNA /PROD = Similar to fucosyltransferase 2 (secretor statusincluded) /DB_XREF = gi: 12804894 /UG = Hs.46328 fucosyltransferase 2 (secretor status included) /FL = gb: BC001899.1 212335_at Consensus includes gb: AW167793 /FEA = EST /DB_XREF = gi: 6399401 /DB_XREF = est: xg56d07.x1 /CLONE = IMAGE: 2632333 /UG = Hs.164036 Homo sapiens AKAP350C mRNA sequence, alternatively spliced 212964_at Consensus includes gb: AI912206 /FEA = EST /DB_XREF = gi: 5632061 /DB_XREF = est: wd71e08.x1 /CLONE = IMAGE: 2337062 /UG = Hs.109445 KIAA1020 protein. 221486_at gb: AF067170.1 /DEF = Homo sapiens alpha endosulfine mRNA, complete cds. /FEA = mRNA /PROD = alpha endosulfine /DB_XREF = gi: 4894373 /UG = Hs.111680 endosulfine alpha /FL = gb: AF067170.1 gb: AF157510.1 208760_at Consensus includes gb: AL031714 /DEF = Human DNA sequence from clone LA16-358B7 on chromosome 16 Contains the UBE21 gene for ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9), and an RPS20 (40S Ribosomal protein S20) pseudogene. Contains ESTs, STSs. GSSs and a putative CpG is . . . /FEA = mRNA /DB_XREF = gi: 4775608 /UG = Hs.84285 ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9) /FL = gb: U45328.1 gb: U31933.1 gb: BC000427.1 gb: BC004429.1 gb: U31882.1 gb: U66818.1 gb: U66867.1 gb: U38785.1 gb: NM_003345.1 gb: U29092.1 218284_at gb: NM_015400.1 /DEF = Homo sapiens DKFZP586N0721 protein (DKFZP586N0721), mRNA. /FEA = mRNA /GEN = DKFZP586N0721 /PROD = DKFZP586N0721 protein /DB_XREF = gi: 7661691 /UG = Hs.99843 DKFZP586N0721 protein /FL = gb: BC000414.1 gb: AF151027.1 gb: NM_015400.1 49452_at Cluster Incl. AI057637: oy31h06.x1 Homo sapiens cDNA, 3 end /clone = IMAGE-1667483 /clone_end = 3 /gb = AI057637 /gi = 3331503 /ug = Hs.21305 /len = 599 212579_at Consensus includes gb: AB014550.1 /DEF = Homo sapiens mRNA for KIAA0650 protein, partial cds. /FEA = mRNA /GEN = KIAA0650 /PROD = KIAA0650 protein /DB_XREF = gi: 3327113 /UG = Hs.8118 KIAA0650 protein 217668_at Consensus includes gb: BF511164 /FEA = EST /DB_XREF = gi: 11594462 /DB_XREF = est: UI-H-BI4-aoi-a-09-0-UI.s1 /CLONE = IMAGE: 3084952 /UG = Hs.293309 ESTs 217733_s_at gb: NM_021103.1 /DEF = Homo sapiens thymosin, beta 10 (TMSB10), mRNA. /FEA = mRNA /GEN = TMSB10 /PROD = thymosin, beta 10 /DB_XREF = gi: 10863894 /UG = Hs.76293 thymosin, beta 10 /FL = gb: NM_021103.1 gb: M92381.1 gb: M20259.1 211995_x_at Consensus includes gb: AL567820 /FEA = EST /DB_XREF = gi: 12921560 /DB_XREF = est: AL567820 /CLONE = CS0DF033YD24 (3 prime) /UG = Hs.14376 actin, gamma 1 209853_s_at gb: BC002684.1 /DEF = Homo sapiens, proteaseome (prosome, macropain) 28 subunit, 3, clone MGC: 3572, mRNA, complete cds. /FEA = mRNA /PROD = proteaseome (prosome, macropain) 28 subunit, 3 /DB_XREF = gi: 12803696 /UG = Hs.152978 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) /FL = gb: BC001423.1 gb: BC002684.1 219079_at gb: NM_016230.1 /DEF = Homo sapiens flavohemoprotein b5 + b5R (LOC51167), mRNA. /FEA = mRNA /GEN = LOC51167 /PROD = flavohemoprotein b5 + b5R /DB_XREF = gi: 7705898 /UG = Hs.5741 flavohemoprotein b5 + b5R /FL = gb: AF169803.1 gb: NM_016230.1 218657_at gb: NM_016339.1 /DEF = Homo sapiens Link guanine nucleotide exchange factor II (LOC51195), mRNA. /FEA = mRNA /GEN = LOC51195 /PROD = Link guanine nucleotide exchange factor II /DB_XREF = gi: 7705938 /UG = Hs.118562 Link guanine nucleotide exchange factor II /FL = gb: AF117946.1 gb: NM_016339.1 205430_at Consensus includes gb: AL133386 /DEF = Human DNA sequence from clone RP1-181C24 on chromosome 6p11.1-12.2. Contains the 3 end of the BMP5 gene for bone morphogenetic protein 5, ESTs, STSs and GSSs /FEA = mRNA /DB_XREF = gi: 6807532 /UG = Hs.1104 bone morphogenetic protein 5 /FL = gb: NM_021073.1 gb: M60314.1 201065_s_at gb: NM_001518.1 /DEF = Homo sapiens general transcription factor II, i (GTF2I), mRNA. /FEA = mRNA /GEN = GTF2I /PROD = general transcription factor II, i /DB_XREF = gi: 4504202 /UG = Hs.278589 general transcription factor II, i /FL = gb: U77948.1 gb: AF015553.1 gb: AF038969.1 gb: NM_001518.1 203638_s_at gb: NM_022969.1 /DEF = Homo sapiens fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome) (FGFR2), transcript variant 2, mRNA. /FEA = mRNA /GEN = FGFR2 /PROD = fibroblast growth factor receptor 2, isoform 2precursor /DB_XREF = gi: 13186252 /UG = Hs.278581 fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson- Weiss syndrome) /FL = gb: NM_022969.1 gb: M97193.1 gb: M80634.1 200884_at gb: NM_001823.1 /DEF = Homo sapiens creatine kinase, brain (CKB), mRNA. /FEA = mRNA. /GEN = CKB /PROD = creatine kinase, brain /DB_XREF = gi: 4502850 /UG = Hs.173724 creatine kinase, brain /FL = gb: L47647.1 gb: BC001190.1 gb: BC004914.1 gb: M16364.1 gb: M16451.1 gb: NM_001823.1 221882_s_at Consensus includes gb: AI636233 /FEA = EST /DB_XREF = gi: 4687563 /DB_XREF = est: tz93b07.x1 /CLONE = IMAGE: 2296117 /UG = Hs.288940 five-span transmembrane protein M83 211737_x_at gb: BC005916.1 /DEF = Homo sapiens, pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1), clone MGC: 14512, mRNA, complete cds. /FEA = mRNA /PROD = pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) /DB_XREF = gi: 13543514 /FL = gb: BC005916.1 203112_s_at gb: NM_005663.1 /DEF = Homo sapiens Wolf-Hirschhorn syndrome candidate 2 (WHSC2), mRNA. /FEA = mRNA /GEN = WHSC2 /PROD = WHSC2 protein /DB_XREF = gi: 5032226 /UG = Hs.21771 Wolf-Hirschhorn syndrome candidate 2 /FL = gb: BC002764.1 gb: AF101434.1 gb: NM_005663.1 212387_at Consensus includes gb: BG495771 /FEA = EST /DB_XREF = gi: 13457287 /DB_XREF = est: 602540396F1 /CLONE = IMAGE: 4671599 /UG = Hs.289068 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272 209574_s_at Consensus includes gb: AI349506 /FEA = EST /DB_XREF = gi: 4086712 /DB_XREF = est: qp71g08.x1 /CLONE = IMAGE: 1928510 /UG = Hs.153498 chromosome 18 open reading frame 1 /FL = gb: AF009424.1 218471_s_at gb: NM_024649.1 /DEF = Homo sapiens hypothetical protein FLJ23590 (FLJ23590), mRNA. /FEA = mRNA /GEN = FLJ23590 /PROD = hypothetical protein FLJ23590 /DB_XREF = gi: 13375892 /UG = Hs.54890 hypothetical protein. FLJ23590 /FL = gb: NM_024649.1 215380_s_at Consensus includes gb: AK021779.1 /DEF = Homo sapiens cDNA FLJ11717 fis, clone HEMBA1005241. /FEA = mRNA /DB_XREF = gi: 10433033 /UG = Hs.288649 hypothetical protein MGC3077 207135_at gb: NM_000621.1 /DEF = Homo sapiens 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A), mRNA. /FEA = mRNA /GEN = HTR2A /PROD = 5-hydroxytryptamine (serotonin) receptor 2A /DB_XREF = gi: 10835174 /UG = Hs.298623 5- hydroxytryptamine (serotonin) receptor 2A /FL = gb: NM_000621.1 201537_s_at gb: BC002682.1 /DEF = Homo sapiens, dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related), clone MGC: 3615, mRNA, complete cds. /FEA = mRNA /PROD = dual specificity phosphatase 3 (vaccinia virusphosphatase VH1-related) /DB_XREF = gi: 12803692 /UG = Hs.181046 dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) /FL = gb: BC002682.1 gb: L05147.1 gb: NM_004090.1 219665_at gb: NM_024815.1 /DEF = Homo sapiens hypothetical protein FLJ22494 (FLJ22494), mRNA. /FEA = mRNA /GEN = FLJ22494 /PROD = hypothetical protein FLJ22494 /DB_XREF = gi: 13376205 /UG = Hs.170132 hypothetical protein FLJ22494 /FL = gb: NM_024815.1 206746_at gb: NM_001195.2 /DEF = Homo sapiens beaded filament structural protein 1, filensin (BFSP1), mRNA. /FEA = mRNA /GEN = BFSP1 /PROD = filensin /DB_XREF = gi: 13518027 /UG = Hs.129702 beaded filament structural protein 1, filensin /FL = gb: Y16717.2 gb: NM_001195.2 gb: AF039655.1 214239_x_at Consensus includes gb: AI560455 /FEA = EST /DB_XREF = gi: 4510796 /DB_XREF = est: tn11b01.x1 /CLONE = IMAGE: 2167273 /UG = Hs.184669 zinc finger protein 144 (Mel-18) 201096_s_at Consensus includes gb: AL537042 /FEA = EST /DB_XREF = gi: 12800535 /DB_XREF = est: AL537042 /CLONE = CS0DF017YF17 (5 prime) /UG = Hs.75290 ADP-ribosylation factor 4 /FL = gb: BC003364.1 gb: M36341.1 gb: NM_001660.2 31845_at Cluster Incl. U32645: Human myeloid elf-1 like factor (MEF) mRNA, complete cds /cds = (382, 2373) /gb = U32645 /gi = 1761934 /ug = Hs.151139 /len = 4167 205453_at gb: NM_002145.1 /DEF = Homo sapiens homeo box B2 (HOXB2), mRNA. /FEA = mRNA /GEN = HOXB2 /PROD = homeo box B2 /DB_XREF = gi: 4504464 /UG = Hs.2733 homeo box B2 /FL = gb: NM_002145.1 205265_s_at gb: NM_005876.1 /DEF = Homo sapiens nuclear protein, marker for differentiated aortic smooth muscle and down- regulated with vascular injury (APEG1), mRNA. /FEA = mRNA /GEN = APEG1 /PROD = nuclear protein, marker for differentiated aortic smooth muscle and down-regulated with vascular injury /DB_XREF = gi: 5031588 /UG = Hs.21639 nuclear protein, marker for differentiated aortic smooth muscle and down-regulated with vascular injury /FL = gb: U57099.1 gb: NM_005876.1 219369_s_at gb: NM_023112.1 /DEF = Homo sapiens hypothetical protein FLJ21916 (FLJ21916), mRNA. /FEA = mRNA /GEN = FLJ21916 /PROD = hypothetical protein FLJ21916 /DB_XREF = gi: 12962938 /UG = Hs.90034 hypothetical protein FLJ21916 /FL = gb: BC000208.1 gb: NM_023112.1 212569_at Consensus includes gb: AV699744 /FEA = EST /DB_XREF = gi: 10301715 /DB_XREF = est: AV699744 /CLONE = GKCEDF05 /UG = Hs.8118 KIAA0650 protein 219127_at gb: NM_024320.1 /DEF = Homo sapiens hypothetical protein MGC11242 (MGC11242), mRNA. /FEA = mRNA /GEN = MGC11242 /PROD = hypothetical protein MGC11242 /DB_XREF = gi: 13236560 /UG = Hs.36529 hypothetical protein MGC11242 /FL = gb: BC002865.1 gb: NM_024320.1 213169_at Consensus includes gb: BG109855 /FEA = EST /DB_XREF = gi: 12603361 /DB_XREF = est: 602279521F1 /CLONE = IMAGE: 4367308 /UG = Hs.49476 Homo sapiens clone TUA8 Cri-du-chat region mRNA 216617_s_at Consensus includes gb: X98405.1 /DEF = H. sapiens mRNA for myelin associated glycoprotein, S-MAG. /FEA = mRNA /GEN = S-MAG /PROD = myelin associated glycoprotein /DB_XREF = gi: 1403054 /UG = Hs.1780 myelin associated glycoprotein 202082_s_at Consensus includes gb: AV748469 /FEA = EST /DB_XREF = gi: 10906317 /DB_XREF = est: AV748469 /CLONE = NPCAXA07 /UG = Hs.75232 SEC14 (S. cerevisiae)-like 1 /FL = gb: D67029.1 gb: NM_003003.1 204791_at gb: NM_003297.1 /DEF = Homo sapiens nuclear receptor subfamily 2, group C, member 1 (NR2C1), mRNA. /FEA = mRNA /GEN = NR2C1 /PROD = nuclear receptor subfamily 2, group C, member 1 /DB_XREF = gi: 4507672 /UG = Hs.108301 nuclear receptor subfamily 2, group C, member 1 /FL = gb: M29960.1 gb: NM_003297.1 53202_at Cluster Incl. AA402435: zt60g10.r1 Homo sapiens cDNA, 5 end /clone = IMAGE-726786 /clone_end = 5 /gb = AA402435 /gi = 2057299 /ug = Hs.59594 /len = 529 203045_at gb: NM_004148.1 /DEF = Homo sapiens ninjurin 1 (NINJ1), mRNA. /FEA = mRNA /GEN = NINJ1 /PROD = ninjurin 1 /DB_XREF = gi: 4758809 /UG = Hs.11342 ninjurin 1 /FL = gb: BC004440.1 gb: U72661.1 gb: U91512.1 gb: NM_004148.1 208891_at gb: BC003143.1 /DEF = Homo sapiens, dual specificity phosphatase 6, clone MGC: 3789, mRNA, complete cds. /FEA = mRNA /PROD = dual specificity phosphatase 6 /DB_XREF = gi: 13111942 /UG = Hs.180383 dual specificity phosphatase 6 /FL = gb: BC003562.1 gb: BC003143.1 gb: BC005047.1 gb: AB013382.1 gb: NM_001946.1 219497_s_at gb: NM_022893.1 /DEF = Homo sapiens B-cell CLLlymphoma 11A (zinc finger protein) (BCL11A), mRNA. /FEA = mRNA /GEN = BCL11A /PROD = B-cell CLLlymphoma 11A (zinc finger protein) /DB_XREF = gi: 13375629 /UG = Hs.130881 B-cell CLLlymphoma 11A (zinc finger protein) /FL = gb: NM_022893.1 gb: NM_018014.1 220221_at gb: NM_018156.1 /DEF = Homo sapiens hypothetical protein FLJ10619 (FLJ10619), mRNA. /FEA = mRNA /GEN = FLJ10619 /PROD = hypothetical protein FLJ10619 /DB_XREF = gi: 8922552 /UG = Hs.191436 hypothetical protein FLJ10619 /FL = gb: NM_018156.1 213636_at Consensus includes gb: AB028968.1 /DEF = Homo sapiens mRNA for KIAA1045 protein, partial cds. /FEA = mRNA /GEN = KIAA1045 /PROD = KIAA1045 protein /DB_XREF = gi: 5689426 /UG = Hs.7989 KIAA1045 protein 219067_s_at gb: NM_017615.1 /DEF = Homo sapiens hypothetical protein FLJ20003 (FLJ20003), mRNA. /FEA = mRNA /GEN = FLJ20003 /PROD = hypothetical protein FLJ20003 /DB_XREF = gi: 8923008 /UG = Hs.258798 hypothetical protein FLJ20003 /FL = gb: NM_017615.1 216776_at Consensus includes gb: AK025206.1 /DEF = Homo sapiens cDNA: FLJ21553 fis, clone COL06329. /FEA = mRNA /DB_XREF = gi: 10437671 /UG = Hs.306786 Homo sapiens cDNA: FLJ21553 fis, clone COL06329 212978_at Consensus includes gb: AU146004 /FEA = EST /DB_XREF = gi: 11007525 /DB_XREF = est: AU146004 /CLONE = HEMBA1006523 /UG = Hs.199243 KIAA0231 protein 201681_s_at Consensus includes gb: AB011155.1 /DEF = Homo sapiens mRNA for KIAA0583 protein, partial cds. /FEA = mRNA /GEN = KIAA0583 /PROD = KIAA0583 protein /DB_XREF = gi: 3043689 /UG = Hs.170290 discs, large (Drosophila) homolog 5 /FL = gb: U61843.1 gb: NM_004747.1 38037_at Cluster Incl. M60278: Human heparin-binding EGF-like growth factor mRNA, complete cds /cds = (261, 887) /gb = M60278 /gi = 183866 /ug = Hs.799 /len = 2342 212693_at Consensus includes gb: BE670928 /FEA = EST /DB_XREF = gi: 10031469 /DB_XREF = est: 7e43b11.x1 /CLONE = IMAGE: 3285213 /UG = Hs.76730 KIAA0301 protein 220333_at gb: NM_017705.1 /DEF = Homo sapiens hypothetical protein FLJ20190 (FLJ20190), mRNA. /FEA = mRNA /GEN = FLJ20190 /PROD = hypothetical protein FLJ20190 /DB_XREF = gi: 8923182 /UG = Hs.257511 hypothetical protein FLJ20190 /FL = gb: NM_017705.1 221438_s_at gb: NM_031275.1 /DEF = Homo sapiens testis expressed sequence 12 (TEX12), mRNA. /FEA = CDS /GEN = TEX12 /PROD = testis expressed sequence 12 /DB_XREF = gi: 13775181 /FL = gb: NM_031275.1 200989_at gb: NM_001530.1 /DEF = Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) (HIF1A), mRNA. /FEA = mRNA /GEN = HIF1A /PROD = hypoxia-inducible factor 1, alpha subunit (basichelix- loop-helix transcription factor) /DB_XREF = gi: 4504384 /UG = Hs.197540 hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) /FL = gb: U29165.1 gb: AF304431.1 gb: NM_001530.1 gb: AF207601.1 gb: AF207602.1 gb: U22431.1 201397_at gb: NM_006623.1 /DEF = Homo sapiens phosphoglycerate dehydrogenase (PHGDH), mRNA. /FEA = mRNA /GEN = PHGDH /PROD = phosphoglycerate dehydrogenase /DB_XREF = gi: 5729973 /UG = Hs.3343 phosphoglycerate dehydrogenase /FL = gb: BC000303.1 gb: BC001349.1 gb: AF006043.1 gb: NM_006623.1 gb: AF171237.1 201583_s_at gb: NM_006363.1 /DEF = Homo sapiens Sec23 (S. cerevisiae) homolog B (SEC23B), mRNA. /FEA = mRNA /GEN = SEC23B /PROD = Sec23 (S. cerevisiae) homolog B /DB_XREF = gi: 5454043 /UG = Hs.173497 Sec23 (S. cerevisiae) homolog B /FL = gb: BC005404.1 gb: NM_006363.1 203297_s_at Consensus includes gb: BG029530 /FEA = EST /DB_XREF = gi: 12418626 /DB_XREF = est: 602297090F1 /CLONE = IMAGE: 4391375 /UG = Hs.40154 jumonji (mouse) homolog /FL = gb: NM_004973.2 gb: U57592.1 208959_s_at gb: BC005374.1 /DEF = Homo sapiens, Similar to RIKEN cDNA 1110001E24 gene, clone MGC: 12490, mRNA, complete cds. /FEA = mRNA /PROD = Similar to RIKEN cDNA 1110001E24 gene /DB_XREF = gi: 13529223 /UG = Hs.154023 KIAA0573 protein /FL = gb: BC005374.1 204168_at gb: NM_002413.1 /DEF = Homo sapiens microsomal glutathione S-transferase 2 (MGST2), mRNA. /FEA = mRNA /GEN = MGST2 /PROD = microsomal glutathione S-transferase 2 /DB_XREF = gi: 4505180 /UG = Hs.81874 microsomal glutathione S-transferase 2 /FL = gb: U77604.1 gb: NM_002413.1 205120_s_at gb: U29586.1 /DEF = Human beta-sarcoglycan dystrophin-associated glycoprotein mRNA, complete cds. /FEA = mRNA /PROD = dystrophin-associated glycoprotein /DB_XREF = gi: 1794188 /UG = Hs.77501 sarcoglycan, beta (43 kD dystrophin associated glycoprotein) /FL = gb: U31116.1 gb: U29586.1 gb: NM_000232.1 214880_x_at Consensus includes gb: D90453.1 /DEF = Human mRNA for 1-caldesmon II. /FEA = mRNA /DB_XREF = gi: 219897 /UG = Hs.325474 caldesmon 1 205804_s_at gb: NM_025228.1 /DEF = Homo sapiens hypothetical protein dJ434O14.3 (DJ434O14.3), mRNA. /FEA = mRNA /GEN = DJ434O14.3 /PROD = hypothetical protein dJ434O14.3 /DB_XREF = gi: 13435126 /UG = Hs.261373 hypothetical protein dJ434O14.3 /FL = gb: NM_025228.1 214696_at Consensus includes gb: AF070569.1 /DEF = Homo sapiens clone 24659 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 3387938 /UG = Hs.29206 Homo sapiens clone 24659 mRNA sequence 218488_at gb: NM_020365.1 /DEF = Homo sapiens eukaryotic translation initiation factor 2B, subunit 3 (gamma, 58 kD) (EIF2B3), mRNA. /FEA = mRNA /GEN = EIF2B3 /PROD = eukaryotic translation initiation factor 2B, subunit 3 (gamma, 58 kD) /DB_XREF = gi: 9966778 /UG = Hs.283627 eukaryotic translation initiation factor 2B, subunit 3 (gamma, 58 kD) /FL = gb: AF257077.1 gb: NM_020365.1 200795_at gb: NM_004684.1 /DEF = Homo sapiens SPARC-like 1 (mast9, hevin) (SPARCL1), mRNA. /FEA = mRNA /GEN = SPARCL1 /PROD = SPARC-like 1 /DB_XREF = gi: 4758521 /UG = Hs.75445 SPARC-like 1 (mast9, hevin) /FL = gb: NM_004684.1 206245_s_at gb: NM_006469.1 /DEF = Homo sapiens NS1-binding protein (NS1-BP), mRNA. /FEA = mRNA /GEN = NS1-BP /PROD = NS1-binding protein /DB_XREF = gi: 5453803 /UG = Hs.197298 NS1-binding protein /FL = gb: NM_006469.1 201297_s_at Consensus includes gb: AK023321.1 /DEF = Homo sapiens cDNA FLJ13259 fis, clone OVARC1000876, moderately similar to MOB1 PROTEIN. /FEA = mRNA /DB_XREF = gi: 10435206 /UG = Hs.196437 hypothetical protein FLJ10788 /FL = gb: AB016839.1 gb: BC003398.1 gb: NM_018221.1 207168_s_at gb: NM_004893.1 /DEF = Homo sapiens H2A histone family, member Y (H2AFY), mRNA. /FEA = mRNA /GEN = H2AFY /PROD = H2A histone family, member Y /DB_XREF = gi: 4758495 /UG = Hs.75258 H2A histone family, member Y /FL = gb: AF054174.1 gb: NM_004893.1 57163_at Cluster Incl. H93026: yv06a08.s1 Homo sapiens cDNA, 3 end /clone = IMAGE-241910 /clone_end = 3 /gb = H93026 /gi = 1099354 /ug = Hs.25597 /len = 600 201247_at Consensus includes gb: BE513151 /FEA = EST /DB_XREF = gi: 9720362 /DB_XREF = est: 601171940F1 /CLONE = IMAGE: 3545697 /UG = Hs.108689 sterol regulatory element binding transcription factor 2 /FL = gb: U02031.1 gb: NM_004599.1 207545_s_at gb: NM_003744.1 /DEF = Homo sapiens numb (Drosophila) homolog (NUMB), mRNA. /FEA = mRNA /GEN = NUMB /PROD = numb (Drosophila) homolog /DB_XREF = gi: 4505478 /UG = Hs.78890 numb (Drosophila) homolog /FL = gb: NM_003744.1 gb: L40393.1 208638_at Consensus includes gb: BE910010 /FEA = EST /DB_XREF = gi: 10406176 /DB_XREF = est: 601498050F1 /CLONE = IMAGE: 3899869 /UG = Hs.182429 protein disulfide isomerase-related protein /FL = gb: BC001312.1 203676_at gb: NM_002076.1 /DEF = Homo sapiens glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS), mRNA. /FEA = mRNA /GEN = GNS /PROD = glucosamine (N-acetyl)-6-sulfatase precursor /DB_XREF = gi: 4504060 /UG = Hs.321070 glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) /FL = gb: NM_002076.1 213283_s_at Consensus includes gb: BG285616 /FEA = EST /DB_XREF = gi: 13037752 /DB_XREF = est: 602380622F1 /CLONE = IMAGE: 4498325 /UG = Hs.79971 sal (Drosophila)-like 2 210747_at gb: M24364.1 /DEF = Human MHC class II lymphocyte antigen DQB mRNA, complete cds, haplotype DR7, DQw9. /FEA = mRNA /PROD = lymphocyte antigen /DB_XREF = gi: 529041 /UG = Hs.73931 major histocompatibility complex, class II, DQ beta 1 /FL = gb: M24364.1 201062_at gb: M81635.1 /DEF = Homo sapiens erythrocyte membrane protein mRNA, complete cds. /FEA = mRNA /GEN = stomatin peptide /PROD = stomatin peptide /DB_XREF = gi: 181183 /UG = Hs.160483 erythrocyte membrane protein band 7.2 (stomatin) /FL = gb: M81635.1 gb: NM_004099.1 222315_at Consensus includes gb: AW972855 /FEA = EST /DB_XREF = gi: 8162701 /DB_XREF = est: EST384950 /UG = Hs.292853 ESTs 208511_at gb: NM_021000.1 /DEF = Homo sapiens pituitary tumor-transforming 3 (PTTG3), mRNA. /FEA = CDS /GEN = PTTG3 /PROD = pituitary tumor-transforming 3 /DB_XREF = gi: 10337606 /UG = Hs.247762 pituitary tumor-transforming 3 /FL = gb: NM_021000.1 gb: AF095289.1 220644_at gb: NM_014137.1 /DEF = Homo sapiens PRO0650 protein (PRO0650), mRNA. /FEA = mRNA /GEN = PRO0650 /PROD = PRO0650 protein /DB_XREF = gi: 7662581 /UG = Hs.177258 PRO0650 protein /FL = gb: AF090941.1 gb: NM_014137.1 36830_at Cluster Incl. U80034: Human mitochondrial intermediate peptidase precursor (MIPEP) mRNA, mitochondrial gene encoding mitochondrial protein, complete cds /cds = (74, 2215) /gb = U80034 /gi = 1763641 /ug = Hs.68583 /len = 2374 208286_x_at gb: NM_002701.1 /DEF = Homo sapiens POU domain, class 5, transcription factor 1 (POU5F1), mRNA. /FEA = mRNA /GEN = POU5F1 /PROD = POU domain, class 5, transcription factor 1 /DB_XREF = gi: 4505966 /UG = Hs.2860 POU domain, class 5, transcription factor 1 /FL = gb: NM_002701.1 222135_at Consensus includes gb: AK022663.1 /DEF = Homo sapiens cDNA FLJ12601 fis, clone NT2RM4001414. /FEA = mRNA /DB_XREF = gi: 10434187 /UG = Hs.288549 Homo sapiens cDNA FLJ12601 fis, clone NT2RM4001414 218264_at gb: NM_016567.1 /DEF = Homo sapiens cdk inhibitor p21 binding protein (TOK-1), mRNA. /FEA = mRNA /GEN = TOK- 1 /PROD = cdk inhibitor p21 binding protein /DB_XREF = gi: 7706580 /UG = Hs.279862 cdk inhibitor p21 binding protein /FL = gb: AB040450.1 gb: NM_016567.1 202401_s_at gb: NM_003131.1 /DEF = Homo sapiens serum response factor (c-fos serum response element-binding transcription factor) (SRF), mRNA. /FEA = mRNA /GEN = SRF /PROD = serum response factor (c-fos serum response element-binding transcription factor) /DB_XREF = gi: 4507204 /UG = Hs.155321 serum response factor (c-fos serum response element- binding transcription factor) /FL = gb: J03161.1 gb: NM_003131.1 220322_at gb: NM_019618.1 /DEF = Homo sapiens interleukin-1 homolog 1 (IL-1H1), mRNA. /FEA = mRNA /GEN = IL-1H1 /PROD = interleukin-1 homolog 1 /DB_XREF = gi: 9665233 /UG = Hs.211238 interleukin-1 homolog 1 /FL = gb: AF206696.1 gb: AF200492.1 gb: NM_019618.1 202083_s_at Consensus includes gb: AI017770 /FEA = EST /DB_XREF = gi: 3232106 /DB_XREF = est: ov32b12.x1 /CLONE = IMAGE: 1639007 /UG = Hs.75232 SEC14 (S. cerevisiae)-like 1 /FL = gb: D67029.1 gb: NM_003003.1 218312_s_at gb: NM_023926.1 /DEF = Homo sapiens hypothetical protein FLJ12895 (FLJ12895), mRNA. /FEA = mRNA /GEN = FLJ12895 /PROD = hypothetical protein FLJ12895 /DB_XREF = gi: 12965194 /UG = Hs.235390 hypothetical protein FLJ12895 /FL = gb: NM_023926.1 212151_at Consensus includes gb: BF967998 /FEA = EST /DB_XREF = gi: 12335213 /DB_XREF = est: 602269506F1 /CLONE = IMAGE: 4357777 /UG = Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321 208671_at gb: AF164794.1 /DEF = Homo sapiens Diff33 protein homolog mRNA, complete cds. /FEA = mRNA /PROD = Diff33 protein homolog /DB_XREF = gi: 8895090 /UG = Hs.146668 KIAA1253 protein /FL = gb: AF164794.1 210879_s_at gb: AF334812.1 /DEF = Homo sapiens Rab11 interacting protein Rip11a mRNA, complete cds. /FEA = mRNA /PROD = Rab11 interacting protein Rip11a /DB_XREF = gi: 13377896 /UG = Hs.24557 KIAA0857 protein /FL = gb: AF334812.1 219252_s_at gb: NM_017856.1 /DEF = Homo sapiens hypothetical protein FLJ20514 (FLJ20514), mRNA. /FEA = mRNA /GEN = FLJ20514 /PROD = hypothetical protein FLJ20514 /DB_XREF = gi: 8923480 /UG = Hs.44423 hypothetical protein FLJ20514 /FL = gb: NM_017856.1 202599_s_at gb: NM_003489.1 /DEF = Homo sapiens nuclear receptor interacting protein 1 (NRIP1), mRNA. /FEA = mRNA /GEN = NRIP1 /PROD = receptor interacting protein 140 /DB_XREF = gi: 4505454 /UG = Hs.155017 nuclear receptor interacting protein 1 /FL = gb: NM_003489.1 213820_s_at Consensus includes gb: T54159 /FEA = EST /DB_XREF = gi: 656020 /DB_XREF = est: ya90f07.s2 /CLONE = IMAGE: 68965 /UG = Hs.172803 hypothetical protein MGC10327 217650_x_at Consensus includes gb: AI088162 /FEA = EST /DB_XREF = gi: 3427138 /DB_XREF = est: oz96b09.x1 /CLONE = IMAGE: 1683161 /UG = Hs.262292 ESTs, Moderately similar to ALU3_HUMAN ALU SUBFAMILY SB1 SEQUENCE CONTAMINATION WARNING ENTRY H. sapiens 222060_at Consensus includes gb: AI357616 /FEA = EST /DB_XREF = gi: 4109237 /DB_XREF = est: qu20g08.x1 /CLONE = IMAGE: 1965374 /UG = Hs.101651 Homo sapiens mRNA; cDNA DKFZp434C107 (from clone DKFZp434C107) 204865_at gb: NM_005181.2 /DEF = Homo sapiens carbonic anhydrase III, muscle specific (CA3), mRNA. /FEA = mRNA /GEN = CA3 /PROD = carbonic anhydrase III /DB_XREF = gi: 6996001 /UG = Hs.82129 carbonic anhydrase III, muscle specific /FL = gb: BC004897.1 gb: NM_005181.2 206739_at gb: NM_018953.1 /DEF = Homo sapiens homeo box C5 (HOXC5), mRNA. /FEA = mRNA /GEN = HOXC5 /PROD = homeo box C5 /DB_XREF = gi: 11321637 /UG = Hs.111473 homeo box C5 /FL = gb: NM_018953.1 203888_at gb: NM_000361.1 /DEF = Homo sapiens thrombomodulin (THBD), mRNA. /FEA = mRNA /GEN = THBD /PROD = thrombomodulin /DB_XREF = gi: 4507482 /UG = Hs.2030 thrombomodulin /FL = gb: M16552.1 gb: NM_000361.1 203367_at gb: NM_007026.1 /DEF = Homo sapiens MKP-1 like protein tyrosine phosphatase (MKP-L), mRNA. /FEA = mRNA /GEN = MKP-L /PROD = MKP-1 like protein tyrosine phosphatase /DB_XREF = gi: 5902001 /UG = Hs.91448 MKP-1 like protein tyrosine phosphatase /FL = gb: BC000370.1 gb: BC001894.1 gb: BC004448.1 gb: AF038844.1 gb: NM_007026.1 gb: AF120032.1 200615_s_at Consensus includes gb: AL567295 /FEA = EST /DB_XREF = gi: 12920509 /DB_XREF = est: AL567295 /CLONE = CS0DF027YO06 (3 prime) /UG = Hs.74626 adaptor-related protein complex 2, beta 1 subunit /FL = gb: M34175.1 gb: NM_001282.1 219736_at gb: NM_018700.1 /DEF = Homo sapiens zinc-binding protein Rbcc728 (Rbcc728), mRNA. /FEA = mRNA /GEN = Rbcc728 /PROD = zinc-binding protein Rbcc728 /DB_XREF = gi: 8924237 /UG = Hs.121429 zinc-binding protein Rbcc728 /FL = gb: NM_018700.1 213978_at Consensus includes gb: AA338945 /FEA = EST /DB_XREF = gi: 1991203 /DB_XREF = est: EST43994 /UG = Hs.319825 Homo sapiens, clone IMAGE: 3616574, mRNA, partial cds 219132_at gb: NM_021255.1 /DEF = Homo sapiens pellino (Drosophila) homolog 2 (PELI2), mRNA. /FEA = mRNA /GEN = PELI2 /PROD = pellino (Drosophila) homolog 2 /DB_XREF = gi: 10864062 /UG = Hs.44038 pellino (Drosophila) homolog 2 /FL = gb: AF302502.1 gb: NM_021255.1 217873_at gb: NM_016289.1 /DEF = Homo sapiens MO25 protein (LOC51719), mRNA. /FEA = mRNA /GEN = LOC51719 /PROD = MO25 protein /DB_XREF = gi: 7706480 /UG = Hs.6406 MO25 protein /FL = gb: AF113536.1 gb: NM_016289.1 37549_g_at Cluster Incl. U87408: Human clone IMAGE-74593 unknown protein mRNA, partial cds /cds = (0, 1362) /gb = U87408 /gi = 1842104 /ug = Hs.79340 /len = 1982 218476_at gb: NM_007171.1 /DEF = Homo sapiens protein-O-mannosyltransferase 1 (POMT1), mRNA. /FEA = mRNA /GEN = POMT1 /PROD = protein-O-mannosyltransferase 1 /DB_XREF = gi: 6005839 /UG = Hs.99654 protein-O- mannosyltransferase 1 /FL = gb: AF095136.1 gb: NM_007171.1 203117_s_at gb: NM_014871.1 /DEF = Homo sapiens KIAA0710 gene product (KIAA0710), mRNA. /FEA = mRNA /GEN = KIAA0710 /PROD = KIAA0710 gene product /DB_XREF = gi: 7662257 /UG = Hs.273397 KIAA0710 gene product /FL = gb: AB014610.1 gb: NM_014871.1 202655_at gb: NM_006010.1 /DEF = Homo sapiens arginine-rich, mutated in early stage tumors (ARMET), mRNA. /FEA = mRNA /GEN = ARMET /PROD = arginine-rich protein /DB_XREF = gi: 5174392 /UG = Hs.75412 arginine-rich, mutated in early stage tumors /FL = gb: M83751.1 gb: NM_006010.1 203304_at gb: NM_012342.1 /DEF = Homo sapiens putative transmembrane protein (NMA), mRNA. /FEA = mRNA /GEN = NMA /PROD = putative transmembrane protein /DB_XREF = gi: 6912533 /UG = Hs.78776 putative transmembrane protein /FL = gb: U23070.1 gb: NM_012342.1 213624_at Consensus includes gb: AA873600 /FEA = EST /DB_XREF = gi: 2969722 /DB_XREF = est: ob12a02.s1 /CLONE = IMAGE: 1323434 /UG = Hs.42945 acid sphingomyelinase-like phosphodiesterase 220544_at gb: NM_021733.1 /DEF = Homo sapiens testis-specific kinase substrate (TSKS), mRNA. /FEA = mRNA /GEN = TSKS /PROD = testis-specific kinase substrate /DB_XREF = gi: 11119429 /UG = Hs.224210 testis-specific kinase substrate /FL = gb: NM_021733.1 203035_s_at gb: NM_006099.1 /DEF = Homo sapiens protein inhibitor of activated STAT3 (PIAS3), mRNA. /FEA = mRNA /GEN = PIAS3 /PROD = protein inhibitor of activated STAT3 /DB_XREF = gi: 5174628 /UG = Hs.76578 protein inhibitor of activated STAT3 /FL = gb: BC001154.1 gb: AB021868.1 gb: NM_006099.1 219055_at gb: NM_018079.1 /DEF = Homo sapiens hypothetical protein FLJ10379 (FLJ10379), mRNA. /FEA = mRNA /GEN = FLJ10379 /PROD = hypothetical protein FLJ10379 /DB_XREF = gi: 8922391 /UG = Hs.14229 hypothetical protein FLJ10379 /FL = gb: NM_018079.1 218497_s_at gb: NM_002936.1 /DEF = Homo sapiens ribonuclease H1 (RNASEH1), mRNA. /FEA = mRNA /GEN = RNASEH1 /PROD = ribonuclease H1 /DB_XREF = gi: 4506554 /UG = Hs.178655 ribonuclease H1 /FL = gb: BC002973.1 gb: AF048994.1 gb: AF048995.1 gb: AF039652.1 gb: NM_002936.1 219635_at gb: NM_025027.1 /DEF = Homo sapiens hypothetical protein FLJ14260 (FLJ14260), mRNA. /FEA = mRNA /GEN = FLJ14260 /PROD = hypothetical protein FLJ14260 /DB_XREF = gi: 13430885 /UG = Hs.287629 hypothetical protein FLJ14260 /FL = gb: NM_025027.1 218689_at gb: NM_022725.1 /DEF = Homo sapiens Fanconi anemia, complementation group F (FANCF), mRNA. /FEA = mRNA /GEN = FANCF /PROD = Fanconi anemia, complementation group F /DB_XREF = gi: 12232376 /UG = Hs.65328 Fanconi anemia, complementation group F /FL = gb: NM_022725.1 gb: AF181994.1 gb: AF181995.1 205405_at gb: NM_003966.1 /DEF = Homo sapiens sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A (SEMA5A), mRNA. /FEA = mRNA /GEN = SEMA5A /PROD = sema domain, seven thrombospondin repeats (type1 and type 1-like), transmembrane domain (TM) and shortcytoplasmic domain, (semaphorin) 5A /DB_XREF = gi: 4506880 /UG = Hs.27621 sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A /FL = gb: U52840.1 gb: NM_003966.1 213060_s_at Consensus includes gb: U58515.1 /DEF = Human chitinase (HUMTCHIT) mRNA, exon 1b form, partial cds. /FEA = mRNA /GEN = HUMTCHIT /PROD = chitinase /DB_XREF = gi: 1439567 /UG = Hs.154138 chitinase 3-like 2 212256_at Consensus includes gb: BE906572 /FEA = EST /DB_XREF = gi: 10399901 /DB_XREF = est: 601502550F1 /CLONE = IMAGE: 3904092 /UG = Hs.107260 hypothetical protein DKFZp586H0623 202860_at gb: NM_014856.1 /DEF = Homo sapiens KIAA0476 gene product (KIAA0476), mRNA. /FEA = mRNA /GEN = KIAA0476 /PROD = KIAA0476 gene product /DB_XREF = gi: 7662151 /UG = Hs.6684 KIAA0476 gene product /FL = gb: AB007945.1 gb: NM_014856.1 209550_at gb: U35139.1 /DEF = Human NECDIN related protein mRNA, complete cds. /FEA = mRNA /PROD = NECDIN related protein /DB_XREF = gi: 1754970 /UG = Hs.50130 necdin (mouse) homolog /FL = gb: NM_002487.2 gb: U35139.1 202905_x_at Consensus includes gb: AI796269 /FEA = EST /DB_XREF = gi: 5361732 /DB_XREF = est: wh44g10.x1 /CLONE = IMAGE: 2383650 /UG = Hs.25812 Nijmegen breakage syndrome 1 (nibrin) /FL = gb: AF058696.1 gb: AF051334.1 gb: NM_002485.2 217528_at Consensus includes gb: BF003134 /FEA = EST /DB_XREF = gi: 10703409 /DB_XREF = est: 7g55f09.x1 /CLONE = IMAGE: 3310409 /UG = Hs.72365 ESTs 206512_at gb: NM_005083.2 /DEF = Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor, small subunit 1 (U2AF1RS1), mRNA. /FEA = mRNA /GEN = U2AF1RS1 /PROD = U2 small nuclear ribonucleoprotein auxiliary factor, small subunit-related protein 1 /DB_XREF = gi: 13186299 /UG = Hs.103962 U2 small nuclear ribonucleoprotein auxiliary factor, small subunit 1 /FL = gb: D49676.1 gb: NM_005083.2 211813_x_at gb: AF138303.1 /DEF = Homo sapiens decorin D mRNA, complete cds, alternatively spliced. /FEA = CDS /PROD = decorin D /DB_XREF = gi: 7381210 /UG = Hs.76152 decorin /FL = gb: AF138303.1 201530_x_at gb: NM_001416.1 /DEF = Homo sapiens eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1), mRNA. /FEA = mRNA /GEN = EIF4A1 /PROD = eukaryotic translation initiation factor 4A, isoform 1 /DB_XREF = gi: 4503528 /UG = Hs.129673 eukaryotic translation initiation factor 4A, isoform 1 /FL = gb: NM_001416.1 209396_s_at gb: M80927.1 /DEF = Human glycoprotein mRNA, complete cds. /FEA = mRNA /PROD = glycoprotein /DB_XREF = gi: 348911 /UG = Hs.75184 chitinase 3-like 1 (cartilage glycoprotein-39) /FL = gb: M80927.1 gb: NM_001276.1 218358_at gb: NM_024324.1 /DEF = Homo sapiens hypothetical protein MGC11256 (MGC11256), mRNA. /FEA = mRNA /GEN = MGC11256 /PROD = hypothetical protein MGC11256 /DB_XREF = gi: 13236568 /UG = Hs.28029 hypothetical protein MGC11256 /FL = gb: BC002894.1 gb: NM_024324.1 204719_at gb: NM_007168.1 /DEF = Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 8 (ABCA8), mRNA. /FEA = mRNA /GEN = ABCA8 /PROD = ATP-binding cassette, sub-family A member 8 /DB_XREF = gi: 6005700 /UG = Hs.38095 ATP-binding cassette, sub-family A (ABC1), member 8 /FL = gb: AB020629.1 gb: NM_007168.1 222149_x_at Consensus includes gb: AL137398.1 /DEF = Homo sapiens mRNA; cDNA DKFZp434K052 (from clone DKFZp434K052). /FEA = mRNA /DB_XREF = gi: 6807944 /UG = Hs.169639 Homo sapiens mRNA; cDNA DKFZp434K052 (from clone DKFZp434K052) 214658_at Consensus includes gb: BG286537 /FEA = EST /DB_XREF = gi: 13039504 /DB_XREF = est: 602382536F1 /CLONE = IMAGE: 4500129 /UG = Hs.278391 CGI-109 protein 201212_at gb: D55696.1 /DEF = Homo sapiens mRNA for cysteine protease, complete cds. /FEA = mRNA /PROD = cysteine protease /DB_XREF = gi: 1890049 /UG = Hs.18069 protease, cysteine, 1 (legumain) /FL = gb: BC003061.1 gb: D55696.1 gb: NM_005606.1 208336_s_at gb: NM_004868.1 /DEF = Homo sapiens glycoprotein, synaptic 2 (GPSN2), mRNA. /FEA = mRNA /GEN = GPSN2 /PROD = glycoprotein, synaptic 2 /DB_XREF = gi: 4759061 /UG = Hs.306122 glycoprotein, synaptic 2 /FL = gb: AF038959.1 gb: NM_004868.1 217551_at Consensus includes gb: AA719797 /FEA = EST /DB_XREF = gi: 2732896 /DB_XREF = est: zg54c07.s1 /CLONE = IMAGE: 397164 /UG = Hs.194362 olfactory receptor, family 7, subfamily E, member 13 pseudogene 203410_at gb: NM_006803.1 /DEF = Homo sapiens adaptor-related protein complex 3, mu 2 subunit (AP3M2), mRNA. /FEA = mRNA /GEN = AP3M2 /PROD = adaptor-related protein complex 3, mu 2 subunit /DB_XREF = gi: 5802999 /UG = Hs.77770 adaptor-related protein complex 3, mu 2 subunit /FL = gb: NM_006803.1 gb: D38293.1 207621_s_at gb: NM_007169.1 /DEF = Homo sapiens phosphatidylethanolamine N-methyltransferase (PEMT), mRNA. /FEA = mRNA /GEN = PEMT /PROD = phosphatidylethanolamine N-methyltransferase /DB_XREF = gi: 6005827 /UG = Hs.15192 phosphatidylethanolamine N-methyltransferase /FL = gb: AB029821.1 gb: AF176806.1 gb: NM_007169.1 203588_s_at Consensus includes gb: BG034328 /FEA = EST /DB_XREF = gi: 12427528 /DB_XREF = est: 602302213F1 /CLONE = IMAGE: 4403787 /UG = Hs.19131 transcription factor Dp-2 (E2F dimerization partner 2) /FL = gb: NM_006286.1 gb: U18422.1 221567_at gb: AF064599.1 /DEF = Homo sapiens nucleolar protein Nop30 (NOP) mRNA, alternatively spliced, complete cds. /FEA = mRNA /GEN = NOP /PROD = nucleolar protein Nop30 /DB_XREF = gi: 3172418 /UG = Hs.278439 nucleolar protein 3 (apoptosis repressor with CARD domain) /FL = gb: AF043244.1 gb: AF064599.1 gb: AF064600.1 gb: NM_003946.1 210239_at gb: U90304.1 /DEF = Human iroquois-class homeodomain protein IRX-2a mRNA, complete cds. /FEA = mRNA /PROD = iroquois-class homeodomain protein IRX-2a /DB_XREF = gi: 1899219 /UG = Hs.25351 iroquois homeobox protein 5 /FL = gb: U90304.1 gb: NM_005853.1 200797_s_at Consensus includes gb: AI275690 /FEA = EST /DB_XREF = gi: 3897964 /DB_XREF = est: qw03a03.x1 /CLONE = IMAGE: 1989964 /UG = Hs.86386 myeloid cell leukemia sequence 1 (BCL2-related) /FL = gb: NM_021960.1 gb: AF118124.1 202561_at Consensus includes gb: AF070613.1 /DEF = Homo sapiens clone 24585 mRNA sequence. /FEA = mRNA /DB_XREF = gi: 3387995 /UG = Hs.131814 tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase /FL = gb: AF082556.1 gb: NM_003747.1 206502_s_at gb: NM_002196.1 /DEF = Homo sapiens insulinoma-associated 1 (INSM1), mRNA. /FEA = mRNA /GEN = INSM1 /PROD = insulinoma-associated 1 /DB_XREF = gi: 4504712 /UG = Hs.89584 insulinoma-associated 1 /FL = gb: M93119.1 gb: NM_002196.1 206188_at gb: NM_014789.1 /DEF = Homo sapiens KIAA0628 gene product (KIAA0628), mRNA. /FEA = mRNA /GEN = KIAA0628 /PROD = KIAA0628 gene product /DB_XREF = gi: 7662213 /UG = Hs.43133 KIAA0628 gene product /FL = gb: AB014528.1 gb: NM_014789.1 217122_s_at Consensus includes gb: AL031282 /DEF = Human DNA sequence from clone 283E3 on chromosome 1p36.21-36.33. Contains the alternatively spliced gene for Matrix Metalloproteinase in the Female Reproductive tract MIFR1, -2, MMP2122A, -B and -C, a novel gene, the alternatively spliced CDC2L2 . . . /FEA = mRNA_6 /DB_XREF = gi: 3860395 /UG = Hs.214646 KIAA0447 gene product 219432_at gb: NM_014556.1 /DEF = Homo sapiens Ellis van Creveld syndrome (EVC), mRNA. /FEA = mRNA /GEN = EVC /PROD = Ellis van Creveld syndrome protein /DB_XREF = gi: 7657072 /UG = Hs.274446 Ellis van Creveld syndrome /FL = gb: AF216184.1 gb: AF239742.1 gb: NM_014556.1 207266_x_at gb: NM_016837.1 /DEF = Homo sapiens RNA binding motif, single stranded interacting protein 1 (RBMS1), transcript variant MSSP-3, mRNA. /FEA = mRNA /GEN = RBMS1 /PROD = RNA binding motif, single stranded interactingprotein 1, isoform e /DB_XREF = gi: 8400719 /UG = Hs.241567 RNA binding motif, single stranded interacting protein 1 /FL = gb: NM_016837.1 209676_at gb: J03225.1 /DEF = Human lipoprotein-associated coagulation inhibitor mRNA, complete cds. /FEA = mRNA /GEN = TFPI /DB_XREF = gi: 180545 /UG = Hs.170279 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) /FL = gb: J03225.1 gb: NM_006287.2 209055_s_at Consensus includes gb: AW268817 /FEA = EST /DB_XREF = gi: 6655847 /DB_XREF = est: xv38c01.x1 /CLONE = IMAGE: 2815392 /UG = Hs.155174 CDC5 (cell division cycle 5, S. pombe, homolog)-like /FL = gb: NM_001253.1 gb: U86753.1 gb: AB007892.1 206874_s_at Consensus includes gb: AL138761 /DEF = Human DNA sequence from clone RP11-16H23 on chromosome 10. Contains the gene KIAA0204 (HSLK) for a protein kinase, the COL17A1 gene for collagen type XVII alpha 1 (BP180), ESTs and GSSs /FEA = mRNA_2 /DB_XREF = gi: 8573811 /UG = Hs.105751 Ste20-related serinethreonine kinase /FL = gb: D86959.1 gb: NM_014720.1 221139_s_at gb: NM_015989.1 /DEF = Homo sapiens cysteine sulfinic acid decarboxylase-related protein 2 (CSAD), mRNA. /FEA = mRNA /GEN = CSAD /PROD = cysteine sulfinic aciddecarboxylase-related protein 2 /DB_XREF = gi: 7705333 /UG = Hs.279815 cysteine sulfinic acid decarboxylase-related protein 2 /FL = gb: AF116546.1 gb: NM_015989.1 204136_at gb: NM_000094.1 /DEF = Homo sapiens collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) (COL7A1), mRNA. /FEA = mRNA /GEN = COL7A1 /PROD = collagen, type VII, alpha 1 (epidermolysisbullosa, dystrophic, dominant and recessive) /DB_XREF = gi: 4502960 /UG = Hs.1640 collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) /FL = gb: NM_000094.1 gb: L02870.1 217841_s_at gb: NM_016147.1 /DEF = Homo sapiens protein phosphatase methylesterase-1 (PME-1), mRNA. /FEA = mRNA /GEN = PME-1 /PROD = protein phosphatase methylesterase-1 /DB_XREF = gi: 7706644 /UG = Hs.63304 protein phosphatase methylesterase-1 /FL = gb: BC003046.1 gb: AF157028.1 gb: NM_016147.1 202735_at gb: NM_006579.1 /DEF = Homo sapiens emopamil-binding protein (sterol isomerase) (EBP), mRNA. /FEA = mRNA /GEN = EBP /PROD = emopamil-binding protein (sterol isomerase) /DB_XREF = gi: 5729809 /UG = Hs.75105 emopamil- binding protein (sterol isomerase) /FL = gb: NM_006579.1 200625_s_at gb: NM_006367.2 /DEF = Homo sapiens adenylyl cyclase-associated protein (CAP), mRNA. /FEA = mRNA /GEN = CAP /PROD = adenylyl cyclase-associated protein /DB_XREF = gi: 10938021 /UG = Hs.104125 adenylyl cyclase-associated protein /FL = gb: NM_006367.2 gb: L12168.1 gb: M98474.1 204288_s_at gb: NM_021069.1 /DEF = Homo sapiens ArgAbl-interacting protein ArgBP2 (ARGBP2), transcript variant 2, mRNA. /FEA = mRNA /GEN = ARGBP2 /PROD = ArgAbl-interacting protein 2, isoform 2 /DB_XREF = gi: 10947117 /UG = Hs.278626 ArgAbl-interacting protein ArgBP2 /FL = gb: NM_021069.1 gb: AB018320.1 211626_x_at gb: M21535.1 /DEF = Human erg protein (ets-related gene) mRNA, complete cds. /FEA = mRNA /DB_XREF = gi: 182182 /FL = gb: M21535.1 209605_at gb: D87292.1 /DEF = Homo sapiens mRNA for rhodanese, complete cds. /FEA = mRNA /PROD = rhodanese /DB_XREF = gi: 1877030 /UG = Hs.248267 thiosulfate sulfurtransferase (rhodanese) /FL = gb: D87292.1 212560_at Consensus includes gb: AV728268 /FEA = EST /DB_XREF = gi: 10837689 /DB_XREF = est: AV728268 /CLONE = HTCACH05 /UG = Hs.82845 Homo sapiens cDNA: FLJ21930 fis, clone HEP04301, highly similar to HSU90916 Human clone 23815 mRNA sequence

indicates data missing or illegible when filed 

1. A non-invasive method for isolating or detecting a protein from an epidermal sample of a human subject, comprising: a) applying an adhesive tape to a target area of the skin of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample comprises cells from the stratum corneum of the subject; b) lysing the cells to extract a protein; and c) isolating or detecting a protein in the epidermal sample.
 2. The method of claim 1, wherein the protein is selected from the group consisting of TNFα, IFNγ, CD2, IL-12B, Krt-16, Krt-17, IL-23A, GAPDH and β-actin.
 3. The method of claim 1, wherein the protein is an expression product of a gene listed in Table VI.
 4. The method of claim 1, wherein the tape comprises a rubber adhesive on a polyurethane film.
 5. The method of claim 1, wherein about one to ten adhesive tapes are applied and removed from the skin.
 6. The method of claim 1, wherein about one to eight adhesive tapes are applied and removed from the skin.
 7. The method of claim 1, wherein about one to five adhesive tapes are applied and removed from the skin.
 8. A method for diagnosing melanoma in a human subject, comprising: a) applying an adhesive tape to a target area suspected of being melanoma on the skin of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample comprises cells from the stratum corneum; b) lysing the cells to extract a protein; and c) comparing the level of target protein to a normal or standard protein profile in similar tissue, wherein an altered level of the target protein is indicative of melanoma, thereby diagnosing melanoma in the subject.
 9. The method of claim 8, wherein the protein is selected from the group consisting of MGSA and TNFα.
 10. The method of claim 8, wherein the tape comprises a rubber adhesive on a polyurethane film.
 11. The method of claim 8, wherein between one and ten adhesive tapes are applied to the skin and removed from the skin.
 12. The method of claim 8, wherein about one to eight adhesive tapes are applied and removed from the skin.
 13. The method of claim 8, wherein about one to five adhesive tapes are applied and removed from the skin.
 14. The method of claim 8, wherein the method further comprises taking a biopsy of the target area of the skin.
 15. The method of claim 14, wherein protein is extracted from the biopsy sample, and the level of protein in the biopsy and the level of protein in the tape sample are analyzed.
 16. The method of claim 8, further comprising obtaining a sample from uninvolved epidermal tissue of the human subject.
 17. The method of claim 16, wherein the sample from uninvolved epidermal tissue is obtained by taking a biopsy of the uninvolved skin.
 18. The method of claim 16, wherein the sample from uninvolved epidermal tissue is obtained by: a) applying an adhesive tape to skin of the subject in a manner sufficient to isolate an epidermal sample adhering to the adhesive tape, wherein the epidermal sample comprises cells from the stratum corneum and wherein the skin is unaffected by a disease to be tested; b) lysing the cells to extract a protein; and c) quantitating the extracted protein.
 19. The method of claim 16, wherein the uninvolved skin is from the upper arm or the upper back.
 20. A non-invasive method for predicting response to treatment for a disease or pathological state, comprising: a) applying an adhesive tape to the skin of a subject afflicted with the disease or pathological state in a manner sufficient to isolate an epidermal sample comprising cells from the stratum corneum of the subject; b) lysing the cells to extract a protein; and c) detecting a target protein in the epidermal sample, wherein the presence of the target protein is indicative of a greater likelihood of response to treatment, thereby predicting response to treatment for the disease or pathological state. 21.-33. (canceled) 